<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35921534</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1942-0870</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>mAbs</Title><ISOAbbreviation>MAbs</ISOAbbreviation></Journal><ArticleTitle>Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice.</ArticleTitle><Pagination><StartPage>2107971</StartPage><MedlinePgn>2107971</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2107971</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/19420862.2022.2107971</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cells 2 (TREM2) plays a crucial role in regulating microglial functions and removal of amyloid plaques in Alzheimer's disease (AD). However, therapeutics based on this knowledge have not been developed due to the low antibody brain penetration and weak TREM2 activation. In this study, we engineered a TREM2 bispecific antibody to potently activate TREM2 and enter the brain. To boost TREM2 activation, we increased the valency of bivalent anti-TREM2 Ab2 IgG to tetra-variable domain immunoglobulin (TVD-Ig), thus improving the EC<sub>50</sub> of amyloid-&#x3b2; oligomer (oA&#x3b2;)-lipid microglial phagocytosis by more than 100-fold. Ab2 TVD-Ig treatment also augmented both microglia migration toward oA&#x3b2; and microglia survival by 100-fold over the bivalent IgG antibody. By targeting the transferrin receptor (TfR), the brain-penetrating Ab2 TVD-Ig/&#x3b1;TfR bispecific antibody realized broad brain parenchyma distribution with a 10-fold increase in brain antibody concentration. Ab2 TVD-Ig/&#x3b1;TfR treatment of 5-month-old 5XFAD mice significantly boosted microglia-plaque interactions and enhanced amyloid plaque phagocytosis by microglia. Thus, potent TREM2 activation by a multivalent agonist antibody coupled with TfR-mediated brain entry can boost microglia clearance of amyloid plaques, which suggests the antibody has potential as an AD treatment.<b>List of abbreviations</b> AD: Alzheimer's disease; Ab: antibody; APOE: apolipoprotein E; A&#x3b2;: amyloid beta; BBB: blood-brain barrier; BLI: bio-layer interferometry; CNS: central nervous system; CSF: colony-stimulating factor; CytoD: cytochalasin d; DAM: microglia type associated with neurodegenerative diseases; DAP12: DNAX-activation protein 12; TVD-Ig: tetra-variable domain immunoglobulin; ECD: extracellular domain; ELISA: enzyme-linked immunoassay; ESC: embryonic stem cell; hMGLs: human embryonic stem cell-derived microglia-like lines; IBA1: ionized calcium-binding adaptor molecule 1; ITAM: immunoreceptor tyrosine-based activation motif; KiH: knob-into-hole; NFAT: nuclear factor of activated t-cells; PC: phosphatidylcholine; PK: pharmacokinetics; PS: phosphatidylserine; pSYK: phosphorylated spleen tyrosine kinase; scFv: single-chain variable fragment; SEC: size-exclusion chromatography; sTREM2: soluble triggering receptor expressed on myeloid cells 2; SYK: spleen tyrosine kinase; TfR: transferrin receptor; TREM2: triggering receptor expressed on myeloid cells 2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, Texas Therapeutics Institute, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuanzhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xuejun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, Texas Therapeutics Institute, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Leike</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, Texas Therapeutics Institute, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, Texas Therapeutics Institute, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arase</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Qingchun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Center for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ningyan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, Texas Therapeutics Institute, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-9309-2335</Identifier><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, Texas Therapeutics Institute, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MAbs</MedlineTA><NlmUniqueID>101479829</NlmUniqueID><ISSNLinking>1942-0862</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D000072377">Syk Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="Y">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072377" MajorTopicYN="N">Syk Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">antibody engineering</Keyword><Keyword MajorTopicYN="N">bispecific antibody</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>The University of Texas System has filed a patent application on the TfR and TREM2 targeting antibodies and PZ, NZ, and ZA are named inventors of the patent application.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>3</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35921534</ArticleId><ArticleId IdType="pmc">PMC9354770</ArticleId><ArticleId IdType="doi">10.1080/19420862.2022.2107971</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bondi MW, Edmonds EC, Salmon DP.. Alzheimer&#x2019;s disease: past, present, and future. J Int Neuropsychol Soc. 2017;23:818&#x2013;17. doi:10.1017/S135561771700100X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S135561771700100X</ArticleId><ArticleId IdType="pmc">PMC5830188</ArticleId><ArticleId IdType="pubmed">29198280</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312&#x2013;39. doi:10.1016/j.cell.2019.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1&#x2013;sr1. doi:10.1126/scitranslmed.3002369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 2010;117:949&#x2013;60. doi:10.1007/s00702-010-0433-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-010-0433-4</ArticleId><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlus H, Heneka MT. Microglia in Alzheimer&#x2019;s disease. J Clin Invest. 2017;127:3240&#x2013;49. doi:10.1172/JCI90606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90606</ArticleId><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH. Anti-amyloid-&#x3b2; monoclonal antibodies for Alzheimer&#x2019;s disease: pitfalls and promise. Biol Psychiatry. 2018;83:311&#x2013;19. doi:10.1016/j.biopsych.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.08.010</ArticleId><ArticleId IdType="pmc">PMC5767539</ArticleId><ArticleId IdType="pubmed">28967385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, et al. Gantenerumab: a novel human anti-A&#x3b2; antibody demonstrates sustained cerebral amyloid-&#x3b2; binding and elicits cell-mediated removal of human amyloid-&#x3b2;. J Alzheimer&#x2019;s Dis. 2012;28:49&#x2013;69. doi:10.3233/JAD-2011-110977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110977</ArticleId><ArticleId IdType="pubmed">21955818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537:50&#x2013;56. doi:10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid &#x3b2;-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;19. doi:10.1038/78682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78682</ArticleId><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;27. doi:10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14:667&#x2013;75. doi:10.1038/s41582-018-0072-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0072-1</ArticleId><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pi&#xf1;a-Crespo JC, Zhang M, et al. TREM2 is a receptor for &#x3b2;-amyloid that mediates microglial function. Neuron. 2018;97:1023&#x2013;31.e7. doi:10.1016/j.neuron.2018.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.01.031</ArticleId><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;71. doi:10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;81.e9. doi:10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2015;212:287&#x2013;95. doi:10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181:1207&#x2013;17. doi:10.1016/j.cell.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.003</ArticleId><ArticleId IdType="pubmed">32531244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, et al. Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer&#x2019;s disease models. Neuron. 2018;97:1032&#x2013;48.e5. doi:10.1016/j.neuron.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.002</ArticleId><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, Monroe KM, Kleinberger G, Cantuti-Castelvetri L, Parhizkar S, Xia D, Willem M, Werner G, Pettkus N, Brunner B, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12:e11227. doi:10.15252/emmm.201911227.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, Li CM, Chui D, Tran D, Koirala S, et al. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer&#x2019;s disease variant Trem2(R47H) on murine myeloid cell function. J Biol Chem. 2018;293:12620&#x2013;33. doi:10.1074/jbc.RA118.001848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.001848</ArticleId><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x2019;s disease model. J Exp Med. 2020;217. doi:10.1084/jem.20200785</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200785</ArticleId><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassler M, Rappaport MS, Cu&#xf1;o CB, George J. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer&#x2019;s disease models. J Neuroinflammation. 2021;18:19. doi:10.1186/s12974-020-01980-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01980-5</ArticleId><ArticleId IdType="pmc">PMC7796541</ArticleId><ArticleId IdType="pubmed">33422057</ArticleId></ArticleIdList></Reference><Reference><Citation>Price BR, Sudduth TL, Weekman EM, Johnson S, Hawthorne D, Woolums A, Wilcock DM. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation. 2020;17:238. doi:10.1186/s12974-020-01915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01915-0</ArticleId><ArticleId IdType="pmc">PMC7427742</ArticleId><ArticleId IdType="pubmed">32795308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9:63&#x2013;73. doi:10.1007/s13238-017-0473-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0473-8</ArticleId><ArticleId IdType="pmc">PMC5777978</ArticleId><ArticleId IdType="pubmed">28986820</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi RE, Colonna M. Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer&#x2019;s Dementia. 2017;13:381&#x2013;87. doi:10.1016/j.jalz.2016.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.004</ArticleId><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka M, Arase H, Takeuchi A, Yamasaki S, Shiina R, Suenaga T, Sakurai D, Yokosuka T, Arase N, Iwashima M, et al. NFAM1, an immunoreceptor tyrosine-based activation motif-bearing molecule that regulates B cell development and signaling. Proc Natl Acad Sci U S A. 2004;101:8126&#x2013;31. doi:10.1073/pnas.0401119101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401119101</ArticleId><ArticleId IdType="pmc">PMC419568</ArticleId><ArticleId IdType="pubmed">15143214</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328&#x2013;40. doi:10.1016/j.neuron.2016.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.06.015</ArticleId><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, et al. iPSC-Derived human microglia-like cells to study neurological diseases. Neuron. 2017;94:278&#x2013;93.e9. doi:10.1016/j.neuron.2017.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zhu B, Liu Y, Zhang X, Yin J, Li X, Jiang L, Hodges AP, Rosenthal SB, Zhou L, et al. Multi-omic comparison of Alzheimer&#x2019;s variants in human ESC-derived microglia reveals convergence at APOE. J Exp Med. 2020;217. doi:10.1084/jem.20200474</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200474</ArticleId><ArticleId IdType="pmc">PMC7953740</ArticleId><ArticleId IdType="pubmed">32941599</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM. Drug transport across the blood&#x2013;brain barrier. J Cerebral Blood Flow Metab. 2012;32:1959&#x2013;72. doi:10.1038/jcbfm.2012.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2012.126</ArticleId><ArticleId IdType="pmc">PMC3494002</ArticleId><ArticleId IdType="pubmed">22929442</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Yeh SH, Madireddi S, Matochko WL, Gu C, Pacheco Sanchez P, Ultsch M, De Leon Boenig G, Harris SF, Leonard B, et al. Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. mAbs. 2019;11:996&#x2013;1011. doi:10.1080/19420862.2019.1625662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2019.1625662</ArticleId><ArticleId IdType="pmc">PMC6748612</ArticleId><ArticleId IdType="pubmed">31156033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother. 2011;55:2369&#x2013;78. doi:10.1128/AAC.00215-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00215-10</ArticleId><ArticleId IdType="pmc">PMC3088204</ArticleId><ArticleId IdType="pubmed">21300827</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;nker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, et al. RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven dr5 hyperclustering and tumor cell apoptosis. Mol Cancer Ther. 2016;15:946&#x2013;57. doi:10.1158/1535-7163.MCT-15-0647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-15-0647</ArticleId><ArticleId IdType="pubmed">27037412</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Malhotra S, Torchia James A, Kerr William G, Coggeshall KM, Humphrey Mary B. TREM2- and DAP12-Dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal. 2010;3:ra38&#x2013;ra. doi:10.1126/scisignal.2000500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2000500</ArticleId><ArticleId IdType="pmc">PMC2900152</ArticleId><ArticleId IdType="pubmed">20484116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#x2019;s disease model. Nat Commun. 2019;10:1365. doi:10.1038/s41467-019-09118-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09118-9</ArticleId><ArticleId IdType="pmc">PMC6433910</ArticleId><ArticleId IdType="pubmed">30911003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the role of TREM2 in Alzheimer&#x2019;s Disease. Neuron. 2017;94:237&#x2013;48. doi:10.1016/j.neuron.2017.02.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.042</ArticleId><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev. 2009;232:59&#x2013;71. doi:10.1111/j.1600-065X.2009.00832.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2009.00832.x</ArticleId><ArticleId IdType="pubmed">19909356</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Morenas-Rodr&#xed;guez E, Kleinberger G, Schlepckow K, Araque Caballero M&#xc1;, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, et al. Early increase of CSF sTREM2 in Alzheimer&#x2019;s disease is associated with tau related-neurodegeneration but not with amyloid-&#x3b2; pathology. Mol Neurodegener. 2019;14:1. doi:10.1186/s13024-018-0301-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0301-5</ArticleId><ArticleId IdType="pmc">PMC6327425</ArticleId><ArticleId IdType="pubmed">30630532</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilalta A, Zhou Y, Sevalle J, Griffin JK, Satoh K, Allendorf DH, De S, Puigdell&#xed;vol M, Bruzas A, Burguillos MA, et al. Wild-type sTREM2 blocks A&#x3b2; aggregation and neurotoxicity, but the Alzheimer&#x2019;s R47H mutant increases A&#x3b2; aggregation. J Biol Chemistry. 2021;296. doi:10.1016/j.jbc.2021.100631</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100631</ArticleId><ArticleId IdType="pmc">PMC8113883</ArticleId><ArticleId IdType="pubmed">33823153</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15:275&#x2013;92. doi:10.1038/nrd.2015.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2015.21</ArticleId><ArticleId IdType="pubmed">26794270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">32461332</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6:261ra154. doi:10.1126/scitranslmed.3009835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009835</ArticleId><ArticleId IdType="pubmed">25378646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44. doi:10.1126/scitranslmed.3002230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002230</ArticleId><ArticleId IdType="pubmed">21613623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P, Anami Y, Gao P, Fan X, Li L, Tsuchikama K, Zhang N, An Z. Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model. mAbs. 2022;14:2057269. doi:10.1080/19420862.2022.2057269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2022.2057269</ArticleId><ArticleId IdType="pmc">PMC8993059</ArticleId><ArticleId IdType="pubmed">35388745</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49&#x2013;60. doi:10.1016/j.neuron.2013.10.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.061</ArticleId><ArticleId IdType="pubmed">24411731</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677&#x2013;81. doi:10.1038/nbt0798-677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt0798-677</ArticleId><ArticleId IdType="pubmed">9661204</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Uma&#xf1;a P, M&#xf6;ssner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Design Selection. 2016;29:457&#x2013;66. doi:10.1093/protein/gzw040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzw040</ArticleId><ArticleId IdType="pubmed">27578889</ArticleId></ArticleIdList></Reference><Reference><Citation>Forner S, Kawauchi S, Balderrama-Gutierrez G, Kram&#xe1;r EA, Matheos DP, Phan J, Javonillo DI, Tran KM, Hingco E, da Cunha C, et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer&#x2019;s disease. Scientific Data. 2021;8:270. doi:10.1038/s41597-021-01054-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-021-01054-y</ArticleId><ArticleId IdType="pmc">PMC8519958</ArticleId><ArticleId IdType="pubmed">34654824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Comerota MM, Wan D, Chen F, Propson NE, Hwang SH, Hammock BD, Zheng H. An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer&#x2019;s disease. Sci Transl Med. 2020;12(573):eabb1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784555</ArticleId><ArticleId IdType="pubmed">33298560</ArticleId></ArticleIdList></Reference><Reference><Citation>Svoboda DS, Barrasa MI, Shu J, Rietjens R, Zhang S, Mitalipova M, Berube P, Fu D, Shultz LD, Bell GW, et al. Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain. Proc Natl Acad Sci U S A. 2019;116:25293&#x2013;303. doi:10.1073/pnas.1913541116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1913541116</ArticleId><ArticleId IdType="pmc">PMC6911218</ArticleId><ArticleId IdType="pubmed">31772018</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya H, Shen MJ, Ichikawa DM, Sedlock AB, Choi Y, Johnson KR, Kim G, Brown MA, Elkahloun AG, Maric D, et al. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat Neurosci. 2017;20:753&#x2013;59. doi:10.1038/nn.4534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4534</ArticleId><ArticleId IdType="pmc">PMC5404968</ArticleId><ArticleId IdType="pubmed">28253233</ArticleId></ArticleIdList></Reference><Reference><Citation>Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6(4):225&#x2013;48. doi:10.15171/bi.2016.30. Epub 2016 Dec 5. PMID: 28265539; PMCID: PMC5326671.</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/bi.2016.30</ArticleId><ArticleId IdType="pmc">PMC5326671</ArticleId><ArticleId IdType="pubmed">28265539</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Siokas V, Pantazi E, Dardioti M, Rikos D, Xiromerisiou G, Markou A, Papadimitriou D, Speletas M, Hadjigeorgiou GM. A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. Neurobiol Aging. 2017;53:194.e13&#x2013;.e22. doi:10.1016/j.neurobiolaging.2017.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.01.015</ArticleId><ArticleId IdType="pubmed">28214109</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605&#x2013;09. doi:10.1038/s41586-018-0615-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0615-z</ArticleId><ArticleId IdType="pmc">PMC6296374</ArticleId><ArticleId IdType="pubmed">30333625</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Hammond SA, Oberst M, Wilkinson RW. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J ImmunoTherapy of Cancer. 2014;2:29. doi:10.1186/s40425-014-0029-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-014-0029-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Translational Med. 2019;7:105. doi:10.21037/atm.2019.01.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2019.01.42</ArticleId><ArticleId IdType="pmc">PMC6462666</ArticleId><ArticleId IdType="pubmed">31019955</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med. 2003;198:669&#x2013;75. doi:10.1084/jem.20030027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20030027</ArticleId><ArticleId IdType="pmc">PMC2194176</ArticleId><ArticleId IdType="pubmed">12925681</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fc&#x3b3; receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14:94&#x2013;108. doi:10.1038/nri3582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3582</ArticleId><ArticleId IdType="pubmed">24445665</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda A, Kurosaki M, Ono M, Takai T, Kurosaki T. Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med. 1998;187:1355&#x2013;60. doi:10.1084/jem.187.8.1355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.187.8.1355</ArticleId><ArticleId IdType="pmc">PMC2212224</ArticleId><ArticleId IdType="pubmed">9547347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskis J, Fink H, Nyberg L, Thyr J, Li J-Y, Enejder A. Plaque-associated lipids in Alzheimer&#x2019;s diseased brain tissue visualized by nonlinear microscopy. Sci Rep. 2015;5:13489. doi:10.1038/srep13489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13489</ArticleId><ArticleId IdType="pmc">PMC4550829</ArticleId><ArticleId IdType="pubmed">26311128</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22:191&#x2013;204. doi:10.1038/s41593-018-0296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao CR, Rak M, Lund J, Unger M, Platt E, Albensi BC, Hirschmugl CJ, Gough KM. Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer&#x2019;s disease brain. Analyst. 2013;138:3991&#x2013;97. doi:10.1039/c3an00295k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c3an00295k</ArticleId><ArticleId IdType="pubmed">23586070</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer&#x2019;s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163&#x2013;66. doi:10.1016/0006-8993(91)91092-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)91092-F</ArticleId><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong F, Ge W, Ma C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dementia. 2019;15:429&#x2013;40. doi:10.1016/j.jalz.2018.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.10.006</ArticleId><ArticleId IdType="pubmed">30502339</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D&#x2019;Hooge R, De Strooper B, et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 2008;27:224&#x2013;33. doi:10.1038/sj.emboj.7601953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601953</ArticleId><ArticleId IdType="pmc">PMC2206134</ArticleId><ArticleId IdType="pubmed">18059472</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci Transl Med. 2011;3:89ra57. doi:10.1126/scitranslmed.3002156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002156</ArticleId><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;18. doi:10.1038/nrneurol.2012.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.263</ArticleId><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, Bu G. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96:1024&#x2013;32.e3. doi:10.1016/j.neuron.2017.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.11.013</ArticleId><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat Commun. 2019;10:3758. doi:10.1038/s41467-019-11674-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11674-z</ArticleId><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117&#x2013;29. doi:10.1016/j.ccell.2015.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2015.12.008</ArticleId><ArticleId IdType="pubmed">26766593</ArticleId></ArticleIdList></Reference><Reference><Citation>Oganesyan V, Peng L, Bee JS, Li J, Perry SR, Comer F, Xu L, Cook K, Senthil K, Clarke L, et al. Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J Biol Chem. 2018;293:8439&#x2013;48. doi:10.1074/jbc.M117.818013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.818013</ArticleId><ArticleId IdType="pmc">PMC5986207</ArticleId><ArticleId IdType="pubmed">29669810</ArticleId></ArticleIdList></Reference><Reference><Citation>Boado RJ, Zhang Y, Zhang Y, C-f X, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008;99:475&#x2013;84. doi:10.1002/bit.21602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.21602</ArticleId><ArticleId IdType="pubmed">17680664</ArticleId></ArticleIdList></Reference><Reference><Citation>Boado RJ, Pardridge WM. Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm. 2017;14:1271&#x2013;77. doi:10.1021/acs.molpharmaceut.6b01166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.6b01166</ArticleId><ArticleId IdType="pubmed">28279069</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliani R, Giugliani L, de Oliveira Poswar F, Donis KC, Corte AD, Schmidt M, Boado RJ, Nestrasil I, Nguyen C, Chen S, et al. Neurocognitive and somatic stabilization in pediatric patients with severe mucopolysaccharidosis type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial. Orphanet J Rare Dis. 2018;13:110. doi:10.1186/s13023-018-0849-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-018-0849-8</ArticleId><ArticleId IdType="pmc">PMC6034233</ArticleId><ArticleId IdType="pubmed">29976218</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM, Boado RJ, Giugliani R, Schmidt M. Plasma pharmacokinetics of valanafusp alpha, a human insulin receptor antibody-iduronidase fusion protein, in patients with mucopolysaccharidosis type I. BioDrugs. 2018;32:169&#x2013;76. doi:10.1007/s40259-018-0264-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-018-0264-7</ArticleId><ArticleId IdType="pubmed">29442294</ArticleId></ArticleIdList></Reference><Reference><Citation>Boado RJ, Lu JZ, Hui EK, Pardridge WM. IgG-single chain Fv fusion protein therapeutic for Alzheimer&#x2019;s disease: expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng. 2010;105:627&#x2013;35. doi:10.1002/bit.22576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.22576</ArticleId><ArticleId IdType="pmc">PMC2838425</ArticleId><ArticleId IdType="pubmed">19816967</ArticleId></ArticleIdList></Reference><Reference><Citation>Boado RJ, Zhang Y, Zhang Y, Xia C-F, Pardridge WM. Fusion antibody for Alzheimer&#x2019;s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem. 2007;18:447&#x2013;55. doi:10.1021/bc060349x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bc060349x</ArticleId><ArticleId IdType="pmc">PMC2596591</ArticleId><ArticleId IdType="pubmed">17315944</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T, Simon MJ, Rana A, Cherf GM, Srivastava A, Davis SS, Low RLY, Chiu C-L, Fang M, Huang F, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184:4651&#x2013;68.e25. doi:10.1016/j.cell.2021.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.08.002</ArticleId><ArticleId IdType="pmc">PMC8489356</ArticleId><ArticleId IdType="pubmed">34450028</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, et al. The adaptive immune system restrains Alzheimer&#x2019;s disease pathogenesis by modulating microglial function. Proc National Academy Sci. 2016;113:E1316&#x2013;E25. doi:10.1073/pnas.1525466113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525466113</ArticleId><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="pubmed">26884167</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Olschowka JA, O&#x2019;Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98. doi:10.1186/1742-2094-11-98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-98</ArticleId><ArticleId IdType="pmc">PMC4060849</ArticleId><ArticleId IdType="pubmed">24889886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987&#x2013;91. doi:10.1038/nn.4338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4338</ArticleId><ArticleId IdType="pubmed">27459405</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Zhu Y, Schultz RD, Li N, He Z, Zhang Z, Caron A, Zhu Q, Sun K, Xiong W, et al. Partial leptin reduction as an insulin sensitization and weight loss strategy. Cell Metab. 2019;30:706&#x2013;19.e6. doi:10.1016/j.cmet.2019.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.08.005</ArticleId><ArticleId IdType="pmc">PMC6774814</ArticleId><ArticleId IdType="pubmed">31495688</ArticleId></ArticleIdList></Reference><Reference><Citation>Shihan MH, Novo SG, Le Marchand SJ, Wang Y, Duncan MK. A simple method for quantitating confocal fluorescent images. Biochemistry Biophysics Rep. 2021;25:100916. doi:10.1016/j.bbrep.2021.100916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2021.100916</ArticleId><ArticleId IdType="pmc">PMC7856428</ArticleId><ArticleId IdType="pubmed">33553685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Wang Z, Wang D, Wang Z, Martens YA, Wu L, Xu Y, Wang K, Li J, Huang R, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegener. 2018;13:15. doi:10.1186/s13024-018-0247-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0247-7</ArticleId><ArticleId IdType="pmc">PMC5870375</ArticleId><ArticleId IdType="pubmed">29587871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-M, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018;128:5647&#x2013;62. doi:10.1172/JCI97570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI97570</ArticleId><ArticleId IdType="pmc">PMC6264729</ArticleId><ArticleId IdType="pubmed">30352428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubin E, Verghese PB, van Nuland N, Broersen K. Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Lett. 2019;593:1144&#x2013;53. doi:10.1002/1873-3468.13428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.13428</ArticleId><ArticleId IdType="pmc">PMC6617784</ArticleId><ArticleId IdType="pubmed">31058310</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CS, Ase AR, Kinsara A, Rao VT, Michell-Robinson M, Leong SY, Butovsky O, Ludwin SK, S&#xe9;gu&#xe9;la P, Bar-Or A, et al. P2Y12 expression and function in alternatively activated human microglia. Neurology Neuroimmunol Neuroinflammation. 2015;2:e80. doi:10.1212/NXI.0000000000000080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000080</ArticleId><ArticleId IdType="pmc">PMC4370387</ArticleId><ArticleId IdType="pubmed">25821842</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35953717</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Plasma p-tau231 and p-tau217 as state markers of amyloid-&#x3b2; pathology in preclinical Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1797</StartPage><EndPage>1801</EndPage><MedlinePgn>1797-1801</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-01925-w</ELocationID><Abstract><AbstractText>Blood biomarkers indicating elevated amyloid-&#x3b2; (A&#x3b2;) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient A&#x3b2; pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and A&#x3b2;42/40) were significantly changed in preclinical Alzheimer's disease. However, plasma p-tau231 reached abnormal levels with the lowest A&#x3b2; burden. Plasma p-tau231 and p-tau217 had the strongest association with A&#x3b2; positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in A&#x3b2; PET uptake in individuals without overt A&#x3b2; pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral A&#x3b2; changes, before overt A&#x3b2; plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer's disease clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mil&#xe0;-Alom&#xe0;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology &amp; Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health &amp; Biomedical Research Unit for Dementia at South London &amp; Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shekari</LastName><ForeName>Mahnaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvad&#xf3;</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-Romero</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6378-6763</Identifier><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montoliu-Gaya</LastName><ForeName>Laia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7684-6318</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedet</LastName><ForeName>Andrea L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0003-1422-4358</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantero-Rodriguez</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7426-678X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanmechelen</LastName><ForeName>Eugeen</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9466-5366</Identifier><AffiliationInfo><Affiliation>ADx NeuroSciences NV, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Theresa A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Escalante</LastName><ForeName>Armand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Benavides</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minguillon</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauria</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-2192-1699</Identifier><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gispert</LastName><ForeName>Juan Domingo</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Bioingenier&#xed;a, Biomateriales y Nanomedicina, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2993-569X</Identifier><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. msuarez@barcelonabeta.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. msuarez@barcelonabeta.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain. msuarez@barcelonabeta.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servei de Neurologia, Hospital del Mar, Barcelona, Spain. msuarez@barcelonabeta.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden. kaj.blennow@neuro.gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden. kaj.blennow@neuro.gu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG068398</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2022 Sep;28(9):1965. doi: 10.1038/s41591-022-02037-1.</RefSource><PMID Version="1">36100683</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>E.V. is a co-founder of ADx NeuroSciences. T.A.D. is an employee and shareholder of Eli Lilly and Company. J.L.M. is currently a full-time employee of Lundbeck and has previously served as a consultant or on advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare and ProMIS Neurosciences. J.L.D. has served as a consultant for Genotix Biotechnologies Inc., Gates Ventures, Karuna Therapeutics, AlzPath Inc. and Cognito Therapeutics, Inc. J.L.D. received research support from ADx Neurosciences, Roche Diagnostics and Eli Lilly and Company in the past 2&#x2009;years. H.Z. has served on scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS). J.D.G. has received speaker&#x2019;s fees from Philips and Biogen and research support from GE Healthcare, Roche and Roche Diagnostics. M.S.C. has served as a consultant and on advisory boards for Roche Diagnostics International Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U. and Roche Farma, S.A. K.B. has served as a consultant, on advisory boards or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Roche Diagnostics and Siemens Healthineers, and is a co-founder of BBS in Gothenburg. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>11</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35953717</ArticleId><ArticleId IdType="pmc">PMC9499867</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01925-w</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-01925-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palmqvist S, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772. doi: 10.1001/jama.2020.12134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer&#x2019;s disease pathology. Acta Neuropathol. 2021;141:709&#x2013;724. doi: 10.1007/s00401-021-02275-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02275-6</ArticleId><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2013;433. doi: 10.1016/S1474-4422(20)30071-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero Rodriguez J, et al. Plasma p-tau181 accurately predicts Alzheimer&#x2019;s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140:267&#x2013;278. doi: 10.1007/s00401-020-02195-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02195-x</ArticleId><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989&#x2013;997. doi: 10.1016/j.jalz.2018.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, et al. Plasma GFAP is an early marker of amyloid-&#x3b2; but not tau pathology in Alzheimer&#x2019;s disease. Brain. 2021;144:3505&#x2013;3516. doi: 10.1093/brain/awab223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab223</ArticleId><ArticleId IdType="pmc">PMC8677538</ArticleId><ArticleId IdType="pubmed">34259835</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat. Med. 2020;26:379&#x2013;386. doi: 10.1038/s41591-020-0755-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer&#x2019;s continuum when only subtle changes in A&#x3b2; pathology are detected. EMBO Mol. Med. 2020;12:e12921. doi: 10.15252/emmm.202012921.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202012921</ArticleId><ArticleId IdType="pmc">PMC7721364</ArticleId><ArticleId IdType="pubmed">33169916</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault, J. et al. Association of plasma P-tau181 with memory decline in non-demented adults. Brain Commun. 3, fcab136 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249102</ArticleId><ArticleId IdType="pubmed">34222875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer&#x2019;s disease. Alzheimers Dement. 2022;18:1141&#x2013;1154. doi: 10.1002/alz.12447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12447</ArticleId><ArticleId IdType="pubmed">34494715</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471. doi: 10.1001/jamaneurol.2021.3671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3671</ArticleId><ArticleId IdType="pmc">PMC8524356</ArticleId><ArticleId IdType="pubmed">34661615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 2021;12:3400. doi: 10.1038/s41467-021-23620-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23620-z</ArticleId><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer&#x2019;s disease. eBioMedicine. 2022;76:103836. doi: 10.1016/j.ebiom.2022.103836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103836</ArticleId><ArticleId IdType="pmc">PMC8850760</ArticleId><ArticleId IdType="pubmed">35158308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil&#xe0;&#x2010;Alom&#xe0; M, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer&#x2019;s continuum. Alzheimers Dement. 2020;16:1358&#x2013;1371. doi: 10.1002/alz.12131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12131</ArticleId><ArticleId IdType="pmc">PMC7586814</ArticleId><ArticleId IdType="pubmed">32573951</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, et al. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer&#x2019;s disease. Alzheimers Dement. (N. Y.) 2016;2:82&#x2013;92. doi: 10.1016/j.trci.2016.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2016.02.003</ArticleId><ArticleId IdType="pmc">PMC5644283</ArticleId><ArticleId IdType="pubmed">29067295</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer&#x2019;s disease. Lancet Neurol. 2003;2:605&#x2013;613. doi: 10.1016/S1474-4422(03)00530-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(03)00530-1</ArticleId><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvad&#xf3; G, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res. Ther. 2019;11:27. doi: 10.1186/s13195-019-0478-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0478-z</ArticleId><ArticleId IdType="pmc">PMC6429814</ArticleId><ArticleId IdType="pubmed">30902090</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer&#x2019;s disease neuropathology. Alzheimers Dement. 2019;15:205&#x2013;216. doi: 10.1016/j.jalz.2018.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.09.001</ArticleId><ArticleId IdType="pmc">PMC6368897</ArticleId><ArticleId IdType="pubmed">30347188</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil&#xe0;-Alom&#xe0; M, et al. Cognitively unimpaired individuals with a low burden of A&#x3b2; pathology have a distinct CSF biomarker profile. Alzheimers Res. Ther. 2021;13:134. doi: 10.1186/s13195-021-00863-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00863-y</ArticleId><ArticleId IdType="pmc">PMC8314554</ArticleId><ArticleId IdType="pubmed">34315519</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain. 2016;139:1226&#x2013;1236. doi: 10.1093/brain/aww015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww015</ArticleId><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullich, S. et al. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res. Ther.13, 67 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005243</ArticleId><ArticleId IdType="pubmed">33773598</ArticleId></ArticleIdList></Reference><Reference><Citation>Amadoru S, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2020;12:22. doi: 10.1186/s13195-020-00587-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00587-5</ArticleId><ArticleId IdType="pmc">PMC7057642</ArticleId><ArticleId IdType="pubmed">32131891</ArticleId></ArticleIdList></Reference><Reference><Citation>Pemberton HG, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur. J. Nucl. Med. Mol. Imaging. 2022;49:3508&#x2013;3528. doi: 10.1007/s00259-022-05784-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05784-y</ArticleId><ArticleId IdType="pmc">PMC9308604</ArticleId><ArticleId IdType="pubmed">35389071</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin. Biochem. 2014;47:288&#x2013;292. doi: 10.1016/j.clinbiochem.2013.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2013.12.024</ArticleId><ArticleId IdType="pubmed">24389077</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739&#x2013;752. doi: 10.1016/S1474-4422(21)00214-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00214-3</ArticleId><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1&#x2013;15. doi: 10.1016/j.jalz.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961&#x2013;970. doi: 10.1001/jamaneurol.2014.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer&#x2019;s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. (N. Y.) 2017;3:668&#x2013;677. doi: 10.1016/j.trci.2017.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.10.004</ArticleId><ArticleId IdType="pmc">PMC5726754</ArticleId><ArticleId IdType="pubmed">29264389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonaitis EM, et al. Measuring longitudinal cognition: Individual tests versus composites. Alzheimers Dement. (Amst) 2019;11:74&#x2013;84. doi: 10.1016/j.dadm.2018.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2018.11.006</ArticleId><ArticleId IdType="pmc">PMC6816509</ArticleId><ArticleId IdType="pubmed">31673596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer&#x2019;s disease: Introducing the Z-scores of zttention, verbal fluency, and episodic memory for nondemented older adults composite score. Alzheimers Dement. (Amst.) 2016;2:19&#x2013;26. doi: 10.1016/j.dadm.2015.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2015.11.003</ArticleId><ArticleId IdType="pmc">PMC4879646</ArticleId><ArticleId IdType="pubmed">27239532</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Yoav, Hochberg Y. Controlling the false discovery rate&#x2014;a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 1995;57:289&#x2013;300.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35985329</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>Human tau mutations in cerebral organoids induce a progressive dyshomeostasis of cholesterol.</ArticleTitle><Pagination><StartPage>2127</StartPage><EndPage>2140</EndPage><MedlinePgn>2127-2140</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2022.07.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(22)00371-X</ELocationID><Abstract><AbstractText>Mutations in the MAPT gene that encodes tau lead to frontotemporal dementia (FTD) with pathology evident in both cerebral neurons and glia. Human cerebral organoids (hCOs) from individuals harboring pathogenic tau mutations can reveal the earliest downstream effects on molecular pathways within a developmental context, generating interacting neurons and glia. We found that in hCOs carrying the V337M and R406W tau mutations, the cholesterol biosynthesis pathway in astrocytes was the top upregulated gene set compared with isogenic controls by single-cell RNA sequencing (scRNA-seq). The 15 upregulated genes included HMGCR, ACAT2, STARD4, LDLR, and SREBF2. This result was confirmed in a homozygous R406W mutant cell line by immunostaining and sterol measurements. Cholesterol abundance in the brain is tightly regulated by efflux and cholesterol biosynthetic enzyme levels in astrocytes, and dysregulation can cause aberrant phosphorylation of tau. Our findings suggest that cholesterol dyshomeostasis is an early event in the etiology of neurodegeneration caused by tau mutations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glasauer</LastName><ForeName>Stella M K</ForeName><Initials>SMK</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goderie</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Jennifer N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Elmer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audouard</LastName><ForeName>Morgane</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertucci</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joy</LastName><ForeName>Shona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rommelfanger</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keane-Rivera</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lotz</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borden</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, Rensselaer, NY 12144, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armando</LastName><ForeName>Aaron M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quehenberger</LastName><ForeName>Oswald</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temple</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Institute, Rensselaer, NY 12144, USA. Electronic address: sallytemple@neuralsci.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA. Electronic address: kosik@lifesci.ucsb.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097277</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG064116</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD010786</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG064116</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056293</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="N">Organoids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MAPT mutation</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">brain organoid</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">disease model</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">single-cell RNA sequencing</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35985329</ArticleId><ArticleId IdType="pmc">PMC9481908</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2022.07.011</ArticleId><ArticleId IdType="pii">S2213-6711(22)00371-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amini-Bavil-Olyaee S., Choi Y.J., Lee J.H., Shi M., Huang I.C., Farzan M., Jung J.U. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe. 2013;13:452&#x2013;464. doi: 10.1016/j.chom.2013.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2013.03.006</ArticleId><ArticleId IdType="pmc">PMC3646482</ArticleId><ArticleId IdType="pubmed">23601107</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas F., Garcia-Ruiz C., Fernandez-Checa J.C. Intracellular cholesterol trafficking and impact in neurodegeneration. Front. Mol. Neurosci. 2017;10:382. doi: 10.3389/fnmol.2017.00382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00382</ArticleId><ArticleId IdType="pmc">PMC5698305</ArticleId><ArticleId IdType="pubmed">29204109</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., Stieler J.T., Holzer M. Tau and tauopathies. Brain Res. Bull. 2016;126:238&#x2013;292. doi: 10.1016/j.brainresbull.2016.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.08.018</ArticleId><ArticleId IdType="pubmed">27615390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ates G., Goldberg J., Currais A., Maher P. CMS121, a fatty acid synthase inhibitor, protects against excess lipid peroxidation and inflammation and alleviates cognitive loss in a transgenic mouse model of Alzheimer&#x2019;s disease. Redox Biol. 2020;36:101648. doi: 10.1016/j.redox.2020.101648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101648</ArticleId><ArticleId IdType="pmc">PMC7394765</ArticleId><ArticleId IdType="pubmed">32863221</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer I.A., Schmidt M.L., Lee V.M., Curry B., Suzuki K., Shin R.W., Pentchev P.G., Carstea E.D., Trojanowski J.Q. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer&#x2019;s disease. Acta Neuropathol. 1995;90:547&#x2013;551. doi: 10.1007/BF00318566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00318566</ArticleId><ArticleId IdType="pubmed">8615074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I. Cerebrotendinous xanthomatosis. Curr. Opin. Lipidol. 2013;24:283&#x2013;287. doi: 10.1097/MOL.0b013e328362df13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0b013e328362df13</ArticleId><ArticleId IdType="pubmed">23759795</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles K.R., Silva M.C., Whitney K., Bertucci T., Berlind J.E., Lai J.D., Garza J.C., Boles N.C., Mahali S., Strang K.H., et al. ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids. Cell. 2021;184:4547&#x2013;4563.e17. doi: 10.1016/j.cell.2021.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.07.003</ArticleId><ArticleId IdType="pmc">PMC8635409</ArticleId><ArticleId IdType="pubmed">34314701</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe M., Kril J., Halliday G.M. Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain. 2004;127:2214&#x2013;2220. doi: 10.1093/brain/awh250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh250</ArticleId><ArticleId IdType="pubmed">15282215</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A., Hoffman P., Smibert P., Papalexi E., Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411&#x2013;420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Camp J.G., Badsha F., Florio M., Kanton S., Gerber T., Wilsch-Br&#xe4;uninger M., Lewitus E., Sykes A., Hevers W., Lancaster M., et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc. Natl. Acad. Sci. USA. 2015;112:15672&#x2013;15677. doi: 10.1073/pnas.1520760112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1520760112</ArticleId><ArticleId IdType="pmc">PMC4697386</ArticleId><ArticleId IdType="pubmed">26644564</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspi R., Billington R., Fulcher C.A., Keseler I.M., Kothari A., Krummenacker M., Latendresse M., Midford P.E., Ong Q., Ong W.K., Paley S. The MetaCyc database of metabolic pathways and enzymes. Nucleic. Acids Res. 2018;46:D633&#x2013;D639. doi: 10.1093/nar/gkx935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx935</ArticleId><ArticleId IdType="pmc">PMC5753197</ArticleId><ArticleId IdType="pubmed">29059334</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke B.E., Taha D.M., Tyzack G.E., Patani R. Regionally encoded functional heterogeneity of astrocytes in health and disease: a perspective. Glia. 2021;69:20&#x2013;27. doi: 10.1002/glia.23877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23877</ArticleId><ArticleId IdType="pubmed">32749770</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornish-Bowden A. John Wiley &amp; Sons; 2013. Fundamentals of Enzyme Kinetics.</Citation></Reference><Reference><Citation>De Strooper B., Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;615. doi: 10.1016/j.cell.2015.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G., McDavid A., Yajima M., Deng J., Gersuk V., Shalek A.K., Slichter C.K., Miller H.W., McElrath M.J., Prlic M., et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015;16:278. doi: 10.1186/s13059-015-0844-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Flach K., Hilbrich I., Schiffmann A., G&#xe4;rtner U., Kr&#xfc;ger M., Leonhardt M., Waschipky H., Wick L., Arendt T., Holzer M. Tau oligomers impair artificial membrane integrity and cellular viability. J.&#xa0;Biol. Chem. 2012;287:43223&#x2013;43233. doi: 10.1074/jbc.M112.396176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.396176</ArticleId><ArticleId IdType="pmc">PMC3527910</ArticleId><ArticleId IdType="pubmed">23129775</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz&#xe9;n O., Gan L.M., Bj&#xf6;rkegren J. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database. 2019:baz046. doi: 10.1093/database/baz046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/baz046</ArticleId><ArticleId IdType="pmc">PMC6450036</ArticleId><ArticleId IdType="pubmed">30951143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H., Hardy J., Duff K.E. Selective vulnerability in neurodegenerative diseases. Nat. Neurosci. 2018;21:1350&#x2013;1358. doi: 10.1038/s41593-018-0221-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0221-2</ArticleId><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Giandomenico S.L., Mierau S.B., Gibbons G.M., Wenger L.M.D., Masullo L., Sit T., Sutcliffe M., Boulanger J., Tripodi M., Derivery E., et al. Cerebral organoids at the air-liquid interface generate diverse nerve tracts with functional output. Nat. Neurosci. 2019;22:669&#x2013;679. doi: 10.1038/s41593-019-0350-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0350-2</ArticleId><ArticleId IdType="pmc">PMC6436729</ArticleId><ArticleId IdType="pubmed">30886407</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez C., Armijo E., Bravo-Alegria J., Becerra-Calixto A., Mays C.E., Soto C. Modeling amyloid beta and tau pathology in human cerebral organoids. Mol. Psychiatry. 2018;23:2363&#x2013;2374. doi: 10.1038/s41380-018-0229-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0229-8</ArticleId><ArticleId IdType="pmc">PMC6594704</ArticleId><ArticleId IdType="pubmed">30171212</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal M.S., Vlassenko A.G., Blazey T.M., Su Y., Couture L.E., Durbin T.J., Bateman R.J., Benzinger T.L.S., Morris J.C., Raichle M.E. Loss of brain aerobic glycolysis in normal human aging. Cell Metab. 2017;26(2):353&#x2013;360. doi: 10.1016/j.cmet.2017.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.07.010</ArticleId><ArticleId IdType="pmc">PMC5573225</ArticleId><ArticleId IdType="pubmed">28768174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory J.A., Hoelzli E., Abdelaal R., Braine C., Cuevas M., Halpern M., Barretto N., Schrode N., Akbalik G., Kang K., et al. Cell type-specific in&#xa0;vitro gene expression profiling of stem cell-derived neural models. Cells. 2020;9:1406. doi: 10.3390/cells9061406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9061406</ArticleId><ArticleId IdType="pmc">PMC7349756</ArticleId><ArticleId IdType="pubmed">32516938</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A., Chew G., Ouyang J.F., Sun G., Choo X.Y., McLean C., Simmons R.K., Buckberry S., Vargas-Landin D.B., Poppe D., et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 2019;22:2087&#x2013;2097. doi: 10.1038/s41593-019-0539-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan K.A., Weigel M.K., Prakash P., Wijewardhane P.R., Hasel P., Rufen-Blanchette U., M&#xfc;nch A.E., Blum J.A., Fine J., Neal M.C., et al. Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature. 2021;599:102&#x2013;107. doi: 10.1038/s41586-021-03960-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03960-y</ArticleId><ArticleId IdType="pubmed">34616039</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N., McCabe C., Medina S., Varshavsky M., Kitsberg D., Dvir-Szternfeld R., Green G., Dionne D., Nguyen L., Marshall J.L., et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 2020;23:701&#x2013;706. doi: 10.1038/s41593-020-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0624-8</ArticleId><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallmann A.L., Ara&#xfa;zo-Bravo M.J., Mavrommatis L., Ehrlich M., R&#xf6;pke A., Brockhaus J., Missler M., Sterneckert J., Sch&#xf6;ler H.R., Kuhlmann T., et al. Astrocyte pathology in a human neural&#xa0;stem cell model of frontotemporal dementia caused by mutant&#xa0;TAU protein. Sci. Rep. 2017;7:42991. doi: 10.1038/srep42991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42991</ArticleId><ArticleId IdType="pmc">PMC5335603</ArticleId><ArticleId IdType="pubmed">28256506</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammouda S., Ghzaiel I., Khamlaoui W., Hammami S., Mhenni S.Y., Samet S., Hammami M., Zarrouk A. Genetic variants in FADS1 and ELOVL2 increase level of arachidonic acid and the risk of Alzhei&#x2019;er's disease in the Tunisian population. Prostaglandins Leukot. Essent. Fatty Acids. 2020;160:102159. doi: 10.1016/j.plefa.2020.102159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2020.102159</ArticleId><ArticleId IdType="pubmed">32682282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez I., Luna G., Rauch J.N., Reis S.A., Giroux M., Karch C.M., Boctor D., Sibih Y.E., Storm N.J., Diaz A., et al. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. Sci. Transl. Med. 2019;11:eaat3005. doi: 10.1126/scitranslmed.aat3005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aat3005</ArticleId><ArticleId IdType="pmc">PMC7961212</ArticleId><ArticleId IdType="pubmed">30918111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C., Saxena S. ER stress and the unfolded protein response in neurodegeneration. Nat. Rev. Neurol. 2017;13:477&#x2013;491. doi: 10.1038/nrneurol.2017.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.99</ArticleId><ArticleId IdType="pubmed">28731040</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M., Wang J., Torre E., Dueck H., Shaffer S., Bonasio R., Murray J.I., Raj A., Li M., Zhang N.R. SAVER: gene expression recovery for single-cell RNA sequencing. Nat. Methods. 2018;15:539&#x2013;542. doi: 10.1038/s41592-018-0033-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-018-0033-z</ArticleId><ArticleId IdType="pmc">PMC6030502</ArticleId><ArticleId IdType="pubmed">29941873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibi D., Nagai T., Nakajima A., Mizoguchi H., Kawase T., Tsuboi D., Kano S.I., Sato Y., Hayakawa M., Lange U.C., et al. Astroglial&#xa0;IFITM3 mediates neuronal impairments following neonatal immune challenge in mice. Glia. 2013;61:679&#x2013;693. doi: 10.1002/glia.22461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22461</ArticleId><ArticleId IdType="pmc">PMC7165731</ArticleId><ArticleId IdType="pubmed">23382131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Wen N., Li Z., Dube U., Del Aguila J., Budde J., Martinez R., Hsu S., Fernandez M.V., Cairns N.J., et al. Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP. Transl. Psychiatry. 2018;8:265. doi: 10.1038/s41398-018-0319-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-018-0319-z</ArticleId><ArticleId IdType="pmc">PMC6293323</ArticleId><ArticleId IdType="pubmed">30546007</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Kao A.W., Karydas A., Onanuga K., Martinez R., Argouarch A., Wang C., Huang C., Sohn P.D., Bowles K.R., et al. A comprehensive resource for induced pluripotent stem cells from patients with primary tauopathies. Stem Cell Rep. 2019;13:939&#x2013;955. doi: 10.1016/j.stemcr.2019.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.09.006</ArticleId><ArticleId IdType="pmc">PMC6895712</ArticleId><ArticleId IdType="pubmed">31631020</ArticleId></ArticleIdList></Reference><Reference><Citation>King M.E., Gamblin T.C., Kuret J., Binder L.I. Differential assembly of human tau isoforms in the presence of arachidonic acid. J.&#xa0;Neurochem. 2000;74:1749&#x2013;1757. doi: 10.1046/j.1471-4159.2000.0741749.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0741749.x</ArticleId><ArticleId IdType="pubmed">10737634</ArticleId></ArticleIdList></Reference><Reference><Citation>Korinek M., Vyklicky V., Borovska J., Lichnerova K., Kaniakova M., Krausova B., Krusek J., Balik A., Smejkalova T., Horak M., Vyklicky L. Cholesterol modulates open probability and desensitization of NMDA receptors. J.&#xa0;Physiol. 2015;593:2279&#x2013;2293. doi: 10.1113/jphysiol.2014.288209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2014.288209</ArticleId><ArticleId IdType="pmc">PMC4457192</ArticleId><ArticleId IdType="pubmed">25651798</ArticleId></ArticleIdList></Reference><Reference><Citation>Korinek M., Gonzalez-Gonzalez I.M., Smejkalova T., Hajdukovic D., Skrenkova K., Krusek J., Horak M., Vyklicky L. Cholesterol modulates presynaptic and postsynaptic properties of excitatory synaptic transmission. Sci. Rep. 2020;10:12651. doi: 10.1038/s41598-020-69454-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69454-5</ArticleId><ArticleId IdType="pmc">PMC7387334</ArticleId><ArticleId IdType="pubmed">32724221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G.G. Astroglia and tau: new perspectives. Front. Aging Neurosci. 2020;12:96. doi: 10.3389/fnagi.2020.00096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00096</ArticleId><ArticleId IdType="pmc">PMC7160822</ArticleId><ArticleId IdType="pubmed">32327993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P., Knoblich J.A. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373&#x2013;379. doi: 10.1038/nature12517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12517</ArticleId><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., Velazquez Sanchez C., Chen M., Morin P.J., Wells J.M., Hanlon E.B., Xia W. Three dimensional human neuro-spheroid model of Alzhei&#x2019;er's disease based on differentiated induced pluripotent stem cells. PLoS One. 2016;11:e0163072. doi: 10.1371/journal.pone.0163072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0163072</ArticleId><ArticleId IdType="pmc">PMC5042502</ArticleId><ArticleId IdType="pubmed">27684569</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., M&#xfc;nch A.E., Chung W.S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.T., Seo J., Gao F., Feldman H.M., Wen H.L., Penney J., Cam H.P., Gjoneska E., Raja W.K., Cheng J., et al. APOE4 causes widespread molecular and cellular Alterations associated with Alzhei&#x2019;er's disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141&#x2013;1154.e7. doi: 10.1016/j.neuron.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J.E., Cobos I., Potter G.B., Rubenstein J.L.R. Dlx1&amp;2 and Mash1 transcription factors control MGE and CGE patterning and differentiation through parallel and overlapping pathways. Cereb. Cortex. 2009;19:i96&#x2013;i106. doi: 10.1093/cercor/bhp045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhp045</ArticleId><ArticleId IdType="pmc">PMC2693539</ArticleId><ArticleId IdType="pubmed">19386638</ArticleId></ArticleIdList></Reference><Reference><Citation>Macosko E.Z., Basu A., Satija R., Nemesh J., Shekhar K., Goldman M., Tirosh I., Bialas A.R., Kamitaki N., Martersteck E.M., et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202&#x2013;1214. doi: 10.1016/j.cell.2015.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.05.002</ArticleId><ArticleId IdType="pmc">PMC4481139</ArticleId><ArticleId IdType="pubmed">26000488</ArticleId></ArticleIdList></Reference><Reference><Citation>Madison B.B. Srebp2: a master regulator of sterol and fatty acid synthesis. J.&#xa0;Lipid Res. 2016;57:333&#x2013;335. doi: 10.1194/jlr.C066712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.C066712</ArticleId><ArticleId IdType="pmc">PMC4766982</ArticleId><ArticleId IdType="pubmed">26798145</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J.Z., Menon M., He L., Abdurrob F., Jiang X., et al. Single-cell transcriptomic analysis of Alzhei&#x2019;er's disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Matias I., Morgado J., Gomes F.C.A. Astrocyte heterogeneity: impact to brain aging and disease. Front. Aging Neurosci. 2019;11:59. doi: 10.3389/fnagi.2019.00059.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00059</ArticleId><ArticleId IdType="pmc">PMC6433753</ArticleId><ArticleId IdType="pubmed">30941031</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaka T., Shimano H., Yahagi N., Kato T., Atsumi A., Yamamoto T., Inoue N., Ishikawa M., Okada S., Ishigaki N., et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat. Med. 2007;13:1193&#x2013;1202. doi: 10.1038/nm1662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1662</ArticleId><ArticleId IdType="pubmed">17906635</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel L., Chiang M.S.R., Higashimori H., Shoneye T., Iyer L.K., Yelick J., Tai A., Yang Y. Molecular and functional properties of regional astrocytes in the adult brain. J.&#xa0;Neurosci. 2017;37:8706&#x2013;8717. doi: 10.1523/JNEUROSCI.3956-16.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3956-16.2017</ArticleId><ArticleId IdType="pmc">PMC5588463</ArticleId><ArticleId IdType="pubmed">28821665</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A., Rinne J.O., Kadir A., L&#xe5;ngstr&#xf6;m B. The use of PET in Alzheimer disease. Nat. Rev. Neurol. 2010;6:78&#x2013;87. doi: 10.1038/nrneurol.2009.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2009.217</ArticleId><ArticleId IdType="pubmed">20139997</ArticleId></ArticleIdList></Reference><Reference><Citation>Pa&#x15f;ca A.M., Sloan S.A., Clarke L.E., Tian Y., Makinson C.D., Huber N., Kim C.H., Park J.Y., O'Rourke N.A., Nguyen K.D., et al. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat. Methods. 2015;12:671&#x2013;678. doi: 10.1038/nmeth.3415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3415</ArticleId><ArticleId IdType="pmc">PMC4489980</ArticleId><ArticleId IdType="pubmed">26005811</ArticleId></ArticleIdList></Reference><Reference><Citation>Polioudakis D., de la Torre-Ubieta L., Langerman J., Elkins A.G., Shi X., Stein J.L., Vuong C.K., Nichterwitz S., Gevorgian M., Opland C.K., et al. A single-cell transcriptomic atlas of human neocortical development during mid-gestation. Neuron. 2019;103:785&#x2013;801.e8. doi: 10.1016/j.neuron.2019.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.06.011</ArticleId><ArticleId IdType="pmc">PMC6831089</ArticleId><ArticleId IdType="pubmed">31303374</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrato G., Nguyen T., Macosko E.Z., Sherwood J.L., Min Yang S., Berger D.R., Maria N., Scholvin J., Goldman M., Kinney J.P., et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature. 2017;545:48&#x2013;53. doi: 10.1038/nature22047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22047</ArticleId><ArticleId IdType="pmc">PMC5659341</ArticleId><ArticleId IdType="pubmed">28445462</ArticleId></ArticleIdList></Reference><Reference><Citation>Quehenberger O., Armando A.M., Brown A.H., Milne S.B., Myers D.S., Merrill A.H., Bandyopadhyay S., Jones K.N., Kelly S., Shaner R.L., et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J.&#xa0;Lipid Res. 2010;51:3299&#x2013;3305. doi: 10.1194/jlr.M009449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M009449</ArticleId><ArticleId IdType="pmc">PMC2952570</ArticleId><ArticleId IdType="pubmed">20671299</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja W.K., Mungenast A.E., Lin Y.T., Ko T., Abdurrob F., Seo J., Tsai L.H. Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzhei&#x2019;er's disease phenotypes. PLoS One. 2016;11:e0161969. doi: 10.1371/journal.pone.0161969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0161969</ArticleId><ArticleId IdType="pmc">PMC5021368</ArticleId><ArticleId IdType="pubmed">27622770</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M., Lancaster M.A., Bian S., Choi H., Ku T., Peer A., Chung K., Knoblich J.A. Self-organized developmental patterning and differentiation in cerebral organoids. EMBO J. 2017;36:1316&#x2013;1329. doi: 10.15252/embj.201694700.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201694700</ArticleId><ArticleId IdType="pmc">PMC5430225</ArticleId><ArticleId IdType="pubmed">28283582</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G., Stumpf S.K. Cholesterol in myelin biogenesis and hypomyelinating disorders. Biochim. Biophys. Acta. 2015;1851:1083&#x2013;1094. doi: 10.1016/j.bbalip.2015.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2015.02.010</ArticleId><ArticleId IdType="pubmed">25724171</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., Rojas J.C., et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527. doi: 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhaye J., Knoblich J.A. Brain organoids: an ensemble of bioassays to investigate human neurodevelopment and disease. Cell Death Differ. 2021;28:52&#x2013;67. doi: 10.1038/s41418-020-0566-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-0566-4</ArticleId><ArticleId IdType="pmc">PMC7853143</ArticleId><ArticleId IdType="pubmed">32483384</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan S.A., Darmanis S., Huber N., Khan T.A., Birey F., Caneda C., Reimer R., Quake S.R., Barres B.A., Pa&#x15f;ca S.P. Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. Neuron. 2017;95:779&#x2013;790.e6. doi: 10.1016/j.neuron.2017.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.035</ArticleId><ArticleId IdType="pmc">PMC5890820</ArticleId><ArticleId IdType="pubmed">28817799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn P.D., Huang C.T.L., Yan R., Fan L., Tracy T.E., Camargo C.M., Montgomery K.M., Arhar T., Mok S.A., Freilich R., et al. Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis. Neuron. 2019;104:458&#x2013;470.e5. doi: 10.1016/j.neuron.2019.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.08.008</ArticleId><ArticleId IdType="pmc">PMC6880876</ArticleId><ArticleId IdType="pubmed">31542321</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T., Butler A., Hoffman P., Hafemeister C., Papalexi E., Mauck W.M., 3rd, Hao Y., Stoeckius M., Smibert P., Satija R. Comprehensive integration of single-cell data. Cell. 2019;177:1888&#x2013;1902.e21. doi: 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K., Parker C.C., Pentchev P.G., Katz D., Ghetti B., D'Agostino A.N., Carstea E.D. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 1995;89:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">7754743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B.L. Glucose, glycolysis, and neurodegenerative diseases. J.&#xa0;Cell. Physiol. 2020;235:7653&#x2013;7662. doi: 10.1002/jcp.29682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29682</ArticleId><ArticleId IdType="pubmed">32239718</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuck B.J., Miller L.V.C., Katsinelos T., Smith A.E., Wilson E.L., Keeling S., Cheng S., Vaysburd M.J., Knox C., Tredgett L., et al. Cholesterol determines the cytosolic entry and seeded aggregation of tau. Cell Rep. 2022;39:110776. doi: 10.1016/j.celrep.2022.110776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110776</ArticleId><ArticleId IdType="pmc">PMC9108550</ArticleId><ArticleId IdType="pubmed">35508140</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kant R., Langness V.F., Herrera C.M., Williams D.A., Fong L.K., Leestemaker Y., Steenvoorden E., Rynearson K.D., Brouwers J.F., Helms J.B., et al. Cholesterol metabolism is a druggable Axis that independently regulates tau and amyloid-&#x3b2; in iPSC-derived Alzhei&#x2019;er's disease neurons. Cell Stem Cell. 2019;24:363&#x2013;375.e9. doi: 10.1016/j.stem.2018.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.12.013</ArticleId><ArticleId IdType="pmc">PMC6414424</ArticleId><ArticleId IdType="pubmed">30686764</ArticleId></ArticleIdList></Reference><Reference><Citation>Velmeshev D., Schirmer L., Jung D., Haeussler M., Perez Y., Mayer S., Bhaduri A., Goyal N., Rowitch D.H., Kriegstein A.R. Single-cell genomics identifies cell type-specific molecular changes in autism. Science. 2019;364:685&#x2013;689. doi: 10.1126/science.aav8130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav8130</ArticleId><ArticleId IdType="pmc">PMC7678724</ArticleId><ArticleId IdType="pubmed">31097668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Zhang H., Wang Y., Zhang M., Zhou Y. Plasma cholesterol in Alzheimer's disease and frontotemporal dementia. Transl. Neurosci. 2020;11:116&#x2013;123. doi: 10.1515/tnsci-2020-0098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/tnsci-2020-0098</ArticleId><ArticleId IdType="pmc">PMC7705987</ArticleId><ArticleId IdType="pubmed">33312717</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson D.M., Binder L.I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In&#xa0;vitro evidence for a common effector of pathogenesis in Alzhei&#x2019;er's disease. Am. J. Pathol. 1997;150:2181&#x2013;2195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858305</ArticleId><ArticleId IdType="pubmed">9176408</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S.J., Elahi L.S., Pa&#x219;ca A.M., Marton R.M., Gordon A., Revah O., Miura Y., Walczak E.M., Holdgate G.M., Fan H.C., et al. Reliability of human cortical organoid generation. Nat. Methods. 2019;16:75&#x2013;78. doi: 10.1038/s41592-018-0255-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-018-0255-0</ArticleId><ArticleId IdType="pmc">PMC6677388</ArticleId><ArticleId IdType="pubmed">30573846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian J.L., Xu L., Foo L.C., Nouri N., Zhou L., Giffard R.G., Barres B.A. Genomic analysis of reactive astrogliosis. J.&#xa0;Neurosci. 2012;32:6391&#x2013;6410. doi: 10.1523/JNEUROSCI.6221-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6221-11.2012</ArticleId><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Lu W., Ren Y., Fu Y., Martens Y.A., Shue F., Davis M.D., Wang X., Chen K., Li F., et al. Apolipoprotein E regulates lipid metabolism and &#x3b1;-synuclein pathology in human iPSC-derived cerebral organoids. Acta Neuropathol. 2021;142:807&#x2013;825. doi: 10.1007/s00401-021-02361-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02361-9</ArticleId><ArticleId IdType="pmc">PMC8500881</ArticleId><ArticleId IdType="pubmed">34453582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36004506</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>19</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Single-molecule imaging reveals Tau trapping at nanometer-sized dynamic hot spots near the plasma membrane that persists after microtubule perturbation and cholesterol depletion.</ArticleTitle><Pagination><StartPage>e111265</StartPage><MedlinePgn>e111265</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e111265</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.2022111265</ELocationID><Abstract><AbstractText>Accumulation of aggregates of the microtubule-binding protein Tau is a pathological hallmark of Alzheimer's disease. While Tau is thought to primarily associate with microtubules, it also interacts with and localizes to the plasma membrane. However, little is known about how Tau behaves and organizes at the plasma membrane of live cells. Using quantitative, single-molecule imaging, we show that Tau exhibits spatial and kinetic heterogeneity near the plasma membrane of live cells, resulting in the formation of nanometer-sized hot spots. The hot spots lasted tens of seconds, much longer than the short dwell time (&#x223c;&#x2009;40&#x2009;ms) of Tau on microtubules. Pharmacological and biochemical disruption of Tau/microtubule interactions did not prevent hot spot formation, suggesting that these are different from the reported Tau condensation on microtubules. Although cholesterol removal has been shown to reduce Tau pathology, its acute depletion did not affect Tau hot spot dynamics. Our study identifies an intrinsic dynamic property of Tau near the plasma membrane that may facilitate the formation of assembly sites for Tau to assume its physiological and pathological functions.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Padmanabhan</LastName><ForeName>Pranesh</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5569-8731</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kneynsberg</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7321-9415</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Esteban</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amor</LastName><ForeName>Rumelo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibarita</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Interdisciplinary Institute for Neuroscience, UMR, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8501-7896</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="Y">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072760" MajorTopicYN="Y">Single Molecule Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">nanodomains</Keyword><Keyword MajorTopicYN="N">single-molecule imaging</Keyword><Keyword MajorTopicYN="N">super-resolution microscopy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36004506</ArticleId><ArticleId IdType="pmc">PMC9531302</ArticleId><ArticleId IdType="doi">10.15252/embj.2022111265</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andronov L, Lutz Y, Vonesch JL, Klaholz BP (2016) SharpViSu: integrated analysis and segmentation of super&#x2010;resolution microscopy data. Bioinformatics 32: 2239&#x2013;2241</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937188</ArticleId><ArticleId IdType="pubmed">27153691</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, P&#xe9;rez M, Avila J (2000) Tau dephosphorylation at tau&#x2010;1 site correlates with its association to cell membrane. Neurochem Res 25: 43&#x2013;50</Citation><ArticleIdList><ArticleId IdType="pubmed">10685603</ArticleId></ArticleIdList></Reference><Reference><Citation>Bademosi AT, Lauwers E, Padmanabhan P, Odierna L, Chai YJ, Papadopulos A, Goodhill GJ, Verstreken P, van Swinderen B, Meunier FA (2017) In vivo single&#x2010;molecule imaging of syntaxin1A reveals polyphosphoinositide&#x2010; and activity&#x2010;dependent trapping in presynaptic nanoclusters. Nat Commun 8: 13660</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5171881</ArticleId><ArticleId IdType="pubmed">28045048</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H (2009) Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 68: 314&#x2013;325</Citation><ArticleIdList><ArticleId IdType="pubmed">19225406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bok E, Leem E, Lee BR, Lee JM, Yoo CJ, Lee EM, Kim J (2021) Role of the lipid membrane and membrane proteins in tau pathology. Front Cell Dev Biol 9: 653815</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119898</ArticleId><ArticleId IdType="pubmed">33996814</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K (2011) Alzheimer's pathogenesis: is there neuron&#x2010;to&#x2010;neuron propagation? Acta Neuropathol 121: 589&#x2013;595</Citation><ArticleIdList><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, Leger J, Lee G (1995) Interaction of tau with the neural plasma membrane mediated by Tau's amino&#x2010;terminal projection domain. J Cell Biol 131: 1327&#x2013;1340</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120645</ArticleId><ArticleId IdType="pubmed">8522593</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, Trushina NI, Bakota L (2020) Much more than a cytoskeletal protein: physiological and pathological functions of the non&#x2010;microtubule binding region of tau. Front Neurol 11: 590059</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604284</ArticleId><ArticleId IdType="pubmed">33193056</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres A, Kosik KS (1990) Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343: 461&#x2013;463</Citation><ArticleIdList><ArticleId IdType="pubmed">2105469</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CW, Shao E, Mucke L (2021) Tau: enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science 371: eabb8255</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118650</ArticleId><ArticleId IdType="pubmed">33632820</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YM, Wang QJ, Hu HS, Yu PC, Zhu J, Drewes G, Piwnica&#x2010;Worms H, Luo ZG (2006) Microtubule affinity&#x2010;regulating kinase 2 functions downstream of the PAR&#x2010;3/PAR&#x2010;6/atypical PKC complex in regulating hippocampal neuronal polarity. Proc Natl Acad Sci USA 103: 8534&#x2013;8539</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482526</ArticleId><ArticleId IdType="pubmed">16717194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho WK, Spille JH, Hecht M, Lee C, Li C, Grube V, Cisse II (2018) Mediator and RNA polymerase II clusters associate in transcription&#x2010;dependent condensates. Science 361: 412&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6543815</ArticleId><ArticleId IdType="pubmed">29930094</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse II, Izeddin I, Causse SZ, Boudarene L, Senecal A, Muresan L, Dugast&#x2010;Darzacq C, Hajj B, Dahan M, Darzacq X (2013) Real&#x2010;time dynamics of RNA polymerase II clustering in live human cells. Science 341: 664&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pubmed">23828889</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft CL, Wade MA, Kurbatskaya K, Mastrandreas P, Hughes MM, Phillips EC, Pooler AM, Perkinton MS, Hanger DP, Noble W (2017) Membrane association and release of wild&#x2010;type and pathological tau from organotypic brain slice cultures. Cell Death Dis 8: e2671</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5386587</ArticleId><ArticleId IdType="pubmed">28300838</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE, Holzbaur EL (2008) Differential regulation of dynein and kinesin motor proteins by tau. Science 319: 1086&#x2013;1089</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>El Beheiry M, Dahan M, Masson JB (2015) InferenceMAP: mapping of single&#x2010;molecule dynamics with Bayesian inference. Nat Methods 12: 594&#x2013;595</Citation><ArticleIdList><ArticleId IdType="pubmed">26125589</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaum&#x2010;Garfinkle S, Ramlall T, Rhoades E (2010) The role of the lipid bilayer in tau aggregation. Biophys J 98: 2722&#x2013;2730</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877329</ArticleId><ArticleId IdType="pubmed">20513417</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans HT, Benetatos J, van Roijen M, Bodea LG, G&#xf6;tz J (2019) Decreased synthesis of ribosomal proteins in tauopathy revealed by non&#x2010;canonical amino acid labelling. EMBO J 38: e101174</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600635</ArticleId><ArticleId IdType="pubmed">31268600</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans HT, Taylor D, Kneynsberg A, Bodea LG, G&#xf6;tz J (2021) Altered ribosomal function and protein synthesis caused by tau. Acta Neuropathol Commun 9: 110</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214309</ArticleId><ArticleId IdType="pubmed">34147135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanni AM, Vander Zanden CM, Majewska PV, Majewski J, Chi EY (2019) Membrane&#x2010;mediated fibrillation and toxicity of the tau hexapeptide PHF6. J Biol Chem 294: 15304&#x2013;15317</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802503</ArticleId><ArticleId IdType="pubmed">31439664</ArticleId></ArticleIdList></Reference><Reference><Citation>Flach K, Hilbrich I, Schiffmann A, G&#xe4;rtner U, Kr&#xfc;ger M, Leonhardt M, Waschipky H, Wick L, Arendt T, Holzer M (2012) Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem 287: 43223&#x2013;43233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527910</ArticleId><ArticleId IdType="pubmed">23129775</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Parajo MF, Cambi A, Torreno&#x2010;Pina JA, Thompson N, Jacobson K (2014) Nanoclustering as a dominant feature of plasma membrane organization. J Cell Sci 127: 4995&#x2013;5005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260763</ArticleId><ArticleId IdType="pubmed">25453114</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier&#x2010;Kemper A, Weissmann C, Golovyashkina N, Sebo&#x2010;Lemke Z, Drewes G, Gerke V, Heinisch JJ, Brandt R (2011) The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2&#x2010;dependent manner. J Cell Biol 192: 647&#x2013;661</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044115</ArticleId><ArticleId IdType="pubmed">21339331</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgieva ER, Xiao S, Borbat PP, Freed JH, Eliezer D (2014) Tau binds to lipid membrane surfaces via short amphipathic helices located in its microtubule&#x2010;binding repeats. Biophys J 107: 1441&#x2013;1452</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4167292</ArticleId><ArticleId IdType="pubmed">25229151</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 9: 4225&#x2013;4230</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552204</ArticleId><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference><Reference><Citation>Gormal RS, Padmanabhan P, Kasula R, Bademosi AT, Coakley S, Giacomotto J, Blum A, Joensuu M, Wallis TP, Lo HP et&#x2009;al (2020) Modular transient nanoclustering of activated &#x3b2;2&#x2010;adrenergic receptors revealed by single&#x2010;molecule tracking of conformation&#x2010;specific nanobodies. Proc Natl Acad Sci USA 117: 30476&#x2013;30487</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720173</ArticleId><ArticleId IdType="pubmed">33214152</ArticleId></ArticleIdList></Reference><Reference><Citation>Gura Sadovsky R, Brielle S, Kaganovich D, England JL (2017) Measurement of rapid protein diffusion in the cytoplasm by photo&#x2010;converted intensity profile expansion. Cell Rep 18: 2795&#x2013;2806</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5368347</ArticleId><ArticleId IdType="pubmed">28297680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyparaki MT, Arab A, Sorokina EM, Santiago&#x2010;Ruiz AN, Bohrer CH, Xiao J, Lakadamyali M (2021) Tau forms oligomeric complexes on microtubules that are distinct from tau aggregates. Proc Natl Acad Sci USA 118: e2021461118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126857</ArticleId><ArticleId IdType="pubmed">33952699</ArticleId></ArticleIdList></Reference><Reference><Citation>Izeddin I, Boulanger J, Racine V, Specht CG, Kechkar A, Nair D, Triller A, Choquet D, Dahan M, Sibarita JB (2012) Wavelet analysis for single molecule localization microscopy. Opt Express 20: 2081&#x2013;2095</Citation><ArticleIdList><ArticleId IdType="pubmed">22330449</ArticleId></ArticleIdList></Reference><Reference><Citation>Izeddin I, R&#xe9;camier V, Bosanac L, Ciss&#xe9; II, Boudarene L, Dugast&#x2010;Darzacq C, Proux F, B&#xe9;nichou O, Voituriez R, Bensaude O et&#x2009;al (2014) Single&#x2010;molecule tracking in live cells reveals distinct target&#x2010;search strategies of transcription factors in the nucleus. eLife 3: e02230</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095940</ArticleId><ArticleId IdType="pubmed">24925319</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson K, Liu P, Lagerholm BC (2019) The lateral organization and mobility of plasma membrane components. Cell 177: 806&#x2013;819</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6541401</ArticleId><ArticleId IdType="pubmed">31051105</ArticleId></ArticleIdList></Reference><Reference><Citation>Janning D, Igaev M, Sundermann F, Bruhmann J, Beutel O, Heinisch JJ, Bakota L, Piehler J, Junge W, Brandt R (2014) Single&#x2010;molecule tracking of tau reveals fast kiss&#x2010;and&#x2010;hop interaction with microtubules in living neurons. Mol Biol Cell 25: 3541&#x2013;3551</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230615</ArticleId><ArticleId IdType="pubmed">25165145</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaqaman K, Kuwata H, Touret N, Collins R, Trimble WS, Danuser G, Grinstein S (2011) Cytoskeletal control of CD36 diffusion promotes its receptor and signaling function. Cell 146: 593&#x2013;606</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160624</ArticleId><ArticleId IdType="pubmed">21854984</ArticleId></ArticleIdList></Reference><Reference><Citation>Joensuu M, Padmanabhan P, Durisic N, Bademosi AT, Cooper&#x2010;Williams E, Morrow IC, Harper CB, Jung W, Parton RG, Goodhill GJ et&#x2009;al (2016) Subdiffractional tracking of internalized molecules reveals heterogeneous motion states of synaptic vesicles. J Cell Biol 215: 277&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5080683</ArticleId><ArticleId IdType="pubmed">27810917</ArticleId></ArticleIdList></Reference><Reference><Citation>Joensuu M, Martinez&#x2010;Marmol R, Padmanabhan P, Glass NR, Durisic N, Pelekanos M, Mollazade M, Balistreri G, Amor R, Cooper&#x2010;White JJ et&#x2009;al (2017) Visualizing endocytic recycling and trafficking in live neurons by subdiffractional tracking of internalized molecules. Nat Protoc 12: 2590&#x2013;2622</Citation><ArticleIdList><ArticleId IdType="pubmed">29189775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y, Andreadis A, Fu Y, Brady ST, Binder LI (2011) Pathogenic forms of tau inhibit kinesin&#x2010;dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 31: 9858&#x2013;9868</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391724</ArticleId><ArticleId IdType="pubmed">21734277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaan NM, Hamel C, Grabinski T, Combs B (2020) Liquid&#x2010;liquid phase separation induces pathogenic tau conformations in&#x2009;vitro . Nat Commun 11: 2809</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272632</ArticleId><ArticleId IdType="pubmed">32499559</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsinelos T, Zeitler M, Dimou E, Karakatsani A, Muller HM, Nachman E, Steringer JP, Ruiz de Almodovar C, Nickel W, Jahn TR (2018) Unconventional secretion mediates the trans&#x2010;cellular spreading of tau. Cell Rep 23: 2039&#x2013;2055</Citation><ArticleIdList><ArticleId IdType="pubmed">29768203</ArticleId></ArticleIdList></Reference><Reference><Citation>King ME, Gamblin TC, Kuret J, Binder LI (2000) Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem 74: 1749&#x2013;1757</Citation><ArticleIdList><ArticleId IdType="pubmed">10737634</ArticleId></ArticleIdList></Reference><Reference><Citation>Knops J, Kosik KS, Lee G, Pardee JD, Cohen&#x2010;Gould L, McConlogue L (1991) Overexpression of tau in a nonneuronal cell induces long cellular processes. J Cell Biol 114: 725&#x2013;733</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289897</ArticleId><ArticleId IdType="pubmed">1678391</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hn T, Ihalainen TO, Hyv&#xe4;luoma J, Dross N, Willman SF, Langowski J, Vihinen&#x2010;Ranta M, Timonen J (2011) Protein diffusion in mammalian cell cytoplasm. PLoS One 6: e22962</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158749</ArticleId><ArticleId IdType="pubmed">21886771</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Phelps C, Huang T, Mostofian B, Wu L, Zhang Y, Tao K, Chang YH, Stork PJ, Gray JW et&#x2009;al (2019) High&#x2010;throughput, single&#x2010;particle tracking reveals nested membrane domains that dictate KRas (G12D) diffusion and trafficking. eLife 8: e46393</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7060040</ArticleId><ArticleId IdType="pubmed">31674905</ArticleId></ArticleIdList></Reference><Reference><Citation>Levet F, Hosy E, Kechkar A, Butler C, Beghin A, Choquet D, Sibarita JB (2015) SR&#x2010;Tesseler: a method to segment and quantify localization&#x2010;based super&#x2010;resolution microscopy data. Nat Methods 12: 1065&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pubmed">26344046</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, G&#xf6;tz J (2017) Somatodendritic accumulation of tau in Alzheimer's disease is promoted by Fyn&#x2010;mediated local protein translation. EMBO J 36: 3120&#x2013;3138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666608</ArticleId><ArticleId IdType="pubmed">28864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, Goedert M, Amos LA, Spillantini MG (2007) Interaction of tau protein with the dynactin complex. EMBO J 26: 4546&#x2013;4554</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063488</ArticleId><ArticleId IdType="pubmed">17932487</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewski J, Jones EM, Vander Zanden CM, Biernat J, Mandelkow E, Chi EY (2020) Lipid membrane templated misfolding and self&#x2010;assembly of intrinsically disordered tau protein. Sci Rep 10: 13324</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414892</ArticleId><ArticleId IdType="pubmed">32770092</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley S, Gillette JM, Patterson GH, Shroff H, Hess HF, Betzig E, Lippincott&#x2010;Schwartz J (2008) High&#x2010;density mapping of single&#x2010;molecule trajectories with photoactivated localization microscopy. Nat Methods 5: 155&#x2013;157</Citation><ArticleIdList><ArticleId IdType="pubmed">18193054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari SA, Wegmann S, Tepper K, Hyman BT, Mandelkow EM, Mandelkow E, M&#xfc;ller DJ (2018) Reversible cation&#x2010;selective attachment and self&#x2010;assembly of human tau on supported brain lipid membranes. Nano Lett 18: 3271&#x2013;3281</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588182</ArticleId><ArticleId IdType="pubmed">29644863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehidi A, Rossier O, Schaks M, Chazeau A, Biname F, Remorino A, Coppey M, Karatas Z, Sibarita JB, Rottner K et&#x2009;al (2019) Transient activations of Rac1 at the lamellipodium tip trigger membrane protrusion. Curr Biol 29: e5</Citation><ArticleIdList><ArticleId IdType="pubmed">31422887</ArticleId></ArticleIdList></Reference><Reference><Citation>Merezhko M, Brunello CA, Yan X, Vihinen H, Jokitalo E, Uronen RL, Huttunen HJ (2018) Secretion of tau via an unconventional non&#x2010;vesicular mechanism. Cell Rep 25: e4</Citation><ArticleIdList><ArticleId IdType="pubmed">30463001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller RL, Combs B, Alhadidy MM, Brady ST, Morfini GA, Kanaan NM (2021) Tau: a signaling hub protein. Front Mol Neurosci 14: 647054</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017207</ArticleId><ArticleId IdType="pubmed">33815057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutreja Y, Combs B, Gamblin TC (2019) FTDP&#x2010;17 mutations alter the aggregation and microtubule stabilization propensity of tau in an isoform&#x2010;specific fashion. Biochemistry 58: 742&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pubmed">30562452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacharaju P, Lewis J, Easson C, Yen S, Hackett J, Hutton M, Yen SH (1999) Accelerated filament formation from tau protein with specific FTDP&#x2010;17 missense mutations. FEBS Lett 447: 195&#x2013;199</Citation><ArticleIdList><ArticleId IdType="pubmed">10214944</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan P, Martinez&#x2010;Marmol R, Xia D, G&#xf6;tz J, Meunier FA (2019) Frontotemporal dementia mutant tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines. eLife 8: e45040</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592683</ArticleId><ArticleId IdType="pubmed">31237563</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan P, Bademosi AT, Kasula R, Lauwers E, Verstreken P, Meunier FA (2020) Need for speed: super&#x2010;resolving the dynamic nanoclustering of syntaxin&#x2010;1 at exocytic fusion sites. Neuropharmacology 169: 107554</Citation><ArticleIdList><ArticleId IdType="pubmed">30826343</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan P, Kneynsberg A, G&#xf6;tz J (2021) Super&#x2010;resolution microscopy: a closer look at synaptic dysfunction in Alzheimer disease. Nat Rev Neurosci 22: 723&#x2013;740</Citation><ArticleIdList><ArticleId IdType="pubmed">34725519</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N, Ramachandran S, Azimov R, Kagan BL, Lal R (2015) Ion channel formation by tau protein: implications for Alzheimer's disease and tauopathies. Biochemistry 54: 7320&#x2013;7325</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690196</ArticleId><ArticleId IdType="pubmed">26575330</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson F, Lind&#xe9;n M, Unoson C, Elf J (2013) Extracting intracellular diffusive states and transition rates from single&#x2010;molecule tracking data. Nat Methods 10: 265&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pubmed">23396281</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC, Li C, Bodea LG, Martinez&#x2010;Marmol R, Meunier FA, G&#xf6;tz J (2018) Amyloid&#x2010;&#x3b2; and tau complexity &#x2010; towards improved biomarkers and targeted therapies. Nat Rev Neurol 14: 22&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">29242522</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC, Hand GR, Briner A, Li C, G&#xf6;tz J (2021) Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol. Acta Neuropathol 141: 235&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847444</ArticleId><ArticleId IdType="pubmed">33417012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP (2012) Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 33: 431</Citation><ArticleIdList><ArticleId IdType="pubmed">21388709</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine V, Hertzog A, Jouanneau J, Salamero J, Kervrann C, Sibarita J&#x2010;B (2006) Multiple&#x2010;target tracking of 3D fluorescent objects based on simulated annealing. In IEEE International Symposium on Biomedical Imaging: Macro to Nano, Vol. 1&#x2013;3, pp 1020&#x2013;1023. Arlington, VA: IEEE;</Citation></Reference><Reference><Citation>Rossier O, Octeau V, Sibarita JB, Leduc C, Tessier B, Nair D, Gatterdam V, Destaing O, Albig&#xe8;s&#x2010;Rizo C, Tamp&#xe9; R et&#x2009;al (2012) Integrins &#x3b2;1 and &#x3b2;3 exhibit distinct dynamic nanoscale organizations inside focal adhesions. Nat Cell Biol 14: 1057&#x2013;1067</Citation><ArticleIdList><ArticleId IdType="pubmed">23023225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallaberry CA, Voss BJ, Majewski J, Biernat J, Mandelkow E, Chi EY, Vander Zanden CM (2021) Tau and membranes: interactions that promote folding and condensation. Front Cell Dev Biol 9: 725241</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491580</ArticleId><ArticleId IdType="pubmed">34621743</ArticleId></ArticleIdList></Reference><Reference><Citation>Siahaan V, Krattenmacher J, Hyman AA, Diez S, Hernandez&#x2010;Vega A, Lansky Z, Braun M (2019) Kinetically distinct phases of tau on microtubules regulate kinesin motors and severing enzymes. Nat Cell Biol 21: 1086&#x2013;1092</Citation><ArticleIdList><ArticleId IdType="pubmed">31481789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R, Lam AJ, Tan T, Han J, Nowakowski DW, Vershinin M, Simo S, Ori&#x2010;McKenney KM, McKenney RJ (2019) Microtubules gate tau condensation to spatially regulate microtubule functions. Nat Cell Biol 21: 1078&#x2013;1085</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748660</ArticleId><ArticleId IdType="pubmed">31481790</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka KA, Suzuki KG, Shirai YM, Shibutani ST, Miyahara MS, Tsuboi H, Yahara M, Yoshimura A, Mayor S, Fujiwara TK et&#x2009;al (2010) Membrane molecules mobile even after chemical fixation. Nat Methods 7: 865&#x2013;866</Citation><ArticleIdList><ArticleId IdType="pubmed">20881966</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega AR, Freeman SA, Grinstein S, Jaqaman K (2018) Multistep track segmentation and motion classification for transient mobility analysis. Biophys J 114: 1018&#x2013;1025</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5883548</ArticleId><ArticleId IdType="pubmed">29539390</ArticleId></ArticleIdList></Reference><Reference><Citation>Vershinin M, Carter BC, Razafsky DS, King SJ, Gross SP (2007) Multiple&#x2010;motor based transport and its regulation by tau. Proc Natl Acad Sci USA 104: 87&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1765483</ArticleId><ArticleId IdType="pubmed">17190808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Eftekharzadeh B, Tepper K, Zoltowska KM, Bennett RE, Dujardin S, Laskowski PR, MacKenzie D, Kamath T, Commins C et&#x2009;al (2018) Tau protein liquid&#x2010;liquid phase separation can initiate tau aggregation. EMBO J 37: e98049</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881631</ArticleId><ArticleId IdType="pubmed">29472250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Fan X, Ding M, Li R, Shao S, Hou Y, Meng S, Tang F, Li C, Sun Y (2020) Nuclear Actin regulates inducible transcription by enhancing RNA polymerase II clustering. Sci Adv 6: eaay6515</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159918</ArticleId><ArticleId IdType="pubmed">32494599</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Schaedel L, Portran D, Aguilar A, Gaillard J, Marinkovich MP, Th&#xe9;ry M, Nachury MV (2017) Microtubules acquire resistance from mechanical breakage through intralumenal acetylation. Science 356: 328&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457157</ArticleId><ArticleId IdType="pubmed">28428427</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Chang H, Zhang Y, Yu J, Wu L, Ji W, Chen J, Liu B, Lu J, Liu Y et&#x2009;al (2012) Rational design of true monomeric and bright photoactivatable fluorescent proteins. Nat Methods 9: 727&#x2013;729</Citation><ArticleIdList><ArticleId IdType="pubmed">22581370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Hancock JF (2015) Ras nanoclusters: versatile lipid&#x2010;based signaling platforms. Biochim Biophys Acta 1853: 841&#x2013;849</Citation><ArticleIdList><ArticleId IdType="pubmed">25234412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36066878</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Is 112 the New 10&#x202f;000?-Step Count and Dementia Risk in the UK Biobank.</ArticleTitle><Pagination><StartPage>973</StartPage><EndPage>974</EndPage><MedlinePgn>973-974</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.2312</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Planalp</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okonkwo</LastName><ForeName>Ozioma C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Neurol. 2022 Oct 1;79(10):1059-1063. doi: 10.1001/jamaneurol.2022.2672.</RefSource><PMID Version="1">36066874</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="Y">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>6</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36066878</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.2312</ArticleId><ArticleId IdType="pii">2795818</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36066874</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Daily Step Count and Intensity With Incident Dementia in 78&#x202f;430 Adults Living in the UK.</ArticleTitle><Pagination><StartPage>1059</StartPage><EndPage>1063</EndPage><MedlinePgn>1059-1063</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.2672</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Step-based recommendations may be appropriate for dementia-prevention guidelines. However, the association of step count and intensity with dementia incidence is unknown.</AbstractText><AbstractText Label="OBJECTIVE">To examine the dose-response association between daily step count and intensity and incidence of all-cause dementia among adults in the UK.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">UK Biobank prospective population-based cohort study (February 2013 to December 2015) with 6.9 years of follow-up (data analysis conducted May 2022). A total of 78&#x202f;430 of 103&#x202f;684 eligible adults aged 40 to 79 years with valid wrist accelerometer data were included. Registry-based dementia was ascertained through October 2021.</AbstractText><AbstractText Label="EXPOSURES">Accelerometer-derived daily step count, incidental steps (less than 40 steps per minute), purposeful steps (40 steps per minute or more), and peak 30-minute cadence (ie, mean steps per minute recorded for the 30 highest, not necessarily consecutive, minutes in a day).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Incident dementia (fatal and nonfatal), obtained through linkage with inpatient hospitalization or primary care records or recorded as the underlying or contributory cause of death in death registers. Spline Cox regressions were used to assess dose-response associations.</AbstractText><AbstractText Label="RESULTS">The study monitored 78&#x202f;430 adults (mean [SD] age, 61.1 [7.9] years; 35&#x202f;040 [44.7%] male and 43&#x202f;390 [55.3%] female; 881 [1.1%] were Asian, 641 [0.8%] were Black, 427 [0.5%] were of mixed race, 75&#x202f;852 [96.7%] were White, and 629 [0.8%] were of another, unspecified race) over a median (IQR) follow-up of 6.9 (6.4-7.5) years, 866 of whom developed dementia (mean [SD] age, 68.3 [5.6] years; 480 [55.4%] male and 386 [54.6%] female; 5 [0.6%] Asian, 6 [0.7%] Black, 4 [0.4%] mixed race, 821 [97.6%] White, and 6 [0.7%] other). Analyses revealed nonlinear associations between daily steps. The optimal dose (ie, exposure value at which the maximum risk reduction was observed) was 9826 steps (hazard ratio [HR], 0.49; 95% CI, 0.39-0.62) and the minimal dose (ie, exposure value at which the risk reduction was 50% of the observed maximum risk reduction) was 3826 steps (HR, 0.75; 95% CI, 0.67-0.83). The incidental cadence optimal dose was 3677 steps (HR, 0.58; 95% CI, 0.44-0.72); purposeful cadence optimal dose was 6315 steps (HR, 0.43; 95% CI, 0.32-0.58); and peak 30-minute cadence optimal dose was 112 steps per minute (HR, 0.38; 95% CI, 0.24-0.60).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study, a higher number of steps was associated with lower risk of all-cause dementia. The findings suggest that a dose of just under 10&#x202f;000 steps per day may be optimally associated with a lower risk of dementia. Steps performed at higher intensity resulted in stronger associations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del Pozo Cruz</LastName><ForeName>Borja</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Sports Science and Clinical Biomechanics, Centre for Active and Healthy Ageing, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Charles Perkins Centre, Faculty of Medicine and Health, School of Health Sciences, The University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naismith</LastName><ForeName>Sharon L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Charles Perkins Centre, Faculty of Science, The University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamatakis</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Charles Perkins Centre, Faculty of Medicine and Health, School of Health Sciences, The University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2022 Oct 1;79(10):973-974. doi: 10.1001/jamaneurol.2022.2312.</RefSource><PMID Version="1">36066878</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2022 Oct 1;79(10):1086. doi: 10.1001/jamaneurol.2022.3612.</RefSource><PMID Version="1">36083577</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Nov;18(11):637. doi: 10.1038/s41582-022-00730-w.</RefSource><PMID Version="1">36151478</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="Y">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Naismith reported honoraria from Roche Pharmaceuticals and Nutrica and grants from the National Health and Medical Research Council, Alzheimer&#x2019;s International, the US Alzheimer&#x2019;s Drug Discovery Foundation, and Medical Research Future Fund outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>6</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36066874</ArticleId><ArticleId IdType="pmc">PMC9449869</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.2672</ArticleId><ArticleId IdType="pii">2795819</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bassett DR Jr, Toth LP, LaMunion SR, Crouter SE. Step counting: a review of measurement considerations and health-related applications. Sports Med. 2017;47(7):1303-1315. doi:10.1007/s40279-016-0663-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40279-016-0663-1</ArticleId><ArticleId IdType="pmc">PMC5488109</ArticleId><ArticleId IdType="pubmed">28005190</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluch AE, Bajpai S, Bassett DR, et al. ; Steps for Health Collaborative . Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022;7(3):e219-e228. doi:10.1016/S2468-2667(21)00302-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(21)00302-9</ArticleId><ArticleId IdType="pmc">PMC9289978</ArticleId><ArticleId IdType="pubmed">35247352</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Maurice PF, Troiano RP, Bassett DR Jr, et al. . Association of daily step count and step intensity with mortality among US adults. JAMA. 2020;323(12):1151-1160. doi:10.1001/jama.2020.1382</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1382</ArticleId><ArticleId IdType="pmc">PMC7093766</ArticleId><ArticleId IdType="pubmed">32207799</ArticleId></ArticleIdList></Reference><Reference><Citation>Garduno AC, LaCroix AZ, LaMonte MJ, et al. . Associations of daily steps and step intensity with incident diabetes in a prospective cohort study of older women: the OPACH study. 2019. doi:10.2337/figshare.17004046.v1</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/figshare.17004046.v1</ArticleId><ArticleId IdType="pmc">PMC8914434</ArticleId><ArticleId IdType="pubmed">35050362</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, Klein H, Kirn DR, et al. . Associations of physical activity and &#x3b2;-amyloid with longitudinal cognition and neurodegeneration in clinically normal older adults. JAMA Neurol. 2019;76(10):1203-1210. doi:10.1001/jamaneurol.2019.1879</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1879</ArticleId><ArticleId IdType="pmc">PMC6635892</ArticleId><ArticleId IdType="pubmed">31312836</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott RD, White LR, Ross GW, Masaki KH, Curb JD, Petrovitch H. Walking and dementia in physically capable elderly men. JAMA. 2004;292(12):1447-1453. doi:10.1001/jama.292.12.1447</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.292.12.1447</ArticleId><ArticleId IdType="pubmed">15383515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, Gallacher J, Allen N, et al. . UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T, Schnier C, Bush K, et al. ; Dementias Platform UK and UK Biobank . Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur J Epidemiol. 2019;34(6):557-565. doi:10.1007/s10654-019-00499-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-019-00499-1</ArticleId><ArticleId IdType="pmc">PMC6497624</ArticleId><ArticleId IdType="pubmed">30806901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavey TG, Gilson ND, Gomersall SR, Clark B, Trost SG. Field evaluation of a random forest activity classifier for wrist-worn accelerometer data. J Sci Med Sport. 2017;20(1):75-80. doi:10.1016/j.jsams.2016.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsams.2016.06.003</ArticleId><ArticleId IdType="pubmed">27372275</ArticleId></ArticleIdList></Reference><Reference><Citation>Femiano R, Werner C, Wilhelm M, Eser P. Validation of open-source step-counting algorithms for wrist-worn tri-axial accelerometers in cardiovascular patients. Gait Posture. 2022;92:206-211. doi:10.1016/j.gaitpost.2021.11.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaitpost.2021.11.035</ArticleId><ArticleId IdType="pubmed">34864486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee IM, Shiroma EJ, Kamada M, Bassett DR, Matthews CE, Buring JE. Association of step volume and intensity with all-cause mortality in older women. JAMA Intern Med. 2019;179(8):1105-1112. doi:10.1001/jamainternmed.2019.0899</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.0899</ArticleId><ArticleId IdType="pmc">PMC6547157</ArticleId><ArticleId IdType="pubmed">31141585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudor-Locke C, Brashear MM, Katzmarzyk PT, Johnson WD. Peak stepping cadence in free-living adults: 2005-2006 NHANES. J Phys Act Health. 2012;9(8):1125-1129. doi:10.1123/jpah.9.8.1125</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/jpah.9.8.1125</ArticleId><ArticleId IdType="pubmed">22207030</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321(6):602-603. doi:10.1001/jama.2018.21554</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.21554</ArticleId><ArticleId IdType="pubmed">30676631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus WE, Janz KF, Powell KE, et al. ; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE . Daily step counts for measuring physical activity exposure and its relation to health. Med Sci Sports Exerc. 2019;51(6):1206-1212. doi:10.1249/MSS.0000000000001932</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/MSS.0000000000001932</ArticleId><ArticleId IdType="pmc">PMC6527133</ArticleId><ArticleId IdType="pubmed">31095077</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatakis E, Owen KB, Shepherd L, Drayton B, Hamer M, Bauman AE. Is cohort representativeness pass&#xe9;? poststratified associations of lifestyle risk factors with mortality in the UK Biobank. Epidemiology. 2021;32(2):179-188. doi:10.1097/EDE.0000000000001316</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001316</ArticleId><ArticleId IdType="pmc">PMC7850587</ArticleId><ArticleId IdType="pubmed">33492009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">36070367</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>661</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>eabq0095</StartPage><MedlinePgn>eabq0095</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abq0095</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cells 2 (TREM2) plays crucial roles in Alzheimer's disease (AD) by regulating microglia migration toward, and phagocytosis of oligomeric amyloid-&#x3b2; (oA&#x3b2;) and amyloid plaques. Studies in rodent models of AD have shown that mice with increased TREM2 expression have reduced amyloid pathology. Here, we identified a TREM2 agonist monoclonal Ab (Ab18) by panning a phage-displayed single-chain variable fragment Ab library. By engineering the bivalent immunoglobulin G1 (IgG1) to tetra-variable domain immunoglobulin (TVD-Ig), we further increased the TREM2 activation by 100-fold. Stronger TREM2 activation led to enhanced microglia phagocytosis of the oA&#x3b2;-lipid complex, migration toward oA&#x3b2;, and improved microglia survival in vitro. Mechanistic studies showed increased TREM2 clustering on microglia by the tetravalent Ab18 TVD-Ig without altering microglial TREM2 amount. An engineered bispecific Ab targeting TREM2 and transferrin receptor (TfR; Ab18 TVD-Ig/&#x3b1;TfR) improved Ab brain entry by more than 10-fold with a broad brain parenchyma distribution. Weekly treatment of 5XFAD mice (a model of AD) with Ab18 TVD-Ig/&#x3b1;TfR showed a considerable reduction of amyloid burden with increased microglia migration to and phagocytosis of amyloid plaques, improved synaptic and neuronal marker intensity, improved cognitive functions, reduced endogenous tau hyperphosphorylation, and decreased phosphorylated neurofilament H immunostaining. This study demonstrated the feasibility of engineering multivalent TREM2 agonistic Ab coupled with TfR-mediated brain delivery to enhance microglia functions and reduce amyloid pathology in vitro and in vivo. This Ab engineering approach enables the development of effective TREM2-targeting therapies for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Peng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9056-623X</Identifier><AffiliationInfo><Affiliation>Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuanzhong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5264-5324</Identifier><AffiliationInfo><Affiliation>Center for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>LuLin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4527-3662</Identifier><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xuejun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Leike</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arase</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1153-3166</Identifier><AffiliationInfo><Affiliation>Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0081, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2832-6590</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen 361102, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8952-9159</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5427-3798</Identifier><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7031-7853</Identifier><AffiliationInfo><Affiliation>Center for Brain Sciences, the First Affiliated Hospital of Xiamen University, Institute of Neuroscience, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Xiamen University, Xiamen 361102, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Brain Science and Disease, Chongqing Medical University, Chongqing 400016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Qingchun</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-4561-2540</Identifier><AffiliationInfo><Affiliation>Center for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ningyan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4348-2180</Identifier><AffiliationInfo><Affiliation>Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-9309-2335</Identifier><AffiliationInfo><Affiliation>Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Nov;18(11):637. doi: 10.1038/s41582-022-00728-4.</RefSource><PMID Version="1">36151476</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>7</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36070367</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abq0095</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36084009</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.</ArticleTitle><Pagination><StartPage>1580</StartPage><EndPage>1591</EndPage><MedlinePgn>1580-1591</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac329</ELocationID><Abstract><AbstractText>Different tau biomarkers become abnormal at different stages of Alzheimer's disease, with CSF phospho-tau typically becoming elevated at subthreshold levels of tau-PET binding. To capitalize on the temporal order of tau biomarker-abnormality and capture the earliest changes of tau accumulation, we implemented an observational study design to examine longitudinal changes in tau-PET, cortical thickness and cognitive decline in amyloid-&#x3b2;-positive individuals with elevated CSF p-tau levels (P+) but subthreshold Tau-PET retention (T-). To this end, individuals without dementia (i.e. cognitively unimpaired or mild cognitive impairment, n = 231) were selected from the BioFINDER-2 study. Amyloid-&#x3b2;-positive (A+) individuals were categorized into biomarker groups based on cut-offs for abnormal CSF p-tau217 and 18F-RO948 (Tau) PET, yielding groups of tau-concordant-negative (A+P-T-; n = 30), tau-discordant (i.e. A+P+T-; n = 48) and tau-concordant-positive (A+P+T+; n = 18) individuals. In addition, 135 amyloid-&#x3b2;-negative, tau-negative, cognitively unimpaired individuals served as controls. Differences in annual change in regional tau-PET, cortical thickness and cognition between the groups were assessed using general linear models, adjusted for age, sex, clinical diagnosis and (for cognitive measures only) education. Mean follow-up time was &#x223c;2 years. Longitudinal increase in tau-PET was faster in the A+P+T- group than in the control and A+P-T- groups across medial temporal and neocortical regions, with the highest accumulation rates in the medial temporal lobe. The A+P+T- group showed a slower rate of increase in tau-PET compared to the A+P+T+ group, primarily in neocortical regions. We did not detect differences in yearly change in cortical thickness or in cognitive decline between the A+P+T- and A+P-T- groups. The A+P+T+ group, however, showed faster cognitive decline compared to all other groups. Altogether, these findings suggest that the A+P+T- biomarker profile in persons without dementia is associated with an isolated effect on increased tau-PET accumulation rates but not on cortical thinning and cognitive decline. While this suggests that the tau-discordant biomarker profile is not strongly associated with short-term clinical decline, this group does represent an interesting population for monitoring the effects of interventions with disease-modifying agents on tau accumulation in early Alzheimer's disease, and for examining the emergence of tau aggregates in Alzheimer's disease. Further, we suggest updating the AT(N) criteria for Alzheimer's disease biomarker classification to APT(N).</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Groot</LastName><ForeName>Colin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5802-6946</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center, Amsterdam UMC Location Vumc, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7147-0112</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund University, 222 42 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, 222 42 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binette</LastName><ForeName>Alexa Pichet</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuzy</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuestefeld</LastName><ForeName>Anika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisse</LastName><ForeName>Laura E M</ForeName><Initials>LEM</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Lund University, 223 62 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, 222 42 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8885-7724</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund University, 222 42 Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, 223 62 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center, Amsterdam UMC Location Vumc, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences in Malm&#xf6;, Lund University, 205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, 222 42 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer</Keyword><Keyword MajorTopicYN="N">CSF</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">discordance</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>S.P. has served on scientific advisory boards and/or given lectures in symposia sponsored by F. Hoffmann-La Roche, Biogen, Eli Lilly and Geras Solutions. R.O. has given lectures in symposia sponsored by GE Healthcare. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche and Siemens. The other authors report no disclosures. This study was supported by MultiPark&#x2014;A Strategic Research Area at Lund University</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>14</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36084009</ArticleId><ArticleId IdType="pmc">PMC10115173</ArticleId><ArticleId IdType="doi">10.1093/brain/awac329</ArticleId><ArticleId IdType="pii">6695020</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P, De Strooper B, Kivipelto M, et al. . Alzheimer&#x2019;s disease. Lancet. 2021;397:1577&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol. 2012;71:362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Ashton NJ, Mattsson-Carlgren N, et al. . 2020 Update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48:2121&#x2013;2139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175301</ArticleId><ArticleId IdType="pubmed">33674895</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Hansson O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimers Dement. 2021;17:1998&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">33984177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Reimand J, Smith R, et al. . Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021;13:e14398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8350902</ArticleId><ArticleId IdType="pubmed">34254442</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Sch&#xf6;ll M, Strandberg O, et al. . 18 F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. EMBO Mol Med. 2017;9:1212&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Bejanin A, Fagan AM, et al. . Associations between [(18)F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology. 2018;90:e282&#x2013;e290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5798657</ArticleId><ArticleId IdType="pubmed">29282337</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, et al. . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun. 2020;11:1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Pontecorvo MJ, Devous MD Sr., et al. . Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="pubmed">32338734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwabara H, Comley RA, Borroni E, et al. . Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59:1877&#x2013;1884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278898</ArticleId><ArticleId IdType="pubmed">30097505</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, et al. . [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease. Sci Adv. 2020;6:eaaz2387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Li Y, Joseph-Mathurin N, et al. . A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med. 2020;26:398&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R. Association of amyloid-&#x3b2; CSF/PET discordance and tau load 5 years later. Neurology. 2020;95:e2648&#x2013;e2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963352</ArticleId><ArticleId IdType="pubmed">32913020</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wilde A, Reimand J, Teunissen CE, et al. . Discordant amyloid-&#x3b2; PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther. 2019;11:78&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6739952</ArticleId><ArticleId IdType="pubmed">31511058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging &#x3b2;-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76:1319&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6646987</ArticleId><ArticleId IdType="pubmed">31314895</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain. 2016;139(Pt 4):1226&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Smith R, Ossenkoppele R, et al. . Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77:955&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. Jama. 2020;324:772&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Sch&#xf6;ll M, Leuzy A, et al. . Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948. Eur J Nucl Med Mol Imaging. 2020;47:342&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974501</ArticleId><ArticleId IdType="pubmed">31612245</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. . Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Sch&#xf6;ll M, Leuzy A, et al. . Head-to-head comparison of tau positron emission tomography tracers [18 F]flortaucipir and [18 F]RO948. Eur J Nucl Med Mol Imaging. 2020;47:342&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974501</ArticleId><ArticleId IdType="pubmed">31612245</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot C, Sudre CH, Barkhof F, et al. . Clinical phenotype, atrophy, and small vessel disease in APOE &#x3b5;2 carriers with Alzheimer disease. Neurology. 2018;91:E1851&#x2013;E1859.</Citation><ArticleIdList><ArticleId IdType="pubmed">30341156</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13:205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, et al. . Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease. J Neuropathol Exp Neurol. 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Berron D, Vogel JW, Insel PS, et al. . Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain. 2021;144:2771&#x2013;2783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557349</ArticleId><ArticleId IdType="pubmed">33725124</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Wisse LEM, Pluta J, et al. . Automated segmentation of medial temporal lobe subregions on in vivo T1-weighted MRI in early stages of Alzheimer's disease. Hum Brain Mapp. 2019;40:3431&#x2013;3451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697377</ArticleId><ArticleId IdType="pubmed">31034738</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hulle C, Jonaitis EM, Betthauser TJ, et al. . An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimers Dement. 2021;17:431&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016695</ArticleId><ArticleId IdType="pubmed">33336877</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. . The preclinical Alzheimer cognitive composite. JAMA Neurol. 2014;71:961&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, et al. . The cortical signature of Alzheimer's disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Janelidze S, Mattsson-Carlgren N, et al. . Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P-Tau181, P-Tau217 and P-Tau231 assays. Neurology. 2022;97:e1681&#x2013;e1694;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8605616</ArticleId><ArticleId IdType="pubmed">34493616</ArticleId></ArticleIdList></Reference><Reference><Citation>Berron D, van Westen D, Ossenkoppele R, Strandberg O, Hansson O. Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. Brain. 2020;143:1233&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174043</ArticleId><ArticleId IdType="pubmed">32252068</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Visani AV, Baker SL, et al. . Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12:eaau5732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691&#x2013;1704.</Citation><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108:5819&#x2013;5824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Lundt ES, Albertson SM, et al. . Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16:561&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067654</ArticleId><ArticleId IdType="pubmed">31784374</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Wibom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 2019;76:310&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439731</ArticleId><ArticleId IdType="pubmed">30508025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Sch&#xf6;ll M, Strandberg O, et al. . (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. EMBO Mol Med. 2017;9:1212&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2:605&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. . Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: A head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240013</ArticleId><ArticleId IdType="pubmed">34180956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Strandberg O, Mattsson-Carlgren N, et al. . The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain. 2020;143:3805&#x2013;3815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7805812</ArticleId><ArticleId IdType="pubmed">33439987</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, et al. . Predicting future rates of tau accumulation on PET. Brain. 2020;143:3136&#x2013;3150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586089</ArticleId><ArticleId IdType="pubmed">33094327</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Berron D, Smith R, et al. . Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78:149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7653537</ArticleId><ArticleId IdType="pubmed">33165506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36075972</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition.</ArticleTitle><Pagination><StartPage>1378</StartPage><EndPage>1393</EndPage><MedlinePgn>1378-1393</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41556-022-00988-8</ELocationID><Abstract><AbstractText>While acetylated, RNA-binding-deficient TDP-43 reversibly phase separates within nuclei into complex droplets (anisosomes) comprised of TDP-43-containing liquid outer shells and liquid centres of HSP70-family chaperones, cytoplasmic aggregates of TDP-43 are hallmarks of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Here we show that transient oxidative stress, proteasome inhibition or inhibition of the ATP-dependent chaperone activity of HSP70 provokes reversible cytoplasmic TDP-43 de-mixing and transition from liquid to gel/solid, independently of RNA binding or stress granules. Isotope labelling mass spectrometry was used to identify that phase-separated cytoplasmic TDP-43 is bound by the small heat-shock protein HSPB1. Binding is direct, mediated through TDP-43's RNA binding and low-complexity domains. HSPB1 partitions into TDP-43 droplets, inhibits TDP-43 assembly into fibrils, and is essential for disassembly of stress-induced TDP-43 droplets. A decrease in HSPB1 promotes cytoplasmic TDP-43 de-mixing and mislocalization. HSPB1 depletion was identified in spinal motor neurons of patients with ALS containing aggregated TDP-43. These findings identify HSPB1 to be a regulator of cytoplasmic TDP-43 phase separation and aggregation.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jiaojiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arogundade</LastName><ForeName>Olubankole Aladesuyi</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goginashvili</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez-Sanchez</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diedrich</LastName><ForeName>Jolene K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>The Scripps Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Jinge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oung</LastName><ForeName>Spencer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Qiaozhen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Haiyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter O'Donnell Jr Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cong</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3425-6672</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Suffix>3rd</Suffix><Identifier Source="ORCID">0000-0001-5267-1672</Identifier><AffiliationInfo><Affiliation>The Scripps Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0002-1934-3682</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, CA, USA. dcleveland@health.ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, San Diego, CA, USA. dcleveland@health.ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, CA, USA. dcleveland@health.ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 GM103533</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS047101</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS114162</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS121604</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088578</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C057725">HSPB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050888">Heat-Shock Proteins, Small</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2022 Sep;24(9):1328-1330. doi: 10.1038/s41556-022-00987-9.</RefSource><PMID Version="1">36075973</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="Y">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050888" MajorTopicYN="Y">Heat-Shock Proteins, Small</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044367" MajorTopicYN="Y">Phase Transition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36075972</ArticleId><ArticleId IdType="mid">NIHMS1860663</ArticleId><ArticleId IdType="pmc">PMC9872726</ArticleId><ArticleId IdType="doi">10.1038/s41556-022-00988-8</ArticleId><ArticleId IdType="pii">10.1038/s41556-022-00988-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ling S-C, Polymenidou M &amp; Cleveland DW Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al. Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. Acta neuropathologica 113, 543&#x2013;548 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17415574</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta neuropathologica 127, 811&#x2013;824 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503&#x2013;1527 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A et al. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell 162, 1066&#x2013;1077 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron 102, 339&#x2013;357. e337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A et al. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. The EMBO journal 37, e97452 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830921</ArticleId><ArticleId IdType="pubmed">29438978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron 102, 321&#x2013;338.e328 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L et al. Poly (ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Molecular cell 71, 703&#x2013;717. e709 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE et al. TDP-43 &#x3b1;-helical structure tunes liquid&#x2013;liquid phase separation and function. Proceedings of the National Academy of Sciences 117, 5883&#x2013;5894 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7084079</ArticleId><ArticleId IdType="pubmed">32132204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C et al. Stress induces dynamic, cytotoxicity-antagonizing TDP-43 nuclear bodies via paraspeckle lncRNA NEAT1-mediated liquid-liquid phase separation. Molecular Cell 79, 443&#x2013;458. e447 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32649883</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science 371 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganassi M et al. A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Molecular cell 63, 796&#x2013;810 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27570075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N &amp; Anderson P Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochemical Society Transactions 30, 963&#x2013;969 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12440955</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl FU &amp; Hayer-Hartl M Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295, 1852&#x2013;1858 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11884745</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyedmers J, Mogk A &amp; Bukau B Cellular strategies for controlling protein aggregation. Nature reviews Molecular cell biology 11, 777&#x2013;788 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20944667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl FU, Bracher A &amp; Hayer-Hartl M Molecular chaperones in protein folding and proteostasis. Nature 475, 324&#x2013;332 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21776078</ArticleId></ArticleIdList></Reference><Reference><Citation>Macario AJ, Grippo TM &amp; de Macario EC Genetic disorders involving molecular-chaperone genes: a perspective. Genetics in Medicine 7, 3&#x2013;12 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15654222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarparanta J, Jonson PH, Kawan S &amp; Udd B.J.I.j.o.m.s. Neuromuscular diseases due to chaperone mutations: a review and some new results. International journal of molecular sciences 21, 1409 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073051</ArticleId><ArticleId IdType="pubmed">32093037</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehme M et al. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell reports 9, 1135&#x2013;1150 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255334</ArticleId><ArticleId IdType="pubmed">25437566</ArticleId></ArticleIdList></Reference><Reference><Citation>Voisine C, Pedersen JS &amp; Morimoto RI Chaperone networks: tipping the balance in protein folding diseases. Neurobiology of disease 40, 12&#x2013;20 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429345</ArticleId><ArticleId IdType="pubmed">20472062</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslbeck M, Franzmann T, Weinfurtner D &amp; Buchner J Some like it hot: the structure and function of small heat-shock proteins. Nature structural molecular biology 12, 842&#x2013;846 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16205709</ArticleId></ArticleIdList></Reference><Reference><Citation>Shashidharamurthy R, Koteiche HA, Dong J &amp; McHaourab HS Mechanism of chaperone function in small heat shock proteins: dissociation of the HSP27 oligomer is required for recognition and binding of destabilized T4 lysozyme. Journal of Biological Chemistry 280, 5281&#x2013;5289 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15542604</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angelo MA, Raices M, Panowski SH &amp; Hetzer MW Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell 136, 284&#x2013;295 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805151</ArticleId><ArticleId IdType="pubmed">19167330</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell stem cell 17, 705&#x2013;718 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="pubmed">26456686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nature communications 6, 1&#x2013;13 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Wander CM, Yuan C-X, Bereman MS &amp; Cohen TJ Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nature communications 8, 1&#x2013;15 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517419</ArticleId><ArticleId IdType="pubmed">28724966</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Hanni KB &amp; Markesbery WR Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mechanisms of ageing and development 113, 61&#x2013;70 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10708250</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Huang F.F.a. &amp; Markesbery WR Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98, 149&#x2013;156 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10858621</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E &amp; Baralle FE Characterization and Functional Implications of the RNA Binding Properties of Nuclear Factor TDP-43, a Novel Splicing Regulator ofCFTR Exon 9. Journal of Biological Chemistry 276, 36337&#x2013;36343 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmon TS, Holehouse AS, Rosen MK &amp; Pappu RV Intrinsically disordered linkers determine the interplay between phase separation and gelation in multivalent proteins. Elife 6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703641</ArticleId><ArticleId IdType="pubmed">29091028</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14, 459&#x2013;468 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 30, 277&#x2013;288 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB &amp; Rohatgi R In Vivo Formation of Vacuolated Multi-phase Compartments Lacking Membranes. Cell Reports 16, 1228&#x2013;1236 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972689</ArticleId><ArticleId IdType="pubmed">27452472</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee H-W et al. Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. Science 339, 1328&#x2013;1331 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916822</ArticleId><ArticleId IdType="pubmed">23371551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam SS et al. Directed evolution of APEX2 for electron microscopy and proximity labeling. Nature methods 12, 51&#x2013;54 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4296904</ArticleId><ArticleId IdType="pubmed">25419960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobingier BT et al. An approach to spatiotemporally resolve protein interaction networks in living cells. Cell 169, 350&#x2013;360. e312 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5616215</ArticleId><ArticleId IdType="pubmed">28388416</ArticleId></ArticleIdList></Reference><Reference><Citation>Paek J et al. Multidimensional tracking of GPCR signaling via peroxidase-catalyzed proximity labeling. Cell 169, 338&#x2013;349. e311 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5514552</ArticleId><ArticleId IdType="pubmed">28388415</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. Journal of Biological Chemistry 284, 20329&#x2013;20339 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM et al. The role of liquid&#x2013;liquid phase separation in aggregation of the TDP-43 low-complexity domain. Journal of Biological Chemistry 294, 6306&#x2013;6317 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy J et al. Structural dissection of amyloid aggregates of TDP-43 and its C-terminal fragments TDP-35 and TDP-16. The FEBS journal 287, 2449&#x2013;2467 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31782904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P &amp; Eisenberg DS Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nature structural &amp; molecular biology 26, 619&#x2013;627 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuo X-F et al. Solid-state NMR reveals the structural transformation of the TDP-43 amyloidogenic region upon fibrillation. Journal of the American Chemical Society 142, 3412&#x2013;3421 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32003979</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Babinchak WM &amp; Surewicz WK Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nature communications 12, 1&#x2013;8 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955110</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry J et al. Human Hsp27 Is Phosphorylated at Serines-78 and Serines-82 by Heat-Shock and Mitogen-Activated Kinases That Recognize the Same Amino-Acid Motif as S6 Kinase-Ii. Journal of Biological Chemistry 267, 794&#x2013;803 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1730670</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaestel M et al. Identification of the Phosphorylation Sites of the Murine Small Heat-Shock Protein Hsp25. Journal of Biological Chemistry 266, 14721&#x2013;14724 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1860870</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z et al. Hsp27 chaperones FUS phase separation under the modulation of stress-induced phosphorylation. Nature structural &amp; molecular biology 27, 363&#x2013;372 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32231288</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J &amp; Fawzi NL ALS Mutations Disrupt Phase Separation Mediated by alpha-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. Structure 24, 1537&#x2013;1549 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Barreau A &amp; Rohatgi R Phase separation-deficient TDP43 remains functional in splicing. Nature communications 10, 1&#x2013;14 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814767</ArticleId><ArticleId IdType="pubmed">31653829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnsperger M, Gr&#xe4;ber S, Gaestel M &amp; Buchner J Binding of non-native protein to Hsp25 during heat shock creates a reservoir of folding intermediates for reactivation. Nature structural &amp; molecular biology 16, 221&#x2013;229 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169629</ArticleId><ArticleId IdType="pubmed">9029143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GJ, Roseman AM, Saibil HR &amp; Vierling E A small heat shock protein stably binds heat-denatured model substrates and can maintain a substrate in a folding-competent state. The EMBO journal 16, 659&#x2013;671 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169668</ArticleId><ArticleId IdType="pubmed">9034347</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G, Basha E, Wysocki VH &amp; Vierling E Insights into small heat shock protein and substrate structure during chaperone action derived from hydrogen/deuterium exchange and mass spectrometry. Journal of Biological Chemistry 283, 26634&#x2013;26642 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546550</ArticleId><ArticleId IdType="pubmed">18621732</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x17b;wirowski S et al. Hsp70 displaces small heat shock proteins from aggregates to initiate protein refolding. The EMBO journal 36, 783&#x2013;796 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5350560</ArticleId><ArticleId IdType="pubmed">28219929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirtori R, Riva C, Ferrarese C &amp; Sala GJNL HSPA8 knock-down induces the accumulation of neurodegenerative disorder-associated proteins. Neuroscience Letters 736, 135272 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32712350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng YC et al. Knocking down of heat-shock protein 27 directs differentiation of functional glutamatergic neurons from placenta-derived multipotent cells. Sci Rep 6, 30314 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4957209</ArticleId><ArticleId IdType="pubmed">27444754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirbach BB &amp; Golenhofen N Differential expression and induction of small heat shock proteins in rat brain and cultured hippocampal neurons. J Neurosci Res 89, 162&#x2013;175 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21162124</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Rahimtula M &amp; Mearow KM Heat shock protein 27 is involved in neurite extension and branching of dorsal root ganglion neurons in vitro. Journal of Neuroscience Research 84, 716&#x2013;723 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16862544</ArticleId></ArticleIdList></Reference><Reference><Citation>Benn SC et al. Hsp27 upregulation and phosphorylation is required for injured sensory and motor neuron survival. Neuron 36, 45&#x2013;56 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12367505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Burnstock G, Vrbova G &amp; Greensmith L The effect of neonatal nerve injury on the expression of heat shock proteins in developing rat motoneurones. J Neurotrauma 19, 667&#x2013;679 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12042100</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SY et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. P Natl Acad Sci USA 112, E6993&#x2013;E7002 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum JA et al. Single-cell transcriptomic analysis of the adult mouse spinal cord reveals molecular diversity of autonomic and skeletal motor neurons. Nat Neurosci 24, 572&#x2013;583 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016743</ArticleId><ArticleId IdType="pubmed">33589834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunkin SM et al. Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res 41, D996&#x2013;D1008 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531093</ArticleId><ArticleId IdType="pubmed">23193282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff FR, Klebe C, Kretschmer J, Wittinghofer A &amp; Ponstingl H RanGAP1 induces GTPase activity of nuclear Ras-related Ran. Proc Natl Acad Sci U S A 91, 2587&#x2013;2591 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43414</ArticleId><ArticleId IdType="pubmed">8146159</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorlich D, Pante N, Kutay U, Aebi U &amp; Bischoff FR Identification of different roles for RanGDP and RanGTP in nuclear protein import. EMBO J 15, 5584&#x2013;5594 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452303</ArticleId><ArticleId IdType="pubmed">8896452</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima JC et al. Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron 94, 93&#x2013;107 e106 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F et al. Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport. Neuron 94, 48&#x2013;57 e44 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479704</ArticleId><ArticleId IdType="pubmed">28384474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita Y et al. Nuclear contour irregularity and abnormal transporter protein distribution in anterior horn cells in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 68, 1184&#x2013;1192 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19816199</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J et al. Aberrant distributions of nuclear pore complex proteins in ALS mice and ALS patients. Neuroscience 350, 158&#x2013;168 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28344074</ArticleId></ArticleIdList></Reference><Reference><Citation>Capponi S et al. Molecular chaperones in the pathogenesis of amyotrophic lateral sclerosis: the role of HSPB1. Human mutation 37, 1202&#x2013;1208 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108433</ArticleId><ArticleId IdType="pubmed">27492805</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz M et al. Mutations in heat shock protein beta-1 (HSPB1) are associated with a range of clinical phenotypes related to different patterns of motor neuron dysfunction: A case series. J Neurol Sci 413, 116809 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32334137</ArticleId></ArticleIdList></Reference><Reference><Citation>Dierick I et al. Genetic variant in the HSPB1 promoter region impairs the HSP27 stress response. Human mutation 28, 830&#x2013;830 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17623484</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Spek RA et al. The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 20, 432&#x2013;440 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893599</ArticleId><ArticleId IdType="pubmed">31280677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97, 1268-+ (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347, 1436&#x2013;1441 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK et al. Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nat Neurosci 22, 1966&#x2013;1974 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919277</ArticleId><ArticleId IdType="pubmed">31768050</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE et al. TDP-43 &#x3b1;-helical structure tunes liquid&#x2013;liquid phase separation and function. Proceedings of the National Academy of Sciences 117, 5883&#x2013;5894 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7084079</ArticleId><ArticleId IdType="pubmed">32132204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A &amp; Kwon YT Protein quality control by molecular chaperones in neurodegeneration. Frontiers in neuroscience 11, 185 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382173</ArticleId><ArticleId IdType="pubmed">28428740</ArticleId></ArticleIdList></Reference><Reference><Citation>Roodveldt C et al. Chaperone proteostasis in Parkinson's disease: Stabilization of the Hsp70/&#x3b1;-synuclein complex by Hip. The EMBO journal 28, 3758&#x2013;3770 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790486</ArticleId><ArticleId IdType="pubmed">19875982</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HE, Trojanowski JQ, Lee VM-Y &amp; Bonini NM Chaperone suppression of &#x3b1;-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865&#x2013;868 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Udan-Johns M et al. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Human molecular genetics 23, 157&#x2013;170 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857952</ArticleId><ArticleId IdType="pubmed">23962724</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman J et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Molecular cell 37, 355&#x2013;369 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20159555</ArticleId></ArticleIdList></Reference><Reference><Citation>Novoselov SS et al. Molecular chaperone mediated late-stage neuroprotection in the SOD1G93A mouse model of amyotrophic lateral sclerosis. PLoS One 8, e73944 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758296</ArticleId><ArticleId IdType="pubmed">24023695</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacker JL et al. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. Journal of Neuroscience 29, 9104&#x2013;9114 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739279</ArticleId><ArticleId IdType="pubmed">19605647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-J et al. The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis. Brain 139, 1417&#x2013;1432 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845254</ArticleId><ArticleId IdType="pubmed">26936937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp PS et al. Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. Neurobiology of disease 30, 42&#x2013;55 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18255302</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V et al. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Human molecular genetics 19, 3440&#x2013;3456 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20570967</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdenx M et al. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell 184, 2696&#x2013;2714 e2625 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152331</ArticleId><ArticleId IdType="pubmed">33891876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes D, Napoli V, Mazurkie A, Stafford WF &amp; Graceffa P Phosphorylation dependence of hsp27 multimeric size and molecular chaperone function. Journal of Biological Chemistry 284, 18801&#x2013;18807 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707219</ArticleId><ArticleId IdType="pubmed">19411251</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderson TR et al. Local unfolding of the HSP27 monomer regulates chaperone activity. Nature communications 10, 1&#x2013;16 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6403371</ArticleId><ArticleId IdType="pubmed">30842409</ArticleId></ArticleIdList></Reference><Reference><Citation>Clouser AF et al. Interplay of disordered and ordered regions of a human small heat shock protein yields an ensemble of &#x2018;quasi-ordered&#x2019;states. Elife 8, e50259 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6791718</ArticleId><ArticleId IdType="pubmed">31573509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yih LH, Huang HM, Jan KY &amp; Lee TC Sodium arsenite induces ATP depletion and mitochondrial damage in HeLa cells. Cell Biol Int Rep 15, 253&#x2013;264 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2032293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanda D, Kim SJ, Lee IK, Shong M &amp; Choi HS Sodium arsenite induces orphan nuclear receptor SHP gene expression via AMP-activated protein kinase to inhibit gluconeogenic enzyme gene expression. Am J Physiol Endocrinol Metab 295, E368&#x2013;379 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18505831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron 102, 321&#x2013;338 e328 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>French RL et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J Biol Chem 294, 6696&#x2013;6709 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497947</ArticleId><ArticleId IdType="pubmed">30824544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ et al. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy. Brain 142, 3753&#x2013;3770 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6885686</ArticleId><ArticleId IdType="pubmed">31605140</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirie E et al. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD. Proceedings of the National Academy of Sciences 118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980404</ArticleId><ArticleId IdType="pubmed">33692125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Hwang AW, Unger T, Trojanowski JQ &amp; Lee VMY Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. The EMBO journal 31, 1241&#x2013;1252 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297986</ArticleId><ArticleId IdType="pubmed">22193716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-k., Chiang M.-h., Toh EK-W, Chang C-F &amp; Huang T.-h. Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. FEBS letters 587, 575&#x2013;582 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23384725</ArticleId></ArticleIdList></Reference><Reference><Citation>Irobi J et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nature genetics 36, 597&#x2013;601 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15122253</ArticleId></ArticleIdList></Reference><Reference><Citation>Boczek EE et al. HspB8 prevents aberrant phase transitions of FUS by chaperoning its folded RNA binding domain. bioRxiv, 2021.2004.2013.439588 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510580</ArticleId><ArticleId IdType="pubmed">34487489</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell BA et al. Ubiquitination is essential for recovery of cellular activities after heat shock. 372, eabc3593 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574219</ArticleId><ArticleId IdType="pubmed">34739326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwon Y et al. Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner. 372, eabf6548 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574224</ArticleId><ArticleId IdType="pubmed">34739333</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust O et al. HSP40 proteins use class-specific regulation to drive HSP70 functional diversity. Nature 587, 489-+ (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33177718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismailov S et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. European Journal of Human Genetics 9, 646&#x2013;650 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11528513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylikallio E et al. Truncated HSPB1 causes axonal neuropathy and impairs tolerance to unfolded protein stress. BBA clinical 3, 233&#x2013;242 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4661565</ArticleId><ArticleId IdType="pubmed">26675522</ArticleId></ArticleIdList></Reference><Reference><Citation>Evgrafov OV et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nature genetics 36, 602&#x2013;606 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15122254</ArticleId></ArticleIdList></Reference><Reference><Citation>Benndorf R, Martin JL, Pond SLK &amp; Wertheim JO Neuropathy-and myopathy-associated mutations in human small heat shock proteins: characteristics and evolutionary history of the mutation sites. Mutation Research/Reviews in Mutation 761, 15&#x2013;30 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157968</ArticleId><ArticleId IdType="pubmed">24607769</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H et al. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology 71, 1660&#x2013;1668 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18832141</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida-Souza L et al. Increased monomerization of mutant HSPB1 leads to protein hyperactivity in Charcot-Marie-Tooth neuropathy. J Biol Chem 285, 12778&#x2013;12786 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857091</ArticleId><ArticleId IdType="pubmed">20178975</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida-Souza L et al. Small heat-shock protein HSPB1 mutants stabilize microtubules in Charcot-Marie-Tooth neuropathy. J Neurosci 31, 15320&#x2013;15328 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703512</ArticleId><ArticleId IdType="pubmed">22031878</ArticleId></ArticleIdList></Reference><Reference><Citation>d'Ydewalle C et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 17, 968&#x2013;974 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21785432</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Method-only References</Title><Reference><Citation>Fernandopulle MS et al. Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol 79, e51 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993937</ArticleId><ArticleId IdType="pubmed">29924488</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlister GC et al. MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes. Analytical Chemistry 86, 7150&#x2013;7158 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215866</ArticleId><ArticleId IdType="pubmed">24927332</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, Diedrich J, Chu YY &amp; Yates JR 3rd Extracting Accurate Precursor Information for Tandem Mass Spectra by RawConverter. Anal Chem 87, 11361&#x2013;11367 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777630</ArticleId><ArticleId IdType="pubmed">26499134</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T et al. ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity. J Proteomics 129, 16&#x2013;24 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4630125</ArticleId><ArticleId IdType="pubmed">26171723</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabb DL, McDonald WH &amp; Yates JR 3rd DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. J Proteome Res 1, 21&#x2013;26 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811961</ArticleId><ArticleId IdType="pubmed">12643522</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SK et al. Census 2: isobaric labeling data analysis. Bioinformatics 30, 2208&#x2013;2209 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155478</ArticleId><ArticleId IdType="pubmed">24681903</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaglio F et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6, 277&#x2013;293 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Tonelli M &amp; Markley JL NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 31, 1325&#x2013;1327 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393527</ArticleId><ArticleId IdType="pubmed">25505092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36099918</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-3791</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell reports. Medicine</Title><ISOAbbreviation>Cell Rep Med</ISOAbbreviation></Journal><ArticleTitle>A genetically modified minipig model for Alzheimer's disease with SORL1 haploinsufficiency.</ArticleTitle><Pagination><StartPage>100740</StartPage><MedlinePgn>100740</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100740</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xcrm.2022.100740</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-3791(22)00289-0</ELocationID><Abstract><AbstractText>The established causal genes in Alzheimer's disease (AD), APP, PSEN1, and PSEN2, are functionally characterized using biomarkers, capturing an in&#xa0;vivo profile reflecting the disease's initial preclinical phase. Mutations in SORL1, encoding the endosome recycling receptor SORLA, are found in 2%-3% of individuals with early-onset AD, and SORL1 haploinsufficiency appears to be causal for AD. To test whether SORL1 can function as an AD causal gene, we use CRISPR-Cas9-based gene editing to develop a model of SORL1 haploinsufficiency in G&#xf6;ttingen minipigs, taking advantage of porcine models for biomarker investigations. SORL1 haploinsufficiency in young adult minipigs is found to phenocopy the preclinical in&#xa0;vivo profile of AD observed with APP, PSEN1, and PSEN2, resulting in elevated levels of &#x3b2;-amyloid (A&#x3b2;) and tau preceding amyloid plaque formation and neurodegeneration, as observed in humans. Our study provides functional support for the theory that SORL1 haploinsufficiency leads to endosome cytopathology with biofluid hallmarks of autosomal dominant AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Olav M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark. Electronic address: o.andersen@biomed.au.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf8;gh</LastName><ForeName>Nikolaj</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pl&#xf8;en</LastName><ForeName>Gro G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Anne Mette G</ForeName><Initials>AMG</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monti</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulh&#xf8;i</LastName><ForeName>Benedicte P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyengaard</LastName><ForeName>Jens R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Core Center for Molecular Morphology, Section for Stereology and Microscopy, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>Kirsten R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Ellegaard G&#xf6;ttingen Minipigs A/S, Dalmose, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf8;rgensen</LastName><ForeName>Margarita M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Randers Regional Hospital, Randers, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Ida E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Pathology, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristensen</LastName><ForeName>Marianne L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alstrup</LastName><ForeName>Aage Kristian O</ForeName><Initials>AKO</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Nuclear Medicine &amp; PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Esben S S</ForeName><Initials>ESS</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breidenbach</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuroscience Research, AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Droescher</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Research, AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Animal Science, Aarhus University, Tjele, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Hanne S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Animal Science, Aarhus University, Tjele, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callesen</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Animal Science, Aarhus University, Tjele, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yonglun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark; Lars Bolund Institute of Regenerative Medicine, Qingdao-Europe Advanced Institute for Life Sciences, BGI-Shenzhen, Qingdao, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolund</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark; Lars Bolund Institute of Regenerative Medicine, Qingdao-Europe Advanced Institute for Life Sciences, BGI-Shenzhen, Qingdao, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Translational and Clinical Research Institute, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laustsen</LastName><ForeName>Christoffer</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikkelsen</LastName><ForeName>Lars F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Ellegaard G&#xf6;ttingen Minipigs A/S, Dalmose, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Charlotte B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: cbs@clin.au.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep Med</MedlineTA><NlmUniqueID>101766894</NlmUniqueID><ISSNLinking>2666-3791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057895" MajorTopicYN="N">Haploinsufficiency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013556" MajorTopicYN="N">Swine, Miniature</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">CRISPR-Cas9</Keyword><Keyword MajorTopicYN="N">SORL1</Keyword><Keyword MajorTopicYN="N">SORLA</Keyword><Keyword MajorTopicYN="N">genome editing</Keyword><Keyword MajorTopicYN="N">large animal model</Keyword><Keyword MajorTopicYN="N">retromer-dependent endosomal recycling</Keyword></KeywordList><CoiStatement>Declaration of interests L.B. and M.D. are employees of AbbVie and own AbbVie stock. AbbVie participated in the design and study conduct for this research as well as in the interpretation of data, review, and approval of the publication. Ellegaard G&#xf6;ttingen Minipigs A/S has the commercialization rights to the genetically altered G&#xf6;ttingen minipig SORL1 model. S.A.S. is a co-founder of Retromer Therapeutics, has equity in the company, and is a paid consultant to the company. O.M.A. also has commercial interests in Retromer Therapeutics, but the company was not involved in any aspects of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36099918</ArticleId><ArticleId IdType="pmc">PMC9512670</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2022.100740</ArticleId><ArticleId IdType="pii">S2666-3791(22)00289-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cacace R., Sleegers K., Van Broeckhoven C. Molecular genetics of early-onset Alzheimer's disease revisited. Alzheimers Dement. 2016;12:733&#x2013;748. doi: 10.1016/j.jalz.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.012</ArticleId><ArticleId IdType="pubmed">27016693</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., De Strooper B., Kivipelto M., Holstege H., Ch&#xe9;telat G., Teunissen C.E., Cummings J., van der Flier W.M. Alzheimer's disease. Lancet. 2021;397:1577&#x2013;1590. doi: 10.1016/S0140-6736(20)32205-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32205-4</ArticleId><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M., Schr&#xf6;der J., Blomberg M., Engvall B., Pantel J., Ida N., Basun H., Wahlund L.O., Werle E., Jauss M., et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 1999;45:504&#x2013;511. doi: 10.1002/1531-8249(199904)45:4&lt;504::aid-ana12&gt;3.0.co;2-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199904)45:4&lt;504::aid-ana12&gt;3.0.co;2-9</ArticleId><ArticleId IdType="pubmed">10211475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N.&#xa0;Engl. J. Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia L.F., Kaeser S.A., Reichwald J., Lambert M., Oberm&#xfc;ller U., Schelle J., Odenthal J., Martus P., Staufenbiel M., Jucker M. Increased CSF Abeta during the very early phase of cerebral Abeta deposition in mouse models. EMBO Mol. Med. 2015;7:895&#x2013;903. doi: 10.15252/emmm.201505026.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201505026</ArticleId><ArticleId IdType="pmc">PMC4520655</ArticleId><ArticleId IdType="pubmed">25978969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB. J. 2017;31:2729&#x2013;2743. doi: 10.1096/fj.201700359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700359</ArticleId><ArticleId IdType="pmc">PMC6137496</ArticleId><ArticleId IdType="pubmed">28663518</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A., Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron. 2006;52:15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A., Kent K., Pierce A., Leung C., Kang M.S., Okada H., Honig L., Vonsattel J.P., Kim T.W. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann. Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A., Flores I., Zhang H., Yu R., Staniszewski A., Planel E., Herman M., Ho L., Kreber R., Honig L.S., et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc. Natl. Acad. Sci. USA. 2008;105:7327&#x2013;7332. doi: 10.1073/pnas.0802545105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802545105</ArticleId><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan N.S., Brickman A.M., Andrews H., Manly J.J., Schupf N., Lantigua R., Wolock C.J., Kamalakaran S., Petrovski S., Tosto G., et al. Whole-exome sequencing in 20, 197 persons for rare variants in Alzheimer's disease. Ann. Clin. Transl. Neurol. 2018;5:832&#x2013;842. doi: 10.1002/acn3.582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.582</ArticleId><ArticleId IdType="pmc">PMC6043775</ArticleId><ArticleId IdType="pubmed">30009200</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H., Hulsman M., Charbonnier C., Grenier-Boley B., Quenez O., Drozeva D., et al. Exome sequencing identifies novel AD-associated genes. Preprint at medRxiv. 2020 doi: 10.1101/2020.07.22.20159251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.22.20159251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjorback A.W., Seaman M., Gustafsen C., Mehmedbasic A., Gokool S., Wu C., Militz D., Schmidt V., Madsen P., Nyengaard J.R., et al. Retromer binds the FANSHY sorting motif in sorLA to regulate amyloid precursor protein sorting and processing. J.&#xa0;Neurosci. 2012;32:1467&#x2013;1480. doi: 10.1523/JNEUROSCI.2272-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2272-11.2012</ArticleId><ArticleId IdType="pmc">PMC6796259</ArticleId><ArticleId IdType="pubmed">22279231</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M., Hartl D., Fjorback A.N., Klose J., Willnow T.E. SORLA-mediated trafficking of TrkB enhances the response of neurons to BDNF. PLoS One. 2013;8:e72164. doi: 10.1371/journal.pone.0072164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0072164</ArticleId><ArticleId IdType="pmc">PMC3747043</ArticleId><ArticleId IdType="pubmed">23977241</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietil&#xe4; M., Sahgal P., Peuhu E., J&#xe4;ntti N.Z., Paatero I., N&#xe4;rv&#xe4; E., Al-Akhrass H., Lilja J., Georgiadou M., Andersen O.M., et al. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat. Commun. 2019;10:2340. doi: 10.1038/s41467-019-10275-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10275-0</ArticleId><ArticleId IdType="pmc">PMC6538630</ArticleId><ArticleId IdType="pubmed">31138794</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes S., Guo J., Buitrago L., Qureshi Y.H., Feng X., Kothiya M., Cortes E., Patel V., Kannan S., Kim Y.H., et al. Alzheimer's vulnerable brain region relies on a distinct retromer core dedicated to endosomal recycling. Cell Rep. 2021;37:110182. doi: 10.1016/j.celrep.2021.110182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110182</ArticleId><ArticleId IdType="pmc">PMC8792909</ArticleId><ArticleId IdType="pubmed">34965419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S., Knupp A., Szabo M.P., Williams C.A., Kinoshita C., Hailey D.W., Wang Y., Andersen O.M., Young J.E. The Alzheimer's gene SORL1 is a regulator of endosomal traffic and recycling in human neurons. Cell. Mol. Life Sci. 2022;79:162. doi: 10.1007/s00018-022-04182-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04182-9</ArticleId><ArticleId IdType="pmc">PMC8885486</ArticleId><ArticleId IdType="pubmed">35226190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A., Kim S., Subbanna S., Bleiwas C., Goulbourne C.N., Stavrides P.H., Jiang Y., Lee J.H., Darji S., Pawlik M., et al. Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer's disease. Cell Rep. 2020;33:108420. doi: 10.1016/j.celrep.2020.108420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108420</ArticleId><ArticleId IdType="pmc">PMC7714675</ArticleId><ArticleId IdType="pubmed">33238112</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A., Petsko G.A. Endosomal recycling reconciles the Alzheimer's disease paradox. Sci. Transl. Med. 2020;12:eabb1717. doi: 10.1126/scitranslmed.abb1717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb1717</ArticleId><ArticleId IdType="pmc">PMC8025181</ArticleId><ArticleId IdType="pubmed">33268506</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrinha T., Martinsson I., Gomes R., Terrasso A.P., Gouras G.K., Almeida C.G. Upregulation of APP endocytosis by neuronal aging drives amyloid-dependent synapse loss. J.&#xa0;Cell Sci. 2021;134:jcs255752. doi: 10.1242/jcs.255752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.255752</ArticleId><ArticleId IdType="pubmed">33910234</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A., Petsko G.A. Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 2015;16:126&#x2013;132. doi: 10.1038/nrn3896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3896</ArticleId><ArticleId IdType="pubmed">25669742</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes S., Neufeld J.L., Triana-Baltzer G., Moughadam S., Chen E.I., Kothiya M., Qureshi Y.H., Patel V., Honig L.S., Kolb H., Small S.A. Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. Sci. Transl. Med. 2020;12:eaba6334. doi: 10.1126/scitranslmed.aba6334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aba6334</ArticleId><ArticleId IdType="pmc">PMC7901670</ArticleId><ArticleId IdType="pubmed">33239387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovtun O., Leneva N., Bykov Y.S., Ariotti N., Teasdale R.D., Schaffer M., Engel B.D., Owen D.J., Briggs J.A.G., Collins B.M. Structure of the membrane-assembled retromer coat determined by cryo-electron tomography. Nature. 2018;561:561&#x2013;564. doi: 10.1038/s41586-018-0526-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0526-z</ArticleId><ArticleId IdType="pmc">PMC6173284</ArticleId><ArticleId IdType="pubmed">30224749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugarcic A., Zhe Y., Kerr M.C., Griffin J., Collins B.M., Teasdale R.D. Vps26A and Vps26B subunits define distinct retromer complexes. Traffic. 2011;12:1759&#x2013;1773. doi: 10.1111/j.1600-0854.2011.01284.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2011.01284.x</ArticleId><ArticleId IdType="pubmed">21920005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D., Gregg A., Scheckel C., Murphy E.A., Paquet D., Duffield M., Fak J., Olsen O., Darnell R.B., Tessier-Lavigne M. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP beta-CTFs, not Abeta. Neuron. 2019;104:256&#x2013;270.e5. doi: 10.1016/j.neuron.2019.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.010</ArticleId><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., von Arnim C.A.F., Breiderhoff T., Jansen P., Wu X., et al. SorLA/LR11, a neuronal sorting receptor that regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen O.M., Rudolph I.M., Willnow T.E. Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease. Acta Neuropathol. 2016;132:653&#x2013;665. doi: 10.1007/s00401-016-1615-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1615-4</ArticleId><ArticleId IdType="pmc">PMC5073117</ArticleId><ArticleId IdType="pubmed">27638701</ArticleId></ArticleIdList></Reference><Reference><Citation>Knupp A., Mishra S., Martinez R., Braggin J.E., Szabo M., Kinoshita C., Hailey D.W., Small S.A., Jayadev S., Young J.E. Depletion of the AD risk gene SORL1 selectively impairs neuronal endosomal traffic independent of amyloidogenic APP processing. Cell Rep. 2020;31:107719. doi: 10.1016/j.celrep.2020.107719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107719</ArticleId><ArticleId IdType="pmc">PMC7409533</ArticleId><ArticleId IdType="pubmed">32492427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung C., Tuck E., Stubbs V., van der Lee S.J., Aalfs C., van Spaendonk R., Scheltens P., Hardy J., Holstege H., Livesey F.J. SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. Cell Rep. 2021;35:109259. doi: 10.1016/j.celrep.2021.109259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109259</ArticleId><ArticleId IdType="pmc">PMC8220253</ArticleId><ArticleId IdType="pubmed">34133918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol. Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Villadsen J., Hansen H.D., J&#xf8;rgensen L.M., Keller S.H., Andersen F.L., Petersen I.N., Knudsen G.M., Svarer C. Automatic delineation of brain regions on MRI and PET images from the pig. J.&#xa0;Neurosci. Methods. 2018;294:51&#x2013;58. doi: 10.1016/j.jneumeth.2017.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2017.11.008</ArticleId><ArticleId IdType="pubmed">29146191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernersson R., Schierup M.H., J&#xf8;rgensen F.G., Gorodkin J., Panitz F., Staerfeldt H.H., Christensen O.F., Mailund T., Hornsh&#xf8;j H., Klein A., et al. Pigs in sequence space: a 0.66X coverage pig genome survey based on shotgun sequencing. BMC Genom. 2005;6:70. doi: 10.1186/1471-2164-6-70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-6-70</ArticleId><ArticleId IdType="pmc">PMC1142312</ArticleId><ArticleId IdType="pubmed">15885146</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X.H., Siman R., Iwata A., Meaney D.F., Trojanowski J.Q., Smith D.H. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am. J. Pathol. 2004;165:357&#x2013;371. doi: 10.1016/s0002-9440(10)63303-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)63303-2</ArticleId><ArticleId IdType="pmc">PMC1618579</ArticleId><ArticleId IdType="pubmed">15277212</ArticleId></ArticleIdList></Reference><Reference><Citation>Brzozowska A., Grimholt U., Kulseth M.A., Wold I., Rogne S. The sequence of porcine apolipoprotein E (APOE) cDNA. DNA Sequence. 1993;4:207&#x2013;210. doi: 10.3109/10425179309015633.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10425179309015633</ArticleId><ArticleId IdType="pubmed">8161823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsoondar J.J., Rucker E.B., Vasquez J.C., Gallagher D.S., Grimm D.R., Lunney J.K., Schook L.B., Piedrahita J.A. Isolation and genetic characterization of the porcine apolipoprotein E gene. Anim. Genet. 1998;29:43&#x2013;47. doi: 10.1046/j.1365-2052.1998.00273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2052.1998.00273.x</ArticleId><ArticleId IdType="pubmed">9682450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso M., Buyssens L., Stroe M., Valenzuela A., Allegaert K., Smits A., Annaert P., Mulder A., Carpentier S., Van Ginneken C., Van Cruchten S. The Neonatal and Juvenile pig in pediatric drug discovery and development. Pharmaceutics. 2021;13:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7823749</ArticleId><ArticleId IdType="pubmed">33396805</ArticleId></ArticleIdList></Reference><Reference><Citation>Motoi Y., Aizawa T., Haga S., Nakamura S., Namba Y., Ikeda K. Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain. Brain Res. 1999;833:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">10375696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermey G., Sj&#xf8;gaard S.S., Petersen C.M., Nykj&#xe6;r A., Gliemann J. Tumour necrosis factor a-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem. J. 2006;395:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422770</ArticleId><ArticleId IdType="pubmed">16393139</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;shaus J., M&#xfc;ller S.A., Kataka E.S., Zaucha J., Sebastian Monasor L., Su M., G&#xfc;ner G., Jocher G., Tahirovic S., Frishman D., et al. An optimized quantitative proteomics method establishes the cell type-resolved mouse brain secretome. EMBO J. 2020;39:e105693. doi: 10.15252/embj.2020105693.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020105693</ArticleId><ArticleId IdType="pmc">PMC7560198</ArticleId><ArticleId IdType="pubmed">32954517</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I., Lah J.J. The lipoprotein receptor LR11 regulates amyloid b production and amyloid precursor protein traffic in endosomal compartments. J.&#xa0;Neurosci. 2006;26:1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Blechingberg J., Poulsen A.S.A., Kj&#xf8;lby M., Monti G., Allen M., Ivarsen A.K., Lincoln S.J., Thotakura G., V&#xe6;gter C.B., Ertekin-Taner N., et al. An alternative transcript of the Alzheimer's disease risk gene SORL1 encodes a truncated receptor. Neurobiol. Aging. 2018;71:266.e11&#x2013;266.e24. doi: 10.1016/j.neurobiolaging.2018.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.06.021</ArticleId><ArticleId IdType="pmc">PMC6769419</ArticleId><ArticleId IdType="pubmed">30078640</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen S.K., Narimatsu Y., Simoes S., Goth C.K., V&#xe6;gter C.B., Small S.A., Clausen H., Andersen O.M. Endosomal trafficking is required for glycosylation and normal maturationof the Alzheimer&#x2019;s-associated protein sorLA. bioRxiv. 2020 doi: 10.1101/2020.07.12.199885. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.12.199885</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson S.E., Andersen O.M., Karmali V., Fritz J.J., Cheng D., Peng J., Levey A.I., Willnow T.E., Lah J.J. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J.&#xa0;Neurosci. 2008;28:12877&#x2013;12886. doi: 10.1523/JNEUROSCI.4582-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4582-08.2008</ArticleId><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P., Kamrowski-Kruck H., Peters O., Heuser I., Jessen F., Popp J., B&#xfc;rger K., Hampel H., Fr&#xf6;lich L., Wolf S., et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol. Psychiatr. 2010;15:138&#x2013;145. doi: 10.1038/mp.2008.84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2008.84</ArticleId><ArticleId IdType="pubmed">18663368</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W., Hattori K., Kanemaru K., Yokoi Y., Omachi Y., Takano H., Sakata M., Yoshida S., Tsukamoto T., Murata M., et al. Re-evaluation of soluble APP-alpha and APP-beta in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders. Biomark. Res. 2017;5:28. doi: 10.1186/s40364-017-0108-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40364-017-0108-5</ArticleId><ArticleId IdType="pmc">PMC5610422</ArticleId><ArticleId IdType="pubmed">29018524</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J.E., Fong L.K., Frankowski H., Petsko G.A., Small S.A., Goldstein L.S.B. Stabilizing the retromer complex in a human stem cell model of Alzheimer's disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Rep. 2018;10:1046&#x2013;1058. doi: 10.1016/j.stemcr.2018.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2018.01.031</ArticleId><ArticleId IdType="pmc">PMC5919412</ArticleId><ArticleId IdType="pubmed">29503090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnozzi A.N., Li J.G., Chiu J., Razmpour R., Warfield R., Ramirez S.H., Pratic&#xf2; D. VPS35 regulates tau phosphorylation and neuropathology in tauopathy. Mol. Psychiatr. 2021;26:6992&#x2013;7005. doi: 10.1038/s41380-019-0453-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0453-x</ArticleId><ArticleId IdType="pmc">PMC6949432</ArticleId><ArticleId IdType="pubmed">31289348</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A.M., Barnett J.L., Pieroni C., Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J.&#xa0;Neurosci. 1997;17:6142&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568334</ArticleId><ArticleId IdType="pubmed">9236226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000;157:277&#x2013;286. doi: 10.1016/s0002-9440(10)64538-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)64538-5</ArticleId><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonvento G., Valette J., Flament J., Mochel F., Brouillet E. Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases. J.&#xa0;Cerebr. Blood Flow Metabol. 2017;37:1927&#x2013;1943. doi: 10.1177/0271678X17697989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X17697989</ArticleId><ArticleId IdType="pmc">PMC5464722</ArticleId><ArticleId IdType="pubmed">28276944</ArticleId></ArticleIdList></Reference><Reference><Citation>Aung W.Y., Mar S., Benzinger T.L. Diffusion tensor MRI as a biomarker in axonal and myelin damage. Imag. Med. 2013;5:427&#x2013;440. doi: 10.2217/iim.13.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/iim.13.49</ArticleId><ArticleId IdType="pmc">PMC4004089</ArticleId><ArticleId IdType="pubmed">24795779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N., Andreasson U., Zetterberg H., Blennow K., Alzheimer&#x2019;s Disease Neuroimaging Initiative Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557&#x2013;566. doi: 10.1001/jamaneurol.2016.6117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H., van der Lee S.J., Hulsman M., Wong T.H., van Rooij J.G., Weiss M., Louwersheimer E., Wolters F.J., Amin N., Uitterlinden A.G., et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. Eur. J. Hum. Genet. 2017;25:973&#x2013;981. doi: 10.1038/ejhg.2017.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2017.87</ArticleId><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M., Carlo A.S., Breyhan H., Sporbert A., Militz D., Schmidt V., Wozny C., Harmeier A., Erdmann B., Bales K.R., et al. Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis. J.&#xa0;Biol. Chem. 2008;283:14826&#x2013;14834. doi: 10.1074/jbc.M710574200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M710574200</ArticleId><ArticleId IdType="pubmed">18362153</ArticleId></ArticleIdList></Reference><Reference><Citation>Corlier F., Rivals I., Lagarde J., Hamelin L., Corne H., Dauphinot L., Ando K., Cossec J.C., Fontaine G., Doroth&#xe9;e G., et al. Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer's disease patients. Transl. Psychiatry. 2015;5:e595. doi: 10.1038/tp.2015.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2015.87</ArticleId><ArticleId IdType="pmc">PMC5068716</ArticleId><ArticleId IdType="pubmed">26151923</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A., Simoes-Spassov S., Mayeux R., Petsko G.A. Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer's disease. Trends Neurosci. 2017;40:592&#x2013;602. doi: 10.1016/j.tins.2017.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2017.08.003</ArticleId><ArticleId IdType="pmc">PMC5654621</ArticleId><ArticleId IdType="pubmed">28962801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi V.J., Berman D.E., Simoes S., Vetanovetz C., Awal M.R., Patel V.M., Schneider R.T., Petsko G.A., Ringe D., Small S.A. Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 2014;10:443&#x2013;449. doi: 10.1038/nchembio.1508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1508</ArticleId><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I., B&#xe9;cot A., Bourgeois A., Pardossi-Piquard R., Biferi M.G., Barkats M., Checler F. Targeting gamma-secretase triggers the selective enrichment of oligomeric APP-CTFs in brain extracellular vesicles from Alzheimer cell and mouse models. Transl. Neurodegener. 2019;8:35. doi: 10.1186/s40035-019-0176-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-019-0176-6</ArticleId><ArticleId IdType="pmc">PMC6894230</ArticleId><ArticleId IdType="pubmed">31827783</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbo B.D., Cechinel L.R., Palazzo R.P., Siqueira I.R. Endosomal dysfunction impacts extracellular vesicle release: central role in Abeta pathology. Ageing Res. Rev. 2020:101006. doi: 10.1016/j.arr.2019.101006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2019.101006</ArticleId><ArticleId IdType="pubmed">31891813</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron. 2000;27:419&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055423</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsen J.E., Johansen M.G., Schmidt M., Liu Y., Li R., Callesen H., Melnikova M., Habekost M., Matrone C., Bouter Y., et al. Expression of the Alzheimer's disease mutations AbetaPP695sw and PSEN1M146I in double-transgenic gottingen minipigs. J.&#xa0;Alzheim. Dis. 2016;53:1617&#x2013;1630. doi: 10.3233/JAD-160408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160408</ArticleId><ArticleId IdType="pubmed">27540966</ArticleId></ArticleIdList></Reference><Reference><Citation>Carosi J.M., Denton D., Kumar S., Sargeant T.J. Retromer dysfunction at the nexus of tauopathies. Cell Death Differ. 2021;28:884&#x2013;899. doi: 10.1038/s41418-020-00727-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00727-2</ArticleId><ArticleId IdType="pmc">PMC7937680</ArticleId><ArticleId IdType="pubmed">33473181</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kant R., Goldstein L.S.B., Ossenkoppele R. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat. Rev. Neurosci. 2020;21:21&#x2013;35. doi: 10.1038/s41583-019-0240-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-019-0240-3</ArticleId><ArticleId IdType="pubmed">31780819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos S.J., Xiong C., Visser P.J., Jasielec M.S., Hassenstab J., Grant E.A., Cairns N.J., Morris J.C., Holtzman D.M., Fagan A.M. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12:957&#x2013;965. doi: 10.1016/S1474-4422(13)70194-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Konijnenberg E., Tomassen J., den Braber A., Ten Kate M., Yaqub M., Mulder S.D., Nivard M.G., Vanderstichele H., Lammertsma A.A., Teunissen C.E., et al. Onset of preclinical Alzheimer disease in monozygotic twins. Ann. Neurol. 2021;89:987&#x2013;1000. doi: 10.1002/ana.26048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26048</ArticleId><ArticleId IdType="pmc">PMC8251701</ArticleId><ArticleId IdType="pubmed">33583080</ArticleId></ArticleIdList></Reference><Reference><Citation>Habekost M., Qvist P., Denham M., Holm I.E., J&#xf8;rgensen A.L. Directly reprogrammed neurons express MAPT and APP splice variants pertinent to ageing and neurodegeneration. Mol. Neurobiol. 2021;58:2075&#x2013;2087. doi: 10.1007/s12035-020-02258-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02258-w</ArticleId><ArticleId IdType="pmc">PMC8018937</ArticleId><ArticleId IdType="pubmed">33415685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode G., Clausing P., Gervais F., Loegsted J., Luft J., Nogues V., Sims J., Steering Group of the RETHINK Project The utility of the minipig as an animal model in regulatory toxicology. J.&#xa0;Pharmacol. Toxicol. Methods. 2010;62:196&#x2013;220. doi: 10.1016/j.vascn.2010.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vascn.2010.05.009</ArticleId><ArticleId IdType="pubmed">20685310</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen H.D., Mikkelsen L.F. Biomarkers in Toxicolgy. Second Edition. 2019. G&#xf4;ttingen minipigs as large animal model in toxicology; pp. 75&#x2013;89.</Citation></Reference><Reference><Citation>Gieling E., Wehkamp W., Willigenburg R., Nordquist R.E., Ganderup N.C., van der Staay F.J. Performance of conventional pigs and Gottingen miniature pigs in a spatial holeboard task: effects of the putative muscarinic cognition impairer Biperiden. Behav. Brain Funct. 2013;9:4. doi: 10.1186/1744-9081-9-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1744-9081-9-4</ArticleId><ArticleId IdType="pmc">PMC3563551</ArticleId><ArticleId IdType="pubmed">23305134</ArticleId></ArticleIdList></Reference><Reference><Citation>Roelofs S., Murphy E., Ni H., Gieling E., Nordquist R.E., van der Staay F.J. Judgement bias in pigs is independent of performance in a spatial holeboard task and conditional discrimination learning. Anim. Cognit. 2017;20:739&#x2013;753. doi: 10.1007/s10071-017-1095-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10071-017-1095-5</ArticleId><ArticleId IdType="pmc">PMC5486501</ArticleId><ArticleId IdType="pubmed">28508125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli M., Rago C., Lengauer C., Kinzler K.W., Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res. 2004;32:e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373311</ArticleId><ArticleId IdType="pubmed">14704360</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander J.D., Maeder M.L., Reyon D., Voytas D.F., Joung J.K., Dobbs D. ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool. Nucleic Acids Res. 2010;38:W462&#x2013;W468. doi: 10.1093/nar/gkq319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq319</ArticleId><ArticleId IdType="pmc">PMC2896148</ArticleId><ArticleId IdType="pubmed">20435679</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science. 2013;339:823&#x2013;826. doi: 10.1126/science.1232033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232033</ArticleId><ArticleId IdType="pmc">PMC3712628</ArticleId><ArticleId IdType="pubmed">23287722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Liu Y., Hussmann D., Br&#xf8;gger P., Al-Saaidi R.A., Tan S., Lin L., Petersen T.S., Zhou G.Q., Bross P., et al. Enhanced genome editing in mammalian cells with a modified dual-fluorescent surrogate system. Cell. Mol. Life Sci. 2016;73:2543&#x2013;2563. doi: 10.1007/s00018-015-2128-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-2128-3</ArticleId><ArticleId IdType="pmc">PMC11108510</ArticleId><ArticleId IdType="pubmed">26755436</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Pedersen H.S., Li R., Adamsen J., Liu Y., Schmidt M., Purup S., Callesen H. Developmental potential of pig embryos reconstructed by use of sow versus pre-pubertal gilt oocytes after somatic cell nuclear transfer. Zygote. 2014;22:356&#x2013;365. doi: 10.1017/S0967199412000676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0967199412000676</ArticleId><ArticleId IdType="pubmed">23331714</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M., Kragh P.M., Li J., Du Y., Lin L., Liu Y., B&#xf8;gh I.B., Winther K.D., Vajta G., Callesen H. Pregnancies and piglets from large white sow recipients after two transfer methods of cloned and transgenic embryos of different pig breeds. Theriogenology. 2010;74:1233&#x2013;1240. doi: 10.1016/j.theriogenology.2010.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.theriogenology.2010.05.026</ArticleId><ArticleId IdType="pubmed">20688371</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae S., Park J., Kim J.S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. 2014;30:1473&#x2013;1475. doi: 10.1093/bioinformatics/btu048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu048</ArticleId><ArticleId IdType="pmc">PMC4016707</ArticleId><ArticleId IdType="pubmed">24463181</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L., Madsen P., Jacobsen C., Nielsen M.S., Gliemann J., Petersen C.M. Activation and functional characterization of the mosaic receptor SorLA/LR11. J.&#xa0;Biol. Chem. 2001;276:22788&#x2013;22796.</Citation><ArticleIdList><ArticleId IdType="pubmed">11294867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M., Beckmann C.F., Behrens T.E.J., Woolrich M.W., Smith S.M. Neuroimage. 2012;62:782&#x2013;790. doi: 10.1016/j.neuroimage.2011.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.09.015</ArticleId><ArticleId IdType="pubmed">21979382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36048943</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>377</Volume><Issue>6610</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>GnRH replacement rescues cognition in Down syndrome.</ArticleTitle><Pagination><StartPage>eabq4515</StartPage><MedlinePgn>eabq4515</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abq4515</ELocationID><Abstract><AbstractText>At the present time, no viable treatment exists for cognitive and olfactory deficits in Down syndrome (DS). We show in a DS model (Ts65Dn mice) that these progressive nonreproductive neurological symptoms closely parallel a postpubertal decrease in hypothalamic as well as extrahypothalamic expression of a master molecule that controls reproduction-gonadotropin-releasing hormone (GnRH)-and appear related to an imbalance in a microRNA-gene network known to regulate GnRH neuron maturation together with altered hippocampal synaptic transmission. Epigenetic, cellular, chemogenetic, and pharmacological interventions that restore physiological GnRH levels abolish olfactory and cognitive defects in Ts65Dn mice, whereas pulsatile GnRH therapy improves cognition and brain connectivity in adult DS patients. GnRH thus plays a crucial role in olfaction and cognition, and pulsatile GnRH therapy holds promise to improve cognitive deficits in DS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Manfredi-Lozano</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3801-1955</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Leysen</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Adamo</LastName><ForeName>Michela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9994-0945</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paiva</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-7607-9390</Identifier><AffiliationInfo><Affiliation>Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR 7364, Universit&#xe9; de Strasbourg-CNRS, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovera</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2017-1451</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Lyon, Universit&#xe9; Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pignat</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Neurorehabilitation Unit, University Hospital CHUV, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timzoura</LastName><ForeName>Fatima Ezzahra</ForeName><Initials>FE</Initials><Identifier Source="ORCID">0000-0002-0499-9785</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Candlish</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Pharmacology, Center for Molecular Signaling (PZMS), Saarland University School of Medicine, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eddarkaoui</LastName><ForeName>Sabiha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5057-9335</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Samuel A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-6824-6854</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Mauro S B</ForeName><Initials>MSB</Initials><Identifier Source="ORCID">0000-0003-4447-6388</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trova</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9270-4977</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imbernon</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Decoster</LastName><ForeName>Laurine</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotellessa</LastName><ForeName>Ludovica</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1124-576X</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tena-Sempere</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4741-5567</Identifier><AffiliationInfo><Affiliation>Universidad de C&#xf3;rdoba, IMIBC/HURS, CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n, Instituto de Salud Carlos III, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claret</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7766-9296</Identifier><AffiliationInfo><Affiliation>Neuronal Control of Metabolism Laboratory, Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red (CIBER) de Diabetes y Enfermedades Metab&#xf3;licas Asociadas (CIBERDEM), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paoloni-Giacobino</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9432-1785</Identifier><AffiliationInfo><Affiliation>Department of Genetic Medicine, University Hospitals of Geneva, Gen&#xe8;ve, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plassard</LastName><ForeName>Damien</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8569-6163</Identifier><AffiliationInfo><Affiliation>CNRS UMR 7104, INSERM U1258, GenomEast Platform, Institut de G&#xe9;n&#xe9;tique et de Biologie Mol&#xe9;culaire et Cellulaire (IGBMC), Universit&#xe9; de Strasbourg, Illkirch, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paccou</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vionnet</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5420-8216</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acierno</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maceski</LastName><ForeName>Aleksandra Maleska</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-1916-5927</Identifier><AffiliationInfo><Affiliation>Neurologic Clinic and Polyclinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutti</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3281-5477</Identifier><AffiliationInfo><Affiliation>Laboratory for Research in Neuroimaging (LREN), Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfrieger</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7085-1431</Identifier><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique, Universit&#xe9; de Strasbourg, Institut des Neurosciences Cellulaires et Int&#xe9;gratives, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasika</LastName><ForeName>S</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8733-4641</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santoni</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3258-4747</Identifier><AffiliationInfo><Affiliation>Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehm</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-2436-6907</Identifier><AffiliationInfo><Affiliation>Experimental Pharmacology, Center for Molecular Signaling (PZMS), Saarland University School of Medicine, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciofi</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Inserm, U1215, Neurocentre Magendie, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu&#xe9;e</LastName><ForeName>Luc</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6261-4230</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddjeri</LastName><ForeName>Nasser</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lyon, Universit&#xe9; Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutillier</LastName><ForeName>Anne-Laurence</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-2317-9280</Identifier><AffiliationInfo><Affiliation>Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR 7364, Universit&#xe9; de Strasbourg-CNRS, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhle</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurologic Clinic and Polyclinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2393-1874</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draganski</LastName><ForeName>Bogdan</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5159-5919</Identifier><AffiliationInfo><Affiliation>Laboratory for Research in Neuroimaging (LREN), Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Giacobini</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3075-1441</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pitteloud</LastName><ForeName>Nelly</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0971-3237</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Prevot</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-7185-3615</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, UMR-S 1172, Labex DistAlz, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, EGID, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>135679</GrantID><Acronym>SNSF_</Acronym><Agency>Swiss National Science Foundation</Agency><Country>Switzerland</Country></Grant><Grant><GrantID>159780</GrantID><Acronym>SNSF_</Acronym><Agency>Swiss National Science Foundation</Agency><Country>Switzerland</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33515-09-2</RegistryNumber><NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2022 Sep 2;377(6610):1042-1043. doi: 10.1126/science.add9456.</RefSource><PMID Version="1">36048939</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2023 Feb 1;8(1):49. doi: 10.1038/s41392-023-01321-x.</RefSource><PMID Version="1">36725840</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="Y">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007987" MajorTopicYN="Y">Gonadotropin-Releasing Hormone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="Y">Olfaction Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> M.M.-L., V.L., A.M. P.G. and V.P. disclose that they are inventors of a patent covering the treatment of cognitive disorder and dementia with pulsatile GnRH (82). All other authors do not have competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36048943</ArticleId><ArticleId IdType="mid">EMS156431</ArticleId><ArticleId IdType="pmc">PMC7613827</ArticleId><ArticleId IdType="doi">10.1126/science.abq4515</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonarakis SE, et al. Down syndrome. Nat Rev Dis Primers. 2020;6:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8428796</ArticleId><ArticleId IdType="pubmed">32029743</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre R, et al. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down&#x2019;s syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:801&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">27302362</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro BL. Down syndrome--a disruption of homeostasis. Am J Med Genet. 1983;14:241&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">6220605</ArticleId></ArticleIdList></Reference><Reference><Citation>Baburamani AA, Patkee PA, Arichi T, Rutherford MA. New approaches to studying early brain development in Down syndrome. Dev Med Child Neurol. 2019;61:867&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618001</ArticleId><ArticleId IdType="pubmed">31102269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull MJ. Down Syndrome. N Engl J Med. 2020;382:2344&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pubmed">32521135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, et al. Clinical and biomarker changes of Alzheimer&#x2019;s disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395:1988&#x2013;1997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7322523</ArticleId><ArticleId IdType="pubmed">32593336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayen E, Possin KL, Chen Y, Cleret de Langavant L, Yaffe K. Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome. JAMA Neurol. 2018;75:1399&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248113</ArticleId><ArticleId IdType="pubmed">30032260</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonarakis SE. Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet. 2017;18:147&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">28029161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dierssen M. Down syndrome: the brain in trisomic mode. Nat Rev Neurosci. 2012;13:844&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">23165261</ArticleId></ArticleIdList></Reference><Reference><Citation>Editorial TL. Strengthening connections between Down syndrome and AD. Lancet Neurol. 2013;12:931.</Citation><ArticleIdList><ArticleId IdType="pubmed">24050729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15:135&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8061428</ArticleId><ArticleId IdType="pubmed">30733618</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Serrano JL, et al. Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination. Neuron. 2016;89:1208&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4795969</ArticleId><ArticleId IdType="pubmed">26924435</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012;8:329&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">22584158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijjar RK, Murphy C. Olfactory impairment increases as a function of age in persons with Down syndrome. Neurobiol Aging. 2002;23:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiang YH, Berkovitz GD, Bland GL, Migeon CJ, Warren AC. Gonadal function in patients with Down syndrome. Am J Med Genet. 1987;27:449&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">2955699</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm U, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11:547&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">26194704</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobil E. The GnRH pulse generator. Am J Obstet Gynecol. 1990;163:1721&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pubmed">2122728</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina A, et al. A microRNA switch regulates the rise in hypothalamic GnRH production before puberty. Nat Neurosci. 2016;19:835&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">27135215</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino G, et al. GnRH neurons recruit astrocytes in infancy to facilitate network integration and sexual maturation. Nat Neurosci. 2021;24:1660&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pubmed">34795451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanciotti L, Cofini M, Leonardi A, Penta L, Esposito S. Up-To-Date Review About Minipuberty and Overview on Hypothalamic-Pituitary-Gonadal Axis Activation in Fetal and Neonatal Life. Front Endocrinol (Lausanne) 2018;9:410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070773</ArticleId><ArticleId IdType="pubmed">30093882</ArticleId></ArticleIdList></Reference><Reference><Citation>Casoni F, et al. Development of the neurons controlling fertility in humans: new insights from 3D imaging and transparent fetal brains. Development. 2016;143:3969&#x2013;3981.</Citation><ArticleIdList><ArticleId IdType="pubmed">27803058</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrapits K, et al. The cryptic gonadotropin-releasing hormone neuronal system of human basal ganglia. Elife. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245125</ArticleId><ArticleId IdType="pubmed">34128468</ArticleId></ArticleIdList></Reference><Reference><Citation>Schang AL, et al. GnRH receptor gene expression in the developing rat hippocampus: transcriptional regulation and potential roles in neuronal plasticity. Endocrinology. 2011;152:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">21123436</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves RH, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11:177&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7550346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kola I, Hertzog PJ. Down syndrome and mouse models. Curr Opin Genet Dev. 1998;8:316&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">9690992</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein CJ, et al. Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Hum Genet. 1991;49:207&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683195</ArticleId><ArticleId IdType="pubmed">1829580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi P, et al. Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome. Exp Neurol. 2014;251:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">24192151</ArticleId></ArticleIdList></Reference><Reference><Citation>Breton-Provencher V, Lemasson M, Peralta MR, 3rd, Saghatelyan A. Interneurons produced in adulthood are required for the normal functioning of the olfactory bulb network and for the execution of selected olfactory behaviors. J Neurosci. 2009;29:15245&#x2013;15257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665973</ArticleId><ArticleId IdType="pubmed">19955377</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson L, et al. Learning and memory as a function of age in Down syndrome: a study using animal-based tasks. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:443&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">15795053</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SJ, et al. The rodent hippocampus is essential for nonspatial object memory. Curr Biol. 2013;23:1685&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775586</ArticleId><ArticleId IdType="pubmed">23954431</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, et al. Hypothalamic programming of systemic ageing involving IKK-beta, NF-kappaB and GnRH. Nature. 2013;497:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756938</ArticleId><ArticleId IdType="pubmed">23636330</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CS, et al. Increased male reproductive success in Ts65Dn &#x201c;Down syndrome&#x201d; mice. Mamm Genome. 2010;21:543&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002156</ArticleId><ArticleId IdType="pubmed">21110029</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinspon RP, et al. Early onset of primary hypogonadism revealed by serum anti-Mullerian hormone determination during infancy and childhood in trisomy 21. Int J Androl. 2011;34:e487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">21831236</ArticleId></ArticleIdList></Reference><Reference><Citation>Belle M, et al. Tridimensional Visualization and Analysis of Early Human Development. Cell. 2017;169:161&#x2013;173.:e112.</Citation><ArticleIdList><ArticleId IdType="pubmed">28340341</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto B, et al. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome. Neuron. 2020;108:887&#x2013;904.:e812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736620</ArticleId><ArticleId IdType="pubmed">33027640</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Zhang Y, Li D, Feng Y. Destabilization and mislocalization of myelin basic protein mRNAs in quaking dysmyelination lacking the QKI RNA-binding proteins. J Neurosci. 2000;20:4944&#x2013;4953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772302</ArticleId><ArticleId IdType="pubmed">10864952</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer S, et al. Translational regulation shapes the molecular landscape of complex disease phenotypes. Nat Commun. 2015;6:7200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4455061</ArticleId><ArticleId IdType="pubmed">26007203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chothani S, et al. Widespread Translational Control of Fibrosis in the Human Heart by RNA-Binding Proteins. Circulation. 2019;140:937&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6749977</ArticleId><ArticleId IdType="pubmed">31284728</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatazza J, et al. Homeoprotein signaling in development, health, and disease: a shaking of dogmas offers challenges and promises from bench to bed. Pharmacol Rev. 2013;65:90&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">23300132</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger DT, et al. Brain grafts reverse hypogonadism of gonadotropin releasing hormone deficiency. Nature. 1982;298:468&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">7045700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman AR, Crowley WF., Jr Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982;307:1237&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">6813732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley DM, et al. Induction of ovulation and fertility in amenorrheic women by pulsatile low-dose gonadotropin-releasing hormone. N Engl J Med. 1984;310:1069&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">6424012</ArticleId></ArticleIdList></Reference><Reference><Citation>Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978;202:631&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">100883</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkert P, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21:246&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">35182510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NR, et al. Hypoplasia of cerebellar afferent networks in Down syndrome revealed by DTI-driven tensor based morphometry. Sci Rep. 2020;10:5447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096514</ArticleId><ArticleId IdType="pubmed">32214129</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Jimenez MD, et al. Resting-state default mode network connectivity in young individuals with Down syndrome. Brain Behav. 2021;11:e01905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821605</ArticleId><ArticleId IdType="pubmed">33179859</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Jimenez MD, et al. Complexity Analysis of the Default Mode Network Using Resting-State fMRI in Down Syndrome: Relationships Highlighted by a Neuropsychological Assessment. Brain Sci. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8001398</ArticleId><ArticleId IdType="pubmed">33801471</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, et al. Age-related changes in resting-state networks of a large sample size of healthy elderly. CNS Neurosci Ther. 2015;21:817&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493082</ArticleId><ArticleId IdType="pubmed">25864728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujol J, et al. Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. Cortex. 2015;64:148&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">25461715</ArticleId></ArticleIdList></Reference><Reference><Citation>Goeldner C, et al. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-alpha5 NAM (basmisanil) on intellectual disability associated with Down syndrome. J Neurodev Disord. 2022;14:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903644</ArticleId><ArticleId IdType="pubmed">35123401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanney M, et al. Memantine for dementia in adults older than 40 years with Down&#x2019;s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:528&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">22236802</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006:CD003154.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625572</ArticleId></ArticleIdList></Reference><Reference><Citation>Boada R, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012;2:e141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410988</ArticleId><ArticleId IdType="pubmed">22806212</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr J. Stability and change in cognitive ability over the life span: a comparison of populations with and without Down&#x2019;s syndrome. J Intellect Disabil Res. 2005;49:915&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down&#x2019;s syndrome. Lancet Neurol. 2016;15:622&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">27302127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hier DB, Crowley WF., Jr Spatial ability in androgen-deficient men. N Engl J Med. 1982;306:1202&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">7070432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wu W, Kim SK, Cai D. GnRH pulse frequency and irregularity play a role in male aging. Nature aging. 2021;1:904&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">37118330</ArticleId></ArticleIdList></Reference><Reference><Citation>Moenter SM, Evans NP. Gonadotropin-releasing hormone (GnRH) measurements in pituitary portal blood: A history. J Neuroendocrinol. 2021:e13065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200367</ArticleId><ArticleId IdType="pubmed">34918405</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J, et al. FSH blockade improves cognition in mice with Alzheimer&#x2019;s disease. Nature. 2022;603:470&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9940301</ArticleId><ArticleId IdType="pubmed">35236988</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidi S, Ciani E, Bonasoni P, Santini D, Bartesaghi R. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol. 2011;21:361&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094247</ArticleId><ArticleId IdType="pubmed">21040072</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan NM, et al. Myelin development in cerebral gray and white matter during adolescence and late childhood. Neuroimage. 2021;227:117678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214999</ArticleId><ArticleId IdType="pubmed">33359342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon D, Pfefferbaum A, Sullivan EV, Pohl KM. Regional growth trajectories of cortical myelination in adolescents and young adults: longitudinal validation and functional correlates. Brain Imaging Behav. 2020;14:242&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506406</ArticleId><ArticleId IdType="pubmed">30406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Benito E, et al. HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest. 2015;125:3572&#x2013;3584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588238</ArticleId><ArticleId IdType="pubmed">26280576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer&#x2019;s disease. Genome Med. 2016;8:104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088659</ArticleId><ArticleId IdType="pubmed">27799057</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, et al. Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. EMBO Mol Med. 2018;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220301</ArticleId><ArticleId IdType="pubmed">30275019</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, et al. Alzheimer&#x2019;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, et al. Progressive age-related cognitive decline in tau mice. J Alzheimers Dis. 2013;37:777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondadi AK, et al. Loss of the m-AAA protease subunit AFG(3)L(2) causes mitochondrial transport defects and tau hyperphosphorylation. EMBO J. 2014;33:1011&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4193934</ArticleId><ArticleId IdType="pubmed">24681487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. The Mitochondrial m-AAA Protease Prevents Demyelination and Hair Greying. PLoS Genet. 2016;12:e1006463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135034</ArticleId><ArticleId IdType="pubmed">27911893</ArticleId></ArticleIdList></Reference><Reference><Citation>Miraoui H, et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet. 2013;92:725&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3644636</ArticleId><ArticleId IdType="pubmed">23643382</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wang M, Marcora EM, Zhang B, Goate AM. Promoter DNA hypermethylation - Implications for Alzheimer&#x2019;s disease. Neurosci Lett. 2019;711:134403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6759378</ArticleId><ArticleId IdType="pubmed">31351091</ArticleId></ArticleIdList></Reference><Reference><Citation>Banzhaf-Strathmann J, et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer&#x2019;s disease. EMBO J. 2014;33:1667&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194100</ArticleId><ArticleId IdType="pubmed">25001178</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer N, Galdzicki Z. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Neural Plast. 2012;2012:101542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3403629</ArticleId><ArticleId IdType="pubmed">22848844</ArticleId></ArticleIdList></Reference><Reference><Citation>Deidda G, et al. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. Nat Med. 2015;21:318&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">25774849</ArticleId></ArticleIdList></Reference><Reference><Citation>Begenisic T, et al. Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome. Neurobiol Dis. 2014;63:12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">24269730</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JM, Knoflach F, Hernandez MC, Bischofberger J. Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome. J Neurosci. 2019;39:5210&#x2013;5221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6595955</ArticleId><ArticleId IdType="pubmed">31000585</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeburn A, Munn RGK. Signalling pathways contributing to learning and memory deficits in the Ts65Dn mouse model of Down syndrome. Neuronal Signal. 2021;5:NS20200011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955101</ArticleId><ArticleId IdType="pubmed">33763235</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson LW, Cowan WM. The connections of the septal region in the rat. J Comp Neurol. 1979;186:621&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">15116692</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelman DM, et al. The embryonic preoptic area is a novel source of cortical GABAergic interneurons. J Neurosci. 2009;29:9380&#x2013;9389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665570</ArticleId><ArticleId IdType="pubmed">19625528</ArticleId></ArticleIdList></Reference><Reference><Citation>Deidda G, et al. Early depolarizing GABA controls critical-period plasticity in the rat visual cortex. Nat Neurosci. 2015;18:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338533</ArticleId><ArticleId IdType="pubmed">25485756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley CG, Lavorgna G, Clark ME, Boncinelli E, Mellon PL. The Otx2 homeoprotein regulates expression from the gonadotropin-releasing hormone proximal promoter. Mol Endocrinol. 2000;14:1246&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">10935548</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevot V, Messina A, Giacobini P, Leysen V, Manfredi-Lozano M. In: WO/2020/221821. Inserm, editor. France: 2020. chap. PCT/EP2020/061943.</Citation></Reference><Reference><Citation>Ahmed MM, Sturgeon X, Ellison M, Davisson MT, Gardiner KJ. Loss of correlations among proteins in brains of the Ts65Dn mouse model of down syndrome. J Proteome Res. 2012;11:1251&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">22214338</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinholdt LG, et al. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome. 2011;22:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3505986</ArticleId><ArticleId IdType="pubmed">21953412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H, Enquist LW, Dulac C. Olfactory inputs to hypothalamic neurons controlling reproduction and fertility. Cell. 2005;123:669&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16290037</ArticleId></ArticleIdList></Reference><Reference><Citation>Harfe BD, McManus MT, Mansfield JH, Hornstein E, Tabin CJ. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci U S A. 2005;102:10898&#x2013;10903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182454</ArticleId><ArticleId IdType="pubmed">16040801</ArticleId></ArticleIdList></Reference><Reference><Citation>Spergel DJ, Kruth U, Hanley DF, Sprengel R, Seeburg PH. GABA- and glutamate-activated channels in green fluorescent protein-tagged gonadotropin-releasing hormone neurons in transgenic mice. J Neurosci. 1999;19:2037&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782541</ArticleId><ArticleId IdType="pubmed">10066257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann HM, et al. Differential CRE Expression in Lhrh-cre and GnRH-cre Alleles and the Impact on Fertility in Otx2-Flox Mice. Neuroendocrinology. 2019;108:328&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753941</ArticleId><ArticleId IdType="pubmed">30739114</ArticleId></ArticleIdList></Reference><Reference><Citation>Slezak M, et al. Relevance of exocytotic glutamate release from retinal glia. Neuron. 2012;74:504&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">22578502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen S, Ai W, Alim Z, Boehm U. Embryonic gonadotropin-releasing hormone signaling is necessary for maturation of the male reproductive axis. Proc Natl Acad Sci U S A. 2010;107:16372&#x2013;16377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941299</ArticleId><ArticleId IdType="pubmed">20805495</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, et al. Development of a methodology for and assessment of pulsatile luteinizing hormone secretion in juvenile and adult male mice. Endocrinology. 2013;154:4939&#x2013;4945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5398599</ArticleId><ArticleId IdType="pubmed">24092638</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal A, Zhang Q, Medigue C, Fabre S, Clement F. DynPeak: an algorithm for pulse detection and frequency analysis in hormonal time series. PLoS One. 2012;7:e39001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389032</ArticleId><ArticleId IdType="pubmed">22802933</ArticleId></ArticleIdList></Reference><Reference><Citation>Scattoni ML, Gandhy SU, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism. PLoS One. 2008;3:e3067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516927</ArticleId><ArticleId IdType="pubmed">18728777</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger M, et al. Object recognition test in mice. Nat Protoc. 2013;8:2531&#x2013;2537.</Citation><ArticleIdList><ArticleId IdType="pubmed">24263092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridoux A, Laloux C, Derambure P, Bordet R, Monaca Charley C. The acute inhibition of rapid eye movement sleep by citalopram may impair spatial learning and passive avoidance in mice. J Neural Transm (Vienna) 2013;120:383&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">23053350</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellu F, Contarino A, Simon H, Koob GF, Gold LH. Genetic differences in response to novelty and spatial memory using a two-trial recognition task in mice. Neurobiol Learn Mem. 2000;73:31&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686122</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. Academic Press; London: 2004.</Citation></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28:2184&#x2013;2185.</Citation><ArticleIdList><ArticleId IdType="pubmed">22743226</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT. svaseq: removing batch effects and other unwanted noise from sequencing data. Nucleic Acids Res. 2014;42</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245966</ArticleId><ArticleId IdType="pubmed">25294822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignatiadis N, Klaus B, Zaugg JB, Huber W. Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat Methods. 2016;13:577&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930141</ArticleId><ArticleId IdType="pubmed">27240256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuscher JJ, Taxier LR, Fortress AM, Frick KM. Chemogenetic inactivation of the dorsal hippocampus and medial prefrontal cortex, individually and concurrently, impairs object recognition and spatial memory consolidation in female mice. Neurobiol Learn Mem. 2018;156:103&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7310386</ArticleId><ArticleId IdType="pubmed">30408525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanchate NK, et al. SEMA3A, a Gene Involved in Axonal Pathfinding, Is Mutated in Patients with Kallmann Syndrome. PLoS Genet. 2012;8:e1002896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426548</ArticleId><ArticleId IdType="pubmed">22927827</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina A, et al. Dysregulation of Semaphorin7A/beta1-integrin signaling leads to defective GnRH-1 cell migration, abnormal gonadal development and altered fertility. Hum Mol Genet. 2011;20:4759&#x2013;4774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221532</ArticleId><ArticleId IdType="pubmed">21903667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrabovszky E, et al. Sexual dimorphism of kisspeptin and neurokinin B immunoreactive neurons in the infundibular nucleus of aged men and women. Front Endocrinol (Lausanne) 2011;2:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356022</ArticleId><ArticleId IdType="pubmed">22654828</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauvillain JC, Tramu G. Immunocytochemical demonstration of LH-RH, somatostatin, and ACTH-like peptide in osmium-postfixed, resin-embedded median eminence. J Histochem Cytochem. 1980;28:1014&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">6157712</ArticleId></ArticleIdList></Reference><Reference><Citation>Erturk A, et al. Three-dimensional imaging of solvent-cleared organs using 3DISCO. Nat Protoc. 2012;7:1983&#x2013;1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">23060243</ArticleId></ArticleIdList></Reference><Reference><Citation>Erturk A, Bradke F. High-resolution imaging of entire organs by 3-dimensional imaging of solvent cleared organs (3DISCO) Exp Neurol. 2013;242:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23124097</ArticleId></ArticleIdList></Reference><Reference><Citation>Belle M, et al. A simple method for 3D analysis of immunolabeled axonal tracts in a transparent nervous system. Cell Rep. 2014;9:1191&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">25456121</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosbah H, et al. GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Hum Reprod. 2020;35:2312&#x2013;2322.</Citation><ArticleIdList><ArticleId IdType="pubmed">32862222</ArticleId></ArticleIdList></Reference><Reference><Citation>Noll C, et al. DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase. PLoS One. 2009;4:e7540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760102</ArticleId><ArticleId IdType="pubmed">19844572</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>De Renzi E, Vignolo LA. The token test: A sensitive test to detect receptive disturbances in aphasics. Brain. 1962;85:665&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">14026018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini MP, et al. Olfaction in People with Down Syndrome: A Comprehensive Assessment across Four Decades of Age. PLoS One. 2016;11:e0146486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4701393</ArticleId><ArticleId IdType="pubmed">26730728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">8628042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitteloud N, et al. The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab. 2008;93:2686&#x2013;2692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2453056</ArticleId><ArticleId IdType="pubmed">18445673</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf N, et al. Quantitative multi-parameter mapping of R1, PD(*), MT, and R2(*) at 3T: a multi-center validation. Front Neurosci. 2013;7:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677134</ArticleId><ArticleId IdType="pubmed">23772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutti A, Hutton C, Finsterbusch J, Helms G, Weiskopf N. Optimization and validation of methods for mapping of the radiofrequency transmit field at 3T. Magn Reson Med. 2010;64:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077518</ArticleId><ArticleId IdType="pubmed">20572153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutti A, et al. Robust and fast whole brain mapping of the RF transmit field B1 at 7T. PLoS One. 2012;7:e32379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299646</ArticleId><ArticleId IdType="pubmed">22427831</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms G, Dathe H, Dechent P. Quantitative FLASH MRI at 3T using a rational approximation of the Ernst equation. Magn Reson Med. 2008;59:667&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">18306368</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms G, Dathe H, Kallenberg K, Dechent P. High-resolution maps of magnetization transfer with inherent correction for RF inhomogeneity and T1 relaxation obtained from 3D FLASH MRI. Magn Reson Med. 2008;60:1396&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">19025906</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabelow K, et al. hMRI - A toolbox for quantitative MRI in neuroscience and clinical research. Neuroimage. 2019;194:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547054</ArticleId><ArticleId IdType="pubmed">30677501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaitsev M, Dold C, Sakas G, Hennig J, Speck O. Magnetic resonance imaging of freely moving objects: prospective real-time motion correction using an external optical motion tracking system. Neuroimage. 2006;31:1038&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600642</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclaren J, et al. Measurement and correction of microscopic head motion during magnetic resonance imaging of the brain. PLoS One. 2012;7:e48088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3492340</ArticleId><ArticleId IdType="pubmed">23144848</ArticleId></ArticleIdList></Reference><Reference><Citation>Castella R, et al. Controlling motion artefact levels in MR images by suspending data acquisition during periods of head motion. Magn Reson Med. 2018;80:2415&#x2013;2426.</Citation><ArticleIdList><ArticleId IdType="pubmed">29687919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutti A, et al. Restoring statistical validity in group analyses of motion-corrupted MRI data. Hum Brain Mapp. 2022;43:1973&#x2013;1983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8933245</ArticleId><ArticleId IdType="pubmed">35112434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Ridgway GR. Symmetric diffeomorphic modeling of longitudinal structural MRI. Front Neurosci. 2012;6:197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564017</ArticleId><ArticleId IdType="pubmed">23386806</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyger L, et al. Temporal trajectory of brain tissue property changes induced by electroconvulsive therapy. Neuroimage. 2021;232:117895.</Citation><ArticleIdList><ArticleId IdType="pubmed">33617994</ArticleId></ArticleIdList></Reference><Reference><Citation>Draganski B, et al. Regional specificity of MRI contrast parameter changes in normal ageing revealed by voxel-based quantification (VBQ) Neuroimage. 2011;55:1423&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093621</ArticleId><ArticleId IdType="pubmed">21277375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutti A, Thomas DL, Hutton C, Weiskopf N. High-resolution functional MRI at 3 T: 3D/2D echo-planar imaging with optimized physiological noise correction. Magn Reson Med. 2013;69:1657&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495253</ArticleId><ArticleId IdType="pubmed">22821858</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzdoerfer R, Fountoulakis M, Lubec G. Reduction of actin-related protein complex 2/3 in fetal Down syndrome brain. Biochem Biophys Res Commun. 2002;293:836&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12054546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y. Comparative transcriptome analysis of the hippocampus from sleep-deprived and Alzheimer&#x2019;s disease mice. Genet Mol Biol. 2020;43:e20190052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249779</ArticleId><ArticleId IdType="pubmed">32338274</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao LV, Cleveland RP, Kimmel RJ, Ataya KM. Hematopoietic stem cell antigen-1 (Sca-1) expression in different lymphoid tissues of female mice treated with GnRH agonist. Am J Reprod Immunol. 1995;34:257&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">8579764</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, et al. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer&#x2019;s disease. J Neurochem. 2002;81:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e-Scherrer, et al. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer&#x2019;s disease. Brain Res Mol Brain Res. 1996;39:79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8804716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36114228</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2373-8057</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>NPJ Parkinson's disease</Title><ISOAbbreviation>NPJ Parkinsons Dis</ISOAbbreviation></Journal><ArticleTitle>Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous &#x3b1;-synuclein in human neurons.</ArticleTitle><Pagination><StartPage>118</StartPage><MedlinePgn>118</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">118</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41531-022-00380-1</ELocationID><Abstract><AbstractText>&#x3b1;-Synuclein (&#x3b1;Syn) aggregation in Lewy bodies and neurites defines both familial and 'sporadic' Parkinson's disease. We previously identified &#x3b1;-helically folded &#x3b1;Syn tetramers, in addition to the long-known unfolded monomers, in normal cells. PD-causing &#x3b1;Syn mutations decrease the tetramer:monomer (T:M) ratio, associated with &#x3b1;Syn hyperphosphorylation and cytotoxicity in neurons and a motor syndrome of tremor and gait deficits in transgenic mice that responds in part to L-DOPA. Here, we asked whether LRRK2 mutations, the most common genetic cause of cases previously considered sporadic PD, also alter tetramer homeostasis. Patient neurons carrying G2019S, the most prevalent LRRK2 mutation, or R1441C each had decreased T:M ratios and pSer129 hyperphosphorylation of their endogenous &#x3b1;Syn along with increased phosphorylation of Rab10, a widely reported substrate of LRRK2 kinase activity. Two LRRK2 kinase inhibitors normalized the T:M ratio and the hyperphosphorylation in the G2019S and R1441C patient neurons. An inhibitor of stearoyl-CoA desaturase, the rate-limiting enzyme for monounsaturated fatty acid synthesis, also restored the &#x3b1;Syn T:M ratio and reversed pSer129 hyperphosphorylation in both mutants. Coupled with the recent discovery that PD-causing mutations of glucocerebrosidase in Gaucher's neurons also decrease T:M ratios, our findings indicate that three dominant genetic forms of PD involve life-long destabilization of &#x3b1;Syn physiological tetramers as a common pathogenic mechanism that can occur upstream of progressive neuronal synucleinopathy. Based on &#x3b1;Syn's finely-tuned interaction with certain vesicles, we hypothesize that the fatty acid composition and fluidity of membranes regulate &#x3b1;Syn's correct binding to highly curved membranes and subsequent assembly into metastable tetramers.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fonseca-Ornelas</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stricker</LastName><ForeName>Jonathan M S</ForeName><Initials>JMS</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano-Cruz</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weykopf</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5541-839X</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dettmer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-6676-0107</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muratore</LastName><ForeName>Christina R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0002-0567-9193</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0001-8846-9767</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. dselkoe@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115144</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS100603</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>NPJ Parkinsons Dis</MedlineTA><NlmUniqueID>101675390</NlmUniqueID><ISSNLinking>2373-8057</ISSNLinking></MedlineJournalInfo><CoiStatement>D.J.S. declares no competing non-financial Interests but the following competing financial interests: DJS is a director and consultant to Prothena Biosciences. All other authors declare no competing non-financial and financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36114228</ArticleId><ArticleId IdType="pmc">PMC9481630</ArticleId><ArticleId IdType="doi">10.1038/s41531-022-00380-1</ArticleId><ArticleId IdType="pii">10.1038/s41531-022-00380-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marras C, et al. Prevalence of Parkinson&#x2019;s disease across North America. NPJ Park Dis. 2018;4:21. doi: 10.1038/s41531-018-0058-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-018-0058-0</ArticleId><ArticleId IdType="pmc">PMC6039505</ArticleId><ArticleId IdType="pubmed">30003140</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson&#x2019;s disease. Genom. Hum. Genet. 2011;12:301&#x2013;325. doi: 10.1146/annurev-genom-082410-101440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genom-082410-101440</ArticleId><ArticleId IdType="pmc">PMC4120236</ArticleId><ArticleId IdType="pubmed">21639795</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091&#x2013;1102. doi: 10.1016/S1474-4422(19)30320-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahmoradian SH, et al. Lewy pathology in Parkinson&#x2019;s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 2019;22:1099&#x2013;1109. doi: 10.1038/s41593-019-0423-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0423-2</ArticleId><ArticleId IdType="pubmed">31235907</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Tredici KD, Braak H. 100 years of Lewy pathology. Nat. Rev. Neurol. 2013;9:13. doi: 10.1038/nrneurol.2012.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.242</ArticleId><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607. doi: 10.1016/j.neuron.2004.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.11.005</ArticleId><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson&#x2019;s disease. Nat. Rev. Neurosci. 2010;11:791&#x2013;797. doi: 10.1038/nrn2935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2935</ArticleId><ArticleId IdType="pmc">PMC4662256</ArticleId><ArticleId IdType="pubmed">21088684</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe R, et al. The in situ structure of Parkinson&#x2019;s disease-linked LRRK2. Cell. 2020;182:1508&#x2013;1518.e16. doi: 10.1016/j.cell.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7869717</ArticleId><ArticleId IdType="pubmed">32783917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis PA, et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Bioph Res Co. 2007;357:668&#x2013;671. doi: 10.1016/j.bbrc.2007.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.04.006</ArticleId><ArticleId IdType="pmc">PMC1939973</ArticleId><ArticleId IdType="pubmed">17442267</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M, et al. Phosphoproteomics reveals that Parkinson&#x2019;s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016;5:e12813. doi: 10.7554/eLife.12813.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.12813</ArticleId><ArticleId IdType="pmc">PMC4769169</ArticleId><ArticleId IdType="pubmed">26824392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z, et al. Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations. Sci. Transl. Med. 2012;4:164ra161. doi: 10.1126/scitranslmed.3004485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004485</ArticleId><ArticleId IdType="pubmed">23241745</ArticleId></ArticleIdList></Reference><Reference><Citation>West A, et al. Parkinson&#x2019;s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA. 2005;102:16842&#x2013;16847. doi: 10.1073/pnas.0507360102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0507360102</ArticleId><ArticleId IdType="pmc">PMC1283829</ArticleId><ArticleId IdType="pubmed">16269541</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson&#x2019;s disease. Mov. Disord. 2012;27:831&#x2013;842. doi: 10.1002/mds.24962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.24962</ArticleId><ArticleId IdType="pmc">PMC3383342</ArticleId><ArticleId IdType="pubmed">22451330</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T, Bendor J, Toupin C, Thorn K, Edwards RH. &#x3b1;-Synuclein promotes dilation of the exocytotic fusion pore. Nat. Neurosci. 2017;20:681. doi: 10.1038/nn.4529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4529</ArticleId><ArticleId IdType="pmc">PMC5404982</ArticleId><ArticleId IdType="pubmed">28288128</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, et al. &#x3b1;-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663&#x2013;1667. doi: 10.1126/science.1195227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1195227</ArticleId><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="pubmed">20798282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca-Ornelas L, et al. Altered conformation of &#x3b1;-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson&#x2019;s disease. Cell Rep. 2021;36:109333. doi: 10.1016/j.celrep.2021.109333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109333</ArticleId><ArticleId IdType="pmc">PMC8552450</ArticleId><ArticleId IdType="pubmed">34233191</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT. NACP, a protein implicated in Alzheimer&#x2019;s disease and learning, is natively unfolded&#x2020;. Biochemistry. 1996;35:13709&#x2013;13715. doi: 10.1021/bi961799n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi961799n</ArticleId><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Theillet F-X, et al. Structural disorder of monomeric &#x3b1;-synuclein persists in mammalian cells. Nature. 2016;530:45&#x2013;50. doi: 10.1038/nature16531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16531</ArticleId><ArticleId IdType="pubmed">26808899</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of &#x3b1;-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998;273:9443&#x2013;9449. doi: 10.1074/jbc.273.16.9443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.16.9443</ArticleId><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, Choi JG, Selkoe DJ. &#x3b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107. doi: 10.1038/nature10324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10324</ArticleId><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. In vivo cross-linking reveals principally oligomeric forms of &#x3b1;-synuclein and &#x3b2;-synuclein in neurons and non-neural cells. J. Biol. Chem. 2013;288:6371&#x2013;6385. doi: 10.1074/jbc.M112.403311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.403311</ArticleId><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, et al. Parkinson-causing &#x3b1;-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun. 2015;6:7314. doi: 10.1038/ncomms8314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8314</ArticleId><ArticleId IdType="pmc">PMC4490410</ArticleId><ArticleId IdType="pubmed">26076669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuber S, et al. Abrogating native &#x3b1;-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson&#x2019;s disease. Neuron. 2018;100:75&#x2013;90.e5. doi: 10.1016/j.neuron.2018.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.014</ArticleId><ArticleId IdType="pmc">PMC6211795</ArticleId><ArticleId IdType="pubmed">30308173</ArticleId></ArticleIdList></Reference><Reference><Citation>Glajch KE, et al. Wild-type GBA1 increases the &#x3b1;-synuclein tetramer&#x2013;monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice. Proc. Natl Acad. Sci. USA. 2021;118:e2103425118. doi: 10.1073/pnas.2103425118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2103425118</ArticleId><ArticleId IdType="pmc">PMC8346893</ArticleId><ArticleId IdType="pubmed">34326260</ArticleId></ArticleIdList></Reference><Reference><Citation>Burre J, Sharma M, S&#xfc;dhof TC. &#x3b1;-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl Acad. Sci. USA. 2014;111:E4274&#x2013;E4283. doi: 10.1073/pnas.1416598111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1416598111</ArticleId><ArticleId IdType="pmc">PMC4210039</ArticleId><ArticleId IdType="pubmed">25246573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. &#x3b1;-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 2014;24:2319&#x2013;2326. doi: 10.1016/j.cub.2014.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2014.08.027</ArticleId><ArticleId IdType="pmc">PMC4190006</ArticleId><ArticleId IdType="pubmed">25264250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, J. et al. Functional cooperation of &#x3b1;-synuclein and VAMP2 in synaptic vesicle recycling. Proc. Natl Acad. Sci. USA10.1073/pnas.1903049116 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561242</ArticleId><ArticleId IdType="pubmed">31110017</ArticleId></ArticleIdList></Reference><Reference><Citation>Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson&#x2019;s disease in Ashkenazi jews. N. Engl. J. Med. 2004;351:1972&#x2013;1977. doi: 10.1056/NEJMoa033277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa033277</ArticleId><ArticleId IdType="pubmed">15525722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, et al. GBA1 deficiency negatively affects physiological &#x3b1;-synuclein tetramers and related multimers. Proc. Natl Acad. Sci. USA. 2018;115:798&#x2013;803. doi: 10.1073/pnas.1700465115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1700465115</ArticleId><ArticleId IdType="pmc">PMC5789900</ArticleId><ArticleId IdType="pubmed">29311330</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson JL, et al. Discovery and preclinical profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J. Med. Chem. 2015;58:419&#x2013;432. doi: 10.1021/jm5014055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm5014055</ArticleId><ArticleId IdType="pubmed">25353650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fell MJ, et al. MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J. Pharmacol. Exp. Ther. 2015;355:397&#x2013;409. doi: 10.1124/jpet.115.227587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.115.227587</ArticleId><ArticleId IdType="pubmed">26407721</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanning S, et al. Lipidomic analysis of &#x3b1;-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment. Mol. Cell. 2019;73:1001&#x2013;1014.e8. doi: 10.1016/j.molcel.2018.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.11.028</ArticleId><ArticleId IdType="pmc">PMC6408259</ArticleId><ArticleId IdType="pubmed">30527540</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent BM, et al. Inhibiting stearoyl-CoA desaturase ameliorates &#x3b1;-synuclein cytotoxicity. Cell Rep. 2018;25:2742&#x2013;2754.e31. doi: 10.1016/j.celrep.2018.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.11.028</ArticleId><ArticleId IdType="pubmed">30517862</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuber, S. et al. A stearoyl&#x2010;CoA desaturase inhibitor prevents multiple Parkinson&#x2019;s disease&#x2010;phenotypes in &#x3b1;&#x2010;synuclein mice. Ann. Neurol. 10.1002/ana.25920 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756464</ArticleId><ArticleId IdType="pubmed">32996158</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt P, et al. Genetic correction of a LRRK2 mutation in human iPSCs links Parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12:354&#x2013;367. doi: 10.1016/j.stem.2013.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.01.008</ArticleId><ArticleId IdType="pubmed">23472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785&#x2013;798. doi: 10.1016/j.neuron.2013.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.05.029</ArticleId><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, et al. An in vitro paradigm to assess potential anti-A&#x3b2; antibodies for Alzheimer&#x2019;s disease. Nat. Commun. 2018;9:2676. doi: 10.1038/s41467-018-05068-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05068-w</ArticleId><ArticleId IdType="pmc">PMC6041266</ArticleId><ArticleId IdType="pubmed">29992960</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J. Parkinsons Dis. 2016;6:39&#x2013;51. doi: 10.3233/JPD-160779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-160779</ArticleId><ArticleId IdType="pmc">PMC4927808</ArticleId><ArticleId IdType="pubmed">27003784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, et al. &#x3b1;-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002;4:160&#x2013;164. doi: 10.1038/ncb748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb748</ArticleId><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JP, et al. Phosphorylation of Ser-129 is the dominant pathological modification of &#x3b1;-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006;281:29739&#x2013;29752. doi: 10.1074/jbc.M600933200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600933200</ArticleId><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-R&#xed;os P, et al. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A. J. Biol. Chem. 2019;294:4738&#x2013;4758. doi: 10.1074/jbc.RA118.005008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005008</ArticleId><ArticleId IdType="pmc">PMC6442034</ArticleId><ArticleId IdType="pubmed">30709905</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JM, et al. Small GTPase Rab11b regulates degradation of surface membrane L-type Ca v 1.2 channels. Am. J. Physiol. Cell Physiol. 2011;300:C1023&#x2013;C1033. doi: 10.1152/ajpcell.00288.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00288.2010</ArticleId><ArticleId IdType="pmc">PMC3093944</ArticleId><ArticleId IdType="pubmed">21248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiol. Dis. 2020;144:105049. doi: 10.1016/j.nbd.2020.105049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105049</ArticleId><ArticleId IdType="pubmed">32800998</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, et al. Interrogating Parkinson&#x2019;s disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem. J. 2018;475:23&#x2013;44. doi: 10.1042/BCJ20170803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20170803</ArticleId><ArticleId IdType="pmc">PMC5748842</ArticleId><ArticleId IdType="pubmed">29127255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, et al. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathol. 2021;142:475&#x2013;494. doi: 10.1007/s00401-021-02325-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02325-z</ArticleId><ArticleId IdType="pmc">PMC8357670</ArticleId><ArticleId IdType="pubmed">34125248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. Sci. Rep.-UK. 2021;11:12900. doi: 10.1038/s41598-021-91943-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91943-4</ArticleId><ArticleId IdType="pmc">PMC8213766</ArticleId><ArticleId IdType="pubmed">34145320</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M, et al. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife. 2017;6:e31012. doi: 10.7554/eLife.31012.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.31012</ArticleId><ArticleId IdType="pmc">PMC5695910</ArticleId><ArticleId IdType="pubmed">29125462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito G, et al. Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors. Biochem. J. 2016;473:2671&#x2013;2685. doi: 10.1042/BCJ20160557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160557</ArticleId><ArticleId IdType="pmc">PMC5003698</ArticleId><ArticleId IdType="pubmed">27474410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ysselstein D, et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson&#x2019;s disease patients. Nat. Commun. 2019;10:5570. doi: 10.1038/s41467-019-13413-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13413-w</ArticleId><ArticleId IdType="pmc">PMC6895201</ArticleId><ArticleId IdType="pubmed">31804465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal A, Novis HS, Gasser E, Lin S, LaVoie MJ. LRRK2 kinase inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-derived neurons. Front Neurosci. 2020;14:442. doi: 10.3389/fnins.2020.00442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00442</ArticleId><ArticleId IdType="pmc">PMC7243441</ArticleId><ArticleId IdType="pubmed">32499675</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanning S, Selkoe D, Dettmer U. Parkinson&#x2019;s disease: proteinopathy or lipidopathy? NPJ Park Dis. 2020;6:3. doi: 10.1038/s41531-019-0103-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-019-0103-7</ArticleId><ArticleId IdType="pmc">PMC6941970</ArticleId><ArticleId IdType="pubmed">31909184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallett PJ, Engelender S, Isacson O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson&#x2019;s disease. J. Neuroinflammation. 2019;16:153. doi: 10.1186/s12974-019-1532-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1532-2</ArticleId><ArticleId IdType="pmc">PMC6647317</ArticleId><ArticleId IdType="pubmed">31331333</ArticleId></ArticleIdList></Reference><Reference><Citation>Brekk OR, Moskites A, Isacson O, Hallett PJ. Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. Sci. Rep. 2018;8:15207. doi: 10.1038/s41598-018-33474-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33474-z</ArticleId><ArticleId IdType="pmc">PMC6185981</ArticleId><ArticleId IdType="pubmed">30315256</ArticleId></ArticleIdList></Reference><Reference><Citation>Imberdis T, et al. Cell models of lipid-rich &#x3b1;-synuclein aggregation validate known modifiers of &#x3b1;-synuclein biology and identify stearoyl-CoA desaturase. Proc. Natl Acad. Sci. USA. 2019;116:20760&#x2013;20769. doi: 10.1073/pnas.1903216116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1903216116</ArticleId><ArticleId IdType="pmc">PMC6789936</ArticleId><ArticleId IdType="pubmed">31548371</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson KA, et al. N-Benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors. Bioorg. Med. Chem. Lett. 2011;21:1621&#x2013;1625. doi: 10.1016/j.bmcl.2011.01.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2011.01.113</ArticleId><ArticleId IdType="pubmed">21324691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriks S, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson&#x2019;s disease. Nature. 2011;480:547&#x2013;551. doi: 10.1038/nature10648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10648</ArticleId><ArticleId IdType="pmc">PMC3245796</ArticleId><ArticleId IdType="pubmed">22056989</ArticleId></ArticleIdList></Reference><Reference><Citation>Weykopf B, et al. Induced pluripotent stem cell&#x2010;based modeling of mutant LRRK2&#x2010;associated Parkinson&#x2019;s disease. Eur. J. Neurosci. 2019;49:561&#x2013;589. doi: 10.1111/ejn.14345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.14345</ArticleId><ArticleId IdType="pmc">PMC7114274</ArticleId><ArticleId IdType="pubmed">30656775</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakopoulou V, et al. Interferon-&#x3b3; signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells. Nat. Commun. 2020;11:5163. doi: 10.1038/s41467-020-18755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18755-4</ArticleId><ArticleId IdType="pmc">PMC7560616</ArticleId><ArticleId IdType="pubmed">33057020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C-H, et al. Functional impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson&#x2019;s disease. Cell Stem Cell. 2016;19:709&#x2013;724. doi: 10.1016/j.stem.2016.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2016.08.002</ArticleId><ArticleId IdType="pmc">PMC5135570</ArticleId><ArticleId IdType="pubmed">27618216</ArticleId></ArticleIdList></Reference><Reference><Citation>Maio, R. D. et al. LRRK2 activation in idiopathic Parkinson&#x2019;s disease. Sci. Transl. Med. 10, eaar5429 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344941</ArticleId><ArticleId IdType="pubmed">30045977</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Saucken VE, von, Bartels T, Selkoe D. KTKEGV repeat motifs are key mediators of normal &#x3b1;-synuclein tetramerization: their mutation causes excess monomers and neurotoxicity. Proc. Natl Acad. Sci. USA. 2015;112:9596&#x2013;9601. doi: 10.1073/pnas.1505953112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1505953112</ArticleId><ArticleId IdType="pmc">PMC4534262</ArticleId><ArticleId IdType="pubmed">26153422</ArticleId></ArticleIdList></Reference><Reference><Citation>Orenstein SJ, et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 2013;16:394&#x2013;406. doi: 10.1038/nn.3350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3350</ArticleId><ArticleId IdType="pmc">PMC3609872</ArticleId><ArticleId IdType="pubmed">23455607</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez&#x2010;Dan&#xe9;s A, et al. Disease&#x2010;specific phenotypes in dopamine neurons from human iPS&#x2010;based models of genetic and sporadic Parkinson&#x2019;s disease. EMBO Mol. Med. 2012;4:380&#x2013;395. doi: 10.1002/emmm.201200215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201200215</ArticleId><ArticleId IdType="pmc">PMC3403296</ArticleId><ArticleId IdType="pubmed">22407749</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum. Mol. Genet. 2014;23:4201&#x2013;4214. doi: 10.1093/hmg/ddu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu138</ArticleId><ArticleId IdType="pmc">PMC4103671</ArticleId><ArticleId IdType="pubmed">24682598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders LH, et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson&#x2019;s disease patients: reversal by gene correction. Neurobiol. Dis. 2014;62:381&#x2013;386. doi: 10.1016/j.nbd.2013.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.10.013</ArticleId><ArticleId IdType="pmc">PMC3877733</ArticleId><ArticleId IdType="pubmed">24148854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper O, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson&#x2019;s disease. Sci. Transl. Med. 2012;4:141ra90&#x2013;141ra90. doi: 10.1126/scitranslmed.3003985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003985</ArticleId><ArticleId IdType="pmc">PMC3462009</ArticleId><ArticleId IdType="pubmed">22764206</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G-H, et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature. 2012;491:603&#x2013;607. doi: 10.1038/nature11557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11557</ArticleId><ArticleId IdType="pmc">PMC3504651</ArticleId><ArticleId IdType="pubmed">23075850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8:267&#x2013;280. doi: 10.1016/j.stem.2011.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2011.01.013</ArticleId><ArticleId IdType="pmc">PMC3578553</ArticleId><ArticleId IdType="pubmed">21362567</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgs L, et al. Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects. Sci. Rep.-UK. 2016;6:33377. doi: 10.1038/srep33377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33377</ArticleId><ArticleId IdType="pmc">PMC5027571</ArticleId><ArticleId IdType="pubmed">27640816</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing X, et al. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and &#x3b1;-Synuclein modulation in dopaminergic neurons. Stem Cell Res. 2017;24:44&#x2013;50. doi: 10.1016/j.scr.2017.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2017.08.013</ArticleId><ArticleId IdType="pubmed">28826027</ArticleId></ArticleIdList></Reference><Reference><Citation>Novello S, et al. G2019S LRRK2 mutation facilitates &#x3b1;-synuclein neuropathology in aged mice. Neurobiol. Dis. 2018;120:21&#x2013;33. doi: 10.1016/j.nbd.2018.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.08.018</ArticleId><ArticleId IdType="pubmed">30172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieri G, et al. LRRK2 modifies &#x3b1;-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 2019;137:961&#x2013;980. doi: 10.1007/s00401-019-01995-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01995-0</ArticleId><ArticleId IdType="pmc">PMC6531417</ArticleId><ArticleId IdType="pubmed">30927072</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugarvoll K, et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson diseaseSYMBOL. Neurology. 2008;70:1456&#x2013;1460. doi: 10.1212/01.wnl.0000304044.22253.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000304044.22253.03</ArticleId><ArticleId IdType="pmc">PMC3906630</ArticleId><ArticleId IdType="pubmed">18337586</ArticleId></ArticleIdList></Reference><Reference><Citation>Giesert F, et al. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson&#x2019;s disease in the mouse. Neurobiol. Dis. 2017;105:179&#x2013;193. doi: 10.1016/j.nbd.2017.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.05.013</ArticleId><ArticleId IdType="pubmed">28576705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl Acad. Sci. USA. 2009;106:14622&#x2013;14627. doi: 10.1073/pnas.0906334106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0906334106</ArticleId><ArticleId IdType="pmc">PMC2732807</ArticleId><ArticleId IdType="pubmed">19667187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 2020;16:97&#x2013;107. doi: 10.1038/s41582-019-0301-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0301-2</ArticleId><ArticleId IdType="pubmed">31980808</ArticleId></ArticleIdList></Reference><Reference><Citation>Migheli R, et al. LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS ONE. 2013;8:e77198. doi: 10.1371/journal.pone.0077198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077198</ArticleId><ArticleId IdType="pmc">PMC3805556</ArticleId><ArticleId IdType="pubmed">24167564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur E-M, Jang E-H, Jeong GR, Lee BD. LRRK2 and membrane trafficking: nexus of Parkinson&#x2019;s disease. BMB Rep. 2019;52:533&#x2013;539. doi: 10.5483/BMBRep.2019.52.9.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2019.52.9.186</ArticleId><ArticleId IdType="pmc">PMC6774422</ArticleId><ArticleId IdType="pubmed">31383252</ArticleId></ArticleIdList></Reference><Reference><Citation>NTR. https://www.trialregister.nl/trial/9172.</Citation></Reference><Reference><Citation>Cote Y, Delarue P, Scheraga HA, Senet P, Maisuradze GG. From a highly disordered to a metastable state: uncovering insights of &#x3b1;-synuclein. ACS Chem. Neurosci. 2018;9:1051&#x2013;1065. doi: 10.1021/acschemneuro.7b00446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00446</ArticleId><ArticleId IdType="pmc">PMC5955826</ArticleId><ArticleId IdType="pubmed">29451381</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Bhattacharya S, Thompson D. On the ubiquity of helical &#x3b1;-synuclein tetramers. Phys. Chem. Chem. Phys. 2019;21:12036&#x2013;12043. doi: 10.1039/C9CP02464F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9CP02464F</ArticleId><ArticleId IdType="pubmed">31135803</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranczak A, Kelly JW. A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases. Curr. Opin. Chem. Biol. 2016;32:10&#x2013;21. doi: 10.1016/j.cbpa.2016.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpa.2016.01.009</ArticleId><ArticleId IdType="pmc">PMC4907839</ArticleId><ArticleId IdType="pubmed">26859714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36121669</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.</ArticleTitle><Pagination><StartPage>1113</StartPage><EndPage>1121</EndPage><MedlinePgn>1113-1121</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.2909</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Alzheimer disease (AD), a neurodegenerative disease characterized by &#x3b2;-amyloid plaques and &#x3c4; tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the safety and efficacy of crenezumab, a humanized monoclonal immunoglobulin G4 antibody targeting &#x3b2;-amyloid oligomers, in participants with prodromal to mild (early) AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Two phase 3 multicenter randomized double-blind placebo-controlled parallel-group efficacy and safety studies of crenezumab in participants with early AD, CREAD and CREAD2, were initiated in 2016 and 2017, respectively, and were designed to evaluate the efficacy and safety of crenezumab in participants with early AD. CREAD (194 sites in 30 countries) and CREAD2 (209 sites in 27 countries) were global multicenter studies. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. Both trials enrolled individuals aged 50 to 85 years with early AD. Participants with some comorbidities and evidence of cerebral infarction or more than 4 microbleeds or areas of leptomeningeal hemosiderosis on magnetic resonance imaging were excluded. After 2923 and 2858 were excluded, respectively, 813 participants in CREAD and 806 in CREAD2 were randomly assigned in a 1:1 ratio to either placebo or crenezumab. In the final analysis, there were 409 participants in the placebo group and 404 in the crenezumab group in CREAD and 399 in the placebo group and 407 in the crenezumab group in CREAD2. Data were analyzed up until January 2019 and August 2019, respectively.</AbstractText><AbstractText Label="INTERVENTIONS">Participants received placebo or 60 mg/kg crenezumab intravenously every 4 weeks for up to 100 weeks.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was change from baseline to week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score.</AbstractText><AbstractText Label="RESULTS">There were 813 participants in CREAD (mean [SD] age, 70.7 [8.2] years; 483 female and 330 male) and 806 in CREAD2 (mean [SD] age, 70.9 [7.7] years; 456 female and 350 male). Baseline characteristics were balanced between both groups. The between-group difference in mean change from baseline in CDR-SB score (placebo minus crenezumab) was -0.17 (95% CI, -0.86 to 0.53; P&#x2009;=&#x2009;.63) at week 105 in the CREAD study (88 placebo; 86 crenezumab). Compared with previous trials, no new safety signals were identified, and amyloid-related imaging abnormalities with edema were rare, mild, and transient. No meaningful changes in AD biomarkers were observed. Both studies were discontinued following a preplanned interim analysis indicating that CREAD was unlikely to meet the primary end point.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Crenezumab was well tolerated but did not reduce clinical decline in participants with early AD.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifiers: CREAD, NCT02670083; CREAD2, NCT03114657.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostrowitzki</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackey</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabe</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassetta</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fatebenefratelli Foundation, Associazione Fatebenefratelli Per la Ricerca Division, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Austin Health Continuing Care Clinical Service Unit, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blondeau</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quartino</LastName><ForeName>Angelica</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolton</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roche Products Australia Pty Ltd, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanofi Genzyme, Waltham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanabria-Boh&#xf3;rquez</LastName><ForeName>Sandra M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabbia</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Balazs</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichenlaub</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jillian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Roche Products Ltd, Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honigberg</LastName><ForeName>Lee A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genentech, Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03114657</AccessionNumber><AccessionNumber>NCT02670083</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>O8AS5277H0</RegistryNumber><NameOfSubstance UI="C573372">crenezumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Ostrowitzki, Bittner, Schneider, Blondeau, and Hu and Ms Smith are full-time employees of F. Hoffmann-La Roche and stockholders in F. Hoffmann-La Roche. Drs Sink, Mackey, Rabe, Hu, Clayton, and Sanabria-Boh&#xf3;rquez; Mr Rabbia, Dr Toth; and Drs Eichenlaub, Honigberg, and Doody are full-time employees of Genentech, part of F. Hoffmann-La Roche, and stockholders in F. Hoffmann-La Roche. Dr Honig reports consultant fees from Cortexyme, Eisai, and Prevail; study research funding from AbbVie, Alector, Biogen, Eisai, Genentech, F. Hoffmann-LaRoche, and Eli Lilly; grants from Roche during the conduct of the study; and grants from Abbvie, Eisai, Alector, Acumen, Genentech, Union Chimique Belge, Vaccinex, Biogen, Aprinoia, Cyclerion, Johnson &amp; Johnson, Transposon, and Neurokine Therapeutics and personal fees from Eisai, Prevail, Cortexyme, and Biogen outside the submitted work. Dr Woodward has received research funding and speaker/consultancy fees from F. Hoffmann-La Roche, Eli Lilly, Johnson &amp; Johnson/Janssen Cilag, AbbVie, Actinogen, Axovant, Anavex, Cognition Therapies, Pfizer, Novartis, Biogen, Nutricia, Mundipharma, Abbott, Merck, Eisai, and GlaxoSmithKline. Dr Boada reports grants from Merck, AbbVie, Araclon, Biogen, Bioib&#xe9;rica, Grifols, Kyowa Hakko Kirin, Eli Lilly; grants and other support from Merck Sharp &amp; Dohme, Nutricia, Oryzon Genomics, Piramal Imaging Limited, and Schwabe Farma Iberica outside the submitted work; and for Caixabank, but does not receive them directly; fees from Servier and Eli Lilly for consulting; from Eli Lilly, Nutricia, Roche, and Schwabe for lectures; from Eli Lilly, Biogen, Roche, Bioiberica, Eisai, and Schwabe for serving on advisory boards; from Grifols, Roche, Biogen Araclon Biotech for consulting, advisory boards, and lectures; from Merck and Zambon for consulting and advisory boards; from Novo-Nordisk and Servier for advisory boards and lectures; grants from Grifols, La Caixa, Ciberned, European Federation of Pharmaceutical Industries and Associations, the EuroNanoMed III program, the Innovative Medicines Initiative Eranet Call 2012, Programa Misiones IA-2021&#x2014;Spain, the EU Joint Programme &#x2013; Neurodegenerative Disease Research PRE-ADAPT project, European Marie Sklodowska Curie, Instituto de Salud Carlos III, and Fondo Europeo Desarrollo Regional during the conduct of the study.Dr van Dyck has received recent speaker/consultancy fees from F. Hoffmann-La Roche, Eisai, Ono, and Cerevel and recent study research funding from Biogen, Biohaven, Eisai, Genentech, F. Hoffmann-La Roche, Johnson &amp; Johnson/Janssen, Eli Lilly, Merck, Novartis, Union Chimique Belge, and Cerevel as well as grants from Biogen, Eli Lilly, Biohaven, Janssen, Union Chimique Belge, Roche, Genentech, Eisai, and Cerevel and personal fees from Roche (scientific advisor), Eisai (scientific advisor), Ono (consultant), and Cerevel (consultant) outside the submitted work. Dr Grimmer has received consulting fees from AbbVie,Alector, Anavex, Biogen, Bracket, Eli Lilly, Functional Neuromodulation, Grifols, Iqvia/Quintiles, Life Molecular Imaging, Novartis, Novo Nordisk, Noselab, NuiCare, Roche Pharma, Toyama, and Vivoryon; lecture fees from Actelion, B.Braun, Biogen, Eli Lilly, Life Molecular Imaging, Novartis, Parexel, Roche Diagnostics, Roche Pharma, Schwabe, Toyama, Union Chimique Belge, and Vivoryon; and grants to his institution from Actelion and Novartis. Dr Selkoe is a director and consultant to Prothena Biosciences. Dr Quartino was a full-time employee of Genentech, part of F. Hoffmann-La Roche, at the time of this work and is now a full-time employee of Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden. Dr Dolton was a full-time employee of Genentech, part of F. Hoffmann-La Roche, at the time of this work and is now a full-time employee of Roche Products and owns stock or stock options in Roche. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121669</ArticleId><ArticleId IdType="pmc">PMC9486635</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.2909</ArticleId><ArticleId IdType="pii">2796551</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-&#x3b2;-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(2):73-88. doi:10.1038/s41582-018-0116-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0116-6</ArticleId><ArticleId IdType="pubmed">30610216</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Maloney JA, Imperio J, et al. . Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A&#x3b2;. Alzheimers Res Ther. 2019;11(1):97. doi:10.1186/s13195-019-0553-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0553-5</ArticleId><ArticleId IdType="pmc">PMC6886224</ArticleId><ArticleId IdType="pubmed">31787113</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Cohen S, van Dyck CH, et al. . ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889-e1897. doi:10.1212/WNL.0000000000005550</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005550</ArticleId><ArticleId IdType="pmc">PMC5962917</ArticleId><ArticleId IdType="pubmed">29695589</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Honigberg LA, Cho W, et al. . Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer&#x2019;s disease (BLAZE). Alzheimers Res Ther. 2018;10(1):96. doi:10.1186/s13195-018-0424-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0424-5</ArticleId><ArticleId IdType="pmc">PMC6146627</ArticleId><ArticleId IdType="pubmed">30231896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthrie H, Honig LS, Lin H, et al. . Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer&#x2019;s disease treated with escalating doses for up to 133 weeks. J Alzheimers Dis. 2020;76(3):967-979. doi:10.3233/JAD-200134</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200134</ArticleId><ArticleId IdType="pmc">PMC7505005</ArticleId><ArticleId IdType="pubmed">32568196</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Bryant SE, Waring SC, Cullum CM, et al. ; Texas Alzheimer&#x2019;s Research Consortium . Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer&#x2019;s research consortium study. Arch Neurol. 2008;65(8):1091-1095. doi:10.1001/archneur.65.8.1091</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.8.1091</ArticleId><ArticleId IdType="pmc">PMC3409562</ArticleId><ArticleId IdType="pubmed">18695059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope. the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13-S21. doi:10.1097/00002093-199700112-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199700112-00003</ArticleId><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141(11):1356-1364. doi:10.1176/ajp.141.11.1356</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.141.11.1356</ArticleId><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. . An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease. the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39. doi:10.1097/00002093-199700112-00005</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199700112-00005</ArticleId><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572. doi:10.1192/bjp.140.6.566</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.140.6.566</ArticleId><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, et al. . Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233-239. doi:10.1176/jnp.12.2.233</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/jnp.12.2.233</ArticleId><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer&#x2019;s disease: patient and caregiver reports. J Ment Health Aging. 1999;5(1):21-32. https://psycnet.apa.org/record/1999-05045-003</Citation></Reference><Reference><Citation>Le Scouiller S, Edgar C, Rylands A, et al. . Cross-cultural adaptation of the Zarit Caregiver Interview for Alzheimer&#x2019;s Disease (ZCI-AD) and the Caregiver Global Impression scales in 13 languages. Value Health. 2016;19(7):PA389. doi:10.1016/j.jval.2016.09.244</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2016.09.244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarit SH, Orr NK, Zarit JM. The Hidden Victims of Alzheimer&#x2019;s Disease: Families Under Stress. NYU Press; 1985.</Citation></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, et al. . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-1736. doi:10.1007/s11136-011-9903-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Dage J, Johnson SC, et al. . Exploring the need for robust biomarker assays in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Alzheimers Dement. 2019;15(75):2-231. doi:10.1016/j.jalz.2019.06.2638</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.2638</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Dang Y, Ostaszewski B, et al. . Target engagement in an Alzheimer trial: crenezumab lowers amyloid &#x3b2; oligomers in cerebrospinal fluid. Ann Neurol. 2019;86(2):215-224. doi:10.1002/ana.25513</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25513</ArticleId><ArticleId IdType="pmc">PMC6771589</ArticleId><ArticleId IdType="pubmed">31168802</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.1176/appi.ajp.2011.10111704</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2011.10111704</ArticleId><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninkilampi R, Brothers HM, Eslick GD. Safety and efficacy of anti-amyloid-&#x3b2; immunotherapy in Alzheimer&#x2019;s disease: a systematic review and meta-analysis. J Neuroimmune Pharmacol. 2017;12(1):194-203. doi:10.1007/s11481-016-9722-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-016-9722-5</ArticleId><ArticleId IdType="pubmed">28025724</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson C, Zhang Y, Dhadda S, et al. . DT-01-07: treatment of early AD subjects with BAN2401, an anti-A&#x3b2; protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline. Alzheimer&#x2019;s &amp; Dementia. 2018;14(7S):P1668. doi:10.1016/j.jalz.2018.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn B, Stein P, Cavazzoni P. Approval of aducanumab for Alzheimer disease&#x2014;the FDA&#x2019;s perspective. JAMA Intern Med. 2021;181(10):1276-1278. doi:10.1001/jamainternmed.2021.4607</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.4607</ArticleId><ArticleId IdType="pubmed">34254984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels AM, Lines C, Stern RA, et al. . Cognitive outcomes in trials of two BACE inhibitors in Alzheimer&#x2019;s disease. Alzheimers Dement. 2020;16(11):1483-1492. doi:10.1002/alz.12164</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12164</ArticleId><ArticleId IdType="pubmed">33049114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ultsch M, Li B, Maurer T, et al. . Structure of crenezumab complex with A&#x3b2; shows loss of &#x3b2;-hairpin. Sci Rep. 2016;6:39374. doi:10.1038/srep39374</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39374</ArticleId><ArticleId IdType="pmc">PMC5171940</ArticleId><ArticleId IdType="pubmed">27996029</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Moein A, Bittner T, et al. . Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2020;12(1):16. doi:10.1186/s13195-020-0580-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-0580-2</ArticleId><ArticleId IdType="pmc">PMC6977279</ArticleId><ArticleId IdType="pubmed">31969177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferl GZ, Fuji RN, Atwal JK, Sun T, Ramanujan S, Quartino AL. Mechanistic modeling of soluble A&#x3b2; dynamics and target engagement in the brain by anti-A&#x3b2; mAbs in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2020;17(4):393-406. doi:10.2174/1567205017666200302122307</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205017666200302122307</ArticleId><ArticleId IdType="pubmed">32116192</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36125811</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Association of Multimorbidity, Disease Clusters, and Modification by Genetic Factors With Risk of Dementia.</ArticleTitle><Pagination><StartPage>e2232124</StartPage><MedlinePgn>e2232124</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2232124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.32124</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Individual conditions have been identified as risk factors for dementia; however, it is important to consider the role of multimorbidity, as conditions often co-occur.</AbstractText><AbstractText Label="OBJECTIVE">To investigate whether multimorbidity is associated with incident dementia and whether associations vary by different clusters of disease and genetic risk for dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This population-based prospective cohort study used data from the UK Biobank cohort, with baseline data collected between 2006 and 2010 and with up to 15 years of follow-up. Participants included women and men without dementia and aged at least 60 years at baseline. Medical conditions were captured as part of nurse-led verbal interviews conducted at baseline assessment centers. Data were analyzed from October 2020 to July 2022.</AbstractText><AbstractText Label="EXPOSURES">The presence of at least 2 long-term conditions from a preselected list of 42 conditions was used to define multimorbidity. High genetic risk for dementia was based on presence of 1 or 2 apolipoprotein (APOE) &#x3b5;4 alleles.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The main outcome, incident dementia, was derived from hospital inpatient and death registry records. Associations of multimorbidity with dementia were assessed with Cox proportional hazards models.</AbstractText><AbstractText Label="RESULTS">A total of 206&#x202f;960 participants (mean [SD] age, 64.1 [2.9] years, 108&#x202f;982 [52.7%] women) were included in the final sample, of whom 89&#x202f;201 participants (43.1%) had multimorbidity. Over a mean (SD) of 11.8 (2.2) years of follow-up, 6182 participants (3.0%) developed dementia. The incidence rate was 1.87 (95% CI, 1.80-1.94) per 1000 person-years for those without multimorbidity and 3.41 (95% CI, 3.30-3.53) per 1000 person-years for those with multimorbidity. In Cox proportional hazards models adjusted for age, sex, ethnicity, education, socioeconomic status, and APOE-&#x3b5;4 carrier status, multimorbidity was associated with an increased risk of incident dementia (hazard ratio [HR], 1.63 [95% CI, 1.55-1.71]). The highest dementia risk was observed for the hypertension, diabetes, and coronary heart disease cluster (HR, 2.20 [95% CI, 1.98-2.46]) and pain, osteoporosis, and dyspepsia cluster (HR, 2.00 [95% CI, 1.68-2.37]) in women and in the diabetes and hypertension cluster (HR, 2.24 [95% CI, 1.97-2.55]) and coronary heart disease, hypertension, and stroke cluster (HR, 1.94 [95% CI, 1.71-2.20]) in men, compared with no multimorbidity. The associations between multimorbidity and dementia were greater in those with a lower genetic risk of dementia (HR, 1.96 [95% CI, 1.81-2.11]) than in those with a higher genetic risk of dementia (HR, 1.39 [95% CI, 1.30-1.49]). Similar findings were observed when stratifying diseases clusters by genetic risk for dementia.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These findings suggest that multimorbidity was associated with an increased risk of dementia. The associations varied by clusters of disease and genetic risk for dementia. These findings could help with the identification of individuals at high risk of dementia as well as the development of targeted interventions to reduce or delay dementia incidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calvin</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conroy</LastName><ForeName>Megan C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Sarah F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Elzbieta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Albertinen-Haus Centre for Geriatrics and Gerontology, University of Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Littlejohns</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086822" MajorTopicYN="N">Disease Hotspot</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36125811</ArticleId><ArticleId IdType="pmc">PMC9490497</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.32124</ArticleId><ArticleId IdType="pii">2796543</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2019 Dementia Forecasting Collaborators . Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125. doi:10.1016/S2468-2667(21)00249-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(21)00249-8</ArticleId><ArticleId IdType="pmc">PMC8810394</ArticleId><ArticleId IdType="pubmed">34998485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YT, Beiser AS, Breteler MMB, et al. . The changing prevalence and incidence of dementia over time&#x2014;current evidence. Nat Rev Neurol. 2017;13(6):327-339. doi:10.1038/nrneurol.2017.63</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.63</ArticleId><ArticleId IdType="pubmed">28497805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Satizabal CL, Seshadri S. Role of improved vascular health in the declining incidence of dementia. Stroke. 2017;48(7):2013-2020. doi:10.1161/STROKEAHA.117.013369</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.117.013369</ArticleId><ArticleId IdType="pmc">PMC5505318</ArticleId><ArticleId IdType="pubmed">28596460</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Risk reduction of cognitive decline and dementia: WHO guidelines. Accessed August 18, 2022. https://www.who.int/publications/i/item/9789241550543</Citation><ArticleIdList><ArticleId IdType="pubmed">31219687</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H, Manolova G, Daskalopoulou C, Vitoratou S, Prince M, Prina AM. Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies. J Comorb. 2019;9:X19870934. doi:10.1177/2235042X19870934</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2235042X19870934</ArticleId><ArticleId IdType="pmc">PMC6710708</ArticleId><ArticleId IdType="pubmed">31489279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassell A, Edwards D, Harshfield A, et al. . The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2018;68(669):e245-e251. doi:10.3399/bjgp18X695465</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp18X695465</ArticleId><ArticleId IdType="pmc">PMC5863678</ArticleId><ArticleId IdType="pubmed">29530918</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. doi:10.1016/S0140-6736(12)60240-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)60240-2</ArticleId><ArticleId IdType="pubmed">22579043</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitty CJM, MacEwen C, Goddard A, et al. . Rising to the challenge of multimorbidity. BMJ. 2020;368:l6964. doi:10.1136/bmj.l6964</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l6964</ArticleId><ArticleId IdType="pmc">PMC7190283</ArticleId><ArticleId IdType="pubmed">31907164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Hassen C, Fayosse A, Landr&#xe9; B, et al. . Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study. BMJ. 2022;376:e068005. doi:10.1136/bmj-2021-068005</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068005</ArticleId><ArticleId IdType="pmc">PMC9086721</ArticleId><ArticleId IdType="pubmed">35110302</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande G, Marengoni A, Vetrano DL, et al. . Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics. Alzheimers Dement. 2021;17(5):768-776. doi:10.1002/alz.12237</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12237</ArticleId><ArticleId IdType="pmc">PMC8247430</ArticleId><ArticleId IdType="pubmed">33403740</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, Gallacher J, Allen N, et al. . UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry A, Littlejohns TJ, Sudlow C, et al. . Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017;186(9):1026-1034. doi:10.1093/aje/kwx246</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwx246</ArticleId><ArticleId IdType="pmc">PMC5860371</ArticleId><ArticleId IdType="pubmed">28641372</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Biobank . Verbal interview stage: version 1.1. Accessed August 6, 2021. https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/Interview.pdf</Citation></Reference><Reference><Citation>Jani BD, Hanlon P, Nicholl BI, et al. . Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. BMC Med. 2019;17(1):74. doi:10.1186/s12916-019-1305-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1305-x</ArticleId><ArticleId IdType="pmc">PMC6456941</ArticleId><ArticleId IdType="pubmed">30967141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T, Schnier C, Bush K, et al. ; Dementias Platform UK and UK Biobank . Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur J Epidemiol. 2019;34(6):557-565. doi:10.1007/s10654-019-00499-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-019-00499-1</ArticleId><ArticleId IdType="pmc">PMC6497624</ArticleId><ArticleId IdType="pubmed">30806901</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend P, Phillimore P, Beattie A. Health and Deprivation: Inequality and the North. Croom Helm; 1988.</Citation></Reference><Reference><Citation>Bisquera A, Turner EB, Ledwaba-Chapman L, et al. . Inequalities in developing multimorbidity over time: A population-based cohort study from an urban, multi-ethnic borough in the United Kingdom. Lancet Reg Health Eur. 2021;12:100247. doi:10.1016/j.lanepe.2021.100247</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100247</ArticleId><ArticleId IdType="pmc">PMC8640725</ArticleId><ArticleId IdType="pubmed">34901910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C, Freeman C, Petkova D, et al. . The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0579-z</ArticleId><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Edwards D, Mant J, Payne RA, Kiddle S. Characteristics, service use and mortality of clusters of multimorbid patients in England: a population-based study. BMC Med. 2020;18(1):78. doi:10.1186/s12916-020-01543-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01543-8</ArticleId><ArticleId IdType="pmc">PMC7147068</ArticleId><ArticleId IdType="pubmed">32272927</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421-430. doi:10.1038/gim.2015.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.117</ArticleId><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16(10):1250-1255. doi:10.1161/01.ATV.16.10.1250</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.16.10.1250</ArticleId><ArticleId IdType="pubmed">8857921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei LK, Au A, Menon S, et al. . Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and ischemic stroke: meta-analysis. J Stroke Cerebrovasc Dis. 2017;26(11):2482-2493. doi:10.1016/j.jstrokecerebrovasdis.2017.05.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2017.05.048</ArticleId><ArticleId IdType="pubmed">28760411</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng F, Lu SS, Hu CY, et al. . Association between apolipoprotein E gene polymorphism and depression. J Clin Neurosci. 2015;22(8):1232-1238. doi:10.1016/j.jocn.2015.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2015.02.012</ArticleId><ArticleId IdType="pubmed">25979253</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XL, Liu YL, Zhang HM, et al. . The relationship between apolipoprotein E gene &#x3b5;2/&#x3b5;3/&#x3b5;4 polymorphism and breast cancer risk: a systematic review and meta-analysis. OncoTargets Ther. 2016;9:1241-1249. doi:10.2147/OTT.S94228</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S94228</ArticleId><ArticleId IdType="pmc">PMC4789883</ArticleId><ArticleId IdType="pubmed">27022282</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Tariot PN. Alzheimer&#x2019;s prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med. 2010;4(1):3-14. doi:10.2217/bmm.09.91</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.09.91</ArticleId><ArticleId IdType="pmc">PMC2850446</ArticleId><ArticleId IdType="pubmed">20383319</ArticleId></ArticleIdList></Reference><Reference><Citation>Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF III. Late-life depression and risk of vascular dementia and Alzheimer&#x2019;s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329-335. doi:10.1192/bjp.bp.112.118307</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.112.118307</ArticleId><ArticleId IdType="pmc">PMC3640214</ArticleId><ArticleId IdType="pubmed">23637108</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Kivim&#xe4;ki M, Batty GD. Respiratory disease and lower pulmonary function as risk factors for dementia: a systematic review with meta-analysis. Chest. 2020;157(6):1538-1558. doi:10.1016/j.chest.2019.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2019.12.012</ArticleId><ArticleId IdType="pubmed">31952950</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Starr JM, Stamatakis E, Kivim&#xe4;ki M, Batty GD. Pulmonary function as a risk factor for dementia death: an individual participant meta-analysis of six UK general population cohort studies. J Epidemiol Community Health. 2015;69(6):550-556. doi:10.1136/jech-2014-204959</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2014-204959</ArticleId><ArticleId IdType="pubmed">25691274</ArticleId></ArticleIdList></Reference><Reference><Citation>Peers C, Dallas ML, Boycott HE, Scragg JL, Pearson HA, Boyle JP. Hypoxia and neurodegeneration. Ann N Y Acad Sci. 2009;1177(1):169-177. doi:10.1111/j.1749-6632.2009.05026.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05026.x</ArticleId><ArticleId IdType="pubmed">19845619</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi HB, Tang B, Liu YW, Wang XF, Chen GJ. Alzheimer disease and cancer risk: a meta-analysis. J Cancer Res Clin Oncol. 2015;141(3):485-494. doi:10.1007/s00432-014-1773-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-014-1773-5</ArticleId><ArticleId IdType="pmc">PMC11823988</ArticleId><ArticleId IdType="pubmed">25015770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Guo S, Zhang X, et al. . Inverse relationship between cancer and Alzheimer&#x2019;s disease: a systemic review meta-analysis. Neurol Sci. 2015;36(11):1987-1994. doi:10.1007/s10072-015-2282-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-015-2282-2</ArticleId><ArticleId IdType="pubmed">26248482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T, Ly A, Schnier C, et al. ; UK Biobank Neurodegenerative Outcomes Group and Dementias Platform UK . Identifying dementia cases with routinely collected health data: a systematic review. Alzheimers Dement. 2018;14(8):1038-1051. doi:10.1016/j.jalz.2018.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.016</ArticleId><ArticleId IdType="pmc">PMC6105076</ArticleId><ArticleId IdType="pubmed">29621480</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36129998</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>387</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS.</ArticleTitle><Pagination><StartPage>1099</StartPage><EndPage>1110</EndPage><MedlinePgn>1099-1110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2204705</ELocationID><Abstract><AbstractText Label="BACKGROUND">The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations in <i>SOD1</i> (<i>SOD1</i> ALS).</AbstractText><AbstractText Label="METHODS">In this phase 3 trial, we randomly assigned adults with <i>SOD1</i> ALS in a 2:1 ratio to receive eight doses of tofersen (100 mg) or placebo over a period of 24 weeks. The primary end point was the change from baseline to week 28 in the total score on the ALS Functional Rating Scale-Revised (ALSFRS-R; range, 0 to 48, with higher scores indicating better function) among participants predicted to have faster-progressing disease. Secondary end points included changes in the total concentration of SOD1 protein in cerebrospinal fluid (CSF), in the concentration of neurofilament light chains in plasma, in slow vital capacity, and in handheld dynamometry in 16 muscles. A combined analysis of the randomized component of the trial and its open-label extension at 52 weeks compared the results in participants who started tofersen at trial entry (early-start cohort) with those in participants who switched from placebo to the drug at week 28 (delayed-start cohort).</AbstractText><AbstractText Label="RESULTS">A total of 72 participants received tofersen (39 predicted to have faster progression), and 36 received placebo (21 predicted to have faster progression). Tofersen led to greater reductions in concentrations of SOD1 in CSF and of neurofilament light chains in plasma than placebo. In the faster-progression subgroup (primary analysis), the change to week 28 in the ALSFRS-R score was -6.98 with tofersen and -8.14 with placebo (difference, 1.2 points; 95% confidence interval [CI], -3.2 to 5.5; P&#x2009;=&#x2009;0.97). Results for secondary clinical end points did not differ significantly between the two groups. A total of 95 participants (88%) entered the open-label extension. At 52 weeks, the change in the ALSFRS-R score was -6.0 in the early-start cohort and -9.5 in the delayed-start cohort (difference, 3.5 points; 95% CI, 0.4 to 6.7); non-multiplicity-adjusted differences favoring early-start tofersen were seen for other end points. Lumbar puncture-related adverse events were common. Neurologic serious adverse events occurred in 7% of tofersen recipients.</AbstractText><AbstractText Label="CONCLUSIONS">In persons with <i>SOD1</i> ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events. The potential effects of earlier as compared with delayed initiation of tofersen are being further evaluated in the extension phase. (Funded by Biogen; VALOR and OLE ClinicalTrials.gov numbers, NCT02623699 and NCT03070119; EudraCT numbers, 2015-004098-33 and 2016-003225-41.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucelli</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cochrane</LastName><ForeName>Thos</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chary</LastName><ForeName>Sowmya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Sheena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nestorov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNeill</LastName><ForeName>Manjit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanning</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Toby A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fradette</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) - both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Bonn - both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>VALOR and OLE Working Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02623699</AccessionNumber><AccessionNumber>NCT03070119</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2015-004098-33</AccessionNumber><AccessionNumber>2016-003225-41</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>2NU6F9601K</RegistryNumber><NameOfSubstance UI="C000709090">tofersen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Med. 2022 Nov 11;3(11):733-734. doi: 10.1016/j.medj.2022.10.004.</RefSource><PMID Version="1">36370693</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007278" MajorTopicYN="N">Injections, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="Y">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Beullens</LastName><ForeName>Lien</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claeys</LastName><ForeName>Kristl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claeys</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couwelier</LastName><ForeName>Goedele</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Hondt</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Debien</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Keersmaecker</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Della Faille</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delmotte</LastName><ForeName>Koen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Depoortere</LastName><ForeName>Sofie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Velder</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobbels</LastName><ForeName>Laurens</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gijs</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horckmans</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamaire</LastName><ForeName>Nikita</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liessens</LastName><ForeName>Hannelore</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masrori</LastName><ForeName>Pegah</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nysten</LastName><ForeName>Celine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schotte</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serrien</LastName><ForeName>Anouk</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swinnen</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tilkin</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Daele</LastName><ForeName>Sien</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vynckier</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wouters</LastName><ForeName>Anke</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Agessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Angle</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badawy</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berube</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertone</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Sarah Marie</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobrowolski</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fong</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannouche</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartley</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hogan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khalfallah</LastName><ForeName>Yousra</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kroetsch</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Letourneau</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magnussen</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massie</LastName><ForeName>Rami</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mobach</LastName><ForeName>Theodore</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mookshah</LastName><ForeName>Jahan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozelsel</LastName><ForeName>Timur</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parks</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrillo</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeffer</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pham</LastName><ForeName>Shirley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phung</LastName><ForeName>Liane</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiungsun</LastName><ForeName>Rodney</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pi-Shan</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>Denizart</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salmon</LastName><ForeName>Kristiana</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saunders</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sembinelli</LastName><ForeName>Dylan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tymkow</LastName><ForeName>Kelsey</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Berchman</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlsborg</LastName><ForeName>Merete</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedersen Lomholt</LastName><ForeName>Therese</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvesen</LastName><ForeName>Lisette</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skov</LastName><ForeName>Pernille</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Svenstrup</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruneteau</LastName><ForeName>Gaelle</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calerencon</LastName><ForeName>Frederic</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guimaraes Costa</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hesters</LastName><ForeName>Adele</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kermorvant</LastName><ForeName>Hugo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>Lucette</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forestier</LastName><ForeName>Nadine Le</ForeName><Initials>NL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lenglet</LastName><ForeName>Thimot&#xe9;e</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Retail</LastName><ForeName>Maryvonne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz Del Mar Amador</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salachas</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shotar</LastName><ForeName>Eimad</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sourour</LastName><ForeName>Nader</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Froehlich</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fromm</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kandler</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langer</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leichtle</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michels</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raubold</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuster</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiland</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiesenfarth</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witzel</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casale</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuda</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchese</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salamone</LastName><ForeName>Paolina</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajiki</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akasaka</LastName><ForeName>Aya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ando</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arata</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asuka</LastName><ForeName>Kitamura</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baba</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bekku</LastName><ForeName>Goichi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiba</LastName><ForeName>Tomoya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Date</LastName><ForeName>Yugaku</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eriko</LastName><ForeName>Takeuchi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hashiguchi</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hatatori</LastName><ForeName>Ritsuko</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayano</LastName><ForeName>Eri</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Yuto</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higashi</LastName><ForeName>Keiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Eriko</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hiramatsu</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horikawa</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikenaka</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishiura</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawai</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kikuchi</LastName><ForeName>Junko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuzuyama</LastName><ForeName>Haruko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xuehong</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Chika</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsuura</LastName><ForeName>Eiji</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michizono</LastName><ForeName>Kumiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsui</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsutake</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mochizuki</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Akemi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagano</LastName><ForeName>Seiichi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naruse</LastName><ForeName>Hiroya</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogasawara</LastName><ForeName>Asuka</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okada</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okuno</LastName><ForeName>Tatsusada</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oyama</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozono</LastName><ForeName>Tatsuhiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakiyama</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakuishi</LastName><ForeName>Kaori</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seki</LastName><ForeName>Morinobu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shibata</LastName><ForeName>Shota</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Mikito</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahata</LastName><ForeName>Katsunori</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahito</LastName><ForeName>Yoshizaki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takashima</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takeichi</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toda</LastName><ForeName>Tatsushi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomizu</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomoya</LastName><ForeName>Wadayama</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ujiakira</LastName><ForeName>Nishiike</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yashita</LastName><ForeName>Daiki</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alix</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bangalore</LastName><ForeName>Priyadarshini</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiwera</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clegg</LastName><ForeName>Rosie</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collins</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emery</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Louisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Callum</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hobson</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Islam</LastName><ForeName>Mahjabim</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Thomas Michael</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kazoka</LastName><ForeName>Mbombe</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelly</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korley</LastName><ForeName>Mercy</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madarshahaian</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayl</LastName><ForeName>Keith</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher John</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radford</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidebottom</LastName><ForeName>Joe</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smart</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sreedharan</LastName><ForeName>Jemeen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stone</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsironis</LastName><ForeName>Theocharis</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuddenham</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verber</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wollff</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adamo</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Arubah</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajroud-Driss</LastName><ForeName>Senda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alameda</LastName><ForeName>Gustave</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arcila-Londono</LastName><ForeName>Ximena</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baird</LastName><ForeName>Candy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bazan</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berry</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordeau</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradford</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brook</LastName><ForeName>Nyda</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bucelli</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckner</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budler</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burba</LastName><ForeName>Lindita</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calhoun</LastName><ForeName>Ashley D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carey</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caristo</LastName><ForeName>Irys B</ForeName><Initials>IB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carty</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaudhry</LastName><ForeName>Vinay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Ricky</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chow</LastName><ForeName>Saephanh</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clawson</LastName><ForeName>Lora L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clemens</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cloninger</LastName><ForeName>Suzann E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman-Wood</LastName><ForeName>Krista</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Thomas N</ForeName><Initials>TN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Arlena</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniels</LastName><ForeName>Jacquelyn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeSaro</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeWitt</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dedi</LastName><ForeName>Brixhilda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dempsey</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denny</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doherty</LastName><ForeName>Jenna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doherty</LastName><ForeName>Leana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doyle</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duncan</LastName><ForeName>Jessie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eloge</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Echiti</LastName><ForeName>Desirae R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrey</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fournier</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fukumura</LastName><ForeName>Yuriko</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garaycoa</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrett</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibson</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gifford</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gogol</LastName><ForeName>Danuta</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golden</LastName><ForeName>Shea</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Alexa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodman</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goolsby</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goslin</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goulbourne</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Granit</LastName><ForeName>Volkan</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grignon</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>GuhaRay</LastName><ForeName>Adreeja</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guide</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gundogdu</LastName><ForeName>Melek Betul</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Gil</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hastings</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayzen</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herzog</LastName><ForeName>Hilary</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holloway</LastName><ForeName>Raegan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>Bill</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jockel-Balsarotti</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Linda Carol</ForeName><Initials>LC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jose</LastName><ForeName>Sunil</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joslin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karanja</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keener</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittle</LastName><ForeName>Gale</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreple</LastName><ForeName>Collin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rebecca</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuenzler</LastName><ForeName>Kuenzler</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kusnir</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labbe</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lachica-Encinas</LastName><ForeName>Nicolet</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leimer</LastName><ForeName>Lesli</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yingji</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Likanje</LastName><ForeName>Marie-France</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Livigni</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luppino</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malcolm</LastName><ForeName>Amber</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marin</LastName><ForeName>Horia</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markowitz</LastName><ForeName>Clyde</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markway</LastName><ForeName>Jesse</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCaffrey</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCoy</LastName><ForeName>Arita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCoy Gross</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>Kush</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milan</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morales</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosmiller</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mott</LastName><ForeName>Donovan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moulton</LastName><ForeName>Kelsey</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Christine A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Negron</LastName><ForeName>Tirso</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newman</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nissinen</LastName><ForeName>Janne Kristoffer</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norman</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohkubo</LastName><ForeName>Takuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olney</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Natasha</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bjorn</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pace</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Packard</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padgett</LastName><ForeName>Denny</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Partlow</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary L</ForeName><Initials>GL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paulett</LastName><ForeName>Jany</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelot</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeifer</LastName><ForeName>Kyle M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pijanowski</LastName><ForeName>Olivia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polak</LastName><ForeName>Meraida</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prakash</LastName><ForeName>Ahalya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Previte</LastName><ForeName>Rosemarie</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pukenas</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Razavi</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Regan</LastName><ForeName>Tyler</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riley</LastName><ForeName>Kristen M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>Danica</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scalia</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwen</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Jaimin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Stuti</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheldon</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simmons</LastName><ForeName>Karon</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Navneet K</ForeName><Initials>NK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smiley</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>William B</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sotirchos</LastName><ForeName>Elias</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorenson</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Staff</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steele</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steijlen</LastName><ForeName>Kara</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stirrat</LastName><ForeName>Taylor</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoica</LastName><ForeName>George S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strong</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sufit</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sultze</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swartz</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szymanski</LastName><ForeName>April</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tay</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thakore</LastName><ForeName>Nimish</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiessen</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thotala</LastName><ForeName>Sukrutha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trudell</LastName><ForeName>Randall G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turcotte</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uchil</LastName><ForeName>Alpa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Upadhyay</LastName><ForeName>Vihar</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Usman</LastName><ForeName>Uzma</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vallis</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaporean-Bussey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vladimirova</LastName><ForeName>Valentine</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Harli</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winbigler</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wojanowski</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wulf</LastName><ForeName>Charlie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yasek</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoo</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zivalic</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cole</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>File</LastName><ForeName>Greta</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foate</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newton</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sellwood</LastName><ForeName>Cory Dean</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swan</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werno</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhong</LastName><ForeName>Cathy</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36129998</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36130946</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Preclinical and randomized clinical evaluation of the p38&#x3b1; kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.</ArticleTitle><Pagination><StartPage>5308</StartPage><MedlinePgn>5308</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5308</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-32944-3</ELocationID><Abstract><AbstractText>The endosome-associated GTPase Rab5 is a central player in the molecular mechanisms leading to degeneration of basal forebrain cholinergic neurons (BFCN), a long-standing target for drug development. As p38&#x3b1; is a Rab5 activator, we hypothesized that inhibition of this kinase holds potential as an approach to treat diseases associated with BFCN loss. Herein, we report that neflamapimod (oral small molecule p38&#x3b1; inhibitor) reduces Rab5 activity, reverses endosomal pathology, and restores the numbers and morphology of BFCNs in a mouse model that develops BFCN degeneration. We also report on the results of an exploratory (hypothesis-generating) phase 2a randomized double-blind 16-week placebo-controlled clinical trial (Clinical trial registration: NCT04001517/EudraCT #2019-001566-15) of neflamapimod in mild-to-moderate dementia with Lewy bodies (DLB), a disease in which BFCN degeneration is an important driver of disease expression. A total of 91 participants, all receiving background cholinesterase inhibitor therapy, were randomized 1:1 between neflamapimod 40&#x2009;mg or matching placebo capsules (taken orally twice-daily if weight &lt;80&#x2009;kg or thrice-daily if weight &gt;80&#x2009;kg). Neflamapimod does not show an effect in the clinical study on the primary endpoint, a cognitive-test battery. On two secondary endpoints, a measure of functional mobility and a dementia rating-scale, improvements were seen that are consistent with an effect on BFCN function. Neflamapimod treatment is well-tolerated with no study drug associated treatment discontinuations. The combined preclinical and clinical observations inform on the validity of the Rab5-based pathogenic model of cholinergic degeneration and provide a foundation for confirmatory (hypothesis-testing) clinical evaluation of neflamapimod in DLB.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Alam</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-1285-1115</Identifier><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA. jalam@eippharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomperts</LastName><ForeName>Stephen N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Massachusetts Alzheimer's Disease Research Center, 114 16th Street, Massachusetts General Hospital, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6947-9537</Identifier><AffiliationInfo><Affiliation>Cogstate Ltd, Runway East Borough Market, 20 St. Thomas St, London, SE1 9RS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemstra</LastName><ForeName>Afina W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Research Center, Cronenburg 2, 1081 GN, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Germann</LastName><ForeName>Ursula A</ForeName><Initials>UA</Initials><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrides</LastName><ForeName>Philip H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darji</LastName><ForeName>Sandipkumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malampati</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peddy</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleiwas</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlik</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pensalfini</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dun-Sheng</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbanna</LastName><ForeName>Shivakumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basavarajappa</LastName><ForeName>Balapal S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, 1051 Riverside Dr., New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smiley</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>EIP Pharma Inc, 20 Park Plaza, Suite 424, Boston, MA, 02116, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Hui-May</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Anoixis Corporation, 214 N. Main St. #104, Natick, MA, 01760, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Niels D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Brain Research Center, Cronenburg 2, 1081 GN, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>John E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-0225-4923</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metis Cognition Ltd, Park House, Kilmington Common, Warminster, BA12 6QY, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration, Amsterdam UMC at VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA. ralph.nixon@nki.rfmh.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA. ralph.nixon@nki.rfmh.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, NYU Grossman School of Medicine, 550 First Ave, New York, NY, 10016, USA. ralph.nixon@nki.rfmh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04001517</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2019-001566-15</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AA019443</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062376</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048308">Mitogen-Activated Protein Kinase 14</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066187" MajorTopicYN="Y">Basal Forebrain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048308" MajorTopicYN="N">Mitogen-Activated Protein Kinase 14</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>J.J.A, A.G., and K.B. are employees of EIP Pharma, the sponsor of the clinical study. J.J.A. is also founder of and has stock ownership in EIP Pharma. U.A.G. receives compensation as a scientific consultant to EIP Pharma. S.N.G. has served on Advisory Boards of Jannsen, Acadia, and Sanofi, has received consulting fees from EIP Pharma, and has received funding from the NIH, the DOD CDMRP, the Michael J. Fox Foundation, the FFFPRI, and the Lewy Body Dementia Association. N.D.P. is CEO and co-owner of Brain Research Center. P.M. is a full-time employee at Cogstate Ltd. J.E.H. reports receipt of personal fees in the past 2 years from Actinogen, AlzeCure, Aptinyx, Astra Zeneca, Athira Therapeutics, Axon Neuroscience, Axovant, Bial Biotech, Biogen Idec, BlackThornRx, Boehringer Ingelheim, Brands2life, Cerecin, Cognito, Cognition Therapeutics, Compass Pathways, Corlieve, Curasen, EIP Pharma, Eisai, G4X Discovery, GfHEU, Heptares, Ki Elements, Lundbeck, Lysosome Therapeutics, MyCognition, Neurocentria, Neurocog, Neurodyn Inc, Neurotrack, the NHS, Novartis, Novo Nordisk, Nutricia, Probiodrug, Prothena, Recognify, Regeneron, reMYND, Rodin Therapeutics, Samumed, Sanofi, Signant, Syndesi Therapeutics, Takeda, Vivoryon Therapeutics and Winterlight Labs. In addition, he holds stock options in Neurotrack Inc. and is a joint holder of patents with My Cognition Ltd. C.E.T. has a collaboration contracts with ADx Neurosciences, Quanterix and Eli Lilly; performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon; and has had speaker contracts for Roche, Grifols, and Novo Nordisk. P.S. has received consultancy fees (paid to the institution) from AC Immune, Brainstorm Cell, EIP Pharma, ImmunoBrain Checkpoint, Genentech, Novartis, Novo Nordisk. P.S. is also principal investigator of studies with AC Immune, FUJI-film/Toyama, UCB, and Vivoryon; and is an employee of EQT Life Sciences (formerly LSP). The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36130946</ArticleId><ArticleId IdType="pmc">PMC9492778</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32944-3</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-32944-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grothe MJ, et al. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer&#x2019;s disease dementia. J. Neurol. 2014;261:1939&#x2013;1948. doi: 10.1007/s00415-014-7439-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7439-z</ArticleId><ArticleId IdType="pubmed">25059393</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr. Cogn. Disord. 2004;17:3&#x2013;14. doi: 10.1159/000074677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000074677</ArticleId><ArticleId IdType="pubmed">14676464</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher, J. et al. Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer&#x2019;s disease. Brain (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166545</ArticleId><ArticleId IdType="pubmed">34605858</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher J, et al. In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies. Neuroimage Clin. 2021;30:102604. doi: 10.1016/j.nicl.2021.102604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2021.102604</ArticleId><ArticleId IdType="pmc">PMC7972982</ArticleId><ArticleId IdType="pubmed">33711623</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Spreng RN, The-Alzheimer&#x2019;s-Disease-Neuroimaging-Initiative. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer&#x2019;s pathology. Nat. Commun. 2016;7:13249. doi: 10.1038/ncomms13249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13249</ArticleId><ArticleId IdType="pmc">PMC5097157</ArticleId><ArticleId IdType="pubmed">27811848</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, et al. Revisiting the cholinergic hypothesis in alzheimer&#x2019;s disease: emerging evidence from translational and clinical research. J. Prev. Alzheimers Dis. 2019;6:2&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30569080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Cabello S, et al. Basal forebrain volume reliably predicts the cortical spread of Alzheimer&#x2019;s degeneration. Brain. 2020;143:993&#x2013;1009. doi: 10.1093/brain/awaa012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa012</ArticleId><ArticleId IdType="pmc">PMC7092749</ArticleId><ArticleId IdType="pubmed">32203580</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J, et al. Cholinergic basal forebrain volumes predict gait decline in Parkinson&#x2019;s Disease. Mov. Disord. 2021;36:611&#x2013;621. doi: 10.1002/mds.28453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28453</ArticleId><ArticleId IdType="pmc">PMC8048433</ArticleId><ArticleId IdType="pubmed">33382126</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins KB, Parker JE, Bronte-Stewart HM. Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson&#x2019;s disease. Neurobiol. Dis. 2020;146:105134. doi: 10.1016/j.nbd.2020.105134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105134</ArticleId><ArticleId IdType="pmc">PMC7711311</ArticleId><ArticleId IdType="pubmed">33045357</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalrymple WA, et al. Cholinergic nucleus 4 atrophy and gait impairment in Parkinson&#x2019;s disease. J. Neurol. 2021;268:95&#x2013;101. doi: 10.1007/s00415-020-10111-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10111-2</ArticleId><ArticleId IdType="pubmed">32725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarzebowski, P., Tang, C.S., Paulsen, O. &amp; Hay, Y.A. Impaired spatial learning and suppression of sharp wave ripples by cholinergic activation at the goal location. Elife10, e65998 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064750</ArticleId><ArticleId IdType="pubmed">33821790</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer&#x2019;s disease: inseparable partners in a multifactorial disease. FASEB J. 2017;31:2729&#x2013;2743. doi: 10.1096/fj.201700359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700359</ArticleId><ArticleId IdType="pmc">PMC6137496</ArticleId><ArticleId IdType="pubmed">28663518</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl Acad. Sci. USA. 1996;93:13333&#x2013;13338. doi: 10.1073/pnas.93.23.13333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.23.13333</ArticleId><ArticleId IdType="pmc">PMC24093</ArticleId><ArticleId IdType="pubmed">8917591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, et al. Evidence that the rab5 effector APPL1 mediates APP-betaCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer&#x2019;s disease. Mol. Psychiatry. 2016;21:707&#x2013;716. doi: 10.1038/mp.2015.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.97</ArticleId><ArticleId IdType="pmc">PMC4721948</ArticleId><ArticleId IdType="pubmed">26194181</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi AH, et al. NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. Neuron. 2000;27:279&#x2013;288. doi: 10.1016/S0896-6273(00)00036-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00036-2</ArticleId><ArticleId IdType="pubmed">10985348</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000;157:277&#x2013;286. doi: 10.1016/S0002-9440(10)64538-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64538-5</ArticleId><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol. 2008;173:370&#x2013;384. doi: 10.2353/ajpath.2008.071053.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.071053</ArticleId><ArticleId IdType="pmc">PMC2475775</ArticleId><ArticleId IdType="pubmed">18535180</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiol. Aging. 2016;39:90&#x2013;98. doi: 10.1016/j.neurobiolaging.2015.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4773919</ArticleId><ArticleId IdType="pubmed">26923405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JD, et al. Failed retrograde transport of NGF in a mouse model of Down&#x2019;s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl Acad. Sci. USA. 2001;98:10439&#x2013;10444. doi: 10.1073/pnas.181219298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.181219298</ArticleId><ArticleId IdType="pmc">PMC56979</ArticleId><ArticleId IdType="pubmed">11504920</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XQ, Mobley WC. Exploring the pathogenesis of Alzheimer Disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses. Front Neurosci. 2019;13:446. doi: 10.3389/fnins.2019.00446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00446</ArticleId><ArticleId IdType="pmc">PMC6514132</ArticleId><ArticleId IdType="pubmed">31133787</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli V, et al. The stress-induced MAP kinase p38 regulates endocytic trafficking via the GDI:Rab5 complex. Mol. Cell. 2001;7:421&#x2013;432. doi: 10.1016/S1097-2765(01)00189-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(01)00189-7</ArticleId><ArticleId IdType="pubmed">11239470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs KL, et al. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596. doi: 10.1038/s41419-018-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0624-8</ArticleId><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam JJ. Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves Morris water maze performance in aged rats. J. Alzheimers Dis. 2015;48:219&#x2013;227. doi: 10.3233/JAD-150277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150277</ArticleId><ArticleId IdType="pmc">PMC4923728</ArticleId><ArticleId IdType="pubmed">26401942</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam J, Blackburn K, Patrick D. Neflamapimod: Clinical phase 2b-ready oral small molecule inhibitor of p38alpha to reverse synaptic dysfunction in early Alzheimer&#x2019;s disease. J. Prev. Alzheimer&#x2019;s Dis. 2017;4:273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">29181493</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins ND, et al. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther. 2021;13:106. doi: 10.1186/s13195-021-00843-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00843-2</ArticleId><ArticleId IdType="pmc">PMC8157623</ArticleId><ArticleId IdType="pubmed">34044875</ArticleId></ArticleIdList></Reference><Reference><Citation>Trempolec N, Dave-Coll N, Nebreda AR. SnapShot: p38 MAPK substrates. Cell. 2013;152:924&#x2013;924.e921. doi: 10.1016/j.cell.2013.01.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.01.047</ArticleId><ArticleId IdType="pubmed">23415236</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson SK, Dobrikova EY, Shveygert M, Gromeier M. p38alpha mitogen-activated protein kinase depletion and repression of signal transduction to translation machinery by miR-124 and &#x2212;128 in neurons. Mol. Cell Biol. 2013;33:127&#x2013;135. doi: 10.1128/MCB.00695-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00695-12</ArticleId><ArticleId IdType="pmc">PMC3536301</ArticleId><ArticleId IdType="pubmed">23109423</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnoder L, et al. Deficiency of neuronal p38alpha MAPK attenuates amyloid pathology in Alzheimer disease mouse and cell models through facilitating lysosomal degradation of BACE1. J. Biol. Chem. 2016;291:2067&#x2013;2079. doi: 10.1074/jbc.M115.695916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.695916</ArticleId><ArticleId IdType="pmc">PMC4732195</ArticleId><ArticleId IdType="pubmed">26663083</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88&#x2013;100. doi: 10.1212/WNL.0000000000004058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004058</ArticleId><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas AJ, et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology. 2017;88:276&#x2013;283. doi: 10.1212/WNL.0000000000003512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003512</ArticleId><ArticleId IdType="pmc">PMC5272795</ArticleId><ArticleId IdType="pubmed">27940650</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesnes KA, et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr. Cogn. Disord. 2002;13:183&#x2013;192. doi: 10.1159/000048651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000048651</ArticleId><ArticleId IdType="pubmed">11893841</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, B. et al. Outcome measures for dementia with lewy body clinical trials: a review. Alzheimer Dis. Assoc. Disord.36, 64&#x2013;72 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847491</ArticleId><ArticleId IdType="pubmed">34393189</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. Dement Geriatr. Cogn. Disord. 2004;18:94&#x2013;100. doi: 10.1159/000077816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000077816</ArticleId><ArticleId IdType="pubmed">15087584</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewiadomska G, Komorowski S, Baksalerska-Pazera M. Amelioration of cholinergic neurons dysfunction in aged rats depends on the continuous supply of NGF. Neurobiol. Aging. 2002;23:601&#x2013;613. doi: 10.1016/S0197-4580(01)00345-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00345-1</ArticleId><ArticleId IdType="pubmed">12009509</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy B, et al. p38alpha and p38beta mitogen-activated protein kinases determine cholinergic transdifferentiation of sympathetic neurons. J. Neurosci. 2011;31:12059&#x2013;12067. doi: 10.1523/JNEUROSCI.0448-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0448-11.2011</ArticleId><ArticleId IdType="pmc">PMC6623226</ArticleId><ArticleId IdType="pubmed">21865449</ArticleId></ArticleIdList></Reference><Reference><Citation>Scali C, et al. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience. 2003;117:909&#x2013;919. doi: 10.1016/S0306-4522(02)00839-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(02)00839-4</ArticleId><ArticleId IdType="pubmed">12654342</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci. 2001;21:5239&#x2013;5250. doi: 10.1523/JNEUROSCI.21-14-05239.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-14-05239.2001</ArticleId><ArticleId IdType="pmc">PMC6762828</ArticleId><ArticleId IdType="pubmed">11438599</ArticleId></ArticleIdList></Reference><Reference><Citation>Valuskova P, Riljak V, Forczek ST, Farar V, Myslivecek J. Variability in the drug response of M4 muscarinic receptor knockout mice during day and night time. Front Pharm. 2019;10:237. doi: 10.3389/fphar.2019.00237.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00237</ArticleId><ArticleId IdType="pmc">PMC6431655</ArticleId><ArticleId IdType="pubmed">30936831</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepeu, G., Scali, C. &amp; Giovannini, M.G. Chapter 25. The role of cholinergic system in novel object recognition. in Handbook of Behavioral Neuroscience (eds. Ennaceur, A. &amp; deSouza Silva, M.) 371&#x2013;378 (Elsevier, Amsterdam, 2018).</Citation></Reference><Reference><Citation>Kaur G, et al. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down&#x2019;s syndrome. J. Neurosci. 2014;34:5099&#x2013;5106. doi: 10.1523/JNEUROSCI.5338-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5338-13.2014</ArticleId><ArticleId IdType="pmc">PMC3983795</ArticleId><ArticleId IdType="pubmed">24719089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurt MA, Kafa MI, Dierssen M, Davies DC. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 2004;1022:101&#x2013;109. doi: 10.1016/j.brainres.2004.06.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.06.075</ArticleId><ArticleId IdType="pubmed">15353219</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson-Anson H, et al. Acetylcholine-secreting cells improve age-induced memory deficits. Mol. Ther. 2003;8:51&#x2013;61. doi: 10.1016/S1525-0016(03)00145-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1525-0016(03)00145-X</ArticleId><ArticleId IdType="pubmed">12842428</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam JJ, Krakovsky M, Germann U, Levy A. Continuous administration of a p38alpha inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level. PLoS ONE. 2020;15:e0233073. doi: 10.1371/journal.pone.0233073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0233073</ArticleId><ArticleId IdType="pmc">PMC7717516</ArticleId><ArticleId IdType="pubmed">33275615</ArticleId></ArticleIdList></Reference><Reference><Citation>Conner JM, Chiba AA, Tuszynski MH. The basal forebrain cholinergic system is essential for cortical plasticity and functional recovery following brain injury. Neuron. 2005;46:173&#x2013;179. doi: 10.1016/j.neuron.2005.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.03.003</ArticleId><ArticleId IdType="pubmed">15848797</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A, et al. Endosomal dysfunction induced by directly overactivating rab5 recapitulates prodromal and neurodegenerative features of Alzheimer&#x2019;s Disease. Cell Rep. 2020;33:108420. doi: 10.1016/j.celrep.2020.108420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108420</ArticleId><ArticleId IdType="pmc">PMC7714675</ArticleId><ArticleId IdType="pubmed">33238112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge B, et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science. 2002;295:1291&#x2013;1294. doi: 10.1126/science.1067289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067289</ArticleId><ArticleId IdType="pubmed">11847341</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam J, Scheper W. Targeting neuronal MAPK14/p38alpha activity to modulate autophagy in the Alzheimer disease brain. Autophagy. 2016;12:2516&#x2013;2520. doi: 10.1080/15548627.2016.1238555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1238555</ArticleId><ArticleId IdType="pmc">PMC5173254</ArticleId><ArticleId IdType="pubmed">27715387</ArticleId></ArticleIdList></Reference><Reference><Citation>Colie S, et al. Neuronal p38alpha mediates synaptic and cognitive dysfunction in an Alzheimer&#x2019;s mouse model by controlling beta-amyloid production. Sci. Rep. 2017;7:45306. doi: 10.1038/srep45306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep45306</ArticleId><ArticleId IdType="pmc">PMC5374488</ArticleId><ArticleId IdType="pubmed">28361984</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnoder L, et al. P38alpha-MAPK phosphorylates Snapin and reduces Snapin-mediated BACE1 transportation in APP-transgenic mice. FASEB J. 2021;35:e21691. doi: 10.1096/fj.202100017R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202100017R</ArticleId><ArticleId IdType="pubmed">34118085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanel P, et al. Topography of cholinergic changes in dementia with lewy bodies and key neural network hubs. J. Neuropsychiatry Clin. Neurosci. 2020;32:370&#x2013;375. doi: 10.1176/appi.neuropsych.19070165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.neuropsych.19070165</ArticleId><ArticleId IdType="pmc">PMC10018718</ArticleId><ArticleId IdType="pubmed">32498602</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller P, et al. Structural MRI of the basal forebrain as predictor of cognitive response to galantamine in healthy older adults-A randomized controlled double-blinded crossover study. Alzheimers Dement (N.Y.) 2021;7:e12153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020325</ArticleId><ArticleId IdType="pubmed">33842683</ArticleId></ArticleIdList></Reference><Reference><Citation>Avram M, et al. Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. Neuropsychopharmacology. 2021;46:2320&#x2013;2329. doi: 10.1038/s41386-021-01070-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-021-01070-x</ArticleId><ArticleId IdType="pmc">PMC8580980</ArticleId><ArticleId IdType="pubmed">34188186</ArticleId></ArticleIdList></Reference><Reference><Citation>Oswal A, et al. Cortical connectivity of the nucleus basalis of Meynert in Parkinson&#x2019;s disease and Lewy body dementias. Brain. 2021;144:781&#x2013;788. doi: 10.1093/brain/awaa411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa411</ArticleId><ArticleId IdType="pmc">PMC8041337</ArticleId><ArticleId IdType="pubmed">33521808</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga, S., Kishi, T., Yasue, I. &amp; Iwata, N. Cholinesterase inhibitors for lewy body disorders: a meta-analysis. Int. J. Neuropsychopharmacol19, 10.1093/ijnp/pyv086 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772820</ArticleId><ArticleId IdType="pubmed">26221005</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo, H.S. et al. Association of beta-amyloid and basal forebrain with cortical thickness and cognition in alzheimer and lewy body disease spectra. Neurology, 98 e947&#x2013;e957 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901177</ArticleId><ArticleId IdType="pubmed">34969939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall S, et al. Plasma phospho-tau identifies Alzheimer&#x2019;s co-pathology in patients with lewy body disease. Mov. Disord. 2021;36:767&#x2013;771. doi: 10.1002/mds.28370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28370</ArticleId><ArticleId IdType="pmc">PMC8048822</ArticleId><ArticleId IdType="pubmed">33285015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, et al. Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Commun. 2022;4:fcac013. doi: 10.1093/braincomms/fcac013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac013</ArticleId><ArticleId IdType="pmc">PMC8994111</ArticleId><ArticleId IdType="pubmed">35415608</ArticleId></ArticleIdList></Reference><Reference><Citation>Asih PR, et al. Functions of p38 MAP kinases in the Central Nervous System. Front Mol. Neurosci. 2020;13:570586. doi: 10.3389/fnmol.2020.570586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.570586</ArticleId><ArticleId IdType="pmc">PMC7509416</ArticleId><ArticleId IdType="pubmed">33013322</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachstetter AD, Van Eldik LJ. The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging Dis. 2010;1:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377763</ArticleId><ArticleId IdType="pubmed">22720195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracco L, Bessi V, Padiglioni S, Marini S, Pepeu G. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer&#x2019;s disease patients. J. Alzheimers Dis. 2014;40:737&#x2013;742. doi: 10.3233/JAD-131154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-131154</ArticleId><ArticleId IdType="pubmed">24577458</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, et al. Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer&#x2019;s disease. Neuropharmacology. 2016;108:128&#x2013;135. doi: 10.1016/j.neuropharm.2016.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.02.005</ArticleId><ArticleId IdType="pubmed">26876309</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds EC, et al. Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: a secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N.Y.) 2018;4:11&#x2013;18. doi: 10.1016/j.trci.2017.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.11.001</ArticleId><ArticleId IdType="pmc">PMC5738722</ArticleId><ArticleId IdType="pubmed">29296659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF. Early-onset Alzheimer disease and its variants. Contin. (Minneap. Minn.) 2019;25:34&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538053</ArticleId><ArticleId IdType="pubmed">30707186</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Shaikh FSH, et al. Selective vulnerability of the nucleus basalis of Meynert among neuropathic subtypes of Alzheimer disease. JAMA Neurol. 2021;77:225&#x2013;233. doi: 10.1001/jamaneurol.2019.3606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3606</ArticleId><ArticleId IdType="pmc">PMC6820048</ArticleId><ArticleId IdType="pubmed">31657834</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez JL, Zammit MD, West NR, Christian BT, Bhattacharyya A. Basal forebrain cholinergic neurons: linking down syndrome and Alzheimer&#x2019;s disease. Front Aging Neurosci. 2021;13:703876. doi: 10.3389/fnagi.2021.703876.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.703876</ArticleId><ArticleId IdType="pmc">PMC8311593</ArticleId><ArticleId IdType="pubmed">34322015</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, et al. Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson&#x2019;s disease. Sci. Rep. 2017;7:3868. doi: 10.1038/s41598-017-04232-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04232-4</ArticleId><ArticleId IdType="pmc">PMC5478665</ArticleId><ArticleId IdType="pubmed">28634349</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer B, et al. Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol. Commun. 2017;5:7. doi: 10.1186/s40478-016-0410-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0410-8</ArticleId><ArticleId IdType="pmc">PMC5237270</ArticleId><ArticleId IdType="pubmed">28086964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassil F, et al. Amyloid-beta (abeta) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of lewy body disorders with abeta pathology. Neuron. 2020;105:260&#x2013;275 e266. doi: 10.1016/j.neuron.2019.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.10.010</ArticleId><ArticleId IdType="pmc">PMC6981053</ArticleId><ArticleId IdType="pubmed">31759806</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandler M, et al. Effects of single and combined immunotherapy approach targeting amyloid beta protein and alpha-synuclein in a dementia with Lewy bodies-like model. Alzheimers Dement. 2019;15:1133&#x2013;1148. doi: 10.1016/j.jalz.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.02.002</ArticleId><ArticleId IdType="pmc">PMC7503212</ArticleId><ArticleId IdType="pubmed">31378574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. App gene dosage modulates endosomal abnormalities of Alzheimer&#x2019;s disease in a segmental trisomy 16 mouse model of down syndrome. J. Neurosci. 2003;23:6788&#x2013;6792. doi: 10.1523/JNEUROSCI.23-17-06788.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-17-06788.2003</ArticleId><ArticleId IdType="pmc">PMC6740714</ArticleId><ArticleId IdType="pubmed">12890772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Alzheimer&#x2019;s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl Acad. Sci. USA. 2010;107:1630&#x2013;1635. doi: 10.1073/pnas.0908953107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908953107</ArticleId><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Lysosomal dysfunction in down syndrome is app-dependent and mediated by APP-betaCTF (C99) J. Neurosci. 2019;39:5255&#x2013;5268. doi: 10.1523/JNEUROSCI.0578-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0578-19.2019</ArticleId><ArticleId IdType="pmc">PMC6607756</ArticleId><ArticleId IdType="pubmed">31043483</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991;231:482&#x2013;497. doi: 10.1002/ar.1092310411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.1092310411</ArticleId><ArticleId IdType="pubmed">1793176</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibenhener, M.L. &amp; Wooten, M.C. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. J. Vis. Exp.96, e52434 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354627</ArticleId><ArticleId IdType="pubmed">25742564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanninen L, Pastell M. CowLog: open-source software for coding behaviors from digital video. Behav. Res Methods. 2009;41:472&#x2013;476. doi: 10.3758/BRM.41.2.472.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/BRM.41.2.472</ArticleId><ArticleId IdType="pubmed">19363187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez A, et al. ToxTrac: a fast and robust software for tracking organisms. Methods Ecol. Evolution. 2018;9:460&#x2013;464. doi: 10.1111/2041-210X.12874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/2041-210X.12874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36138153</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Temporal order of clinical and biomarker changes in familial frontotemporal dementia.</ArticleTitle><Pagination><StartPage>2194</StartPage><EndPage>2206</EndPage><MedlinePgn>2194-2206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-01942-9</ELocationID><Abstract><AbstractText>Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Staffaroni</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-3903-9805</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. adam.staffaroni@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1763-2704</Identifier><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendelberger</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4426-9602</Identifier><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuer</LastName><ForeName>Hilary W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Lucy L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0001-5023-5893</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobigo</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0354-4092</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goh</LastName><ForeName>Sheng-Yang Matt</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0002-7335-2627</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heller</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1934-6162</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Annie L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Jack Carson</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-6431-9956</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wise</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brushaber</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VandeVrede</LastName><ForeName>Lawren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8304-6711</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ljubenkov</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casaletto</LastName><ForeName>Kaitlin B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appleby</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botha</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4390-685X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domoto-Reilly</LastName><ForeName>Kimiko</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7396-1633</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5549-2212</Identifier><AffiliationInfo><Affiliation>Indiana University School of Medicine, National Centralized Repository for Alzheimer's, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavrilova</LastName><ForeName>Ralitza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2896-3450</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Precision Health, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>Nupur</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6680-6731</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Washington University School of Medicine, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Jonathon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Matthew G H</ForeName><Initials>MGH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0002-8017-0856</Identifier><AffiliationInfo><Affiliation>Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>David T</ForeName><Initials>DT</Initials><Identifier Source="ORCID">0000-0002-4807-9833</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6544-066X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremers</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lago</LastName><ForeName>Argentina Lario</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapid</LastName><ForeName>Maria I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0002-1163-5584</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3485-3445</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucente</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0001-6441-7989</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mester</LastName><ForeName>Carly</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi U</ForeName><Initials>CU</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4049-0863</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanan</LastName><ForeName>Vijay K</ForeName><Initials>VK</Initials><Identifier Source="ORCID">0000-0001-6591-8734</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Eliana Marisa</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Meghana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascovsky</LastName><ForeName>Katya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Katherine P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><Identifier Source="ORCID">0000-0002-1810-9763</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savica</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>M Carmela</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-5944-8497</Identifier><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0001-7833-616X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzigues</LastName><ForeName>Arabella</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0267-8590</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swift</LastName><ForeName>Imogen J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peakman</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3319-138X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchetta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1814-5024</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Emily G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Convery</LastName><ForeName>Rhian S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0001-7216-8679</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9284-5953</Identifier><AffiliationInfo><Affiliation>Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiraboschi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1989-7527</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiskoot</LastName><ForeName>Lize C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0380-6670</Identifier><AffiliationInfo><Affiliation>Department of Neurofarba, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Chris R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8071-6062</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Geriatric Medicine and Nuclear Medicine, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langheinrich</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4714-8657</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cerebral Function Unit, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforce</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2031-490X</Identifier><AffiliationInfo><Affiliation>Clinique Interdisciplinaire de M&#xe9;moire, D&#xe9;partement des Sciences Neurologiques, CHU de Qu&#xe9;bec, and Facult&#xe9; de M&#xe9;decine, Universit&#xe9; Laval, Qu&#xe9;bec City, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7750-896X</Identifier><AffiliationInfo><Affiliation>Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Cl&#xed;nic, Institut d'Investigaci&#xf3;ns Biom&#xe8;diques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Synofzik</LastName><ForeName>Matthis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducharme</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, Montreal Neurological Institute, Department of Neurology &amp; Neurosurgery, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence des d&#xe9;mences rares ou pr&#xe9;coces, IM2A, D&#xe9;partement de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8857-5383</Identifier><AffiliationInfo><Affiliation>Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9880-9788</Identifier><AffiliationInfo><Affiliation>University of Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Service, Faculty of Medicine, University Hospital of Coimbra (HUC), University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-4153-8187</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-1215-5064</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. adam.boxer@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Frontotemporal Dementia Prevention Initiative (FPI) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG061253</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058233</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG072122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD001459</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG059888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BRC149/NS/MH</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/T046015/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K23 AG073514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BRC-1215-20014</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>L30 AG069301</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SUAG/092 G116768</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG029577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K010395/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>220258</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG045390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bozoki</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Darby</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapid</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leger</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masdeux</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGinnis</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pascual</LastName><ForeName>M Belen</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pressman</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramanan</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritter</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Syrjanen</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Jack C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esteve</LastName><ForeName>Aitana Sogorb</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Annabel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greaves</LastName><ForeName>Caroline V</ForeName><Initials>CV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benotmane</LastName><ForeName>Hanya</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samra</LastName><ForeName>Kiran</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shafei</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timberlake</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cope</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rittman</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benussi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Premi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasparotti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gazzina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantoni</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borracci</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giaccone</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Fede</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caroppo</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prioni</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redaelli</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castelo-Branco</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>Morris</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keren</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Robart</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poos</LastName><ForeName>Jackie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papma</LastName><ForeName>Janne M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giannini</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Minkelen</LastName><ForeName>Rick</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polito</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bessi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veldsman</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersson</LastName><ForeName>Christin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thonberg</LastName><ForeName>Hakan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xd6;ijerstedt</LastName><ForeName>Linn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jelic</LastName><ForeName>Vesna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llad&#xf3;</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olives</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasa</LastName><ForeName>Mircea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bargall&#xf3;</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrego-Ecija</LastName><ForeName>Sergi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdelho</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maruta</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Catarina B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miltenberger</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sim&#xf5;es do Couto</LastName><ForeName>Frederico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabilondo</LastName><ForeName>Alazne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorostidi</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanua</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ca&#xf1;ada</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tainta</LastName><ForeName>Mikel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barandiaran</LastName><ForeName>Myriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bender</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilke</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graf</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogels</LastName><ForeName>Annick</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandenbulcke</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruffaerts</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camuzat</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Funkiewiez</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saracino</LastName><ForeName>Dario</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colliot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sayah</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prix</LastName><ForeName>Catharina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wlasich</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagemann</LastName><ForeName>Olivia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loosli</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xf6;necker</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoegen</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Jolina</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rollin</LastName><ForeName>Adeline</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuchcinski</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertoux</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebouvier</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santiago</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duro</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leit&#xe3;o</LastName><ForeName>Maria Jo&#xe3;o</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Almeida</LastName><ForeName>Maria Rosario</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>T&#xe1;buas-Pereira</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Afonso</LastName><ForeName>S&#xf3;nia</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36138153</ArticleId><ArticleId IdType="mid">NIHMS1830996</ArticleId><ArticleId IdType="pmc">PMC9951811</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01942-9</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-01942-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Knopman DS &amp; Roberts RO Estimating the number of persons with frontotemporal lobar degeneration in the US population. J. Mol. Neurosci 45, 330&#x2013;335 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208074</ArticleId><ArticleId IdType="pubmed">21584654</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves CV &amp; Rohrer JD An update on genetic frontotemporal dementia. J. Neurol 266, 2075&#x2013;2086 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647117</ArticleId><ArticleId IdType="pubmed">31119452</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai RM &amp; Boxer AL Therapy and clinical trials in frontotemporal dementia: past, present, and future. J. Neurochem 138, 211&#x2013;221 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5217534</ArticleId><ArticleId IdType="pubmed">27306957</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y &amp; Rohrer JD Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet. Neurol 21, 258&#x2013;272 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35182511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N. Engl. J. Med 378, 625&#x2013;635 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med 383, 109&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. The DIAN-TU Next Generation Alzheimer&#x2019;s prevention trial: Adaptive design and disease progression model. Alzheimers. Dement 13, 8&#x2013;19 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer&#x2019;s disease. Nat Med 27, 1187&#x2013;1196 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988051</ArticleId><ArticleId IdType="pubmed">34155411</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL et al. New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer&#x2019;s Dement 16, 131&#x2013;143 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949386</ArticleId><ArticleId IdType="pubmed">31668596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease. N. Engl. J. Med 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB et al. A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain 130, 1360&#x2013;1374 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17439980</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KM et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol 19, 145&#x2013;156 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7007771</ArticleId><ArticleId IdType="pubmed">31810826</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD &amp; Boxer AL The Frontotemporal Dementia Prevention Initiative: Linking Together Genetic Frontotemporal Dementia Cohort Studies. Adv. Exp. Med. Biol 1281, 113&#x2013;121 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33433872</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food &amp; Drug Administration. Human Gene Therapy for Neurodegenerative Diseases. Draft Guidance for Industry. FDA-2020-D-2101</Citation></Reference><Reference><Citation>Rentz DM et al. Building clinically relevant outcomes across the Alzheimer&#x2019;s disease spectrum. Alzheimer&#x2019;s Dement. Transl. Res. Clin. Interv 7, e12181 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8234696</ArticleId><ArticleId IdType="pubmed">34195350</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni AM et al. Rates of Brain Atrophy across Disease Stages in Familial Frontotemporal Dementia Associated with MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Netw. Open 3, e2022847&#x2013;e2022847 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7593814</ArticleId><ArticleId IdType="pubmed">33112398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 14, 253&#x2013;262 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q et al. Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer&#x2019;s Dement. Transl. Res. Clin. Interv 5, 338&#x2013;346 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675939</ArticleId><ArticleId IdType="pubmed">31388560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. NeuroImage Clin 14, 286&#x2013;297 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Caverzasi E et al. Gyrification abnormalities in presymptomatic c9orf72 expansion carriers. J. Neurol. Neurosurg. Psychiatry 90, 1005&#x2013;1010 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820159</ArticleId><ArticleId IdType="pubmed">31079065</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL et al. Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur. J. Neurol 22, 745&#x2013;52 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390434</ArticleId><ArticleId IdType="pubmed">25683866</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD et al. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 53, 1070&#x2013;6 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941039</ArticleId><ArticleId IdType="pubmed">20045477</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu SA et al. Brain volumetric deficits in MAPT mutation carriers: a multisite study. Ann. Clin. Transl. Neurol 8, 95&#x2013;110 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818091</ArticleId><ArticleId IdType="pubmed">33247623</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL et al. Characterizing the Clinical Features and Atrophy Patterns of MAPT-Related Frontotemporal Dementia With Disease Progression Modeling. Neurology 97, e941&#x2013;52 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8408507</ArticleId><ArticleId IdType="pubmed">34158384</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet. Neurol 18, 1103&#x2013;1111 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31701893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I et al. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology 96, e671&#x2013;e683 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884995</ArticleId><ArticleId IdType="pubmed">33199433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Med 3, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044101</ArticleId><ArticleId IdType="pubmed">35492244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 76, 1035&#x2013;1048 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling CS et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol 75, 116&#x2013;126 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020786</ArticleId><ArticleId IdType="pubmed">24242746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC et al. Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology 7, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8166434</ArticleId><ArticleId IdType="pubmed">33827960</ArticleId></ArticleIdList></Reference><Reference><Citation>Panman JL et al. Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry (2021). doi:10.1136/jnnp-2020-323541</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323541</ArticleId><ArticleId IdType="pmc">PMC8053353</ArticleId><ArticleId IdType="pubmed">33452053</ArticleId></ArticleIdList></Reference><Reference><Citation>Saracino D et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. J. Neurol. Neurosurg. Psychiatry (2021). doi:10.1136/jnnp-2021-326914</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-326914</ArticleId><ArticleId IdType="pmc">PMC8606463</ArticleId><ArticleId IdType="pubmed">34349004</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher SA, Wong C, Pearson IE &amp; Pal S Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis. JAMA Neurol 77, 367&#x2013;376 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865318</ArticleId><ArticleId IdType="pubmed">31738367</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K et al. A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Appl. Neuropsychol. Adult 1&#x2013;8 (2020). doi:10.1080/23279095.2020.1716357</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23279095.2020.1716357</ArticleId><ArticleId IdType="pubmed">32024404</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni AM et al. Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. Alzheimers. Dement 16, 11&#x2013;21 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6842665</ArticleId><ArticleId IdType="pubmed">31914230</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker MS et al. Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex 139, 99&#x2013;115 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119343</ArticleId><ArticleId IdType="pubmed">33857770</ArticleId></ArticleIdList></Reference><Reference><Citation>Poos JM et al. Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimers. Res. Ther 14, 10 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772227</ArticleId><ArticleId IdType="pubmed">35045872</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana M et al. Bayesian model of disease progression in GNE myopathy. Stat. Med 38, 1459&#x2013;1474 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30511500</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S et al. Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Ann. Neurol 91, 165&#x2013;175 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34935174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C et al. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17, 548&#x2013;558 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237181</ArticleId><ArticleId IdType="pubmed">29724592</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL et al. A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain 145, 1805&#x2013;1817 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166533</ArticleId><ArticleId IdType="pubmed">34633446</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni AM et al. Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer&#x2019;s Dement 16, 37&#x2013;48 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6938544</ArticleId><ArticleId IdType="pubmed">31272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxtoby NP et al. Data-driven models of dominantly-inherited Alzheimer&#x2019;s disease progression. Brain 141, 1529&#x2013;1544 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920320</ArticleId><ArticleId IdType="pubmed">29579160</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyike CU, Shinagawa S &amp; Ellajosyula R Frontotemporal Dementia: A Cross-Cultural Perspective. Adv. Exp. Med. Biol 1281, 141&#x2013;150 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33433874</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok K et al. Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol. Aging 33, 209.e3&#x2013;8 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312749</ArticleId><ArticleId IdType="pubmed">21925771</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J et al. A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain 129, 841&#x2013;852 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16495329</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods-only references</Title><Reference><Citation>Boeve B et al. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. in Alzheimer&#x2019;s and Dementia 16, 22&#x2013;36 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949411</ArticleId><ArticleId IdType="pubmed">31636026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos EM et al. Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimers. Dement 16, 118&#x2013;130 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199807</ArticleId><ArticleId IdType="pubmed">31914217</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa T et al. Utility of the global CDR&#xae; plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimers. Dement 16, 106&#x2013;117 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202045</ArticleId><ArticleId IdType="pubmed">31914218</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni AM et al. Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain 142, 443&#x2013;459 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351779</ArticleId><ArticleId IdType="pubmed">30698757</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa T et al. Use of the CDR&#xae; plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium. Alzheimer&#x2019;s Dement 16, 79&#x2013;90 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949373</ArticleId><ArticleId IdType="pubmed">31477517</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell SE et al. Results From the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study. Alzheimer Dis. Assoc. Disord 30, 134&#x2013;139 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4834278</ArticleId><ArticleId IdType="pubmed">26485498</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer&#x2019;s disease. Neurology 49, 786&#x2013;94 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT et al. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer&#x2019;s Dement 16, 49&#x2013;59 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988137</ArticleId><ArticleId IdType="pubmed">31784375</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell LL et al. Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex 133, 384&#x2013;398 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754789</ArticleId><ArticleId IdType="pubmed">33221702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP &amp; Evans AC A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87&#x2013;97 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J &amp; Friston KJ Unified segmentation. Neuroimage 26, 839&#x2013;51 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J &amp; Friston KJ Diffeomorphic registration using geodesic shooting and Gauss-Newton optimisation. Neuroimage 55, 954&#x2013;67 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221052</ArticleId><ArticleId IdType="pubmed">21216294</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968&#x2013;80 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M et al. Thalamic atrophy in frontotemporal dementia - Not just a C9orf72 problem. NeuroImage. Clin 18, 675&#x2013;681 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5988457</ArticleId><ArticleId IdType="pubmed">29876259</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat. Commun 9, 4273 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189176</ArticleId><ArticleId IdType="pubmed">30323170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M et al. Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage. Clin 30, 102646 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099608</ArticleId><ArticleId IdType="pubmed">33895632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36138150</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Metabolomic profiles predict individual multidisease outcomes.</ArticleTitle><Pagination><StartPage>2309</StartPage><EndPage>2320</EndPage><MedlinePgn>2309-2320</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-01980-3</ELocationID><Abstract><AbstractText>Risk stratification is critical for the early identification of high-risk individuals and disease prevention. Here we explored the potential of nuclear magnetic resonance (NMR) spectroscopy-derived metabolomic profiles to inform on multidisease risk beyond conventional clinical predictors for the onset of 24&#x2009;common conditions, including metabolic, vascular, respiratory, musculoskeletal and neurological diseases and cancers. Specifically, we trained a neural network to learn disease-specific metabolomic states from 168&#x2009;circulating metabolic markers measured in 117,981&#x2009;participants with ~1.4&#x2009;million person-years of follow-up from the UK Biobank and validated the model in four independent cohorts. We found metabolomic states to be associated with incident event rates in all the investigated conditions, except breast cancer. For 10-year outcome prediction for 15&#x2009;endpoints, with and without established metabolic contribution, a combination of age and sex and the metabolomic state equaled or outperformed established predictors. Moreover, metabolomic state added predictive information over comprehensive clinical variables for eight common diseases, including type&#x2009;2 diabetes, dementia and heart failure. Decision curve analyses showed that predictive improvements translated into clinical utility for a wide range of potential decision thresholds. Taken together, our study demonstrates both the potential and limitations of NMR-derived metabolomic profiles as a multidisease assay to inform on the risk of many common diseases simultaneously.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Buergel</LastName><ForeName>Thore</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1159-007X</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Steinfeldt</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Campus Benjamin Franklin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruyoga</LastName><ForeName>Greg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietzner</LastName><ForeName>Maik</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizzarri</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6881-273X</Identifier><AffiliationInfo><Affiliation>Molecular Epidemiology, LUMC, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden Computational Biology Center, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vojinovic</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Upmeier Zu Belzen</LastName><ForeName>Julius</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0966-4458</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loock</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kittner</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christmann</LastName><ForeName>Lara</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollmann</LastName><ForeName>Noah</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8556-518X</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strangalies</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunger</LastName><ForeName>Jana M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wild</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7492-8448</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiesa</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0003-4323-2189</Identifier><AffiliationInfo><Affiliation>Institute of Cardiovascular Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spranger</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8900-4467</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology &amp; Metabolism, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Cardiovascular Research, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klostermann</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Mind and Brain, Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Akker</LastName><ForeName>Erik B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-7693-0728</Identifier><AffiliationInfo><Affiliation>Molecular Epidemiology, LUMC, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden Computational Biology Center, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, TU Delft, Delft, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trompet</LastName><ForeName>Stella</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5006-0528</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mooijaart</LastName><ForeName>Simon P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattar</LastName><ForeName>Naveed</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1604-2593</Identifier><AffiliationInfo><Affiliation>Institute of Cardiovascular and Medical Sciences, Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jukema</LastName><ForeName>J Wouter</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-3246-8359</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Netherlands Heart Institute, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavrijssen</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavousi</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanbari</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9476-7143</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>Mohammad A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slagboom</LastName><ForeName>Eline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular Epidemiology, LUMC, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck Institute for the Biology of Ageing, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivimaki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4699-5627</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langenberg</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deanfield</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eils</LastName><ForeName>Roland</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0034-4036</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany. roland.eils@bih-charite.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Science Unit, Heidelberg University Hospital and BioQuant, Heidelberg, Germany. roland.eils@bih-charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landmesser</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-0214-3203</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Campus Benjamin Franklin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/T033371/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024227/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG056477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>221854/Z/20/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S011676/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00006/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>U.L. received grants from Bayer, Novartis and Amgen, consulting fees from Bayer, Sanofi, Amgen, Novartis and Daichy Sankyo and honoraria from Novartis, Sanofi, Bayer, Amgen and Daichy Sankyo. J.D. received consulting fees from GENinCode UK Ltd, honoraria from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk and Bayer and is Chief Medical Advisor to Our Future Health. R.E. received honoraria from Sanofi and consulting fees from Boehringer Ingelheim. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36138150</ArticleId><ArticleId IdType="pmc">PMC9671812</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01980-3</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-01980-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob. Health. 2019;7:e1332&#x2013;e1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025029</ArticleId><ArticleId IdType="pubmed">31488387</ArticleId></ArticleIdList></Reference><Reference><Citation>A and B recommendations. U.S. Preventive Services Task Forcehttps://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-and-b-recommendations (2022).</Citation></Reference><Reference><Citation>Goff David C, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129:S49&#x2013;S73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24222018</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xfc;rtz P, et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care. 2012;35:1749&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402262</ArticleId><ArticleId IdType="pubmed">22563043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahendran Y, et al. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. Diabetes. 2013;62:3618&#x2013;3626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781437</ArticleId><ArticleId IdType="pubmed">23557707</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes MV, et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J. Am. Coll. Cardiol. 2018;71:620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811927</ArticleId><ArticleId IdType="pubmed">29420958</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;cuyer L, et al. NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer. Int. J. Epidemiol. 2018;47:484&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365091</ArticleId></ArticleIdList></Reference><Reference><Citation>Tynkkynen J, et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer&#x2019;s disease: a prospective study in eight cohorts. Alzheimers Dement. 2018;14:723&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6082422</ArticleId><ArticleId IdType="pubmed">29519576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahadi S, et al. Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nat. Med. 2020;26:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301912</ArticleId><ArticleId IdType="pubmed">31932806</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;ssler-Fiorenza Rose SM, et al. A longitudinal big data approach for precision health. Nat. Med. 2019;25:792&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713274</ArticleId><ArticleId IdType="pubmed">31068711</ArticleId></ArticleIdList></Reference><Reference><Citation>Deelen J, et al. A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals. Nat. Commun. 2019;10:3346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6702196</ArticleId><ArticleId IdType="pubmed">31431621</ArticleId></ArticleIdList></Reference><Reference><Citation>Markley JL, et al. The future of NMR-based metabolomics. Curr. Opin. Biotechnol. 2017;43:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305426</ArticleId><ArticleId IdType="pubmed">27580257</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen P, Kangas AJ, W&#xfc;rtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 2015;8:192&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">25691689</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xfc;rtz P, et al. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am. J. Epidemiol. 2017;186:1084&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860146</ArticleId><ArticleId IdType="pubmed">29106475</ArticleId></ArticleIdList></Reference><Reference><Citation>Ala-Korpela, M., Zhao, S., J&#xe4;rvelin, M.-R., M&#xe4;kinen, V.-P. &amp; Ohukainen, P. Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology: disclosure of fundamental structural and metabolic relationships. Int. J. Epidemiol. 51, 996&#x2013;1011 (2021)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189959</ArticleId><ArticleId IdType="pubmed">34405869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer K, et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med. 2014;11:e1001606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934819</ArticleId><ArticleId IdType="pubmed">24586121</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xfc;rtz P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131:774&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351161</ArticleId><ArticleId IdType="pubmed">25573147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fizelova M, et al. Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men. Atherosclerosis. 2015;240:272&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">25818853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahola-Olli AV, et al. Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts. Diabetologia. 2019;62:2298&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6861432</ArticleId><ArticleId IdType="pubmed">31584131</ArticleId></ArticleIdList></Reference><Reference><Citation>Julkunen H, Cicho&#x144;ska A, Slagboom PE, W&#xfc;rtz P, Nightingale Health UK Biobank Initiative. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. eLife. 2021;10:e63033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172246</ArticleId><ArticleId IdType="pubmed">33942721</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietzner M, et al. Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat. Med. 2021;27:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8127079</ArticleId><ArticleId IdType="pubmed">33707775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression models and life-tables. J. R. Stat. Soc. Ser. B Stat. Methodol. 1972;34:187&#x2013;202.</Citation></Reference><Reference><Citation>Marmot M, Brunner E. Cohort profile: the Whitehall II study. Int. J. Epidemiol. 2005;34:251&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram MA, et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur. J. Epidemiol. 2017;32:807&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662692</ArticleId><ArticleId IdType="pubmed">29064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker M, et al. Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study. Eur. J. Hum. Genet. 2006;14:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251894</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd J, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pubmed">12457784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, et al. Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study. Hypertension. 2011;57:1094&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">21536985</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruijn RFAG, Ikram MA. Cardiovascular risk factors and future risk of Alzheimer&#x2019;s disease. BMC Med. 2014;12:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226863</ArticleId><ArticleId IdType="pubmed">25385322</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can. J. Cardiol. 2016;32:900&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">27343745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstr&#xf6;m J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26:725&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610029</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindi S, et al. The CAIDE Dementia Risk Score App: the development of an evidence-based mobile application to predict the risk of dementia. Alzheimers Dement. 2015;1:328&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878198</ArticleId><ArticleId IdType="pubmed">27239514</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Velde M, et al. Screening for albuminuria identifies individuals at increased renal risk. J. Am. Soc. Nephrol. 2009;20:852&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663830</ArticleId><ArticleId IdType="pubmed">19211710</ArticleId></ArticleIdList></Reference><Reference><Citation>Mars N, et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat. Med. 2020;26:549&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">32273609</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. Performance metrics for the comparative analysis of clinical risk prediction models employing machine learning. Circ. Cardiovasc. Qual. Outcomes. 2021;14:e007526.</Citation><ArticleIdList><ArticleId IdType="pubmed">34601947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry A, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 2017;186:1026&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860371</ArticleId><ArticleId IdType="pubmed">28641372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making. 2006;26:565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577036</ArticleId><ArticleId IdType="pubmed">17099194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hingorani, A. D. et al. Polygenic scores in disease prediction: evaluation using the relevant performance metrics. Preprint at medRxiv10.1101/2022.02.18.22271049 (2022).</Citation></Reference><Reference><Citation>Gilpin, L. H. et al. Explaining explanations: an overview of interpretability of machine learning. Preprint at https://arxiv.org/abs/1806.00069v3 (2018).</Citation></Reference><Reference><Citation>Lundberg, S. &amp; Lee, S.-I. A unified approach to interpreting model predictions. Preprint at https://arxiv.org/abs/1705.07874v2 (2017).</Citation></Reference><Reference><Citation>Mahendran Y, et al. Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. Diabetes Care. 2013;36:3732&#x2013;3738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816902</ArticleId><ArticleId IdType="pubmed">24026559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JHY, et al. Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. Lancet Diabetes Endocrinol. 2017;5:965&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029721</ArticleId><ArticleId IdType="pubmed">29032079</ArticleId></ArticleIdList></Reference><Reference><Citation>Virtanen JK, Mursu J, Voutilainen S, Uusitupa M, Tuomainen T-P. Serum omega-3 polyunsaturated fatty acids and risk of incident type 2 diabetes in men: the Kuopio Ischemic Heart Disease Risk Factor study. Diabetes Care. 2014;37:189&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">24026545</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee SJ, et al. Circulating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies. Alzheimers Dement. 2018;14:707&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29316447</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, Saul N, Gro&#xdf;berger L. UMAP: Uniform Manifold Approximation and Projection. J. Open Source Softw. 2018;3:861.</Citation></Reference><Reference><Citation>Steyerberg EW, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10:e1001381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564751</ArticleId><ArticleId IdType="pubmed">23393430</ArticleId></ArticleIdList></Reference><Reference><Citation>Delles C, et al. Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. Eur. J. Heart Fail. 2018;20:663&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947152</ArticleId><ArticleId IdType="pubmed">29226610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28:557&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">9056611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronit A, et al. Plasma albumin and incident cardiovascular disease: results From the CGPS and an updated meta-analysis. Arterioscler. Thromb. Vasc. Biol. 2020;40:473&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">31852221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettunen J, et al. Biomarker glycoprotein acetyls is associated with the risk of a wide spectrum of incident diseases and stratifies mortality risk in angiography patients. Circ. Genom. Precis. Med. 2018;11:e002234.</Citation><ArticleIdList><ArticleId IdType="pubmed">30571186</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaromy A, Reider B, Jarvas G, Guttman A. Glycoprotein biomarkers and analysis in chronic obstructive pulmonary disease and lung cancer with special focus on serum immunoglobulin G. Clin. Chim. Acta. 2020;506:204&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">32243984</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Health Check. NHShttps://www.nhs.uk/conditions/nhs-health-check/ (accessed 23 August 2022).</Citation></Reference><Reference><Citation>Balk EM, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann. Intern. Med. 2015;163:437&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692590</ArticleId><ArticleId IdType="pubmed">26167912</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364185</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SA, Winkel M, Ali MK, Narayan KMV, Mehta NK. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann. Intern. Med. 2015;163:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121190</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Silarova B, et al. Effect of communicating phenotypic and genetic risk of coronary heart disease alongside web-based lifestyle advice: the INFORM randomised controlled trial. Heart. 2019;105:982&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582721</ArticleId><ArticleId IdType="pubmed">30928969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu, T. et al. The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER). Alzheimers Dement. 10.1002/alz.12492 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34668644</ArticleId></ArticleIdList></Reference><Reference><Citation>Emwas A-HM. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Methods Mol. Biol. 2015;1277:161&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">25677154</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KGM, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. Ann. Intern. Med. 2015;162:W1&#x2013;W73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25560730</ArticleId></ArticleIdList></Reference><Reference><Citation>SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J. 2021;42:2439&#x2013;2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248998</ArticleId><ArticleId IdType="pubmed">34120177</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinfeldt J, et al. Neural network-based integration of polygenic and clinical information: development and validation of a prediction model for 10-year risk of major adverse cardiac events in the UK Biobank cohort. Lancet Digit Health. 2022;4:e84&#x2013;e94.</Citation><ArticleIdList><ArticleId IdType="pubmed">35090679</ArticleId></ArticleIdList></Reference><Reference><Citation>Stekhoven DJ, B&#xfc;hlmann P. MissForest&#x2013;non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">22039212</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava N, Hinton G, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: a simple way to prevent neural networks from overfitting. J. Mach. Learn. Res. 2014;15:1929&#x2013;1958.</Citation></Reference><Reference><Citation>Elfwing, S., Uchibe, E. &amp; Doya, K. Sigmoid-weighted linear units for neural network function approximation in reinforcement learning. ScienceDirect108, 3&#x2013;11 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29395652</ArticleId></ArticleIdList></Reference><Reference><Citation>He, K., Zhang, X., Ren, S. &amp; Sun, J. Deep Residual Learning for Image Recognition. In 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) 770&#x2013;778 (2016).</Citation></Reference><Reference><Citation>Katzman, J. L. et al. DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med. Res. Methodol.18, 24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828433</ArticleId><ArticleId IdType="pubmed">29482517</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingma, D. P. &amp; Ba, J. L. Adam: a method for stochastic optimization. Preprint at https://arxiv.org/abs/1412.6980v8 (2015).</Citation></Reference><Reference><Citation>Paszke, A. et al. Automatic differentiation in PyTorch. Semanticscholarhttps://www.semanticscholar.org/paper/Automatic-differentiation-in-PyTorch-Paszke-Gross/b36a5bb1707bb9c70025294b3a310138aae8327a (2017).</Citation></Reference><Reference><Citation>Davidson-Pilon, C. et al. CamDavidsonPilon/lifelines: v0.25.8. (2021) 10.5281/zenodo.4457577</Citation></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2020).</Citation></Reference><Reference><Citation>Lundberg SM, et al. Explainable machine-learning predictions for the prevention of hypoxaemia during surgery. Nat. Biomed. Eng. 2018;2:749&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467492</ArticleId><ArticleId IdType="pubmed">31001455</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrikumar, A., Greenside, P. &amp; Kundaje, A. Learning important features through propagating activation differences. Preprint at https://arxiv.org/abs/1704.02685. (2019).</Citation></Reference><Reference><Citation>Lundberg, S. shap: A game theoretic approach to explain the output of any machine learning model. Githubhttps://github.com/slundberg/shap (2022).</Citation></Reference><Reference><Citation>UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction&#x2014;UMAP 0.5 documentation. UMAPhttps://umap-learn.readthedocs.io/en/latest/index.html (2018).</Citation></Reference><Reference><Citation>onnx: Open standard for machine learning interoperability. Githubhttps://github.com/onnx/onnx (2022).</Citation></Reference><Reference><Citation>Shepherd J, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am. J. Cardiol. 1999;84:1192&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569329</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36197966</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>665</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Assessment of cholesterol homeostasis in the living human brain.</ArticleTitle><Pagination><StartPage>eadc9967</StartPage><MedlinePgn>eadc9967</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.adc9967</ELocationID><Abstract><AbstractText>Alterations in brain cholesterol homeostasis have been broadly implicated in neurological disorders. Notwithstanding the complexity by which cholesterol biology is governed in the mammalian brain, excess neuronal cholesterol is primarily eliminated by metabolic clearance via cytochrome P450 46A1 (CYP46A1). No methods are currently available for visualizing cholesterol metabolism in the living human brain; therefore, a noninvasive technology that quantitatively measures the extent of brain cholesterol metabolism via CYP46A1 could broadly affect disease diagnosis and treatment options using targeted therapies. Here, we describe the development and testing of a CYP46A1-targeted positron emission tomography (PET) tracer, <sup>18</sup>F-CHL-2205 (<sup>18</sup>F-Cholestify). Our data show that PET imaging readouts correlate with CYP46A1 protein expression and with the extent to which cholesterol is metabolized in the brain, as assessed by cross-species postmortem analyses of specimens from rodents, nonhuman primates, and humans. Proof of concept of in vivo efficacy is provided in the well-established 3xTg-AD murine model of Alzheimer's disease (AD), where we show that the probe is sensitive to differences in brain cholesterol metabolism between 3xTg-AD mice and control animals. Furthermore, our clinical observations point toward a considerably higher baseline brain cholesterol clearance via CYP46A1 in women, as compared to age-matched men. These findings illustrate the vast potential of assessing brain cholesterol metabolism using PET and establish PET as a sensitive tool for noninvasive assessment of brain cholesterol homeostasis in the clinic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haider</LastName><ForeName>Achi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5204-4473</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Chunyu</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0168-2130</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8049-1991</Identifier><AffiliationInfo><Affiliation>Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, First Affiliated Hospital of Jinan University, Guangzhou 510630, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rong</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Xiaotian</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3917-4361</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-6289-4332</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfister</LastName><ForeName>Stefanie K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0002-1394-3716</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mast</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6427-640X</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yutuc</LastName><ForeName>Eylan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9971-1950</Identifier><AffiliationInfo><Affiliation>Institute of Life Science, Swansea University Medical School, SA2 8PP Swansea, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiahui</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9186-1110</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yinlong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8864-1712</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Tuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warnock</LastName><ForeName>Geoffrey I</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Alyaa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8140-1070</Identifier><AffiliationInfo><Affiliation>Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, 11835 Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connors</LastName><ForeName>Theresa R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0002-9706-8217</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Alzheimer's Disease Research Center, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakley</LastName><ForeName>Derek H</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-6998-9510</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Massachusetts General Hospital, Boston, MA 02114-2696, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Alzheimer's Disease Research Center, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Huiyi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, First Affiliated Hospital of Jinan University, Guangzhou 510630, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinghao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, First Affiliated Hospital of Jinan University, Guangzhou 510630, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zhihua</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-9312-5846</Identifier><AffiliationInfo><Affiliation>Guangdong Province Pharmaceutical Association, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, First Affiliated Hospital of Jinan University, Guangzhou 510630, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>April T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daunais</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Yihan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuqin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3063-3066</Identifier><AffiliationInfo><Affiliation>Institute of Life Science, Swansea University Medical School, SA2 8PP Swansea, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ming-Rong</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebhard</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7240-5822</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pikuleva</LastName><ForeName>Irina</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9742-6232</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0002-3153-502X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4129-6616</Identifier><AffiliationInfo><Affiliation>Institute of Life Science, Swansea University Medical School, SA2 8PP Swansea, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Steven H</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-1413-6315</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG070060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BB/L001942/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R21 AA028007</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BB/N015932/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R21 AG074218</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BB/S019588/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG067552</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.25</RegistryNumber><NameOfSubstance UI="D000072556">Cholesterol 24-Hydroxylase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072556" MajorTopicYN="N">Cholesterol 24-Hydroxylase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36197966</ArticleId><ArticleId IdType="mid">NIHMS1841494</ArticleId><ArticleId IdType="pmc">PMC9581941</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adc9967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dietschy JM, Turley SD, Cholesterol metabolism in the brain. Curr Opin Lipidol 12, 105&#x2013;112 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11264981</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G, Kim T-W, Linking lipids to Alzheimer&#x2019;s disease: cholesterol and beyond. Nature Reviews Neuroscience 12, 284&#x2013;296 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321383</ArticleId><ArticleId IdType="pubmed">21448224</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto A, Pfrieger FW, CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354&#x2013;1357 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres BA, Smith SJ, Neurobiology. Cholesterol--making or breaking the synapse. Science 294, 1296&#x2013;1297 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11701918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund EG, Guileyardo JM, Russell DW, cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A 96, 7238&#x2013;7243 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22064</ArticleId><ArticleId IdType="pubmed">10377398</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;tjohann D, Breuer O, Ahlborg G, Nennesmo I, Sid&#xe9;n A, Diczfalusy U, Bj&#xf6;rkhem I, Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 93, 9799&#x2013;9804 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38509</ArticleId><ArticleId IdType="pubmed">8790411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast N, White MA, Bjorkhem I, Johnson EF, Stout CD, Pikuleva IA, Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc Natl Acad Sci U S A 105, 9546&#x2013;9551 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474539</ArticleId><ArticleId IdType="pubmed">18621681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund EG, Guileyardo JM, Russell DW, cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proceedings of the National Academy of Sciences of the United States of America 96, 7238&#x2013;7243 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22064</ArticleId><ArticleId IdType="pubmed">10377398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I, L&#xfc;tjohann D, Diczfalusy U, St&#xe5;hle L, Ahlborg G, Wahren J, Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39, 1594&#x2013;1600 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9717719</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasinska JM, Hayden MR, Cholesterol metabolism in Huntington disease. Nature Reviews Neurology 7, 561&#x2013;572 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21894212</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Sobue G, Getting a handle on Huntington&#x2019;s disease: the case for cholesterol. Nature Medicine 15, 253&#x2013;254 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19265827</ArticleId></ArticleIdList></Reference><Reference><Citation>Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bi&#xe8;che I, Marquer C, Chali F, Ayciriex S, Auzeil N, Alves S, Langui D, Potier M-C, Laprevote O, Vidaud M, Duyckaerts C, Miles R, Aubourg P, Cartier N, CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer&#x2019;s disease. Brain 138, 2383&#x2013;2398 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26141492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotti Tiina J, Ramirez Denise MO, Pfeiffer Brad E, Huber Kimberly M, Russell David W, Brain cholesterol turnover required for geranylgeraniol production and learning in mice. PNAS 103, 3869&#x2013;3874 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450160</ArticleId><ArticleId IdType="pubmed">16505352</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussicault L, Alves S, Lamazi&#xe8;re A, Planques A, Heck N, Moumn&#xe9; L, Despres G, Bolte S, Hu A, Pag&#xe8;s C, Galvan L, Piguet F, Aubourg P, Cartier N, Caboche J, Betuing S, CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington&#x2019;s disease. Brain 139, 953&#x2013;970 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766376</ArticleId><ArticleId IdType="pubmed">26912634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreilaus F, Spiro AS, McLean CA, Garner B, Jenner AM, Evidence for altered cholesterol metabolism in Huntington&#x2019;s disease post mortem brain tissue. Neuropathol Appl Neurobiol 42, 535&#x2013;546 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26373857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kacher R, Lamazi&#xe8;re A, Heck N, Kappes V, Mounier C, Despres G, Dembitskaya Y, Perrin E, Christaller W, Sasidharan Nair S, Messent V, Cartier N, Vanhoutte P, Venance L, Saudou F, N&#xe9;ri C, Caboche J, Betuing S, CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington&#x2019;s disease. Brain 142, 2432&#x2013;2450 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31286142</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;lsch H, L&#xfc;tjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, von Bergmann K, Rao ML, Maier W, Heun R, Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer&#x2019;s disease. Molecular Psychiatry 7, 899&#x2013;902 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12232784</ArticleId></ArticleIdList></Reference><Reference><Citation>Habchi J, Chia S, Galvagnion C, Michaels TCT, Bellaiche MMJ, Ruggeri FS, Sanguanini M, Idini I, Kumita JR, Sparr E, Linse S, Dobson CM, Knowles TPJ, Vendruscolo M, Cholesterol catalyses A&#x3b2;42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. Nature Chemistry 10, 673&#x2013;683 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29736006</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, Steenvoorden E, Rynearson KD, Brouwers JF, Helms JB, Ovaa H, Giera M, Wagner SL, Bang AG, Goldstein LSB, Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-&#x3b2; in iPSC-Derived Alzheimer&#x2019;s Disease Neurons. Cell Stem Cell 24, 363&#x2013;375.e369 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414424</ArticleId><ArticleId IdType="pubmed">30686764</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K, Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95, 6460&#x2013;6464 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM, Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3, 905&#x2013;912 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11584272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G, Di Paolo G, Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287, 2678&#x2013;2688 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268426</ArticleId><ArticleId IdType="pubmed">22134919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM, The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer&#x2019;s disease. Neuron 44, 227&#x2013;238 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15473963</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR, The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168&#x2013;1171 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528355</ArticleId><ArticleId IdType="pubmed">22654059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB, Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proceedings of the National Academy of Sciences 118, e2102191118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8379952</ArticleId><ArticleId IdType="pubmed">34385305</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamba P, Giannelli S, Staurenghi E, Testa G, Sottero B, Biasi F, Poli G, Leonarduzzi G, The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer&#x2019;s Disease. Antioxidants (Basel) 10, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8151638</ArticleId><ArticleId IdType="pubmed">34067119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuliani G, Donnorso MP, Bosi C, Passaro A, Dalla Nora E, Zurlo A, Bonetti F, Mozzi AF, Cortese C, Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer&#x2019;s disease or vascular dementia: a case-control study. BMC Neurol 11, 121&#x2013;121 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199239</ArticleId><ArticleId IdType="pubmed">21970714</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa AC, Joaquim HPG, Nunes VS, Kerr DS, Ferreira GS, Forlenza OV, Gattaz WF, Talib LL, Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer&#x2019;s disease patients. European Archives of Psychiatry and Clinical Neuroscience 268, 501&#x2013;507 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28861608</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS, Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis 55, 37&#x2013;43 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671851</ArticleId><ArticleId IdType="pubmed">23557875</ArticleId></ArticleIdList></Reference><Reference><Citation>Grayaa S, Zerbinati C, Messedi M, HadjKacem I, Chtourou M, Ben Touhemi D, Naifar M, Ayadi H, Ayedi F, Iuliano L, Plasma oxysterol profiling in children reveals 24-hydroxycholesterol as a potential marker for Autism Spectrum Disorders. Biochimie 153, 80&#x2013;85 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29730299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanin A, Baudin P, Demeret S, Roussel D, Lecas S, Teyssou E, Damiano M, Luis D, Lambrecq V, Frazzini V, Decav&#xe8;le M, Plu I, Bonnefont-Rousselot D, Bittar R, Lamari F, Navarro V, Disturbances of brain cholesterol metabolism: A new excitotoxic process associated with status epilepticus. Neurobiology of Disease 154, 105346 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33774180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik B, Cenik C, Snyder MP, Brown ES, Plasma sterols and depressive symptom severity in a population-based cohort. PLoS One 12, e0184382-e0184382 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5590924</ArticleId><ArticleId IdType="pubmed">28886149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I, Patra K, Boxer AL, Svenningsson P, 24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson&#x2019;s Disease and Corticobasal Syndrome. Front Neurol 9, 756&#x2013;756 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137204</ArticleId><ArticleId IdType="pubmed">30245667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretillon L, L&#xfc;tjohann D, St&#xe5;hle L, Widhe T, Bindl L, Eggertsen G, Diczfalusy U, Bj&#xf6;rkhem I, Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. Journal of Lipid Research 41, 840&#x2013;845 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10787445</ArticleId></ArticleIdList></Reference><Reference><Citation>Norlin M, Toll A, Bj&#xf6;rkhem I, Wikvall K, 24-hydroxycholesterol is a substrate for hepatic cholesterol 7alpha-hydroxylase (CYP7A). J Lipid Res 41, 1629&#x2013;1639 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11013305</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen Institute for Brain Science (2004). Allen Mouse Brain Atlas [dataset]. Available from mouse.brain-map.org.Allen Institute for Brain Science, (2021).</Citation></Reference><Reference><Citation>Mast N, Charvet C, Pikuleva IA, Stout CD, Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain. J Biol Chem 285, 31783&#x2013;31795 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951250</ArticleId><ArticleId IdType="pubmed">20667828</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi T, Kondo S, Miyamoto M, Watanabe S, Hasegawa S, Kondo S, Yano J, Watanabe E, Ishi T, Yoshikawa M, Ando HK, Farnaby W, Fujimoto S, Sunahara E, Ohori M, During MJ, Kuroita T, Koike T, Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Scientific Reports 10, 17081 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553946</ArticleId><ArticleId IdType="pubmed">33051477</ArticleId></ArticleIdList></Reference><Reference><Citation>Yutuc E, Angelini R, Baumert M, Mast N, Pikuleva I, Newton J, Clench MR, Skibinski DOF, Howell OW, Wang Y, Griffiths WJ, Localization of sterols and oxysterols in mouse brain reveals distinct spatial cholesterol metabolism. Proceedings of the National Academy of Sciences 117, 5749&#x2013;5760 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7084107</ArticleId><ArticleId IdType="pubmed">32132201</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM, Intraneuronal Abeta causes the onset of early Alzheimer&#x2019;s disease-related cognitive deficits in transgenic mice. Neuron 45, 675&#x2013;688 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterniczuk R, Antle MC, Laferla FM, Dyck RH, Characterization of the 3xTg-AD mouse model of Alzheimer&#x2019;s disease: part 2. Behavioral and cognitive changes. Brain Res 1348, 149&#x2013;155 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20558146</ArticleId></ArticleIdList></Reference><Reference><Citation>Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS, Molecular imaging in drug development. Nature Reviews Drug Discovery 7, 591&#x2013;607 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18591980</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudin M, Weissleder R, Molecular imaging in drug discovery and development. Nature Reviews Drug Discovery 2, 123&#x2013;131 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12563303</ArticleId></ArticleIdList></Reference><Reference><Citation>Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE, Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27, 1533&#x2013;1539 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17519979</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL, Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16, 834&#x2013;840 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov AM, Pikuleva IA, Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases. Neurotherapeutics 16, 635&#x2013;648 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6694357</ArticleId><ArticleId IdType="pubmed">31001737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW, Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278, 22980&#x2013;22988 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12686551</ArticleId></ArticleIdList></Reference><Reference><Citation>Popp J, Meichsner S, K&#xf6;lsch H, Lewczuk P, Maier W, Kornhuber J, Jessen F, L&#xfc;tjohann D, Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer&#x2019;s disease. Biochemical Pharmacology 86, 37&#x2013;42 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23291240</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafaati M, Solomon A, Kivipelto M, Bj&#xf6;rkhem I, Leoni V, Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neuroscience Letters 425, 78&#x2013;82 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17822846</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, L&#xfc;tjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bj&#xf6;rkhem I, von Bergmann K, Heun R, 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. Journal of Psychiatric Research 36, 27&#x2013;32 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11755458</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni V, Shafaati M, Salomon A, Kivipelto M, Bj&#xf6;rkhem I, Wahlund L-O, Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? Neuroscience Letters 397, 83&#x2013;87 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16406316</ArticleId></ArticleIdList></Reference><Reference><Citation>Besga A, Cedazo-Minguez A, K&#xe5;reholt I, Solomon A, Bj&#xf6;rkhem I, Winblad B, Leoni V, Hooshmand B, Spulber G, Gonzalez-Pinto A, Kivipelto M, Wahlund LO, Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms. Neuroscience Letters 510, 121&#x2013;126 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22281444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Bayer TA, Neuron loss in transgenic mouse models of Alzheimer&#x2019;s disease. Int J Alzheimers Dis 2010, 723782 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943100</ArticleId><ArticleId IdType="pubmed">20871861</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson KW, Mast N, Hudgens JW, Lin JB, Turko IV, Pikuleva IA, Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity. J Biol Chem 291, 11876&#x2013;11886 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882454</ArticleId><ArticleId IdType="pubmed">27056331</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikuleva IA, Efavirenz as a cholesterol-targeting drug for AD. Alzheimer&#x2019;s &amp; Dementia 16, e040603 (2020).</Citation></Reference><Reference><Citation>Mast N, El-Darzi N, Petrov AM, Li Y, Pikuleva IA, CYP46A1-dependent and independent effects of efavirenz treatment. Brain Communications 2, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713991</ArticleId><ArticleId IdType="pubmed">33305262</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikuleva IA, Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases. Explor Neuroprotective Ther 1, 159&#x2013;172 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8835717</ArticleId><ArticleId IdType="pubmed">35156102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, Benraiss A, Delacourte A, Bougn&#xe8;res P, Aubourg P, Cartier N, Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer&#x2019;s disease. Mol Ther 18, 44&#x2013;53 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839219</ArticleId><ArticleId IdType="pubmed">19654569</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama 278, 1349&#x2013;1356 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD, Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 75, 563&#x2013;573 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Kim MJ, Kim S, Kang HS, Lim SW, Myung W, Lee Y, Hong CH, Choi SH, Na DL, Seo SW, Ku BD, Kim SY, Kim SY, Jeong JH, Park SA, Carroll BJ, Kim DK, Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer&#x2019;s disease: A CREDOS study. Compr Psychiatry 62, 114&#x2013;122 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26343475</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, Wang LS, Romero K, Arneric SP, Redolfi A, Orlandi D, Frisoni GB, Au R, Devine S, Auerbach S, Espinosa A, Boada M, Ruiz A, Johnson SC, Koscik R, Wang JJ, Hsu WC, Chen YL, Toga AW, Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74, 1178&#x2013;1189 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivim&#xe4;ki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selb&#xe6;k G, Teri L, Mukadam N, Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413&#x2013;446 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KA, Choudhury KR, Rathakrishnan BG, Marks DM, Petrella JR, Doraiswamy PM, Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement (N Y) 1, 103&#x2013;110 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593067</ArticleId><ArticleId IdType="pubmed">26451386</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider A, Xiao Z, Xia X, Chen J, Van RS, Kuang S, Zhao C, Rong J, Shao T, Ramesh P, Aravind A, Shao Y, Ran C, Young LJ, Liang SH, Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging. Pharmacol Res 173, 105886 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8581590</ArticleId><ArticleId IdType="pubmed">34536549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yutuc E, Angelini R, Baumert M, Mast N, Pikuleva I, Newton J, Clench MR, Skibinski DOF, Howell OW, Wang Y, Griffiths WJ, Localization of sterols and oxysterols in mouse brain reveals distinct spatial cholesterol metabolism. Proc Natl Acad Sci U S A 117, 5749&#x2013;5760 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7084107</ArticleId><ArticleId IdType="pubmed">32132201</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider A, Herde AM, Kr&#xe4;mer SD, Varisco J, Keller C, Frauenknecht K, Auberson YP, Temme L, Robaa D, Sippl W, Preclinical evaluation of benzazepine-based PET radioligands (R)-and (S)-11C-Me-NB1 reveals distinct enantiomeric binding patterns and a tightrope walk between GluN2B-and &#x3c3;1-receptor&#x2013;targeted PET imaging. Journal of Nuclear Medicine 60, 1167&#x2013;1173 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6681693</ArticleId><ArticleId IdType="pubmed">30683765</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Z, Wei H, Xu Y, Haider A, Wei J, Yuan S, Rong J, Zhao C, Li G, Zhang W, Chen H, Li Y, Zhang L, Sun J, Zhang S, Luo H-B, Yan S, Cai Q, Hou L, Che C, Liang SH, Wang L, Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination. Acta Pharmaceutica Sinica B 12, 1963&#x2013;1975 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279629</ArticleId><ArticleId IdType="pubmed">35847497</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren DG, Kosmatka KJ, Oakes TR, Kroenke CD, Kohama SG, Matochik JA, Ingram DK, Johnson SC, A population-average MRI-based atlas collection of the rhesus macaque. NeuroImage 45, 52&#x2013;59 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659879</ArticleId><ArticleId IdType="pubmed">19059346</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie B, Wang L, Hu Y, Liang S, Tan Z, Chai P, Tang Y, Shang J, Pan Z, Zhao X, Zhang X, Gong J, Zheng C, Xu H, Wey H-Y, Liang SH, Shan B, A population stereotaxic positron emission tomography brain template for the macaque and its application to ischemic model. NeuroImage 203, 116163 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31494249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36201573</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>378</Volume><Issue>6615</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration.</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>99</EndPage><MedlinePgn>94-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abq7860</ELocationID><Abstract><AbstractText>Frontotemporal dementia and amyotrophic lateral sclerosis (FTD-ALS) are associated with both a repeat expansion in the <i>C9orf72</i> gene and mutations in the TANK-binding kinase 1 (<i>TBK1</i>) gene. We found that TBK1 is phosphorylated in response to <i>C9orf72</i> poly(Gly-Ala) [poly(GA)] aggregation and sequestered into inclusions, which leads to a loss of TBK1 activity and contributes to neurodegeneration. When we reduced TBK1 activity using a TBK1-R228H (Arg<sup>228</sup>&#x2192;His) mutation in mice, poly(GA)-induced phenotypes were exacerbated. These phenotypes included an increase in TAR DNA binding protein 43 (TDP-43) pathology and the accumulation of defective endosomes in poly(GA)-positive neurons. Inhibiting the endosomal pathway induced TDP-43 aggregation, which highlights the importance of this pathway and TBK1 activity in pathogenesis. This interplay between <i>C9orf72</i>, <i>TBK1</i>, and TDP-43 connects three different facets of FTD-ALS into one coherent pathway.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8782-4904</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Tiffany W</ForeName><Initials>TW</Initials><Identifier Source="ORCID">0000-0003-4327-6114</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yanwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Caroline Y</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0002-8230-1549</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jimei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1234-7103</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daughrity</LastName><ForeName>Lillian M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0003-4644-7265</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jinyoung</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6579-4356</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5067-8579</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanedes-Casey</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8441-7801</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Rosso</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunmore</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-0190-0089</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanetti Alepuz</LastName><ForeName>Desiree</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1725-9866</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0002-5963-8442</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudencio</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4894-4858</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0002-7335-2627</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Scottsdale, AZ 85259, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong-Jie</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0002-9900-4313</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2959-129X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062171</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062077</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS123743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS120992</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS117461</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C403191">TBK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">Tardbp protein, mouse</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2022 Oct 7;378(6615):28-29. doi: 10.1126/science.ade4210.</RefSource><PMID Version="1">36201587</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Dec;18(12):699. doi: 10.1038/s41582-022-00738-2.</RefSource><PMID Version="1">36316486</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2022 Dec;23(12):709. doi: 10.1038/s41583-022-00657-7.</RefSource><PMID Version="1">36319859</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="Y">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> L.P. and Mayo Clinic have licensed technology involving C9orf72 Repeat Expansion Constructs and Virus and AAV-C9orf72&#x2013;149 Repeat Expansion Mouse Model. L.P. is a consultant for Expansion Therapeutics. M.P. is a consultant for Target ALS. B.O. has consulted for Biogen, Medicinova, Mitsubishi, AnnJi and Tsumura. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>14</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36201573</ArticleId><ArticleId IdType="mid">NIHMS1865202</ArticleId><ArticleId IdType="pmc">PMC9942492</ArticleId><ArticleId IdType="doi">10.1126/science.abq7860</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shahheydari H et al., Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum. Front Mol Neurosci 10, 119 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5423993</ArticleId><ArticleId IdType="pubmed">28539871</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui R, Tuo M, Li P, Zhou C, Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis. Neurol Sci 39, 811&#x2013;820 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29349657</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D et al., Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J Exp Med 216, 267&#x2013;278 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D et al., TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. Cell 174, 1477&#x2013;1491 e1419 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128749</ArticleId><ArticleId IdType="pubmed">30146158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino V et al., The Loss of TBK1 Kinase Activity in Motor Neurons or in All Cell Types Differentially Impacts ALS Disease Progression in SOD1 Mice. Neuron 106, 789&#x2013;805 e785 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S et al., Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiol Aging 84, 239 e239&#x2013;239 e214 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31000212</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S et al., Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain 139, 452&#x2013;467 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805085</ArticleId><ArticleId IdType="pubmed">26674655</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M et al., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE et al., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J et al., Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener 14, 9 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE et al., Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF et al., Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 126, 829&#x2013;844 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K et al., The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K et al., Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol 126, 881&#x2013;893 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ et al., C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci 19, 668&#x2013;677 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN et al., C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med 12, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ et al., Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science 363, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes JA, Davies MC, Collins MO, TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain 10, 5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C et al., Structural basis of STING binding with and phosphorylation by TBK1. Nature 567, 394&#x2013;398 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6862768</ArticleId><ArticleId IdType="pubmed">30842653</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S et al., Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25636800</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A et al., C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 582, 89&#x2013;94 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="pubmed">32483373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao J et al., Loss of TBK1 activity leads to TDP-43 proteinopathy through lysosomal dysfunction in human motor neurons. bioRxiv, 2021.2010.2011.464011 (2021).</Citation></Reference><Reference><Citation>Coyne AN et al., G4C2 Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD. Neuron 107, 1124&#x2013;1140 e1111 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077944</ArticleId><ArticleId IdType="pubmed">32673563</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC et al., TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci 21, 228&#x2013;239 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga RE et al., In Vivo Evidence for Lysosome Depletion and Impaired Autophagic Clearance in Hereditary Spastic Paraplegia Type SPG11. PLoS Genet 11, e1005454 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4540459</ArticleId><ArticleId IdType="pubmed">26284655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunita R et al., Homo-oligomerization of ALS2 through its unique carboxyl-terminal regions is essential for the ALS2-associated Rab5 guanine nucleotide exchange activity and its regulatory function on endosome trafficking. J Biol Chem 279, 38626&#x2013;38635 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15247254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow CY et al., Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 448, 68&#x2013;72 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2271033</ArticleId><ArticleId IdType="pubmed">17572665</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G et al., Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37, 806&#x2013;808 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmisano R et al., Endosomal accumulation of APP in wobbler motor neurons reflects impaired vesicle trafficking: implications for human motor neuron disease. BMC Neurosci 12, 24 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058068</ArticleId><ArticleId IdType="pubmed">21385376</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A et al., Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell 185, 1346&#x2013;1355 e1315 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9018563</ArticleId><ArticleId IdType="pubmed">35247328</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YX et al., Amyloid fibrils in disease FTLD-TDP are composed of TMEM106B not TDP-43. Nature, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844993</ArticleId><ArticleId IdType="pubmed">35344984</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M et al., Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095482</ArticleId><ArticleId IdType="pubmed">35344985</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM et al., Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42, 234&#x2013;239 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S et al., Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6, 973&#x2013;985 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10455399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J et al., Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151&#x2013;1154 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Janocko NJ et al., Neuropathologically defined subtypes of Alzheimer&#x2019;s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 124, 681&#x2013;692 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483034</ArticleId><ArticleId IdType="pubmed">22968369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36203054</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2522-5812</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature metabolism</Title><ISOAbbreviation>Nat Metab</ISOAbbreviation></Journal><ArticleTitle>Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to &#x3b2;-amyloid clearance.</ArticleTitle><Pagination><StartPage>1287</StartPage><EndPage>1305</EndPage><MedlinePgn>1287-1305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s42255-022-00643-4</ELocationID><Abstract><AbstractText>Microglial cells consume adenosine triphosphate (ATP) during phagocytosis to clear neurotoxic &#x3b2;-amyloid in Alzheimer's disease (AD). However, the contribution of energy metabolism to microglial function in AD remains unclear. Here, we demonstrate that hexokinase 2 (HK2) is elevated in microglia from an AD mouse model (5xFAD) and AD patients. Genetic deletion or pharmacological inhibition of HK2 significantly promotes microglial phagocytosis, lowers the amyloid plaque burden and attenuates cognitive impairment in male AD mice. Notably, the ATP level is dramatically increased in HK2-deficient or inactive microglia, which can be attributed to a marked upregulation in lipoprotein lipase (LPL) expression and subsequent increase in lipid metabolism. We further show that two downstream metabolites of HK2, glucose-6-phosphate and fructose-6-phosphate, can reverse HK2-deficiency-induced upregulation of LPL, thus supporting ATP production and microglial phagocytosis. Our findings uncover a crucial role for HK2 in phagocytosis through regulation of microglial energy metabolism, suggesting a potential therapeutic strategy for AD by targeting HK2.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Lige</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4288-4743</Identifier><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China. lenglige@xmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Ziqi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ruiyuan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2057-5237</Identifier><AffiliationInfo><Affiliation>The Brain Science Center, Beijing Institute of Basic Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Ju</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5893-9406</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhenlei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wenting</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huifang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhenyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Keke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Basic Medicine, Fourth Military Medcial University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology &amp; Visual Sciences Key Lab, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenting</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8344-0102</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, School of Basic Medicine, Fourth Military Medcial University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Zi-Bing</ForeName><Initials>ZB</Initials><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology &amp; Visual Sciences Key Lab, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shengxi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Basic Medicine, Fourth Military Medcial University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinglong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zengqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Brain Science Center, Beijing Institute of Basic Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7031-7853</Identifier><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Hei-Man</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0003-1203-2096</Identifier><AffiliationInfo><Affiliation>School of Life Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1040-5848</Identifier><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China. jiezhang@xmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China. jiezhang@xmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience, Fujian Medical University, Fuzhou, China. jiezhang@xmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nat Metab</MedlineTA><NlmUniqueID>101736592</NlmUniqueID><ISSNLinking>2522-5812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.1.34</RegistryNumber><NameOfSubstance UI="D008071">Lipoprotein Lipase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D006593">Hexokinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-73-5</RegistryNumber><NameOfSubstance UI="D019298">Glucose-6-Phosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Metab. 2022 Oct;4(10):1223-1224. doi: 10.1038/s42255-022-00647-0.</RefSource><PMID Version="1">36203055</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Metab. 2022 Oct;4(10):1420. doi: 10.1038/s42255-022-00682-x.</RefSource><PMID Version="1">36241712</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008071" MajorTopicYN="N">Lipoprotein Lipase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006593" MajorTopicYN="N">Hexokinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019298" MajorTopicYN="N">Glucose-6-Phosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36203054</ArticleId><ArticleId IdType="doi">10.1038/s42255-022-00643-4</ArticleId><ArticleId IdType="pii">10.1038/s42255-022-00643-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy, J. &amp; Selkoe, D. J. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId><ArticleId IdType="doi">10.1126/science.1072994</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman, D. M., Goate, A., Kelly, J. &amp; Sperling, R. Mapping the road forward in Alzheimer&#x2019;s disease. Sci. Transl. Med. 3, 114ps148 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003529</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, T. et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer&#x2019;s disease. Mol. Neurodegener. 15, 40 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32677986</ArticleId><ArticleId IdType="pmc">7364557</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00391-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Z. &amp; Zhong, C. Decoding Alzheimer&#x2019;s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 108, 21&#x2013;43 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23850509</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2013.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield, D. A. &amp; Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 20, 148&#x2013;160 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30737462</ArticleId><ArticleId IdType="pmc">9382875</ArticleId><ArticleId IdType="doi">10.1038/s41583-019-0132-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W., Zhao, F., Ma, X., Perry, G. &amp; Zhu, X. Mitochondria dysfunction in the pathogenesis of Alzheimer&#x2019;s disease: recent advances. Mol. Neurodegener. 15, 30 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32471464</ArticleId><ArticleId IdType="pmc">7257174</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00376-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Elder, G. J., Colloby, S. J., Firbank, M. J., McKeith, I. G. &amp; Taylor, J. P. Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial. Alzheimers Res Ther. 11, 9 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30658705</ArticleId><ArticleId IdType="pmc">6339360</ArticleId><ArticleId IdType="doi">10.1186/s13195-018-0465-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, J. J., Jolivet, R. &amp; Attwell, D. Synaptic energy use and supply. Neuron 75, 762&#x2013;777 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22958818</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2012.08.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Camandola, S. &amp; Mattson, M. P. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 36, 1474&#x2013;1492 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28438892</ArticleId><ArticleId IdType="pmc">5452017</ArticleId><ArticleId IdType="doi">10.15252/embj.201695810</ArticleId></ArticleIdList></Reference><Reference><Citation>Suss, P. &amp; Schlachetzki, J. C. M. Microglia in Alzheimer&#x2019;s disease. Curr. Alzheimer Res. 17, 29&#x2013;43 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32048973</ArticleId><ArticleId IdType="doi">10.2174/1567205017666200212155234</ArticleId></ArticleIdList></Reference><Reference><Citation>Claes, C. et al. Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 16, 50 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34301296</ArticleId><ArticleId IdType="pmc">8305935</ArticleId><ArticleId IdType="doi">10.1186/s13024-021-00473-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton, K. et al. Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model. Mol. Neurodegener. 16, 18 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33752701</ArticleId><ArticleId IdType="pmc">7986521</ArticleId><ArticleId IdType="doi">10.1186/s13024-021-00440-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Engl, E. &amp; Attwell, D. Non-signalling energy use in the brain. J. Physiol. 593, 3417&#x2013;3429 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25639777</ArticleId><ArticleId IdType="pmc">4560575</ArticleId><ArticleId IdType="doi">10.1113/jphysiol.2014.282517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhart, E. et al. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics 10, 141&#x2013;158 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19899077</ArticleId><ArticleId IdType="pmc">4060044</ArticleId><ArticleId IdType="doi">10.1002/pmic.200900195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalsbeek, M. J., Mulder, L. &amp; Yi, C. X. Microglia energy metabolism in metabolic disorder. Mol. Cell. Endocrinol. 438, 27&#x2013;35 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27687525</ArticleId><ArticleId IdType="doi">10.1016/j.mce.2016.09.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathe, G. et al. Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer&#x2019;s disease. Proteom. Clin. Appl 13, e1800105 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.201800105</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor, F., Izak, M. &amp; Cohen, I. R. Identification of aldolase as a target antigen in Alzheimer&#x2019;s disease. J. Immunol. 175, 3439&#x2013;3445 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16116239</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.175.5.3439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, J. E. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol. 206, 2049&#x2013;2057 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12756287</ArticleId><ArticleId IdType="doi">10.1242/jeb.00241</ArticleId></ArticleIdList></Reference><Reference><Citation>Robey, R. B. &amp; Hay, N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25, 4683&#x2013;4696 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16892082</ArticleId><ArticleId IdType="doi">10.1038/sj.onc.1209595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow, H. M. et al. Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. Nat. Neurosci. 22, 1806&#x2013;1819 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31636448</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0505-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon, J. S. et al. mTORC1-Induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation. Cell Rep. 12, 102&#x2013;115 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26119735</ArticleId><ArticleId IdType="pmc">4858438</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.05.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. et al. Hexokinase 2-dependent hyperglycolysis driving microglial activation contributes to ischemic brain injury. J. Neurochem. 144, 186&#x2013;200 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29205357</ArticleId><ArticleId IdType="doi">10.1111/jnc.14267</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik, S. H. et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer&#x2019;s disease. Cell Metab. 30, 493&#x2013;507 e496 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31257151</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2019.06.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva, L. M. et al. Amyloid-beta triggers the release of neuronal hexokinase 1 from mitochondria. PLoS ONE 5, e15230 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21179577</ArticleId><ArticleId IdType="pmc">3002973</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0015230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon, T. R. et al. Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer Metab. 1, 2 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24280485</ArticleId><ArticleId IdType="pmc">3782751</ArticleId><ArticleId IdType="doi">10.1186/2049-3002-1-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt, E. et al. Regulation and cytoprotective role of hexokinase III. PLoS ONE 5, e13823 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21072205</ArticleId><ArticleId IdType="pmc">2972215</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0013823</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, B. et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23622250</ArticleId><ArticleId IdType="pmc">3677161</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.03.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg, E. E. et al. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain 139, 1265&#x2013;1281 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921617</ArticleId><ArticleId IdType="pmc">5006229</ArticleId><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, G. et al. Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis. Arthritis Res Ther. 21, 87 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30944034</ArticleId><ArticleId IdType="pmc">6446273</ArticleId><ArticleId IdType="doi">10.1186/s13075-019-1865-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudard, S. et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 63, 81&#x2013;86 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12814259</ArticleId><ArticleId IdType="doi">10.1023/A:1023756707900</ArticleId></ArticleIdList></Reference><Reference><Citation>Carapella, C. M. et al. The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study. J. Neurooncol. 7, 103&#x2013;108 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2666593</ArticleId><ArticleId IdType="doi">10.1007/BF00149384</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, L., Wei, Y., Yu, X., Peng, J. &amp; Leng, X. 3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells: in vitro and in vivo findings. Anticancer Agents Med. Chem. 14, 771&#x2013;776 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24738957</ArticleId><ArticleId IdType="doi">10.2174/1871520614666140416105309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour, M. A., Ibrahim, W. M., Salama, M. M. &amp; Salama, A. F. Dual inhibition of glycolysis and autophagy as a therapeutic strategy in the treatment of Ehrlich ascites carcinoma. J. Biochem. Mol. Toxicol. 34, e22498 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32198814</ArticleId><ArticleId IdType="doi">10.1002/jbt.22498</ArticleId></ArticleIdList></Reference><Reference><Citation>Landel, V. et al. Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer&#x2019;s disease. Mol. Neurodegener. 9, 33 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25213090</ArticleId><ArticleId IdType="pmc">4237952</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-9-33</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, L. et al. Inhibition of mitochondrial complex II by the anticancer agent lonidamine. J. Biol. Chem. 291, 42&#x2013;57 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26521302</ArticleId><ArticleId IdType="doi">10.1074/jbc.M115.697516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, M.-L. et al. Functional microglia derived from human pluripotent stem cells empower retinal organ. Sci. China Life Sci. 65, 1057&#x2013;1071 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35451725</ArticleId><ArticleId IdType="doi">10.1007/s11427-021-2086-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert, D., Haller, R. G. &amp; Walton, M. E. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 23, 5928&#x2013;5935 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12843297</ArticleId><ArticleId IdType="pmc">6741266</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.23-13-05928.2003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, X. L. &amp; Weckwerth, W. COVAIN: a toolbox for uni- and multivariate statistics, time-series and correlation network analysis and inverse estimation of the differential Jacobian from metabolomics covariance data. Metabolomics 8, S81&#x2013;S93 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-012-0399-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, J. L. et al. Inverse data-driven modeling and multiomics analysis reveals Phgdh as a metabolic checkpoint of macrophage polarization and proliferation. Cell Rep. 30, 1542&#x2013;1552 e1547 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32023468</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.01.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson-Ehle, P., Egelrud, T., Belfrage, P., Olivecrona, T. &amp; Borgstrom, B. Positional specificity of purified milk lipoprotein lipase. J. Biol. Chem. 248, 6734&#x2013;6737 (1973).</Citation><ArticleIdList><ArticleId IdType="pubmed">4355505</ArticleId><ArticleId IdType="doi">10.1016/S0021-9258(19)43414-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio, C. et al. The major risk factors for Alzheimer&#x2019;s disease: age, sex, and genes modulate the microglia response to abeta plaques. Cell Rep. 27, 1293&#x2013;1306 e1296 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31018141</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.03.099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lookene, A., Skottova, N. &amp; Olivecrona, G. Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Eur. J. Biochem. 222, 395&#x2013;403 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8020477</ArticleId><ArticleId IdType="doi">10.1111/j.1432-1033.1994.tb18878.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano, S. &amp; Doi, M. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats. Metabolism 55, 151&#x2013;158 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16423620</ArticleId><ArticleId IdType="doi">10.1016/j.metabol.2005.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura, M. et al. Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. Drug Metab. Pharmacokinet. 19, 422&#x2013;429 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15681896</ArticleId><ArticleId IdType="doi">10.2133/dmpk.19.422</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman, D. L. &amp; Eicher, E. M. Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse. J. Hered. 81, 424&#x2013;427 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2250094</ArticleId><ArticleId IdType="doi">10.1093/oxfordjournals.jhered.a111019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziboh, V. A., Dreize, M. A. &amp; Hsia, S. L. Inhibition of lipid synthesis and glucose-6-phosphate dehydrogenase in rat skin by dehydroepiandrosterone. J. Lipid Res. 11, 346&#x2013;354 (1970).</Citation><ArticleIdList><ArticleId IdType="pubmed">4394096</ArticleId><ArticleId IdType="doi">10.1016/S0022-2275(20)42971-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessoule, J. J., Lessire, R., Rigoulet, M., Guerin, B. &amp; Cassagne, C. Fatty acid synthesis in mitochondria from Saccharomyces cerevisiae. FEBS Lett. 214, 158&#x2013;162 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3552725</ArticleId><ArticleId IdType="doi">10.1016/0014-5793(87)80033-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, F. F. &amp; Xu, H. Insulin signaling in sporadic Alzheimer&#x2019;s disease. Sci. Signal 2, pe36 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19509405</ArticleId><ArticleId IdType="pmc">4419569</ArticleId><ArticleId IdType="doi">10.1126/scisignal.274pe36</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier, L. P. et al. Microglial metabolic flexibility supports immune surveillance of the brain parenchyma. Nat. Commun. 11, 1559 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32214088</ArticleId><ArticleId IdType="pmc">7096448</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-15267-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst, C. N. &amp; Gan, W. B. Microglia dynamics and function in the CNS. Curr. Opin. Neurobiol. 20, 595&#x2013;600 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20705452</ArticleId><ArticleId IdType="pmc">3708473</ArticleId><ArticleId IdType="doi">10.1016/j.conb.2010.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann, H., Hanisch, U. K., Noda, M. &amp; Verkhratsky, A. Physiology of microglia. Physiol. Rev. 91, 461&#x2013;553 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId><ArticleId IdType="doi">10.1152/physrev.00011.2010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson, L. J., Perry, V. H. &amp; Gordon, S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48, 405&#x2013;415 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1603325</ArticleId><ArticleId IdType="doi">10.1016/0306-4522(92)90500-2</ArticleId></ArticleIdList></Reference><Reference><Citation>van Furth, R. &amp; Cohn, Z. A. The origin and kinetics of mononuclear phagocytes. J. Exp. Med. 128, 415&#x2013;435 (1968).</Citation><ArticleIdList><ArticleId IdType="pubmed">5666958</ArticleId><ArticleId IdType="pmc">2138527</ArticleId><ArticleId IdType="doi">10.1084/jem.128.3.415</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst, C. N. et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596&#x2013;1609 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24360280</ArticleId><ArticleId IdType="pmc">4033691</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.11.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25186741</ArticleId><ArticleId IdType="pmc">4152602</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldana, B. I. Microglia-specific metabolic changes in neurodegeneration. J. Mol. Biol. 431, 1830&#x2013;1842 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30878483</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2019.03.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, F., Faustino, J., Woo, M. S., Derugin, N. &amp; Vexler, Z. S. Lack of the scavenger receptor CD36 alters microglial phenotypes after neonatal stroke. J. Neurochem. 135, 445&#x2013;452 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26223273</ArticleId><ArticleId IdType="pmc">4844456</ArticleId><ArticleId IdType="doi">10.1111/jnc.13239</ArticleId></ArticleIdList></Reference><Reference><Citation>Spriet, L. L. New insights into the interaction of carbohydrate and fat metabolism during exercise. Sports Med 44, S87&#x2013;S96 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24791920</ArticleId><ArticleId IdType="doi">10.1007/s40279-014-0154-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. &amp; Eckel, R. H. Lipoprotein lipase in the brain and nervous system. Annu Rev. Nutr. 32, 147&#x2013;160 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22540257</ArticleId><ArticleId IdType="pmc">4065112</ArticleId><ArticleId IdType="doi">10.1146/annurev-nutr-071811-150703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, Y. et al. Disruption of lipid uptake in astroglia exacerbates diet-induced obesity. Diabetes 66, 2555&#x2013;2563 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28710138</ArticleId><ArticleId IdType="pmc">6463752</ArticleId><ArticleId IdType="doi">10.2337/db16-1278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitsuji, K., Hosono, T., Uchimura, K. &amp; Michikawa, M. Lipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes. J. Biol. Chem. 286, 6393&#x2013;6401 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21177248</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.172106</ArticleId></ArticleIdList></Reference><Reference><Citation>Scacchi, R. et al. The H+ allele of the lipoprotein lipase (LPL) HindIII intronic polymorphism and the risk for sporadic late-onset Alzheimer&#x2019;s disease. Neurosci. Lett. 367, 177&#x2013;180 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15331147</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2004.05.111</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. S. et al. Myelin injury in the central nervous system and Alzheimer&#x2019;s disease. Brain Res. Bull. 140, 162&#x2013;168 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29730417</ArticleId><ArticleId IdType="doi">10.1016/j.brainresbull.2018.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce, K. D. et al. Lipoprotein lipase is a feature of alternatively-activated microglia and may facilitate lipid uptake in the CNS during demyelination. Front Mol. Neurosci. 11, 57 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29599706</ArticleId><ArticleId IdType="pmc">5862862</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2018.00057</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman, B. A. et al. GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors. PLoS ONE 7, e35943 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22574128</ArticleId><ArticleId IdType="pmc">3344841</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0035943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36203055</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2522-5812</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature metabolism</Title><ISOAbbreviation>Nat Metab</ISOAbbreviation></Journal><ArticleTitle>Lipid fuel for hungry-angry microglia.</ArticleTitle><Pagination><StartPage>1223</StartPage><EndPage>1224</EndPage><MedlinePgn>1223-1224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s42255-022-00647-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hayoung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, SNU Dementia Research Center, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mook-Jung</LastName><ForeName>Inhee</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-7085-4085</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, SNU Dementia Research Center, Seoul National University College of Medicine, Seoul, South Korea. inhee@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nat Metab</MedlineTA><NlmUniqueID>101736592</NlmUniqueID><ISSNLinking>2522-5812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Nat Metab. 2022 Oct;4(10):1287-1305. doi: 10.1038/s42255-022-00643-4.</RefSource><PMID Version="1">36203054</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006815" MajorTopicYN="Y">Hunger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36203055</ArticleId><ArticleId IdType="doi">10.1038/s42255-022-00647-0</ArticleId><ArticleId IdType="pii">10.1038/s42255-022-00647-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings, J. et al. Alzheimers Dement. (NY) 8, e12295 (2022).</Citation></Reference><Reference><Citation>Hansen, D. V., Hanson, J. E. &amp; Sheng, M. J. Cell Biol. 217, 459&#x2013;472 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201709069</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng, F. &amp; Edison, P. Nat. Rev. Neurol. 17, 157&#x2013;172 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00435-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng, L. Nat. Metab. https://doi.org/10.1038/s42255-022-00643-4 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-022-00643-4</ArticleId><ArticleId IdType="pubmed">36241712</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts, D. J. &amp; Miyamoto, S. Cell Death Differ. 22, 248&#x2013;257 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2014.173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalsbeek, M. J. T., Mulder, L. &amp; Yi, C.-X. Mol. Cell. Endocrinol. 438, 27&#x2013;35 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2016.09.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik, S. H. et al. Cell Metab. 30, 493&#x2013;507.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.06.005</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill, L. A. J., Kishton, R. J. &amp; Rathmell, J. Nat. Rev. Immunol. 16, 553&#x2013;565 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.70</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan, R.-Y. et al. Cell Metab. 34, 634&#x2013;648.e6 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2022.02.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Camandola, S. &amp; Mattson, M. P. EMBO J. 36, 1474&#x2013;1492 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201695810</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhayaza, R., Haque, E., Karbasiafshar, C., Sellke, F. W. &amp; Abid, M. R. Front Chem. 8, 592688 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2020.592688</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Mohsen, A. W., Mihalik, S. J., Goetzman, E. S. &amp; Vockley, J. J. Biol. Chem. 285, 29834&#x2013;29841 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.139493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36209495</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4.</ArticleTitle><Pagination><StartPage>307</StartPage><EndPage>317</EndPage><MedlinePgn>307-317</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12797</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022.</AbstractText><AbstractText Label="METHODS">ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (&#x223c;3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials.</AbstractText><AbstractText Label="RESULTS AND DISCUSSION">ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veitch</LastName><ForeName>Dallas P</ForeName><Initials>DP</Initials><Identifier Source="ORCID">0000-0002-9918-0640</Identifier><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northern California Institute for Research and Education (NCIRE), Department of Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Melanie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northern California Institute for Research and Education (NCIRE), Department of Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albala</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Irvine School of Medicine, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute Ariadne Labs and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nosheny</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okonkwo</LastName><ForeName>Ozioma C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center and Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Mindt</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, Latin American and Latino Studies Institute, &amp; African and African American Studies, Fordham University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosun</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD093654</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051618</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062517</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD076189</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS079202</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062240</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072972</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HD103526</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536596">Alzheimer disease type 4</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003256" MajorTopicYN="N">Community Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073597" MajorTopicYN="N">Stakeholder Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">cerebrovascular disease</Keyword><Keyword MajorTopicYN="N">digital biomarkers</Keyword><Keyword MajorTopicYN="N">generalizability</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">plasma biomarkers</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">underrepresented populations</Keyword></KeywordList><CoiStatement>Dr. Aisen reports research agreements with Janssen, Lilly, and Eisai; grants from NIA, the Alzheimer's Association, and FNIH; and consulting fees from Biogen, Roche, Merck, Abbvie, Immunobrain Checkpoint, Rainbow Medical, and Shionogi. Dr. Albala has no conflicts to declare. Dr. Beckett receives support from NIH grants U01AG024904, R01AG062517, and B639943, and has received support from the National Institute of Justice (2014&#x2010;R2&#x2010;CX&#x2010;0012). Dr. Green is supported by NIH grants AG24904, HD090019, HG009922, HL143295, HG008685, TR003201, has received compensation for advising the following companies: AIA, Allelica, Embryome, Genomic Life, Grail, Humanity, Kneed Media, Meenta, OptumLabs, Plumcare, Verily, VinBigData; and is co&#x2010;founder of Genome Medical, Inc. Dr. Harvey receives support from NIH grants P30AG072972, U01AG024904, U54NS079202, R01AG051618, R01HD093654, R01AG062240, R01AG062689, R01AG064688, P50HD103526, R01HD076189, R01AG066748, R01AG067541 and a California Department of Public Health Alzheimer's Award (1910611&#x2010;0). She has also served as a consultant for NervGen Pharma Corp and receives support for serving as a Statistical Advisor for PLOS ONE. Dr. Jack serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR Foundation, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Jagust receives support from NIH grants AG034570, AG062542 and AG067418. He serves as a consultant to Bioclinica, Biogen, and Lilly and has an equity position in Optoceutics. Dr. Landau has received travel funding from the Alzheimer's Association, served on the Scientific Advisory Board and DSMB for KeifeRx, and has received speaker fees from Eisai, Inc. Dr. Miller has no conflicts to declare. Dr. Morris is funded by NIH grants P30 AG066444, P01AG003991, P01AG026276, U19 AG032438, and U19 AG024904. Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Dr. Nosheny receives support in the form of grants to UCSF from NIH, The Alzheimer's Association, and Genentech, Inc. Dr. Okonkwo has no conflicts to declare. Dr. Perrin is supported by NIH grants R01AG068319, R01 AG053267, R01AG054567, P01 AG003991, P30 AG066444, U19AG024904, U19 AG032438, R01 AG052550, R01 AG070883, R01NS097799, R01NS092865, R01AG054513, and R01 NS075321. Neither Dr. Perrin nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Dr. Petersen has consulted for Roche, Inc., Merck, Inc., Biogen, Inc., Eisai, Inc., Nestle, Inc., and Genentech, Inc. Dr. Rivera Mindt receives support from multiple NIH grants (R01AG065110&#x2010;01A1, R01AG066471&#x2010;01A1, 5U19AG024904, R13 AG071313&#x2010;01, SC3GM141996) and the Genentech Health Equity Innovations 2020 Fund (G&#x2010;89294). She serves on the following Boards: ALL&#x2010;FTD External Advisory Board, Alzheimer's Association New York City, Brown University Carney Center, Harlem Community and Academic Partnership, South Texas Alzheimer's Disease Research Center (ADRC) External Advisory Board, and University of Washington ADRC External Advisory Board. Dr. Saykin receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); and Springer&#x2010;Nature Publishing (Editorial Office Support as Editor&#x2010;in&#x2010;Chief, Brain Imaging and Behavior). Dr. Shaw receives support from NIH grants P30 AG072979, U19AG024904, R01MH117114; grant support from the Michael J Fox Foundation for Parkinson's Disease Research and support from Roche (IIS and in&#x2010;kind reagents and instrumentation support for CSF AD biomarkers); he has received honoraria from Roche, Biogen, and Fujirebio for participation in teaching programs and served on Advisory Boards for Roche and Biogen. Dr. Toga has no conflicts to declare. Dr. Tosun receives support from NIH grant U01AG024904 and from the Department of Defense (grant numbers W81XWH&#x2010;12&#x2010;2&#x2010;0012, W81XWH&#x2010;13&#x2010;1&#x2010;0259, and W81XWH&#x2010;14&#x2010;1&#x2010;0462), Dr. Veitch has no conflicts to declare. Dr. Weiner serves on Editorial Boards for Alzheimer's &amp; Dementia, MRI and TMRI. He has served on Advisory Boards for Acumen Pharmaceutical, ADNI, Alzheon, Inc., Biogen, Brain Health Registry, Cerecin, Dolby Family Ventures, Eli Lilly, Merck Sharp &amp; Dohme Corp., National Institute on Aging (NIA), Nestle/Nestec, PCORI/PPRN, Roche, University of Southern California (USC), andNervGen. He has provided consulting to Baird Equity Capital, BioClinica, Cerecin, Inc., Cytox, Dolby Family Ventures, Duke University, Eisai, FUJIFILM&#x2010;Toyama Chemical (Japan), Garfield Weston, Genentech, Guidepoint Global, Indiana University, Japanese Organization for Medical Device Development, Inc. (JOMDD), Medscape, Nestle/Nestec, NIH, Peerview Internal Medicine, Roche, T3D Therapeutics, University of Southern California (USC), and Vida Ventures. He has acted as a speaker/lecturer to The Buck Institute for Research on Aging; China Association for Alzheimer's Disease (CAAD); Japan Society for Dementia Research; and Korean Dementia Society He holds stock options with Alzheon, Inc., Alzeca, and Anven. The following entities have provided funding for academic travel; University of Southern California (USC), NervGen, ASFNR, and CTAD Congress. 
Author disclosures are available in the supporting information.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>9</Day><Hour>14</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36209495</ArticleId><ArticleId IdType="mid">NIHMS1875529</ArticleId><ArticleId IdType="pmc">PMC10042173</ArticleId><ArticleId IdType="doi">10.1002/alz.12797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Veitch DP, Weiner MW, Aisen PS, et&#xa0;al. Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2021;epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9158456</ArticleId><ArticleId IdType="pubmed">34581485</ArticleId></ArticleIdList></Reference><Reference><Citation>Veitch DP, Weiner MW, Aisen PS, et&#xa0;al. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2019;15:106&#x2010;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">30321505</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et&#xa0;al. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9:e111&#x2010;e194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108198</ArticleId><ArticleId IdType="pubmed">23932184</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et&#xa0;al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8:S1&#x2010;S68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et&#xa0;al. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: reviewing progress toward improved AD clinical trials. Alzheimers Dement. 2017;13:e1&#x2010;e85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6818723</ArticleId><ArticleId IdType="pubmed">28342697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Bennett DA, Blennow K, et&#xa0;al. NIA&#x2010;AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535&#x2010;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Nelson PT, Besser LM, Heller KB, Kukull WA. Cerebral amyloid angiopathy and its co&#x2010;occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes. Neurobiol Aging. 2015;36:2702&#x2010;2708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562901</ArticleId><ArticleId IdType="pubmed">26239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement (Amst). 2017;7:69&#x2010;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5328683</ArticleId><ArticleId IdType="pubmed">28275702</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Bennett DA, Boyle PA, Leurgans S, Schneider JA. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA, J Am Med Assoc. 2012;307:1798&#x2010;1800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368581</ArticleId><ArticleId IdType="pubmed">22550192</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison WT, Lusk JB, Liu B, et&#xa0;al. Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy neuropathological change (LATE&#x2010;NC) is independently associated with dementia and strongly associated with arteriolosclerosis in the oldest&#x2010;old. Acta Neuropathol. 2021;142:917&#x2010;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8816525</ArticleId><ArticleId IdType="pubmed">34415381</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Monsell SE, Schmitt FA, Kukull WA, Nelson PT. Hippocampal sclerosis of aging is a key Alzheimer's disease mimic: clinical&#x2010;pathologic correlations and comparisons with both alzheimer's disease and non&#x2010;tauopathic frontotemporal lobar degeneration. Journal of Alzheimer's disease : JAD. 2014;39:691&#x2010;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946156</ArticleId><ArticleId IdType="pubmed">24270205</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Schultz C, Botez G, et&#xa0;al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease&#x2010;related pathology. Neuropathol Appl Neurobiol. 2005;31:270&#x2010;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">15885064</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan A, De Paula Franca Resende E, Petersen C, et&#xa0;al. Astrocytic tau deposition is frequent in typical and atypical Alzheimer disease presentations. J Neuropathol Exp Neurol. 2019;78:1112&#x2010;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967845</ArticleId><ArticleId IdType="pubmed">31626288</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zissimopoulos JM. Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions. 2018;4:510&#x2010;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197734</ArticleId><ArticleId IdType="pubmed">30364652</ArticleId></ArticleIdList></Reference><Reference><Citation>Babulal GM, Quiroz YT, Albensi BC, et&#xa0;al. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2019;15:292&#x2010;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368893</ArticleId><ArticleId IdType="pubmed">30555031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashford MT, Raman R, Miller G, et&#xa0;al. Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimer's &amp; Dementia. 2022;EPUB ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402812</ArticleId><ArticleId IdType="pubmed">35213778</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Nosheny R, Camacho M, et&#xa0;al. The Brain Health Registry: An internet&#x2010;based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies. Alzheimers Dement. 2018;14:1063&#x2010;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126911</ArticleId><ArticleId IdType="pubmed">29754989</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias ST, Mungas D, Harvey DJ, Simmons A, Reed BR, DeCarli C. The measurement of everyday cognition: development and validation of a short form of the Everyday Cognition scales. Alzheimer's &amp; Dementia. 2011;7:593&#x2010;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3211103</ArticleId><ArticleId IdType="pubmed">22055976</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias ST, Weakley A, Harvey D, Chandler J, Huss O, Mungas D. The measurement of everyday cognition (ECog): revisions and updates. Alzheimer Dis Assoc Disord. 2021;35:258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387334</ArticleId><ArticleId IdType="pubmed">33901047</ArticleId></ArticleIdList></Reference><Reference><Citation>Skirrow C, Meszaros M, Meepegama U, et&#xa0;al. Validation of a novel fully automated story recall task for repeated remote high&#x2010;frequency administration. MedrXiv. 2021.</Citation></Reference><Reference><Citation>Nosheny RL, Camacho MR, Insel PS, et&#xa0;al. Online study partner&#x2010;reported cognitive decline in the Brain Health Registry. Alzheimer's &amp; dementia (New York, N Y). 2018;4:565&#x2010;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6205111</ArticleId><ArticleId IdType="pubmed">30386821</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamar M, Durazo&#x2010;Arvizu RA, Sachdeva S, et&#xa0;al. Cardiovascular disease risk factor burden and cognition: Implications of ethnic diversity within the Hispanic Community Health Study/Study of Latinos. PLoS One. 2019;14:e0215378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476505</ArticleId><ArticleId IdType="pubmed">31009492</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Mattsson&#x2010;Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood&#x2010;based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022;14:e14408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8749476</ArticleId><ArticleId IdType="pubmed">34859598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirmess KM, Meyer MR, Holubasch MS, et&#xa0;al. The PrecivityAD test: accurate and reliable LC&#x2010;MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta. 2021;519:267&#x2010;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292789</ArticleId><ArticleId IdType="pubmed">34015303</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan A, Pannee J, Karikari TK, et&#xa0;al. Population&#x2010;based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain. 2021;144:434&#x2010;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940173</ArticleId><ArticleId IdType="pubmed">33479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Palmqvist S, Leuzy A, et&#xa0;al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42/Abeta40 and p&#x2010;tau. Alzheimers Dement. 2021;on line ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">34151519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Nakamura A, Washimi Y, et&#xa0;al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proceedings of the Japan Academy Series B, Physical and biological sciences. 2014;90:353&#x2010;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324927</ArticleId><ArticleId IdType="pubmed">25391320</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Schindler SE, Bollinger JG, et&#xa0;al. Validation of plasma amyloid&#x2010;&#x3b2; 42/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022;98:e688&#x2010;e99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865895</ArticleId><ArticleId IdType="pubmed">34906975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanon O, Vidal JS, Lehmann S, et&#xa0;al. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimers Dement. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35187794</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Pedrini S, Ashton NJ, et&#xa0;al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34494715</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Tideman P, Cullen N, et&#xa0;al. Prediction of future Alzheimer's disease dementia using plasma phospho&#x2010;tau combined with other accessible measures. Nat Med. 2021;27:1034&#x2010;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">34031605</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n J, Leuzy A, Karikari TK, et&#xa0;al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimers Dement. 2021;17:1145&#x2010;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8359457</ArticleId><ArticleId IdType="pubmed">33491853</ArticleId></ArticleIdList></Reference><Reference><Citation>Fockler J, Ashford M, Eichenbaum J, et&#xa0;al. Remote blood collection from older adults in the Brain Health Registry for plasma biomarker and genetic analysis. Alzheimers Dement. 2022; In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998146</ArticleId><ArticleId IdType="pubmed">35226409</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et&#xa0;al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2010;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, et&#xa0;al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease&#x2010;Related beta&#x2010;Amyloid Status. JAMA Neurol. 2019;76:1060&#x2010;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et&#xa0;al. The Alzheimer's Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement. 2017;13:561&#x2010;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536850</ArticleId><ArticleId IdType="pubmed">27931796</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz CG, Kremers WK, Wiste HJ, et&#xa0;al. Changing the face of neuroimaging research: comparing a new MRI de&#x2010;facing technique with popular alternatives. Neuroimage. 2021;231:117845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8154695</ArticleId><ArticleId IdType="pubmed">33582276</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Ayakta N, Seeley WW, et&#xa0;al. Multisite study of the relationships between antemortem [(11)C]PIB&#x2010;PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement. 2019;15:205&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368897</ArticleId><ArticleId IdType="pubmed">30347188</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Pejoska S, Mulligan RS, et&#xa0;al. Head&#x2010;to&#x2010;head comparison of 11C&#x2010;PiB and 18F&#x2010;AZD4694 (NAV4694) for beta&#x2010;amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880&#x2010;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">23575995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Pontecorvo MJ, Devous MD, et&#xa0;al. Positron Emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer Disease neuropathologic changes. JAMA Neurol. 2020;77:829&#x2010;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="pubmed">32338734</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et&#xa0;al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1&#x2010;15.e1&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJ, et&#xa0;al. The FAIR Guiding Principles for scientific data management and stewardship. Scientific data. 2016;3:160018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkenbihl C, Salimi Y, Domingo&#x2010;Fern&#xe1;nd&#xe9;z D, Lovestone S, Fr&#xf6;hlich H, Hofmann&#x2010;Apitius M. Evaluating the Alzheimer's disease data landscape. Alzheimer's &amp; dementia (New York, N Y). 2020;6:e12102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744022</ArticleId><ArticleId IdType="pubmed">33344750</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36216933</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Association of step counts over time with the risk of chronic disease in the All of Us Research Program.</ArticleTitle><Pagination><StartPage>2301</StartPage><EndPage>2308</EndPage><MedlinePgn>2301-2308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-02012-w</ELocationID><Abstract><AbstractText>The association between physical activity and human disease has not been examined using commercial devices linked to electronic health records. Using the electronic health records data from the All of Us Research Program, we show that step count volumes as captured by participants' own Fitbit devices were associated with risk of chronic disease across the entire human phenome. Of the 6,042 participants included in the study, 73% were female, 84% were white and 71% had a college degree, and participants had a median age of 56.7 (interquartile range 41.5-67.6) years and body mass index of 28.1 (24.3-32.9) kg&#x2009;m<sup>-2</sup>. Participants walked a median of 7,731.3 (5,866.8-9,826.8) steps per day over the median activity monitoring period of 4.0 (2.2-5.6) years with a total of 5.9 million person-days of monitoring. The relationship between steps per day and incident disease was inverse and linear for obesity (n&#x2009;=&#x2009;368), sleep apnea (n&#x2009;=&#x2009;348), gastroesophageal reflux disease (n&#x2009;=&#x2009;432) and major depressive disorder (n&#x2009;=&#x2009;467), with values above 8,200 daily steps associated with protection from incident disease. The relationships with incident diabetes (n&#x2009;=&#x2009;156) and hypertension (n&#x2009;=&#x2009;482) were nonlinear with no further risk reduction above 8,000-9,000 steps. Although validation in a more diverse sample is needed, these findings provide a real-world evidence-base for clinical guidance regarding activity levels that are necessary to reduce disease risk.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Master</LastName><ForeName>Hiral</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0019-3087</Identifier><AffiliationInfo><Affiliation>Vanderbilt Institute of Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annis</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vanderbilt Institute of Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckman</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratsimbazafy</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vanderbilt Institute of Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marginean</LastName><ForeName>Kayla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vanderbilt Institute of Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3802-8183</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9066-9431</Identifier><AffiliationInfo><Affiliation>Department Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrell</LastName><ForeName>Frank E</ForeName><Initials>FE</Initials><Identifier Source="ORCID">0000-0001-5843-3392</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roden</LastName><ForeName>Dan M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1744-2011</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Biomedical Engineering and Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brittain</LastName><ForeName>Evan L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. evan.brittain@vumc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 OD026556</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U2C OD023196</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025315</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026551</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OD023121</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026552</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025337</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL146588</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025277</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026555</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026550</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026553</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD023205</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025276</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026557</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026554</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OD023163</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD023206</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OD023176</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026548</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026549</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R61 HL158941</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Rep Med. 2022 Dec 20;3(12):100874. doi: 10.1016/j.xcrm.2022.100874.</RefSource><PMID Version="1">36543094</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2023 Dec;29(12):3270. doi: 10.1038/s41591-023-02313-8.</RefSource><PMID Version="1">37046000</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075485" MajorTopicYN="Y">Population Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072936" MajorTopicYN="N">Fitness Trackers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests. The sponsor, <i>All of Us</i> Research Program, as well as Fitbit, had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36216933</ArticleId><ArticleId IdType="pmc">PMC9671804</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02012-w</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-02012-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saint-Maurice PF, et al. Association of daily step count and step intensity with mortality among US adults. JAMA. 2020;323:1151&#x2013;1160. doi: 10.1001/jama.2020.1382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1382</ArticleId><ArticleId IdType="pmc">PMC7093766</ArticleId><ArticleId IdType="pubmed">32207799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I-M, et al. Association of step volume and intensity with all-cause mortality in older women. JAMA Intern Med. 2019;179:1105&#x2013;1112. doi: 10.1001/jamainternmed.2019.0899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.0899</ArticleId><ArticleId IdType="pmc">PMC6547157</ArticleId><ArticleId IdType="pubmed">31141585</ArticleId></ArticleIdList></Reference><Reference><Citation>Piercy KL, et al. The physical activity guidelines for Americans. JAMA. 2018;320:2020&#x2013;2028. doi: 10.1001/jama.2018.14854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.14854</ArticleId><ArticleId IdType="pmc">PMC9582631</ArticleId><ArticleId IdType="pubmed">30418471</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudor-Locke C, et al. How many steps/day are enough? For older adults and special populations. Int J. Behav. Nutr. Phys. Act. 2011;8:79. doi: 10.1186/1479-5868-8-79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5868-8-79</ArticleId><ArticleId IdType="pmc">PMC3169444</ArticleId><ArticleId IdType="pubmed">21798044</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluch AE, et al. Steps per day and all-cause mortality in middle-aged adults in the coronary artery risk development in young adults study. JAMA Netw. Open. 2021;4:e2124516&#x2013;e2124516. doi: 10.1001/jamanetworkopen.2021.24516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.24516</ArticleId><ArticleId IdType="pmc">PMC8417757</ArticleId><ArticleId IdType="pubmed">34477847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett DR, Jr., Toth LP, LaMunion SR, Crouter SE. Step counting: a review of measurement considerations and health-related applications. Sports Med. 2017;47:1303&#x2013;1315. doi: 10.1007/s40279-016-0663-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40279-016-0663-1</ArticleId><ArticleId IdType="pmc">PMC5488109</ArticleId><ArticleId IdType="pubmed">28005190</ArticleId></ArticleIdList></Reference><Reference><Citation>Freimer N, Sabatti C. The Human Phenome Project. Nat. Genet. 2003;34:15&#x2013;21. doi: 10.1038/ng0503-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0503-15</ArticleId><ArticleId IdType="pubmed">12721547</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators AoURP. The &#x2018;All of Us&#x2019; research program. N. Engl. J. Med. 2019;381:668&#x2013;676. doi: 10.1056/NEJMsr1809937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1809937</ArticleId><ArticleId IdType="pmc">PMC8291101</ArticleId><ArticleId IdType="pubmed">31412182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendergrass SA, Crawford DC. Using electronic health records to generate phenotypes for research. Curr. Protoc. Hum. Genet. 2019;100:e80&#x2013;e80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6318047</ArticleId><ArticleId IdType="pubmed">30516347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall KS, et al. Systematic review of the prospective association of daily step counts with risk of mortality, cardiovascular disease, and dysglycemia. Int J. Behav. Nutr. Phys. Act. 2020;17:78. doi: 10.1186/s12966-020-00978-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12966-020-00978-9</ArticleId><ArticleId IdType="pmc">PMC7305604</ArticleId><ArticleId IdType="pubmed">32563261</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluch AE, et al. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022;7:e219&#x2013;e228. doi: 10.1016/S2468-2667(21)00302-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(21)00302-9</ArticleId><ArticleId IdType="pmc">PMC9289978</ArticleId><ArticleId IdType="pubmed">35247352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballin M, et al. Daily step count and incident diabetes in community-dwelling 70-year-olds: a prospective cohort study. BMC Public Health. 2020;20:1830. doi: 10.1186/s12889-020-09929-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09929-2</ArticleId><ArticleId IdType="pmc">PMC7706282</ArticleId><ArticleId IdType="pubmed">33256704</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemes SA, Matchett N, Wane SL. Reactivity: an issue for short-term pedometer studies? Br. J. Sports Med. 2008;42:68&#x2013;70. doi: 10.1136/bjsm.2007.038521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsm.2007.038521</ArticleId><ArticleId IdType="pubmed">18178685</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller D, et al. Reliability and validity of commercially available wearable devices for measuring steps, energy expenditure, and heart rate: systematic review. JMIR Mhealth Uhealth. 2020;8:e18694. doi: 10.2196/18694.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/18694</ArticleId><ArticleId IdType="pmc">PMC7509623</ArticleId><ArticleId IdType="pubmed">32897239</ArticleId></ArticleIdList></Reference><Reference><Citation>Garriga A, Sempere-Rubio N, Molina-Prados MJ, Faubel R. Impact of seasonality on physical activity: a systematic review. Int J. Environ. Res Public Health. 2021;19:2. doi: 10.3390/ijerph19010002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19010002</ArticleId><ArticleId IdType="pmc">PMC8751121</ArticleId><ArticleId IdType="pubmed">35010262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudor-Locke C, et al. Normative steps/day values for older adults: NHANES 2005-2006. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 2013;68:1426&#x2013;1432. doi: 10.1093/gerona/glt116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glt116</ArticleId><ArticleId IdType="pubmed">23913932</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer, J., Wasmann, M., Heuten, W., El Ali, A. &amp; Boll, S. C. Identification and classification of usage patterns in long-term activity tracking. In Proc. 2017 CHI Conference on Human Factors in Computing Systems, 667&#x2013;678 (Association for Computing Machinery, 2017).</Citation></Reference><Reference><Citation>Tudor-Locke C, et al. How many days of pedometer monitoring predict weekly physical activity in adults? Prev. Med. 2005;40:293&#x2013;298. doi: 10.1016/j.ypmed.2004.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2004.06.003</ArticleId><ArticleId IdType="pubmed">15533542</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen RT, et al. Effectiveness of physical activity monitors in adults: systematic review and meta-analysis. Brit. Med. J. 2022;376:e068047. doi: 10.1136/bmj-2021-068047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068047</ArticleId><ArticleId IdType="pmc">PMC8791066</ArticleId><ArticleId IdType="pubmed">35082116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuch FB, et al. Physical activity and incident depression: a meta-analysis of prospective cohort studies. Am. J. Psychiatry. 2018;175:631&#x2013;648. doi: 10.1176/appi.ajp.2018.17111194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2018.17111194</ArticleId><ArticleId IdType="pubmed">29690792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelson M, et al. Obstructive sleep apnea syndrome, objectively measured physical activity and exercise training interventions: a systematic review and meta-analysis. Front Neurol. 2018;9:73. doi: 10.3389/fneur.2018.00073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00073</ArticleId><ArticleId IdType="pmc">PMC5827163</ArticleId><ArticleId IdType="pubmed">29520251</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall SJ, et al. Translating physical activity recommendations into a pedometer-based step goal: 3000 steps in 30 minutes. Am. J. Prev. Med. 2009;36:410&#x2013;415. doi: 10.1016/j.amepre.2009.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2009.01.021</ArticleId><ArticleId IdType="pubmed">19362695</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudor-Locke C, et al. How fast is fast enough? Walking cadence (steps/min) as a practical estimate of intensity in adults: a narrative review. Br. J. Sports Med. 2018;52:776. doi: 10.1136/bjsports-2017-097628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsports-2017-097628</ArticleId><ArticleId IdType="pmc">PMC6029645</ArticleId><ArticleId IdType="pubmed">29858465</ArticleId></ArticleIdList></Reference><Reference><Citation>Troiano RP, et al. Physical activity in the United States measured by accelerometer. Med Sci. Sports Exerc. 2008;40:181. doi: 10.1249/mss.0b013e31815a51b3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/mss.0b013e31815a51b3</ArticleId><ArticleId IdType="pubmed">18091006</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooke SM, et al. Concurrent validity of wearable activity trackers under free-living conditions. J. Strength Cond. Res. 2017;31:1097&#x2013;1106. doi: 10.1519/JSC.0000000000001571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1519/JSC.0000000000001571</ArticleId><ArticleId IdType="pubmed">27465631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedesco S, et al. Validity evaluation of the Fitbit Charge2 and the Garmin vivosmart HR+ in free-living environments in an older adult cohort. JMIR Mhealth Uhealth. 2019;7:e13084. doi: 10.2196/13084.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13084</ArticleId><ArticleId IdType="pmc">PMC6607774</ArticleId><ArticleId IdType="pubmed">31219048</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Joss MAH, Embree K, Murphy SN. Data model harmonization for the All Of Us Research Program: transforming i2b2 data into the OMOP common data model. PLoS ONE. 2019;14:e0212463. doi: 10.1371/journal.pone.0212463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez AH, et al. The All of Us Research Program: data quality, utility, and diversity. Patterns. 2022;3:100570. doi: 10.1016/j.patter.2022.100570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patter.2022.100570</ArticleId><ArticleId IdType="pmc">PMC9403360</ArticleId><ArticleId IdType="pubmed">36033590</ArticleId></ArticleIdList></Reference><Reference><Citation>The Observational Medical Outcomes Partnership. OMOP Common Data Model.https://ohdsi.github.io/CommonDataModel/ (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng NS, et al. PheMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records. J. Am. Med Inf. Assoc. 2020;27:1675&#x2013;1687. doi: 10.1093/jamia/ocaa104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa104</ArticleId><ArticleId IdType="pmc">PMC7751140</ArticleId><ArticleId IdType="pubmed">32974638</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau, T. A package for survival analysis in R, version 2.38 (2015).</Citation></Reference><Reference><Citation>Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Med. Res. Methodol. 2014;14:75. doi: 10.1186/1471-2288-14-75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-75</ArticleId><ArticleId IdType="pmc">PMC4051964</ArticleId><ArticleId IdType="pubmed">24903709</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell, F. E., Jr. rms: regression modeling strategies (R package version 5) (2016).</Citation></Reference><Reference><Citation>Marrie RA, Dawson NV, Garland A. Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. J. Clin. Epidemiol. 2009;62:511&#x2013;517.e511. doi: 10.1016/j.jclinepi.2008.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2008.05.015</ArticleId><ArticleId IdType="pubmed">19135859</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell, F. E. Jr &amp; Dupont, M. C. The hmisc package (R package version 3) (2006).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36219197</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>220</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Chronic TREM2 activation exacerbates A&#x3b2;-associated tau seeding and spreading.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20220654</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20220654</ELocationID><Abstract><AbstractText>Variants in the triggering receptor expressed on myeloid cells 2 (TREM2) gene are associated with increased risk for late-onset AD. Genetic loss of or decreased TREM2 function impairs the microglial response to amyloid-&#x3b2; (A&#x3b2;) plaques, resulting in more diffuse A&#x3b2; plaques and increased peri-plaque neuritic dystrophy and AD-tau seeding. Thus, microglia and TREM2 are at a critical intersection of A&#x3b2; and tau pathologies in AD. Since genetically decreasing TREM2 function increases A&#x3b2;-induced tau seeding, we hypothesized that chronically increasing TREM2 signaling would decrease amyloid-induced tau-seeding and spreading. Using a mouse model of amyloidosis in which AD-tau is injected into the brain to induce A&#x3b2;-dependent tau seeding/spreading, we found that chronic administration of an activating TREM2 antibody increases peri-plaque microglial activation but surprisingly increases peri-plaque NP-tau pathology and neuritic dystrophy, without altering A&#x3b2; plaque burden. Our data suggest that sustained microglial activation through TREM2 that does not result in strong amyloid removal may exacerbate A&#x3b2;-induced tau pathology, which may have important clinical implications.</AbstractText><CopyrightInformation>&#xa9; 2022 Jain et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Nimansha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5360-5466</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Caroline A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-0256-0947</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-4743-926X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG047644</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007200</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021629</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Exp Med. 2023 Jan 2;220(1):e20221850. doi: 10.1084/jem.20221850.</RefSource><PMID Version="1">36399126</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: J.D. Ulrich and D.M. Holtzman reported a patent to anti-TREM2 agonist antibodies pending. D.M. Holtzman reported &#x201c;other&#x201d; from C2N Diagnostics, Genentech, Denali, Cajal Neurosciences, and Alector outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36219197</ArticleId><ArticleId IdType="pmc">PMC9559604</ArticleId><ArticleId IdType="doi">10.1084/jem.20220654</ArticleId><ArticleId IdType="pii">213537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi, Y., Liu C.C., Painter M.M., Chen X.F., Verbeeck C., Zheng H., Li X., Rademakers R., Kang S.S., Xu H., et al. . 2015. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J. Biol. Chem. 290:26043&#x2013;26050. 10.1074/jbc.M115.679043</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.679043</ArticleId><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky, O., and Weiner H.L.. 2018. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 19:622&#x2013;635. 10.1038/s41583-018-0057-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0057-5</ArticleId><ArticleId IdType="pmc">PMC7255106</ArticleId><ArticleId IdType="pubmed">30206328</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, Q., Danao J., Talreja S., Wen P., Yin J., Sun N., Li C.M., Chui D., Tran D., Koirala S., et al. . 2018. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer&#x2019;s disease variant Trem2R47H on murine myeloid cell function. J. Biol. Chem. 293:12620&#x2013;12633. 10.1074/jbc.RA118.001848</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.001848</ArticleId><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cignarella, F., Filipello F., Bollman B., Cantoni C., Locca A., Mikesell R., Manis M., Ibrahim A., Deng L., Benitez B.A., et al. . 2020. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol. 140:513&#x2013;534. 10.1007/s00401-020-02193-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02193-z</ArticleId><ArticleId IdType="pmc">PMC7498497</ArticleId><ArticleId IdType="pubmed">32772264</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna, M., and Wang Y.. 2016. TREM2 variants: New keys to decipher Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 17:201&#x2013;207. 10.1038/nrn.2016.7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.7</ArticleId><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, X., Qiao J., Liu S., Wu M., and Gu W.. 2021. Mechanism of TREM2/DAP12 complex affecting &#x3b2;-amyloid plaque deposition in Alzheimer&#x2019;s disease modeled mice through mediating inflammatory response. Brain Res. Bull. 166:21&#x2013;28. 10.1016/j.brainresbull.2020.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2020.10.006</ArticleId><ArticleId IdType="pubmed">33053435</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska, A., Keren-Shaul H., Weiner A., Colonna M., Schwartz M., and Amit I.. 2018. Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell. 173:1073&#x2013;1081. 10.1016/j.cell.2018.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.003</ArticleId><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues, H.S., Portugal C.C., Socodato R., and Relvas J.B.. 2016. Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair. Front. Cell Dev. Biol. 4:71. 10.3389/fcell.2016.00071</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2016.00071</ArticleId><ArticleId IdType="pmc">PMC4923166</ArticleId><ArticleId IdType="pubmed">27551677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger, D.C., Wang S., Brioschi S., Shao Z., Green L., Case R., Yoo D., Weishuhn D., Rathanaswami P., Bradley J., et al. . 2021. Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 118:e2017742118. 10.1073/PNAS.2017742118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2017742118</ArticleId><ArticleId IdType="pmc">PMC7826333</ArticleId><ArticleId IdType="pubmed">33446504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassler, M., Rappaport M.S., Cu&#xf1;o C.B., and George J.. 2021. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer&#x2019;s disease models. J. Neuroinflammation. 18:19. 10.1186/s12974-020-01980-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01980-5</ArticleId><ArticleId IdType="pmc">PMC7796541</ArticleId><ArticleId IdType="pubmed">33422057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux, F., and Guilliams M.. 2016. Tissue-resident macrophage ontogeny and homeostasis. Immunity. 44:439&#x2013;449. 10.1016/j.immuni.2016.02.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.02.024</ArticleId><ArticleId IdType="pubmed">26982352</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze, M., Chen Y., Parhizkar S., Jain N., Strickland M.R., Serrano J.R., Colonna M., Ulrich J.D., and Holtzman D.M.. 2021. Activated microglia mitigate A&#x3b2;-associated tau seeding and spreading. J. Exp. Med. 218:e20210542. 10.1084/jem.20210542</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210542</ArticleId><ArticleId IdType="pmc">PMC8190588</ArticleId><ArticleId IdType="pubmed">34100905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze, M., Leyns C.E.G., and Holtzman D.M.. 2018. New insights into the role of TREM2 in Alzheimer&#x2019;s disease. Mol. Neurodegener. 13:66. 10.1186/s13024-018-0298-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0298-9</ArticleId><ArticleId IdType="pmc">PMC6302500</ArticleId><ArticleId IdType="pubmed">30572908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze, M., Leyns C.E., Sauerbeck A.D., St-Pierre M.K., Xiong M., Kim N., Serrano J.R., Tremblay M.&#xc8;., Kummer T.T., Colonna M., et al. . 2020. Impact of TREM2R47Hvariant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest. 130:4954&#x2013;4968. 10.1172/JCI138179</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138179</ArticleId><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro, R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S.K., Younkin S., et al. . 2013. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:117&#x2013;127. 10.1056/nejmoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, J.L., Narasimhan S., Changolkar L., He Z., Stieber A., Zhang B., Gathagan R.J., Iba M., McBride J.D., Trojanowski J.Q., and Lee V.M.Y.. 2016. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J. Exp. Med. 213:2635&#x2013;2654. 10.1084/jem.20160833</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160833</ArticleId><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Z., Guo J.L., McBride J.D., Narasimhan S., Kim H., Changolkar L., Zhang B., Gathagan R.J., Yue C., Dengler C., et al. . 2018. Amyloid-&#x3b2; plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 24:29&#x2013;38. 10.1038/nm.4443</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4443</ArticleId><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman, D.M., Morris J.C., &amp; Goate A.M.. 2011. Alzheimer&#x2019;s disease: The challenge of the second century. Sci. Transl. Med. 3:77sr1. 10.1126/scitranslmed.3002369</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson, T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.v., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. . 2013. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:107&#x2013;116. 10.1056/nejmoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul, H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. . 2017. A unique microglia type Associated with restricting development of Alzheimer&#x2019;s disease. Cell. 169:1276&#x2013;1290.e17. 10.1016/j.cell.2017.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann, S., Madore C., Cialic R., Baufeld C., Calcagno N., el Fatimy R., Beckers L., O&#x2019;Loughlin E., Xu Y., Fanek Z., et al. . 2017. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 47:566&#x2013;581.e9. 10.1016/j.immuni.2017.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanier, L.L., Corliss B., Wu J., and Phillips J.H.. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 8:693&#x2013;701. 10.1016/S1074-7613(00)80574-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80574-9</ArticleId><ArticleId IdType="pubmed">9655483</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns, C.E.G., Gratuze M., Narasimhan S., Jain N., Koscal L.J., Jiang H., Manis M., Colonna M., Lee V.M.Y., Ulrich J.D., and Holtzman D.M.. 2019. TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22:1217&#x2013;1222. 10.1038/s41593-019-0433-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0433-0</ArticleId><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns, C.E.G., Ulrich J.D., Finn M.B., Stewart F.R., Koscal L.J., Serrano J., Robinson G.O., Anderson E., Colonna M., and Holtzman D.M.. 2017. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. USA. 114:11524&#x2013;11529. 10.1073/pnas.1710311114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Long, J.M., and Holtzman D.M.. 2019. Alzheimer disease: An update on pathobiology and treatment strategies. Cell. 179:312&#x2013;339. 10.1016/j.cell.2019.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri, F., Snaidero N., Kleinberger G., Madore C., Daria A., Werner G., Krasemann S., Capell A., Tr&#xfc;mbach D., Wurst W., et al. . 2017. TREM 2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 18:1186&#x2013;1198. 10.15252/embr.201743922</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201743922</ArticleId><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del Tredici K., et al. . 2012. Correlation of alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71:362&#x2013;381. 10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea, M.G., Dom&#xed;nguez-Andr&#xe9;s J., Barreiro L.B., Chavakis T., Divangahi M., Fuchs E., Joosten L.A.B., van der Meer J.W.M., Mhlanga M.M., Mulder W.J.M., et al. . 2020. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20:375&#x2013;388. 10.1038/s41577-020-0285-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0285-6</ArticleId><ArticleId IdType="pmc">PMC7186935</ArticleId><ArticleId IdType="pubmed">32132681</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent, A.A., Lin K., van Lengerich B., Lianoglou S., Przybyla L., Davis S.S., Llapashtica C., Wang J., Kim D.J., Xia D., et al. . 2020. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 105:837&#x2013;854.e9. 10.1016/j.neuron.2019.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.12.007</ArticleId><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley, H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., van Eldik L., et al. . 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26:10129&#x2013;10140. 10.1523/JNEUROSCI.1202-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Price, B.R., Sudduth T.L., Weekman E.M., Johnson S., Hawthorne D., Woolums A., and Wilcock D.M.. 2020. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J. Neuroinflammation. 17:238. 10.1186/s12974-020-01915-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01915-0</ArticleId><ArticleId IdType="pmc">PMC7427742</ArticleId><ArticleId IdType="pubmed">32795308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff, R.M. 2016. How neuroinflammation contributes to neurodegeneration. Science. 353:777&#x2013;783. 10.1126/science.aag2590</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan, Z., Pathak D., Venkatesan Kalavai S., Yoshii-Kitahara A., Muraoka S., Bhatt N., Takamatsu-Yukawa K., Hu J., Wang Y., Hersh S., et al. . 2021. Alzheimer&#x2019;s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain. 144:288&#x2013;309. 10.1093/brain/awaa376</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa376</ArticleId><ArticleId IdType="pmc">PMC7880668</ArticleId><ArticleId IdType="pubmed">33246331</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow, K., Monroe K.M., Kleinberger G., Cantuti-Castelvetri L., Parhizkar S., Xia D., Willem M., Werner G., Pettkus N., Brunner B., et al. . 2020. Enhancing protective microglial activities with a dual function TREM 2 antibody to the stalk region. EMBO Mol. Med. 12:e11227. 10.15252/emmm.201911227</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland, T.K., Song W.M., Huang S.C., Ulrich J.D., Sergushichev A., Beatty W.L., Loboda A.A., Zhou Y., Cairns N.J., Kambal A., et al. . 2017. TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell. 170:649&#x2013;663.e13. 10.1016/j.cell.2017.07.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich, J.D., Ulland T.K., Colonna M., and Holtzman D.M.. 2017. Elucidating the role of TREM2 in Alzheimer&#x2019;s disease. Neuron. 94:237&#x2013;248. 10.1016/j.neuron.2017.02.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.042</ArticleId><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S., Mustafa M., Yuede C.M., Salazar S.V., Kong P., Long H., Ward M., Siddiqui O., Paul R., Gilfillan S., et al. . 2020. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x2019;s disease model. J. Exp. Med. 217:e20200785. 10.1084/jem.20200785</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200785</ArticleId><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H., et al. . 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 160:1061&#x2013;1071. 10.1016/j.cell.2015.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Ulland T.K., Ulrich J.D., Song W., Tzaferis J.A., Hole J.T., Yuan P., Mahan T.E., Shi Y., Gilfillan S., et al. . 2016. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213:667&#x2013;675. 10.1084/jem.20151948</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, P., Condello C., Keene C.D., Wang Y., Bird T.D., Paul S.M., Luo W., Colonna M., Baddeley D., and Grutzendler J.. 2016. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 90:724&#x2013;739. 10.1016/j.neuron.2016.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36251300</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>1250</StartPage><EndPage>1259</EndPage><MedlinePgn>1250-1259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.3392</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes.</AbstractText><AbstractText Label="OBJECTIVE">To analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">TRAILBLAZER-ALZ was a randomized, double-blind, placebo-controlled clinical trial conducted from December 18, 2017, to December 4, 2020, across 56 sites in the US and Canada. Exploratory biomarkers were prespecified with the post hoc addition of plasma glial fibrillary acidic protein and amyloid-&#x3b2;. Men and women aged 60 to 85 years with gradual and progressive change in memory function for at least 6 months were included. A total of 1955 participants were assessed for eligibility. Key eligibility criteria include Mini-Mental State Examination scores of 20 to 28 and elevated amyloid and intermediate tau levels.</AbstractText><AbstractText Label="INTERVENTIONS">Randomized participants received donanemab or placebo every 4 weeks for up to 72 weeks. The first 3 doses of donanemab were given at 700 mg and then increased to 1400 mg with blinded dose reductions as specified based on amyloid reduction.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Change in plasma biomarker levels after donanemab treatment.</AbstractText><AbstractText Label="RESULTS">In TRAILBLAZER-ALZ, 272 participants (mean [SD] age, 75.2 [5.5] years; 145 [53.3%] female) were randomized. Plasma levels of phosphorylated tau217 (pTau217) and glial fibrillary acidic protein were significantly lower with donanemab treatment compared with placebo as early as 12 weeks after the start of treatment (least square mean change difference vs placebo, -0.04 [95% CI, -0.07 to -0.02]; P&#x2009;=&#x2009;.002 and -0.04 [95% CI, -0.07 to -0.01]; P&#x2009;=&#x2009;.01, respectively). No significant differences in plasma levels of amyloid-&#x3b2; 42/40 and neurofilament light chain were observed between treatment arms at the end of treatment. Changes in plasma pTau217 and glial fibrillary acidic protein were significantly correlated with the Centiloid percent change in amyloid (Spearman rank correlation coefficient [R]&#x2009;=&#x2009;0.484 [95% CI, 0.359-0.592]; P&#x2009;&lt;&#x2009;.001 and R&#x2009;=&#x2009;0.453 [95% CI, 0.306-0.579]; P&#x2009;&lt;&#x2009;.001, respectively) following treatment. Additionally, plasma levels of pTau217 and glial fibrillary acidic protein were significantly correlated at baseline and following treatment (R&#x2009;=&#x2009;0.399 [95% CI, 0.278-0.508], P&#x2009;&lt;&#x2009;.001 and R&#x2009;=&#x2009;0.393 [95% CI, 0.254-0.517]; P&#x2009;&lt;&#x2009;.001, respectively).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Significant reductions in plasma biomarkers pTau217 and glial fibrillary acidic protein compared with placebo were observed following donanemab treatment in patients with early symptomatic Alzheimer disease. These easily accessible plasma biomarkers might provide additional evidence of Alzheimer disease pathology change through anti-amyloid therapy. Usefulness in assessing treatment response will require further evaluation.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT03367403.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnham</LastName><ForeName>Samantha C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schade</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbinin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Emily C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03367403</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Pontecorvo, Lu, Burnham, Schade, Shcherbinin, Collins, Sims, Mintun, and Dage are minor stockholders of Eli Lilly and Company. Dr Burnham reported a patent for 20140086836, a method for detection of a neurological disease, issued. Dr Dage reported personal fees, nonfinancial support, and research support from Eli Lilly and Company; personal fees from AlzPath Inc, Genotix Biotechnologies Inc, Gates Ventures, Karuna Therapeutics, and Cognito; nonfinancial support from ADx Neurosciences; grants from Roche Diagnostics outside the submitted work; and is an inventor on patents associated with the pTau217 assay used in this work. Drs Shcherbinin, Sims, and Mintun have a patent for Eli Lilly and Company relevant to this research. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>17</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36251300</ArticleId><ArticleId IdType="pmc">PMC9577883</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.3392</ArticleId><ArticleId IdType="pii">2797022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>2021 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2021;17(3):327-406. doi:10.1002/alz.12328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12328</ArticleId><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloret A, Esteve D, Lloret MA, et al. . When does Alzheimer&#x2019;s disease really start? the role of biomarkers. Int J Mol Sci. 2019;20(22):E5536. doi:10.3390/ijms20225536</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20225536</ArticleId><ArticleId IdType="pmc">PMC6888399</ArticleId><ArticleId IdType="pubmed">31698826</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer&#x2019;s disease. EMBO Mol Med. 2022;14(1):e14408. doi:10.15252/emmm.202114408</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202114408</ArticleId><ArticleId IdType="pmc">PMC8749476</ArticleId><ArticleId IdType="pubmed">34859598</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Verberk IMW, Thijssen EH, et al. . Blood-based biomarkers for Alzheimer&#x2019;s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66-77. doi:10.1016/S1474-4422(21)00361-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00361-6</ArticleId><ArticleId IdType="pubmed">34838239</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Berron D, Smith R, et al. . Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149-156. doi:10.1001/jamaneurol.2020.4201</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4201</ArticleId><ArticleId IdType="pmc">PMC7653537</ArticleId><ArticleId IdType="pubmed">33165506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. . Longitudinal plasma p-tau217 is increased in early stages of Alzheimer&#x2019;s disease. Brain. 2020;143(11):3234-3241. doi:10.1093/brain/awaa286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa286</ArticleId><ArticleId IdType="pmc">PMC7719022</ArticleId><ArticleId IdType="pubmed">33068398</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Pedrini S, Stoops E, et al. . Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer&#x2019;s disease. Transl Psychiatry. 2021;11(1):27. doi:10.1038/s41398-020-01137-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01137-1</ArticleId><ArticleId IdType="pmc">PMC7801513</ArticleId><ArticleId IdType="pubmed">33431793</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Janelidze S, Smith R, et al. . Plasma GFAP is an early marker of amyloid-&#x3b2; but not tau pathology in Alzheimer&#x2019;s disease. Brain. 2021;144(11):3505-3516. doi:10.1093/brain/awab223</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab223</ArticleId><ArticleId IdType="pmc">PMC8677538</ArticleId><ArticleId IdType="pubmed">34259835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Leuzy A, Lim YM, et al. . Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7(1):5. doi:10.1186/s40478-018-0649-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0649-3</ArticleId><ArticleId IdType="pmc">PMC6327431</ArticleId><ArticleId IdType="pubmed">30626432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557-566. doi:10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, Verberk IMW, Vanbrabant J, et al. . Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer&#x2019;s disease. Sci Rep. 2021;11(1):9736-9736. doi:10.1038/s41598-021-89004-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89004-x</ArticleId><ArticleId IdType="pmc">PMC8102604</ArticleId><ArticleId IdType="pubmed">33958661</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, et al. . Performance of fully automated plasma assays as screening tests for Alzheimer disease-related &#x3b2;-amyloid status. JAMA Neurol. 2019;76(9):1060-1069. doi:10.1001/jamaneurol.2019.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Palmqvist S, Leuzy A, et al. . Detecting amyloid positivity in early Alzheimer&#x2019;s disease using combinations of plasma A&#x3b2;42/A&#x3b2;40 and p-tau. Alzheimers Dement. 2021. doi:10.1002/alz.052117</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.052117</ArticleId><ArticleId IdType="pubmed">34151519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe SL, Willis BA, Hawdon A, et al. . Donanemab (LY3002813) dose-escalation study in Alzheimer&#x2019;s disease. Alzheimers Dement (N Y). 2021;7(1):e12112. doi:10.1002/trc2.12112</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12112</ArticleId><ArticleId IdType="pmc">PMC7882532</ArticleId><ArticleId IdType="pubmed">33614890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe SL, Duggan Evans C, Shcherbinin S, et al. . Donanemab (LY3002813) phase 1b study in Alzheimer&#x2019;s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8(4):414-424. doi:10.14283/jpad.2021.56</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2021.56</ArticleId><ArticleId IdType="pubmed">34585215</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels AM, Rentz DM, Case M, Lauzon S, Sims JR. Integrated Alzheimer&#x2019;s Disease Rating Scale: Clinically meaningful change estimates. Alzheimers Dement (N Y). 2022;8(1):e12312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169866</ArticleId><ArticleId IdType="pubmed">35676941</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S, Aisen PS, Barkhof F, et al. . Two randomized phase 3 studies of aducanumab in early Alzheimer&#x2019;s disease. J Prev Alzheimers Dis. 2022;9(2):197-210. doi:10.14283/jpad.2022.30</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2022.30</ArticleId><ArticleId IdType="pubmed">35542991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Lasser RA, Dorflinger E, et al. ; SCarlet RoAD Investigators . A phase III randomized trial of gantenerumab in prodromal Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2017;9(1):95. doi:10.1186/s13195-017-0318-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0318-y</ArticleId><ArticleId IdType="pmc">PMC5723032</ArticleId><ArticleId IdType="pubmed">29221491</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Honigberg LA, Cho W, et al. . Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer&#x2019;s disease (BLAZE). Alzheimers Res Ther. 2018;10(1):96. doi:10.1186/s13195-018-0424-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0424-5</ArticleId><ArticleId IdType="pmc">PMC6146627</ArticleId><ArticleId IdType="pubmed">30231896</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Liu X, Liu T, et al. . Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes. Glia. 2020;68(5):878-897. doi:10.1002/glia.23734</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23734</ArticleId><ArticleId IdType="pubmed">31626364</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Mil&#xe0;-Alom&#xe0; M, Vrillon A, et al. ; Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer&#x2019;s and Families (ALFA) study, and BioCogBank Paris Lariboisi&#xe8;re cohort . Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471-1483. doi:10.1001/jamaneurol.2021.3671</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3671</ArticleId><ArticleId IdType="pmc">PMC8524356</ArticleId><ArticleId IdType="pubmed">34661615</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost GR, Li YM. The role of astrocytes in amyloid production and Alzheimer&#x2019;s disease. Open Biol. 2017;7(12):170228. doi:10.1098/rsob.170228</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.170228</ArticleId><ArticleId IdType="pmc">PMC5746550</ArticleId><ArticleId IdType="pubmed">29237809</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Teunissen CE, Zetterberg H, et al. . Head-to-head comparison of 8 plasma amyloid-&#x3b2; 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375-1382. doi:10.1001/jamaneurol.2021.3180</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3180</ArticleId><ArticleId IdType="pmc">PMC8453354</ArticleId><ArticleId IdType="pubmed">34542571</ArticleId></ArticleIdList></Reference><Reference><Citation>West T, Kirmess KM, Meyer MR, et al. . A blood-based diagnostic test incorporating plasma A&#x3b2;42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021;16(1):30. doi:10.1186/s13024-021-00451-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00451-6</ArticleId><ArticleId IdType="pmc">PMC8088704</ArticleId><ArticleId IdType="pubmed">33933117</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589. doi:10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Zhang J, Ye F, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Plasma neurofilament light chain levels in Alzheimer&#x2019;s disease. Neurosci Lett. 2017;650:60-64. doi:10.1016/j.neulet.2017.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.04.027</ArticleId><ArticleId IdType="pubmed">28428015</ArticleId></ArticleIdList></Reference><Reference><Citation>Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. . Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128-1140. doi:10.1002/alz.12466</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12466</ArticleId><ArticleId IdType="pmc">PMC8957642</ArticleId><ArticleId IdType="pubmed">34569696</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791-799. doi:10.1001/jamaneurol.2019.0765</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer&#x2019;s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21(8):726-734. doi:10.1016/S1474-4422(22)00168-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00168-5</ArticleId><ArticleId IdType="pubmed">35643092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennstr&#xf6;m M, Janelidze S, Nilsson KPR, et al. ; Netherlands Brain Bank . Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. Acta Neuropathol Commun. 2022;10(1):3. doi:10.1186/s40478-021-01307-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01307-2</ArticleId><ArticleId IdType="pmc">PMC8734209</ArticleId><ArticleId IdType="pubmed">34991721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer&#x2019;s disease. Sci Adv. 2020;6(16):eaaz2387. doi:10.1126/sciadv.aaz2387</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35. doi:10.1007/s00401-009-0619-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0619-8</ArticleId><ArticleId IdType="pmc">PMC2799634</ArticleId><ArticleId IdType="pubmed">20012068</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36257314</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>22</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>SYK coordinates neuroprotective microglial responses in neurodegenerative disease.</ArticleTitle><Pagination><StartPage>4135</StartPage><EndPage>4152.e22</EndPage><MedlinePgn>4135-4152.e22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2022.09.030</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(22)01249-1</ELocationID><Abstract><AbstractText>Recent studies have begun to reveal critical roles for the brain's professional phagocytes, microglia, and their receptors in the control of neurotoxic amyloid beta (A&#x3b2;) and myelin debris accumulation in neurodegenerative disease. However, the critical intracellular molecules that orchestrate neuroprotective functions of microglia remain poorly understood. In our studies, we find that targeted deletion of SYK in microglia leads to exacerbated A&#x3b2; deposition, aggravated neuropathology, and cognitive defects in the 5xFAD mouse model of Alzheimer's disease (AD). Disruption of SYK signaling in this AD model was further shown to impede the development of disease-associated microglia (DAM), alter AKT/GSK3&#x3b2;-signaling, and restrict A&#x3b2; phagocytosis by microglia. Conversely, receptor-mediated activation of SYK limits A&#x3b2; load. We also found that SYK critically regulates microglial phagocytosis and DAM acquisition in demyelinating disease. Collectively, these results broaden our understanding of the key innate immune signaling molecules that instruct beneficial microglial functions in response to neurotoxic material.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ennerfelt</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA; Neuroscience Graduate Program, UVA, Charlottesville, VA 22908, USA; Cell and Molecular Biology Graduate Training Program, UVA, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holliday</LastName><ForeName>Coco</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zengeler</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA; Neuroscience Graduate Program, UVA, Charlottesville, VA 22908, USA; Cell and Molecular Biology Graduate Training Program, UVA, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voithofer</LastName><ForeName>Gabrielle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolte</LastName><ForeName>Ashley C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA; Department of Microbiology, Immunology and Cancer Biology, UVA, Charlottesville, VA 22908, USA; Medical Scientist Training Program, UVA, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lammert</LastName><ForeName>Catherine R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA; Neuroscience Graduate Program, UVA, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulas</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulland</LastName><ForeName>Tyler K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukens</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia (UVA), Charlottesville, VA 22908, USA; Neuroscience Graduate Program, UVA, Charlottesville, VA 22908, USA; Cell and Molecular Biology Graduate Training Program, UVA, Charlottesville, VA 22908, USA; Department of Microbiology, Immunology and Cancer Biology, UVA, Charlottesville, VA 22908, USA; Medical Scientist Training Program, UVA, Charlottesville, VA 22908, USA. Electronic address: jrl7n@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007267</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037639</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI007496</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S06 GM008136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS106383</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071996</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG069396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG070973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK007646</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008328</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C000606897">Syk protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2022 Oct 27;185(22):4043-4045. doi: 10.1016/j.cell.2022.09.043.</RefSource><PMID Version="1">36306731</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">SYK</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">disease-associated microglia</Keyword><Keyword MajorTopicYN="N">experimental autoimmune encephalomyelitis</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">neuroimmunology</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36257314</ArticleId><ArticleId IdType="mid">NIHMS1838973</ArticleId><ArticleId IdType="pmc">PMC9617784</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.09.030</ArticleId><ArticleId IdType="pii">S0092-8674(22)01249-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Back SA, Tuohy TMF, Chen H, Wallingford N, Craig A, Struve J, Luo NL, Banine F, Liu Y, Chang A, et al. (2005). Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 11, 966&#x2013;972. 10.1038/nm1279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1279</ArticleId><ArticleId IdType="pubmed">16086023</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista SJ, Still KM, Johanson D, Thompson JA, O&#x2019;Brien CA, Lukens JR, and Harris TH (2020). Gasdermin-D-dependent IL-1&#x3b1; release from microglia promotes protective immunity during chronic Toxoplasma gondii infection. Nat. Commun. 11, 3687. 10.1038/s41467-020-17491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17491-z</ArticleId><ArticleId IdType="pmc">PMC7378823</ArticleId><ArticleId IdType="pubmed">32703941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, et al. (2017). TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener. 12, 74. 10.1186/s13024-017-0216-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0216-6</ArticleId><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MR, Radford SE, and Hewitt EW (2020). Modulation of beta-Amyloid Fibril Formation in Alzheimer&#x2019;s Disease by Microglia and Infection. Front. Mol. Neurosci. 13, 609073. 10.3389/fnmol.2020.609073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.609073</ArticleId><ArticleId IdType="pmc">PMC7725705</ArticleId><ArticleId IdType="pubmed">33324164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu E, Mychasiuk R, Hibbs ML, and Semple BD (2021). Dysregulated phosphoinositide 3-kinase signaling in microglia: shaping chronic neuroinflammation. J. Neuroinflammation 18, 276. 10.1186/s12974-021-02325-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02325-6</ArticleId><ArticleId IdType="pmc">PMC8627624</ArticleId><ArticleId IdType="pubmed">34838047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CG, Lee H, and Lee SB (2018). Mechanisms of protein toxicity in neurodegenerative diseases. Cell. Mol. Life Sci. 75, 3159&#x2013;3180. 10.1007/s00018-018-2854-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2854-4</ArticleId><ArticleId IdType="pmc">PMC6063327</ArticleId><ArticleId IdType="pubmed">29947927</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YH, Kim HY, Yoon BR, Kang YJ, and Lee WW (2019). Suppression of Syk activation by resveratrol inhibits MSU crystal-induced inflammation in human monocytes. J. Mol. Med. (Berl.) 97, 369&#x2013;383. 10.1007/s00109-018-01736-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-018-01736-y</ArticleId><ArticleId IdType="pubmed">30637441</ArticleId></ArticleIdList></Reference><Reference><Citation>Cignarella F, Filipello F, Bollman B, Cantoni C, Locca A, Mikesell R, Manis M, Ibrahim A, Deng L, Benitez BA, et al. (2020). TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol. 140, 513&#x2013;534. 10.1007/s00401-020-02193-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02193-z</ArticleId><ArticleId IdType="pmc">PMC7498497</ArticleId><ArticleId IdType="pubmed">32772264</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark EA, and Giltiay NV (2018). CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity. Front. Immunol. 9, 2235. 10.3389/fimmu.2018.02235.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02235</ArticleId><ArticleId IdType="pmc">PMC6173129</ArticleId><ArticleId IdType="pubmed">30323814</ArticleId></ArticleIdList></Reference><Reference><Citation>Colie S, Sarroca S, Palenzuela R, Garcia I, Matheu A, Corpas R, Dotti CG, Esteban JA, Sanfeliu C, and Nebreda AR (2017). Neuronal p38&#x3b1; mediates synaptic and cognitive dysfunction in an Alzheimer&#x2019;s mouse model by controlling &#x3b2;-amyloid production. Sci. Rep. 7, 45306. 10.1038/srep45306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep45306</ArticleId><ArticleId IdType="pmc">PMC5374488</ArticleId><ArticleId IdType="pubmed">28361984</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, and Grutzendler J (2018). Microglia-Mediated Neuroprotection, TREM2, and Alzheimer&#x2019;s Disease: Evidence From Optical Imaging. Biol Psychiatry 83, 377&#x2013;387. 10.1016/j.biopsych.2017.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.10.007</ArticleId><ArticleId IdType="pmc">PMC5767550</ArticleId><ArticleId IdType="pubmed">29169609</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, and Grutzendler J (2015). Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun. 6, 6176. 10.1038/ncomms7176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7176</ArticleId><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu CS, Farooqi N, O&#x2019;Brien K, and Gran B (2011). Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 164, 1079&#x2013;1106. 10.1111/j.1476-5381.2011.01302.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01302.x</ArticleId><ArticleId IdType="pmc">PMC3229753</ArticleId><ArticleId IdType="pubmed">21371012</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Green C, Altschuler G, Wei W, Bury JJ, Heath PR, Wyles M, Gelsthorpe C, Highley JR, Lorente-Pons A, et al. (2017). A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis. Acta Neuropathol Commun 5, 23. 10.1186/s40478-017-0424-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0424-x</ArticleId><ArticleId IdType="pmc">PMC5353945</ArticleId><ArticleId IdType="pubmed">28302159</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornall RJ, Cheng AM, Pawson T, and Goodnow CC (2000). Role of Syk in B-cell development and antigen-receptor signaling. Proc. Natl. Acad. Sci. USA. 97, 1713&#x2013;1718. 10.1073/pnas.97.4.1713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.4.1713</ArticleId><ArticleId IdType="pmc">PMC26501</ArticleId><ArticleId IdType="pubmed">10677523</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, et al. (2018). Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191. 10.1038/s41586-018-0368-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0368-8</ArticleId><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P, Hashimoto T, Fan Z, Hudry E, Barroeta I, et al. (2012). Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer&#x2019;s disease. Neurobiol. Dis. 45, 425&#x2013;437. 10.1016/j.nbd.2011.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.09.002</ArticleId><ArticleId IdType="pmc">PMC3694284</ArticleId><ArticleId IdType="pubmed">21945540</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, and Amit I (2018). Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell 173, 1073&#x2013;1081. 10.1016/j.cell.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.003</ArticleId><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble BW, and Woodgett JR (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175&#x2013;1186. 10.1242/jcs.00384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00384</ArticleId><ArticleId IdType="pmc">PMC3006448</ArticleId><ArticleId IdType="pubmed">12615961</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond RA, Saijo S, Iwakura Y, and Brown GD (2011). The role of Syk/CARD9 coupled C-type lectins in antifungal immunity. Eur. J. Immunol. 41, 276&#x2013;281. 10.1002/eji.201041252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201041252</ArticleId><ArticleId IdType="pmc">PMC3434674</ArticleId><ArticleId IdType="pubmed">21267996</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, and Goate AM (2017). Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43. 10.1186/s13024-017-0184-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0184-x</ArticleId><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, and Petrucelli L (2009). The role of tau in neurodegeneration. Mol. Neurodegener. 4, 13. 10.1186/1750-1326-4-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-4-13</ArticleId><ArticleId IdType="pmc">PMC2663562</ArticleId><ArticleId IdType="pubmed">19284597</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, Brendecke SM, Kierdorf K, Staszewski O, Datta M, et al. (2013). A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat. Neurosci. 16, 1618&#x2013;1626. 10.1038/nn.3531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3531</ArticleId><ArticleId IdType="pubmed">24077561</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, Cereghetti G, McGinty D, Anselmo A, Sadreyev RI, et al. (2019). TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer&#x2019;s Disease. Neuron 103, 820&#x2013;835.e7. e827. 10.1016/j.neuron.2019.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.06.010</ArticleId><ArticleId IdType="pmc">PMC6728215</ArticleId><ArticleId IdType="pubmed">31301936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudi V, Gingele S, Skripuletz T, and Stangel M (2014). Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front. Cell. Neurosci. 8, 73. 10.3389/fncel.2014.00073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00073</ArticleId><ArticleId IdType="pmc">PMC3952085</ArticleId><ArticleId IdType="pubmed">24659953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha J, Kim EJ, Lim S, Shin DW, Kang YJ, Bae SM, Yoon HK, and Oh KS (2012). Altered risk-aversion and risk-taking behaviour in patients with Alzheimer&#x2019;s disease. Psychogeriatrics 12, 151&#x2013;158. 10.1111/j.1479-8301.2011.00396.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1479-8301.2011.00396.x</ArticleId><ArticleId IdType="pubmed">22994612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadas S, Spira M, Hanisch UK, Reichert F, and Rotshenker S (2012). Complement receptor-3 negatively regulates the phagocytosis of degenerated myelin through tyrosine kinase Syk and cofilin. J. Neuroinflammation 9, 166. 10.1186/1742-2094-9-166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-166</ArticleId><ArticleId IdType="pmc">PMC3418574</ArticleId><ArticleId IdType="pubmed">22776089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez F, Lucas JJ, and Avila J (2012). GSK3 and tau: two convergence points in Alzheimer&#x2019;s disease. J Alzheimers Dis 33 (Suppl 1), S141&#x2013;S144. 10.3233/JAD-2012-129025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-129025</ArticleId><ArticleId IdType="pubmed">22710914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, and El Khoury J (2018). Microglia in neurodegeneration. Nat. Neurosci. 21, 1359&#x2013;1369. 10.1038/s41593-018-0242-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0242-x</ArticleId><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, Coleman U, Kingery-Gallagher ND, and El Khoury J (2019). Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal beta-Amyloid Clearance Pathways and Slows Progression of Alzheimer&#x2019;s Like-Disease in PS1-APP Mice. Front. Immunol. 10, 2780. 10.3389/fimmu.2019.02780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02780</ArticleId><ArticleId IdType="pmc">PMC6900980</ArticleId><ArticleId IdType="pubmed">31849963</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Happonen KE, Burrola PG, O&#x2019;Connor C, Hah N, Huang L, Nimmerjahn A, and Lemke G (2021). Microglia use TAM receptors to detect and engulf amyloid beta plaques. Nat. Immunol. 22, 586&#x2013;594. 10.1038/s41590-021-00913-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00913-5</ArticleId><ArticleId IdType="pmc">PMC8102389</ArticleId><ArticleId IdType="pubmed">33859405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado DE, Molina-Porcel L, Carroll JC, Macdonald C, Aboagye AK, Trojanowski JQ, and Lee VMY (2012). Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer&#x2019;s disease. J. Neurosci. 32, 7392&#x2013;7402. 10.1523/JNEUROSCI.0889-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0889-12.2012</ArticleId><ArticleId IdType="pmc">PMC3368584</ArticleId><ArticleId IdType="pubmed">22623685</ArticleId></ArticleIdList></Reference><Reference><Citation>International Multiple Sclerosis Genetics Consortium, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong G, Beecham AH, James T, Replogle J, Vlachos IS, McCabe C, et al. (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188. 10.1126/science.aav7188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav7188</ArticleId><ArticleId IdType="pmc">PMC7241648</ArticleId><ArticleId IdType="pubmed">31604244</ArticleId></ArticleIdList></Reference><Reference><Citation>The International Multiple Sclerosis Genetics Consortium and The Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, et al. (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214&#x2013;219. 10.1038/nature10251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10251</ArticleId><ArticleId IdType="pmc">PMC3182531</ArticleId><ArticleId IdType="pubmed">21833088</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar S, Trawicka A, Jenneckens C, Bayer TA, and Wirths O (2012). Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A&#x3b2; aggregation in the 5XFAD mouse model of Alzheimer&#x2019;s disease. Neurobiol. Aging 33, 196.e29. e129&#x2013;196.e40. 10.1016/j.neurobiolaging.2010.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.027</ArticleId><ArticleId IdType="pubmed">20619937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanno T, Tsuchiya A, and Nishizaki T (2014). Hyperphosphorylation of Tau at Ser396 occurs in the much earlier stage than appearance of learning and memory disorders in 5XFAD mice. Behav. Brain Res. 274, 302&#x2013;306. 10.1016/j.bbr.2014.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.08.034</ArticleId><ArticleId IdType="pubmed">25172181</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17. e1217. 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e9. e569. 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammert CR, Frost EL, Bellinger CE, Bolte AC, McKee CA, Hurt ME, Paysour MJ, Ennerfelt HE, and Lukens JR (2020). AIM2 inflammasome surveillance of DNA damage shapes neurodevelopment. Nature 580, 647&#x2013;652. 10.1038/s41586-020-2174-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2174-3</ArticleId><ArticleId IdType="pmc">PMC7788527</ArticleId><ArticleId IdType="pubmed">32350463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampron A, Larochelle A, Laflamme N, Prefontaine P, Plante MM, Sanchez MG, Yong VW, Stys PK, Tremblay ME, and Rivest S (2015). Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J. Exp. Med. 212, 481&#x2013;495. 10.1084/jem.20141656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20141656</ArticleId><ArticleId IdType="pmc">PMC4387282</ArticleId><ArticleId IdType="pubmed">25779633</ArticleId></ArticleIdList></Reference><Reference><Citation>Latour S, Fournel M, and Veillette A (1997). Regulation of T-cell antigen receptor signalling by Syk tyrosine protein kinase. Mol. Cell Biol. 17, 4434&#x2013;4441. 10.1128/MCB.17.8.4434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.17.8.4434</ArticleId><ArticleId IdType="pmc">PMC232297</ArticleId><ArticleId IdType="pubmed">9234701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Borjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, et al. (2018). Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 15, e1002660. 10.1371/journal.pmed.1002660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002660</ArticleId><ArticleId IdType="pmc">PMC6152871</ArticleId><ArticleId IdType="pubmed">30248105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, et al. (2018). Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer&#x2019;s Disease Models. Neuron 97, 1032&#x2013;1048.e5. e1035. 10.1016/j.neuron.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.002</ArticleId><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionakis MS, Iliev ID, and Hohl TM (2017). Immunity against fungi. JCI Insight 2, 93156. 10.1172/jci.insight.93156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.93156</ArticleId><ArticleId IdType="pmc">PMC5453709</ArticleId><ArticleId IdType="pubmed">28570272</ArticleId></ArticleIdList></Reference><Reference><Citation>Loving BA, Tang M, Neal MC, Gorkhali S, Murphy R, Eckel RH, and Bruce KD (2021). Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation 10, 198. Cells. 10.3390/cells10020198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020198</ArticleId><ArticleId IdType="pmc">PMC7909280</ArticleId><ArticleId IdType="pubmed">33498265</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik A, Sharma D, Malireddi RS, Guy CS, Chang TC, Olsen SR, Neale G, Vogel P, and Kanneganti TD (2018). SYK-CARD9 Signaling Axis Promotes Gut Fungi-Mediated Inflammasome Activation to Restrict Colitis and Colon Cancer. Immunity 49, 515&#x2013;530.e5. e515. 10.1016/j.immuni.2018.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.024</ArticleId><ArticleId IdType="pmc">PMC6541497</ArticleId><ArticleId IdType="pubmed">30231985</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik M, Simpson JF, Parikh I, Wilfred BR, Fardo DW, Nelson PT, and Estus S (2013). CD33 Alzheimer&#x2019;s risk-altering polymorphism, CD33 expression, and exon 2 splicing. J. Neurosci. 33, 13320&#x2013;13325. 10.1523/JNEUROSCI.1224-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1224-13.2013</ArticleId><ArticleId IdType="pmc">PMC3742922</ArticleId><ArticleId IdType="pubmed">23946390</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, Pluvinage JV, Mathur V, Hahn O, Morgens DW, et al. (2020). Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat. Neurosci. 23, 194&#x2013;208. 10.1038/s41593-019-0566-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0566-1</ArticleId><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Pardo CA, Cork LC, and Price DL (1994). Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am. J. Pathol. 145, 1358&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887492</ArticleId><ArticleId IdType="pubmed">7992840</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateo I, Infante J, Llorca J, Rodriguez E, Berciano J, and Combarros O (2006). Association between Glycogen Synthase Kinase-3&#x3b2; Genetic Polymorphism and Late-Onset Alzheimer&#x2019;s Disease. Dement Geriatr Cogn Disord 21, 228&#x2013;232. 10.1159/000091044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000091044</ArticleId><ArticleId IdType="pubmed">16428884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Guire C, Wieghofer P, Elton L, Muylaert D, Prinz M, Beyaert R, and van Loo G (2013). Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J. Immunol. 190, 2896&#x2013;2903. 10.4049/jimmunol.1201351.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1201351</ArticleId><ArticleId IdType="pubmed">23401595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocsai A, Ruland J, and Tybulewicz VLJ (2010). The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387&#x2013;402. 10.1038/nri2765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2765</ArticleId><ArticleId IdType="pmc">PMC4782221</ArticleId><ArticleId IdType="pubmed">20467426</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinero LL, Cubre A, Mora-Solano C, Wang Y, and Alegre ML (2012). T cell receptor/CARMA1/NF-&#x3ba;B signaling controls T-helper (Th) 17 differentiation. Proc. Natl. Acad. Sci. USA. 109, 18529&#x2013;18534. 10.1073/pnas.1204557109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1204557109</ArticleId><ArticleId IdType="pmc">PMC3494911</ArticleId><ArticleId IdType="pubmed">23091043</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris GT, Smirnov I, Filiano AJ, Shadowen HM, Cody KR, Thompson JA, Harris TH, Gaultier A, Overall CC, and Kipnis J (2018). Neuronal integrity and complement control synaptic material clearance by microglia after CNS injury. J. Exp. Med. 215, 1789&#x2013;1801. 10.1084/jem.20172244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20172244</ArticleId><ArticleId IdType="pmc">PMC6028515</ArticleId><ArticleId IdType="pubmed">29941548</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum RL, and Ellis CE (2003). Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. N. Engl. J. Med. 348, 1356&#x2013;1364. 10.1056/NEJM2003ra020003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM2003ra020003</ArticleId><ArticleId IdType="pubmed">12672864</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakalan R, Jiang B, Nimmi B, Janani M, Jayapal M, Lu J, Tay SS, Ling EA, and Dheen ST (2012). Transcriptome analysis of amoeboid and ramified microglia isolated from the corpus callosum of rat brain. BMC Neurosci. 13, 64. 10.1186/1471-2202-13-64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-13-64</ArticleId><ArticleId IdType="pmc">PMC3441342</ArticleId><ArticleId IdType="pubmed">22697290</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, Jin C, Crawford F, and Mullan M (2014). The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-beta production and Tau hyperphosphorylation. J. Biol. Chem. 289, 33927&#x2013;33944. 10.1074/jbc.M114.608091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.608091</ArticleId><ArticleId IdType="pmc">PMC4256331</ArticleId><ArticleId IdType="pubmed">25331948</ArticleId></ArticleIdList></Reference><Reference><Citation>Plastini MJ, Desu HL, and Brambilla R (2020). Dynamic Responses of Microglia in Animal Models of Multiple Sclerosis. Front. Cell. Neurosci. 14, 269. 10.3389/fncel.2020.00269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00269</ArticleId><ArticleId IdType="pmc">PMC7468479</ArticleId><ArticleId IdType="pubmed">32973458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluvinage JV, Haney MS, Smith BAH, Sun J, Iram T, Bonanno L, Li L, Lee DP, Morgens DW, Yang AC, et al. (2019). CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568, 187&#x2013;192. 10.1038/s41586-019-1088-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1088-4</ArticleId><ArticleId IdType="pmc">PMC6574119</ArticleId><ArticleId IdType="pubmed">30944478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramagopalan SV, Dobson R, Meier UC, and Giovannoni G (2010). Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 9, 727&#x2013;739. 10.1016/S1474-4422(10)70094-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70094-6</ArticleId><ArticleId IdType="pubmed">20610348</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH (2013). Amyloid beta-induced glycogen synthase kinase 3&#x3b2; phosphorylated VDAC1 in Alzheimer&#x2019;s disease: Implications for synaptic dysfunction and neuronal damage. Biochim. Biophys. Acta 1832, 1913&#x2013;1921. 10.1016/j.bbadis.2013.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.06.012</ArticleId><ArticleId IdType="pmc">PMC3825775</ArticleId><ArticleId IdType="pubmed">23816568</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, and Wirths O (2015). Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer&#x2019;s Disease. J Alzheimers Dis 45, 1223&#x2013;1236. 10.3233/JAD-143120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-143120</ArticleId><ArticleId IdType="pubmed">25697701</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffer BAJ, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, Bigio EH, Mesulam M, Wiedau-Pazos M, Jackson GR, et al. (2008). Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch. Neurol. 65, 1368&#x2013;1374. 10.1001/archneur.65.10.1368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.10.1368</ArticleId><ArticleId IdType="pmc">PMC2841136</ArticleId><ArticleId IdType="pubmed">18852354</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweig JE, Yao H, Beaulieu-Abdelahad D, Ait-Ghezala G, Mouzon B, Crawford F, Mullan M, and Paris D (2017). Alzheimer&#x2019;s disease pathological lesions activate the spleen tyrosine kinase. Acta Neuropathol Commun 5, 69. 10.1186/s40478-017-0472-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0472-2</ArticleId><ArticleId IdType="pmc">PMC5588676</ArticleId><ArticleId IdType="pubmed">28877763</ArticleId></ArticleIdList></Reference><Reference><Citation>Steen E, Terry BM, J Rivera E, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, and de la Monte SM (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer&#x2019;s disease&#x2013;is this type 3 diabetes? J Alzheimers Dis 7, 63&#x2013;80. 10.3233/jad-2005-7107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-2005-7107</ArticleId><ArticleId IdType="pubmed">15750215</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jungbauer L, Yu C, and LaDu MJ (2011). Preparing Synthetic A&#x3b2; in Different Aggregation States. Methods Mol. Biol. 670, 13&#x2013;32. 10.1007/978-1-60761-744-0_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-744-0_2</ArticleId><ArticleId IdType="pmc">PMC3752843</ArticleId><ArticleId IdType="pubmed">20967580</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Prinz M, Stagi M, Chechneva O, and Neumann H (2007). TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 4, e124. 10.1371/journal.pmed.0040124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0040124</ArticleId><ArticleId IdType="pmc">PMC1851623</ArticleId><ArticleId IdType="pubmed">17425404</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Hardy J, and Fischbeck KH (2002). Toxic proteins in neurodegenerative disease. Science 296, 1991&#x2013;1995. 10.1126/science.1067122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067122</ArticleId><ArticleId IdType="pubmed">12065827</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapp BD, and Nave KA (2008). Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247&#x2013;269. 10.1146/annurev.neuro.30.051606.094313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.30.051606.094313</ArticleId><ArticleId IdType="pubmed">18558855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SCC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. (2017). TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell 170, 649&#x2013;663.e13. e613. 10.1016/j.cell.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers JC, King AE, Woodhouse A, Kirkcaldie MT, Staal JA, McCormack GH, Blizzard CA, Musgrove RE, Mitew S, Liu Y, et al. (2009). Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res. Bull. 80, 217&#x2013;223. 10.1016/j.brainresbull.2009.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2009.08.004</ArticleId><ArticleId IdType="pubmed">19683034</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, and Lue LF (2015). Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimer&#x2019;s Res. Ther. 7, 56. 10.1186/s13195-015-0139-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0139-9</ArticleId><ArticleId IdType="pmc">PMC4543480</ArticleId><ArticleId IdType="pubmed">26286145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich J, Young K, Robinette M, Gilfillan S, Krishnan G, Sudhakar S, Zinselmeyer B, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071. 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. (2016). TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667&#x2013;675. 10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinger JG, Brosnan CF, Loudig O, Goldberg MF, Macian F, Arnett HA, Prieto AL, Tsiperson V, and Shafit-Zagardo B (2011). Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J. Neuroinflammation 8, 49. 10.1186/1742-2094-8-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-49</ArticleId><ArticleId IdType="pmc">PMC3121615</ArticleId><ArticleId IdType="pubmed">21569627</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker Hawkins RF, Patenaude A, Dumas A, Jain R, Tesfagiorgis Y, Kerfoot S, Matsui T, Gunzer M, Poubelle PE, Larochelle C, et al. (2017). ICAM1+ neutrophils promote chronic inflammation via ASPRV1 in B cell-dependent autoimmune encephalomyelitis. JCI Insight 2, 96882. 10.1172/jci.insight.96882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.96882</ArticleId><ArticleId IdType="pmc">PMC5752297</ArticleId><ArticleId IdType="pubmed">29212956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#xdf;feld J, Nozaki I, Mathews M, Raschka T, Ebeling C, Hornung V, Brustle O, and Neumann H (2021). Deletion of Alzheimer&#x2019;s disease-associated CD33 results in an inflammatory human microglia phenotype. Glia 69, 1393&#x2013;1412. 10.1002/glia.23968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23968</ArticleId><ArticleId IdType="pubmed">33539598</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Saito T, Saido TC, Barron AM, and Ruedl C (2021). Microglia and CD206(+) border-associated mouse macrophages maintain their embryonic origin during Alzheimer&#x2019;s disease. Elife 10, e71879. 10.7554/eLife.71879.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.71879</ArticleId><ArticleId IdType="pmc">PMC8523151</ArticleId><ArticleId IdType="pubmed">34609281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, Coppola K, Schweig JE, Crawford F, Mullan M, and Paris D (2019). Distinct Signaling Pathways Regulate TREM2 Phagocytic and NF&#x3ba;B Antagonistic Activities. Front. Cell. Neurosci. 13, 457. 10.3389/fncel.2019.00457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00457</ArticleId><ArticleId IdType="pmc">PMC6795686</ArticleId><ArticleId IdType="pubmed">31649511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye XC, Hao Q, Ma WJ, Zhao QC, Wang WW, Yin HH, Zhang T, Wang M, Zan K, Yang XX, et al. (2020). Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice. J. Neuroinflammation 17, 17. 10.1186/s12974-019-1693-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1693-z</ArticleId><ArticleId IdType="pmc">PMC6954534</ArticleId><ArticleId IdType="pubmed">31926564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan J, Mann T, Joost S, Behrangi N, Frank M, and Kipp M (2020). The Cuprizone Model: Dos and Do Nots 9, 843. Cells. 10.3390/cells9040843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040843</ArticleId><ArticleId IdType="pmc">PMC7226799</ArticleId><ArticleId IdType="pubmed">32244377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegenfuss JS, Biswas R, Avery MA, Hong K, Sheehan AE, Yeung YG, Stanley ER, and Freeman MR (2008). Draper-dependent glial phagocytic activity is mediated by Src and Syk family kinase signalling. Nature 453, 935&#x2013;939. 10.1038/nature06901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06901</ArticleId><ArticleId IdType="pmc">PMC2493287</ArticleId><ArticleId IdType="pubmed">18432193</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36260685</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>42</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Numb regulates Tau levels and prevents neurodegeneration in tauopathy mouse models.</ArticleTitle><Pagination><StartPage>eabm4295</StartPage><MedlinePgn>eabm4295</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabm4295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abm4295</ELocationID><Abstract><AbstractText>Accumulation of the microtubule-associated protein Tau is linked to neuronal cell death in tauopathies, but how intraneuronal Tau levels are regulated in health and disease remains unclear. Here, we show that conditional inactivation of the trafficking adaptor protein Numb in retinal ganglion cells (RGCs) increases Tau levels and leads to axonal blebbing, which is followed by neuronal cell loss in aged mice. In the TauP301S mouse model of tauopathy, conditional inactivation of Numb in RGCs and spinal motoneurons accelerates neurodegeneration, and loss of Numb in motoneurons also leads to precocious hindlimb paralysis. Conversely, overexpression of the long isoform of Numb (Numb-72) decreases intracellular Tau levels and reduces axonal blebbing in TauP301S RGCs, leading to improved electrical activity in cultured neurons and improves performance in a visually guided behavior test in vivo. These results uncover Numb as a key regulator of intracellular Tau levels and identify Numb-72 as a potential therapeutic factor for tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacomme</LastName><ForeName>Marine</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0969-9615</Identifier><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hales</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevanovic</LastName><ForeName>Katarina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jolicoeur</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9683-9817</Identifier><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bois</LastName><ForeName>Therence</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desrosiers</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2776-9664</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalkara</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4112-9321</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cayouette</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4655-9048</Identifier><AffiliationInfo><Affiliation>Cellular Neurobiology Research Unit, Institut de recherches cliniques de Montr&#xe9;al (IRCM), Montreal, QC H2W 1R7, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Universit&#xe9; de Montr&#xe9;al, Montreal, QC H3T 1J4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, Division of Experimental Medicine, McGill University, Montreal, QC H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106293">Numb protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Dec;18(12):699. doi: 10.1038/s41582-022-00745-3.</RefSource><PMID Version="1">36323923</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36260685</ArticleId><ArticleId IdType="pmc">PMC9581485</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abm4295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Qiang L., Sun X., Austin T. O., Muralidharan H., Jean D. C., Liu M., Yu W., Baas P. W., Tau does not stabilize axonal microtubules but rather enables them to have long labile domains. Curr. Biol. 28, 2181&#x2013;2189.e4 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30008334</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H., Choi J. Y., Lee H. S., Lee J. H., Ryu Y. H., Lee M. S., Jack C. R. Jr., Lyoo C. H., Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J. Nucl. Med. 60, 1611&#x2013;1621 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836867</ArticleId><ArticleId IdType="pubmed">30926651</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K., Liu F., Gong C. X., Grundke-Iqbal I., Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656&#x2013;664 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090074</ArticleId><ArticleId IdType="pubmed">20678074</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H., Bagarinao E., Yokoi T., Yamaguchi H., Ishigaki S., Mausuda M., Katsuno M., Sobue G., Tau accumulation and network breakdown in Alzheimer&#x2019;s disease. Adv. Exp. Med. Biol. 1184, 231&#x2013;240 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">32096042</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A., Polydoro M., Su&#xe1;rez-Calvet M., William C., Adamowicz D. H., Kopeikina K. J., Pitstick R., Sahara N., Ashe K. H., Carlson G. A., Spires-Jones T. L., Hyman B. T., Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Sarmiento J., Troncoso J., Jackson G. R., Kayed R., Identification of oligomers at early stages of tau aggregation in Alzheimer&#x2019;s disease. FASEB J. 26, 1946&#x2013;1959 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y., Higuchi M., Zhang B., Huang S.-M., Iwata N., Saido T. C., Maeda J., Suhara T., Trojanowski J. Q., Lee V. M.-Y., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei P., Ayton S., Finkelstein D. I., Spoerri L., Ciccotosto G. D., Wright D. K., Wong B. X. W., Adlard P. A., Cherny R. A., Lam L. Q., Roberts B. R., Volitakis I., Egan G. F., McLean C. A., Cappai R., Duce J. A., Bush A. I., Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291&#x2013;295 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22286308</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Hall A. M., Kelinske M., Roberson E. D., Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol. Aging 35, 2617&#x2013;2624 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171213</ArticleId><ArticleId IdType="pubmed">24908165</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N., Clelland C. L., Emrani S., Kukushkin N. V., Yu W. H., Goldberg A. L., Duff K. E., Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat. Med. 22, 46&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Catarina Silva M., Nandi G. A., Tentarelli S., Gurrell I. K., Jamier T., Lucente D., Dickerson B. C., Brown D. G., Brandon N. J., Haggarty S. J., Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons. Nat. Commun. 11, 3258 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320012</ArticleId><ArticleId IdType="pubmed">32591533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C. A., de Haro M., Hao S., Park J., Rousseaux M. W. C., Al-Ramahi I., Jafar-Nejad P., Vilanova-Velez L., See L., De Maio A., Nitschke L., Wu Z., Troncoso J. C., Westbrook T. F., Tang J., Botas J., Zoghbi H. Y., Reduction of Nuak1 decreases tau and reverses phenotypes in a tauopathy mouse model. Neuron 92, 407&#x2013;418 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745060</ArticleId><ArticleId IdType="pubmed">27720485</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos S. L., Miller R. L., Schoch K. M., Holmes B. B., Kebodeaux C. S., Wegener A. J., Chen G., Shen T., Tran H., Nichols B., Zanardi T. A., Kordasiewicz H. B., Swayze E. E., Bennett C. F., Diamond M. I., Miller T. M., Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9, eaag0481 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId></ArticleIdList></Reference><Reference><Citation>Spana E. P., Doe C. Q., Numb antagonizes notch signaling to specify sibling neuron cell fates. Neuron 17, 21&#x2013;26 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8755475</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill M. A., McGlade C. J., Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J. Biol. Chem. 278, 23196&#x2013;23203 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12682059</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., McGill M. A., Dermer M., Dho S. E., Wolting C. D., McGlade C. J., LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant Numb for ubiquitin-dependent degradation. EMBO J. 21, 93&#x2013;102 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125803</ArticleId><ArticleId IdType="pubmed">11782429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cayouette M., Raff M., Asymmetric segregation of Numb: A mechanism for neural specification from Drosophila to mammals. Nat. Neurosci. 5, 1265&#x2013;1269 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12447381</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Alfaro J., Chang E. H., Zhao X., Porcionatto M., Segal R. A., Numb links extracellular cues to intracellular polarity machinery to promote chemotaxis. Dev. Cell 20, 610&#x2013;622 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103748</ArticleId><ArticleId IdType="pubmed">21571219</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang E. J., Li H., Tang A. A., Wiggins A. K., Neve R. L., Zhong W., Jan L. Y., Jan Y. N., Targeted deletion of numb and numblike in sensory neurons reveals their essential functions in axon arborization. Genes Dev. 19, 138&#x2013;151 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC540232</ArticleId><ArticleId IdType="pubmed">15598981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura T., Fukata Y., Kato K., Yamaguchi T., Matsuura Y., Kamiguchi H., Kaibuchi K., CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. Nat. Cell Biol. 5, 819&#x2013;826 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12942088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferent J., Gigu&#xe8;re F., Jolicoeur C., Morin S., Michaud J.-F., Makihara S., Yam P. T., Cayouette M., Charron F., Boc acts via numb as a Shh-dependent endocytic platform for Ptch1 internalization and Shh-mediated axon guidance. Neuron 102, 1157&#x2013;1171.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31054872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntelios D., Berninger B., Tzimagiorgis G., Numb and Alzheimer&#x2019;s disease: The current picture. Front. Neurosci. 6, 145 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463830</ArticleId><ArticleId IdType="pubmed">23060745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap C. C., Winckler B., Adapting for endocytosis: Roles for endocytic sorting adaptors in directing neural development. Front. Cell. Neurosci. 9, 119 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389405</ArticleId><ArticleId IdType="pubmed">25904845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chigurupati S., Madan M., Okun E., Wei Z., Pattisapu J. V., Mughal M. R., Mattson M. P., Chan S. L., Evidence for altered Numb isoform levels in Alzheimer&#x2019;s disease patients and a triple transgenic mouse model. J. Alzheimers Dis. 24, 349&#x2013;361 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21258150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashok A., Singh N., Chaudhary S., Bellamkonda V., Kritikos A. E., Wise A. S., Rana N., Donald D. M., Ayyagari R., Retinal degeneration and Alzheimer&#x2019;s disease: An evolving link. Int. J. Mol. Sci. 21, 7290 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7582766</ArticleId><ArticleId IdType="pubmed">33023198</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart N. J., Koronyo Y., Black K. L., Koronyo-Hamaoui M., Ocular indicators of Alzheimer&#x2019;s: Exploring disease in the retina. Acta Neuropathol. 132, 767&#x2013;787 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5106496</ArticleId><ArticleId IdType="pubmed">27645291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho W. L., Leung Y., Cheng S. S. Y., Lok C. K. M., Ho Y.-S., Baum L., Yang X., Chiu K., Chang R. C.-C., Investigating degeneration of the retina in young and aged tau P301L mice. Life Sci. 124, 16&#x2013;23 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25592136</ArticleId></ArticleIdList></Reference><Reference><Citation>London A., Benhar I., Schwartz M., The retina as a window to the brain&#x2014;FXro eye research to CNS disorders. Nat. Rev. Neurol. 9, 44&#x2013;53 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23165340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull N. D., Guidi A., Goedert M., Martin K. R., Spillantini M. G., Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau. PLOS ONE 7, e34724 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319610</ArticleId><ArticleId IdType="pubmed">22496848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L., Crowther R. A., Martin K. R., Berg N., Coleman M., Goedert M., Spillantini M. G., Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability. Neurobiol. Aging 32, 419&#x2013;433 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">19356824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiasseu M., Alarcon-Martinez L., Belforte N., Quintero H., Dotigny F., Destroismaisons L., Velde C. V., Panayi F., Louis C., Polo A. D., Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 12, 58 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543446</ArticleId><ArticleId IdType="pubmed">28774322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamurthy V., Jolicoeur C., Koutroumbas D., M&#xfc;hlhans J., Le Y.-Z., Hauswirth W. W., Giessl A., Cayouette M., Numb regulates the polarized delivery of cyclic nucleotide-gated ion channels in rod photoreceptor cilia. J. Neurosci. 34, 13976&#x2013;13987 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4577571</ArticleId><ArticleId IdType="pubmed">25319694</ArticleId></ArticleIdList></Reference><Reference><Citation>Kechad A., Jolicoeur C., Tufford A., Mattar P., Chow R. W. Y., Harris W. A., Cayouette M., Numb is required for the production of terminal asymmetric cell divisions in the developing mouse retina. J. Neurosci. 32, 17197&#x2013;17210 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4650329</ArticleId><ArticleId IdType="pubmed">23197712</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivas S., Watanabe T., Lin C. S., William C. M., Tanabe Y., Jessell T. M., Costantini F., Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31338</ArticleId><ArticleId IdType="pubmed">11299042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilian O., Saner C., Hagedorn L., Lee H. Y., S&#xe4;uberli E., Suter U., Sommer L., Aguet M., Multiple roles of mouse Numb in tuning developmental cell fates. Curr. Biol. 11, 494&#x2013;501 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11412999</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen P. H., Zou K., Krauss S., Zhong W., Continuing role for mouse numb and numbl in maintaining progenitor cells during cortical neurogenesis. Nat. Neurosci. 7, 803&#x2013;811 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15273690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson A., Ardiet D. L., Saner C., Vilain N., Beermann F., Aguet M., MacDonald H. R., Zilian O., Normal hemopoiesis and lymphopoiesis in the combined absence of numb and numblike. J. Immunol. 178, 6746&#x2013;6751 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17513721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejarano-Escobar R., &#xc1;lvarez-Hern&#xe1;n G., Morona R., Gonz&#xe1;lez A., Mart&#xed;n-Partido G., Francisco-Morcillo J., Expression and function of the LIM-homeodomain transcription factor Islet-1 in the developing and mature vertebrate retina. Exp. Eye Res. 138, 22&#x2013;31 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26122047</ArticleId></ArticleIdList></Reference><Reference><Citation>Danias J., Lee K. C., Zamora M. F., Chen B., Shen F., Filippopoulos T., Su Y., Goldblum D., Podos S. M., Mittag T., Quantitative analysis of retinal ganglion cell (RGC) loss in aging DBA/2NNia glaucomatous mice: Comparison with RGC loss in aging C57/BL6 mice. Invest. Ophthalmol. Vis. Sci. 44, 5151&#x2013;5162 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14638711</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel M. A., Zhang Y., Meister M., Sanes J. R., Age-related alterations in neurons of the mouse retina. J. Neurosci. 31, 16033&#x2013;16044 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3238393</ArticleId><ArticleId IdType="pubmed">22049445</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike T., Yang Y., Suzuki K., Zheng X., Axon &amp; dendrite degeneration: Its mechanisms and protective experimental paradigms. Neurochem. Int. 52, 751&#x2013;760 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18029056</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L., O&#x2019;Leary D. D., Axon retraction and degeneration in development and disease. Annu. Rev. Neurosci. 28, 127&#x2013;156 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16022592</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin K. R., Klein R. L., Quigley H. A., Gene delivery to the eye using adeno-associated viral vectors. Methods 28, 267&#x2013;275 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12413426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Shu Y., Axonal bleb recording. Neurosci. Bull. 28, 342&#x2013;350 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5561888</ArticleId><ArticleId IdType="pubmed">22833034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneynsberg A., Combs B., Christensen K., Morfini G., Kanaan N. M., Axonal degeneration in Tauopathies: Disease relevance and underlying mechanisms. Front. Neurosci. 11, 572 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651019</ArticleId><ArticleId IdType="pubmed">29089864</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahrenthold B. K., Fernandes K. A., Libby R. T., Assessment of intrinsic and extrinsic signaling pathway in excitotoxic retinal ganglion cell death. Sci. Rep. 8, 4641 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854579</ArticleId><ArticleId IdType="pubmed">29545615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam T. T., Abler A. S., Kwong J. M., Tso M. O., N-methyl-D-aspartate (NMDA)--induced apoptosis in rat retina. Invest. Ophthalmol. Vis. Sci. 40, 2391&#x2013;2397 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10476807</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M., Maeda S., Vossel K., Mucke L., The many faces of tau. Neuron 70, 410&#x2013;426 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ericson J., Thor S., Edlund T., Jessell T. M., Yamada T., Early stages of motor neuron differentiation revealed by expression of homeobox gene Islet-1. Science 256, 1555&#x2013;1560 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1350865</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff S. L., Mendelsohn M., Stewart C. L., Edlund T., Jessell T. M., Requirement for LIM homeobox gene Isl1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. Cell 84, 309&#x2013;320 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8565076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T., Ensini M., Morton S. B., Baldassare M., Edlund T., Jessell T. M., Pfaff S. L., Topographic organization of embryonic motor neurons defined by expression of LIM homeobox genes. Cell 79, 957&#x2013;970 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7528105</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B., Ingram E., Takao M., Smith M. J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P. C., Atzori C., Migheli A., Crowther R. A., Ghetti B., Spillantini M. G., Goedert M., Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340&#x2013;9351 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruch J., Xu H., R&#xf6;sler T. W., de Andrade A., Kuhn P. H., Lichtenthaler S. F., Arzberger T., Winklhofer K. F., M&#xfc;ller U., H&#xf6;glinger G. U., PERK activation mitigates tau pathology in vitroandin vivo. EMBO Mol. Med. 9, 371&#x2013;384 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5331260</ArticleId><ArticleId IdType="pubmed">28148553</ArticleId></ArticleIdList></Reference><Reference><Citation>Scattoni M. L., Gasparini L., Alleva E., Goedert M., Calamandrei G., Spillantini M. G., Early behavioural markers of disease in P301S tau transgenic mice. Behav. Brain Res. 208, 250&#x2013;257 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20004218</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Valkenburg F., Hornix B. E., Mantingh-Otter I., Zhou X., Mari M., Reggiori F., van Dam D., Eggen B. J. L., de Deyn P. P., Boddeke E., Progressive motor deficit is mediated by the denervation of neuromuscular junctions and axonal degeneration in transgenic mice expressing mutant (P301S) Tau protein. J. Alzheimers Dis. 60, S41&#x2013;S57 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28222529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei P., Ayton S., Moon S., Zhang Q., Volitakis I., Finkelstein D. I., Bush A. I., Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol. Neurodegener. 9, 29 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4141346</ArticleId><ArticleId IdType="pubmed">25124182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J. W., Li Y. F., Wang Z. T., Jia W. Q., Xu R. X., Toll-like receptor 4 deficiency impairs motor coordination. Front. Neurosci. 10, 33 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754460</ArticleId><ArticleId IdType="pubmed">26909014</ArticleId></ArticleIdList></Reference><Reference><Citation>Miedel C. J., Patton J. M., Miedel A. N., Miedel E. S., Levenson J. M., Assessment of spontaneous alternation, novel object recognition and limb clasping in transgenic mouse models of amyloid-beta and tau neuropathology. J. Vis. Exp. 55523 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608159</ArticleId><ArticleId IdType="pubmed">28605382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M. J., Lee J. H., Rubinsztein D. C., Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system. Prog. Neurobiol. 105, 49&#x2013;59 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23528736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorantla N. V., Chinnathambi S., Autophagic pathways to clear the Tau aggregates in Alzheimer&#x2019;s disease. Cell. Mol. Neurobiol. 41, 1175&#x2013;1181 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11448645</ArticleId><ArticleId IdType="pubmed">32529542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H., Liu Y., Zhang L., Shao X., Liu K., Ding Z., Liu X., Jiang C., Li H., Li H., Numb positively regulates autophagic flux via regulating lysosomal function. Biochem. Biophys. Res. Commun. 491, 780&#x2013;786 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28720501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I., Ueno T., Kominami E., LC3 and autophagy. Methods Mol. Biol. 445, 77&#x2013;88 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18425443</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Bhaskar K., Degradation and transmission of tau by autophagic-endolysosomal networks and potential therapeutic targets for Tauopathy. Front. Mol. Neurosci. 13, 586731 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596180</ArticleId><ArticleId IdType="pubmed">33177989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernegre C., Duquette A., Leclerc N., Tau secretion: Good and bad for neurons. Front. Neurosci. 13, 649 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606725</ArticleId><ArticleId IdType="pubmed">31293374</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi A., Brighi C., Peruzzi G., Ragozzino D., Bonanni V., Limatola C., Ruocco G., di Angelantonio S., Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer&#x2019;s disease in the 3xTg-AD mouse model. Cell Death Dis. 9, 685 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5992214</ArticleId><ArticleId IdType="pubmed">29880901</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinkovi&#x107; P., Blumenstock S., Goltstein P. M., Korzhova V., Peters F., Knebl A., Herms J., In vivo imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model. Brain 142, 1051&#x2013;1062 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30847469</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason C., Slavi N., Retinal ganglion cell axon wiring establishing the binocular circuit. Annu. Rev. Vis. Sci. 6, 215&#x2013;236 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32396770</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox M. W., The visual cliff test for the study of visual depth perception in the mouse. Anim. Behav. 13, 232&#x2013;233 (1965).</Citation><ArticleIdList><ArticleId IdType="pubmed">5835839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzaro N., Barini E., Spillantini M. G., Goedert M., Medini P., Gasparini L., Tau-driven neuronal and neurotrophic dysfunction in a mouse model of early Tauopathy. J. Neurosci. 36, 2086&#x2013;2100 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756149</ArticleId><ArticleId IdType="pubmed">26888921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W., Jiang M. M., Schonemann M. D., Meneses J. J., Pedersen R. A., Jan L. Y., Jan Y. N., Mouse numb is an essential gene involved in cortical neurogenesis. Proc. Natl. Acad. Sci. U.S.A. 97, 6844&#x2013;6849 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18761</ArticleId><ArticleId IdType="pubmed">10841580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanovi&#x107; O., Delfino-Mach&#xed;n M., Nicol&#xe1;s-P&#xe9;rez M., Gavil&#xe1;n M. P., Gago-Rodrigues I., Fern&#xe1;ndez-Mi&#xf1;&#xe1;n A., Lillo C., R&#xed;os R. M., Wittbrodt J., Mart&#xed;nez-Morales J. R., Numb/Numbl-Opo antagonism controls retinal epithelium morphogenesis by regulating integrin endocytosis. Dev. Cell 23, 782&#x2013;795 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23041384</ArticleId></ArticleIdList></Reference><Reference><Citation>Belanger M. C., Robert B., Cayouette M., Msx1-positive progenitors in the retinal ciliary margin give rise to both neural and non-neural progenies in mammals. Dev. Cell 40, 137&#x2013;150 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28011038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai M., Arita Y., McGlade C. J., Lee K. F., Chen J., Evans S. M., Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J. Clin. Invest. 127, 569&#x2013;582 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5272190</ArticleId><ArticleId IdType="pubmed">28067668</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B., Mueller R. L., Morfini G., Brady S. T., Kanaan N. M., Tau and axonal transport misregulation in Tauopathies. Adv. Exp. Med. Biol. 1184, 81&#x2013;95 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099581</ArticleId><ArticleId IdType="pubmed">32096030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey M., Chaudhury P., Kabiru H., Shea T. B., Tau inhibits anterograde axonal transport and perturbs stability in growing axonal neurites in part by displacing kinesin cargo: Neurofilaments attenuate tau-mediated neurite instability. Cell Motil. Cytoskeleton 65, 89&#x2013;99 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18000878</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson J. E., Sengupta U., Lasagna-Reeves C. A., Guerrero-Mu&#xf1;oz M. J., Troncoso J., Kayed R., Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2, 73 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229782</ArticleId><ArticleId IdType="pubmed">24927818</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson K. R., Ward S. M., Combs B., Voss K., Kanaan N. M., Morfini G., Brady S. T., Gamblin T. C., Binder L. I., Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry 50, 10300&#x2013;10310 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387688</ArticleId><ArticleId IdType="pubmed">22039833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S., Son S. M., Baik S. H., Yang J., Mook-Jung I., Autophagy-mediated secretory pathway is responsible for both normal and pathological Tau in neurons. J. Alzheimers Dis. 70, 667&#x2013;680 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31256134</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Balaji V., Kaniyappan S., Kr&#xfc;ger L., Irsen S., Tepper K., Chandupatla R. R., Maetzler W., Schneider A., Mandelkow E., Mandelkow E. M., The release and trans-synaptic transmission of Tau via exosomes. Mol. Neurodegener. 12, 5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237256</ArticleId><ArticleId IdType="pubmed">28086931</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Du S., Marsh J. A., Horie K., Sato C., Ballabio A., Karch C. M., Holtzman D. M., Zheng H., TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. Mol. Psychiatry 26, 5925&#x2013;5939 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609570</ArticleId><ArticleId IdType="pubmed">32366951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazis G. A., Wei Z., Vandermey M., Jo D. G., Xin O., Mattson M. P., Chan S. L., Numb endocytic adapter proteins regulate the transport and processing of the amyloid precursor protein in an isoform-dependent manner: Implications for Alzheimer disease pathogenesis. J. Biol. Chem. 283, 25492&#x2013;25502 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533073</ArticleId><ArticleId IdType="pubmed">18599481</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieger J. C., Choi V. W., Samulski R. J., Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412&#x2013;1428 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406430</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurnhammer C., Haase M., Muether N., Hausl M., Rauschhuber C., Huber I., Nitschko H., Busch U., Sing A., Ehrhardt A., Baiker A., Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18&#x2013;28 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22428977</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda T., Cepko C. L., Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 101, 16&#x2013;22 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314130</ArticleId><ArticleId IdType="pubmed">14603031</ArticleId></ArticleIdList></Reference><Reference><Citation>Cayouette M., Gravel C., Adenovirus-mediated gene transfer to retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 37, 2022&#x2013;2028 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8814142</ArticleId></ArticleIdList></Reference><Reference><Citation>Radstake F. D. W., Raaijmakers E. A. L., Luttge R., Zinger S., Frimat J. P., CALIMA: The semi-automated open-source calcium imaging analyzer. Comput. Methods Programs Biomed. 179, 104991 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718774</ArticleId><ArticleId IdType="pubmed">31443860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36260691</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>667</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Synaptogenic effect of <i>APP</i>-Swedish mutation in familial Alzheimer's disease.</ArticleTitle><Pagination><StartPage>eabn9380</StartPage><MedlinePgn>eabn9380</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abn9380</ELocationID><Abstract><AbstractText>Mutations in &#x3b2;-amyloid (A&#x3b2;) precursor protein (<i>APP</i>) cause familial Alzheimer's disease (AD) probably by enhancing A&#x3b2; peptides production from APP. An antibody targeting A&#x3b2; (aducanumab) was approved as an AD treatment; however, some A&#x3b2; antibodies have been reported to accelerate, instead of ameliorating, cognitive decline in individuals with AD. Using conditional APP mutations in human neurons for perfect isogenic controls and translational relevance, we found that the <i>APP</i>-Swedish mutation in familial AD increased synapse numbers and synaptic transmission, whereas the <i>APP</i> deletion decreased synapse numbers and synaptic transmission. Inhibition of BACE1, the protease that initiates A&#x3b2; production from APP, lowered synapse numbers, suppressed synaptic transmission in wild-type neurons, and occluded the phenotype of <i>APP</i>-Swedish-mutant neurons. Modest elevations of A&#x3b2;, conversely, elevated synapse numbers and synaptic transmission. Thus, the familial AD-linked <i>APP</i>-Swedish mutation under physiologically relevant conditions increased synaptic connectivity in human neurons via a modestly enhanced production of A&#x3b2;. These data are consistent with the relative inefficacy of BACE1 and anti-A&#x3b2; treatments in AD and the chronic nature of AD pathogenesis, suggesting that AD pathogenesis is not simply caused by overproduction of toxic A&#x3b2; but rather by a long-term effect of elevated A&#x3b2; concentrations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Bo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2082-7737</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jacqueline G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddu</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6117-0375</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wernig</LastName><ForeName>Marius</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5309-515X</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0003-3361-9275</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG070919</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> T.C.S. serves on the Board of Directors for Sanofi S.A. and for CytoDel Inc., and is a member of the Scientific Advisory Board of REATA Pharmaceuticals, Simcere America Inc., Alector, Elysium, Jupiter, Danaher, Boost, Recognify, and Neuralight. In addition, T.C.S. has equity in Sanofi S.A., CytoDel, REATA, Alector, Jupiter, Boost, Recognify and NeuraLight. None of the consulting activity is directly related to the studies described in the current manuscript, and no research funding was obtained from any company for the present studies or for other studies in T.C.S.&#x2019; laboratory. No patents were filed in connection with the current study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36260691</ArticleId><ArticleId IdType="mid">NIHMS1863569</ArticleId><ArticleId IdType="pmc">PMC9894682</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abn9380</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long JM, Holtzman DM, Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Amieva H, Petersen RC, Ch&#xe9;telat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT, Alzheimer disease. Nature Reviews Disease Primers 7, 33 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM, Alzheimer&#x2019;s disease. The Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J, The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, Zhou J, Yan R, Vanmechelen E, De Vos A, Nistic&#xf2; R, Corbo M, Imbimbo BP, Streffer J, Voytyuk I, Timmers M, Tahami Monfared AA, Irizarry M, Albala B, Koyama A, Watanabe N, Kimura T, Yarenis L, Lista S, Kramer L, Vergallo A, The &#x3b2;-Secretase BACE1 in Alzheimer&#x2019;s Disease. Biol Psychiatry 89, 745&#x2013;756 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7533042</ArticleId><ArticleId IdType="pubmed">32223911</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Take five--BACE and the gamma-secretase quartet conduct Alzheimer&#x2019;s amyloid beta-peptide generation. EMBO J 23, 483&#x2013;488 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GC, Knopman DS, Emerson SS, Ovbiagele B, Kryscio RJ, Perlmutter JS, Kesselheim AS, Revisiting FDA Approval of Aducanumab. New England Journal of Medicine 385, 769&#x2013;771 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11694499</ArticleId><ArticleId IdType="pubmed">34320282</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, S&#xe1;nchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr., Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ, A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer&#x2019;s disease. Nat Med 27, 1187&#x2013;1196 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988051</ArticleId><ArticleId IdType="pubmed">34155411</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G, Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer&#x2019;s Disease. N Engl J Med 380, 1483&#x2013;1485 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30970197</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D, Randomized Trial of Verubecestat for Prodromal Alzheimer&#x2019;s Disease. N Engl J Med 380, 1408&#x2013;1420 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G, Holtzman DM, Amyloid-&#x3b2; and Tau at the Crossroads of Alzheimer&#x2019;s Disease. Adv Exp Med Biol 1184, 187&#x2013;203 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">32096039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho A, Shen J, Presenilins in synaptic function and disease. Trends Mol Med 17, 617&#x2013;624 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205282</ArticleId><ArticleId IdType="pubmed">21795114</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ, The Swedish mutation causes early-onset Alzheimer&#x2019;s disease by beta-secretase cleavage within the secretory pathway. Nat Med 1, 1291&#x2013;1296 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TVP, Hyman BT, Younkin SG, Hsiao KK, Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience 2, 271&#x2013;276 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, Smith D, Reynolds DS, Davies CH, Collingridge GL, Seabrook GR, Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 21, 4691&#x2013;4698 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762352</ArticleId><ArticleId IdType="pubmed">11425896</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid Lena C., Mittag M, Poll S, Steffen J, Wagner J, Geis H-R, Schwarz I, Schmidt B, Schwarz Martin K., Remy S, Fuhrmann M, Dysfunction of Somatostatin-Positive Interneurons Associated with Memory Deficits in an Alzheimer&#x2019;s Disease Model. Neuron 92, 114&#x2013;125 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27641495</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Jackson RJ, Hong W, Taylor WM, Corbett GT, Moreno A, Liu W, Li S, Frosch MP, Slutsky I, Young-Pearse TL, Spires-Jones TL, Walsh DM, Human Brain-Derived A&#x3b2; Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. J Neurosci 37, 11947&#x2013;11966 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719975</ArticleId><ArticleId IdType="pubmed">29101243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei M, Xu H, Li Z, Wang Z, O&#x2019;Malley TT, Zhang D, Walsh DM, Xu P, Selkoe DJ, Li S, Soluble A&#x3b2; oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance. Neurobiol Dis 85, 111&#x2013;121 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4778388</ArticleId><ArticleId IdType="pubmed">26525100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG, Soluble amyloid-&#x3b2; oligomers as synaptotoxins leading to cognitive impairment in Alzheimer&#x2019;s disease. Front Cell Neurosci 9, 191 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443025</ArticleId><ArticleId IdType="pubmed">26074767</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana IC, Zimmer AR, Rocha AS, Gosmann G, Souza DO, Lourenco MV, Ferreira ST, Zimmer ER, Amyloid-&#x3b2; oligomers in cellular models of Alzheimer&#x2019;s disease. J Neurochem 155, 348&#x2013;369 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32320074</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu X, Yuan FN, Corona C, Pasini S, Pero ME, Gundersen GG, Shelanski ML, Bartolini F, Stabilization of dynamic microtubules by mDia1 drives Tau-dependent A&#x3b2;(1&#x2013;42) synaptotoxicity. J Cell Biol 216, 3161&#x2013;3178 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626542</ArticleId><ArticleId IdType="pubmed">28877993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, Sabatini B, S&#xfc;dhof T, Synapses and Alzheimer&#x2019;s Disease. Cold Spring Harb Perspect Biol, (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331702</ArticleId><ArticleId IdType="pubmed">22491782</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P, Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nature Neuroscience 8, 1051&#x2013;1058 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinders NR, Pao Y, Renner MC, da Silva-Matos CM, Lodder TR, Malinow R, Kessels HW, Amyloid-&#x3b2; effects on synapses and memory require AMPA receptor subunit GluA3. Proceedings of the National Academy of Sciences 113, E6526&#x2013;E6534 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081598</ArticleId><ArticleId IdType="pubmed">27708157</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R, AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831&#x2013;843 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B, The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nature Neuroscience 15, 349&#x2013;357 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ, Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2, a006338&#x2013;a006338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L, Amyloid-&#x3b2;&#x2013;induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nature Neuroscience 13, 812&#x2013;818 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, F&#xe0; M, Staniszewski A, Palmeri A, Arancio O, Picomolar Amyloid-&#x3b2; Positively Modulates Synaptic Plasticity and Memory in Hippocampus. The Journal of Neuroscience 28(53), 14537&#x2013;14545 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I, Amyloid-&#x3b2; as a positive endogenous regulator of release probability at hippocampal synapses. Nature Neuroscience 12, 1567&#x2013;1576 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19935655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekinci FJ, Malik KU, Shea TB, Activation of the L Voltage-sensitive Calcium Channel by Mitogen-activated Protein (MAP) Kinase following Exposure of Neuronal Cells to &#x3b2;-Amyloid: MAP KINASE MEDIATES &#x3b2;-AMYLOID-INDUCED NEURODEGENERATION*. Journal of Biological Chemistry 274, 30322&#x2013;30327 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10514528</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnie SB, Nader K, Amyloid Beta Secreted during Consolidation Prevents Memory Malleability. Current Biology 30, 1934&#x2013;1940.e1934 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32243855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghatak S, Dolatabadi N, Trudler D, Zhang X, Wu Y, Mohata M, Ambasudhan R, Talantova M, Lipton SA, Mechanisms of hyperexcitability in Alzheimer&#x2019;s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. eLife 8, e50333 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6905854</ArticleId><ArticleId IdType="pubmed">31782729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyan S-H, Shih AY-J, Walsh JJ, Maruyama H, Sarsoza F, Ku L, Eggert S, Hof PR, Koo EH, Dickstein DL, Amyloid precursor protein (APP) regulates synaptic structure and function. Molecular and Cellular Neuroscience 51, 43&#x2013;52 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538857</ArticleId><ArticleId IdType="pubmed">22884903</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Jucker M, The Exceptional Vulnerability of Humans to Alzheimer&#x2019;s Disease. Trends Mol Med 23, 534&#x2013;545 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521004</ArticleId><ArticleId IdType="pubmed">28483344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, De Strooper B, Alzheimer&#x2019;s Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annu Rev Neurosci 39, 57&#x2013;79 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27050320</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungenast AE, Siegert S, Tsai LH, Modeling Alzheimer&#x2019;s disease with human induced pluripotent stem (iPS) cells. Mol Cell Neurosci 73, 13&#x2013;31 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5930170</ArticleId><ArticleId IdType="pubmed">26657644</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy EA, Paquet D, Duffield M, Fak J, Olsen O, Darnell RB, Tessier-Lavigne M, A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP &#x3b2;-CTFs, Not A&#x3b2;. Neuron 104, 256&#x2013;270.e255 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ, Mutation of the beta-amyloid precursor protein in familial Alzheimer&#x2019;s disease increases beta-protein production. Nature 360, 672&#x2013;674 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, Golde T, Younkin S, Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259, 514&#x2013;516 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8424174</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LSB, Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature 482, 216&#x2013;220 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H, Modeling Alzheimer&#x2019;s disease with iPSCs reveals stress phenotypes associated with intracellular A&#x3b2; and differential drug responsiveness. Cell Stem Cell 12, 487&#x2013;496 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S, Evans Lewis D. B., Andersson T, Portelius E, Smith J, Dias Tatyana B., Saurat N, McGlade A, Kirwan P, Blennow K, Hardy J, Zetterberg H, Livesey Frederick J., APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons. Cell Reports 11, 689&#x2013;696 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431668</ArticleId><ArticleId IdType="pubmed">25921538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, Rueda R, Kritskiy O, Abdurrob F, Peng Z, Milo B, Yu CJ, Elmsaouri S, Dey D, Ko T, Yankner BA, Tsai LH, APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron 98, 1141&#x2013;1154.e1147 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, Xu W, Yang N, Danko T, Chen L, Wernig M, S&#xfc;dhof Thomas C., Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem Cells. Neuron 78, 785&#x2013;798 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J, Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci 25, 6755&#x2013;6764 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725351</ArticleId><ArticleId IdType="pubmed">16033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT, Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25, 7278&#x2013;7287 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Cruz C, Nolte MW, van Gaalen MM, Rustay NR, Termont A, Tanghe A, Kirchhoff F, Ebert U, Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer&#x2019;s disease. J Neurosci 31, 3926&#x2013;3934 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622797</ArticleId><ArticleId IdType="pubmed">21389247</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis J-C, Collins F, Treanor J, Rogers G, Citron M, &#x3b2;-Secretase Cleavage of Alzheimer&#x2019;s Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE. Science 286, 735&#x2013;741 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Mart&#xe9;nyi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ, The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A&#x3b2; Pharmacodynamic Responses in Mice, Dogs, and Humans. The Journal of Neuroscience 35, 1199&#x2013;1210 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605527</ArticleId><ArticleId IdType="pubmed">25609634</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorfi M, D&#x2019;Avanzo C, Tanzi RE, Kim DY, Irimia D, Human Neurospheroid Arrays for In Vitro Studies of Alzheimer&#x2019;s Disease. Scientific Reports 8, 2450 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5799361</ArticleId><ArticleId IdType="pubmed">29402979</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL, Natural Oligomers of the Alzheimer Amyloid-&#x3b2; Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. The Journal of Neuroscience 27, 2866&#x2013;2875 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL, Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106, 4012&#x2013;4017 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito Y, Tanabe Y, Lee AK, Hamel E, Takahashi H, Amyloid-&#x3b2; Oligomers Interact with Neurexin and Diminish Neurexin-mediated Excitatory Presynaptic Organization. Sci Rep 7, 42548 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304201</ArticleId><ArticleId IdType="pubmed">28211900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillen H, The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer&#x2019;s Disease. Front Neurosci 13, 1154 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853841</ArticleId><ArticleId IdType="pubmed">31787864</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y-WA, Zhou B, Wernig M, S&#xfc;dhof TC, ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A&#x3b2; Secretion. Cell 168, 427&#x2013;441.e421 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y-WA, Zhou B, Nabet AM, Wernig M, S&#xfc;dhof TC, Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer&#x2019;s Disease Risk. The Journal of Neuroscience 39, 7408&#x2013;7427 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6759032</ArticleId><ArticleId IdType="pubmed">31331998</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof TC, The cell biology of synapse formation. J Cell Biol 220 (7), e202103052 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8186004</ArticleId><ArticleId IdType="pubmed">34086051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R et al. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol 78, 293&#x2013;301, doi:10.1001/jamaneurol.2020.4857 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4857</ArticleId><ArticleId IdType="pmc">PMC7816119</ArticleId><ArticleId IdType="pubmed">33464300</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L, Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron 55, 697&#x2013;711 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KJ, Moussa CE, Lee Y, Sung Y, Howell BW, Turner RS, Pak DT, Hoe HS, Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Neuroscience 169, 344&#x2013;356 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900520</ArticleId><ArticleId IdType="pubmed">20451588</ArticleId></ArticleIdList></Reference><Reference><Citation>Hark TJ, Rao NR, Castillon C, Basta T, Smukowski S, Bao H, Upadhyay A, Bomba-Warczak E, Nomura T, O&#x2019;Toole ET, Morgan GP, Ali L, Saito T, Guillermier C, Saido TC, Steinhauser ML, Stowell MHB, Chapman ER, Contractor A, Savas JN, Pulse-Chase Proteomics of the App Knockin Mouse Models of Alzheimer&#x2019;s Disease Reveals that Synaptic Dysfunction Originates in Presynaptic Terminals. Cell Systems 12, 141&#x2013;158.e149 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897324</ArticleId><ArticleId IdType="pubmed">33326751</ArticleId></ArticleIdList></Reference><Reference><Citation>Southam KA, Stennard F, Pavez C, Small DH, Knockout of Amyloid &#x3b2; Protein Precursor (APP) Expression Alters Synaptogenesis, Neurite Branching and Axonal Morphology of Hippocampal Neurons. Neurochem Res 44, 1346&#x2013;1355 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">29572646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi F, Danko T, Botelho SC, Patzke C, Pak C, Wernig M, S&#xfc;dhof TC, Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. Science 352, aaf2669 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4901875</ArticleId><ArticleId IdType="pubmed">26966193</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak C, Danko T, Zhang Y, Aoto J, Anderson G, Maxeiner S, Yi F, Wernig M, S&#xfc;dhof TC, Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1. Cell Stem Cell 17, 316&#x2013;328 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4560990</ArticleId><ArticleId IdType="pubmed">26279266</ArticleId></ArticleIdList></Reference><Reference><Citation>Patzke C, Han Y, Covy J, Yi F, Maxeiner S, Wernig M, S&#xfc;dhof TC, Analysis of conditional heterozygous STXBP1 mutations in human neurons. J Clin Invest 125, 3560&#x2013;3571 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588304</ArticleId><ArticleId IdType="pubmed">26280581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36306735</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>22</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>TREM2 drives microglia response to amyloid-&#x3b2; via SYK-dependent and -independent pathways.</ArticleTitle><Pagination><StartPage>4153</StartPage><EndPage>4169.e19</EndPage><MedlinePgn>4153-4169.e19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2022.09.033</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(22)01252-1</ELocationID><Abstract><AbstractText>Genetic studies have highlighted microglia as pivotal in orchestrating Alzheimer's disease (AD). Microglia that adhere to A&#x3b2; plaques acquire a transcriptional signature, "disease-associated microglia" (DAM), which largely emanates from the TREM2-DAP12 receptor complex that transmits intracellular signals through the protein tyrosine kinase SYK. The human TREM2<sup>R47H</sup> variant associated with high AD risk fails to activate microglia via SYK. We found that SYK-deficient microglia cannot encase A&#x3b2; plaques, accelerating brain pathology and behavioral deficits. SYK deficiency impaired the PI3K-AKT-GSK-3&#x3b2;-mTOR pathway, incapacitating anabolic support required for attaining the DAM profile. However, SYK-deficient microglia proliferated and advanced to an Apoe-expressing prodromal stage of DAM; this pathway relied on the adapter DAP10, which also binds TREM2. Thus, microglial responses to A&#x3b2; involve non-redundant SYK- and DAP10-pathways. Systemic administration of an antibody against CLEC7A, a receptor that directly activates SYK, rescued microglia activation in mice expressing the TREM2<sup>R47H</sup> allele, unveiling new options for AD immunotherapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shoutang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudan</LastName><ForeName>Raki</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yingyue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Siling</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuede</LastName><ForeName>Carla M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Jinchao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Zhangying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Khai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poliani</LastName><ForeName>Pietro L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Pathology Unit, Molecular and Translational Medicine Department, University of Brescia, Brescia 25123, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beatty</LastName><ForeName>Wandy L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Siyan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Kent</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, Devon EX4 4QD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellebedy</LastName><ForeName>Ali H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Gordon D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, Devon EX4 4QD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brioschi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: mcolonna@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR073752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK007130</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059082</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/N006364/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V033417/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R21 AG059176</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/N006364/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>102705/Z/13/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 DK052574</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C000606896">SYK protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D000072377">Syk Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2022 Oct 27;185(22):4043-4045. doi: 10.1016/j.cell.2022.09.043.</RefSource><PMID Version="1">36306731</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072377" MajorTopicYN="N">Syk Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">ApoE</Keyword><Keyword MajorTopicYN="N">Dectin1</Keyword><Keyword MajorTopicYN="N">GSK-3&#x3b2;</Keyword><Keyword MajorTopicYN="N">Syk</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">signaling</Keyword></KeywordList><CoiStatement>Declaration of interests M. Colonna is a member of Vigil Neuro scientific advisory board (SAB), is consultant for Cell Signaling Technology and NGM Bio, has received research grants from Vigil Neuro during the conduct of the study, and has a patent to TREM2 pending. DMH co-founded and is on the SAB of C2N Diagnostics; is on the SAB of Denali, Genentech, and Cajal Neuroscience; consults for Alector; and is on the Advisory Board for Cell.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36306735</ArticleId><ArticleId IdType="mid">NIHMS1843761</ArticleId><ArticleId IdType="pmc">PMC9625082</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.09.033</ArticleId><ArticleId IdType="pii">S0092-8674(22)01252-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman MA, Riecken K, Beccari S, et al. (2017). Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain. Cell Rep. 18, 391&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263237</ArticleId><ArticleId IdType="pubmed">28076784</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. (2015). Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J. Biol. Chem 290, 26043&#x2013;26050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berge K, Roux de B&#xe9;zieux H, Street K, Saelens W, Cannoodt R, Saeys Y, Dudoit S, and Clement L (2020). Trajectory-based differential expression analysis for single-cell sequencing data. Nat. Commun 11, 1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058077</ArticleId><ArticleId IdType="pubmed">32139671</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SYC, and Gordon S (2002). Dectin-1 is a major &#x3b2;-glucan receptor on macrophages. J. Exp. Med 196, 407&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193936</ArticleId><ArticleId IdType="pubmed">12163569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, and Colonna M (2021). Microglia in Alzheimer&#x2019;s disease at single-cell level. Are there common patterns in humans and mice? J. Exp. Med 218, 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302448</ArticleId><ArticleId IdType="pubmed">34292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu DH, Morita CT, and Weiss A (1998). The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol. Rev 165, 167&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850860</ArticleId></ArticleIdList></Reference><Reference><Citation>Claes C, Danhash EP, Hasselmann J, Chadarevian JP, Shabestari SK, England WE, Lim TE, Hidalgo JLS, Spitale RC, Davtyan H, et al. (2021). Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer&#x2019;s disease. Mol. Neurodegener 16, 50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8305935</ArticleId><ArticleId IdType="pubmed">34301296</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, and Grutzendler J (2015). Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun 6, 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell HL, Soneson C, Germain PL, Calini D, Collin L, Raposo C, Malhotra D, and Robinson MD (2020). Muscat Detects Subpopulation-Specific State Transitions From Multi-Sample Multi-Condition Single-Cell Transcriptomics Data. Nat. Commun 11, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705760</ArticleId><ArticleId IdType="pubmed">33257685</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, and Spiegelman B (2003). PGC-1&#x3b1;-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet 34, 267&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldar-Finkelman H (2002). Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol. Med 8, 126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger DC, Wang S, Brioschi S, Shao Z, Green L, Case R, Yoo D, Weishuhn D, Rathanaswami P, Bradley J, et al. (2021). Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A 118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826333</ArticleId><ArticleId IdType="pubmed">33446504</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. (2018). Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer&#x2019;s Disease Not Evident in Mouse Models. Cell Rep. 22, 832&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilfillan S, Ho EL, Cella M, Yokohama WM, and Colonna M (2002). NKG2D recriuts two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol 3, 1150&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">12426564</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, et al. (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (80-.). 330, 841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, Brendecke SM, Kierdorf K, Staszewski O, Datta M, et al. (2013). A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat. Neurosci 16, 1618&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">24077561</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Wieghofer P, Jord&#xe3;o MJC, Prutek F, Hagemeyer N, Frenzel K, Amann L, Staszewski O, Kierdorf K, Krueger M, et al. (2016). Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol 17, 797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet C, De Bruijn MF, Geissmann F, et al. (2015). Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997177</ArticleId><ArticleId IdType="pubmed">25470051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C, and Satija R (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. BioRxiv 576827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, Ni M, Killebrew JR, Chu CL, and Lowell CA (2009). The expanding roles of ITAM adapters FcR&#x3b3; and DAP12 in myeloid cells. Immunol. Rev 232, 42&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248395</ArticleId><ArticleId IdType="pubmed">19909355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, et al. (2021). Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587.e29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Herre J, Marshall ASJ, Caron E, Edwards AD, Williams DL, Schweighoffer E, Tybulewicz V, Reis E Sousa C, Gordon S, and Brown GD (2004). Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 104, 4038&#x2013;4045.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304394</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. (2015). TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med 212, 287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, and Landreth GE (2017). Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci 37, 637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanier LL (2009). DAP10- and DAP12-associated receptors in innate immunity. Immunol. Rev 227, 150&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794881</ArticleId><ArticleId IdType="pubmed">19120482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, Rezzonico MG, Imperio J, Lalehzadeh G, Huntley MA, et al. (2021). Trem2 restrains the enhancement of tau accumulation and neurodegeneration by &#x3b2;-amyloid pathology. Neuron 109, 1283&#x2013;1301.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, and Holtzman DM (2019). Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SE, Walker AJ, Kamath T, Dissing-Olesen L, Hammond TR, de Soysa TY, Young AMH, Murphy S, Abdulraouf A, Nadaf N, et al. (2022). Dissection of artifactual and confounding glial signatures by single-cell sequencing of mouse and human brain. Nat. Neurosci 25, 306&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11645269</ArticleId><ArticleId IdType="pubmed">35260865</ArticleId></ArticleIdList></Reference><Reference><Citation>Mass E, Jacome-Galarza CE, Blank T, Lazarov T, Durham BH, Ozkaya N, Pastore A, Schwabenland M, Chung YR, Rosenblum MK, et al. (2017). A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature 549, 389&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6047345</ArticleId><ArticleId IdType="pubmed">28854169</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, and Selkoe DJ (2012). Biochemistry of amyloid &#x3b2;-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367542</ArticleId><ArticleId IdType="pubmed">22675658</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Amann L, Monaco G, Sankowski R, Staszewski O, Krueger M, Del Gaudio F, He L, Paterson N, Nent E, et al. (2022). Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature 604, 740&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">35444273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, and Tsai LH (2017). Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 21, 366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf3;csai A, Abram CL, Jakus Z, Hu Y, Lanier LL, and Lowell CA (2006). Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat. Immunol 7, 1326&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698344</ArticleId><ArticleId IdType="pubmed">17086186</ArticleId></ArticleIdList></Reference><Reference><Citation>Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, et al. (2020). TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell 182, 886&#x2013;900.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7485282</ArticleId><ArticleId IdType="pubmed">32783918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, and Selkoe DJ (2012). Neurotoxicity of amyloid &#x3b2;-protein: Synaptic and network dysfunction. Cold Spring Harb. Perspect. Med 2, 1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D, et al. (2020). TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron 105, 837&#x2013;854.e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. (2006). Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Malhotra S, Torchia JA, Kerr WG, Coggeshall KM, and Humphrey MB (2010). TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci. Signal 3, 1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900152</ArticleId><ArticleId IdType="pubmed">20484116</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Masuda T, Wheeler MA, and Quintana FJ (2021). Microglia and Central Nervous System-Associated Macrophages mdash from Origin to Disease Modulation. Annu. Rev. Immunol 39, 251&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8085109</ArticleId><ArticleId IdType="pubmed">33556248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, Williams DL, Gordon S, Tybulewicz VL, Brown GD, et al. (2005). Syk-dependent cytokine induction by dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22, 507&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845454</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, Besson-Girard S, Kaya T, Cantuti-Castelvetri L, Liu L, Ji H, Schifferer M, Gouna G, Usifo F, Kannaiyan N, et al. (2021). White matter aging drives microglial diversity. Neuron 109, 1100&#x2013;1117.e10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33606969</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo K, Schmedt C, Su I hsin, Karasuyama H, Lowell CA, Reth M, Adachi T, Patke A, Santana A, and Tarakhovsky A (2003). Essential role of Src-family protein tyrosine kinases in NF-&#x3ba;B activation during B cell development. Nat. Immunol 4, 274&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">12563261</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, Mancuso R, Chen WT, Woodbury ME, Srivastava G, et al. (2019). The Major Risk Factors for Alzheimer&#x2019;s Disease: Age, Sex, and Genes Modulate the Microglia Response to A&#x3b2; Plaques. Cell Rep. 27, 1293&#x2013;1306.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C, Perdiguero EG, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SEW, Pollard JW, et al. (2012). A lineage of myeloid cells independent of myb and hematopoietic stem cells. Science (80-.). 335, 86&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, and Colonna M (2018). Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med 215, 745&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, et al. (2019). Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat. Commun 10, 1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, Purdom E, and Dudoit S (2018). Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 19, 477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6007078</ArticleId><ArticleId IdType="pubmed">29914354</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902.e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A 102, 15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay TL, Mai D, Dautzenberg J, Fern&#xe1;ndez-Klett F, Lin G, Sagar S, Datta M, Drougard A, Stempfl T, Ardura-Fabregat A, et al. (2017). A new fate mapping system reveals context-dependent random or clonal expansion of microglia. Nat. Neurosci 20, 793&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">28414331</ArticleId></ArticleIdList></Reference><Reference><Citation>Thion MS, Ginhoux F, and Garel S (2018). Microglia and early brain development: An intimate journey. Science (80-.). 362, 185&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309946</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasello E, Desmoulins PO, Chemin K, Guia S, Cremer H, Ortaldo J, Love P, Kaiserlian D, and Vivier E (2000). Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. Immunity 13, 355&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">11021533</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M, Schweighoffer E, Colucci F, Di Santo JP, and Tybulewicz VL (2000). Tyrosine kinase SYK: Essential functions for immunoreceptor signalling. Immunol. Today 21, 148&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">10689303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, and Colonna M (2018). TREM2 &#x2014; a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol 14, 667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SCC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. (2017). TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell 170, 649&#x2013;663.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Underhill DM, Rossnagle E, Lowell CA, and Simmons RM (2005). Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood 106, 2543&#x2013;2550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895265</ArticleId><ArticleId IdType="pubmed">15956283</ArticleId></ArticleIdList></Reference><Reference><Citation>Utz SG, See P, Mildenberger W, Thion MS, Silvin A, Lutz M, Ingelfinger F, Rayan NA, Lelios I, Buttgereit A, et al. (2020). Early Fate Defines Microglia and Non-parenchymal Brain Macrophage Development. Cell 181, 557&#x2013;573.e18.</Citation><ArticleIdList><ArticleId IdType="pubmed">32259484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, et al. (2020). Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x2019;s disease model. J. Exp. Med 217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. (2016). TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med 213, 667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wes PD, Sayed FA, Bard F, and Gan L (2016). Targeting microglia for the treatment of Alzheimer&#x2019;s Disease. Glia 64, 1710&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">27100611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak DF, Hartman RE, Boyle MP, Vogt SK, Brooks AR, Tenkova T, Young C, Olney JW, and Muglia LJ (2004). Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol. Dis 17, 403&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571976</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak DF, Diggs-Andrews KA, Conyers S, Yuede CM, Dearborn JT, Brown JA, Tokuda K, Izumi Y, Zorumski CF, and Gutmann DH (2013). Motivational Disturbances and Effects of L-dopa Administration in Neurofibromatosis-1 Model Mice. PLoS One 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677926</ArticleId><ArticleId IdType="pubmed">23762458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, et al. (2003). Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD200. J. Immunol 171, 3034&#x2013;3046.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960329</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong M, Jiang H, Serrano JR, Gonzales ER, Wang C, Gratuze M, Hoyle R, Bien-Ly N, Silverman AP, Sullivan PM, et al. (2021). APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci. Transl. Med 13, 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128342</ArticleId><ArticleId IdType="pubmed">33597265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanishi Y, Kitaura J, Izawa K, Matsuoka T, Oki T, Lu Y, Shibata F, Yamazaki S, Kumagai H, Nakajima H, et al. (2008). Analysis of mouse LMIR5/CLM-7 as an activating receptor: Differential regulation of LMIR5/CLM-7 in mouse versus human cells. Blood 111, 688&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928527</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, Coppola K, Schweig JE, Crawford F, Mullan M, and Paris D (2019). Distinct Signaling Pathways Regulate TREM2 Phagocytic and NF&#x3ba;B Antagonistic Activities. Front. Cell. Neurosci 13, 1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6795686</ArticleId><ArticleId IdType="pubmed">31649511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, and Sheng M (2016). TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron 91, 328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, Misharin A, et al. (2013). Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis. Immunity 38, 79&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3908543</ArticleId><ArticleId IdType="pubmed">23273845</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, and Grutzendler J (2016). TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 90, 724&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pi&#xf1;a-Crespo JC, Zhang M, et al. (2018). TREM2 Is a Receptor for &#x3b2;-Amyloid that Mediates Microglial Function. Neuron 97, 1023&#x2013;1031.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, et al. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegenfuss JS, Biswas R, Avery MA, Hong K, Sheehan AE, Yeung Y-G, Stanley ER, and Freeman MR (2008). Draper-dependent glial phagocytic activity is mediated by Src and Syk family kinase signalling. Nature 453, 935&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493287</ArticleId><ArticleId IdType="pubmed">18432193</ArticleId></ArticleIdList></Reference><Reference><Citation>(2021). 2021 Alzheimer&#x2019;s disease facts and figures. Alzheimers. Dement 17, 327&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36459969</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>A reference human induced pluripotent stem cell line for large-scale collaborative studies.</ArticleTitle><Pagination><StartPage>1685</StartPage><EndPage>1702.e22</EndPage><MedlinePgn>1685-1702.e22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2022.11.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(22)00451-9</ELocationID><Abstract><AbstractText>Human induced pluripotent stem cell (iPSC) lines are a powerful tool for studying development and disease, but the considerable phenotypic variation between lines makes it challenging to replicate key findings and integrate data across research groups. To address this issue, we sub-cloned candidate human iPSC lines and deeply characterized their genetic properties using whole genome sequencing, their genomic stability upon CRISPR-Cas9-based gene editing, and their phenotypic properties including differentiation to commonly used cell types. These studies identified KOLF2.1J as an all-around well-performing iPSC line. We then shared KOLF2.1J with groups around the world who tested its performance in head-to-head comparisons with their own preferred iPSC lines across a diverse range of differentiation protocols and functional assays. On the strength of these findings, we have made KOLF2.1J and its gene-edited derivative clones readily accessible to promote the standardization required for large-scale collaborative science in the stem cell field.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pantazis</LastName><ForeName>Caroline B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK; Wellcome Trust - Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK; Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lara</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonough</LastName><ForeName>Justin A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blauwendraat</LastName><ForeName>Cornelis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Lirong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington, DC, USA; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oguro</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Cell Biology, University of Connecticut Health Center, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanaujiya</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Cell Biology, University of Connecticut Health Center, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Jizhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>iPS Cell Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sebesta</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Gretchen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cross</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blockwick</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buxton</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinner-Bibeau</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medura</LastName><ForeName>Constance</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tompkins</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>KromaTiD Inc., Longmont, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santiana</LastName><ForeName>Marianita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faghri</LastName><ForeName>Faraz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitale</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Yue A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kailyn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadler</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayan</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Genetics and Biochemistry Branch, NIDDK, NINDS, National Institutes of Health, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papademetriou</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reilly</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Sanya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wellcome Trust - Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK; Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Leah U</ForeName><Initials>LU</Initials><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirwan</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Wellcome Trust - Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK; Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisupati</LastName><ForeName>Venkat</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coon</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Molecular Genomics Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Sonja W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priebe</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;ttl</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijer</LastName><ForeName>Marieke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Lara J M</ForeName><Initials>LJM</Initials><AffiliationInfo><Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lourenco</LastName><ForeName>Vanessa S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Kant</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan 1087, 1081 HV Amsterdam, the Netherlands; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crusius</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquet</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital, LMU Munich, 81377 Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raulin</LastName><ForeName>Ana-Caroline</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wainger</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Anesthesiology, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA; Broad Institute of Harvard University and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriele</LastName><ForeName>Rebecca M C</ForeName><Initials>RMC</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casey</LastName><ForeName>Jackie M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu-Bonsrah</LastName><ForeName>Dad</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience &amp; Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia; Department of Pediatrics, University of Melbourne, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parish</LastName><ForeName>Clare L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience &amp; Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beccari</LastName><ForeName>Melinda S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine and Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine and Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Emmy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases and Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Indigo V L</ForeName><Initials>IVL</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases and Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases and Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calatayud Aristoy</LastName><ForeName>Carles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Mission Lucidity, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verstreken</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Mission Lucidity, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinrich</LastName><ForeName>Laurin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Max Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;le</LastName><ForeName>Birgitt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dou</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holzbaur</LastName><ForeName>Erika L F</ForeName><Initials>ELF</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanellati</LastName><ForeName>Maria Clara</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basundra</LastName><ForeName>Richa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deshmukh</LastName><ForeName>Mohanish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>Richa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Developmental Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Malavika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Developmental Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nevin</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matia</LastName><ForeName>Madeline</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Lent</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Peripheral Neuropathy Research Group, Department of Biomedical Sciences, University of Antwerp, Antwerp 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmerman</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Peripheral Neuropathy Research Group, Department of Biomedical Sciences, University of Antwerp, Antwerp 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conklin</LastName><ForeName>Bruce R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson Chase</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funes</LastName><ForeName>Salome</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMass Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Daryl A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMass Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erlebach</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany; German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welzer</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany; German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kronenberg-Versteeg</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany; German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Guochang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenas</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coccia</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience; Departments of Neurology and Cell, Developmental and Regenerative Biology; Ronald M. Loeb Center for Alzheimer's Disease; Friedman Brain Institute; Black Family Stem Cell Institute at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarrafha</LastName><ForeName>Lily</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience; Departments of Neurology and Cell, Developmental and Regenerative Biology; Ronald M. Loeb Center for Alzheimer's Disease; Friedman Brain Institute; Black Family Stem Cell Institute at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahfeldt</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience; Departments of Neurology and Cell, Developmental and Regenerative Biology; Ronald M. Loeb Center for Alzheimer's Disease; Friedman Brain Institute; Black Family Stem Cell Institute at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marioni</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skarnes</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic address: bill.skarnes@jax.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. Electronic address: cookson@mail.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: michael.ward4@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkle</LastName><ForeName>Florian T</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>Wellcome Trust - Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK; Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK. Electronic address: fm436@medschl.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/R015724/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T32 AG000255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060698</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS115706</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG072052</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG072052</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS114319</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS117461</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AG000535</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM127557</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK125747</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG066596</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRISPR</Keyword><Keyword MajorTopicYN="N">differentiation</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">karyotype</Keyword><Keyword MajorTopicYN="N">p53</Keyword><Keyword MajorTopicYN="N">pluripotent</Keyword><Keyword MajorTopicYN="N">reference</Keyword><Keyword MajorTopicYN="N">single-cell</Keyword><Keyword MajorTopicYN="N">stem cell</Keyword><Keyword MajorTopicYN="N">whole-genome</Keyword></KeywordList><CoiStatement>Declaration of interests S.W.S. is on the scientific advisory council of the Lewy Body Dementia Association and the MSA Coalition. S.W.S. is an editorial board member for the Journal of Parkinson Disease and JAMA Neurology. S.W.S. received research support from Cerevel Therapeutics. M.K. serves on the scientific advisory boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, and Alector and is a consultant to Modulo Bio and Recursion Therapeutics. Participation by researchers from Data Tecnica International, LLC in this project was part of a competitive contract awarded to Data Tecnica International, LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc. E.A. is founder, shareholder, and scientific advisor of Cholestenix, Ltd.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36459969</ArticleId><ArticleId IdType="mid">NIHMS1855600</ArticleId><ArticleId IdType="pmc">PMC9782786</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2022.11.004</ArticleId><ArticleId IdType="pii">S1934-5909(22)00451-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy EA, Paquet D, Duffield M, Fak J, Olsen O, Darnell RB, and Tessier-Lavigne M (2019). A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP beta-CTFs, Not Abeta. Neuron 104, 256&#x2013;270 e255. 10.1016/j.neuron.2019.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.010</ArticleId><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Konttinen H, Cabral-da-Silva MEC, Ohtonen S, Wojciechowski S, Shakirzyanova A, Caligola S, Giugno R, Ishchenko Y, Hernandez D, Fazaludeen MF, et al. (2019). PSEN1DeltaE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. Stem Cell Reports 13, 669&#x2013;683. 10.1016/j.stemcr.2019.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.08.004</ArticleId><ArticleId IdType="pmc">PMC6829767</ArticleId><ArticleId IdType="pubmed">31522977</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttikonda SR, Sikkema L, Tchieu J, Saurat N, Walsh RM, Harschnitz O, Ciceri G, Sneeboer M, Mazutis L, Setty M, et al. (2021). Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer&#x2019;s disease. Nat Neurosci 24, 343&#x2013;354. 10.1038/s41593-020-00796-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00796-z</ArticleId><ArticleId IdType="pmc">PMC8382543</ArticleId><ArticleId IdType="pubmed">33558694</ArticleId></ArticleIdList></Reference><Reference><Citation>Doetschman T (2009). Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol 530, 423&#x2013;433. 10.1007/978-1-59745-471-1_23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-471-1_23</ArticleId><ArticleId IdType="pmc">PMC2805848</ArticleId><ArticleId IdType="pubmed">19266333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, Farrall M, and Akhurst RJ (1997). Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. Nat Genet 15, 207&#x2013;211. 10.1038/ng0297-207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0297-207</ArticleId><ArticleId IdType="pubmed">9020852</ArticleId></ArticleIdList></Reference><Reference><Citation>Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, and et al. (1995). Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230&#x2013;234. 10.1126/science.7618084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7618084</ArticleId><ArticleId IdType="pubmed">7618084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterken MG, Snoek LB, Kammenga JE, and Andersen EC (2015). The laboratory domestication of Caenorhabditis elegans. Trends Genet 31, 224&#x2013;231. 10.1016/j.tig.2015.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2015.02.009</ArticleId><ArticleId IdType="pmc">PMC4417040</ArticleId><ArticleId IdType="pubmed">25804345</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay TFC, and Huang W (2018). Charting the genotype-phenotype map: lessons from the Drosophila melanogaster Genetic Reference Panel. Wiley Interdiscip Rev Dev Biol 7. 10.1002/wdev.289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wdev.289</ArticleId><ArticleId IdType="pmc">PMC5746472</ArticleId><ArticleId IdType="pubmed">28834395</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittig LJ, Carbonetto P, Engel KA, Krauss KS, Barrios-Camacho CM, and Palmer AA (2016). Genetic Background Limits Generalizability of Genotype-Phenotype Relationships. Neuron 91, 1253&#x2013;1259. 10.1016/j.neuron.2016.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.08.013</ArticleId><ArticleId IdType="pmc">PMC5033712</ArticleId><ArticleId IdType="pubmed">27618673</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts B, Haupt A, Tucker A, Grancharova T, Arakaki J, Fuqua MA, Nelson A, Hookway C, Ludmann SA, Mueller IA, et al. (2017). Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization. Mol Biol Cell 28, 2854&#x2013;2874. 10.1091/mbc.E17-03-0209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E17-03-0209</ArticleId><ArticleId IdType="pmc">PMC5638588</ArticleId><ArticleId IdType="pubmed">28814507</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts B, Hendershott MC, Arakaki J, Gerbin KA, Malik H, Nelson A, Gehring J, Hookway C, Ludmann SA, Yang R, et al. (2019). Fluorescent Gene Tagging of Transcriptionally Silent Genes in hiPSCs. Stem Cell Reports 12, 1145&#x2013;1158. 10.1016/j.stemcr.2019.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.03.001</ArticleId><ArticleId IdType="pmc">PMC6522946</ArticleId><ArticleId IdType="pubmed">30956114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos DM, Skarnes WC, Singleton AB, Cookson MR, and Ward ME (2021). Tackling neurodegenerative diseases with genomic engineering: A new stem cell initiative from the NIH. Neuron 109, 1080&#x2013;1083. 10.1016/j.neuron.2021.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.03.022</ArticleId><ArticleId IdType="pmc">PMC8985232</ArticleId><ArticleId IdType="pubmed">33831364</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly L, Peng L, Lara E, Ramos D, Fernandopulle M, Pantazis CB, Stadler J, Santiana M, Dadu A, Iben J, et al. (2021). A fully automated FAIMS-DIA proteomic pipeline for high-throughput characterization of iPSC-derived neurons. bioRxiv, 2021.2011.2024.469921. 10.1101/2021.11.24.469921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.24.469921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekhoubad S, Bock C, de Boer AS, Kiskinis E, Meissner A, and Eggan K (2012). Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 10, 595&#x2013;609. 10.1016/j.stem.2012.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2012.02.014</ArticleId><ArticleId IdType="pmc">PMC3603710</ArticleId><ArticleId IdType="pubmed">22560080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar S, Seaton LR, Weissbein U, Eldar-Geva T, and Benvenisty N (2019). Global Characterization of X Chromosome Inactivation in Human Pluripotent Stem Cells. Cell Rep 27, 20&#x2013;29 e23. 10.1016/j.celrep.2019.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.03.019</ArticleId><ArticleId IdType="pubmed">30943402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrandt MR, Reuter MS, Wei W, Tayebi N, Liu J, Sharmin S, Mulder J, Lesperance LS, Brauer PM, Mok RSF, et al. (2019). Precision Health Resource of Control iPSC Lines for Versatile Multilineage Differentiation. Stem Cell Reports 13, 1126&#x2013;1141. 10.1016/j.stemcr.2019.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.11.003</ArticleId><ArticleId IdType="pmc">PMC6915802</ArticleId><ArticleId IdType="pubmed">31813827</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson E, McKenna MJ, Bedford JS, Goodwin EH, Cornforth MN, Bailey SM, and Ray FA (2019). Directional Genomic Hybridization (dGH) for Detection of Intrachromosomal Rearrangements. Methods Mol Biol 1984, 107&#x2013;116. 10.1007/978-1-4939-9432-8_13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9432-8_13</ArticleId><ArticleId IdType="pubmed">31267426</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, McCarthy DJ, and Stegle O (2019). Vireo: Bayesian demultiplexing of pooled single-cell RNA-seq data without genotype reference. Genome Biol 20, 273. 10.1186/s13059-019-1865-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1865-2</ArticleId><ArticleId IdType="pmc">PMC6909514</ArticleId><ArticleId IdType="pubmed">31836005</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliwell J, Barbaric I, and Andrews PW (2020). Acquired genetic changes in human pluripotent stem cells: origins and consequences. Nat Rev Mol Cell Biol 21, 715&#x2013;728. 10.1038/s41580-020-00292-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-020-00292-z</ArticleId><ArticleId IdType="pubmed">32968234</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkle FT, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C, Kashin S, Mekhoubad S, Ilic D, Charlton M, et al. (2017). Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 545, 229&#x2013;233. 10.1038/nature22312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22312</ArticleId><ArticleId IdType="pmc">PMC5427175</ArticleId><ArticleId IdType="pubmed">28445466</ArticleId></ArticleIdList></Reference><Reference><Citation>Avior Y, Lezmi E, Eggan K, and Benvenisty N (2021). Cancer-Related Mutations Identified in Primed Human Pluripotent Stem Cells. Cell Stem Cell 28, 10&#x2013;11. 10.1016/j.stem.2020.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.11.013</ArticleId><ArticleId IdType="pubmed">33321073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, Kommineni S, Chen J, Sondey M, Ye C, et al. (2018). p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med 24, 939&#x2013;946. 10.1038/s41591-018-0050-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0050-6</ArticleId><ArticleId IdType="pubmed">29892062</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434&#x2013;443. 10.1038/s41586-020-2308-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Nothen MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehmkuhl G, Poustka F, Schmidt M, Catalano M, Fimmers R, and et al. (1994). Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 3, 2207&#x2013;2212. 10.1093/hmg/3.12.2207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/3.12.2207</ArticleId><ArticleId IdType="pubmed">7881421</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaheen R, Sebai MA, Patel N, Ewida N, Kurdi W, Altweijri I, Sogaty S, Almardawi E, Seidahmed MZ, Alnemri A, et al. (2017). The genetic landscape of familial congenital hydrocephalus. Ann Neurol 81, 890&#x2013;897. 10.1002/ana.24964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24964</ArticleId><ArticleId IdType="pubmed">28556411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, et al. (2019). Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51, 414&#x2013;430. 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, et al. (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18, 1091&#x2013;1102. 10.1016/S1474-4422(19)30320-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarnes WC, Ning G, Giansiracusa S, Cruz AS, Blauwendraat C, Saavedra B, Holden K, Cookson MR, Ward ME, and McDonough JA (2021). Controlling homology-directed repair outcomes in human stem cells with dCas9. bioRxiv, 2021.2012.2016.472942. 10.1101/2021.12.16.472942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.16.472942</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarnes WC, Pellegrino E, and McDonough JA (2019). Improving homology-directed repair efficiency in human stem cells. Methods 164&#x2013;165, 18&#x2013;28. 10.1016/j.ymeth.2019.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2019.06.016</ArticleId><ArticleId IdType="pubmed">31216442</ArticleId></ArticleIdList></Reference><Reference><Citation>Apte SS, Mattei MG, and Olsen BR (1994). Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 19, 86&#x2013;90. 10.1006/geno.1994.1016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1994.1016</ArticleId><ArticleId IdType="pubmed">8188246</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisheit I, Kroeger JA, Malik R, Klimmt J, Crusius D, Dannert A, Dichgans M, and Paquet D (2020). Detection of Deleterious On-Target Effects after HDR-Mediated CRISPR Editing. Cell Rep 31, 107689. 10.1016/j.celrep.2020.107689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107689</ArticleId><ArticleId IdType="pubmed">32460021</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkle FT, Neuhausser WM, Santos D, Valen E, Gagnon JA, Maas K, Sandoe J, Schier AF, and Eggan K (2015). Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus. Cell Rep 11, 875&#x2013;883. 10.1016/j.celrep.2015.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.04.007</ArticleId><ArticleId IdType="pmc">PMC5533178</ArticleId><ArticleId IdType="pubmed">25937281</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C, Faghri F, Pihlstrom L, Geiger JT, Elbaz A, Lesage S, Corvol JC, May P, Nicolas A, Abramzon Y, et al. (2017). NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging 57, 247 e249&#x2013;247 e213. 10.1016/j.neurobiolaging.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.009</ArticleId><ArticleId IdType="pmc">PMC5534378</ArticleId><ArticleId IdType="pubmed">28602509</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, and Sham PC (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559&#x2013;575. 10.1086/519795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>International Stem Cell I, Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, et al. (2011). Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 29, 1132&#x2013;1144. 10.1038/nbt.2051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2051</ArticleId><ArticleId IdType="pmc">PMC3454460</ArticleId><ArticleId IdType="pubmed">22119741</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee S, Barrero MJ, et al. (2011). Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8, 106&#x2013;118. 10.1016/j.stem.2010.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2010.12.003</ArticleId><ArticleId IdType="pmc">PMC3043464</ArticleId><ArticleId IdType="pubmed">21211785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefort N, Feyeux M, Bas C, Feraud O, Bennaceur-Griscelli A, Tachdjian G, Peschanski M, and Perrier AL (2008). Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat Biotechnol 26, 1364&#x2013;1366. 10.1038/nbt.1509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1509</ArticleId><ArticleId IdType="pubmed">19029913</ArticleId></ArticleIdList></Reference><Reference><Citation>Narva E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P, et al. (2010). High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 28, 371&#x2013;377. 10.1038/nbt.1615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1615</ArticleId><ArticleId IdType="pubmed">20351689</ArticleId></ArticleIdList></Reference><Reference><Citation>Spits C, Mateizel I, Geens M, Mertzanidou A, Staessen C, Vandeskelde Y, Van der Elst J, Liebaers I, and Sermon K (2008). Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol 26, 1361&#x2013;1363. 10.1038/nbt.1510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1510</ArticleId><ArticleId IdType="pubmed">19029912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Kim KJ, Mehta K, Paxia S, Sundstrom A, Anantharaman T, Kuraishy AI, Doan T, Ghosh J, Pyle AD, et al. (2008). Copy number variant analysis of human embryonic stem cells. Stem Cells 26, 1484&#x2013;1489. 10.1634/stemcells.2007-0993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.2007-0993</ArticleId><ArticleId IdType="pmc">PMC3901366</ArticleId><ArticleId IdType="pubmed">18369100</ArticleId></ArticleIdList></Reference><Reference><Citation>Markouli C, Couvreu De Deckersberg E, Regin M, Nguyen HT, Zambelli F, Keller A, Dziedzicka D, De Kock J, Tilleman L, Van Nieuwerburgh F, et al. (2019). Gain of 20q11.21 in Human Pluripotent Stem Cells Impairs TGF-beta-Dependent Neuroectodermal Commitment. Stem Cell Reports 13, 163&#x2013;176. 10.1016/j.stemcr.2019.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.05.005</ArticleId><ArticleId IdType="pmc">PMC6627003</ArticleId><ArticleId IdType="pubmed">31178415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Park IH, Gao Y, Li JB, Li Z, Daley GQ, Zhang K, and Church GM (2009). A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet 5, e1000718. 10.1371/journal.pgen.1000718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000718</ArticleId><ArticleId IdType="pmc">PMC2766639</ArticleId><ArticleId IdType="pubmed">19911041</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouhani FJ, Zou X, Danecek P, Badja C, Amarante TD, Koh G, Wu Q, Memari Y, Durbin R, Martincorena I, et al. (2022). Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells. Nat Genet 54, 1406&#x2013;1416. 10.1038/s41588-022-01147-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01147-3</ArticleId><ArticleId IdType="pmc">PMC9470532</ArticleId><ArticleId IdType="pubmed">35953586</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadista J, Oskolkov N, Hansson O, and Groop L (2017). LoFtool: a gene intolerance score based on loss-of-function variants in 60 706 individuals. Bioinformatics 33, 471&#x2013;474. 10.1093/bioinformatics/btv602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv602</ArticleId><ArticleId IdType="pubmed">27563026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin CL, Nussbaum RL, et al. (2015). ClinGen--the Clinical Genome Resource. N Engl J Med 372, 2235&#x2013;2242. 10.1056/NEJMsr1406261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1406261</ArticleId><ArticleId IdType="pmc">PMC4474187</ArticleId><ArticleId IdType="pubmed">26014595</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenske P, Grauel MK, Brockmann MM, Dorrn AL, Trimbuch T, and Rosenmund C (2019). Autaptic cultures of human induced neurons as a versatile platform for studying synaptic function and neuronal morphology. Sci Rep 9, 4890. 10.1038/s41598-019-41259-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41259-1</ArticleId><ArticleId IdType="pmc">PMC6427022</ArticleId><ArticleId IdType="pubmed">30894602</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee HJ, Shaib AH, Rehbach K, Lee C, Seif P, Thomas C, Gideons E, Guenther A, Krutenko T, Hebisch M, et al. (2019). An Autaptic Culture System for Standardized Analyses of iPSC-Derived Human Neurons. Cell Rep 27, 2212&#x2013;2228 e2217. 10.1016/j.celrep.2019.04.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.059</ArticleId><ArticleId IdType="pubmed">31091457</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer M, Rehbach K, Brunner JW, Classen JA, Lammertse HCA, van Linge LA, Schut D, Krutenko T, Hebisch M, Cornelisse LN, et al. (2019). A Single-Cell Model for Synaptic Transmission and Plasticity in Human iPSC-Derived Neurons. Cell Rep 27, 2199&#x2013;2211 e2196. 10.1016/j.celrep.2019.04.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.058</ArticleId><ArticleId IdType="pubmed">31091456</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, and Yamanaka S (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861&#x2013;872. 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, and Schneider JA (2018). Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 64, S161&#x2013;S189. 10.3233/JAD-179939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Umekage M, Sato Y, and Takasu N (2019). Overview: an iPS cell stock at CiRA. Inflamm Regen 39, 17. 10.1186/s41232-019-0106-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-019-0106-0</ArticleId><ArticleId IdType="pmc">PMC6717959</ArticleId><ArticleId IdType="pubmed">31497180</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerber J, Seaton DD, Cuomo ASE, Kumasaka N, Haldane J, Steer J, Patel M, Pearce D, Andersson M, Bonder MJ, et al. (2021). Population-scale single-cell RNA-seq profiling across dopaminergic neuron differentiation. Nat Genet 53, 304&#x2013;312. 10.1038/s41588-021-00801-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00801-6</ArticleId><ArticleId IdType="pmc">PMC7610897</ArticleId><ArticleId IdType="pubmed">33664506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JM, Nemesh J, Ghosh S, Handsaker RE, Mello CJ, Meyer D, Raghunathan K, de Rivera H, Tegtmeyer M, Hawes D, et al. (2020). Mapping genetic effects on cellular phenotypes with &#x201c;cell villages&#x201d;. bioRxiv, 2020.2006.2029.174383. 10.1101/2020.06.29.174383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.29.174383</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkle FT, Ghosh S, Genovese G, Handsaker RE, Kashin S, Meyer D, Karczewski KJ, O&#x2019;Dushlaine C, Pato C, Pato M, et al. (2022). Whole-genome analysis of human embryonic stem cells enables rational line selection based on genetic variation. Cell Stem Cell 29, 472&#x2013;486 e477. 10.1016/j.stem.2022.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2022.01.011</ArticleId><ArticleId IdType="pmc">PMC8900618</ArticleId><ArticleId IdType="pubmed">35176222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpinen H, Goncalves A, Leha A, Afzal V, Alasoo K, Ashford S, Bala S, Bensaddek D, Casale FP, Culley OJ, et al. (2017). Common genetic variation drives molecular heterogeneity in human iPSCs. Nature 546, 370&#x2013;375. 10.1038/nature22403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22403</ArticleId><ArticleId IdType="pmc">PMC5524171</ArticleId><ArticleId IdType="pubmed">28489815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruntraeger M, Byrne M, Long K, and Bassett AR (2019). Editing the Genome of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9 Ribonucleoprotein Complexes. Methods Mol Biol 1961, 153&#x2013;183. 10.1007/978-1-4939-9170-9_11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9170-9_11</ArticleId><ArticleId IdType="pubmed">30912046</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R, Abarientos A, Hong J, Hashemi SH, Yan R, Drager N, Leng K, Nalls MA, Singleton AB, Xu K, et al. (2021). Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis. Nat Neurosci 24, 1020&#x2013;1034. 10.1038/s41593-021-00862-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00862-0</ArticleId><ArticleId IdType="pmc">PMC8254803</ArticleId><ArticleId IdType="pubmed">34031600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R, Gachechiladze MA, Ludwig CH, Laurie MT, Hong JY, Nathaniel D, Prabhu AV, Fernandopulle MS, Patel R, Abshari M, et al. (2019). CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. Neuron 104, 239&#x2013;255 e212. 10.1016/j.neuron.2019.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.014</ArticleId><ArticleId IdType="pmc">PMC6813890</ArticleId><ArticleId IdType="pubmed">31422865</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Farias FHG, Dube U, Del-Aguila JL, Mihindukulasuriya KA, Fernandez MV, Ibanez L, Budde JP, Wang F, Lake AM, et al. (2020). The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol 139, 45&#x2013;61. 10.1007/s00401-019-02066-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02066-0</ArticleId><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Assou S, Girault N, Plinet M, Bouckenheimer J, Sansac C, Combe M, Mianne J, Bourguignon C, Fieldes M, Ahmed E, et al. (2020). Recurrent Genetic Abnormalities in Human Pluripotent Stem Cells: Definition and Routine Detection in Culture Supernatant by Targeted Droplet Digital PCR. Stem Cell Reports 14, 1&#x2013;8. 10.1016/j.stemcr.2019.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.12.004</ArticleId><ArticleId IdType="pmc">PMC6962701</ArticleId><ArticleId IdType="pubmed">31902703</ArticleId></ArticleIdList></Reference><Reference><Citation>el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817&#x2013;825. 10.1016/0092-8674(93)90500-p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90500-p</ArticleId><ArticleId IdType="pubmed">8242752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusa K, Zhou L, Li MA, Bradley A, and Craig NL (2011). A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A 108, 1531&#x2013;1536. 10.1073/pnas.1008322108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008322108</ArticleId><ArticleId IdType="pmc">PMC3029773</ArticleId><ArticleId IdType="pubmed">21205896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray FA, Zimmerman E, Robinson B, Cornforth MN, Bedford JS, Goodwin EH, and Bailey SM (2013). Directional genomic hybridization for chromosomal inversion discovery and detection. Chromosome Res 21, 165&#x2013;174. 10.1007/s10577-013-9345-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10577-013-9345-0</ArticleId><ArticleId IdType="pmc">PMC3627024</ArticleId><ArticleId IdType="pubmed">23572395</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe B, Umrigar A, and Tsien F (2014). Chromosome preparation from cultured cells. J Vis Exp, e50203. 10.3791/50203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/50203</ArticleId><ArticleId IdType="pmc">PMC4091199</ArticleId><ArticleId IdType="pubmed">24513647</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, and Hakonarson H (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38, e164. 10.1093/nar/gkq603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq603</ArticleId><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O&#x2019;Connell J, et al. (2018). The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203&#x2013;209. 10.1038/s41586-018-0579-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0579-z</ArticleId><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogarten SM, Bhangale T, Conomos MP, Laurie CA, McHugh CP, Painter I, Zheng X, Crosslin DR, Levine D, Lumley T, et al. (2012). GWASTools: an R/Bioconductor package for quality control and analysis of genome-wide association studies. Bioinformatics 28, 3329&#x2013;3331. 10.1093/bioinformatics/bts610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts610</ArticleId><ArticleId IdType="pmc">PMC3519456</ArticleId><ArticleId IdType="pubmed">23052040</ArticleId></ArticleIdList></Reference><Reference><Citation>Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwham A, Keane T, McCarthy SA, Davies RM, and Li H (2021). Twelve years of SAMtools and BCFtools. Gigascience 10. 10.1093/gigascience/giab008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giab008</ArticleId><ArticleId IdType="pmc">PMC7931819</ArticleId><ArticleId IdType="pubmed">33590861</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JT, Thorvaldsdottir H, Wenger AM, Zehir A, and Mesirov JP (2017). Variant Review with the Integrative Genomics Viewer. Cancer Res 77, e31&#x2013;e34. 10.1158/0008-5472.CAN-17-0337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0337</ArticleId><ArticleId IdType="pmc">PMC5678989</ArticleId><ArticleId IdType="pubmed">29092934</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, and Ward ME (2018). Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol 79, e51. 10.1002/cpcb.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpcb.51</ArticleId><ArticleId IdType="pmc">PMC6993937</ArticleId><ArticleId IdType="pubmed">29924488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan P, Jura M, and Merkle FT (2017). Generation and Characterization of Functional Human Hypothalamic Neurons. Curr Protoc Neurosci 81, 3 33 31&#x2013;33 33 24. 10.1002/cpns.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpns.40</ArticleId><ArticleId IdType="pubmed">29064566</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkle FT, Maroof A, Wataya T, Sasai Y, Studer L, Eggan K, and Schier AF (2015). Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cells. Development 142, 633&#x2013;643. 10.1242/dev.117978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.117978</ArticleId><ArticleId IdType="pmc">PMC4325380</ArticleId><ArticleId IdType="pubmed">25670790</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Patterson DM, Winkler J, Conrad DN, Hein MY, Srivastava V, Hu JL, Murrow LM, Weissman JS, Werb Z, et al. (2019). MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. Nat Methods 16, 619&#x2013;626. 10.1038/s41592-019-0433-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0433-8</ArticleId><ArticleId IdType="pmc">PMC6837808</ArticleId><ArticleId IdType="pubmed">31209384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, Riesenfeld S, Andrews T, Dao TP, Gomes T, participants in the 1st Human Cell Atlas J, and Marioni JC (2019). EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol 20, 63. 10.1186/s13059-019-1662-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1662-y</ArticleId><ArticleId IdType="pmc">PMC6431044</ArticleId><ArticleId IdType="pubmed">30902100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun AT, McCarthy DJ, and Marioni JC (2016). A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122. 10.12688/f1000research.9501.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.9501.2</ArticleId><ArticleId IdType="pmc">PMC5112579</ArticleId><ArticleId IdType="pubmed">27909575</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. (2016). Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189&#x2013;196. 10.1126/science.aad0501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad0501</ArticleId><ArticleId IdType="pmc">PMC4944528</ArticleId><ArticleId IdType="pubmed">27124452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, et al. (2021). Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587 e3529. 10.1016/j.cell.2021.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.048</ArticleId><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bais AS, and Kostka D (2020). scds: computational annotation of doublets in single-cell RNA sequencing data. Bioinformatics 36, 1150&#x2013;1158. 10.1093/bioinformatics/btz698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz698</ArticleId><ArticleId IdType="pmc">PMC7703774</ArticleId><ArticleId IdType="pubmed">31501871</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L, Lun ATL, Morgan MD, and Marioni JC (2018). Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol 36, 421&#x2013;427. 10.1038/nbt.4091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4091</ArticleId><ArticleId IdType="pmc">PMC6152897</ArticleId><ArticleId IdType="pubmed">29608177</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, and Melville J (2018). Umap: Uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:1802.03426.</Citation></Reference><Reference><Citation>Cs&#xe1;rdi G, and Nepusz T (2006). The igraph software package for complex network research.</Citation></Reference><Reference><Citation>Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, Kahler DJ, Yamaki M, Davidow L, et al. (2011). A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 29, 279&#x2013;286. 10.1038/nbt.1783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1783</ArticleId><ArticleId IdType="pmc">PMC3229307</ArticleId><ArticleId IdType="pubmed">21293464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Tristan CA, Chen L, Jovanovic VM, Malley C, Chu PH, Ryu S, Deng T, Ormanoglu P, Tao D, et al. (2021). A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells. Nat Methods 18, 528&#x2013;541. 10.1038/s41592-021-01126-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-021-01126-2</ArticleId><ArticleId IdType="pmc">PMC8314867</ArticleId><ArticleId IdType="pubmed">33941937</ArticleId></ArticleIdList></Reference><Reference><Citation>Carles Calatayud, E.M.-P., Sandra Fern&#xe1;ndez-Gallego, and Patrik Verstreken (n.d.). Modular Generation of Cortical, Striatal and Ventral Midbrain Progenitor Cells v1.</Citation></Reference><Reference><Citation>Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson&#x2019;s disease. Nature 480, 547&#x2013;551. 10.1038/nature10648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10648</ArticleId><ArticleId IdType="pmc">PMC3245796</ArticleId><ArticleId IdType="pubmed">22056989</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, and Livesey FJ (2012). Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 7, 1836&#x2013;1846. 10.1038/nprot.2012.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.116</ArticleId><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C, Precious SV, Cambray S, Risner-Janiczek JR, Kelly C, Noakes Z, Fjodorova M, Heuer A, Ungless MA, Rodriguez TA, et al. (2015). Activin A directs striatal projection neuron differentiation of human pluripotent stem cells. Development 142, 1375&#x2013;1386. 10.1242/dev.117093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.117093</ArticleId><ArticleId IdType="pmc">PMC4378247</ArticleId><ArticleId IdType="pubmed">25804741</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmacz B, Fox H, Gutteridge A, Fish P, Lubitz S, and Whiting P (2012). Directing differentiation of human embryonic stem cells toward anterior neural ectoderm using small molecules. Stem Cells 30, 1875&#x2013;1884. 10.1002/stem.1166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1166</ArticleId><ArticleId IdType="pubmed">22761025</ArticleId></ArticleIdList></Reference><Reference><Citation>Moya N, Cutts J, Gaasterland T, Willert K, and Brafman DA (2014). Endogenous WNT signaling regulates hPSC-derived neural progenitor cell heterogeneity and specifies their regional identity. Stem Cell Reports 3, 1015&#x2013;1028. 10.1016/j.stemcr.2014.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2014.10.004</ArticleId><ArticleId IdType="pmc">PMC4264562</ArticleId><ArticleId IdType="pubmed">25458891</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich L, Zafar F, Morato Torres CA, Singh J, Khan A, Chen MY, Hempel C, Nikulina N, Mulholland J, Braubach O, and Schule B (2022). Multiplex imaging of human induced pluripotent stem cell-derived neurons with CO-Detection by indEXing (CODEX) technology. J Neurosci Methods 378, 109653. 10.1016/j.jneumeth.2022.109653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2022.109653</ArticleId><ArticleId IdType="pubmed">35724898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar FTA; Heinrich L; Singh J; Hempel C; Braubch O; Schuele B (2022). Protocol for CODEX Fixation Steps and Primary Antibody Staining for Induced Pluripotent Stem Cell-Derived Neurons.</Citation></Reference><Reference><Citation>Srinivasaraghavan V, Zafar F, and Schuele B (2022). Gene Expression Analysis in Stem Cell-derived Cortical Neuronal Cultures Using Multi-well SYBR Green Quantitative PCR Arrays. Bio-Protocol 12, e4283. 10.21769/BioProtoc.4283.</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/BioProtoc.4283</ArticleId><ArticleId IdType="pmc">PMC9350924</ArticleId><ArticleId IdType="pubmed">35978575</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan TA, Revah O, Gordon A, Yoon SJ, Krawisz AK, Goold C, Sun Y, Kim CH, Tian Y, Li MY, et al. (2020). Neuronal defects in a human cellular model of 22q11.2 deletion syndrome. Nat Med 26, 1888&#x2013;1898. 10.1038/s41591-020-1043-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1043-9</ArticleId><ArticleId IdType="pmc">PMC8525897</ArticleId><ArticleId IdType="pubmed">32989314</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid B, Holst B, Poulsen U, Jorring I, Clausen C, Rasmussen M, Mau-Holzmann UA, Steeg R, Nuthall H, Ebneth A, and Cabrera-Socorro A (2021). Generation of two gene edited iPSC-lines carrying a DOX-inducible NGN2 expression cassette with and without GFP in the AAVS1 locus. Stem Cell Res 52, 102240. 10.1016/j.scr.2021.102240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2021.102240</ArticleId><ArticleId IdType="pubmed">33610017</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KM, Gregg A, Noggle S, and Tessier-Lavigne M (2016). Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533, 125&#x2013;129. 10.1038/nature17664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17664</ArticleId><ArticleId IdType="pubmed">27120160</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, and Blurton-Jones M (2018). Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener 13, 67. 10.1186/s13024-018-0297-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0297-x</ArticleId><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Reifschneider A, Robinson S, van Lengerich B, Gnorich J, Logan T, Heindl S, Vogt MA, Weidinger E, Riedl L, Wind K, et al. (2022). Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO J 41, e109108. 10.15252/embj.2021109108.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021109108</ArticleId><ArticleId IdType="pmc">PMC8844989</ArticleId><ArticleId IdType="pubmed">35019161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, and Ciccarone VC (2004). Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33, 95&#x2013;103. 10.1016/j.ymeth.2003.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2003.11.023</ArticleId><ArticleId IdType="pubmed">15121163</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C, Toombs J, Lovejoy C, Ryan NS, Paterson RW, Willumsen N, Gkanatsiou E, Portelius E, Blennow K, Heslegrave A, et al. (2020). Familial Alzheimer&#x2019;s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol Psychiatry 25, 2919&#x2013;2931. 10.1038/s41380-019-0410-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0410-8</ArticleId><ArticleId IdType="pmc">PMC7577860</ArticleId><ArticleId IdType="pubmed">30980041</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T, Preza E, Mahoney CJ, Seto-Salvia N, Ryan NS, Morris HR, Arber C, Devine MJ, Houlden H, Warner TT, et al. (2015). Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Hum Mol Genet 24, 5260&#x2013;5269. 10.1093/hmg/ddv246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv246</ArticleId><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chal J, Al Tanoury Z, Hestin M, Gobert B, Aivio S, Hick A, Cherrier T, Nesmith AP, Parker KK, and Pourquie O (2016). Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro. Nat Protoc 11, 1833&#x2013;1850. 10.1038/nprot.2016.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.110</ArticleId><ArticleId IdType="pubmed">27583644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantner CW, Hunt CPJ, Niclis JC, Penna V, McDougall SJ, Thompson LH, and Parish CL (2021). FGF-MAPK signaling regulates human deep-layer corticogenesis. Stem Cell Reports 16, 1262&#x2013;1275. 10.1016/j.stemcr.2021.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.03.014</ArticleId><ArticleId IdType="pmc">PMC8185433</ArticleId><ArticleId IdType="pubmed">33836146</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Zaepfel BL, Hayes L, Fitchman B, Salzberg Y, Luo EC, Bowen K, Trost H, Aigner S, Rigo F, et al. (2020). G4C2 Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD. Neuron 107, 1124&#x2013;1140 e1111. 10.1016/j.neuron.2020.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.06.027</ArticleId><ArticleId IdType="pmc">PMC8077944</ArticleId><ArticleId IdType="pubmed">32673563</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FJ, Pratt GA, Van Nostrand EL, Batra R, Huelga SC, Kapeli K, Freese P, Chun SJ, Ling K, Gelboin-Burkhart C, et al. (2016). Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System. Neuron 92, 780&#x2013;795. 10.1016/j.neuron.2016.09.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.050</ArticleId><ArticleId IdType="pmc">PMC5123850</ArticleId><ArticleId IdType="pubmed">27773581</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutbier S, Wanke F, Dahm N, Rummelin A, Zimmermann S, Christensen K, Kochl F, Rautanen A, Hatje K, Geering B, et al. (2020). Large-Scale Production of Human iPSC-Derived Macrophages for Drug Screening. Int J Mol Sci 21. 10.3390/ijms21134808.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21134808</ArticleId><ArticleId IdType="pmc">PMC7370446</ArticleId><ArticleId IdType="pubmed">32645954</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt EJ, Funes S, McKeon JE, Morgan BR, Boopathy S, O&#x2019;Connor LC, Bilsel O, Massi F, Jegou A, and Bosco DA (2021). ALS-linked PFN1 variants exhibit loss and gain of functions in the context of formin-induced actin polymerization. Proc Natl Acad Sci U S A 118. 10.1073/pnas.2024605118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024605118</ArticleId><ArticleId IdType="pmc">PMC8201830</ArticleId><ArticleId IdType="pubmed">34074767</ArticleId></ArticleIdList></Reference><Reference><Citation>Tcw J, Wang M, Pimenova AA, Bowles KR, Hartley BJ, Lacin E, Machlovi SI, Abdelaal R, Karch CM, Phatnani H, et al. (2017). An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells. Stem Cell Reports 9, 600&#x2013;614. 10.1016/j.stemcr.2017.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.06.018</ArticleId><ArticleId IdType="pmc">PMC5550034</ArticleId><ArticleId IdType="pubmed">28757165</ArticleId></ArticleIdList></Reference><Reference><Citation>Novotny R, Langer F, Mahler J, Skodras A, Vlachos A, Wegenast-Braun BM, Kaeser SA, Neher JJ, Eisele YS, Pietrowski MJ, et al. (2016). Conversion of Synthetic Abeta to In Vivo Active Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model. J Neurosci 36, 5084&#x2013;5093. 10.1523/JNEUROSCI.0258-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0258-16.2016</ArticleId><ArticleId IdType="pmc">PMC6601857</ArticleId><ArticleId IdType="pubmed">27147660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer D, Fischer H, Schneider U, Heimrich B, and Schwemmle M (2005). Borna disease virus replication in organotypic hippocampal slice cultures from rats results in selective damage of dentate granule cells. J Virol 79, 11716&#x2013;11723. 10.1128/JVI.79.18.11716-11723.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.18.11716-11723.2005</ArticleId><ArticleId IdType="pmc">PMC1212617</ArticleId><ArticleId IdType="pubmed">16140749</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, Utami KH, Fidan K, Park DS, Malleret B, et al. (2017). Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. Immunity 47, 183&#x2013;198 e186. 10.1016/j.immuni.2017.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.06.017</ArticleId><ArticleId IdType="pubmed">28723550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. (2017). QuPath: Open source software for digital pathology image analysis. Sci Rep 7, 16878. 10.1038/s41598-017-17204-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17204-5</ArticleId><ArticleId IdType="pmc">PMC5715110</ArticleId><ArticleId IdType="pubmed">29203879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TW, Piao J, Koo SY, Kriks S, Chung SY, Betel D, Socci ND, Choi SJ, Zabierowski S, Dubose BN, et al. (2021). Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell 28, 343&#x2013;355 e345. 10.1016/j.stem.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC8006469</ArticleId><ArticleId IdType="pubmed">33545081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrafha L, Parfitt GM, Reyes R, Goldman C, Coccia E, Kareva T, and Ahfeldt T (2021). High-throughput generation of midbrain dopaminergic neuron organoids from reporter human pluripotent stem cells. STAR Protoc 2, 100463. 10.1016/j.xpro.2021.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2021.100463</ArticleId><ArticleId IdType="pmc">PMC8086141</ArticleId><ArticleId IdType="pubmed">33997803</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36333818</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Single-cell spatial proteomic imaging for human neuropathology.</ArticleTitle><Pagination><StartPage>158</StartPage><MedlinePgn>158</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-022-01465-x</ELocationID><Abstract><AbstractText>Neurodegenerative disorders are characterized by phenotypic changes and hallmark proteopathies. Quantifying these in archival human brain tissues remains indispensable for validating animal models and understanding disease mechanisms. We present a framework for nanometer-scale, spatial proteomics with multiplex ion beam imaging (MIBI) for capturing neuropathological features. MIBI facilitated simultaneous, quantitative imaging of 36 proteins on archival human hippocampus from individuals spanning cognitively normal to dementia. Customized analysis strategies identified cell types and proteopathies in the hippocampus across stages of Alzheimer's disease (AD) neuropathologic change. We show microglia-pathologic tau interactions in hippocampal CA1 subfield in AD dementia. Data driven, sample independent creation of spatial proteomic regions identified persistent neurons in pathologic tau neighborhoods expressing mitochondrial protein MFN2, regardless of cognitive status, suggesting a survival advantage. Our study revealed unique insights from multiplexed imaging and data-driven approaches for neuropathologic analysis and serves broadly as a methodology for spatial proteomic analysis of archival human neuropathology. TEASER: Multiplex Ion beam Imaging enables deep spatial phenotyping of human neuropathology-associated cellular and disease features.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Vijayaragavan</LastName><ForeName>Kausalia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cannon</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tebaykin</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boss&#xe9;</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baranski</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveria</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukhari</LastName><ForeName>Syed A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mrdjen</LastName><ForeName>Dunja</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corces</LastName><ForeName>M Ryan</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>The Gladstone Institutes, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCaffrey</LastName><ForeName>Erin F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwald</LastName><ForeName>Noah F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigal</LastName><ForeName>Yari</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ionpath, Inc, Menlo Park, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marquez</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khair</LastName><ForeName>Zumana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Trevor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldston</LastName><ForeName>Mako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bharadwaj</LastName><ForeName>Anusha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Kathleen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelo</LastName><ForeName>R Michael</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendall</LastName><ForeName>Sean C</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0003-1341-2453</Identifier><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA. bendall@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI007290</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068279</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 CA246880</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA224309</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057915</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG065156</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH3 CA246633</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>MA and SCB are consultants for and shareholders in Ionpath Inc. that commercializes MIBI technology. MA and SCB are inventors on and receive royalties for patents relating to MIBI technology licensed to Ionpath Inc. YS was an employee of Ionpath Inc. at the time analysis was done on this manuscript. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>5</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36333818</ArticleId><ArticleId IdType="pmc">PMC9636771</ArticleId><ArticleId IdType="doi">10.1186/s40478-022-01465-x</ArticleId><ArticleId IdType="pii">10.1186/s40478-022-01465-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D, Pavlovic A, Hartmann FJ, Schreiner B, Utz SG, Leung BP, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48:599.</Citation><ArticleIdList><ArticleId IdType="pubmed">29562204</ArticleId></ArticleIdList></Reference><Reference><Citation>Acioglu C, Li L, Elkabes S. Contribution of astrocytes to neuropathology of neurodegenerative diseases. Brain Res. 2021;1758:147291.</Citation><ArticleIdList><ArticleId IdType="pubmed">33516810</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dementia. 2012;8:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D, Fox EJ, Bukhari SA, Montine KS, Bendall SC, Montine TJ. The basis of cellular and regional vulnerability in Alzheimer&#x2019;s disease. Acta Neuropathol. 2019;138:729&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802290</ArticleId><ArticleId IdType="pubmed">31392412</ArticleId></ArticleIdList></Reference><Reference><Citation>Thul PJ, &#xc5;kesson L, Wiking M, Mahdessian D, Geladaki A, Blal HA, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321.</Citation><ArticleIdList><ArticleId IdType="pubmed">28495876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilissen EP, Staneva-Dobrovski L. Distinct types of lipofuscin pigment in the hippocampus and cerebellum of aged cheirogaleid primates. Anat Rec. 2013;296:1895&#x2013;1906.</Citation><ArticleIdList><ArticleId IdType="pubmed">24124014</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardo GD. Lipofuscin, lipofuscin-like pigments and autofluorescence. Eur J Histochem EJH. 2015;59:2485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4378218</ArticleId><ArticleId IdType="pubmed">25820564</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174:1373&#x2013;1387.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132072</ArticleId><ArticleId IdType="pubmed">30193111</ArticleId></ArticleIdList></Reference><Reference><Citation>Dora L, Agrawal S, Panda R, Abraham A. State-of-the-Art methods for brain tissue segmentation: a review. IEEE Rev Biomed Eng. 2017;10:235&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">28622675</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenbaum S, Averbukh I, Soon E, Rizzuto G, Baranski A, Greenwald N, et al. Spatio-temporal coordination at the maternal-fetal interface promotes trophoblast invasion and vascular remodeling in the first half of human pregnancy. Biorxiv. 2021;28:406.</Citation></Reference><Reference><Citation>McCaffrey EF, Donato M, Keren L, Chen Z, Delmastro A, Fitzpatrick MB, et al. The immunoregulatory landscape of human tuberculosis granulomas. Nat Immunol. 2022;23:318&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8810384</ArticleId><ArticleId IdType="pubmed">35058616</ArticleId></ArticleIdList></Reference><Reference><Citation>Risom T, Glass DR, Averbukh I, Liu CC, Baranski A, Kagel A, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell. 2022;185:299&#x2013;310.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8792442</ArticleId><ArticleId IdType="pubmed">35063072</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, McCaffrey EF, Greenwald NF, Soon E, Risom T, Vijayaragavan K, et al. Multiplexed ion beam imaging: insights into pathobiology. Annu Rev Pathol Mech Dis. 2021;17:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">34752710</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Bosse M, Kong A, Kagel A, Kinders R, Hewitt SM, et al. Reproducible, high-dimensional imaging in archival human tissue by multiplexed ion beam imaging by time-of-flight (MIBI-TOF) Lab Invest. 2022;102:762&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10357968</ArticleId><ArticleId IdType="pubmed">35351966</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey JW, Neumann EK, Radtke AJ, Camarillo JM, Beuschel RT, Albanese A, et al (2021) Spatial mapping of protein composition and tissue organization: a primer for multiplexed antibody-based imaging. Nat Methods 1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9264278</ArticleId><ArticleId IdType="pubmed">34811556</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltzfus CR, Filipek J, Gern BH, Olin BE, Leal JM, Wu Y, et al. CytoMAP: a spatial analysis toolbox reveals features of myeloid cell organization in lymphoid tissues. Cell Rep. 2020;31:107523&#x2013;107622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233132</ArticleId><ArticleId IdType="pubmed">32320656</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem. 1999;47:719&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">10330448</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren L, Bosse M, Thompson S, Risom T, Vijayaragavan K, McCaffrey E, et al. MIBI-TOF: a multiplexed imaging platform relates cellular phenotypes and tissue structure. Sci Adv. 2019;5:eaax5851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6785247</ArticleId><ArticleId IdType="pubmed">31633026</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog E, Takamori S, Jahn R, Brose N, Wojcik SM. Synaptic and vesicular co-localization of the glutamate transporters VGLUT1 and VGLUT2 in the mouse hippocampus. J Neurochem. 2006;99:1011&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">16942593</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguz-Lecznar M, Skangiel-Kramska J. Vesicular glutamate transporters (VGLUTs): the three musketeers of glutamatergic system. Acta Neurobiol Exp. 2007;67:207&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">17957901</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigneault &#xc9;, Poirel O, Riad M, Prud&#x2019;homme J, Dumas S, Turecki G, et al. Distribution of vesicular glutamate transporters in the human brain. Front Neuroanat. 2015;9:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350397</ArticleId><ArticleId IdType="pubmed">25798091</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera P, Arrabal S, Cifuentes M, Grondona JM, P&#xe9;rez-Mart&#xed;n M, Rubio L, et al. Localization of the cannabinoid CB1 receptor and the 2-AG synthesizing (DAGL&#x3b1;) and degrading (MAGL, FAAH) enzymes in cells expressing the Ca2+-binding proteins calbindin, calretinin, and parvalbumin in the adult rat hippocampus. Front Neuroanat. 2014;8:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073216</ArticleId><ArticleId IdType="pubmed">25018703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243026</ArticleId><ArticleId IdType="pubmed">22996553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Glezer II, Cond&#xe9; F, Flagg RA, Rubin MB, Nimchinsky EA, et al. Cellular distribution of the calcium-binding proteins parvalbumin, calbindin, and calretinin in the neocortex of mammals: phylogenetic and developmental patterns. J Chem Neuroanat. 1999;16:77&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">10223310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerke IE, Yates SC, Laja A, Witter MP, Puchades MA, Bjaalie JG, et al. Densities and numbers of calbindin and parvalbumin positive neurons across the rat and mouse brain. Iscience. 2021;24:101906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7770605</ArticleId><ArticleId IdType="pubmed">33385111</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin M, Marchand R, Parent A. Calcium-binding proteins in primate cerebellum. Neurosci Res. 1998;30:155&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">9579649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastianelli E. Distribution of calcium-binding proteins in the cerebellum. Cerebellum. 2003;2:242&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">14964684</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass DR, Tsai AG, Oliveria JP, Hartmann FJ, Kimmey SC, Calderon AA, et al. An integrated multi-omic single cell atlas to redefine human B cell memory. BioRxiv. 2019;226:223&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7369630</ArticleId><ArticleId IdType="pubmed">32668225</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann FJ, Bendall SC. Immune monitoring using mass cytometry and related high-dimensional imaging approaches. Nat Rev Rheumatol. 2020;16:87&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232872</ArticleId><ArticleId IdType="pubmed">31892734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann FJ, Mrdjen D, McCaffrey E, Glass DR, Greenwald NF, Bharadwaj A, et al. Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol. 2021;39:186&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7878201</ArticleId><ArticleId IdType="pubmed">32868913</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore AR, Gonzalez NV, Plummer KA, Mitchel OR, Kaur H, Rivera M, et al (2021) Gestationally-dependent immune organization at the maternal-fetal interface. Biorxiv</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9681661</ArticleId><ArticleId IdType="pubmed">36384130</ArticleId></ArticleIdList></Reference><Reference><Citation>Moen E, Bannon D, Kudo T, Graf W, Covert M, Valen DV. Deep learning for cellular image analysis. Nat Methods. 2019;16:1233&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8759575</ArticleId><ArticleId IdType="pubmed">31133758</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwald NF, Miller G, Moen E, Kong A, Kagel A, Dougherty T, et al (2021) Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning. Nat Biotechnol 1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9010346</ArticleId><ArticleId IdType="pubmed">34795433</ArticleId></ArticleIdList></Reference><Reference><Citation>Valen DAV, Kudo T, Lane KM, Macklin DN, Quach NT, DeFelice MM, et al. Deep learning automates the quantitative analysis of individual cells in live-cell imaging experiments. PLOS Comput Biol. 2016;12:e1005177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5096676</ArticleId><ArticleId IdType="pubmed">27814364</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, Melville J (2018) UMAP: Uniform manifold approximation and projection for dimension reduction. https://arxiv.org/abs/1802.03426</Citation></Reference><Reference><Citation>Uchihara T. Pretangles and neurofibrillary changes: similarities and differences between AD and CBD based on molecular and morphological evolution. Neuropathology. 2014;34:571&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">24612177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Kulas JA, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Biorxiv. 2020;62:1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8379952</ArticleId><ArticleId IdType="pubmed">34385305</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold K-H, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci. 1999;96:14088&#x2013;14093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun. 2017;8:15295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437271</ArticleId><ArticleId IdType="pubmed">28492240</ArticleId></ArticleIdList></Reference><Reference><Citation>Heithoff BP, George KK, Phares AN, Zuidhoek IA, Munoz-Ballester C, Robel S. Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. Biorxiv. 2020;99:125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736206</ArticleId><ArticleId IdType="pubmed">32955153</ArticleId></ArticleIdList></Reference><Reference><Citation>Liedtke W, Edelmann W, Bieri PL, Chiu F-C, Cowan NJ, Kucherlapati R, et al. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron. 1996;17:607&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">8893019</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangalos EG, Petersen RC. Mild cognitive impairment in geriatrics. Clin Geriatr Med. 2018;34:563&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30336988</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HH, Jacova C. Mild cognitive impairment. Am J Geriat Psychiat. 2005;13:645&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">16085780</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg PB, Lyketsos C. Mild cognitive impairment: searching for the prodrome of Alzheimer&#x2019;s disease. World Psychiatry. 2008;7:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430721</ArticleId><ArticleId IdType="pubmed">18563204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente-de-N&#xf3; R. Studies on the structure of the cerebral cortex II continuation of the study of the ammonic system. J Psychol Neurol. 1934;46:113&#x2013;177.</Citation></Reference><Reference><Citation>Ram&#xf2;n y Cajal S (1902) Fourth-order olfactory areas: Ammon&#x2019;s Horn and the dentate gyrus. In: Press OU (ed). Histology of the Nervous System: Chapter XXXI II, pp 603&#x2013;57</Citation></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bj&#xf6;rk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassen SV, Callebaut B, Helden MJV, Lambrecht BN, Demeester P, Dhaene T, et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytom Part A. 2015;87:636&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">25573116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopperton KE, Mohammad D, Tr&#xe9;panier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer&#x2019;s disease: a systematic review. Mol Psychiatr. 2018;23:177&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794890</ArticleId><ArticleId IdType="pubmed">29230021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunello CA, Merezhko M, Uronen R-L, Huttunen HJ. Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci. 2020;77:1721&#x2013;1744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190606</ArticleId><ArticleId IdType="pubmed">31667556</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H-C, Wang BY, Serrano-Pozo A, Frosch MP, Spires-Jones TL, Hyman BT. Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2014;2:146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209049</ArticleId><ArticleId IdType="pubmed">25330988</ArticleId></ArticleIdList></Reference><Reference><Citation>Phongpreecha T, Gajera CR, Liu CC, Vijayaragavan K, Chang AL, Becker M, et al. Single-synapse analyses of Alzheimer&#x2019;s disease implicate pathologic tau DJ1, CD47 and ApoE. Sci Adv. 2021;7:eabk0473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673771</ArticleId><ArticleId IdType="pubmed">34910503</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR, Shcherbina A, Kundu S, Gloudemans MJ, Fr&#xe9;sard L, Granja JM, et al. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Nat Genet. 2020;52:1158&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606627</ArticleId><ArticleId IdType="pubmed">33106633</ArticleId></ArticleIdList></Reference><Reference><Citation>Motori E, Atanassov I, Kochan SMV, Folz-Donahue K, Sakthivelu V, Giavalisco P, et al. Neuronal metabolic rewiring promotes resilience to neurodegeneration caused by mitochondrial dysfunction. Sci Adv. 2020;6:eaba8271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455195</ArticleId><ArticleId IdType="pubmed">32923630</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer&#x2019;s disease. Mol Neurodegener. 2020;15:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364557</ArticleId><ArticleId IdType="pubmed">32677986</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Selkoe DJ. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A&#x3b2; oligomers from Alzheimer&#x2019;s brain. J Neurochem. 2020;154:583&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487043</ArticleId><ArticleId IdType="pubmed">32180217</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SN, Funk KE, Wan Y, Liao Z, Davies P, Kuret J, et al. Dual modification of Alzheimer&#x2019;s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol. 2012;123:105&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249157</ArticleId><ArticleId IdType="pubmed">22033876</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez ET, Pehar M, Vargas MR, Barbeito L, Maccioni RB. Production of nerve growth factor by &#x3b2;-amyloid-stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hippocampal neurons. J Neurosci Res. 2006;84:1098&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemke N, Melis V, Lauer D, Magbagbeolu M, Neumann B, Harrington CR, et al. Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia. J Biol Chem. 2020;295:18508&#x2013;18523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7939472</ArticleId><ArticleId IdType="pubmed">33127647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Murayama M, Higuchi M, Suhara T, Takashima A. Biochemical distribution of tau protein in synaptosomal fraction of transgenic mice expressing human P301L tau. Front Neurol. 2014;5:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949102</ArticleId><ArticleId IdType="pubmed">24653715</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevenco FC, Schreiner SJ, Preti MG, van Bergen JMG, Kirchner T, Wyss M, et al. GABA and glutamate moderate beta-amyloid related functional connectivity in cognitively unimpaired old-aged adults. Neuroimage Clin. 2019;22:101776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439267</ArticleId><ArticleId IdType="pubmed">30927605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Jackson RJ, Hong W, Taylor WM, Corbett GT, Moreno A, et al. Human brain-derived A&#x3b2; oligomers bind to synapses and disrupt synaptic activity in a manner that requires APP. J Neurosci. 2017;37:11947&#x2013;11966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719975</ArticleId><ArticleId IdType="pubmed">29101243</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y, Sakamoto S, Tsuji K, Ayaki T, Tokunaga F, Ito H. Identification of linear polyubiquitin chain immunoreactivity in tau pathology of Alzheimer&#x2019;s disease. Neurosci Lett. 2019;703:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">30885635</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mund T, Masuda-Suzukake M, Goedert M, Pelham HR. Ubiquitination of alpha-synuclein filaments by Nedd4 ligases. PLOS ONE. 2018;13:e0200763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051637</ArticleId><ArticleId IdType="pubmed">30021006</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Nandy P, Austria Q, Siedlak SL, Torres S, Fujioka H, et al. Mfn2 ablation in the adult mouse hippocampus and cortex causes neuronal death. Cells. 2020;9:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7017224</ArticleId><ArticleId IdType="pubmed">31947766</ArticleId></ArticleIdList></Reference><Reference><Citation>Sita G, Hrelia P, Graziosi A, Morroni F. Back to the fusion: mitofusin-2 in Alzheimer&#x2019;s disease. J Clin Medicine. 2020;9:126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7019958</ArticleId><ArticleId IdType="pubmed">31906578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Su B, Lee H, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer&#x2019;s disease. J Neurosci. 2009;29:9090&#x2013;9103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735241</ArticleId><ArticleId IdType="pubmed">19605646</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendall SC, Davis KL, Amir ED, Tadmor MD, Simonds EF, Chen TJ, et al. Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development. Cell. 2014;157:714&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4045247</ArticleId><ArticleId IdType="pubmed">24766814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cid E, Marquez-Galera A, Valero M, Gal B, Medeiros DC, Navarron CM, et al. Sublayer- and cell-type-specific neurodegenerative transcriptional trajectories in hippocampal sclerosis. Cell Rep. 2021;35:109229.</Citation><ArticleIdList><ArticleId IdType="pubmed">34107264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmey SC, Borges L, Baskar R, Bendall SC. Parallel analysis of tri-molecular biosynthesis with cell identity and function in single cells. Nat Commun. 2019;10:1185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414513</ArticleId><ArticleId IdType="pubmed">30862852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang C, Campbell KR, Ryan BJ, Carling P, Attar M, Vowles J, et al. Single-cell sequencing of iPSC-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of Parkinson cell phenotypes. Cell Stem Cell. 2019;24:93&#x2013;106.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327112</ArticleId><ArticleId IdType="pubmed">30503143</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler-Wirth H, Binder H, Willscher E, Gerber T, Kunz M. Pseudotime dynamics in melanoma single-cell transcriptomes reveals different mechanisms of tumor progression. Biology. 2018;7:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022966</ArticleId><ArticleId IdType="pubmed">29614062</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb C, Rodriguez-Fraticelli A, Camargo FD, Klein AM. Lineage tracing on transcriptional landscapes links state to fate during differentiation. Science. 2020;367:3381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608074</ArticleId><ArticleId IdType="pubmed">31974159</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175:1014&#x2013;1030.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6501221</ArticleId><ArticleId IdType="pubmed">30343900</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Miah MR, Aschner M. Metals and neurodegeneration. F1000Research. 2016;5:366&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4798150</ArticleId><ArticleId IdType="pubmed">27006759</ArticleId></ArticleIdList></Reference><Reference><Citation>Livet J, Weissman TA, Kang H, Draft RW, Lu J, Bennis RA, et al. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature. 2007;450:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17972876</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JM, Dehkordi SK, Fracassi A, Vanschoiack A, Pavenko A, Taglialatela G, et al. Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling. Acta Neuropathol Commun. 2022;10:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8842950</ArticleId><ArticleId IdType="pubmed">35164877</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokop S, Miller KR, Labra SR, Pitkin RM, Hoxha K, Narasimhan S, et al. Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer&#x2019;s disease patient brain samples. Acta Neuropathol. 2019;138:613&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939638</ArticleId><ArticleId IdType="pubmed">31350575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat Neurosci. 2018;21:811&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Carter EK, Dammer EB, Duong DM, Gerasimov ES, Liu Y, et al. Large-scale deep multi-layer analysis of Alzheimer&#x2019;s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat Neurosci. 2022;25:213&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825285</ArticleId><ArticleId IdType="pubmed">35115731</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer&#x2019;s disease pathogenesis. Nat Genet. 2021;53:143&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8130821</ArticleId><ArticleId IdType="pubmed">33510477</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2011;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendall SC, Spitzer M, Simonds EF, Nolan GP (2013) Conjugation and characterization of immunoglobulins with stable mass isotope reporters for single-cell mass cytometry analysis, pp 1&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687300</ArticleId><ArticleId IdType="pubmed">31077099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosse MM, Bendall S, Angelo M (2021) Metal-antibody MIBItag conjugation kit. protocols.io [Internet]. Available from: https://protocols.io/view/metal-antibody-mibitag-conjugation-kit-bhyej7te.html</Citation></Reference><Reference><Citation>Camacho C, Bosse MM, Bendall S, Angelo M (2021) Antibody lyophilization v1. Protocols.io</Citation></Reference><Reference><Citation>Bosse MM, Bendall S, Angelo M (2021) MIBI staining V.3. protocols.io [Internet]. Available from: https://protocols.io/view/mibi-staining-byzrpx56.html</Citation></Reference><Reference><Citation>Bosse MM, Bendall S, Angelo M (2021) IHC staining. protocols.io [Internet]. Available from: https://protocols.io/view/ihc-staining-bf6ajrae.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36344699</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Bassoon contributes to tau-seed propagation and neurotoxicity.</ArticleTitle><Pagination><StartPage>1597</StartPage><EndPage>1607</EndPage><MedlinePgn>1597-1607</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01191-6</ELocationID><Abstract><AbstractText>Tau aggregation is a defining histopathological feature of Alzheimer's disease and other tauopathies. However, the cellular mechanisms involved in tau propagation remain unclear. Here, we performed an unbiased quantitative proteomic study to identify proteins that specifically interact with this tau seed. We identified Bassoon (BSN), a presynaptic scaffolding protein, as an interactor of the tau seed isolated from a mouse model of tauopathy, and from Alzheimer's disease and progressive supranuclear palsy postmortem samples. We show that BSN exacerbates tau seeding and toxicity in both mouse and Drosophila models for tauopathy, and that BSN downregulation decreases tau spreading and overall disease pathology, rescuing synaptic and behavioral impairments and reducing brain atrophy. Our findings improve the understanding of how tau seeds can be stabilized by interactors such as BSN. Inhibiting tau-seed interactions is a potential new therapeutic approach for neurodegenerative tauopathies.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Henika</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Yanwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jury</LastName><ForeName>Nur</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7562-1635</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee-Gosselin</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Yingjian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viana Di Prisco</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Sayan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijeratne</LastName><ForeName>Aruna B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0001-8366-2074</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redding-Ochoa</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahid</LastName><ForeName>Syed Salman</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-0914-6933</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology &amp; Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Codocedo</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Sehong</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4511-850X</Identifier><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Amber L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0001-5822-2894</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Chien</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology &amp; Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinzie</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochet</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-6484-1541</Identifier><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>Brady K</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-7441-2724</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasagna-Reeves</LastName><ForeName>Cristian A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-5499-3082</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA. clasagna@iu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology &amp; Physiology, Indiana University School of Medicine, Indianapolis, IN, USA. clasagna@iu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA. clasagna@iu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG075541</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG033655</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS119280</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059639</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053993</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS112303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>7</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36344699</ArticleId><ArticleId IdType="pmc">PMC9708566</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01191-6</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01191-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso AC, Li B, Grundke-Iqbal I, Iqbal K. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 2008;5:375&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">18690834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 2014;211:387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 2016;19:1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat. Commun. 2015;6:8490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, et al. Seeding activity-based detection uncovers the different release mechanisms of seed-competent tau versus inert tau via lysosomal exocytosis. Front Neurosci. 2019;13:1258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6881304</ArticleId><ArticleId IdType="pubmed">31824253</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, et al. Tau protein disrupts nucleocytoplasmic transport in Alzheimer&#x2019;s disease. Neuron. 2018;99:925&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="pubmed">30189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Gotz J. Phosphorylated tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 2009;284:20909&#x2013;20916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742856</ArticleId><ArticleId IdType="pubmed">19491104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes J, et al. Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. Neuron. 2018;97:823&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">29398363</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn PD, et al. Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis. Neuron. 2019;104:458&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880876</ArticleId><ArticleId IdType="pubmed">31542321</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, et al. Interaction of tau with the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity. Cell Rep. 2016;15:1455&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="pubmed">27160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70:410&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Song X, Nisbet R, Gotz J. Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions and highlights a putative role for 2N Tau in disease. J. Biol. Chem. 2016;291:8173&#x2013;8188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825019</ArticleId><ArticleId IdType="pubmed">26861879</ArticleId></ArticleIdList></Reference><Reference><Citation>Maziuk BF, et al. RNA-binding proteins colocalize with small tau inclusions in tauopathy. Acta Neuropathol. Commun. 2018;6:71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6069705</ArticleId><ArticleId IdType="pubmed">30068389</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H, et al. Acetylation changes tau interactome to degrade tau in Alzheimer&#x2019;s disease animal and organoid models. Aging Cell. 2020;19:e13081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974726</ArticleId><ArticleId IdType="pubmed">31763743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, et al. Tau interactome mapping based identification of Otub1 as tau deubiquitinase involved in accumulation of pathological tau forms in vitro and in vivo. Acta Neuropathol. 2017;133:731&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390007</ArticleId><ArticleId IdType="pubmed">28083634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardana CG, et al. The human tau interactome: binding to the ribonucleoproteome, and impaired binding of the proline-to-leucine mutant at position 301 (P301L) to chaperones and the proteasome. Mol. Cell Proteomics. 2015;14:3000&#x2013;3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4638042</ArticleId><ArticleId IdType="pubmed">26269332</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Tau interactome analyses in CRISPR&#x2013;Cas9 engineered neuronal cells reveal ATPase-dependent binding of wild-type but not P301L tau to non-muscle myosins. Sci. Rep. 2019;9:16238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838314</ArticleId><ArticleId IdType="pubmed">31700063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy TE, et al. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell. 2022;185:712&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8857049</ArticleId><ArticleId IdType="pubmed">35063084</ArticleId></ArticleIdList></Reference><Reference><Citation>Annamneedi A, et al. Ablation of the presynaptic organizer Bassoon in excitatory neurons retards dentate gyrus maturation and enhances learning performance. Brain Struct. Funct. 2018;223:3423&#x2013;3445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132633</ArticleId><ArticleId IdType="pubmed">29915867</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl Acad. Sci. USA. 2014;111:E4376&#x2013;E4385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hnasko R, Lin A, McGarvey J, Stanker L. Enhanced detection of infectious prions by direct ELISA from the brains of asymptomatic animals using DRM2-118 monoclonal antibody and Gdn-HCl. J. Immunol. Methods. 2018;456:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">29462604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, et al. Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer&#x2019;s disease. Sci. Transl. Med. 2022;14:eabg0253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9549419</ArticleId><ArticleId IdType="pubmed">34985969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodes RJ, Buckholtz N. Accelerating medicines partnership: Alzheimer&#x2019;s disease (AMP-AD) knowledge portal aids alzheimer&#x2019;s drug discovery through open data sharing. Expert Opin. Ther. Targets. 2016;20:389&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">26853544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N. Identifying therapeutic targets for Alzheimer&#x2019;s disease with big data. Neurodegener. Dis. Manag. 2017;7:101&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">28540771</ArticleId></ArticleIdList></Reference><Reference><Citation>Okerlund ND, et al. Bassoon controls presynaptic autophagy through Atg5. Neuron. 2017;93:897&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">28231469</ArticleId></ArticleIdList></Reference><Reference><Citation>Waites CL, et al. Bassoon and Piccolo maintain synapse integrity by regulating protein ubiquitination and degradation. EMBO J. 2013;32:954&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616282</ArticleId><ArticleId IdType="pubmed">23403927</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenegro-Venegas C, et al. Bassoon inhibits proteasome activity via interaction with PSMB4. Cell. Mol. Life Sci. 2021;78:1545&#x2013;1563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904567</ArticleId><ArticleId IdType="pubmed">32651614</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabe I, et al. Mutations in Bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome. Sci. Rep. 2018;8:819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770378</ArticleId><ArticleId IdType="pubmed">29339765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashida, H. et al. Cloning and mapping of ZNF231, a novel brain-specific gene encoding neuronal double zinc finger protein whose expression is enhanced in a neurodegenerative disorder, multiple system atrophy. Genomics54, 50&#x2013;58 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9806829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schattling B, et al. Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. Nat. Neurosci. 2019;22:887&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">31011226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, et al. The role of pathological tau in synaptic dysfunction in Alzheimer&#x2019;s diseases. Transl. Neurodegener. 2021;10:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579533</ArticleId><ArticleId IdType="pubmed">34753506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat. Commun. 2017;8:15295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437271</ArticleId><ArticleId IdType="pubmed">28492240</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzscha H, et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell. 2011;144:67&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">21215370</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, et al. Experimental evidence for the age dependence of tau protein spread in the brain. Sci. Adv. 2019;5:eaaw6404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6594764</ArticleId><ArticleId IdType="pubmed">31249873</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel H, et al. Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiol. Aging. 2022;109:52&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8671336</ArticleId><ArticleId IdType="pubmed">34655981</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 2019;28:2111&#x2013;2123.</Citation><ArticleIdList><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Altrock WD, et al. Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein Bassoon. Neuron. 2003;37:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628169</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin&#x2013;proteasome system. Am. J. Pathol. 2012;181:1426&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaishi M, Yokoo H, Nakazato Y. Tau-positive glial cytoplasmic granules in multiple system atrophy. Neuropathology. 2011;31:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062361</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. The release and trans-synaptic transmission of tau via exosomes. Mol. Neurodegener. 2017;12:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237256</ArticleId><ArticleId IdType="pubmed">28086931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA. Rethinking protein aggregation and drug discovery in neurodegenerative diseases: why we need to embrace complexity? Curr. Opin. Chem. Biol. 2021;64:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">34174698</ArticleId></ArticleIdList></Reference><Reference><Citation>Fichou Y, et al. Cofactors are essential constituents of stable and seeding-active tau fibrils. Proc. Natl Acad. Sci. USA. 2018;115:13234&#x2013;13239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310788</ArticleId><ArticleId IdType="pubmed">30538196</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH, Zhang W, Falcon B, Goedert M. Cryo-EM structures of tau filaments. Curr. Opin. Struct. Biol. 2020;64:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">32603876</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 2018;136:699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal A, et al. Alpha-synuclein is a target of Fic-mediated adenylylation/AMPylation: possible Implications for Parkinson&#x2019;s disease. J. Mol. Biol. 2019;431:2266&#x2013;2282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554060</ArticleId><ArticleId IdType="pubmed">31034889</ArticleId></ArticleIdList></Reference><Reference><Citation>Peck Justice SA, et al. Mutant thermal proteome profiling for characterization of missense protein variants and their associated phenotypes within the proteome. J. Biol. Chem. 2020;295:16219&#x2013;16238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705321</ArticleId><ArticleId IdType="pubmed">32878984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed H, et al. Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. Nat. Protoc. 2016;11:316&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">26797456</ArticleId></ArticleIdList></Reference><Reference><Citation>Papachristou EK, et al. A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. Nat. Commun. 2018;9:2311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5998130</ArticleId><ArticleId IdType="pubmed">29899353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengoa-Vergniory N, et al. Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 2021;9:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844979</ArticleId><ArticleId IdType="pubmed">33509301</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh I, Martin AJ, Di Domenico T, Tosatto SC. ESpritz: accurate and fast prediction of protein disorder. Bioinformatics. 2012;28:503&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1982;157:105&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">7108955</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsten SL, et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron. 2006;51:549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950154</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer J, et al. Quantitative assessment of eye phenotypes for functional genetic studies using Drosophila melanogaster. G3. 2016;6:1427&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856093</ArticleId><ArticleId IdType="pubmed">26994292</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead JC, et al. A clinical frailty index in aging mice: comparisons with frailty index data in humans. J. Gerontol. A Biol. Sci. Med. Sci. 2014;69:621&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022099</ArticleId><ArticleId IdType="pubmed">24051346</ArticleId></ArticleIdList></Reference><Reference><Citation>Badhwar A, Lerch JP, Hamel E, Sled JG. Impaired structural correlates of memory in Alzheimer&#x2019;s disease mice. Neuroimage Clin. 2013;3:290&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814975</ArticleId><ArticleId IdType="pubmed">24273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Coupe P, et al. An optimized blockwise nonlocal means denoising filter for 3D magnetic resonance images. IEEE Trans. Med. Imaging. 2008;27:425&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881565</ArticleId><ArticleId IdType="pubmed">18390341</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge Cardoso M, et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med. Image Anal. 2013;17:671&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">23510558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tustison NJ, et al. N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging. 2010;29:1310&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071855</ArticleId><ArticleId IdType="pubmed">20378467</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med. Image Anal. 2008;12:26&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276735</ArticleId><ArticleId IdType="pubmed">17659998</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54:2033&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065962</ArticleId><ArticleId IdType="pubmed">20851191</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Tustison NJ, Wu J, Cook PA, Gee JC. An open-source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics. 2011;9:381&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297199</ArticleId><ArticleId IdType="pubmed">21373993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, et al. Reduction of Nuak1 decreases tau and reverses phenotypes in a tauopathy mouse model. Neuron. 2016;92:407&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745060</ArticleId><ArticleId IdType="pubmed">27720485</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav VS, et al. Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. Mol. Neurodegener. 2020;15:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594478</ArticleId><ArticleId IdType="pubmed">33115519</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47:D442&#x2013;D450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch EW, et al. The ProteomeXchange consortium in 2020: enabling &#x2018;big data&#x2019; approaches in proteomics. Nucleic Acids Res. 2020;48:D1145&#x2013;D1152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145525</ArticleId><ArticleId IdType="pubmed">31686107</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y, et al. PRIDE inspector toolsuite: moving toward a universal visualization tool for proteomics data standard formats and quality assessment of proteomexchange datasets. Mol. Cell Proteomics. 2016;15:305&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762524</ArticleId><ArticleId IdType="pubmed">26545397</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36352225</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>611</Volume><Issue>7936</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>585</StartPage><EndPage>593</EndPage><MedlinePgn>585-593</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-05397-3</ELocationID><Abstract><AbstractText>Macrophages are important players in the maintenance of tissue homeostasis<sup>1</sup>. Perivascular and leptomeningeal macrophages reside near the central nervous system (CNS) parenchyma<sup>2</sup>, and their role in CNS physiology has not been sufficiently well studied. Given their continuous interaction with the cerebrospinal fluid (CSF) and strategic positioning, we refer to these cells collectively as parenchymal border macrophages (PBMs). Here we demonstrate that PBMs regulate CSF flow dynamics. We identify a subpopulation of PBMs that express high levels of CD163 and LYVE1 (scavenger receptor proteins), closely associated with the brain arterial tree, and show that LYVE1<sup>+</sup> PBMs regulate arterial motion that drives CSF flow. Pharmacological or genetic depletion of PBMs led to accumulation of extracellular matrix proteins, obstructing CSF access to perivascular spaces and impairing CNS perfusion and clearance. Ageing-associated alterations in PBMs and impairment of CSF dynamics were restored after intracisternal injection of macrophage colony-stimulating factor. Single-nucleus RNA sequencing data obtained from patients with Alzheimer's disease (AD) and from non-AD individuals point to changes in phagocytosis, endocytosis and interferon-&#x3b3; signalling on PBMs, pathways that are corroborated in a mouse model of AD. Collectively, our results identify PBMs as new cellular regulators of CSF flow dynamics, which could be targeted pharmacologically to alleviate brain clearance deficits associated with ageing and AD.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drieu</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6237-4719</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA. drieu@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA. drieu@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Du</LastName><ForeName>Siling</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Graduate Program, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Storck</LastName><ForeName>Steffen E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-6965-2264</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rustenhoven</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5681-1388</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Graduate Program, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dykstra</LastName><ForeName>Taitea</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7756-809X</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Fenghe</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Danforth Campus, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyungdeok</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamuladze</LastName><ForeName>Tornike</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7088-3967</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Graduate Program, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2635-6975</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6854-5547</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3443-7716</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Indiana School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7792-1698</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Danforth Campus, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randolph</LastName><ForeName>Gwendalyn J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-9045-1195</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3714-517X</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St Louis, St Louis, MO, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Graduate Program, School of Medicine, Washington University in St Louis, St Louis, MO, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG057777</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092865</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG067764</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062734</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG072464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG078106</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057496</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 GM136766</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000098902">CD163 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C119248">LYVE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Immunol. 2023 Jan;23(1):3. doi: 10.1038/s41577-022-00814-0.</RefSource><PMID Version="1">36418433</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2023 Mar;22(3):194-195. doi: 10.1016/S1474-4422(23)00028-5.</RefSource><PMID Version="1">36804079</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="Y">Central Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="Y">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="Y">Macrophages</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012212" MajorTopicYN="N">Rheology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016326" MajorTopicYN="N">Extracellular Matrix Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072356" MajorTopicYN="Y">Parenchymal Tissue</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098902" MajorTopicYN="N">CD163 Antigen</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. J.K. is a scientific advisor and collaborator with PureTech. J.K. and A.D. are holding provisional patent applications related to the findings described herein. R.J.B co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. He receives research support from Biogen, Eisai, and the DIAN-TU Pharma Consortium. He is also an advisor to Amgen and Hoffman La-Roche.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Brosch</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buck</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Marty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barthelemy</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandon</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cash</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Charlie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chua</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denner</LastName><ForeName>Darcy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dincer</LastName><ForeName>Aylin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Becca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Shaney</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joseph-Mathurin</LastName><ForeName>Nelly</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gremminger</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groves</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellm</LastName><ForeName>Cortaiga</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herries</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoechst-Swisher</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerome</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keefe</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koudelis</LastName><ForeName>Deb</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCullough</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shady</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinbin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiong</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>Patricio Chrem</ForeName><Initials>PC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egido</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Araki</LastName><ForeName>Aki</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasuga</LastName><ForeName>Kensaku</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bechara</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Snezana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountz</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nadkarni</LastName><ForeName>Neelesh</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patira</LastName><ForeName>Riddhi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodge</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ping</LastName><ForeName>Lingyan</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Day</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Sochenda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruz</LastName><ForeName>Chrismary De La</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mejia</LastName><ForeName>Arlene</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neimeyer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diffenbacher</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yakushev</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>V&#xf6;glein</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Douglas</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grilo</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mummery</LastName><ForeName>Cath</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esposito</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujii</LastName><ForeName>Hisako</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senda</LastName><ForeName>Michio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimada</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardener</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohrabi</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gr&#xe4;ber-Sultan</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe4;sler</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xe4;ser</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preische</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morenas-Rodriguez</LastName><ForeName>Estrella</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ihara</LastName><ForeName>Ryoko</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Akemi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niimi</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Neal Scott</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulricke</ForeName><Initials>U</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>23</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36352225</ArticleId><ArticleId IdType="mid">NIHMS1864902</ArticleId><ArticleId IdType="pmc">PMC9899827</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05397-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-05397-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ginhoux F &amp; Guilliams M Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity 44, 439&#x2013;449 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26982352</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T et al. Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature 604, 740&#x2013;748 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35444273</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves de Lima K et al. Meningeal &#x3b3;&#x3b4; T cells regulate anxiety-like behavior via IL-17a signaling in neurons. Nat Immunol 21, 1421&#x2013;1429 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496952</ArticleId><ArticleId IdType="pubmed">32929273</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ et al. Unexpected role of interferon-&#x3b3; in regulating neuronal connectivity and social behaviour. Nature 535, 425&#x2013;429 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961620</ArticleId><ArticleId IdType="pubmed">27409813</ArticleId></ArticleIdList></Reference><Reference><Citation>Konsman JP, Parnet P &amp; Dantzer R Cytokine-induced sickness behaviour: mechanisms and implications. Trends in Neurosciences 25, 154&#x2013;159 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11852148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat Commun 9, 4878 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6242982</ArticleId><ArticleId IdType="pubmed">30451853</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci 33, 18190&#x2013;18199 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866416</ArticleId><ArticleId IdType="pubmed">24227727</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veluw SJ et al. Vasomotion as a Driving Force for Paravascular Clearance in the Awake Mouse Brain. Neuron 105, 549&#x2013;561.e5 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028316</ArticleId><ArticleId IdType="pubmed">31810839</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci Transl Med 4, 147ra111 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X et al. Meningeal lymphatic vessels mediate neurotropic viral drainage from the central nervous system. Nat Neurosci 25, 577&#x2013;587 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35524140</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell 184, 1000&#x2013;1016.e27 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487654</ArticleId><ArticleId IdType="pubmed">33508229</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Masuda T, Jord&#xe3;o MJC &amp; Prinz M Macrophages at CNS interfaces: ontogeny and function in health and disease. Nat Rev Neurosci 20, 547&#x2013;562 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31358892</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G, Park L, Anrather J &amp; Iadecola C Brain perivascular macrophages: characterization and functional roles in health and disease. J Mol Med (Berl) 95, 1143&#x2013;1152 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5812456</ArticleId><ArticleId IdType="pubmed">28782084</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove H et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat Neurosci 22, 1021&#x2013;1035 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat Immunol 17, 797&#x2013;805 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G et al. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J Clin Invest 126, 4674&#x2013;4689 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127678</ArticleId><ArticleId IdType="pubmed">27841763</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanopoulou K, Fragkouli A, Stylianopoulou F &amp; Georgopoulos S Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc Natl Acad Sci U S A 107, 20816&#x2013;20821 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996412</ArticleId><ArticleId IdType="pubmed">21076037</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L et al. Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer A&#x3b2; Peptides. Circ Res 121, 258&#x2013;269 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522360</ArticleId><ArticleId IdType="pubmed">28515043</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o MJC et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363, eaat7554 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 48, 380&#x2013;395.e6 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM et al. Perivascular spaces in the brain: anatomy, physiology and pathology. Nat Rev Neurol 16, 137&#x2013;153 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32094487</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. Elife 7, e40070 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6307855</ArticleId><ArticleId IdType="pubmed">30561329</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L et al. Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer. J Transl Med 11, 107 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665671</ArticleId><ArticleId IdType="pubmed">23635358</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn JH et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature 572, 62&#x2013;66 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31341278</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H et al. Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science 367, eaax7171 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375109</ArticleId><ArticleId IdType="pubmed">32001524</ArticleId></ArticleIdList></Reference><Reference><Citation>Polfliet MM et al. A method for the selective depletion of perivascular and meningeal macrophages in the central nervous system. J Neuroimmunol 116, 188&#x2013;195 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11438173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hablitz LM et al. Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci Adv 5, eaav5447 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6392807</ArticleId><ArticleId IdType="pubmed">30820460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gakuba C et al. General Anesthesia Inhibits the Activity of the &#x2018;Glymphatic System&#x2019;. Theranostics 8, 710&#x2013;722 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5771087</ArticleId><ArticleId IdType="pubmed">29344300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HY et al. Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen. Immunity 49, 326&#x2013;341.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30054204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow BW et al. Caveolae in CNS arterioles mediate neurovascular coupling. Nature 579, 106&#x2013;110 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7060132</ArticleId><ArticleId IdType="pubmed">32076269</ArticleId></ArticleIdList></Reference><Reference><Citation>Baccin C et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat Cell Biol 22, 38&#x2013;48 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610809</ArticleId><ArticleId IdType="pubmed">31871321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N et al. LYVE1+ macrophages of murine peritoneal mesothelium promote omentum-independent ovarian tumor growth. J Exp Med 218, e20210924 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575007</ArticleId><ArticleId IdType="pubmed">34714329</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissonneault V et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer&#x2019;s disease. Brain 132, 1078&#x2013;1092 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19151372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA &amp; McLaurin J Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 106, 1261&#x2013;1266 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al. Meningeal lymphatics affect microglia responses and anti-A&#x3b2; immunotherapy. Nature 593, 255&#x2013;260 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817786</ArticleId><ArticleId IdType="pubmed">33911285</ArticleId></ArticleIdList></Reference><Reference><Citation>Utz SG et al. Early Fate Defines Microglia and Non-parenchymal Brain Macrophage Development. Cell 181, 557&#x2013;573.e18 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32259484</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires PW et al. Improvement in Middle Cerebral Artery Structure and Endothelial Function in Stroke-Prone Spontaneously Hypertensive Rats after Macrophage Depletion. Microcirculation 20, 650&#x2013;661 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603760</ArticleId><ArticleId IdType="pubmed">23647512</ArticleId></ArticleIdList></Reference><Reference><Citation>Cs&#xe1;sz&#xe1;r E et al. Microglia modulate blood flow, neurovascular coupling, and hypoperfusion via purinergic actions. Journal of Experimental Medicine 219, e20211071 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8932534</ArticleId><ArticleId IdType="pubmed">35201268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Method References:</Title><Reference><Citation>Erde J, Loo RRO &amp; Loo JA Improving Proteome Coverage and Sample Recovery with Enhanced FASP (eFASP) for Quantitative Proteomic Experiments. Methods Mol Biol 1550, 11&#x2013;18 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6205185</ArticleId><ArticleId IdType="pubmed">28188519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, McCarthy DJ &amp; Marioni JC A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112579</ArticleId><ArticleId IdType="pubmed">27909575</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Campbell KR, Lun ATL &amp; Wills QF Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179&#x2013;1186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408845</ArticleId><ArticleId IdType="pubmed">28088763</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berge K et al. Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications. Genome Biol 19, 24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251479</ArticleId><ArticleId IdType="pubmed">29478411</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ &amp; Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong G, Zhang W, Li H, Shen X &amp; Guo Z Separate enrichment analysis of pathways for up- and downregulated genes. J R Soc Interface 11, 20130950 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899863</ArticleId><ArticleId IdType="pubmed">24352673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36368315</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>219.e7</EndPage><MedlinePgn>202-219.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2022.10.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(22)00955-2</ELocationID><Abstract><AbstractText>In addition to tau and A&#x3b2; pathologies, inflammation plays an important role in Alzheimer's disease (AD). Variants in APOE and TREM2 increase AD risk. ApoE4 exacerbates tau-linked neurodegeneration and inflammation in P301S tau mice and removal of microglia blocks tau-dependent neurodegeneration. Microglia adopt a heterogeneous population of transcriptomic states in response to pathology, at least some of which are dependent on TREM2. Previously, we reported that knockout (KO) of TREM2 attenuated neurodegeneration in P301S mice that express mouse Apoe. Because of the possible common pathway of ApoE and TREM2 in AD, we tested whether TREM2 KO (T2KO) would block neurodegeneration in P301S Tau mice expressing ApoE4 (TE4), similar to that observed with microglial depletion. Surprisingly, we observed exacerbated neurodegeneration and tau pathology in TE4-T2KO versus TE4 mice, despite decreased TREM2-dependent microgliosis. Our results suggest that tau pathology-dependent microgliosis, that is, TREM2-independent microgliosis, facilitates tau-mediated neurodegeneration in the presence of ApoE4.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gratuze</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlachetzki</LastName><ForeName>Johannes C M</ForeName><Initials>JCM</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Oliveira Albanus</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, NeuroGenomics and Informatics Center, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Nimansha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novotny</LastName><ForeName>Brenna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, NeuroGenomics and Informatics Center, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brase</LastName><ForeName>Logan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, NeuroGenomics and Informatics Center, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Lea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansel</LastName><ForeName>Clayton</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Sydney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasillas</LastName><ForeName>Martina P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Choonghee</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, NeuroGenomics and Informatics Center, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Christopher K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: holtzman@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG057777</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG072464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG069701</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021629</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG067764</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD026929</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG074012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2023 Jan 18;111(2):142-144. doi: 10.1016/j.neuron.2022.12.032.</RefSource><PMID Version="1">36657395</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="Y">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">ApoE4</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">microgliosis</Keyword><Keyword MajorTopicYN="N">tau pathology</Keyword><Keyword MajorTopicYN="N">tau-mediated neurodegeneration</Keyword></KeywordList><CoiStatement>Declaration of interests D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. and J.D.U. are inventors on a submitted patent on TREM2 antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Genentech (South San Francisco, CA), and Cajal Neuroscience and consults for Alector. D.M.H. is on the advisory board for Neuron.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36368315</ArticleId><ArticleId IdType="mid">NIHMS1844615</ArticleId><ArticleId IdType="pmc">PMC9852006</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2022.10.022</ArticleId><ArticleId IdType="pii">S0896-6273(22)00955-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Castellani RJ, Rolston RK, and Smith MA (2010). Alzheimer disease. Disease-a-Month 56, 484&#x2013;546. 10.1016/j.disamonth.2010.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2010.06.001</ArticleId><ArticleId IdType="pmc">PMC2941917</ArticleId><ArticleId IdType="pubmed">20831921</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, and Goate AM (2011). Alzheimer&#x2019;s disease: The challenge of the second century. Sci. Transl. Med. 3. 10.1126/scitranslmed.3002369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek MS, Cho H, Lee HS, Lee JH, Ryu YH, and Lyoo CH (2020). Effect of APOE &#x3b5;4 genotype on amyloid-&#x3b2; and tau accumulation in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther. 12, 1&#x2013;12. 10.1186/S13195-020-00710-6/FIGURES/5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13195-020-00710-6/FIGURES/5</ArticleId><ArticleId IdType="pmc">PMC7603688</ArticleId><ArticleId IdType="pubmed">33129364</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, Thomas E, Kang MS, Lussier F, Tissot C, et al. (2020). Association of Apolipoprotein E &#x3b5;4 With Medial Temporal Tau Independent of Amyloid-&#x3b2;. JAMA Neurol. 77, 470&#x2013;479. 10.1001/JAMANEUROL.2019.4421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANEUROL.2019.4421</ArticleId><ArticleId IdType="pmc">PMC6990684</ArticleId><ArticleId IdType="pubmed">31860000</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigand AJ, Thomas KR, Bangen KJ, Eglit GML, Delano-Wood L, Gilbert PE, Brickman AM, and Bondi MW (2021). APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia. Alzheimers. Dement. 17, 61&#x2013;69. 10.1002/ALZ.12173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ALZ.12173</ArticleId><ArticleId IdType="pubmed">32886451</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527. 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, and Holtzman DM (2017). Glial contributions to neurodegeneration in tauopathies . Mol. Neurodegener 12. 10.1186/s13024-017-0192-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0192-x</ArticleId><ArticleId IdType="pmc">PMC5492997</ArticleId><ArticleId IdType="pubmed">28662669</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, and Holtzman DM (2019). Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med. 216, 2546&#x2013;2561. 10.1084/jem.20190980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190980</ArticleId><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, and Tsai LH (2017). Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 21, 366&#x2013;380. 10.1016/J.CELREP.2017.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELREP.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, Mancuso R, Chen WT, Woodbury ME, Srivastava G, et al. (2019). The Major Risk Factors for Alzheimer&#x2019;s Disease: Age, Sex, and Genes Modulate the Microglia Response to A&#x3b2; Plaques. Cell Rep. 27, 1293&#x2013;1306.e6. 10.1016/J.CELREP.2019.03.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELREP.2019.03.099</ArticleId><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, and Colonna M (2021). Microglia in Alzheimer&#x2019;s disease at single-cell level. Are there common patterns in humans and mice? J. Exp. Med. 218. 10.1084/JEM.20202717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20202717</ArticleId><ArticleId IdType="pmc">PMC8302448</ArticleId><ArticleId IdType="pubmed">34292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17. 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi RE, and Colonna M (2017). Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer&#x2019;s Dement. 13, 381&#x2013;387. 10.1016/j.jalz.2016.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.004</ArticleId><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. (2016). TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn M, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, and Holtzman DM (2014). Altered microglial response to A&#x3b2; plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol. Neurodegener. 9, 20. 10.1186/1750-1326-9-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, Von Saucken VE, Williams RY, Karlo JC, Moutinho M, et al. (2018). The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer&#x2019;s disease. Mol. Neurodegener. 13. 10.1186/s13024-018-0262-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0262-8</ArticleId><ArticleId IdType="pmc">PMC5984804</ArticleId><ArticleId IdType="pubmed">29859094</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. (2015). TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med. 212, 287&#x2013;295. 10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, et al. (2019). TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22, 1217&#x2013;1222. 10.1038/s41593-019-0433-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0433-0</ArticleId><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, Chen Y, Parhizkar S, Jain N, Strickland MR, Serrano JR, Colonna M, Ulrich JD, and Holtzman DM (2021). Activated microglia mitigate A&#x3b2;-associated tau seeding and spreading. J. Exp. Med. 218, e20210542. 10.1084/jem.20210542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210542</ArticleId><ArticleId IdType="pmc">PMC8190588</ArticleId><ArticleId IdType="pubmed">34100905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, Rezzonico MG, Imperio J, Lalehzadeh G, Huntley MA, et al. (2021). Trem2 restrains the enhancement of tau accumulation and neurodegeneration by &#x3b2;-amyloid pathology. Neuron 109, 1&#x2013;19. 10.1016/j.neuron.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.02.010</ArticleId><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, Telpoukhovskaia M, Kodama L, Li Y, Zhou Y, Le D, Hauduc A, Ludwig C, Gao F, Clelland C, et al. (2018). Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc. Natl. Acad. Sci. U. S. A. 115, 10172&#x2013;10177. 10.1073/pnas.1811411115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1811411115</ArticleId><ArticleId IdType="pmc">PMC6176614</ArticleId><ArticleId IdType="pubmed">30232263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, Leyns CEG, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, Serrano JR, Tremblay M&#xc8;, Kummer TT, Colonna M, et al. (2020). Impact of TREM2R47Hvariant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest. 10.1172/JCI138179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138179</ArticleId><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Serrano JR, Robinson GO, Anderson E, Colonna M, and Holtzman DM (2017). TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. U. S. A. 114, 11524&#x2013;11529. 10.1073/pnas.1710311114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, Liu YU, Zhao S, Zhang L, Bosco DB, Pang YP, Zhong J, Sheth U, Martens YA, Zhao N, et al. (2022). TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. Nat. Neurosci. 25, 26&#x2013;38. 10.1038/S41593-021-00975-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41593-021-00975-6</ArticleId><ArticleId IdType="pmc">PMC8741737</ArticleId><ArticleId IdType="pubmed">34916658</ArticleId></ArticleIdList></Reference><Reference><Citation>Reifschneider A, Robinson S, Van Lengerich B, Gn&#xf6;rich J, Logan T, Heindl S, Vogt MA, Weidinger E, Riedl L, Wind K, et al. (2022). Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO J. 41, e109108. 10.15252/EMBJ.2021109108.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/EMBJ.2021109108</ArticleId><ArticleId IdType="pmc">PMC8844989</ArticleId><ArticleId IdType="pubmed">35019161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TCC, Maeda J, Suhara T, Trojanowski JQ, and Lee VMY (2007). Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. Neuron 53, 337&#x2013;351. 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Andhey PS, Ising C, Wang K, Snipes LL, Boyer K, Lawson S, Yamada K, Qin W, Manis M, et al. (2021). Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron 109, 2413&#x2013;2426.e7. 10.1016/J.NEURON.2021.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NEURON.2021.05.034</ArticleId><ArticleId IdType="pmc">PMC8349883</ArticleId><ArticleId IdType="pubmed">34157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, et al. (2018). Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018 1410 14, 577&#x2013;589. 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, et al. (2017). TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener. 12. 10.1186/s13024-017-0216-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0216-6</ArticleId><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Fryatt G, Cleal M, Obst J, Pipi E, Monz&#xf3;n-Sandoval J, Ribe E, Winchester L, Webber C, Nevado A, et al. (2019). CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 142, 3243&#x2013;3264. 10.1093/brain/awz241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz241</ArticleId><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, Manis M, Schroeder C, Yin Z, Madore C, et al. (2021). Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron 109, 1657&#x2013;1674.e7. 10.1016/j.neuron.2021.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.03.024</ArticleId><ArticleId IdType="pmc">PMC8141024</ArticleId><ArticleId IdType="pubmed">33831349</ArticleId></ArticleIdList></Reference><Reference><Citation>Arhzaouy K, Papadopoulos C, Schulze N, Pittman SK, Meyer H, and Weihl CC (2019). VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle. Autophagy 15, 1082&#x2013;1099. 10.1080/15548627.2019.1569933/SUPPL_FILE/KAUP_A_1569933_SM9194.ZIP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1569933/SUPPL_FILE/KAUP_A_1569933_SM9194.ZIP</ArticleId><ArticleId IdType="pmc">PMC6526815</ArticleId><ArticleId IdType="pubmed">30654731</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos C, and Meyer H (2017). Detection and Clearance of Damaged Lysosomes by the Endo-Lysosomal Damage Response and Lysophagy. Curr. Biol. 27, R1330&#x2013;R1341. 10.1016/J.CUB.2017.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CUB.2017.11.012</ArticleId><ArticleId IdType="pubmed">29257971</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J, Claude-Taupin A, Gu Y, Choi SW, Peters R, Bissa B, Mudd MH, Allers L, Pallikkuth S, Lidke KA, et al. (2020). Galectin-3 Coordinates a Cellular System for Lysosomal Repair and Removal. Dev. Cell 52, 69&#x2013;87.e8. 10.1016/J.DEVCEL.2019.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DEVCEL.2019.10.025</ArticleId><ArticleId IdType="pmc">PMC6997950</ArticleId><ArticleId IdType="pubmed">31813797</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, and Ballabio A (2014). Lysosome: Regulator of lipid degradation pathways. Trends Cell Biol. 24, 743&#x2013;750. 10.1016/J.TCB.2014.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.TCB.2014.06.006</ArticleId><ArticleId IdType="pmc">PMC4247383</ArticleId><ArticleId IdType="pubmed">25061009</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze H, and Sandhoff K (2011). Lysosomal lipid storage diseases. Cold Spring Harb. Perspect. Biol. 3, 1&#x2013;19. 10.1101/cshperspect.a004804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a004804</ArticleId><ArticleId IdType="pmc">PMC3098676</ArticleId><ArticleId IdType="pubmed">21502308</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaband&#xe9;-Rodr&#xed;guez E, P&#xe9;rez-Ca&#xf1;am&#xe1;s A, Soto-Huelin B, Mitroi DN, S&#xe1;nchez-Redondo S, Mart&#xed;nez-S&#xe1;ez E, Venero C, Peinado H, Mar&#xed;a, &amp;, and Ledesma, D. (2019). Lipid-induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders. EMBO J. 38, e99553. 10.15252/EMBJ.201899553.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/EMBJ.201899553</ArticleId><ArticleId IdType="pmc">PMC6331723</ArticleId><ArticleId IdType="pubmed">30530526</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor MB, Leary N, Luna X, Meharena HS, Scannail AN, Bozzelli PL, Samaan G, Murdock MH, von Maydell D, Effenberger AH, et al. (2022). Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell 29, 1197&#x2013;1212.e8. 10.1016/j.stem.2022.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2022.07.005</ArticleId><ArticleId IdType="pmc">PMC9623845</ArticleId><ArticleId IdType="pubmed">35931030</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, and Ballabio A (2011). Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 20, 3852&#x2013;3866. 10.1093/hmg/ddr306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr306</ArticleId><ArticleId IdType="pubmed">21752829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cegli R De Carrella D., Siciliano D, Gambardella G, Napolitano G, Malta C. Di, Ballabio A, and Bernardo D. di (2022). TFEBexplorer: An integrated tool to study genes regulated by the stress-responsive Transcription Factor EB. 10.1080/27694127.2022.2097822 1, 295&#x2013;305. 10.1080/27694127.2022.2097822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/27694127.2022.2097822</ArticleId><ArticleId IdType="doi">10.1080/27694127.2022.2097822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, et al. (2019). NLRP3 inflammasome activation drives tau pathology. Nature 575, 669. 10.1038/S41586-019-1769-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41586-019-1769-Z</ArticleId><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, Huntley MA, De Mazi&#xe8;re A, Meilandt WJ, Wu T, Srinivasan K, Jiang Z, Gandham V, Friedman BA, Ngu H, et al. (2018). Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. Neuron 100, 1322&#x2013;1336.e7. 10.1016/j.neuron.2018.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.10.014</ArticleId><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley MA, Wang Y, Wang TM, et al. (2019). Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Rep. 28, 2111&#x2013;2123.e6. 10.1016/j.celrep.2019.07.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.07.060</ArticleId><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, Wang Q, Zhang B, Liu Z, and Zheng H (2018). Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer&#x2019;s disease. Neuron 100, 1337. 10.1016/J.NEURON.2018.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NEURON.2018.10.031</ArticleId><ArticleId IdType="pmc">PMC6309202</ArticleId><ArticleId IdType="pubmed">30415998</ArticleId></ArticleIdList></Reference><Reference><Citation>Brase L, You S-F, Del-Aguila JL, Dai Y, Novotny BC, Soriano-Tarraga C, Dykstra T, Fernandez MV, Budde JP, Bergmann K, et al. (2022). A landscape of the genetic and cellular heterogeneity in Alzheimer disease. medRxiv 10, 2021.11.30.21267072. 10.1101/2021.11.30.21267072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.30.21267072</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, Jiang H, Kodira CD, de Lima KA, Herz J, et al. (2021). Meningeal lymphatics affect microglia responses and anti-A&#x3b2; immunotherapy. Nature 593, 255&#x2013;260. 10.1038/S41586-021-03489-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41586-021-03489-0</ArticleId><ArticleId IdType="pmc">PMC8817786</ArticleId><ArticleId IdType="pubmed">33911285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, et al. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 26, 131&#x2013;142. 10.1038/S41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, and Holtzman DM (2015). Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. 10.1186/s40478-015-0250-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0250-y</ArticleId><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Acker ZP, Bretou M, and Annaert W (2019). Endo-lysosomal dysregulations and late-onset Alzheimer&#x2019;s disease: Impact of genetic risk factors. Mol. Neurodegener. 14. 10.1186/s13024-019-0323-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0323-7</ArticleId><ArticleId IdType="pmc">PMC6547588</ArticleId><ArticleId IdType="pubmed">31159836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I, Zhou B, Kim J, Mathews PM, Duff KE, Nuriel T, Peng KY, Ashok A, Dillman AA, Figueroa HY, et al. (2017). The Endosomal-Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo. Front. Neurosci. | www.frontiersin.org
11, 702. 10.3389/fnins.2017.00702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00702</ArticleId><ArticleId IdType="pmc">PMC5733017</ArticleId><ArticleId IdType="pubmed">29311783</ArticleId></ArticleIdList></Reference><Reference><Citation>TCW J, Qian L, Pipalia NH, Chao MJ, Liang SA, Shi Y, Jain BR, Bertelsen SE, Kapoor M, Marcora E, et al. (2022). Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell 185, 2213&#x2013;2233.e25. 10.1016/J.CELL.2022.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2022.05.017</ArticleId><ArticleId IdType="pmc">PMC9340815</ArticleId><ArticleId IdType="pubmed">35750033</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz NF, Wolfe CM, Playso BE, Biedrzycki RJ, Lu Y, Nam KN, Lefterov I, and Koldamova R (2020). Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Mol. Neurodegener. 15. 10.1186/S13024-020-00394-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13024-020-00394-4</ArticleId><ArticleId IdType="pmc">PMC7379780</ArticleId><ArticleId IdType="pubmed">32703241</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e9. 10.1016/J.IMMUNI.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IMMUNI.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, and Holtzman DM (2018). Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18, 759&#x2013;772. 10.1038/S41577-018-0051-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41577-018-0051-1</ArticleId><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Mahan TE, Nystr&#xf6;m S, Peter Nilsson K, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, et al. (2018). ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med. 215, 1047&#x2013;1058. 10.1084/JEM.20171265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20171265</ArticleId><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D, et al. (2020). TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron 105, 837&#x2013;854.e9. 10.1016/J.NEURON.2019.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NEURON.2019.12.007</ArticleId><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. (2015). Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J. Biol. Chem. 290, 26043&#x2013;26050. 10.1074/JBC.M115.679043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/JBC.M115.679043</ArticleId><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, and Sheng M (2016). TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron 91, 328&#x2013;340. 10.1016/J.NEURON.2016.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NEURON.2016.06.015</ArticleId><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh ER, Van Deerlin VM, Choi D, Roeder K, et al. (2020). APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer&#x2019;s disease. Acta Neuropathol. 140, 477&#x2013;493. 10.1007/S00401-020-02200-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00401-020-02200-3</ArticleId><ArticleId IdType="pmc">PMC7520051</ArticleId><ArticleId IdType="pubmed">32840654</ArticleId></ArticleIdList></Reference><Reference><Citation>Rexach JE, Polioudakis D, Yin A, Swarup V, Chang TS, Nguyen T, Sarkar A, Chen L, Huang J, Lin LC, et al. (2020). Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression. Cell Rep. 33. 10.1016/J.CELREP.2020.108398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELREP.2020.108398</ArticleId><ArticleId IdType="pmc">PMC7842189</ArticleId><ArticleId IdType="pubmed">33207193</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy ER, Chiu G, Li S, Propson NE, Kanchi R, Wang B, Coarfa C, Zheng H, and Cao W (2022). Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid &#x3b2; plaques. Immunity 55, 879&#x2013;894.e6. 10.1016/J.IMMUNI.2022.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IMMUNI.2022.03.018</ArticleId><ArticleId IdType="pmc">PMC9109419</ArticleId><ArticleId IdType="pubmed">35443157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, and Binder LI (1995). Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc. Natl. Acad. Sci. U. S. A. 92, 10369&#x2013;10373. 10.1073/PNAS.92.22.10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.92.22.10369</ArticleId><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersuker K, Peterson CWH, To M, Sahl SJ, Savikhin V, Grossman EA, Nomura DK, and Olzmann JA (2018). A Proximity Labeling Strategy Provides Insights into the Composition and Dynamics of Lipid Droplet Proteomes. Dev. Cell 44, 97&#x2013;112.e7. 10.1016/J.DEVCEL.2017.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DEVCEL.2017.11.020</ArticleId><ArticleId IdType="pmc">PMC5764092</ArticleId><ArticleId IdType="pubmed">29275994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, and Davies P (1997). Alz-50 and MC-1, a New Monoclonal Antibody Raised to Paired Helical Filaments, Recognize Conformational Epitopes on Recombinant Tau. J. Neurosci. Res 48, 128&#x2013;132. 10.1002/(SICI)1097-4547(19970415)48:2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19970415)48:2</ArticleId><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey AP, Koster G, Guillermier C, Hirst EMA, MacRae JI, Lechene CP, Postle AD, and Gould AP (2015). Antioxidant Role for Lipid Droplets in a Stem Cell Niche of Drosophila. Cell 163, 340&#x2013;353. 10.1016/J.CELL.2015.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2015.09.020</ArticleId><ArticleId IdType="pmc">PMC4601084</ArticleId><ArticleId IdType="pubmed">26451484</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. (2014). Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131&#x2013;143. 10.1038/NN.3599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NN.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF, and Regev A (2015). Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 2015 335 33, 495&#x2013;502. 10.1038/nbt.3192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3192</ArticleId><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, and Maeda N (1999). Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579&#x2013;1586. 10.1172/JCI6172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI6172</ArticleId><ArticleId IdType="pmc">PMC408371</ArticleId><ArticleId IdType="pubmed">10359567</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902.e21. 10.1016/J.CELL.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, and Colonna M (2006). Cutting Edge: TREM-2 Attenuates Macrophage Activation. J. Immunol. 10.4049/jimmunol.177.6.3520.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.6.3520</ArticleId><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, Davila-Velderrain J, Sumida TS, Hafler DA, Kellis M, and Kulminski AM (2021). NEBULA is a fast negative binomial mixed model for differential or co-expression analysis of large-scale multi-subject single-cell data. Commun. Biol 4. 10.1038/S42003-021-02146-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S42003-021-02146-6</ArticleId><ArticleId IdType="pmc">PMC8155058</ArticleId><ArticleId IdType="pubmed">34040149</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. (2016). Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189&#x2013;196. 10.1126/SCIENCE.AAD0501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.AAD0501</ArticleId><ArticleId IdType="pmc">PMC4944528</ArticleId><ArticleId IdType="pubmed">27124452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36368316</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Microglial Piezo1 senses A&#x3b2; fibril stiffness to restrict Alzheimer's disease.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>29.e8</EndPage><MedlinePgn>15-29.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2022.10.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(22)00954-0</ELocationID><Abstract><AbstractText>The pathology of Alzheimer's disease (AD) is featured with extracellular amyloid-&#x3b2; (A&#x3b2;) plaques, whose impact on the mechanical properties of the surrounding brain tissues is unclear. Microglia sense and integrate biochemical cues of the microenvironment. However, whether the microglial mechanosensing pathways influence AD pathogenesis is unknown. Here, we surveyed the elevated stiffness of A&#x3b2;-plaque-associated tissues and observed the selective upregulation of the mechanosensitive ion channel Piezo1 in A&#x3b2;-plaque-associated microglia. Piezo1 sensed the stiffness stimuli of A&#x3b2; fibrils and subsequently induced Ca<sup>2+</sup> influx for microglial clustering, phagocytosis, and compacting of A&#x3b2; plaques. Microglia lacking Piezo1 led to the exacerbation of A&#x3b2; pathology and cognitive decline, whereas pharmacological activation of microglial Piezo1 ameliorated brain A&#x3b2; burden and cognitive impairment in 5&#xa0;&#xd7;&#xa0;FAD mice. Together, our results reveal that Piezo1, a mechanosensor of A&#x3b2; fibril stiffness in microglia, represents a potential therapeutic target for AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China. Electronic address: jinhu@xmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hongrui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; Department of Anesthesiology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Lichao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qihua</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Huidan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China; Department of Anesthesiology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Guolin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Boxin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shaoxuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Zhiyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chongxin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hongda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Sifang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Xiamen Key Laboratory of Brain Center, the First Affiliated Hospital, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Naian</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Xiamen Key Laboratory of Brain Center, the First Affiliated Hospital, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhan-Xiang</ForeName><Initials>ZX</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Xiamen Key Laboratory of Brain Center, the First Affiliated Hospital, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xueqin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China. Electronic address: lzhangxmu@xmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Department of Neuroscience, the First Affiliated Hospital, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China. Electronic address: wmo@xmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552920">Piezo1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2023 Jan;24(1):1. doi: 10.1038/s41583-022-00664-8.</RefSource><PMID Version="1">36446902</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2023 Jan 4;111(1):1-2. doi: 10.1016/j.neuron.2022.11.014.</RefSource><PMID Version="1">36603547</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2; plaque</Keyword><Keyword MajorTopicYN="N">Piezo1</Keyword><Keyword MajorTopicYN="N">microglial mechanosensor</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36368316</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2022.10.021</ArticleId><ArticleId IdType="pii">S0896-6273(22)00954-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36385530</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>612</Volume><Issue>7938</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Medin co-aggregates with vascular amyloid-&#x3b2; in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>131</EndPage><MedlinePgn>123-131</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-05440-3</ELocationID><Abstract><AbstractText>Aggregates of medin amyloid (a fragment of the protein MFG-E8,&#xa0;also known as lactadherin) are found in the vasculature of almost all humans over 50 years of age<sup>1,2</sup>, making it the most common amyloid currently known. We recently reported that medin also aggregates in blood vessels of ageing wild-type mice, causing cerebrovascular dysfunction<sup>3</sup>. Here we demonstrate in amyloid-&#x3b2; precursor protein (APP) transgenic mice and in patients with Alzheimer's disease that medin co-localizes with vascular amyloid-&#x3b2; deposits, and that in mice, medin deficiency reduces vascular amyloid-&#x3b2; deposition by half. Moreover, in&#xa0;both the mouse and human brain, MFG-E8 is highly enriched in the vasculature and both MFG-E8 and medin levels increase with the severity of vascular amyloid-&#x3b2; burden. Additionally, analysing data from 566 individuals in the ROSMAP cohort, we find that patients with Alzheimer's disease have higher MFGE8 expression levels, which are attributable to vascular cells and are associated with increased measures of cognitive decline, independent of plaque and tau pathology. Mechanistically, we demonstrate that medin interacts directly with amyloid-&#x3b2; to promote its aggregation, as medin forms heterologous fibrils with amyloid-&#x3b2;, affects amyloid-&#x3b2; fibril structure, and cross-seeds amyloid-&#x3b2; aggregation both in vitro and in vivo. Thus, medin could be a therapeutic target for prevention of vascular damage and cognitive decline resulting from amyloid-&#x3b2; deposition in the blood vessels of the brain.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wagner</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Degenhardt</LastName><ForeName>Karoline</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veit</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louros</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4030-1022</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantoulea</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0960-6274</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skodras</LastName><ForeName>Angelos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wild</LastName><ForeName>Katleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Vikas</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0944-7226</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalmia</LastName><ForeName>Anupriya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;sler</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vleeschouwer</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Hannah A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madine</LastName><ForeName>Jillian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9963-5871</Identifier><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kronenberg-Versteeg</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3981-367X</Identifier><AffiliationInfo><Affiliation>Monoclonal Antibody Core Facility, Institute for Diabetes and Obesity, Helmholtz Zentrum M&#xfc;nchen, Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Turco</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroanatomy, Dr. Senckenberg Anatomy, Neuroscience Center, Goethe University, Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>K Peter R</ForeName><Initials>KPR</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, University College London Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deller</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroanatomy, Dr. Senckenberg Anatomy, Neuroscience Center, Goethe University, Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0001-9166-3261</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Emory National Primate Research Center, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5218-1737</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9189-7399</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neher</LastName><ForeName>Jonas J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-1346-8924</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany. jonas.neher@dzne.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany. jonas.neher@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51 OD011132</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>FS/12/61/29877</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F/S/12/61/29877</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG079234</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C098942">MFGE8 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490919">Mfge8 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="Y">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>T.D. received funding from Novartis for a lecture on human brain anatomy. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36385530</ArticleId><ArticleId IdType="pmc">PMC9712113</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05440-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-05440-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>H&#xe4;ggqvist B, et al. Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc. Natl Acad. Sci. USA. 1999;96:8669&#x2013;8674. doi: 10.1073/pnas.96.15.8669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.15.8669</ArticleId><ArticleId IdType="pmc">PMC17574</ArticleId><ArticleId IdType="pubmed">10411933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucchiano G, Cornwell GG, Westermark P. Senile aortic amyloid. Evidence for two distinct forms of localized deposits. Am. J. Pathol. 1992;140:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886375</ArticleId><ArticleId IdType="pubmed">1562050</ArticleId></ArticleIdList></Reference><Reference><Citation>Degenhardt K, et al. Medin aggregation causes cerebrovascular dysfunction in aging wild-type mice. Proc. Natl Acad. Sci. USA. 2020;117:23925&#x2013;23931. doi: 10.1073/pnas.2011133117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2011133117</ArticleId><ArticleId IdType="pmc">PMC7519322</ArticleId><ArticleId IdType="pubmed">32900929</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson MD, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27:217&#x2013;222. doi: 10.1080/13506129.2020.1835263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506129.2020.1835263</ArticleId><ArticleId IdType="pubmed">33100054</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188&#x2013;1203. doi: 10.1016/j.cell.2012.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.022</ArticleId><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nat. Rev. Mol. Cell Biol. 2018;19:755&#x2013;773. doi: 10.1038/s41580-018-0060-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0060-8</ArticleId><ArticleId IdType="pubmed">30237470</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, Glennert J, Westermark P. Medin-amyloid: a recently characterized age-associated arterial amyloid form affects mainly arteries in the upper part of the body. Amyloid. 2005;12:96&#x2013;102. doi: 10.1080/13506120500107006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506120500107006</ArticleId><ArticleId IdType="pubmed">16011985</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamanova N, et al. Endothelial immune activation by medin: potential role in cerebrovascular disease and reversal by monosialoganglioside-containing nanoliposomes. J. Am. Heart Assoc. 2020;9:e014810. doi: 10.1161/JAHA.119.014810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.014810</ArticleId><ArticleId IdType="pmc">PMC7033828</ArticleId><ArticleId IdType="pubmed">31928157</ArticleId></ArticleIdList></Reference><Reference><Citation>Migrino RQ, et al. Cerebrovascular medin is associated with Alzheimer&#x2019;s disease and vascular dementia. Alzheimers Dement. 2020;12:e12072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447901</ArticleId><ArticleId IdType="pubmed">32875054</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies HA, et al. Idiopathic degenerative thoracic aneurysms are associated with increased aortic medial amyloid. Amyloid. 2019;26:148&#x2013;155. doi: 10.1080/13506129.2019.1625323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506129.2019.1625323</ArticleId><ArticleId IdType="pmc">PMC6816484</ArticleId><ArticleId IdType="pubmed">31210552</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, et al. Role of aggregated medin in the pathogenesis of thoracic aortic aneurysm and dissection. Lab Invest. 2007;87:1195&#x2013;1205. doi: 10.1038/labinvest.3700679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.3700679</ArticleId><ArticleId IdType="pubmed">17906662</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, et al. Medin and medin-amyloid in ageing inflamed and non-inflamed temporal arteries. J. Pathol. 2002;196:91&#x2013;96. doi: 10.1002/path.1014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1014</ArticleId><ArticleId IdType="pubmed">11748647</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. A&#x3b2;42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. USA. 1997;94:13287&#x2013;13292. doi: 10.1073/pnas.94.24.13287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.24.13287</ArticleId><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestre J-S, et al. Lactadherin promotes VEGF-dependent neovascularization. Nat. Med. 2005;11:499&#x2013;506. doi: 10.1038/nm1233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1233</ArticleId><ArticleId IdType="pubmed">15834428</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl Acad. Sci. USA. 1999;96:14088&#x2013;14093. doi: 10.1073/pnas.96.24.14088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.24.14088</ArticleId><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 2004;7:954&#x2013;960. doi: 10.1038/nn1302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1302</ArticleId><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Robinson KA, Lee VM, Trojanowski JQ. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer&#x2019;s disease and Down&#x2019;s syndrome brains revealed by confocal microscopy. Am. J. Pathol. 1995;147:503&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869826</ArticleId><ArticleId IdType="pubmed">7639340</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler DT, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 2001;21:1619&#x2013;1627. doi: 10.1523/JNEUROSCI.21-05-01619.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-05-01619.2001</ArticleId><ArticleId IdType="pmc">PMC6762950</ArticleId><ArticleId IdType="pubmed">11222652</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, et al. High tissue content of soluble &#x3b2;1&#x2013;40 is linked to cerebral amyloid angiopathy. Am. J. Pathol. 1994;145:452&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887395</ArticleId><ArticleId IdType="pubmed">8053502</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, et al. Cerebral amyloid angiopathy and Alzheimer disease&#x2014;one peptide, two pathways. Nat. Rev. Neurol. 2020;16:30&#x2013;42. doi: 10.1038/s41582-019-0281-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0281-2</ArticleId><ArticleId IdType="pmc">PMC7268202</ArticleId><ArticleId IdType="pubmed">31827267</ArticleId></ArticleIdList></Reference><Reference><Citation>Marazuela P, et al. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy. Acta Neuropathol. Commun. 2021;9:154. doi: 10.1186/s40478-021-01257-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01257-9</ArticleId><ArticleId IdType="pmc">PMC8444498</ArticleId><ArticleId IdType="pubmed">34530925</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat. Neurosci. 2018;21:811&#x2013;819. doi: 10.1038/s41593-018-0154-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci. Data. 2018;5:180142. doi: 10.1038/sdata.2018.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.142</ArticleId><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C, et al. Comprehensive promoter level expression quantitative trait loci analysis of the human frontal lobe. Genome Med. 2016;8:65. doi: 10.1186/s13073-016-0320-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-016-0320-1</ArticleId><ArticleId IdType="pmc">PMC4903003</ArticleId><ArticleId IdType="pubmed">27287230</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibar S, et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods. 2017;14:1083&#x2013;1086. doi: 10.1038/nmeth.4463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4463</ArticleId><ArticleId IdType="pmc">PMC5937676</ArticleId><ArticleId IdType="pubmed">28991892</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG, Grant SGN. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front. Neurosci. 2016;10:16. doi: 10.3389/fnins.2016.00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00016</ArticleId><ArticleId IdType="pmc">PMC4730103</ArticleId><ArticleId IdType="pubmed">26858593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegenast-Braun BM, et al. Spectral discrimination of cerebral amyloid lesions after peripheral application of luminescent conjugated oligothiophenes. Am. J. Pathol. 2012;181:1953&#x2013;1960. doi: 10.1016/j.ajpath.2012.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.08.031</ArticleId><ArticleId IdType="pubmed">23041059</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S, et al. Evidence for age-dependent in vivo conformational rearrangement within A&#x3b2; amyloid deposits. ACS Chem. Biol. 2013;8:1128&#x2013;1133. doi: 10.1021/cb4000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb4000376</ArticleId><ArticleId IdType="pubmed">23521783</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724&#x2013;739. doi: 10.1016/j.neuron.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat. Rev. Neurosci. 2014;15:209&#x2013;216. doi: 10.1038/nrn3710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3710</ArticleId><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Cryo-EM structures of amyloid-&#x3b2; 42 filaments from human brains. Science. 2022;375:167&#x2013;172. doi: 10.1126/science.abm7285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm7285</ArticleId><ArticleId IdType="pmc">PMC7612234</ArticleId><ArticleId IdType="pubmed">35025654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh U, Thurber KR, Yau W-M, Tycko R. Molecular structure of a prevalent amyloid-&#x3b2; fibril polymorph from Alzheimer&#x2019;s disease brain tissue. Proc. Natl Acad. Sci. USA. 2021;118:e2023089118. doi: 10.1073/pnas.2023089118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2023089118</ArticleId><ArticleId IdType="pmc">PMC7848700</ArticleId><ArticleId IdType="pubmed">33431654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, et al. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nat. Commun. 2019;10:4760. doi: 10.1038/s41467-019-12683-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12683-8</ArticleId><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer&#x2019;s disease mice. Neurobiol. Aging. 2015;36:1820&#x2013;1833. doi: 10.1016/j.neurobiolaging.2015.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.02.010</ArticleId><ArticleId IdType="pubmed">25784209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiperij HB, et al. Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2020;46:431&#x2013;440. doi: 10.1111/nan.12595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12595</ArticleId><ArticleId IdType="pubmed">31872472</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrero-Prieto CM, et al. A comprehensive systematic review of CSF proteins and peptides that define Alzheimer&#x2019;s disease. Clin. Proteomics. 2020;17:21. doi: 10.1186/s12014-020-09276-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-020-09276-9</ArticleId><ArticleId IdType="pmc">PMC7273668</ArticleId><ArticleId IdType="pubmed">32518535</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784. doi: 10.1126/science.1131864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1131864</ArticleId><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritschi SK, et al. Highly potent soluble amyloid-&#x3b2; seeds in human Alzheimer brain but not cerebrospinal fluid. Brain. 2014;137:2909&#x2013;2915. doi: 10.1093/brain/awu255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu255</ArticleId><ArticleId IdType="pmc">PMC5367518</ArticleId><ArticleId IdType="pubmed">25212850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokjohn TA, et al. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim. Biophys. Acta. 2011;1812:1508&#x2013;1514. doi: 10.1016/j.bbadis.2011.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.07.004</ArticleId><ArticleId IdType="pmc">PMC3185199</ArticleId><ArticleId IdType="pubmed">21784149</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer&#x2019;s disease. Alzheimers Dement. 2009;5:18&#x2013;29. doi: 10.1016/j.jalz.2008.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2008.10.004</ArticleId><ArticleId IdType="pmc">PMC2663406</ArticleId><ArticleId IdType="pubmed">19118806</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies HA, Madine J, Middleton DA. Comparisons with amyloid-&#x3b2; reveal an aspartate residue that stabilizes fibrils of the aortic amyloid peptide medin. J. Biol. Chem. 2015;290:7791&#x2013;7803. doi: 10.1074/jbc.M114.602177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.602177</ArticleId><ArticleId IdType="pmc">PMC4367279</ArticleId><ArticleId IdType="pubmed">25614623</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson A, et al. Unwinding fibril formation of medin, the peptide of the most common form of human amyloid. Biochem. Biophys. Res. Commun. 2007;361:822&#x2013;828. doi: 10.1016/j.bbrc.2007.06.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.06.187</ArticleId><ArticleId IdType="pubmed">17679143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CP, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nat. Genet. 2017;49:1385&#x2013;1391. doi: 10.1038/ng.3913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3913</ArticleId><ArticleId IdType="pubmed">28714975</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikpay M, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 2015;47:1121&#x2013;1130. doi: 10.1038/ng.3396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3396</ArticleId><ArticleId IdType="pmc">PMC4589895</ArticleId><ArticleId IdType="pubmed">26343387</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ. Res. 2018;122:433&#x2013;443. doi: 10.1161/CIRCRESAHA.117.312086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.312086</ArticleId><ArticleId IdType="pmc">PMC5805277</ArticleId><ArticleId IdType="pubmed">29212778</ArticleId></ArticleIdList></Reference><Reference><Citation>Soubeyrand S, et al. Regulation of MFGE8 by the intergenic coronary artery disease locus on 15q26.1. Atherosclerosis. 2019;284:11&#x2013;17. doi: 10.1016/j.atherosclerosis.2019.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2019.02.012</ArticleId><ArticleId IdType="pubmed">30861420</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, et al. Early role of vascular dysregulation on late-onset Alzheimer&#x2019;s disease based on multifactorial data-driven analysis. Nat. Commun. 2016;7:11934. doi: 10.1038/ncomms11934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11934</ArticleId><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, et al. Interactive associations of vascular risk and &#x3b2;-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75:1124&#x2013;1131. doi: 10.1001/jamaneurol.2018.1123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.1123</ArticleId><ArticleId IdType="pmc">PMC6143121</ArticleId><ArticleId IdType="pubmed">29799986</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology. 2015;85:1930&#x2013;1936. doi: 10.1212/WNL.0000000000002175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002175</ArticleId><ArticleId IdType="pmc">PMC4664125</ArticleId><ArticleId IdType="pubmed">26537052</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlmann RE, et al. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat. Neurosci. 2020;23:1580&#x2013;1588. doi: 10.1038/s41593-020-00737-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00737-w</ArticleId><ArticleId IdType="pmc">PMC7783656</ArticleId><ArticleId IdType="pubmed">33199898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendeln A-C, et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature. 2018;556:332&#x2013;338. doi: 10.1038/s41586-018-0023-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0023-4</ArticleId><ArticleId IdType="pmc">PMC6038912</ArticleId><ArticleId IdType="pubmed">29643512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y-K, Uchida H, Smith H, Ito A, Sanchez T. The isolation and molecular characterization of cerebral microvessels. Nat. Protoc. 2019;14:3059&#x2013;3081. doi: 10.1038/s41596-019-0212-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-019-0212-0</ArticleId><ArticleId IdType="pmc">PMC11571963</ArticleId><ArticleId IdType="pubmed">31586162</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulay A-C, Saubam&#xe9;a B, Decl&#xe8;ves X, Cohen-Salmon M. Purification of mouse brain vessels. J. Vis. Exp. 2015;10:e53208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692710</ArticleId><ArticleId IdType="pubmed">26574794</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthes F, et al. An improved method for physical separation of cerebral vasculature and parenchyma enables detection of blood&#x2013;brain-barrier dysfunction. NeuroSci. 2021;2:59&#x2013;74. doi: 10.3390/neurosci2010004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/neurosci2010004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourassa P, Tremblay C, Schneider JA, Bennett DA, Calon F. Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. Acta Neuropathol. 2019;137:801&#x2013;823. doi: 10.1007/s00401-019-01967-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01967-4</ArticleId><ArticleId IdType="pmc">PMC6483878</ArticleId><ArticleId IdType="pubmed">30729296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, et al. A&#x3b2; seeding potency peaks in the early stages of cerebral &#x3b2;-amyloidosis. EMBO Rep. 2017;18:1536&#x2013;1544. doi: 10.15252/embr.201744067.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201744067</ArticleId><ArticleId IdType="pmc">PMC5579388</ArticleId><ArticleId IdType="pubmed">28701326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen J, et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2017;114:13018&#x2013;13023. doi: 10.1073/pnas.1713215114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1713215114</ArticleId><ArticleId IdType="pmc">PMC5724274</ArticleId><ArticleId IdType="pubmed">29158413</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied A&#x3b2;-containing inoculates induce cerebral &#x3b2;-amyloidosis. Science. 2010;330:980&#x2013;982. doi: 10.1126/science.1194516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194516</ArticleId><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel NH, et al. Replacement of brain-resident myeloid cells does not alter cerebral amyloid-&#x3b2; deposition in mouse models of Alzheimer&#x2019;s disease. J. Exp. Med. 2015;212:1803&#x2013;1809. doi: 10.1084/jem.20150478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150478</ArticleId><ArticleId IdType="pmc">PMC4612086</ArticleId><ArticleId IdType="pubmed">26458770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai H, et al. Enhanced antigen retrieval of amyloid &#x3b2; immunohistochemistry: re-evaluation of amyloid &#x3b2; pathology in Alzheimer disease and its mouse model. J. Histochem. Cytochem. 2012;60:761&#x2013;769. doi: 10.1369/0022155412456379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155412456379</ArticleId><ArticleId IdType="pmc">PMC3524564</ArticleId><ArticleId IdType="pubmed">22821668</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies HA, et al. Oxidative stress alters the morphology and toxicity of aortic medial amyloid. Biophys. J. 2015;109:2363&#x2013;2370. doi: 10.1016/j.bpj.2015.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2015.10.034</ArticleId><ArticleId IdType="pmc">PMC4675884</ArticleId><ArticleId IdType="pubmed">26636947</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantoulea K, et al. Heterotypic amyloid &#x3b2; interactions facilitate amyloid assembly and modify amyloid structure. EMBO J. 2022;41:e108591. doi: 10.15252/embj.2021108591.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021108591</ArticleId><ArticleId IdType="pmc">PMC8762568</ArticleId><ArticleId IdType="pubmed">34842295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers F, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011;7:539. doi: 10.1038/msb.2011.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2011.75</ArticleId><ArticleId IdType="pmc">PMC3261699</ArticleId><ArticleId IdType="pubmed">21988835</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25:1189&#x2013;1191. doi: 10.1093/bioinformatics/btp033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp033</ArticleId><ArticleId IdType="pmc">PMC2672624</ArticleId><ArticleId IdType="pubmed">19151095</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymkowitz J, et al. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382&#x2013;W388. doi: 10.1093/nar/gki387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki387</ArticleId><ArticleId IdType="pmc">PMC1160148</ArticleId><ArticleId IdType="pubmed">15980494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sall J. Leverage plots for general linear hypotheses. Am. Stat. 1990;44:308&#x2013;315.</Citation></Reference><Reference><Citation>Habib N, et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 2020;23:701&#x2013;706. doi: 10.1038/s41593-020-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0624-8</ArticleId><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, Bansal V, Feschotte C. A single-cell RNA expression map of human coronavirus entry factors. Cell Rep. 2020;32:108175. doi: 10.1016/j.celrep.2020.108175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108175</ArticleId><ArticleId IdType="pmc">PMC7470764</ArticleId><ArticleId IdType="pubmed">32946807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, et al. A human brain vascular atlas reveals diverse mediators of Alzheimer&#x2019;s risk. Nature. 2022;603:885&#x2013;892. doi: 10.1038/s41586-021-04369-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04369-3</ArticleId><ArticleId IdType="pmc">PMC9635042</ArticleId><ArticleId IdType="pubmed">35165441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ximerakis M, et al. Single-cell transcriptomic profiling of the aging mouse brain. Nat. Neurosci. 2019;22:1696&#x2013;1708. doi: 10.1038/s41593-019-0491-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0491-3</ArticleId><ArticleId IdType="pubmed">31551601</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, et al. Single-cell RNA sequencing of mouse brain and lung vascular and vessel-associated cell types. Sci. Data. 2018;5:180160. doi: 10.1038/sdata.2018.160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.160</ArticleId><ArticleId IdType="pmc">PMC6103262</ArticleId><ArticleId IdType="pubmed">30129931</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554:475&#x2013;480. doi: 10.1038/nature25739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25739</ArticleId><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36411364</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1786</StartPage><EndPage>1794</EndPage><MedlinePgn>1786-1794</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-022-01208-7</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD), the leading cause of dementia, has an estimated heritability of approximately 70%<sup>1</sup>. The genetic component of AD has been mainly assessed using genome-wide association studies, which do not capture the risk contributed by rare variants<sup>2</sup>. Here, we compared the gene-based burden of rare damaging variants in exome sequencing data from 32,558 individuals-16,036 AD cases and 16,522 controls. Next to variants in TREM2, SORL1 and ABCA7, we observed a significant association of rare, predicted damaging variants in ATP8B4 and ABCA1 with AD risk, and a suggestive signal in ADAM10. Additionally, the rare-variant burden in RIN3, CLU, ZCWPW1 and ACE highlighted these genes as potential drivers of respective AD-genome-wide association study loci. Variants associated with the strongest effect on AD risk, in particular loss-of-function variants, are enriched in early-onset AD cases. Our results provide additional evidence for a major role for amyloid-&#x3b2; precursor protein processing, amyloid-&#x3b2; aggregation, lipid metabolism and microglial function in AD.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7688-3087</Identifier><AffiliationInfo><Affiliation>Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. h.holstege@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. h.holstege@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands. h.holstege@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands. h.holstege@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hulsman</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9889-3606</Identifier><AffiliationInfo><Affiliation>Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. m.hulsman1@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. m.hulsman1@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands. m.hulsman1@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands. m.hulsman1@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Charbonnier</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quenez</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-8273-8505</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grozeva</LastName><ForeName>Detelina</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3239-8415</Identifier><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rooij</LastName><ForeName>Jeroen G J</ForeName><Initials>JGJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3885-1199</Identifier><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8658-3790</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden Academic Centre for Drug Research, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Najaf</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8944-1771</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Population Health Oxford University, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norsworthy</LastName><ForeName>Penny J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-5572-8491</Identifier><AffiliationInfo><Affiliation>Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols-Icardo</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2656-8748</Identifier><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Networking Center on Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hummerich</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawalia</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9088-234X</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5254-7655</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Montpellier, INSERM, Institute for Neurosciences of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-3409-1110</Identifier><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Commissariat &#xe0; l'&#xc9;nergie Atomique et aux &#xc9;nergies Alternatives, Centre National de Recherche en G&#xe9;nomique Humaine Evry, Gif-sur-Yvette, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boss&#xf9;</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1432-0078</Identifier><AffiliationInfo><Affiliation>Experimental Neuro-psychobiology Laboratory, Department of Clinical and Behavioral Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouwman</LastName><ForeName>Femke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cochran</LastName><ForeName>J Nicholas</ForeName><Initials>JN</Initials><Identifier Source="ORCID">0000-0002-9852-5504</Identifier><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniele</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debette</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8675-7968</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Commissariat &#xe0; l'&#xc9;nergie Atomique et aux &#xc9;nergies Alternatives, Centre National de Recherche en G&#xe9;nomique Humaine Evry, Gif-sur-Yvette, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denning</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>UKDRI Cardiff, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-5533-4225</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Maria Victoria</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0002-9669-5147</Identifier><AffiliationInfo><Affiliation>Neurogenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry Department, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><Identifier Source="ORCID">0000-0002-6660-657X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9284-5953</Identifier><AffiliationInfo><Affiliation>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda, Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genin</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4117-2813</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Brest, INSERM, Etablissement Fran&#xe7;ais du Sang, Centre Hospitalier Universitaire Brest, Unit&#xe9; Mixte de Recherche 1078, GGB, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gille</LastName><ForeName>Johan J P</ForeName><Initials>JJP</Initials><AffiliationInfo><Affiliation>Genome Diagnostics, Department of Human Genetics, VU University, AmsterdamUMC (location VUmc), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Guen</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6649-8364</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-4351-4728</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Science, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Kamran</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Iris E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraaij</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0416-999X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lathrop</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemstra</LastName><ForeName>Afina W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Networking Center on Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luckcuck</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mannens</LastName><ForeName>Marcel M A M</ForeName><Initials>MMAM</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Reproduction and Development Research Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masullo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meggy</LastName><ForeName>Alun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UKDRI Cardiff, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mol</LastName><ForeName>Merel O</ForeName><Initials>MO</Initials><Identifier Source="ORCID">0000-0003-2533-2530</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8217-2396</Identifier><AffiliationInfo><Affiliation>Human Genetics, School of Life Sciences, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9338-9040</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-9621-2942</Identifier><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napolioni</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4378-6838</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomic and Molecular Epidemiology Laboratory, School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9880-9788</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Lille, INSERM, Centre Hospitalier Universitaire Lille, UMR1172, Resources and Research Memory Center (MRRC) of Distalz, Licend, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7493-8777</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Doc&#xe8;ncia i Recerca M&#xfa;tuaTerrassa and Movement Disorders Unit, Department of Neurology, University Hospital M&#xfa;tuaTerrassa, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-7283-8804</Identifier><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raybould</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4673-2381</Identifier><AffiliationInfo><Affiliation>UKDRI Cardiff, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redon</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7751-2280</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Nantes, Centre Hospitalier Universitaire Nantes, Centre National de la Recherche Scientifique, INSERM, l'institut du Thorax, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinders</LastName><ForeName>Marcel J T</ForeName><Initials>MJT</Initials><Identifier Source="ORCID">0000-0002-1148-1562</Identifier><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Anne-Claire</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel-Heller</LastName><ForeName>Steffi G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0003-4321-6090</Identifier><AffiliationInfo><Affiliation>Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivadeneira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9435-9441</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Salha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Juan</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6081-8037</Identifier><AffiliationInfo><Affiliation>Biomedical Research Networking Center on Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, Marqu&#xe9;s de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2059-024X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory for Advanced Hematological Diagnostics, Department of Hematology and Stem Cell Transplant, Lecce, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6135-2622</Identifier><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sie</LastName><ForeName>Daoud</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genome Diagnostics, Department of Human Genetics, VU University, AmsterdamUMC (location VUmc), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sistermans</LastName><ForeName>Erik A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Genome Diagnostics, Department of Human Genetics, VU University, AmsterdamUMC (location VUmc), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Spaendonk</LastName><ForeName>Resie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6077-8725</Identifier><AffiliationInfo><Affiliation>Genome Diagnostics, Department of Human Genetics, VU University, AmsterdamUMC (location VUmc), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7432-4249</Identifier><AffiliationInfo><Affiliation>Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesi</LastName><ForeName>Niccolo'</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1413-5091</Identifier><AffiliationInfo><Affiliation>Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijms</LastName><ForeName>Betty</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andr&#xe9; G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0002-7276-3387</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-1606-8643</Identifier><AffiliationInfo><Affiliation>Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Medical Faculty, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Neurology and CNRMAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarea</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Neurology and CNRMAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Networking Center on Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-7274-2634</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurogenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry Department, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4991-763X</Identifier><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Medical Faculty, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4326-1468</Identifier><AffiliationInfo><Affiliation>Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><Identifier Source="ORCID">0000-0001-8766-6224</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-2374-9204</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Population Health Oxford University, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4069-0259</Identifier><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nicolas</LastName><ForeName>Ga&#xeb;l</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9391-7800</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France. gaelnicolas@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bellenguez</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1240-7874</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0829-7817</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France. jean-charles.lambert@pasteur-lille.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062588</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057234</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R00 AG068271</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577836">ABCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C000607204">ATP8B4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Jan;19(1):3. doi: 10.1038/s41582-022-00759-x.</RefSource><PMID Version="1">36477429</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000251" MajorTopicYN="Y">Adenosine Triphosphatases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="Y">ATP Binding Cassette Transporter 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>21</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36411364</ArticleId><ArticleId IdType="pmc">PMC9729101</ArticleId><ArticleId IdType="doi">10.1038/s41588-022-01208-7</ArticleId><ArticleId IdType="pii">10.1038/s41588-022-01208-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry. 2006;63:168&#x2013;174. doi: 10.1001/archpsyc.63.2.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.2.168</ArticleId><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C, et al. New insights on the genetic etiology of Alzheimer&#x2019;s and related dementias. Nat. Genet. 2022;54:412&#x2013;436. doi: 10.1038/s41588-022-01024-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01024-z</ArticleId><ArticleId IdType="pmc">PMC9005347</ArticleId><ArticleId IdType="pubmed">35379992</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer&#x2019;s disease: a clinical interpretation strategy. Eur. J. Hum. Genet. 2017;25:973&#x2013;981. doi: 10.1038/ejhg.2017.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2017.87</ArticleId><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer&#x2019;s disease. Mol. Psychiatry. 2016;21:831&#x2013;836. doi: 10.1038/mp.2015.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.121</ArticleId><ArticleId IdType="pubmed">26303663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, et al. Mutations in ABCA7 in a Belgian cohort of Alzheimer&#x2019;s disease patients: a targeted resequencing study. Lancet Neurol. 2015;14:814&#x2013;822. doi: 10.1016/S1474-4422(15)00133-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00133-7</ArticleId><ArticleId IdType="pubmed">26141617</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C, et al. Contribution to Alzheimer&#x2019;s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol. Aging. 2017;59:220 e1-&#x2013;220.e9. doi: 10.1016/j.neurobiolaging.2017.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.07.001</ArticleId><ArticleId IdType="pubmed">28789839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, et al. Identification of rare variants in ATP8B4 as a risk factor for systemic sclerosis by whole-exome sequencing. Arthritis Rheumatol. 2016;68:191&#x2013;200. doi: 10.1002/art.39449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39449</ArticleId><ArticleId IdType="pmc">PMC4690763</ArticleId><ArticleId IdType="pubmed">26473621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008;118:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 Mice. J. Biol. Chem. 2005;280:43224&#x2013;43235. doi: 10.1074/jbc.M504513200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M504513200</ArticleId><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard LT, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Loss-of-function mutation in ABCA1 and risk of Alzheimer&#x2019;s disease and cerebrovascular disease. Alzheimers Dement. 2015;11:1430&#x2013;1438. doi: 10.1016/j.jalz.2015.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.04.006</ArticleId><ArticleId IdType="pubmed">26079414</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P, Lichtenthaler SF. The alpha secretase ADAM10: a metalloprotease with multiple functions in the brain. Prog. Neurobiol. 2015;135:1&#x2013;20. doi: 10.1016/j.pneurobio.2015.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.10.003</ArticleId><ArticleId IdType="pubmed">26522965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M, et al. Potential late-onset Alzheimer&#x2019;s disease-associated mutations in the ADAM10 gene attenuate &#x3b1;-secretase activity. Hum. Mol. Genet. 2009;18:3987&#x2013;3996. doi: 10.1093/hmg/ddp323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp323</ArticleId><ArticleId IdType="pmc">PMC2748890</ArticleId><ArticleId IdType="pubmed">19608551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ag&#xfc;ero P, et al. &#x3b1;-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2020;12:139. doi: 10.1186/s13195-020-00708-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00708-0</ArticleId><ArticleId IdType="pmc">PMC7603780</ArticleId><ArticleId IdType="pubmed">33129344</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen R, et al. Upregulation of RIN3 induces endosomal dysfunction in Alzheimer&#x2019;s disease. Transl. Neurodegener. 2020;9:26. doi: 10.1186/s40035-020-00206-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00206-1</ArticleId><ArticleId IdType="pmc">PMC7301499</ArticleId><ArticleId IdType="pubmed">32552912</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen R, Wu C. RIN3 binds to BIN1 and CD2AP to increase APP&#x2010;CTFS in early endosomes. Alzheimers Dement. 2020;16:e047161. doi: 10.1002/alz.047161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.047161</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer&#x2019;s disease: mechanisms, genetics, and lessons from other pathologies. Front. Neurosci. 2019;13:164. doi: 10.3389/fnins.2019.00164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00164</ArticleId><ArticleId IdType="pmc">PMC6403191</ArticleId><ArticleId IdType="pubmed">30872998</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid &#x3b2;-peptide (A&#x3b2;); retards A&#x3b2; aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem. 2001;276:47863&#x2013;47868. doi: 10.1074/jbc.M104068200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104068200</ArticleId><ArticleId IdType="pubmed">11604391</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman JD, et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature. 2021;599:628&#x2013;634. doi: 10.1038/s41586-021-04103-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04103-z</ArticleId><ArticleId IdType="pmc">PMC8596853</ArticleId><ArticleId IdType="pubmed">34662886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis JC, et al. Whole exome sequencing study identifies novel rare and common Alzheimer&#x2019;s-associated variants involved in immune response and transcriptional regulation. Mol. Psychiatry. 2020;25:1859&#x2013;1875. doi: 10.1038/s41380-018-0112-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0112-7</ArticleId><ArticleId IdType="pmc">PMC6375806</ArticleId><ArticleId IdType="pubmed">30108311</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269. doi: 10.1016/j.jalz.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944. doi: 10.1212/WNL.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankish A, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766&#x2013;D773. doi: 10.1093/nar/gky955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky955</ArticleId><ArticleId IdType="pmc">PMC6323946</ArticleId><ArticleId IdType="pubmed">30357393</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122. doi: 10.1186/s13059-016-0974-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-0974-4</ArticleId><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis NM, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am. J. Hum. Genet. 2016;99:877&#x2013;885. doi: 10.1016/j.ajhg.2016.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.08.016</ArticleId><ArticleId IdType="pmc">PMC5065685</ArticleId><ArticleId IdType="pubmed">27666373</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 2020;12:103. doi: 10.1186/s13073-020-00803-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-020-00803-9</ArticleId><ArticleId IdType="pmc">PMC7709417</ArticleId><ArticleId IdType="pubmed">33261662</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;443. doi: 10.1038/s41586-020-2308-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979;6:65&#x2013;70.</Citation></Reference><Reference><Citation>Schwartzentruber J, et al. Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer&#x2019;s disease risk genes. Nat. Genet. 2021;53:392&#x2013;402. doi: 10.1038/s41588-020-00776-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00776-w</ArticleId><ArticleId IdType="pmc">PMC7610386</ArticleId><ArticleId IdType="pubmed">33589840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole P, MacMahon B. Attributable risk percent in case-control studies. Br. J. Prev. Soc. Med. 1971;25:242&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC478665</ArticleId><ArticleId IdType="pubmed">5160433</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMorte, W.W. in Measures of Association (Boston University School of Public Health, 2018). https://sphweb.bumc.bu.edu/otlt/mph-modules/ep/ep713_association/EP713_Association8.html</Citation></Reference><Reference><Citation>Holstege, H. et al. Summary statistics for &#x201c;Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer&#x2019;s Disease&#x201d;. Zenodo (2022) 10.5281/zenodo.6818051</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729101</ArticleId><ArticleId IdType="pubmed">36411364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulsman, M. &amp; Holstege, H. Software (v.0.1.0) used in &#x201c;Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer&#x2019;s Disease&#x201d;. Zenodo (2022) 10.5281/zenodo.6827458</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729101</ArticleId><ArticleId IdType="pubmed">36411364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36424467</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.</ArticleTitle><Pagination><StartPage>2547</StartPage><EndPage>2554</EndPage><MedlinePgn>2547-2554</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-02075-9</ELocationID><Abstract><AbstractText>Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available for other tauopathies. Using immunoprecipitation and mass spectrometry, we show that 4 repeat (4R) isoform-specific tau species from microtubule-binding region (MTBR-tau<sub>275</sub> and MTBR-tau<sub>282</sub>) increase in the brains of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD)-MAPT and AD but decrease inversely in the cerebrospinal fluid (CSF) of CBD, FTLD-MAPT and AD compared to control and other FTLD-tau (for example, Pick's disease). CSF MTBR-tau measures are reproducible in repeated lumbar punctures and can be used to distinguish CBD from control (receiver operating characteristic area under the curve (AUC)&#x2009;=&#x2009;0.889) and other FTLD-tau, such as PSP (AUC&#x2009;=&#x2009;0.886). CSF MTBR-tau<sub>275</sub> and MTBR-tau<sub>282</sub> may represent the first affirmative biomarkers to aid in the diagnosis of primary tauopathies and facilitate clinical trial designs.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horie</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7736-2614</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3570-9143</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VandeVrede</LastName><ForeName>Lawren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8304-6711</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yingxin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2543-4553</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paterson</LastName><ForeName>Ross W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0001-9372-3635</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Brenton A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0001-5133-5538</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Albert A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-2042-8445</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6854-5547</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-3443-7716</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koppisetti</LastName><ForeName>Rama K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaikh</LastName><ForeName>Faris</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lago</LastName><ForeName>Argentina Lario</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuer</LastName><ForeName>Hilary W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>Nupur</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6680-6731</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabelle</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Research and Resources Center, Department of Neurology, University Hospital of Montpellier, Neurosciences Institute of Montpellier, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-1215-5064</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. batemanr@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, St. Louis, MO, USA. batemanr@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, St. Louis, MO, USA. batemanr@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7639-8727</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. satochihiro@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, St. Louis, MO, USA. satochihiro@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG069301</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG057437</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD001459</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG064029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG052648</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095773</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS110890</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG073514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073482</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS101118</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS110890</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG062796</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received salary from Eisai. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. R.J.B., N.R.B., K.H. and C.S. may receive income based on technology (Methods to detect MTBR tau isoforms and use thereof) licensed by Washington University to C2N Diagnostics. R.J.B. has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. RJB serves on the Roche Gantenerumab Steering Committee as an unpaid member. S.S. has received consultation fees from Techspert.io, Acsel Health and PRECISIONxtract. L.V. has served as a consultant for Retrotope. R.W.P. has received honoraria as an educational speaker for GE Healthcare. B.A.W. has participated or is currently participating in clinical research sponsored by Acadia, Biogen, Global Kinetics, Neurocrine, Prilenia, PTC, Roche, Sage, Vaccinex, Transposon and Triplet Therapeutics. G.S.D.&#x2019;s research is supported by the NIH (K23AG064029, U01AG057195, U19AG032438), the Alzheimer&#x2019;s Association and Chan Zuckerberg Initiative. He serves as a consultant for Parabon NanoLabs, as a topic editor (dementia) for DynaMed (EBSCO) and as the Clinical Director of the Anti-NMDA Receptor Encephalitis Foundation (Canada; uncompensated). He is the co-project principal investigator for a clinical trial in anti-<i>N</i>-methyl-D-aspartate receptor encephalitis, which receives support from Horizon Pharmaceuticals. He has developed educational materials for PeerView Media and Continuing Education. His institution has received support from Eli Lilly for the development and presentation of educational content at an academic conference. He owns stock in ANI Pharmaceuticals. A.A.D. received compensation for performing procedures related to a clinical trial sponsored by Roche and received honoraria as a speaker from the Glaucoma Research and BrightFocus Foundations. W.W.S. received consulting fees from Guidepoint Global, GLG Council and BridgeBio. N.G. has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by the following companies: Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth and Roche. B.L.M. receives royalties from Cambridge University Press, Johns Hopkins University Press, Taylor &amp; Francis Group, Guilford Publications, Oxford University Press and Elsevier, and honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, such as UCLA Grand Rounds, UCI MIND seminar series, Taipei Medical University, Dementia Center and Korean Dementia Society talks. A.L.B. has served as a consultant for Alector Therapeutics, Arkuda, Arvinas, AZTherapeutics, Boehringer Ingelheim, Denali, GSK, Humana, Oligomerix, Oscotec, Roche, Third Rock, Transposon Therapeutics, TrueBinding and Wave. Y.H., C.M.K., R.J.P., R.K.K., F.S., A.L.L., H.W.H. and A.G. declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36424467</ArticleId><ArticleId IdType="pmc">PMC9800273</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02075-9</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-02075-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ovod V, et al. Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841&#x2013;849. doi: 10.1016/j.jalz.2017.06.2266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554:249&#x2013;254. doi: 10.1038/nature25456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat. Med. 2020;26:387&#x2013;397. doi: 10.1038/s41591-020-0762-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat. Med. 2020;26:379&#x2013;386. doi: 10.1038/s41591-020-0755-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat. Commun. 2020;11:1683. doi: 10.1038/s41467-020-15436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther. 2020;12:26. doi: 10.1186/s13195-020-00596-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772&#x2013;781. doi: 10.1001/jama.2020.12134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Horle K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J. Exp. Med. 2020;217:e20200861. doi: 10.1084/jem.20200861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200861</ArticleId><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, et al. Donanemab in early Alzheimer&#x2019;s disease. N. Engl. J. Med. 2021;384:1691&#x2013;1704. doi: 10.1056/NEJMoa2100708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer&#x2019;s disease. Nat. Med. 2021;27:1187&#x2013;1196. doi: 10.1038/s41591-021-01369-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01369-8</ArticleId><ArticleId IdType="pmc">PMC8988051</ArticleId><ArticleId IdType="pubmed">34155411</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer&#x2019;s disease with lecanemab, an anti-A&#x3b2; protofibril antibody. Alzheimers Res. Ther. 2021;13:80. doi: 10.1186/s13195-021-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00813-8</ArticleId><ArticleId IdType="pmc">PMC8053280</ArticleId><ArticleId IdType="pubmed">33865446</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Dor&#xe9; V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-&#x3b2; proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol. 2018;14:225&#x2013;236. doi: 10.1038/nrneurol.2018.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2018.9</ArticleId><ArticleId IdType="pubmed">29449700</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526. doi: 10.1016/0896-6273(89)90210-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(89)90210-9</ArticleId><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190. doi: 10.1038/nature23002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23002</ArticleId><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature. 2018;561:137&#x2013;140. doi: 10.1038/s41586-018-0454-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0454-y</ArticleId><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Novel tau filament fold in corticobasal degeneration. Nature. 2020;580:283&#x2013;287. doi: 10.1038/s41586-020-2043-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2043-0</ArticleId><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359&#x2013;363. doi: 10.1038/s41586-021-03911-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03911-7</ArticleId><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420&#x2013;423. doi: 10.1038/s41586-019-1026-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1026-5</ArticleId><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie K, Barth&#xe9;lemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer&#x2019;s disease. Brain. 2021;144:515&#x2013;527. doi: 10.1093/brain/awaa373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa373</ArticleId><ArticleId IdType="pmc">PMC7940175</ArticleId><ArticleId IdType="pubmed">33283854</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain. 2020;143:650&#x2013;660. doi: 10.1093/brain/awz346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz346</ArticleId><ArticleId IdType="pmc">PMC7009597</ArticleId><ArticleId IdType="pubmed">31834365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672&#x2013;1682. doi: 10.1016/S0140-6736(15)00461-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00461-4</ArticleId><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J, et al. Amyloid &#x3b2; peptide ratio 42/40 but not A&#x3b2;42 correlates with phospho-Tau in patients with low- and high-CSF A&#x3b2;40 load. J. Neurochem. 2007;101:1053&#x2013;1059. doi: 10.1111/j.1471-4159.2006.04404.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04404.x</ArticleId><ArticleId IdType="pubmed">17254013</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa T, et al. Utility of the global CDR&#xae; plus NACC FTLD rating and development of scoring rules: data from the ARTFL/LEFFTDS Consortium. Alzheimers Dement. 2020;16:106&#x2013;117. doi: 10.1002/alz.12033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12033</ArticleId><ArticleId IdType="pmc">PMC7202045</ArticleId><ArticleId IdType="pubmed">31914218</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97:1284&#x2013;1298.e7. doi: 10.1016/j.neuron.2018.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology. Ann. Clin. Transl. Neurol. 2021;8:1817&#x2013;1830. doi: 10.1002/acn3.51435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51435</ArticleId><ArticleId IdType="pmc">PMC8419397</ArticleId><ArticleId IdType="pubmed">34342183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H. Clinical approach to progressive supranuclear palsy. J. Mov. Disord. 2016;9:3&#x2013;13. doi: 10.14802/jmd.15060.</Citation><ArticleIdList><ArticleId IdType="doi">10.14802/jmd.15060</ArticleId><ArticleId IdType="pmc">PMC4734991</ArticleId><ArticleId IdType="pubmed">26828211</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, et al. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Ann. Neurol. 2017;82:247&#x2013;258. doi: 10.1002/ana.24996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24996</ArticleId><ArticleId IdType="pmc">PMC5776747</ArticleId><ArticleId IdType="pubmed">28719018</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, et al. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph. Lateral Scler. Frontotemporal Degener. 2015;16:86&#x2013;91. doi: 10.3109/21678421.2014.971812.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.971812</ArticleId><ArticleId IdType="pubmed">25352065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81:1945&#x2013;1952. doi: 10.1212/01.wnl.0000436625.63650.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000436625.63650.27</ArticleId><ArticleId IdType="pmc">PMC3843382</ArticleId><ArticleId IdType="pubmed">24174584</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagshal D, et al. Divergent CSF &#x3c4; alterations in two common tauopathies: Alzheimer&#x2019;s disease and progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry. 2015;86:244&#x2013;250. doi: 10.1136/jnnp-2014-308004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308004</ArticleId><ArticleId IdType="pmc">PMC4256124</ArticleId><ArticleId IdType="pubmed">24899730</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, et al. Biomarkers for tau pathology. Mol. Cell. Neurosci. 2019;97:18&#x2013;33. doi: 10.1016/j.mcn.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.12.001</ArticleId><ArticleId IdType="pmc">PMC6584358</ArticleId><ArticleId IdType="pubmed">30529601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140:99&#x2013;119. doi: 10.1007/s00401-020-02158-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02158-2</ArticleId><ArticleId IdType="pmc">PMC7360645</ArticleId><ArticleId IdType="pubmed">32383020</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo T, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J. Neuropathol. Exp. Neurol. 2002;61:547&#x2013;556. doi: 10.1093/jnen/61.6.547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/61.6.547</ArticleId><ArticleId IdType="pubmed">12071638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat. Rev. Neurol. 2011;7:263&#x2013;272. doi: 10.1038/nrneurol.2011.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.43</ArticleId><ArticleId IdType="pmc">PMC10006729</ArticleId><ArticleId IdType="pubmed">21487420</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Kamphorst W, Heutink P, van Swieten JC. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. Am. J. Pathol. 1998;153:1359&#x2013;1363. doi: 10.1016/S0002-9440(10)65721-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65721-5</ArticleId><ArticleId IdType="pmc">PMC1853390</ArticleId><ArticleId IdType="pubmed">9811325</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J. Neurol. 1999;246:II6&#x2013;II15. doi: 10.1007/BF03161076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03161076</ArticleId><ArticleId IdType="pubmed">10525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie K, et al. Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain. Acta Neuropathol. Commun. 2020;8:149. doi: 10.1186/s40478-020-01019-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01019-z</ArticleId><ArticleId IdType="pmc">PMC7450927</ArticleId><ArticleId IdType="pubmed">32854776</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995;57:289&#x2013;300.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36442130</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>49</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e2211999119</StartPage><MedlinePgn>e2211999119</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2211999119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2211999119</ELocationID><Abstract><AbstractText>Impairments in neural lysosomal- and autophagic-mediated degradation of cellular debris contribute to neuritic dystrophy and synaptic loss. While these are well-characterized features of neurodegenerative disorders such as Alzheimer's disease (AD), the upstream cellular processes driving deficits in pathogenic protein mishandling are less understood. Using a series of fluorescent biosensors and optical imaging in model cells, AD mouse models and human neurons derived from AD patients, we reveal a previously undescribed cellular signaling cascade underlying protein mishandling mediated by intracellular calcium dysregulation, an early component of AD pathogenesis. Increased Ca<sup>2+</sup> release via the endoplasmic reticulum (ER)-resident ryanodine receptor (RyR) is associated with reduced expression of the lysosome proton pump vacuolar-ATPase (vATPase) subunits (V1B2 and V0a1), resulting in lysosome deacidification and disrupted proteolytic activity in AD mouse models and human-induced neurons (HiN). As a result of impaired lysosome digestive capacity, mature autophagosomes with hyperphosphorylated tau accumulated in AD murine neurons and AD HiN, exacerbating proteinopathy. Normalizing AD-associated aberrant RyR-Ca<sup>2+</sup> signaling with the negative allosteric modulator, dantrolene (Ryanodex), restored vATPase levels, lysosomal acidification and proteolytic activity, and autophagic clearance of intracellular protein aggregates in AD neurons. These results highlight that prior to overt AD histopathology or cognitive deficits, aberrant upstream Ca<sup>2+</sup> signaling disrupts lysosomal acidification and contributes to pathological accumulation of intracellular protein aggregates. Importantly, this is demonstrated in animal models of AD, and in human iPSC-derived neurons from AD patients. Furthermore, pharmacological suppression of RyR-Ca<sup>2+</sup> release rescued proteolytic function, revealing a target for therapeutic intervention that has demonstrated effects in clinically-relevant assays.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mustaly-Kalimi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallegos</LastName><ForeName>Wacey</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8822-6877</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marr</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilman-Sachs</LastName><ForeName>Alice</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8358-3509</Identifier><AffiliationInfo><Affiliation>Center for Cancer Cell Biology, Immunology and Infection, Rosalind Franklin University of Medicine and Science, Immunology, and Infection, North Chicago, IL 60064.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-7275-6403</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sekler</LastName><ForeName>Israel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7550-1550</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Faculty of Health Science and Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stutzmann</LastName><ForeName>Grace E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">0000-0003-2841-8532</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG065628</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG065628</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002136">Calcium, Dietary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>F64QU97QCR</RegistryNumber><NameOfSubstance UI="D003620">Dantrolene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Feb;19(2):65. doi: 10.1038/s41582-022-00766-y.</RefSource><PMID Version="1">36624209</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="Y">Calcium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002136" MajorTopicYN="N">Calcium, Dietary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003620" MajorTopicYN="N">Dantrolene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">calcium</Keyword><Keyword MajorTopicYN="N">lysosome</Keyword><Keyword MajorTopicYN="N">ryanodine receptor</Keyword><Keyword MajorTopicYN="N">vATPase</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>28</Day><Hour>17</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36442130</ArticleId><ArticleId IdType="pmc">PMC9894236</ArticleId><ArticleId IdType="doi">10.1073/pnas.2211999119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nixon R. A., Autophagy in neurodegenerative disease: Friend, foe or turncoat?&#xa0;Trends Neurosci. 29, 528&#x2013;535 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16859759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein D. C., The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780&#x2013;786 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17051204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N., Autophagy: process and function. Genes Dev. 21, 2861&#x2013;2873 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18006683</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B., et al. , Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer&#x2019;s disease. J. Neurosci. 28, 6926&#x2013;6937 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="pubmed">18596167</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky D. J., et al. , Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 12, 1&#x2013;222 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835977</ArticleId><ArticleId IdType="pubmed">26799652</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P., Klumperman J., Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets function. Nat. Rev. Mol. Cell Biol. 10, 623&#x2013;635 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19672277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M., et al. , A gene network regulating lysosomal biogenesis and function. Science 325, 473&#x2013;477 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R. A., The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983&#x2013;997 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe D. M., et al. , Autophagy failure in Alzheimer&#x2019;s disease and the role of defective lysosomal acidification. Eur. J. Neurosci. 37, 1949&#x2013;1961 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694736</ArticleId><ArticleId IdType="pubmed">23773064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustaly S., Littlefield A., Stutzmann G. E., Calcium signaling deficits in glia and autophagic pathways contributing to neurodegenerative disease. Antioxid. Redox Signal.&#xa0;29, ars.2017.7266&#x2013;ars.2017.7266 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29634342</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A., et al. , Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 23, 33&#x2013;42 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9639028</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgac M., Vacuolar ATPases: Rotary proton pumps in physiology and pathophysiology. Nat. Rev. Mol. Cell Biol. 8, 917&#x2013;929 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17912264</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotter K., Stransky L., McGuire C., Forgac M., Recent insights into the structure, regulation, and function of the V-ATPases. Trends Biochem. Sci. 40, 611&#x2013;622 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589219</ArticleId><ArticleId IdType="pubmed">26410601</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel N., Dedieu J.-C., Philippe J.-M., Specific sorting of the a1 isoform of the V-H+ATPase a subunit to nerve terminals where it associates with both synaptic vesicles and the presynaptic plasma membrane. J. Cell Sci. 116, 4751&#x2013;4762 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14600261</ArticleId></ArticleIdList></Reference><Reference><Citation>Saw N. M. N., et al. , Vacuolar H(+)-ATPase subunits Voa1 and Voa2 cooperatively regulate secretory vesicle acidification, transmitter uptake, and storage. Mol. Biol. Cell 22, 3394&#x2013;3409 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172264</ArticleId><ArticleId IdType="pubmed">21795392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. H., et al. , Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146&#x2013;1158 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagh M. B., et al. , Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. Nat. Commun. 8, 14612&#x2013;14612 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344305</ArticleId><ArticleId IdType="pubmed">28266544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., et al. , Complete analysis of the presenilin 1 gene in early onset Alzheimer&#x2019;s disease. Neuroreport 7, 801&#x2013;805 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8733749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T. W., Pettingell W. H., Jung Y. K., Kovacs D. M., Tanzi R. E., Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 277, 373&#x2013;376 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9219695</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J., Kelleher R. J., The presenilin hypothesis of Alzheimer&#x2019;s disease: Evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U.S.A. 104, 403&#x2013;409 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W. H., et al. , Macroautophagy&#x2013;a novel Beta-amyloid peptide-generating pathway activated in Alzheimer&#x2019;s disease. J. Cell Biol. 171, 87&#x2013;98 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. H., et al. , Presenilin 1 Maintains Lysosomal Ca2+ Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep. 12, 1430&#x2013;1444 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4558203</ArticleId><ArticleId IdType="pubmed">26299959</ArticleId></ArticleIdList></Reference><Reference><Citation>Avrahami L., et al. , Inhibition of glycogen synthase kinase-3 ameliorates &#x3b2;-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the alzheimer disease mouse model: In vivo and in vitro studies. J. Biol. Chem. 288, 1295&#x2013;1306 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543013</ArticleId><ArticleId IdType="pubmed">23155049</ArticleId></ArticleIdList></Reference><Reference><Citation>McBrayer M., Nixon R. A., Lysosome and calcium dysregulation in Alzheimer&#x2019;s disease: Partners in crime. Biochem. Soc. Trans. 41, 1495&#x2013;1502 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960943</ArticleId><ArticleId IdType="pubmed">24256243</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey E. E., Beckel J. M., Laties A. M., Mitchell C. H., Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer&#x2019;s disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience 263, 111&#x2013;124 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028113</ArticleId><ArticleId IdType="pubmed">24418614</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian Z. S., Hypothesis on the regulation of cytosol calcium concentration and the aging brain. Neurobiol. Aging 8, 345&#x2013;346 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3627349</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla F. M., Calcium dyshomeostasis and intracellular signalling in Alzheimer&#x2019;s disease. Nat. Rev. Neurosci. 3, 862&#x2013;872 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-K., et al. , Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer&#x2019;s disease. Exp. Neurol. 195, 484&#x2013;496 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16085017</ArticleId></ArticleIdList></Reference><Reference><Citation>Clapham D. E., Calcium signaling. Cell 131, 1047&#x2013;1058 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18083096</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge M. J., Calcium signalling and Alzheimer&#x2019;s disease. Neurochem. Res. 36, 1149&#x2013;1156 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21184278</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann G. E., et al. , Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer&#x2019;s disease mice. J. Neurosci. 26, 5180&#x2013;5189 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S., Goussakov I., Miller M. B., Stutzmann G. E., Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J. Neurosci. 29, 9458&#x2013;9470 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666542</ArticleId><ArticleId IdType="pubmed">19641109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S., et al. , Reduced presynaptic vesicle stores mediate cellular and network plasticity defects in an early-stage mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener.&#xa0;14, 7&#xa0;(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343260</ArticleId><ArticleId IdType="pubmed">30670054</ArticleId></ArticleIdList></Reference><Reference><Citation>Oul&#xe8;s B., et al. , Leaky Ryanodine receptors increases Amyloid-beta load and induces memory impairments in Tg2576 mouse model of Alzheimer disease. Mol. Neurodegener. 8, P54&#x2013;P54 (2013).</Citation></Reference><Reference><Citation>Chakroborty S., et al. , Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer&#x2019;s disease. PLoS One 7, e52056&#x2013;e52056 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528716</ArticleId><ArticleId IdType="pubmed">23284867</ArticleId></ArticleIdList></Reference><Reference><Citation>Oul&#xe8;s B., et al. , Ryanodine receptor blockade reduces amyloid-&#x3b2; load and memory impairments in Tg2576 mouse model of Alzheimer disease. J. Neurosci. 32, 11820&#x2013;11834 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458216</ArticleId><ArticleId IdType="pubmed">22915123</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J., et al. , Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci. Lett. 516, 274&#x2013;279 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351794</ArticleId><ArticleId IdType="pubmed">22516463</ArticleId></ArticleIdList></Reference><Reference><Citation>Penny C. J., Kilpatrick B. S., Eden E. R., Patel S., Coupling acidic organelles with the ER through Ca2+microdomains at membrane contact sites. Cell Calcium 58, 387&#x2013;396 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25866010</ArticleId></ArticleIdList></Reference><Reference><Citation>Atakpa P., Thillaiappan N. B., Mataragka S., Prole D. L., Taylor C. W., IP3 receptors preferentially associate with ER-lysosome contact sites and selectively deliver Ca2+ to lysosomes. Cell Rep. 25, 3180&#x2013;3193.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6302550</ArticleId><ArticleId IdType="pubmed">30540949</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zkan N., et al. , ER &#x2013; lysosome contacts at a pre-axonal region regulate axonal lysosome availability. Nat. Commun. 12, 4493 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302662</ArticleId><ArticleId IdType="pubmed">34301956</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervliet T., Ryanodine receptors in autophagy: Implications for neurodegenerative diseases?. Front. Cell Neurosci. 12, 89&#x2013;89 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880912</ArticleId><ArticleId IdType="pubmed">29636667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hett K., et al. , Multimodal hippocampal subfield grading for Alzheimer&#x2019;s disease classification. Sci. Rep. 9, 13845 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6761169</ArticleId><ArticleId IdType="pubmed">31554909</ArticleId></ArticleIdList></Reference><Reference><Citation>Im E., et al. ,Lysosomal dysfunction in Down Syndrome and Alzheimer mouse models is caused by selective v-ATPase inhibition by Tyr682 phosphorylated APP &#x3b2;CTF. bioRxiv&#xa0;[Preprint] (2022). &#xa0;10.1101/2022.06.02.494546. Accessed 6 October 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.02.494546</ArticleId><ArticleId IdType="pmc">PMC10371027</ArticleId><ArticleId IdType="pubmed">37494443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., et al. , Dantrolene ameliorates impaired neurogenesis and synaptogenesis in induced pluripotent stem cell lines derived from patients with Alzheimer&#x2019;s disease. Anesthesiology 132, 1062&#x2013;1079 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160009</ArticleId><ArticleId IdType="pubmed">32149777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan S. L., Mayne M., Holden C. P., Geiger J. D., Mattson M. P., Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 275, 18195&#x2013;18200 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10764737</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann G. E., et al. , Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer&#x2019;s-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J. Neurosci. 24, 508&#x2013;513 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Goussakov I., Miller M. B., Stutzmann G. E., NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer&#x2019;s disease mice. J. Neurosci. 30, 12128&#x2013;12137 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944253</ArticleId><ArticleId IdType="pubmed">20826675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacampagne A., et al. , Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer&#x2019;s disease-like pathologies and cognitive deficits. Acta Neuropathol. 134, 749&#x2013;767 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28631094</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng W., et al. , Structural basis for the gating mechanism of the type 2 ryanodine receptor RyR2. Science 354, aah5324 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27708056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J., et al. , Limiting RyR2 open time prevents Alzheimer&#x2019;s disease-related neuronal hyperactivity and memory loss but not &#x3b2;-amyloid accumulation. Cell Rep. 32, 108169&#xa0;(2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532726</ArticleId><ArticleId IdType="pubmed">32966798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S. R. W., Li X., Ebisawa K., Zhang L., Functional characterization of the recombinant Type 3 Ca2+ release channel (Ryanodine Receptor) expressed in HEK293 cells. J. Biol. Chem. 272, 24234&#x2013;24246 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9305876</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Chen S. R. W., Molecular basis of Ca2+ activation of the mouse cardiac Ca2+ release channel (Ryanodine Receptor). J. Gen. Physiol. 118, 33&#x2013;44 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2233748</ArticleId><ArticleId IdType="pubmed">11429443</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrank S., et al. , Human-induced neurons from presenilin 1 mutant patients model aspects of Alzheimer&#x2019;s disease pathology. Int. J. Mol. Sci. 21, 1030 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7037274</ArticleId><ArticleId IdType="pubmed">32033164</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelqvist H., W&#xe4;ster P., K&#xe5;gedal K., &#xd6;llinger K., The lysosome: From waste bag to potential therapeutic target. J. Mol. Cell Biol. 5, 214&#x2013;226 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23918283</ArticleId></ArticleIdList></Reference><Reference><Citation>Padamsey Z., et al. , Activity-dependent exocytosis of lysosomes regulates the structural plasticity of dendritic spines. Neuron 93, 132&#x2013;146 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5222721</ArticleId><ArticleId IdType="pubmed">27989455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wu D., Robinson C. V., Wu H., Fu T.-M., Structures of a complete human V-ATPase reveal mechanisms of its assembly. Mol. Cell 80, 501&#x2013;511.e3 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7655608</ArticleId><ArticleId IdType="pubmed">33065002</ArticleId></ArticleIdList></Reference><Reference><Citation>Haukedal H., Freude K. K., Implications of glycosylation in Alzheimer&#x2019;s disease. Front. Neurosci. 14, 625348&#xa0;(2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838500</ArticleId><ArticleId IdType="pubmed">33519371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., et al. , Contacts between the endoplasmic reticulum and other membranes in neurons. Proc. Natl. Acad. Sci. U.S.A. 114, E4859&#x2013;E4867 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474793</ArticleId><ArticleId IdType="pubmed">28559323</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva B. S. C., et al. , Maintaining social contacts: The physiological relevance of organelle interactions. Biochim. Biophys. Acta Mol. Cell. Res.&#xa0;1867, 118800&#xa0;(2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377706</ArticleId><ArticleId IdType="pubmed">32712071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-H., et al. , &#x3b2;2&#xa0;-&#xa0;adrenergic agonists rescue lysosome acidification and function in PSEN1 deficiency by reversing defective ER-to-lysosome delivery of ClC-7. J. Mol. Biol. 432, 2633&#x2013;2650 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211125</ArticleId><ArticleId IdType="pubmed">32105735</ArticleId></ArticleIdList></Reference><Reference><Citation>Soyombo A. A., et al. , TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity. J. Biol. Chem. 281, 7294&#x2013;7301 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16361256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Hao B., Graeff R., Yue J., NAADP/TPC2/Ca2+ signaling inhibits autophagy. Commun. Integr. Biol. 6, e27595&#xa0;(2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984295</ArticleId><ArticleId IdType="pubmed">24753792</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Ren D., Lysosomal physiology. Annu. Rev. Physiol. 77, 57&#x2013;80 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4524569</ArticleId><ArticleId IdType="pubmed">25668017</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchionda M., Pittman J. K., Mayor R., Patel S., Ca2+/H+&#xa0;exchange by acidic organelles regulates cell migration in vivo. J. Cell Biol. 212, 803&#x2013;813 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810305</ArticleId><ArticleId IdType="pubmed">27002171</ArticleId></ArticleIdList></Reference><Reference><Citation>Overly C. C., Hollenbeck P. J., Dynamic organization of endocytic pathways in axons of cultured sympathetic neurons. J. Neurosci. 16, 6056&#x2013;6064 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579168</ArticleId><ArticleId IdType="pubmed">8815888</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S., Wallace K. E., Holzbaur E. L. F., Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J. Cell Biol. 196, 407&#x2013;417 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283992</ArticleId><ArticleId IdType="pubmed">22331844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X.-T., Zhou B., Lin M.-Y., Cai Q., Sheng Z.-H., Axonal autophagosomes recruit dynein for retrograde transport through fusion with late endosomes. J. Cell Biol. 209, 377&#x2013;386 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427784</ArticleId><ArticleId IdType="pubmed">25940348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie P. P. Y., et al. , Post-Golgi carriers, not lysosomes, confer lysosomal properties to pre-degradative organelles in normal and dystrophic axons. Cell Rep. 35, 109034&#xa0;(2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135226</ArticleId><ArticleId IdType="pubmed">33910020</ArticleId></ArticleIdList></Reference><Reference><Citation>Siintola E., et al. , Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 129, 1438&#x2013;1445 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16670177</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi&#x161;lar A., Kos J., Cysteine cathepsins in neurological disorders. Mol. Neurobiol. 49, 1017&#x2013;1030 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24234234</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R. A., et al. , Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113&#x2013;122 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordi M., et al. , Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy 12, 2467&#x2013;2483 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173282</ArticleId><ArticleId IdType="pubmed">27813694</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervliet T., et al. , Basal ryanodine receptor activity suppresses autophagic flux. Biochem. Pharmacol. 132, 133&#x2013;142 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28322744</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-H., et al. , Faulty autolysosome acidification in Alzheimer&#x2019;s disease mouse models induces autophagic build-up of A&#x3b2; in neurons, yielding senile plaques. Nat. Neurosci. 25, 688&#x2013;701 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174056</ArticleId><ArticleId IdType="pubmed">35654956</ArticleId></ArticleIdList></Reference><Reference><Citation>Maesako M., Houser M. C. Q., Turchyna Y., Wolfe M. S., Berezovska O., Presenilin/&#x3b3;-secretase activity is located in acidic compartments of live neurons. J. Neurosci. 42, 145&#x2013;154 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8741161</ArticleId><ArticleId IdType="pubmed">34810230</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete D., Checler F., Chami M., Ryanodine receptors: Physiological function and deregulation in Alzheimer disease. Mol. Neurodegener. 9, 21 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063224</ArticleId><ArticleId IdType="pubmed">24902695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., et al. , Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol. 72, 15&#x2013;24 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344367</ArticleId><ArticleId IdType="pubmed">25365775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery. PLoS Med. 14, e1002256&#xa0;(2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349649</ArticleId><ArticleId IdType="pubmed">28291788</ArticleId></ArticleIdList></Reference><Reference><Citation>Canchi S., et al. , Integrating gene and protein expression reveals perturbed functional networks in Alzheimer&#x2019;s disease. Cell Rep. 28, 1103&#x2013;1116.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503200</ArticleId><ArticleId IdType="pubmed">31340147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., et al. , Transformative network modeling of multi-omics data reveals detailed circuits, key regulators, and potential therapeutics for Alzheimer&#x2019;s disease. Neuron 109, 257&#x2013;272.e14 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855384</ArticleId><ArticleId IdType="pubmed">33238137</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Acker Z. P., Bretou M., Annaert W., Endo-lysosomal dysregulations and late-onset Alzheimer&#x2019;s disease: Impact of genetic risk factors. Mol. Neurodegener. 14, 20 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547588</ArticleId><ArticleId IdType="pubmed">31159836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito E., et al. , Intracellular calcium signals are enhanced for days after Pavlovian conditioning. J. Neurochem. 62, 1337&#x2013;1344 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8133264</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann G. E., The pathogenesis of Alzheimers disease-Is it a lifelong &#x201c;calciumopathy&#x201d;?&#xa0;Neuroscientist 13, 546&#x2013;559 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17901262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I., Mattson M. P., Neuronal calcium mishandling and the pathogenesis of Alzheimer&#x2019;s disease. Trends Neurosci. 31, 454&#x2013;463 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gant J. C., Disrupting function of FK506-binding protein 1b/12.6 induces the Ca2+-dysregulation aging phenotype in hippocampal neurons. J. Neurosci.&#xa0;31, 1693&#x2013;1703&#xa0;(2011),&#xa0; 10.1523/JNEUROSCI.4805-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4805-10.2011</ArticleId><ArticleId IdType="pmc">PMC3092371</ArticleId><ArticleId IdType="pubmed">21289178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakizawa S., et al. , Nitric oxide-induced calcium release via ryanodine receptors regulates neuronal function. EMBO J. 31, 417&#x2013;428 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261553</ArticleId><ArticleId IdType="pubmed">22036948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidalgo C., Arias-Cavieres A., Calcium, reactive oxygen species, and synaptic plasticity. Physiology 31, 201&#x2013;215 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27053734</ArticleId></ArticleIdList></Reference><Reference><Citation>More J., et al. , Calcium release mediated by redox-sensitive RyR2 channels has a central role in hippocampal structural plasticity and spatial memory. Antioxid. Redox Signal. 29, ars.2017.7277&#x2013;ars.2017.7277 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29357673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidalgo C., Bull R., Behrens M. I., Donoso P., Redox regulation of RyR-mediated Ca2+ release in muscle and neurons. Biol. Res. 37, 539&#x2013;552 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15709680</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., et al. , Triple-transgenic model of Alzheimer&#x2019;s Disease with plaques and tangles: Intracellular A&#x3b2; and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Guha S., et al. , Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: Evidence for a role in retinal degenerations. Exp. Eye Res. 126, 68&#x2013;76 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4143779</ArticleId><ArticleId IdType="pubmed">25152362</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36449413</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>388</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Lecanemab in Early Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>21</EndPage><MedlinePgn>9-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2212948</ELocationID><Abstract><AbstractText Label="BACKGROUND">The accumulation of soluble and insoluble aggregated amyloid-beta (A&#x3b2;) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to A&#x3b2; soluble protofibrils, is being tested in persons with early Alzheimer's disease.</AbstractText><AbstractText Label="METHODS">We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing. Participants were randomly assigned in a 1:1 ratio to receive intravenous lecanemab (10 mg per kilogram of body weight every 2 weeks) or placebo. The primary end point was the change from baseline at 18 months in the score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB; range, 0 to 18, with higher scores indicating greater impairment). Key secondary end points were the change in amyloid burden on PET, the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90; higher scores indicate greater impairment), the Alzheimer's Disease Composite Score (ADCOMS; range, 0 to 1.97; higher scores indicate greater impairment), and the score on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL; range, 0 to 53; lower scores indicate greater impairment).</AbstractText><AbstractText Label="RESULTS">A total of 1795 participants were enrolled, with 898 assigned to receive lecanemab and 897 to receive placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, -0.45; 95% confidence interval [CI], -0.67 to -0.23; P&lt;0.001). In a substudy involving 698 participants, there were greater reductions in brain amyloid burden with lecanemab than with placebo (difference, -59.1 centiloids; 95% CI, -62.6 to -55.6). Other mean differences between the two groups in the change from baseline favoring lecanemab were as follows: for the ADAS-cog14 score, -1.44 (95% CI, -2.27 to -0.61; P&lt;0.001); for the ADCOMS, -0.050 (95% CI, -0.074 to -0.027; P&lt;0.001); and for the ADCS-MCI-ADL score, 2.0 (95% CI, 1.2 to 2.8; P&lt;0.001). Lecanemab resulted in infusion-related reactions in 26.4% of the participants and amyloid-related imaging abnormalities with edema or effusions in 12.6%.</AbstractText><AbstractText Label="CONCLUSIONS">Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer's disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Chad J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gee</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanekiyo</LastName><ForeName>Michio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyderman</LastName><ForeName>Larisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froelich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katayama</LastName><ForeName>Sadao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhadda</LastName><ForeName>Shobha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irizarry</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Lynn D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield, United Kingdom (M.G.); Toronto Memory Program, Toronto (S.C.); Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (L.F.); Katayama Medical Clinic, Okayama (S.K.), and the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, and the National Center of Neurology and Psychiatry, Tokyo (T.I.) - all in Japan; Barrow Neurological Institute, Phoenix, AZ (M.S.); Toulouse Gerontopole University Hospital, Universit&#xe9; Paul Sabatier, INSERM Unit&#xe9; 1295, Toulouse, France (B.V.); and Alzheimer's Research and Treatment Center, Wellington, FL (D.W.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03887455</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>12PYH0FTU9</RegistryNumber><NameOfSubstance UI="C000612089">lecanemab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Dec;612(7939):197-198. doi: 10.1038/d41586-022-04240-z.</RefSource><PMID Version="1">36456815</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148.</RefSource><PMID Version="1">36599061</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Jan 5;388(1):80-81. doi: 10.1056/NEJMe2214981.</RefSource><PMID Version="1">36599066</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Feb 2;388(5):480. doi: 10.1056/NEJMc2215907.</RefSource><PMID Version="1">36599073</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Mar;19(3):132-133. doi: 10.1038/s41582-022-00768-w.</RefSource><PMID Version="1">36609712</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2023 Jan;613(7943):227-228. doi: 10.1038/d41586-023-00030-3.</RefSource><PMID Version="1">36627422</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2023 Mar;615(7950):42-43. doi: 10.1038/d41586-023-00393-7.</RefSource><PMID Version="1">36781970</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Nucl Med Mol Imaging. 2023 May;50(6):1553-1555. doi: 10.1007/s00259-023-06177-5.</RefSource><PMID Version="1">36869178</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2023 Apr;165(8):26-27. doi: 10.1007/s15006-023-2589-5.</RefSource><PMID Version="1">37081342</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Apr 27;388(17):1630. doi: 10.1056/NEJMc2301380.</RefSource><PMID Version="1">37099351</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Apr 27;388(17):1630. doi: 10.1056/NEJMc2301380.</RefSource><PMID Version="1">37099352</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Apr 27;388(17):1630-1631. doi: 10.1056/NEJMc2301380.</RefSource><PMID Version="1">37099353</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Apr 27;388(17):1631. doi: 10.1056/NEJMc2301380.</RefSource><PMID Version="1">37099354</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Apr 27;388(17):1631-1632. doi: 10.1056/NEJMc2301380.</RefSource><PMID Version="1">37099355</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="Y">Nootropic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>13</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36449413</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2212948</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36450991</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>612</Volume><Issue>7939</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>PLD3 affects axonal spheroids and network defects in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>328</StartPage><EndPage>337</EndPage><MedlinePgn>328-337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-05491-6</ELocationID><Abstract><AbstractText>The precise mechanisms that lead to cognitive decline in Alzheimer's disease are unknown. Here we identify amyloid-plaque-associated axonal spheroids as prominent contributors to neural network dysfunction. Using intravital calcium and voltage imaging, we show that a mouse model of Alzheimer's disease demonstrates severe disruption in long-range axonal connectivity. This disruption is caused by action-potential conduction blockades due to enlarging spheroids acting as electric current sinks in a size-dependent manner. Spheroid growth was associated with an age-dependent accumulation of large endolysosomal vesicles and was mechanistically linked with Pld3-a potential Alzheimer's-disease-associated risk gene<sup>1</sup> that encodes a lysosomal protein<sup>2,3</sup> that is highly enriched in axonal spheroids. Neuronal overexpression of Pld3 led to endolysosomal vesicle accumulation and spheroid enlargement, which worsened axonal conduction blockades. By contrast, Pld3 deletion reduced endolysosomal vesicle and spheroid size, leading to improved electrical conduction and neural network function. Thus, targeted modulation of endolysosomal biogenesis in neurons could potentially reverse axonal spheroid-induced neural circuit abnormalities in Alzheimer's disease, independent of amyloid removal.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yuan</LastName><ForeName>Peng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4051-4447</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Institute for Translational Brain Research, MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Mengyang</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9544-8099</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tong</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morse</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-2902-8272</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDougal</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grutzendler</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5000-243X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT, USA. jaime.grutzendler@yale.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale University, New Haven, CT, USA. jaime.grutzendler@yale.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Institute, Yale University, New Haven, CT, USA. jaime.grutzendler@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 NS079193</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115544</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>22ZR1415000</GrantID><Agency>National Science Foundation</Agency><Country/></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058257</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR019895</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC009977</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS111961</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007056</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR029676-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="C542157">Pld3 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Dec;612(7939):218-220. doi: 10.1038/d41586-022-03800-7.</RefSource><PMID Version="1">36450951</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="Y">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="Y">Phospholipase D</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018874" MajorTopicYN="N">Spheroids, Cellular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>J.G. is a member of the scientific advisory board at Vigil Neuro. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36450991</ArticleId><ArticleId IdType="pmc">PMC9729106</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05491-6</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-05491-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cruchaga C, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature. 2014;505:550&#x2013;554. doi: 10.1038/nature12825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12825</ArticleId><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazzari P, et al. PLD3 gene and processing of APP. Nature. 2017;541:E1&#x2013;E2. doi: 10.1038/nature21030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21030</ArticleId><ArticleId IdType="pubmed">28128235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez AC, et al. Unconventional trafficking of mammalian phospholipase D3 to lysosomes. Cell Rep. 2018;22:1040&#x2013;1053. doi: 10.1016/j.celrep.2017.12.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.100</ArticleId><ArticleId IdType="pubmed">29386126</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer&#x2019;s disease progression. J. Neurosci. 2012;32:8890&#x2013;8899. doi: 10.1523/JNEUROSCI.5698-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5698-11.2012</ArticleId><ArticleId IdType="pmc">PMC3458508</ArticleId><ArticleId IdType="pubmed">22745490</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and &#x2018;wingmen&#x2019;. Nat. Neurosci. 2015;18:800&#x2013;806. doi: 10.1038/nn.4018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4018</ArticleId><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-&#x3b2;-induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nat. Neurosci. 2010;13:812&#x2013;818. doi: 10.1038/nn.2583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2583</ArticleId><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD. Cell death or synaptic loss in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2000;59:1118&#x2013;1119. doi: 10.1093/jnen/59.12.1118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/59.12.1118</ArticleId><ArticleId IdType="pubmed">11138931</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Schneider LS, Koo EH. Anti-A&#x3b2; therapeutics in Alzheimer&#x2019;s disease: the need for a paradigm shift. Neuron. 2011;69:203&#x2013;213. doi: 10.1016/j.neuron.2011.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.01.002</ArticleId><ArticleId IdType="pmc">PMC3058906</ArticleId><ArticleId IdType="pubmed">21262461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer O. Miliaere nekrosen mit drusigen wucherungen der neurofibrillen, eine regelmassige veraenderung der hirnrinde bei seniler demenz. Monatsschr. Psychiat. Neurol. 1907;22:12.</Citation></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 2004;7:1181&#x2013;1183. doi: 10.1038/nn1335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1335</ArticleId><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson TC, Vickers JC. The morphological phenotype of &#x3b2;-amyloid plaques and associated neuritic changes in Alzheimer&#x2019;s disease. Neuroscience. 2001;105:99&#x2013;107. doi: 10.1016/S0306-4522(01)00169-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(01)00169-5</ArticleId><ArticleId IdType="pubmed">11483304</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Schain A, Grutzendler J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci. Rep. 2011;1:19. doi: 10.1038/srep00019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00019</ArticleId><ArticleId IdType="pmc">PMC3216507</ArticleId><ArticleId IdType="pubmed">22355538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Varo R, et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer&#x2019;s mice hippocampus. Acta Neuropathol. 2012;123:53&#x2013;70. doi: 10.1007/s00401-011-0896-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0896-x</ArticleId><ArticleId IdType="pmc">PMC3249205</ArticleId><ArticleId IdType="pubmed">22020633</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazquez-Llorca L, et al. High plasticity of axonal pathology in Alzheimer&#x2019;s disease mouse models. Acta Neuropathol. Commun. 2017;5:14. doi: 10.1186/s40478-017-0415-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0415-y</ArticleId><ArticleId IdType="pmc">PMC5296955</ArticleId><ArticleId IdType="pubmed">28173876</ArticleId></ArticleIdList></Reference><Reference><Citation>Adalbert R, et al. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain. 2009;132:402&#x2013;416. doi: 10.1093/brain/awn312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn312</ArticleId><ArticleId IdType="pubmed">19059977</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science. 2005;307:1282&#x2013;1288. doi: 10.1126/science.1105681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1105681</ArticleId><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HY, et al. Amyloid &#x3b2; induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J. Neurosci. 2010;30:2636&#x2013;2649. doi: 10.1523/JNEUROSCI.4456-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4456-09.2010</ArticleId><ArticleId IdType="pmc">PMC2841957</ArticleId><ArticleId IdType="pubmed">20164348</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005;64:113&#x2013;122. doi: 10.1093/jnen/64.2.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/64.2.113</ArticleId><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli BV, et al. PLD3 gene variants and Alzheimer&#x2019;s disease. Nature. 2015;520:E7&#x2013;E8. doi: 10.1038/nature14040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14040</ArticleId><ArticleId IdType="pubmed">25832413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. PLD3 and sporadic Alzheimer&#x2019;s disease risk. Nature. 2015;520:E1. doi: 10.1038/nature14036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14036</ArticleId><ArticleId IdType="pubmed">25832408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohmann H, Rorig B. Long-range horizontal connections between supragranular pyramidal cells in the extrastriate visual cortex of the rat. J. Comp. Neurol. 1994;344:543&#x2013;558. doi: 10.1002/cne.903440405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.903440405</ArticleId><ArticleId IdType="pubmed">7929891</ArticleId></ArticleIdList></Reference><Reference><Citation>Villette V, et al. Ultrafast two-photon imaging of a high-gain voltage indicator in awake behaving mice. Cell. 2019;179:1590&#x2013;1608. doi: 10.1016/j.cell.2019.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.11.004</ArticleId><ArticleId IdType="pmc">PMC6941988</ArticleId><ArticleId IdType="pubmed">31835034</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer&#x2019;s disease. II. Progressive transformation and developmental sequence of dystrophic neurites. Acta Neuropathol. 1998;96:463&#x2013;471. doi: 10.1007/s004010050920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050920</ArticleId><ArticleId IdType="pubmed">9829809</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper RC, Katzmann DJ. Biogenesis and function of multivesicular bodies. Annu. Rev. Cell Dev. Biol. 2007;23:519&#x2013;547. doi: 10.1146/annurev.cellbio.23.090506.123319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.23.090506.123319</ArticleId><ArticleId IdType="pmc">PMC2911632</ArticleId><ArticleId IdType="pubmed">17506697</ArticleId></ArticleIdList></Reference><Reference><Citation>Tooze SA, Abada A, Elazar Z. Endocytosis and autophagy: exploitation or cooperation? Cold Spring Harb. Perspect. Biol. 2014;6:a018358. doi: 10.1101/cshperspect.a018358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a018358</ArticleId><ArticleId IdType="pmc">PMC3996471</ArticleId><ArticleId IdType="pubmed">24789822</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YB, Dammer EB, Ren RJ, Wang G. The endosomal&#x2013;lysosomal system: from acidification and cargo sorting to neurodegeneration. Transl. Neurodegener. 2015;4:18. doi: 10.1186/s40035-015-0041-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0041-1</ArticleId><ArticleId IdType="pmc">PMC4596472</ArticleId><ArticleId IdType="pubmed">26448863</ArticleId></ArticleIdList></Reference><Reference><Citation>Nackenoff AG, et al. PLD3 is a neuronal lysosomal phospholipase D associated with &#x3b2;-amyloid plaques and cognitive function in Alzheimer&#x2019;s disease. PLoS Genet. 2021;17:e1009406. doi: 10.1371/journal.pgen.1009406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1009406</ArticleId><ArticleId IdType="pmc">PMC8031396</ArticleId><ArticleId IdType="pubmed">33830999</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J, et al. PLD3 is accumulated on neuritic plaques in Alzheimer&#x2019;s disease brains. Alzheimers Res. Ther. 2014;6:70. doi: 10.1186/s13195-014-0070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0070-5</ArticleId><ArticleId IdType="pmc">PMC4255636</ArticleId><ArticleId IdType="pubmed">25478031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Wang C, Qi R, Fu H, Ma Q. scREAD: a single-cell RNA-seq database for Alzheimer&#x2019;s disease. iScience. 2020;23:101769. doi: 10.1016/j.isci.2020.101769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101769</ArticleId><ArticleId IdType="pmc">PMC7674513</ArticleId><ArticleId IdType="pubmed">33241205</ArticleId></ArticleIdList></Reference><Reference><Citation>Fader CM, Colombo MI. Autophagy and multivesicular bodies: two closely related partners. Cell Death Differ. 2009;16:70&#x2013;78. doi: 10.1038/cdd.2008.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2008.168</ArticleId><ArticleId IdType="pubmed">19008921</ArticleId></ArticleIdList></Reference><Reference><Citation>Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Biochim. Biophys. Acta. 2009;1793:605&#x2013;614. doi: 10.1016/j.bbamcr.2008.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2008.10.016</ArticleId><ArticleId IdType="pubmed">19046998</ArticleId></ArticleIdList></Reference><Reference><Citation>Willen K, et al. A&#x3b2; accumulation causes MVB enlargement and is modelled by dominant negative VPS4A. Mol. Neurodegener. 2017;12:61. doi: 10.1186/s13024-017-0203-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0203-y</ArticleId><ArticleId IdType="pmc">PMC5569475</ArticleId><ArticleId IdType="pubmed">28835279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, et al. Selectivity of neuromodulatory projections from the basal forebrain and locus ceruleus to primary sensory cortices. J. Neurosci. 2016;36:5314&#x2013;5327. doi: 10.1523/JNEUROSCI.4333-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4333-15.2016</ArticleId><ArticleId IdType="pmc">PMC6601800</ArticleId><ArticleId IdType="pubmed">27170128</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer&#x2019;s disease. Lancet. 1976;2:1403. doi: 10.1016/S0140-6736(76)91936-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(76)91936-X</ArticleId><ArticleId IdType="pubmed">63862</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science. 2008;321:1686&#x2013;1689. doi: 10.1126/science.1162844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1162844</ArticleId><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 2016;17:777&#x2013;792. doi: 10.1038/nrn.2016.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.141</ArticleId><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411. doi: 10.1212/01.wnl.0000171450.97464.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000171450.97464.49</ArticleId><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr MF, Jadhav SP, Frank LM. Hippocampal replay in the awake state: a potential substrate for memory consolidation and retrieval. Nat. Neurosci. 2011;14:147&#x2013;153. doi: 10.1038/nn.2732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2732</ArticleId><ArticleId IdType="pmc">PMC3215304</ArticleId><ArticleId IdType="pubmed">21270783</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar JR, Willen K, Gouras GK, Futter CE. ESCRTs regulate amyloid precursor protein sorting in multivesicular bodies and intracellular amyloid-&#x3b2; accumulation. J. Cell Sci. 2015;128:2520&#x2013;2528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510853</ArticleId><ArticleId IdType="pubmed">26002056</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, et al. Intraneuronal Alzheimer a&#x3b2;42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 2002;161:1869&#x2013;1879. doi: 10.1016/S0002-9440(10)64463-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64463-X</ArticleId><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Takahashi RH, Gouras GK. &#x3b2;-Amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci. 2006;26:4277&#x2013;4288. doi: 10.1523/JNEUROSCI.5078-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5078-05.2006</ArticleId><ArticleId IdType="pmc">PMC6673997</ArticleId><ArticleId IdType="pubmed">16624948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir KR, et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A&#x3b2; generation in Alzheimer&#x2019;s disease. Acta Neuropathol. 2016;132:235&#x2013;256. doi: 10.1007/s00401-016-1558-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1558-9</ArticleId><ArticleId IdType="pmc">PMC4947125</ArticleId><ArticleId IdType="pubmed">26993139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 2010;117:949&#x2013;960. doi: 10.1007/s00702-010-0433-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-010-0433-4</ArticleId><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, et al. Amyloid-&#x3b2; plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 2018;24:29&#x2013;38. doi: 10.1038/nm.4443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4443</ArticleId><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Grutzendler J. Microglia-mediated neuroprotection, TREM2, and Alzheimer&#x2019;s disease: evidence from optical imaging. Biol. Psychiatry. 2018;83:377&#x2013;387. doi: 10.1016/j.biopsych.2017.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.10.007</ArticleId><ArticleId IdType="pmc">PMC5767550</ArticleId><ArticleId IdType="pubmed">29169609</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724&#x2013;739. doi: 10.1016/j.neuron.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 2005;6:889&#x2013;898. doi: 10.1038/nrn1788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1788</ArticleId><ArticleId IdType="pubmed">16224497</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Conforti L. Axonopathy in Huntington&#x2019;s disease. Exp. Neurol. 2013;246:62&#x2013;71. doi: 10.1016/j.expneurol.2012.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.08.010</ArticleId><ArticleId IdType="pubmed">22921535</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyanagi K, et al. Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu-Hakola disease: lesion staging and dynamic changes of axons and microglial subsets. Brain Pathol. 2017;27:748&#x2013;769. doi: 10.1111/bpa.12443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12443</ArticleId><ArticleId IdType="pmc">PMC8029200</ArticleId><ArticleId IdType="pubmed">27608278</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Grutzendler J. Attenuation of &#x3b2;-amyloid deposition and neurotoxicity by chemogenetic modulation of neural activity. J. Neurosci. 2016;36:632&#x2013;641. doi: 10.1523/JNEUROSCI.2531-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2531-15.2016</ArticleId><ArticleId IdType="pmc">PMC4710779</ArticleId><ArticleId IdType="pubmed">26758850</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 2003;7:839&#x2013;850. doi: 10.1016/S1525-0016(03)00095-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1525-0016(03)00095-9</ArticleId><ArticleId IdType="pubmed">12788658</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun. 2015;6:6176. doi: 10.1038/ncomms7176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7176</ArticleId><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SW, et al. A mesoscale connectome of the mouse brain. Nature. 2014;508:207&#x2013;214. doi: 10.1038/nature13186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13186</ArticleId><ArticleId IdType="pmc">PMC5102064</ArticleId><ArticleId IdType="pubmed">24695228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TW, et al. Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature. 2013;499:295&#x2013;300. doi: 10.1038/nature12354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12354</ArticleId><ArticleId IdType="pmc">PMC3777791</ArticleId><ArticleId IdType="pubmed">23868258</ArticleId></ArticleIdList></Reference><Reference><Citation>Pnevmatikakis EA, Giovannucci A. NoRMCorre: an online algorithm for piecewise rigid motion correction of calcium imaging data. J. Neurosci. Methods. 2017;291:83&#x2013;94. doi: 10.1016/j.jneumeth.2017.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2017.07.031</ArticleId><ArticleId IdType="pubmed">28782629</ArticleId></ArticleIdList></Reference><Reference><Citation>Inan, H. et al. Fast and statistically robust cell extraction from large-scale neural calcium imaging datasets. Preprint at 10.1101/2021.03.24.436279 (2021).</Citation></Reference><Reference><Citation>Deneux T, et al. Accurate spike estimation from noisy calcium signals for ultrafast three-dimensional imaging of large neuronal populations in vivo. Nat. Commun. 2016;7:12190. doi: 10.1038/ncomms12190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12190</ArticleId><ArticleId IdType="pmc">PMC4960309</ArticleId><ArticleId IdType="pubmed">27432255</ArticleId></ArticleIdList></Reference><Reference><Citation>Timme NM, Lapish C. A tutorial for information theory in neuroscience. eNeuro. 2018;5:ENEURO.0052-18.2018. doi: 10.1523/ENEURO.0052-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0052-18.2018</ArticleId><ArticleId IdType="pmc">PMC6131830</ArticleId><ArticleId IdType="pubmed">30211307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucha PJ, Richardson T, Macon K, Porter MA, Onnela JP. Community structure in time-dependent, multiscale, and multiplex networks. Science. 2010;328:876&#x2013;878. doi: 10.1126/science.1184819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1184819</ArticleId><ArticleId IdType="pubmed">20466926</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry Ii MJ, Tka&#x10d;ik G, Dubuis J, Marre O, da Silveira RA. A simple method for estimating the entropy of neural activity. J. Stat. Mech Theory Exp. 2013;2013:P03015. doi: 10.1088/1742-5468/2013/03/P03015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1742-5468/2013/03/P03015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogan P, Gueritaud JP, Tyc-Dumont S. Comparison of antidromic and orthodromic action potentials of identified motor axons in the cat&#x2019;s brain stem. J. Physiol. 1983;335:205&#x2013;220. doi: 10.1113/jphysiol.1983.sp014529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.1983.sp014529</ArticleId><ArticleId IdType="pmc">PMC1197348</ArticleId><ArticleId IdType="pubmed">6875874</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, et al. Cortical change in Alzheimer&#x2019;s disease detected with a disease-specific population-based brain atlas. Cereb. Cortex. 2001;11:1&#x2013;16. doi: 10.1093/cercor/11.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/11.1.1</ArticleId><ArticleId IdType="pubmed">11113031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill RA, Medved J, Patel KD, Nishiyama A. Organotypic slice cultures to study oligodendrocyte dynamics and myelination. J. Vis. Exp. 2014;25:e51835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828019</ArticleId><ArticleId IdType="pubmed">25177825</ArticleId></ArticleIdList></Reference><Reference><Citation>Miesenbock G, De Angelis DA, Rothman JE. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature. 1998;394:192&#x2013;195. doi: 10.1038/28190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/28190</ArticleId><ArticleId IdType="pubmed">9671304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Tillberg PW, Boyden ES. Optical imaging. Expansion microscopy. Science. 2015;347:543&#x2013;548. doi: 10.1126/science.1260088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260088</ArticleId><ArticleId IdType="pmc">PMC4312537</ArticleId><ArticleId IdType="pubmed">25592419</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillberg PW, et al. Protein-retention expansion microscopy of cells and tissues labeled using standard fluorescent proteins and antibodies. Nat. Biotechnol. 2016;34:987&#x2013;992. doi: 10.1038/nbt.3625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3625</ArticleId><ArticleId IdType="pmc">PMC5068827</ArticleId><ArticleId IdType="pubmed">27376584</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse TM, Carnevale NT, Mutalik PG, Migliore M, Shepherd GM. Abnormal excitability of oblique dendrites implicated in early Alzheimer&#x2019;s: a computational study. Front. Neural Circuits. 2010;4:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901152</ArticleId><ArticleId IdType="pubmed">20725509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines ML, Carnevale NT. NEURON: a tool for neuroscientists. Neuroscientist. 2001;7:123&#x2013;135. doi: 10.1177/107385840100700207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/107385840100700207</ArticleId><ArticleId IdType="pubmed">11496923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivagnanam, S. et al. Introducing the neuroscience gateway. In Proc. IWSG 993 (2013).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36490316</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>50</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers.</ArticleTitle><Pagination><StartPage>e2213157119</StartPage><MedlinePgn>e2213157119</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2213157119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2213157119</ELocationID><Abstract><AbstractText>The formation of toxic Amyloid &#x3b2;-peptide (A&#x3b2;) oligomers is one of the earliest events in the molecular pathology of Alzheimer's Disease (AD). These oligomers lead to a variety of downstream effects, including impaired neuronal signaling, neuroinflammation, tau phosphorylation, and neurodegeneration, and it is estimated that these events begin 10 to 20 y before the presentation of symptoms. Toxic A&#x3b2; oligomers contain a nonstandard protein structure, termed &#x3b1;-sheet, and designed &#x3b1;-sheet peptides target this main-chain structure in toxic oligomers independent of sequence. Here we show that a designed &#x3b1;-sheet peptide inhibits the deleterious effects on neuronal signaling and also serves as a capture agent in our soluble oligomer binding assay (SOBA). Pre-incubated synthetic &#x3b1;-sheet-containing A&#x3b2; oligomers produce strong SOBA signals, while monomeric and &#x3b2;-sheet protofibrillar A&#x3b2; do not. &#x3b1;-sheet containing oligomers were also present in cerebrospinal fluid (CSF) from an AD patient versus a noncognitively impaired control. For the detection of toxic oligomers in plasma, we developed a plate coating to increase the density of the capture peptide. The proof of concept was achieved by testing 379 banked human plasma samples. SOBA detected A&#x3b2; oligomers in patients on the AD continuum, including controls who later progressed to mild cognitive impairment. In addition, SOBA discriminated AD from other forms of dementia, yielding sensitivity and specificity of 99% relative to clinical and neuropathological diagnoses. To explore the broader potential of SOBA, we adapted the assay for a-synuclein oligomers and confirmed their presence in CSF from patients with Parkinson's disease and Lewy body dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Molecular Engineering Program, University of Washington, Seattle, WA 98105.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, University of Washington, Seattle, WA 98105.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colasurdo</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3259-0098</Identifier><AffiliationInfo><Affiliation>Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Veteran Affairs Puget Sound Health Care System, Seattle, WA 98108.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Alec</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0001-8484</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, University of Washington, Seattle, 98105.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paschall</LastName><ForeName>Courtnie</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7614-9408</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, University of Washington, Seattle, WA 98105.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA 98195.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayadev</LastName><ForeName>Suman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA 98195.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0002-5291-1469</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6253-9891</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA 98195.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7780-2042</Identifier><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Center Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Veteran Affairs Puget Sound Health Care System, Seattle, WA 98108.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daggett</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Molecular Engineering Program, University of Washington, Seattle, WA 98105.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, University of Washington, Seattle, WA 98105.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067476</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 EB001650</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">SOBA</Keyword><Keyword MajorTopicYN="N">alpha-sheet</Keyword><Keyword MajorTopicYN="N">detection</Keyword><Keyword MajorTopicYN="N">toxic oligomer</Keyword></KeywordList><CoiStatement>The authors declare a competing interest. The authors have organizational affiliations to disclose. V.D. has a start up in this space, but the work reported here was performed at UW. V.D. and D.S. have stock in startup. V.D. and D.S. are inventors on a patent together and V.D. has other patents.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>13</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36490316</ArticleId><ArticleId IdType="pmc">PMC9897489</ArticleId><ArticleId IdType="doi">10.1073/pnas.2213157119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association, Alzheimer&#x2019;s disease facts and figures.https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf, https://www.alz.org/alzheimers-dementia/facts-figures (2022). Accessed 26 November 2022.</Citation></Reference><Reference><Citation>Selkoe D. J., Hardy J., The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cline E. N., Bicca M. A., Viola K. L., Klein W. L., The amyloid-beta oligomer hypothesis: Beginning of the third decade. J. Alz. Dis. 64, S567&#x2013;S610 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004937</ArticleId><ArticleId IdType="pubmed">29843241</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Selkoe D. J., A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Abeta oligomers from Alzheimer&#x2019;s brain. J. Neurochem. 154, 583&#x2013;597 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487043</ArticleId><ArticleId IdType="pubmed">32180217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic J. L., Pensalfini A., Head E., Glabe C. G., Soluble fibrillar oligomer levels are elevated in Alzheimer&#x2019;s disease brain and correlate with cognitive dysfunction. Neurobio. Dis. 35, 352&#x2013;358 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725199</ArticleId><ArticleId IdType="pubmed">19523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia A. Y., et al. , Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc. Natl. Acad. Sci. U.S.A. 96, 3228&#x2013;3233 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T., Shimada H., APP Osaka mutation in familial Alzheimer&#x2019;s Disease&#x2014;Its discovery, phenotypes, and mechanism of recessive inheritance. Int. J. Mol. Sci. 21, 1413 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073033</ArticleId><ArticleId IdType="pubmed">32093100</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo, et al. , Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFelice F. G., et al. , Alzheimer&#x2019;s disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobio. Aging 29, 1334&#x2013;1347 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Amar F., et al. , Amyloid-beta oligomer A&#x3b2;*56 induces specific alterations of tau phosphorylation and neuronal signaling. Sci. Signal. 10, eaal2021 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5859319</ArticleId><ArticleId IdType="pubmed">28487416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H., Thies E., Mandelkow E., Mandelkow E.-M., Abeta oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines J. Neurosci. 30, 11938&#x2013;11950 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T., et al. , Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer&#x2019;s model. Science 341, 1399&#x2013;1404 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea D., et al. , &#x3b1;-Sheet secondary structure in amyloid &#x3b2;-peptide drives aggregation and toxicity in Alzheimer&#x2019;s disease. Proc. Natl., Acad. Sci. U.S.A. 116, 8895&#x2013;8900 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6500163</ArticleId><ArticleId IdType="pubmed">31004062</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr., et al., Tracking pathophysiological processes in Alzheimer&#x2019;s disease: An updated hypothetical model of dynamic biomarkers. Neurology 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts S. E., Ikonomovic M. D., Mercado N., Vega I. E., Mufson E. J., Biomarkers for the early detection and progression of Alzheimer&#x2019;s Disease. Neurother. 14, 35&#x2013;53 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233625</ArticleId><ArticleId IdType="pubmed">27738903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbagh M. N., Lue L.-F., Fayard D., Shi J., Increasing precision of clinical diagnosis of Alzheimer&#x2019;s disease using a combined algorithm incorporating clinical and novel biomarker data. Neurol. Therapy 6, S83&#x2013;S95 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520815</ArticleId><ArticleId IdType="pubmed">28733959</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., A review of fluid biomarkers for Alzheimer&#x2019;s disease: Moving from CSF to blood. Neurol. Ther. 6, S15&#x2013;S24 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520819</ArticleId><ArticleId IdType="pubmed">28733960</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B., et al. , Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: The IWG-2 criteria. Lancet Neurol 13, 614&#x2013;629 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P. D., et al. , Plasma and cerebrospinal fluid levels of amyloid beta proteins 1&#x2013;40 and 1&#x2013;42 in Alzheimer disease. Arch. Neurol. 57, 100&#x2013;105 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10634455</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabers A., Hafermann H., Wiltfang J., Gerwert K., Abeta and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer&#x2019;s disease. Alzheimer Dement. Diag. Assess. Dis. Mon. 11, 257&#x2013;263 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416642</ArticleId><ArticleId IdType="pubmed">30911600</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S., et al. , Plasma beta-amyloid in Alzheimer&#x2019;s disease and vascular disease. Sci. Rep. 6, 26801 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldeiras I., et al. , Addition of the Abeta42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer&#x2019;s disease dementia in mild cognitive impairment. Alz. Res. Ther. 10, 33 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5861634</ArticleId><ArticleId IdType="pubmed">29558986</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler S. E., et al. , High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurol. 93, e1645&#x2013;e1659 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O., Lehmann S., Otto M., Zetterberg H., Lewczuk P., Advantages and disadvantages of the use of the CSF amyloid beta 42/40 ratio in the diagnosis of Alzheimer&#x2019;s Disease. Alz. Res. &amp; Ther. 11, 34 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477717</ArticleId><ArticleId IdType="pubmed">31010420</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S., et al. , Discriminative accuracy of plasma phosphor-tau217 for Alzheimer disease vs other neurodegenerative disorders. J. Am. Med. Assoc. 324, 772&#x2013;781 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy N. R., Horie K., Sato C., Bateman R. J., Blood plasma phosphortylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J. Exp. Med. 217, e20200861 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H., et al. , Standardization of measurement of beta-amyloid (1&#x2013;42) in cerebrospinal fluid and plasma. Amyloid Int. J. Exp Clin. Invest. 7, 245&#x2013;258 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11132093</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B., et al. , CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Lancet Neurol. 15, 673&#x2013;684 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Herukka S. K., et al. , Recommendations for cerebrospinal fluid Alzheimer&#x2019;s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 13, 285&#x2013;295 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28341066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W., et al. , Diffusible, highly bioactive oligomers represent a critical minority of soluble A&#x3b2; in Alzheimer&#x2019;s disease brain. Acta. Neuropath. 136, 19&#x2013;40 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="pubmed">29687257</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody D. L., Jiang H., Wildburger N., Esparza T. J., Non-canonical soluble amyloid-beta aggregates and plaque buffering: Controversies and future directions for target discovery in Alzheimer&#x2019;s disease. Alz. Res. Ther. 9, 62 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5561579</ArticleId><ArticleId IdType="pubmed">28818091</ArticleId></ArticleIdList></Reference><Reference><Citation>Maris N., Shea D., Bleem A., Bryers J. D., Daggett V., Chemical and physical variability in structural isomers of an L/D &#x3b1;-sheet peptide designed to inhibit amyloidogenesis. Biochemistry 57, 507&#x2013;510 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801053</ArticleId><ArticleId IdType="pubmed">29202245</ArticleId></ArticleIdList></Reference><Reference><Citation>Armen R. S., DeMarco M. L., Alonso D. O. V., Daggett V., Pauling and Corey&#x2019;s alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. Proc. Natl. Acad. Sci. U.S.A. 101, 11622&#x2013;11627 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC511030</ArticleId><ArticleId IdType="pubmed">15280548</ArticleId></ArticleIdList></Reference><Reference><Citation>Daggett V., Alpha-Sheet: The toxic conformer in amyloid diseases? Acc. Chem. Res. 39, 594&#x2013;602 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16981675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopping G., et al. , Designed alpha-sheet peptides inhibit amyloid formation by targeting toxic oligomers. eLife 3, e01681 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091096</ArticleId><ArticleId IdType="pubmed">25027691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleem A., Francisco R., Bryers J. D., Daggett V., Designed alpha-sheet peptides suppress amyloid formation in Staphylococcus aureus biofilms. Nature Biofilms Microbiomes 3, 16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495782</ArticleId><ArticleId IdType="pubmed">28685098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellock J., Hopping G., Caughey B., Daggett V., Peptides composed of alternating L- and D-amino acids inhibit amyloidogenesis in three distinct amyloid systems independent of sequence. J. Mol. Biol. 428, 2317&#x2013;2328 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4884539</ArticleId><ArticleId IdType="pubmed">27012425</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranjapye N., Daggett V., De novo designed &#x3b1;-sheet peptides inhibit functional amyloid formation of Streptococcus mutans biofilms. J. Mol. Biol. 430, 3764&#x2013;3773 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168415</ArticleId><ArticleId IdType="pubmed">30006266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36516855</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>26</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment.</ArticleTitle><Pagination><StartPage>5028</StartPage><EndPage>5039.e13</EndPage><MedlinePgn>5028-5039.e13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2022.11.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(22)01463-5</ELocationID><Abstract><AbstractText>Cerebrospinal fluid (CSF) contains a tightly regulated immune system. However, knowledge is lacking about how CSF immunity is altered with aging or neurodegenerative disease. Here, we performed single-cell RNA sequencing on CSF from 45 cognitively normal subjects ranging from 54 to 82 years old. We uncovered an upregulation of lipid transport genes in monocytes with age. We then compared this cohort with 14 cognitively impaired subjects. In cognitively impaired subjects, downregulation of lipid transport genes in monocytes occurred concomitantly with altered cytokine signaling to CD8 T&#xa0;cells. Clonal CD8&#xa0;T effector memory cells upregulated C-X-C motif chemokine receptor 6 (CXCR6) in cognitively impaired subjects. The CXCR6 ligand, C-X-C motif chemokine ligand 16 (CXCL16), was elevated in the CSF of cognitively impaired subjects, suggesting CXCL16-CXCR6 signaling as a mechanism for antigen-specific T&#xa0;cell entry into the brain. Cumulatively, these results reveal cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piehl</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Olst</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakrishnan</LastName><ForeName>Abhirami</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teregulova</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonton</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapp</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Channappa</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Hamilton</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA; Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA; Graduate Program in Stem Cell and Regenerative Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losada</LastName><ForeName>Patricia M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutledge</LastName><ForeName>Jarod</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA; Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA; Department of Genetics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trelle</LastName><ForeName>Alexandra N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Psychology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA; Department of Psychology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elahi</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Victor W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Anthony D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA; Department of Psychology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA; Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA; The Phil and Penny Initiative for Brain Resilience, Stanford University, Stanford, CA, USA; Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Ken &amp; Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: dgate@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG048076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG075184</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG074339</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG078713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS112458</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS112458</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">adaptive immunity</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">cognitive impairment</Keyword></KeywordList><CoiStatement>Declaration of interests T.W.-C. and D.G. are co-inventors on a patent related to this work. Patent US-2022-0170908-A1 is for compositions and methods for measuring T&#xa0;cell markers associated with AD.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36516855</ArticleId><ArticleId IdType="mid">NIHMS1853123</ArticleId><ArticleId IdType="pmc">PMC9815831</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.11.019</ArticleId><ArticleId IdType="pii">S0092-8674(22)01463-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wyss-Coray T, and Mucke L. (2002). Inflammation in neurodegenerative disease--a double-edged sword. Neuron 35, 419&#x2013;432. 10.1016/s0896-6273(02)00794-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(02)00794-8</ArticleId><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, and Alitalo K. (2015). A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212, 991&#x2013;999. 10.1084/jem.20142290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142290</ArticleId><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, et al. (2015). Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341. 10.1038/nature14432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartholomaus I, Kawakami N, Odoardi F, Schlager C, Miljkovic D, Ellwart JW, Klinkert WE, Flugel-Koch C, Issekutz TB, Wekerle H, and Flugel A. (2009). Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462, 94&#x2013;98. 10.1038/nature08478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08478</ArticleId><ArticleId IdType="pubmed">19829296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivisakk P, Mahad DJ, Callahan MK, Trebst C, Tucky B, Wei T, Wu L, Baekkevold ES, Lassmann H, Staugaitis SM, et al. (2003). Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A 100, 8389&#x2013;8394. 10.1073/pnas.1433000100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1433000100</ArticleId><ArticleId IdType="pmc">PMC166239</ArticleId><ArticleId IdType="pubmed">12829791</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, and Sallusto F. (2009). C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10, 514&#x2013;523. 10.1038/ni.1716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1716</ArticleId><ArticleId IdType="pubmed">19305396</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlager C., Korner H., Krueger M., Vidoli S., Haberl M., Mielke D., Brylla E., Issekutz T., Cabanas C., Nelson PJ., et al.. (2016). Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 530, 349&#x2013;353. 10.1038/nature16939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16939</ArticleId><ArticleId IdType="pubmed">26863192</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Deczkowska A, David E, Castellano JM, Miller O, Kertser A, Berkutzki T, BarnettItzhaki Z, Bezalel D, Wyss-Coray T, et al. (2014). Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89&#x2013;93. 10.1126/science.1252945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1252945</ArticleId><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M. (2017). Can immunotherapy treat neurodegeneration? Science 357, 254&#x2013;255. 10.1126/science.aai8231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aai8231</ArticleId><ArticleId IdType="pubmed">28729500</ArticleId></ArticleIdList></Reference><Reference><Citation>Cugurra A, Mamuladze T, Rustenhoven J, Dykstra T, Beroshvili G, Greenberg ZJ, Baker W, Papadopoulos Z, Drieu A, Blackburn S, et al. (2021). Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science 373. 10.1126/science.abf7844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7844</ArticleId><ArticleId IdType="pmc">PMC8863069</ArticleId><ArticleId IdType="pubmed">34083447</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli JA, Smyth LCD, Cross KA, Dykstra T, Sun J, Du S, Mamuladze T, Smirnov I, Rustenhoven J, and Kipnis J. (2022). Cerebrospinal fluid regulates skull bone marrow niches via direct access through dural channels. Nat Neurosci 25, 555&#x2013;560. 10.1038/s41593-022-01029-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01029-1</ArticleId><ArticleId IdType="pmc">PMC9081158</ArticleId><ArticleId IdType="pubmed">35301477</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulous FE, Cruz-Hernandez JC, Yang C, Kaya Z, Paccalet A, Wojtkiewicz G, Capen D, Brown D, Wu JW, Schloss MJ, et al. (2022). Cerebrospinal fluid can exit into the skull bone marrow and instruct cranial hematopoiesis in mice with bacterial meningitis. Nat Neurosci 25, 567&#x2013;576. 10.1038/s41593-022-01060-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01060-2</ArticleId><ArticleId IdType="pmc">PMC9081225</ArticleId><ArticleId IdType="pubmed">35501382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehallier B, Channappa D, De Los Santos MB, et al. (2020). Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer&#x2019;s disease. Nature 577, 399&#x2013;404. 10.1038/s41586-019-1895-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1895-7</ArticleId><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D, Tapp E, Leventhal O, Shahid M, Nonninger TJ, Yang AC, Strempfl K, Unger MS, Fehlmann T, Oh H, et al. (2021). CD4(+) T cells contribute to neurodegeneration in Lewy body dementia. Science 374, 868&#x2013;874. 10.1126/science.abf7266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7266</ArticleId><ArticleId IdType="pmc">PMC9122025</ArticleId><ArticleId IdType="pubmed">34648304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowarik MC, Grummel V, Wemlinger S, Buck D, Weber MS, Berthele A, and Hemmer B. (2014). Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. J Neurol 261, 130&#x2013;143. 10.1007/s00415-013-7145-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-7145-2</ArticleId><ArticleId IdType="pubmed">24162037</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenningsson A., Hansson GK., Andersen O., Andersson R., Patarroyo M., and Stemme S. (1993). Adhesion molecule expression on cerebrospinal fluid T lymphocytes: evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. Ann Neurol 34, 155&#x2013;161. 10.1002/ana.410340210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410340210</ArticleId><ArticleId IdType="pubmed">8338339</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Leventhal O, Channappa D, Henderson VW, Wyss-Coray T, Lehallier B, and Gate D. (2021). Methods to investigate intrathecal adaptive immunity in neurodegeneration. Mol Neurodegener 16, 3. 10.1186/s13024-021-00423-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00423-w</ArticleId><ArticleId IdType="pmc">PMC7824942</ArticleId><ArticleId IdType="pubmed">33482851</ArticleId></ArticleIdList></Reference><Reference><Citation>Young MD, and Behjati S. (2020). SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9. 10.1093/gigascience/giaa151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giaa151</ArticleId><ArticleId IdType="pmc">PMC7763177</ArticleId><ArticleId IdType="pubmed">33367645</ArticleId></ArticleIdList></Reference><Reference><Citation>Baecher-Allan C, Wolf E, and Hafler DA (2006). MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 176, 4622&#x2013;4631. 10.4049/jimmunol.176.8.4622.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.8.4622</ArticleId><ArticleId IdType="pubmed">16585553</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva DP, Jacinto A, Borralho P, Braga S, and Cabral MG (2018). HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients&#x2019; Response to Neoadjuvant Chemotherapy. Front Immunol 9, 2605. 10.3389/fimmu.2018.02605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02605</ArticleId><ArticleId IdType="pmc">PMC6282034</ArticleId><ArticleId IdType="pubmed">30555458</ArticleId></ArticleIdList></Reference><Reference><Citation>Tippalagama R, Singhania A, Dubelko P, Lindestam Arlehamn CS, Crinklaw A, Pomaznoy M, Seumois G, deSilva AD, Premawansa S, Vidanagama D, et al. (2021). HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients. J Immunol 207, 523&#x2013;533. 10.4049/jimmunol.2100011.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100011</ArticleId><ArticleId IdType="pmc">PMC8516689</ArticleId><ArticleId IdType="pubmed">34193602</ArticleId></ArticleIdList></Reference><Reference><Citation>Viallard JF, Bloch-Michel C, Neau-Cransac M, Taupin JL, Garrigue S, Miossec V, Mercie P, Pellegrin JL, and Moreau JF (2001). HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 125, 485&#x2013;491. 10.1046/j.1365-2249.2001.01623.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.2001.01623.x</ArticleId><ArticleId IdType="pmc">PMC1906149</ArticleId><ArticleId IdType="pubmed">11531958</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters PJ, Borst J, Oorschot V, Fukuda M, Krahenbuhl O, Tschopp J, Slot JW, and Geuze HJ (1991). Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 173, 1099&#x2013;1109. 10.1084/jem.173.5.1099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.173.5.1099</ArticleId><ArticleId IdType="pmc">PMC2118839</ArticleId><ArticleId IdType="pubmed">2022921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, and Tanzi RE (2007). Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39, 17&#x2013;23. 10.1038/ng1934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1934</ArticleId><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC., Parfitt M., Legrain S., Perez-Tur J., Brousseau T., Evans A., Berr C., Vidal O., Roques P., Gourlet V., and et al.. (1994). Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer&#x2019;s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 3, 569&#x2013;574. 10.1093/hmg/3.4.569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/3.4.569</ArticleId><ArticleId IdType="pubmed">8069300</ArticleId></ArticleIdList></Reference><Reference><Citation>Drigalenko E, Poduslo S, and Elston R. (1998). Interaction of the apolipoprotein E and CI loci in predisposing to late-onset Alzheimer&#x2019;s disease. Neurology 51, 131&#x2013;135. 10.1212/wnl.51.1.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.51.1.131</ArticleId><ArticleId IdType="pubmed">9674791</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, and van Duijn CM (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ki CS, Na DL, Kim DK, Kim HJ, and Kim JW (2002). Genetic association of an apolipoprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer&#x2019;s disease. Neurosci Lett 319, 75&#x2013;78. 10.1016/s0304-3940(01)02559-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3940(01)02559-9</ArticleId><ArticleId IdType="pubmed">11825674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuerban B, Shibata N, Komatsu M, Ohnuma T, and Arai H. (2010). Genetic association between PLTP gene polymorphisms and Alzheimer&#x2019;s disease in a Japanese population. Dement Geriatr Cogn Disord 30, 78&#x2013;82. 10.1159/000318855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000318855</ArticleId><ArticleId IdType="pubmed">20714154</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko B, Lee JH, Ciappa A, Saxena A, Li CM, Feng L, Arriaga A, Stern Y, Lantigua R, Shachter N, and Mayeux R. (2004). APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals. Arch Neurol 61, 1434&#x2013;1439. 10.1001/archneur.61.9.1434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.9.1434</ArticleId><ArticleId IdType="pubmed">15364690</ArticleId></ArticleIdList></Reference><Reference><Citation>Desrumaux C, Lemaire-Ewing S, Ogier N, Yessoufou A, Hammann A, Sequeira-Le Grand A, Deckert V, Pais de Barros JP, Le Guern N, Guy J, et al. (2016). Plasma phospholipid transfer protein (PLTP) modulates adaptive immune functions through alternation of T helper cell polarization. Cell Mol Immunol 13, 795&#x2013;804. 10.1038/cmi.2015.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2015.75</ArticleId><ArticleId IdType="pmc">PMC5101448</ArticleId><ArticleId IdType="pubmed">26320740</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, et al. (2015). MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol 16, 278. 10.1186/s13059-015-0844-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehallier B., Gate D., Schaum N., Nanasi T., Lee SE., Yousef H., Moran Losada P., Berdnik D., Keller A., Verghese J., et al.. (2019). Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 25, 1843&#x2013;1850. 10.1038/s41591-019-0673-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0673-</ArticleId><ArticleId IdType="pmc">PMC7062043</ArticleId><ArticleId IdType="pubmed">31806903</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, Grinberg LT, Geschwind D, Seeley WW, Miller BL, et al. (2013). Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 70, 774&#x2013;778. 10.1001/2013.jamaneurol.393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamaneurol.393</ArticleId><ArticleId IdType="pmc">PMC3743672</ArticleId><ArticleId IdType="pubmed">23609919</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, and Spillantini MG (2006). Frontotemporal lobar degeneration through loss of progranulin function. Brain 129, 2808&#x2013;2810. 10.1093/brain/awl291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl291</ArticleId><ArticleId IdType="pubmed">17071919</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M, Laquerriere A, De Pooter T, Camuzat A, Van den Broeck M, et al. (2007). Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 28, 846&#x2013;855. 10.1002/humu.20520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20520</ArticleId><ArticleId IdType="pubmed">17436289</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, Spina S, Coppola G, Karydas AM, Stewart H, et al. (2007). Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C--&gt;T (Arg493X) mutation: an international initiative. Lancet Neurol 6, 857&#x2013;868. 10.1016/S1474-4422(07)70221-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70221-1</ArticleId><ArticleId IdType="pubmed">17826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, and Nishihara M. (2014). Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol Commun 2, 78. 10.1186/s40478-014-0078-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0078-x</ArticleId><ArticleId IdType="pmc">PMC4149276</ArticleId><ArticleId IdType="pubmed">25022663</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, Pluvinage JV, Mathur V, Hahn O, Morgens DW, et al. (2020). Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci 23, 194&#x2013;208. 10.1038/s41593-019-0566-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0566-1</ArticleId><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV, and Nie Q. (2021). Inference and analysis of cell-cell communication using CellChat. Nat Commun 12, 1088. 10.1038/s41467-021-21246-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21246-9</ArticleId><ArticleId IdType="pmc">PMC7889871</ArticleId><ArticleId IdType="pubmed">33597522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC, Greenberg HB, and Butcher EC (2001). Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 107, 595&#x2013;601. 10.1172/JCI11902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI11902</ArticleId><ArticleId IdType="pmc">PMC199429</ArticleId><ArticleId IdType="pubmed">11238560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariyar M, and Borg A. (2010). The RecordLinkage Package: Detecting Errors in Data. R J. 2, 61.</Citation></Reference><Reference><Citation>Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, et al. (2021). Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587 e3529. 10.1016/j.cell.2021.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.048</ArticleId><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O., Schultz SA., Ape A., Kuhle J., Kaeser SA., Barro C., Graber S., Kuder-Buletta E., LaFougere C., Laske C., et al.. (2019). Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat Med 25, 277&#x2013;283. 10.1038/s41591-018-0304-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, et al. (2016). Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53. 10.1016/j.neuron.2015.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O&#x2019;Connor C, Fitzpatrick C, Pasillas MP, et al. (2017). An environment-dependent transcriptional network specifies human microglia identity. Science 356. 10.1126/science.aal3222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3222</ArticleId><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, et al. (2009). Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet 84, 445&#x2013;458. 10.1016/j.ajhg.2009.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2009.03.011</ArticleId><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hagg S, Athanasiu L, et al. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat Genet 51, 404&#x2013;413. 10.1038/s41588-018-0311-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, et al. (2019). Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51, 414&#x2013;430. 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Vest RT, Kern F, Lee DP, Agam M, Maat CA, Losada PM, Chen MB, Schaum N, Khoury N, et al. (2022). A human brain vascular atlas reveals diverse mediators of Alzheimer&#x2019;s risk. Nature 603, 885&#x2013;892. 10.1038/s41586-021-04369-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04369-3</ArticleId><ArticleId IdType="pmc">PMC9635042</ArticleId><ArticleId IdType="pubmed">35165441</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW (1988). Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622&#x2013;630. 10.1126/science.3283935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3283935</ArticleId><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T, and Yonehara S. (2000). Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 275, 40663&#x2013;40666. 10.1074/jbc.C000761200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C000761200</ArticleId><ArticleId IdType="pubmed">11060282</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen SF., Soung AL., Yang W., Ai S., Kanmogne M., Dave VA., Artyomov M., Magee JA., and Klein RS. (2022). Single-cell RNA transcriptome analysis of CNS immune cells reveals CXCL16/CXCR6 as maintenance factors for tissue-resident T cells that drive synapse elimination. Genome Med 14, 108. 10.1186/s13073-022-01111-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-022-01111-0</ArticleId><ArticleId IdType="pmc">PMC9509564</ArticleId><ArticleId IdType="pubmed">36153630</ArticleId></ArticleIdList></Reference><Reference><Citation>Trelle AN, Carr VA, Guerin SA, Thieu MK, Jayakumar M, Guo W, Nadiadwala A, Corso NK, Hunt MP, Litovsky CP, et al. (2020). Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults. Elife 9. 10.7554/eLife.55335.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.55335</ArticleId><ArticleId IdType="pmc">PMC7259949</ArticleId><ArticleId IdType="pubmed">32469308</ArticleId></ArticleIdList></Reference><Reference><Citation>Trelle AN, Carr VA, Wilson EN, Swarovski MS, Hunt MP, Toueg TN, Tran TT, Channappa D, Corso NK, Thieu MK, et al. (2021). Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease. Neurology 96, e1470&#x2013;e1481. 10.1212/WNL.0000000000011477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011477</ArticleId><ArticleId IdType="pmc">PMC8055319</ArticleId><ArticleId IdType="pubmed">33408146</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, and Gartner ZJ (2019). DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst 8, 329&#x2013;337 e324. 10.1016/j.cels.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2019.03.003</ArticleId><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36517604</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>613</Volume><Issue>7942</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Microglia regulate central nervous system myelin growth and integrity.</ArticleTitle><Pagination><StartPage>120</StartPage><EndPage>129</EndPage><MedlinePgn>120-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-05534-y</ELocationID><Abstract><AbstractText>Myelin is required for the function of neuronal axons in the central nervous system, but the mechanisms that support myelin health are unclear. Although macrophages in the central nervous system have been implicated in myelin health<sup>1</sup>, it is unknown which macrophage populations are involved and which aspects they influence. Here we show that resident microglia are crucial for the maintenance of myelin health in adulthood in both mice and humans. We demonstrate that microglia are dispensable for developmental myelin ensheathment. However, they are required for subsequent regulation of myelin growth and associated cognitive function, and for preservation of myelin integrity by preventing its degeneration. We show that loss of myelin health due to the absence of microglia is associated with the appearance of a myelinating oligodendrocyte state with altered lipid metabolism. Moreover, this mechanism is regulated through disruption of the TGF&#x3b2;1-TGF&#x3b2;R1 axis. Our findings highlight microglia as promising therapeutic targets for conditions in which myelin growth and integrity are dysregulated, such as in ageing and neurodegenerative disease<sup>2,3</sup>.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>Niamh B</ForeName><Initials>NB</Initials><Identifier Source="ORCID">0000-0002-9769-367X</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munro</LastName><ForeName>David A D</ForeName><Initials>DAD</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bestard-Cuche</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uyeda</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Molecular Pharmacology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogie</LastName><ForeName>Jeroen F J</ForeName><Initials>JFJ</Initials><AffiliationInfo><Affiliation>Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University MS Centre, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Alana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holloway</LastName><ForeName>Rebecca K</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0002-9396-7776</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barlo Multiple Sclerosis Centre, St Michael's Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, The University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Gonzalez</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-5966-0351</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askew</LastName><ForeName>Katharine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wellcome Trust Centre for Cell Biology, King's Buildings, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungall</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Biological and Veterinary Services, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodds</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biological and Veterinary Services, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dittmayer</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuropathology and Neurocure Clinical Research Center, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szymkowiak</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8363-373X</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, Centre for Basics in NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McColl</LastName><ForeName>Barry W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-0521-9656</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0349-1955</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, Centre for Basics in NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><Identifier Source="ORCID">0000-0003-2530-0598</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stenzel</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuropathology and Neurocure Clinical Research Center, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horsburgh</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendriks</LastName><ForeName>Jerome J A</ForeName><Initials>JJA</Initials><Identifier Source="ORCID">0000-0002-7717-8582</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University MS Centre, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pridans</LastName><ForeName>Clare</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9423-557X</Identifier><AffiliationInfo><Affiliation>Centre for Inflammation Research, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Simons Initiative for the Developing Brain, Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Muir Maxwell Epilepsy Centre, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muramatsu</LastName><ForeName>Rieko</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5342-7823</Identifier><AffiliationInfo><Affiliation>Departments of Molecular Pharmacology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6329-382X</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropsychiatry and Laboratory of Molecular Psychiatry, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin and DZNE, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Miron</LastName><ForeName>Veronique E</ForeName><Initials>VE</Initials><Identifier Source="ORCID">0000-0003-1738-0647</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK. Veronique.Miron@unityhealth.to.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK. Veronique.Miron@unityhealth.to.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK. Veronique.Miron@unityhealth.to.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barlo Multiple Sclerosis Centre, St Michael's Hospital, Toronto, Ontario, Canada. Veronique.Miron@unityhealth.to.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Ontario, Canada. Veronique.Miron@unityhealth.to.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, The University of Toronto, Toronto, Ontario, Canada. Veronique.Miron@unityhealth.to.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/T015594/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L003384/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M019969/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M020827/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V031260/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.30</RegistryNumber><NameOfSubstance UI="D000077293">Receptor, Transforming Growth Factor-beta Type I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2024 Jul;631(8021):E11. doi: 10.1038/s41586-024-07696-3.</RefSource><PMID Version="1">38961305</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="Y">Central Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="Y">Myelin Sheath</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077293" MajorTopicYN="N">Receptor, Transforming Growth Factor-beta Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36517604</ArticleId><ArticleId IdType="pmc">PMC9812791</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05534-y</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-05534-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McNamara NB, Miron VE. Microglia in developing white matter and perinatal brain injury. Neurosci. Lett. 2020;714:134539. doi: 10.1016/j.neulet.2019.134539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.134539</ArticleId><ArticleId IdType="pubmed">31614181</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanelli E, et al. Myelinosome formation represents an early stage of oligodendrocyte damage in multiple sclerosis and its animal model. Nat. Commun. 2016;7:13275. doi: 10.1038/ncomms13275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13275</ArticleId><ArticleId IdType="pmc">PMC5116090</ArticleId><ArticleId IdType="pubmed">27848954</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A. The effects of normal aging on myelin and nerve fibers: a review. J Neurocytol. 2002;31:581&#x2013;593. doi: 10.1023/A:1025731309829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1025731309829</ArticleId><ArticleId IdType="pubmed">14501200</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JM, Lyons DA. Myelin dynamics throughout life: an ever-changing landscape? Front. Cell Neurosci. 2018;12:424. doi: 10.3389/fncel.2018.00424.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00424</ArticleId><ArticleId IdType="pmc">PMC6252314</ArticleId><ArticleId IdType="pubmed">30510502</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 2016;19:995&#x2013;998. doi: 10.1038/nn.4325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4325</ArticleId><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Inagawa K, Watanabe S, Tsukada Y, Mikoshiba K. The role of myelination in learning performance observed in two strains of myelin-deficient mutant mice (shiverer and mld) Behav. Neural. Biol . 1988;50:184&#x2013;192. doi: 10.1016/S0163-1047(88)90871-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0163-1047(88)90871-0</ArticleId><ArticleId IdType="pubmed">2465759</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Moss MB, Sethares C. Effects of aging on myelinated nerve fibers in monkey primary visual cortex. J. Comp. Neurol. 2000;419:364&#x2013;376. doi: 10.1002/(SICI)1096-9861(20000410)419:3&lt;364::AID-CNE8&gt;3.0.CO;2-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9861(20000410)419:3&lt;364::AID-CNE8&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">10723011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie SJ, et al. Coupled changes in brain white matter microstructure and fluid intelligence in later life. J. Neurosci. 2015;35:8672&#x2013;8682. doi: 10.1523/JNEUROSCI.0862-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0862-15.2015</ArticleId><ArticleId IdType="pmc">PMC4452562</ArticleId><ArticleId IdType="pubmed">26041932</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson EM, et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell. 2019;176:43&#x2013;55.e13. doi: 10.1016/j.cell.2018.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.049</ArticleId><ArticleId IdType="pmc">PMC6329664</ArticleId><ArticleId IdType="pubmed">30528430</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo R, et al. Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. Nat. Commun. 2019;10:3215. doi: 10.1038/s41467-019-11053-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11053-8</ArticleId><ArticleId IdType="pmc">PMC6642117</ArticleId><ArticleId IdType="pubmed">31324781</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro DAD, et al. CNS macrophages differentially rely on an intronic Csf1r enhancer for their development. Development. 2020;147:dev194449. doi: 10.1242/dev.194449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.194449</ArticleId><ArticleId IdType="pmc">PMC7758622</ArticleId><ArticleId IdType="pubmed">33323375</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips KA, et al. Age-related changes in myelin of axons of the corpus callosum and cognitive decline in common marmosets. Am. J. Primatol. 2019;81:e22949. doi: 10.1002/ajp.22949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajp.22949</ArticleId><ArticleId IdType="pmc">PMC6685070</ArticleId><ArticleId IdType="pubmed">30620098</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraghty AC, et al. Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment. Neuron. 2019;103:250&#x2013;265.e8. doi: 10.1016/j.neuron.2019.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.04.032</ArticleId><ArticleId IdType="pmc">PMC6697075</ArticleId><ArticleId IdType="pubmed">31122677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiramoto T, et al. Tbx1, a gene encoded in 22q11.2 copy number variant, is a link between alterations in fimbria myelination and cognitive speed in mice. Mol. Psychiatry. 2022;27:929&#x2013;938. doi: 10.1038/s41380-021-01318-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01318-4</ArticleId><ArticleId IdType="pmc">PMC9054676</ArticleId><ArticleId IdType="pubmed">34737458</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AI, et al. Cyfip1 haploinsufficient rats show white matter changes, myelin thinning, abnormal oligodendrocytes and behavioural inflexibility. Nat. Commun. 2019;10:3455. doi: 10.1038/s41467-019-11119-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11119-7</ArticleId><ArticleId IdType="pmc">PMC6671959</ArticleId><ArticleId IdType="pubmed">31371763</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie IA, et al. Motor skill learning requires active central myelination. Science. 2014;346:318&#x2013;322. doi: 10.1126/science.1254960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254960</ArticleId><ArticleId IdType="pmc">PMC6324726</ArticleId><ArticleId IdType="pubmed">25324381</ArticleId></ArticleIdList></Reference><Reference><Citation>Steadman PE, et al. Disruption of oligodendrogenesis impairs memory consolidation in adult mice. Neuron. 2020;105:150&#x2013;164.e6. doi: 10.1016/j.neuron.2019.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.10.013</ArticleId><ArticleId IdType="pmc">PMC7579726</ArticleId><ArticleId IdType="pubmed">31753579</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterhof N, et al. Colony-stimulating factor 1 receptor (CSF1R) regulates microglia density and distribution, but not microglia differentiation in vivo. Cell Rep. 2018;24:1203&#x2013;1217.e6. doi: 10.1016/j.celrep.2018.06.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.06.113</ArticleId><ArticleId IdType="pubmed">30067976</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G, et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 2005;8:468&#x2013;475. doi: 10.1038/nn1426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1426</ArticleId><ArticleId IdType="pubmed">15793579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempthorne L, et al. Loss of homeostatic microglial phenotype in CSF1R-related leukoencephalopathy. Acta Neuropathol. Commun. 2020;8:72. doi: 10.1186/s40478-020-00947-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00947-0</ArticleId><ArticleId IdType="pmc">PMC7236286</ArticleId><ArticleId IdType="pubmed">32430064</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci. 2017;20:1162&#x2013;1171. doi: 10.1038/nn.4597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottcher C, et al. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat. Neurosci. 2019;22:78&#x2013;90. doi: 10.1038/s41593-018-0290-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0290-2</ArticleId><ArticleId IdType="pubmed">30559476</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael DR, Salter RC, Ramji DP. TGF-&#x3b2; inhibits the uptake of modified low density lipoprotein by human macrophages through a Smad-dependent pathway: a dominant role for Smad-2. Biochim. Biophys. Acta. 2012;1822:1608&#x2013;1616. doi: 10.1016/j.bbadis.2012.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2012.06.002</ArticleId><ArticleId IdType="pmc">PMC3497875</ArticleId><ArticleId IdType="pubmed">22705205</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat. Neurosci. 2014;17:131&#x2013;143. doi: 10.1038/nn.3599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, et al. Astrocytic YAP protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model through TGF-&#x3b2; signaling. Theranostics. 2021;11:8480&#x2013;8499. doi: 10.7150/thno.60031.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.60031</ArticleId><ArticleId IdType="pmc">PMC8344002</ArticleId><ArticleId IdType="pubmed">34373754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AN, Appel B. Microglia phagocytose myelin sheaths to modify developmental myelination. Nat. Neurosci. 2020;23:1055&#x2013;1066. doi: 10.1038/s41593-020-0654-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0654-2</ArticleId><ArticleId IdType="pmc">PMC7483351</ArticleId><ArticleId IdType="pubmed">32632287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. Robust myelination of regenerated axons induced by combined manipulations of GPR17 and microglia. Neuron. 2020;108:876&#x2013;886.e4. doi: 10.1016/j.neuron.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7736523</ArticleId><ArticleId IdType="pubmed">33108748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, et al. Myelin degeneration and diminished myelin renewal contribute to age-related deficits in memory. Nat. Neurosci. 2020;23:481&#x2013;486. doi: 10.1038/s41593-020-0588-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0588-8</ArticleId><ArticleId IdType="pmc">PMC7306053</ArticleId><ArticleId IdType="pubmed">32042174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson EM, et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science. 2014;344:1252304. doi: 10.1126/science.1252304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1252304</ArticleId><ArticleId IdType="pmc">PMC4096908</ArticleId><ArticleId IdType="pubmed">24727982</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, et al. White matter aging drives microglial diversity. Neuron. 2021;109:1100&#x2013;1117.e10. doi: 10.1016/j.neuron.2021.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.01.027</ArticleId><ArticleId IdType="pubmed">33606969</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 2018;9:539. doi: 10.1038/s41467-018-02926-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WT, et al. Spatial transcriptomics and in situ sequencing to study Alzheimer&#x2019;s disease. Cell. 2020;182:976&#x2013;991.e19. doi: 10.1016/j.cell.2020.06.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.038</ArticleId><ArticleId IdType="pubmed">32702314</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen K, et al. Multiple sclerosis risk gene Mertk is required for microglial activation and subsequent remyelination. Cell Rep. 2021;34:108835. doi: 10.1016/j.celrep.2021.108835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108835</ArticleId><ArticleId IdType="pubmed">33691116</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcao AM, et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat. Med. 2018;24:1837&#x2013;1844. doi: 10.1038/s41591-018-0236-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0236-y</ArticleId><ArticleId IdType="pmc">PMC6544508</ArticleId><ArticleId IdType="pubmed">30420755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 2020;26:131&#x2013;142. doi: 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulken BW, et al. Single-cell analysis reveals T cell infiltration in old neurogenic niches. Nature. 2019;571:205&#x2013;210. doi: 10.1038/s41586-019-1362-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1362-5</ArticleId><ArticleId IdType="pmc">PMC7111535</ArticleId><ArticleId IdType="pubmed">31270459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenigsbuch M, et al. A shared disease-associated oligodendrocyte signature among multiple CNS pathologies. Nat. Neurosci. 2022;25:876&#x2013;886. doi: 10.1038/s41593-022-01104-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01104-7</ArticleId><ArticleId IdType="pmc">PMC9724210</ArticleId><ArticleId IdType="pubmed">35760863</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips GR, et al. Cholesteryl ester levels are elevated in the caudate and putamen of Huntington&#x2019;s disease patients. Sci Rep. 2020;10:20314. doi: 10.1038/s41598-020-76973-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-76973-8</ArticleId><ArticleId IdType="pmc">PMC7680097</ArticleId><ArticleId IdType="pubmed">33219259</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitkanen AS, Halonen TO, Kilpelainen HO, Riekkinen PJ. Cholesterol esterase activity in cerebrospinal fluid of multiple sclerosis patients. J. Neurol. Sci. 1986;74:45&#x2013;53. doi: 10.1016/0022-510X(86)90190-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(86)90190-5</ArticleId><ArticleId IdType="pubmed">3723135</ArticleId></ArticleIdList></Reference><Reference><Citation>Berghoff SA, et al. Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nat. Neurosci. 2021;24:47&#x2013;60. doi: 10.1038/s41593-020-00757-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00757-6</ArticleId><ArticleId IdType="pmc">PMC7116742</ArticleId><ArticleId IdType="pubmed">33349711</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdowski WM, et al. Dominant-acting CSF1R variants cause microglial depletion and altered astrocytic phenotype in zebrafish and adult-onset leukodystrophy. Acta Neuropathol. 2022;144:211&#x2013;239. doi: 10.1007/s00401-022-02440-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02440-5</ArticleId><ArticleId IdType="pmc">PMC9288387</ArticleId><ArticleId IdType="pubmed">35713703</ArticleId></ArticleIdList></Reference><Reference><Citation>Colangelo V, et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J. Neurosci. Res. 2002;70:462&#x2013;473. doi: 10.1002/jnr.10351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10351</ArticleId><ArticleId IdType="pubmed">12391607</ArticleId></ArticleIdList></Reference><Reference><Citation>Tichauer JE, et al. Age-dependent changes on TGF&#x3b2;1 Smad3 pathway modify the pattern of microglial cell activation. Brain Behav. Immun. 2014;37:187&#x2013;196. doi: 10.1016/j.bbi.2013.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3951654</ArticleId><ArticleId IdType="pubmed">24380849</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron VE, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 2013;16:1211&#x2013;1218. doi: 10.1038/nn.3469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3469</ArticleId><ArticleId IdType="pmc">PMC3977045</ArticleId><ArticleId IdType="pubmed">23872599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillenburg A, et al. Activin receptors regulate the oligodendrocyte lineage in health and disease. Acta Neuropathol. 2018;135:887&#x2013;906. doi: 10.1007/s00401-018-1813-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1813-3</ArticleId><ArticleId IdType="pmc">PMC5954071</ArticleId><ArticleId IdType="pubmed">29397421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd AF, et al. Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat. Neurosci. 2019;22:1046&#x2013;1052. doi: 10.1038/s41593-019-0418-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0418-z</ArticleId><ArticleId IdType="pmc">PMC6597360</ArticleId><ArticleId IdType="pubmed">31182869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity. 2019;50:253&#x2013;271.e6. doi: 10.1016/j.immuni.2018.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.11.004</ArticleId><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Plemel JR, et al. Microglia response following acute demyelination is heterogeneous and limits infiltrating macrophage dispersion. Sci. Adv. 2020;6:eaay6324. doi: 10.1126/sciadv.aay6324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aay6324</ArticleId><ArticleId IdType="pmc">PMC6962036</ArticleId><ArticleId IdType="pubmed">31998844</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019;566:388&#x2013;392. doi: 10.1038/s41586-019-0924-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0924-x</ArticleId><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, et al. Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron. 2019;101:207&#x2013;223.e10. doi: 10.1016/j.neuron.2018.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.12.006</ArticleId><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest AD, et al. Focal adhesion kinase (FAK): a regulator of CNS myelination. J. Neurosci. Res. 2009;87:3456&#x2013;3464. doi: 10.1002/jnr.22022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22022</ArticleId><ArticleId IdType="pmc">PMC2760606</ArticleId><ArticleId IdType="pubmed">19224576</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh F, et al. Poor vessel formation in embryos from knock-in mice expressing ALK5 with L45 loop mutation defective in Smad activation. Lab. Invest. 2009;89:800&#x2013;810. doi: 10.1038/labinvest.2009.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2009.37</ArticleId><ArticleId IdType="pubmed">19398960</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36538329</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Associations of Greenness, Parks, and Blue Space With Neurodegenerative Disease Hospitalizations Among Older US Adults.</ArticleTitle><Pagination><StartPage>e2247664</StartPage><MedlinePgn>e2247664</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2247664</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.47664</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Exposure to natural environments has been associated with health outcomes related to neurological diseases. However, the few studies that have examined associations of natural environments with neurological diseases report mixed findings.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate associations of natural environments with hospital admissions for Alzheimer disease and related dementias (ADRD) and Parkinson disease (PD) among older adults in the US.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This open cohort study included fee-for-service Medicare beneficiaries aged 65 years or older who lived in the contiguous US from January 1, 2000, to December 31, 2016. Beneficiaries entered the cohort on January 1, 2000, or January 1 of the year after enrollment. Data from US Medicare enrollment and Medicare Provider Analysis and Review files, which contain information about individual-level covariates and all hospital admissions for Medicare fee-for-service beneficiaries, were analyzed between January 2021 and September 2022.</AbstractText><AbstractText Label="EXPOSURES">Differences in IQRs for zip code-level greenness (normalized difference vegetation index [NDVI]), percentage park cover, and percentage blue space cover (surface water; &#x2265;1.0% vs &lt;1.0%).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The main outcome was first hospitalizations with a primary or secondary discharge diagnosis of ADRD or PD. To examine associations of exposures to natural environments with ADRD and PD hospitalization, we used Cox-equivalent Poisson models.</AbstractText><AbstractText Label="RESULTS">We included 61 662 472 and 61 673 367 Medicare beneficiaries in the ADRD and PD cohorts, respectively. For both cohorts, 55.2% of beneficiaries were women. Most beneficiaries in both cohorts were White (84.4%), were not eligible for Medicaid (87.6%), and were aged 65 to 74 years (76.6%) at study entry. We observed 7&#x202f;737&#x202f;609 and 1&#x202f;168&#x202f;940 first ADRD and PD hospitalizations, respectively. After adjustment for potential individual- and area-level confounders (eg, Medicaid eligibility and zip code-level median household income), NDVI was negatively associated with ADRD hospitalization (hazard ratio [HR],&#x2009;0.95 [95% CI, 0.94-0.96], per IQR increase). We found no evidence of an association of percentage park and blue space cover with ADRD hospitalization. In contrast, NDVI (HR,&#x2009;0.94 [95% CI, 0.93-0.95], per IQR increase), percentage park cover (HR,&#x2009;0.97 [95% CI, 0.97-0.98], per IQR increase), and blue space cover (HR,&#x2009;0.97 [95% CI, 0.96-0.98], &#x2265;1.0% vs &lt;1.0%) were associated with a decrease in PD hospitalizations. Patterns of effect modification by demographics differed between exposures.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The findings of this cohort study suggest that some natural environments are associated with a decreased risk of ADRD and PD hospitalization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klompmaker</LastName><ForeName>Jochem O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laden</LastName><ForeName>Francine</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Browning</LastName><ForeName>Matthew H E M</ForeName><Initials>MHEM</Initials><AffiliationInfo><Affiliation>Department of Parks, Recreation and Tourism Management, Clemson University, Clemson, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dominici</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Marcia P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogletree</LastName><ForeName>S Scott</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>OPENspace Research Centre, School of Architecture and Landscape Architecture, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigolon</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of City and Metropolitan Planning, University of Utah, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanobetti</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Jaime E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 ES028033</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL150119</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071024</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES000002</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MD012769</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES029950</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES024332</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES034373</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES030616</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG066949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066793</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG074372</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES026217</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Klompmaker, Laden, Dominici, Jimenez, Zanobetti, Hart, and James reported receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36538329</ArticleId><ArticleId IdType="pmc">PMC9856892</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.47664</ArticleId><ArticleId IdType="pii">2799727</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feigin VL, Nichols E, Alam T, et al. ; GBD 2016 Neurology Collaborators . Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30499-X</ArticleId><ArticleId IdType="pmc">PMC6459001</ArticleId><ArticleId IdType="pubmed">30879893</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association . Alzheimer&#x2019;s Facts and Figures Report. 2021. Accessed January 4, 2022. https://www.alz.org/alzheimers-dementia/facts-figures</Citation></Reference><Reference><Citation>Parkinson&#x2019;s Foundation . Statistics. 2022. Accessed January 4, 2022. https://www.parkinson.org/Understanding-Parkinsons/Statistics</Citation></Reference><Reference><Citation>Yang W, Hamilton JL, Kopil C, et al. . Current and projected future economic burden of Parkinson&#x2019;s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15. doi:10.1038/s41531-020-0117-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-020-0117-1</ArticleId><ArticleId IdType="pmc">PMC7347582</ArticleId><ArticleId IdType="pubmed">32665974</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Adar SD, Yanosky JD, Weuve J. Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: a systematic review of epidemiologic research. Neurotoxicology. 2016;56:235-253. doi:10.1016/j.neuro.2016.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2016.06.004</ArticleId><ArticleId IdType="pmc">PMC5048530</ArticleId><ArticleId IdType="pubmed">27328897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Schwarzschild MA. The epidemiology of Parkinson&#x2019;s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257-1272. doi:10.1016/S1474-4422(16)30230-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30230-7</ArticleId><ArticleId IdType="pubmed">27751556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasdagli MI, Katsouyanni K, Dimakopoulou K, Samoli E. Air pollution and Parkinson&#x2019;s disease: a systematic review and meta-analysis up to 2018. Int J Hyg Environ Health. 2019;222(3):402-409. doi:10.1016/j.ijheh.2018.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijheh.2018.12.006</ArticleId><ArticleId IdType="pubmed">30606679</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, Bennett EE, Ranker L, et al. . Exposure to air pollution in relation to risk of dementia and related outcomes: an updated systematic review of the epidemiological literature. Environ Health Perspect. 2021;129(9):96001. doi:10.1289/EHP8716</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/EHP8716</ArticleId><ArticleId IdType="pmc">PMC8462495</ArticleId><ArticleId IdType="pubmed">34558969</ArticleId></ArticleIdList></Reference><Reference><Citation>Markevych I, Schoierer J, Hartig T, et al. . Exploring pathways linking greenspace to health: theoretical and methodological guidance. Environ Res. 2017;158:301-317. doi:10.1016/j.envres.2017.06.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2017.06.028</ArticleId><ArticleId IdType="pubmed">28672128</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong KC, Hart JE, James P. A review of epidemiologic studies on greenness and health: updated literature through 2017. Curr Environ Health Rep. 2018;5(1):77-87. doi:10.1007/s40572-018-0179-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40572-018-0179-y</ArticleId><ArticleId IdType="pmc">PMC5878143</ArticleId><ArticleId IdType="pubmed">29392643</ArticleId></ArticleIdList></Reference><Reference><Citation>de Keijzer C, Tonne C, Basaga&#xf1;a X, et al. . Residential surrounding greenness and cognitive decline: a 10-year follow-up of the Whitehall II cohort. Environ Health Perspect. 2018;126(7):077003. doi:10.1289/EHP2875</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/EHP2875</ArticleId><ArticleId IdType="pmc">PMC6108840</ArticleId><ArticleId IdType="pubmed">30028296</ArticleId></ArticleIdList></Reference><Reference><Citation>James P, Hart JE, Banay RF, Laden F. Exposure to greenness and mortality in a nationwide prospective cohort study of women. Environ Health Perspect. 2016;124(9):1344-1352. doi:10.1289/ehp.1510363</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.1510363</ArticleId><ArticleId IdType="pmc">PMC5010419</ArticleId><ArticleId IdType="pubmed">27074702</ArticleId></ArticleIdList></Reference><Reference><Citation>Klompmaker JO, Janssen NAH, Bloemsma LD, et al. . Effects of exposure to surrounding green, air pollution and traffic noise with non-accidental and cause-specific mortality in the Dutch national cohort. Environ Health. 2021;20(1):82. doi:10.1186/s12940-021-00769-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12940-021-00769-0</ArticleId><ArticleId IdType="pmc">PMC8281461</ArticleId><ArticleId IdType="pubmed">34261495</ArticleId></ArticleIdList></Reference><Reference><Citation>Orioli R, Antonucci C, Scortichini M, et al. . Exposure to residential greenness as a predictor of cause-specific mortality and stroke incidence in the Rome Longitudinal Study. Environ Health Perspect. 2019;127(2):27002. doi:10.1289/EHP2854</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/EHP2854</ArticleId><ArticleId IdType="pmc">PMC6752936</ArticleId><ArticleId IdType="pubmed">30775931</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuchi W, Sbihi H, Davies H, Tamburic L, Brauer M. Road proximity, air pollution, noise, green space and neurologic disease incidence: a population-based cohort study. Environ Health. 2020;19(1):8. doi:10.1186/s12940-020-0565-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12940-020-0565-4</ArticleId><ArticleId IdType="pmc">PMC6974975</ArticleId><ArticleId IdType="pubmed">31964412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Wei F, Zhang X, et al. . Air pollution, surrounding green, road proximity and Parkinson&#x2019;s disease: a prospective cohort study. Environ Res. 2021;197:111170. doi:10.1016/j.envres.2021.111170</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2021.111170</ArticleId><ArticleId IdType="pubmed">33887274</ArticleId></ArticleIdList></Reference><Reference><Citation>Slawsky ED, Hajat A, Rhew IC, et al. . Neighborhood greenspace exposure as a protective factor in dementia risk among U.S. adults 75&#x2009;years or older: a cohort study. Environ Health. 2022;21(1):14. doi:10.1186/s12940-022-00830-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12940-022-00830-6</ArticleId><ArticleId IdType="pmc">PMC8760791</ArticleId><ArticleId IdType="pubmed">35033073</ArticleId></ArticleIdList></Reference><Reference><Citation>Koay L, Rose J, Abdelhafiz AH. Factors that lead to hospitalisation in patients with Parkinson disease&#x2014;a systematic review. Int J Clin Pract. 2018;72(1):e13039. doi:10.1111/ijcp.13039</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13039</ArticleId><ArticleId IdType="pubmed">29119656</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Wu X, Danesh Yazdi M, et al. . Long-term effects of PM2.5 on neurological disorders in the American Medicare population: a longitudinal cohort study. Lancet Planet Health. 2020;4(12):e557-e565. doi:10.1016/S2542-5196(20)30227-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2542-5196(20)30227-8</ArticleId><ArticleId IdType="pmc">PMC7720425</ArticleId><ArticleId IdType="pubmed">33091388</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic Conditions Data Warehouse . Condition Categories. Accessed February 22, 2022. https://www2.ccwdata.org/web/guest/condition-categories</Citation></Reference><Reference><Citation>National Aeronautics and Space Administration . Measuring Vegetation (NDVI and EVI). Accessed June 16, 2020. https://earthobservatory.nasa.gov/features/MeasuringVegetation/measuring_vegetation_2.php</Citation></Reference><Reference><Citation>Pekel JF, Cottam A, Gorelick N, Belward AS. High-resolution mapping of global surface water and its long-term changes. Nature. 2016;540(7633):418-422. doi:10.1038/nature20584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20584</ArticleId><ArticleId IdType="pubmed">27926733</ArticleId></ArticleIdList></Reference><Reference><Citation>Filice CE, Joynt KE. Examining race and ethnicity information in Medicare administrative data. Med Care. 2017;55(12):e170-e176. doi:10.1097/MLR.0000000000000608</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000608</ArticleId><ArticleId IdType="pubmed">29135782</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller D, Bynum JPW. Dementia in the USA: state variation in prevalence. J Public Health (Oxf). 2015;37(4):597-604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6283394</ArticleId><ArticleId IdType="pubmed">25330771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantri S, Fullard ME, Beck J, Willis AW. State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease. NPJ Parkinsons Dis. 2019;5:1. doi:10.1038/s41531-019-0074-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-019-0074-8</ArticleId><ArticleId IdType="pmc">PMC6345811</ArticleId><ArticleId IdType="pubmed">30701188</ArticleId></ArticleIdList></Reference><Reference><Citation>Adkins-Jackson PB, Chantarat T, Bailey ZD, Ponce NA. Measuring structural racism: a guide for epidemiologists and other health researchers. Am J Epidemiol. 2022;191(4):539-547. doi:10.1093/aje/kwab239</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwab239</ArticleId><ArticleId IdType="pmc">PMC9077112</ArticleId><ArticleId IdType="pubmed">34564723</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia?: a systematic review and meta-analysis of longitudinal studies. BMC Public Health. 2014;14:510. doi:10.1186/1471-2458-14-510</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-510</ArticleId><ArticleId IdType="pmc">PMC4064273</ArticleId><ArticleId IdType="pubmed">24885250</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman TE, Miller-Martinez DM, Stein Merkin S, Lachman ME, Tun PA, Karlamangla AS. Histories of social engagement and adult cognition: midlife in the U.S. study. J Gerontol B Psychol Sci Soc Sci. 2011;66(suppl 1):i141-i152. doi:10.1093/geronb/gbq091</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/gbq091</ArticleId><ArticleId IdType="pmc">PMC3132769</ArticleId><ArticleId IdType="pubmed">21196438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertel KA, Glymour MM, Berkman LF. Effects of social integration on preserving memory function in a nationally representative US elderly population. Am J Public Health. 2008;98(7):1215-1220. doi:10.2105/AJPH.2007.113654</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2007.113654</ArticleId><ArticleId IdType="pmc">PMC2424091</ArticleId><ArticleId IdType="pubmed">18511736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Han D, Cheng Q, et al. . Association of levels of physical activity with risk of Parkinson disease: a systematic review and meta-analysis. JAMA Netw Open. 2018;1(5):e182421. doi:10.1001/jamanetworkopen.2018.2421</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.2421</ArticleId><ArticleId IdType="pmc">PMC6324511</ArticleId><ArticleId IdType="pubmed">30646166</ArticleId></ArticleIdList></Reference><Reference><Citation>Banay RF, James P, Hart JE, et al. . Greenness and depression incidence among older women. Environ Health Perspect. 2019;127(2):27001. doi:10.1289/EHP1229</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/EHP1229</ArticleId><ArticleId IdType="pmc">PMC6752939</ArticleId><ArticleId IdType="pubmed">30735068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar C, Webster C, Gallacher J. Residential greenness and prevalence of major depressive disorders: a cross-sectional, observational, associational study of 94&#x2009;879 adult UK Biobank participants. Lancet Planet Health. 2018;2(4):e162-e173. doi:10.1016/S2542-5196(18)30051-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2542-5196(18)30051-2</ArticleId><ArticleId IdType="pubmed">29615217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wei F, Yu Z, et al. . Association of residential greenness and incident depression: investigating the mediation and interaction effects of particulate matter. Sci Total Environ. 2022;811:152372. doi:10.1016/j.scitotenv.2021.152372</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2021.152372</ArticleId><ArticleId IdType="pubmed">34914979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530-538. doi:10.1001/archpsyc.63.5.530</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.5.530</ArticleId><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Mao S, Xiang D, Fang C. Association between depression and the subsequent risk of Parkinson&#x2019;s disease: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:186-192. doi:10.1016/j.pnpbp.2018.05.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2018.05.025</ArticleId><ArticleId IdType="pubmed">29859854</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Burnett RT, Bai L, et al. . Residential greenness and cardiovascular disease incidence, readmission, and mortality. Environ Health Perspect. 2020;128(8):87005. doi:10.1289/EHP6161</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/EHP6161</ArticleId><ArticleId IdType="pmc">PMC7446772</ArticleId><ArticleId IdType="pubmed">32840393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang BY, Markevych I, Heinrich J, et al. . Associations of greenness with diabetes mellitus and glucose-homeostasis markers: the 33 Communities Chinese Health Study. Int J Hyg Environ Health. 2019;222(2):283-290. doi:10.1016/j.ijheh.2018.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijheh.2018.12.001</ArticleId><ArticleId IdType="pubmed">30545606</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve PJ, Jerrett M, Su JG, Weichenthal S, Sandler DP. Association of residential greenness with obesity and physical activity in a US cohort of women. Environ Res. 2018;160:372-384. doi:10.1016/j.envres.2017.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2017.10.005</ArticleId><ArticleId IdType="pmc">PMC5872815</ArticleId><ArticleId IdType="pubmed">29059619</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11(6):718-726. doi:10.1016/j.jalz.2015.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.016</ArticleId><ArticleId IdType="pubmed">26045020</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning MHEM, Rigolon A, McAnirlin O, Yoon HV. Where greenspace matters most: a systematic review of urbanicity, greenspace, and physical health. Landsc Urban Plan. 2022;217:104233. doi:10.1016/j.landurbplan.2021.104233</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.landurbplan.2021.104233</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigolon A, Browning MHEM, McAnirlin O, Yoon HV. Green space and health equity: a systematic review on the potential of green space to reduce health disparities. Int J Environ Res Public Health. 2021;18(5):1-29. doi:10.3390/ijerph18052563</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052563</ArticleId><ArticleId IdType="pmc">PMC7967323</ArticleId><ArticleId IdType="pubmed">33806546</ArticleId></ArticleIdList></Reference><Reference><Citation>Homer C, Dewitz J, Jin S, et al. . Conterminous United States land cover change patterns 2001-2016 from the 2016 National Land Cover Database. ISPRS J Photogramm Remote Sens. 2020;162:184-199. doi:10.1016/j.isprsjprs.2020.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isprsjprs.2020.02.019</ArticleId><ArticleId IdType="pmc">PMC9214659</ArticleId><ArticleId IdType="pubmed">35746921</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36572122</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.</ArticleTitle><Pagination><StartPage>1152</StartPage><EndPage>1165</EndPage><MedlinePgn>1152-1165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac407</ELocationID><Abstract><AbstractText>Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease. However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau. Recent studies suggest that blood total-tau originates principally from peripheral, non-brain sources. We sought to address this challenge by generating an anti-tau antibody that selectively binds brain-derived tau and avoids the peripherally expressed 'big tau' isoform. We applied this antibody to develop an ultrasensitive blood-based assay for brain-derived tau, and validated it in five independent cohorts (n = 609) including a blood-to-autopsy cohort, CSF biomarker-classified cohorts and memory clinic cohorts. In paired samples, serum and CSF brain-derived tau were significantly correlated (rho = 0.85, P &lt; 0.0001), while serum and CSF total-tau were not (rho = 0.23, P = 0.3364). Blood-based brain-derived tau showed equivalent diagnostic performance as CSF total-tau and CSF brain-derived tau to separate biomarker-positive Alzheimer's disease participants from biomarker-negative controls. Furthermore, plasma brain-derived tau accurately distinguished autopsy-confirmed Alzheimer's disease from other neurodegenerative diseases (area under the curve = 86.4%) while neurofilament light did not (area under the curve = 54.3%). These performances were independent of the presence of concomitant pathologies. Plasma brain-derived tau (rho = 0.52-0.67, P = 0.003), but not neurofilament light (rho = -0.14-0.17, P = 0.501), was associated with global and regional amyloid plaque and neurofibrillary tangle counts. These results were further verified in two memory clinic cohorts where serum brain-derived tau differentiated Alzheimer's disease from a range of other neurodegenerative disorders, including frontotemporal lobar degeneration and atypical parkinsonian disorders (area under the curve up to 99.6%). Notably, plasma/serum brain-derived tau correlated with neurofilament light only in Alzheimer's disease but not in the other neurodegenerative diseases. Across cohorts, plasma/serum brain-derived tau was associated with CSF and plasma AT(N) biomarkers and cognitive function. Brain-derived tau is a new blood-based biomarker that outperforms plasma total-tau and, unlike neurofilament light, shows specificity to Alzheimer's disease-type neurodegeneration. Thus, brain-derived tau demonstrates potential to complete the AT(N) scheme in blood, and will be useful to evaluate Alzheimer's disease-dependent neurodegenerative processes for clinical and research purposes.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonzalez-Ortiz</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turton</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bioventix Plc, Romans Business Park, Farnham, Surrey GU9 7SX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kac</LastName><ForeName>Przemys&#x142;aw R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 405 30, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnov</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of California, San Diego and Shiely-Marcos Alzheimer's Disease Research Center, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, BS 25121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia 25121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia 25121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantoni</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, BS 25121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraceno</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia 25121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivolta</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, BS 25121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 405 30, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg 405 30, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, SE5 8AF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9340-9814</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, BS 25121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of California, San Diego and Shiely-Marcos Alzheimer's Disease Research Center, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bioventix Plc, Romans Business Park, Farnham, Surrey GU9 7SX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 405 30, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, 431 80, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Shatin, N.T., Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 405 30, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, 431 80, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0003-1422-4358</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 405 30, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>#1R01AG068398-01</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Brain. 2023 Oct 3;146(10):e89-e90. doi: 10.1093/brain/awad208.</RefSource><PMID Version="1">37365902</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">neurofilament light</Keyword><Keyword MajorTopicYN="N">plasma brain-derived-tau</Keyword><Keyword MajorTopicYN="N">total-tau</Keyword></KeywordList><CoiStatement>M.T. and P.H. are employees of Bioventix Plc. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche. K.B. has served as a consultant or at advisory boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics and Siemens Healthineers. H.Z. and K.B. are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>26</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36572122</ArticleId><ArticleId IdType="pmc">PMC9976981</ArticleId><ArticleId IdType="doi">10.1093/brain/awac407</ArticleId><ArticleId IdType="pii">6960988</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Bennett DA, Blennow K, et al. . NIA-AA research framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, et al. . A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Villain N, Frisoni GB, et al. . Clinical diagnosis of Alzheimer&#x2019;s disease: Recommendations of the international working group. Lancet Neurol. 2021;20:484&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8339877</ArticleId><ArticleId IdType="pubmed">33933186</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association . 2020 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2020;16:391&#x2013;460.</Citation></Reference><Reference><Citation>Ashton NJ, Hye A, Rajkumar AP, et al. . An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol. 2020;16:265&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">32322100</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Ashton NJ, Brinkmalm G, et al. . Blood phospho-tau in Alzheimer&#x2019;s disease: Analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18:400&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585226</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Verberk IMW, Thijssen EH, et al. . Blood-based biomarkers for Alzheimer&#x2019;s disease: Towards clinical implementation. Lancet Neurol. 2021;21:66&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">34838239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Leuzy A, Karikari TK, et al. . The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021;48:2140&#x2013;2156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175325</ArticleId><ArticleId IdType="pubmed">33677733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbagh MN, Hendrix S, Harrison JE. FDA position statement &#x201c;Early Alzheimer&#x2019;s disease: Developing drugs for treatment, guidance for industry&#x201d;. Alzheimers Dement (N Y). 2019;5:13&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6804505</ArticleId><ArticleId IdType="pubmed">31650002</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan A, Pannee J, Karikari TK, et al. . Population-based blood screening for preclinical Alzheimer&#x2019;s disease in a British birth cohort at age 70. Brain. 2021;144:434&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940173</ArticleId><ArticleId IdType="pubmed">33479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Teunissen CE, Zetterberg H, et al. . Head-to-head comparison of 8 plasma amyloid-&#x3b2; 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453354</ArticleId><ArticleId IdType="pubmed">34542571</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et al. . High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, et al. . High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647&#x2013;e1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma p-tau181 in Alzheimer&#x2019;s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26:379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. . Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, Joie RL, Strom A, et al. . Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. Lancet Neurol. 2021;20:739&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Pascoal TA, Karikari TK, et al. . Plasma p-tau231: A new biomarker for incipient Alzheimer&#x2019;s disease pathology. Acta Neuropathol. 2021;141:709&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. . Soluble p-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13:e14022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185545</ArticleId><ArticleId IdType="pubmed">33949133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al Khleifat A, et al. . A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. . Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. JAMA Neurol. 2019;17:1035&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Leuzy A, Pascoal TA, et al. . Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer&#x2019;s disease. Brain. 2020;143:3793&#x2013;3804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7805809</ArticleId><ArticleId IdType="pubmed">33210117</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark C, Lewczuk P, Kornhuber J, et al. . Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer&#x2019;s disease pathology and clinical disease progression. Alzheimers Res Ther. 2021;13:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995778</ArticleId><ArticleId IdType="pubmed">33766131</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J Exp Med. 2020;217:e20200861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank B, Ally M, Brekke B, et al. . Plasma p-tau181 shows stronger network association to Alzheimer&#x2019;s disease dementia than neurofilament light and total tau. Alzheimers Dement. 2022;18:1523&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9160800</ArticleId><ArticleId IdType="pubmed">34854549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Janelidze S, et al. . Plasma tau in Alzheimer disease. Neurology. 2016;87:1827&#x2013;1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089525</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller S, Preische O, G&#xf6;pfert JC, et al. . Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Sci Rep. 2017;7:9529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573353</ArticleId><ArticleId IdType="pubmed">28842559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Wilson D, Andreasson U, et al. . Plasma tau levels in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707015</ArticleId><ArticleId IdType="pubmed">23551972</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Moscoso A, Ashton NJ, et al. . Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy. Neurology. 2021;97:e1229&#x2013;e1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480485</ArticleId><ArticleId IdType="pubmed">34266917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillb&#xe4;ck T, Farahmand BY, Ros&#xe9;n C, et al. . Cerebrospinal fluid tau and amyloid-&#x3b2;1-42 in patients with dementia. Brain. 2015;138:2716&#x2013;2731.</Citation><ArticleIdList><ArticleId IdType="pubmed">26133663</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren M, Davidsson P, Tullberg M, et al. . Both total and phosphorylated tau are increased in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2001;70:624&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737352</ArticleId><ArticleId IdType="pubmed">11309456</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomann PA, Kaiser E, Sch&#xf6;nknecht P, Pantel J, Essig M, Schr&#xf6;der J. Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci. 2009;34:136&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647572</ArticleId><ArticleId IdType="pubmed">19270764</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugger BN, Whiteside CM, Maarouf CL, et al. . The presence of select tau species in human peripheral tissues and their relation to Alzheimer&#x2019;s disease. J Alzheimers Dis. 2016;51:345&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6074044</ArticleId><ArticleId IdType="pubmed">26890756</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer I, Baas PW. Resurrecting the mysteries of big tau. Trends Neurosci. 2020;43:493&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999525</ArticleId><ArticleId IdType="pubmed">32434664</ArticleId></ArticleIdList></Reference><Reference><Citation>Couchie D, Mavilia C, Georgieff IS, Liem RK, Shelanski ML, Nunez J. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci U S A. 1992;89:4378&#x2013;4381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49085</ArticleId><ArticleId IdType="pubmed">1374898</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgieff IS, Liem RK, Mellado W, Nunez J, Shelanski ML. High molecular weight tau: Preferential localization in the peripheral nervous system. J Cell Sci. 1991;100(Pt 1):55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">1724450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Wennberg AMV, et al. . Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol. 2017;74:1073&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710182</ArticleId><ArticleId IdType="pubmed">28692710</ArticleId></ArticleIdList></Reference><Reference><Citation>Neselius S, Zetterberg H, Blennow K, et al. . Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj. 2013;27:425&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">23473386</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera A, Lejbman N, Jeromin A, et al. . Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol. 2015;72:1109&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">26237304</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Himali JJ, Aparicio HJ, et al. . Plasma total-tau as a biomarker of stroke risk in the community. Ann Neurol. 2019;86:463&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297542</ArticleId><ArticleId IdType="pubmed">31271449</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein R, Chang B, Yue JK, et al. . Comparing plasma phospho tau, total tau, and phospho tau&#x2013;total tau ratio as acute and chronic traumatic brain injury biomarkers. JAMA Neurol. 2017;74:1063&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710183</ArticleId><ArticleId IdType="pubmed">28738126</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Tegner Y, Wilson DH, et al. . Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol. 2014;71:684&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">24627036</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne J, Harrison P, Butcher R, Ebsworth N, Tan K. Novel super-high affinity sheep monoclonal antibodies against CEA bind colon and lung adenocarcinoma. Hybridoma. 1999;18:183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">10380018</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Emer&#x161;i&#x10d; A, Vrillon A, et al. . Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer&#x2019;s disease diagnosis. Alzheimers Dement. 2021;17:755&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8246793</ArticleId><ArticleId IdType="pubmed">33252199</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. . National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirnov DS, Ashton NJ, Blennow K, et al. . Plasma biomarkers for Alzheimer&#x2019;s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022;143:487&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8960664</ArticleId><ArticleId IdType="pubmed">35195758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Respondek G, Stamelou M, et al. . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32:853&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, et al. . Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590050</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the national institute on aging-Alzheimer&#x2019;s association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Karikari TK, Ashton N, et al. . Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91:960&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">32611664</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, et al. . A practical guide to immunoassay method validation. Front Neurol. 2015;6:179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4541289</ArticleId><ArticleId IdType="pubmed">26347708</ArticleId></ArticleIdList></Reference><Reference><Citation>Saracino D, Dorgham K, Camuzat A, et al. . Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: From tailored references to clinical applications. J Neurol Neurosurg Psychiatry. 2021;92:1278&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8606463</ArticleId><ArticleId IdType="pubmed">34349004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, et al. . Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein I, Wilson EN, Swarovski MS, Andreasson KI, Angst MS, Greicius MD. Plasma biomarkers of tau and neurodegeneration during major cardiac and noncardiac surgery. JAMA Neurol. 2021;78:1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453356</ArticleId><ArticleId IdType="pubmed">34542578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulut M, Koksal O, Dogan S, et al. . Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results. Adv Ther. 2006;23:12&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16644603</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgieff IS, Liem RK, Couchie D, Mavilia C, Nunez J, Shelanski ML. Expression of high molecular weight tau in the central and peripheral nervous systems. J Cell Sci. 1993;105:729&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">8408300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Janelidze S, Hall S, et al. . Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88:930&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333515</ArticleId><ArticleId IdType="pubmed">28179466</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong JR, Ashton NJ, Karikari TK, et al. . Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer&#x2019;s disease: A focused review on recent advances. J Neurol Neurosurg Psychiatry. 2021;92:1231&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">34510001</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Benedet AL, Ashton NJ, et al. . Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">33106600</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Delaby C, Mu&#xf1;oz L, et al. . Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry. 2021;92:1206&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">34103344</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36584406</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>220</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Engineering an inhibitor-resistant human CSF1R variant for microglia replacement.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20220857</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20220857</ELocationID><Abstract><AbstractText>Hematopoietic stem cell transplantation (HSCT) can replace endogenous microglia with circulation-derived macrophages but has high mortality. To mitigate the risks of HSCT and expand the potential for microglia replacement, we engineered an inhibitor-resistant CSF1R that enables robust microglia replacement. A glycine to alanine substitution at position 795 of human CSF1R (G795A) confers resistance to multiple CSF1R inhibitors, including PLX3397 and PLX5622. Biochemical and cell-based assays show no discernable gain or loss of function. G795A- but not wildtype-CSF1R expressing macrophages efficiently engraft the brain of PLX3397-treated mice and persist after cessation of inhibitor treatment. To gauge translational potential, we CRISPR engineered human-induced pluripotent stem cell-derived microglia (iMG) to express G795A. Xenotransplantation studies demonstrate that G795A-iMG exhibit nearly identical gene expression to wildtype iMG, respond to inflammatory stimuli, and progressively expand in the presence of PLX3397, replacing endogenous microglia to fully occupy the brain. In sum, we engineered a human CSF1R variant that enables nontoxic, cell type, and tissue-specific replacement of microglia.</AbstractText><CopyrightInformation>&#xa9; 2022 Chadarevian et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chadarevian</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-2478-6592</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lombroso</LastName><ForeName>Sonia I</ForeName><Initials>SI</Initials><Identifier Source="ORCID">0000-0003-2348-0417</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology Graduate Group, Biomedical Graduate Studies Program, University of Pennsylvania , Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania , Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peet</LastName><ForeName>Graham C</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0003-1566-2835</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program and Department of Cell and Developmental Biology, University of Colorado Anschutz Medical Campus , Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasselmann</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2630-9850</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3904-2366</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzan</LastName><ForeName>Dave E</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000-0003-0209-6715</Identifier><AffiliationInfo><Affiliation>Department of Biology, The College of New Jersey , Ewing, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capocchi</LastName><ForeName>Joia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3433-5904</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purnell</LastName><ForeName>Freddy S</ForeName><Initials>FS</Initials><Identifier Source="ORCID">0000-0001-5060-8485</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemec</LastName><ForeName>Kelsey M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-3036-254X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Perelman School of Medicine , Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahian</LastName><ForeName>Alina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3598-2158</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escobar</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2288-5789</Identifier><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>England</LastName><ForeName>Whitney</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-6712-0101</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaluvadi</LastName><ForeName>Sai</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0055-149X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Perelman School of Medicine , Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Carleigh A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-4549-0640</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaqoob</LastName><ForeName>Fazeela</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9058-9810</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisenberg</LastName><ForeName>William H</ForeName><Initials>WH</Initials><Identifier Source="ORCID">0000-0002-8715-1439</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras-Paniagua</LastName><ForeName>Matias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4868-8479</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, University of Pennsylvania , Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Mariko L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-1642-2887</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Perelman School of Medicine , Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Children's Hospital of Philadelphia , Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8554-6456</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spitale</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0002-3511-8098</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7770-7157</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine , Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bennett</LastName><ForeName>F Chris</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0000-0003-2570-0620</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine , University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Children's Hospital of Philadelphia , Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R43 NS125730</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021718</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG073088</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR025496</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH014654</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD010794</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA062203</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008076</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS120960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007170</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007413</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 GM081259</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 DA048813</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000631">Aminopyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000604004">Csf1r protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>6783M2LV5X</RegistryNumber><NameOfSubstance UI="C000600259">pexidartinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016187">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Exp Med. 2023 Mar 6;220(3):e20222070. doi: 10.1084/jem.20222070.</RefSource><PMID Version="1">36648421</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000631" MajorTopicYN="N">Aminopyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015202" MajorTopicYN="Y">Protein Engineering</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016187" MajorTopicYN="Y">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: M.L. Bennett and F.C. Bennett are co-inventors on a pending patent filed by The Board of Trustees of The Leland Stanford Junior University (application 16/566,675) related to methods of microglia replacement. M. Blurton-Jones, J.P. Chadarevian, H. Davtyan, J. Hasselmann, W. England, and R.C. Spitale are co-inventors on a pending patent filed by the University of California Regents (application 63/169,578) related to genetic modification of cells to confer resistance to CSF1R antagonists. M. Blurton-Jones is a co-inventor of patent WO/2018/160496, related to the differentiation of human pluripotent stem cells into microglia. F.C. Bennett is a consultant for and shareholder in Glia Biotherapeutics Inc. M. Blurton-Jones and R.C. Spitale are co-founders of NovoGlia Inc. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>17</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36584406</ArticleId><ArticleId IdType="doi">10.1084/jem.20220857</ArticleId><ArticleId IdType="pii">213788</ArticleId><ArticleId IdType="pmc">PMC9814156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abud, E.M., Ramirez R.N., Martinez E.S., Healy L.M., Nguyen C.H.H., Newman S.A., Yeromin A.V., Scarfone V.M., Marsh S.E., Fimbres C., et al. . 2017. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 94:278&#x2013;293.e9. 10.1016/j.neuron.2017.03.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin, S., Carling G., and Gan L.. 2022. New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia. Curr. Opin. Neurobiol. 72:131&#x2013;139. 10.1016/j.conb.2021.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2021.10.001</ArticleId><ArticleId IdType="pubmed">34826653</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews, S.
2014. FastQC a quality-control tool for high-throughput sequence data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</Citation></Reference><Reference><Citation>Bennett, F.C., Bennett M.L., Yaqoob F., Mulinyawe S.B., Grant G.A., Hayden Gephart M., Plowey E.D., and Barres B.A.. 2018. A combination of ontogeny and CNS environment establishes microglial identity. Neuron. 98:1170&#x2013;1183.e8. 10.1016/j.neuron.2018.05.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.014</ArticleId><ArticleId IdType="pmc">PMC6023731</ArticleId><ArticleId IdType="pubmed">29861285</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, M.L., Bennett F.C., Liddelow S.A., Ajami B., Zamanian J.L., Fernhoff N.B., Mulinyawe S.B., Bohlen C.J., Adil A., Tucker A., et al. . 2016. New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. USA. 113:E1738&#x2013;E1746. 10.1073/pnas.1525528113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525528113</ArticleId><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, M.L., and Bennett F.C.. 2020. The influence of environment and origin on brain resident macrophages and implications for therapy. Nat. Neurosci. 23:157&#x2013;166. 10.1038/s41593-019-0545-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0545-6</ArticleId><ArticleId IdType="pubmed">31792468</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdowski, W.M., Sanderson L.E., and van Ham T.J.. 2021. The multicellular interplay of microglia in health and disease: Lessons from leukodystrophy. Dis. Model. Mech. 14:dmm048925. 10.1242/dmm.048925</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.048925</ArticleId><ArticleId IdType="pmc">PMC8319551</ArticleId><ArticleId IdType="pubmed">34282843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia, S., Francisco L., Carter A., Sun C.L., Baker K.S., Gurney J.G., McGlave P.B., Nademanee A., O&#x2019;Donnell M., Ramsay N.K., et al. . 2007. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the bone marrow transplant survivor study. Blood. 110:3784&#x2013;3792. 10.1182/blood-2007-03-082933</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-03-082933</ArticleId><ArticleId IdType="pmc">PMC2077324</ArticleId><ArticleId IdType="pubmed">17671231</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi, A., Montini E., Lorioli L., Cesani M., Fumagalli F., Plati T., Baldoli C., Martino S., Calabria A., Canale S., et al. . 2013. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 341:1233158. 10.1126/science.1233158</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1233158</ArticleId><ArticleId IdType="pubmed">23845948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisht, K., Okojie K.A., Sharma K., Lentferink D.H., Sun Y.Y., Chen H.R., Uweru J.O., Amancherla S., Calcuttawala Z., Campos-Salazar A.B., et al. . 2021. Capillary-associated microglia regulate vascular structure and function through PANX1-P2RY12 coupling in mice. Nat. Commun. 12:5289. 10.1038/s41467-021-25590-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25590-8</ArticleId><ArticleId IdType="pmc">PMC8421455</ArticleId><ArticleId IdType="pubmed">34489419</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen, C.J., Bennett F.C., Tucker A.F., Collins H.Y., Mulinyawe S.B., and Barres B.A.. 2017. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron. 94:759&#x2013;773.e8. 10.1016/j.neuron.2017.04.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun, T.P., Eide C.A., and Druker B.J.. 2020. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 37:530&#x2013;542. 10.1016/j.ccell.2020.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.03.006</ArticleId><ArticleId IdType="pmc">PMC7722523</ArticleId><ArticleId IdType="pubmed">32289275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray, N.L., Pimentel H., Melsted P., and Pachter L.. 2016. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34:525&#x2013;527. 10.1038/nbt.3519</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3519</ArticleId><ArticleId IdType="pubmed">27043002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushnell, B. 2018. BBMap short-read aligner, and other bioinformatics tools. 2016</Citation></Reference><Reference><Citation>Claes, C., Danhash E.P., Hasselmann J., Chadarevian J.P., Shabestari S.K., England W.E., Lim T.E., Hidalgo J.L.S., Spitale R.C., Davtyan H., and Blurton-Jones M.. 2021. Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 16:50. 10.1186/s13024-021-00473-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00473-0</ArticleId><ArticleId IdType="pmc">PMC8305935</ArticleId><ArticleId IdType="pubmed">34301296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogle, C.R., Yachnis A.T., Laywell E.D., Zander D.S., Wingard J.R., Steindler D.A., and Scott E.W.. 2004. Bone marrow transdifferentiation in brain after transplantation: A retrospective study. Lancet. 363:1432&#x2013;1437. 10.1016/S0140-6736(04)16102-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16102-3</ArticleId><ArticleId IdType="pubmed">15121406</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronk, J.C., Filiano A.J., Louveau A., Marin I., Marsh R., Ji E., Goldman D.H., Smirnov I., Geraci N., Acton S., et al. . 2018. Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. J. Exp. Med. 215:1627&#x2013;1647. 10.1084/jem.20180247</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180247</ArticleId><ArticleId IdType="pmc">PMC5987928</ArticleId><ArticleId IdType="pubmed">29643186</ArticleId></ArticleIdList></Reference><Reference><Citation>Cs&#xe1;sz&#xe1;r, E., L&#xe9;n&#xe1;rt N., Cser&#xe9;p C., K&#xf6;rnyei Z., Fekete R., P&#xf3;sfai B., Bal&#xe1;zsfi D., Hangya B., Schwarcz A.D., Szabadits E., et al. . 2022. Microglia modulate blood flow, neurovascular coupling, and hypoperfusion via purinergic actions. J. Exp. Med. 219:e20211071. 10.1084/jem.20211071</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211071</ArticleId><ArticleId IdType="pmc">PMC8932534</ArticleId><ArticleId IdType="pubmed">35201268</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher, N.N., Najafi A.R., Kayala K.M., Elmore M.R., White T.E., Medeiros R., West B.L., and Green K.N.. 2015. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J. Neuroinflammation. 12:139. 10.1186/s12974-015-0366-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0366-9</ArticleId><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, X.-M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., Sylvestre V., and Stanley E.R.. 2002. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 99:111&#x2013;120. 10.1182/blood.V99.1.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.1.111</ArticleId><ArticleId IdType="pubmed">11756160</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska, A., Keren-Shaul H., Weiner A., Colonna M., Schwartz M., and Amit I.. 2018. Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell. 173:1073&#x2013;1081. 10.1016/j.cell.2018.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.003</ArticleId><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lucia, C., Rinchon A., Olmos-Alonso A., Riecken K., Fehse B., Boche D., Perry V.H., and Gomez-Nicola D.. 2016. Microglia regulate hippocampal neurogenesis during chronic neurodegeneration. Brain Behav. Immun. 55:179&#x2013;190. 10.1016/j.bbi.2015.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.11.001</ArticleId><ArticleId IdType="pmc">PMC4907582</ArticleId><ArticleId IdType="pubmed">26541819</ArticleId></ArticleIdList></Reference><Reference><Citation>Diem, K., Magaret A., Klock A., Jin L., Zhu J., and Corey L.. 2015. Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue. J. Virol. Methods. 222:117&#x2013;121. 10.1016/j.jviromet.2015.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2015.06.004</ArticleId><ArticleId IdType="pmc">PMC4558892</ArticleId><ArticleId IdType="pubmed">26073660</ArticleId></ArticleIdList></Reference><Reference><Citation>Difilippantonio, M.J., Zhu J., Chen H.T., Meffre E., Nussenzweig M.C., Max E.E., Ried T., and Nussenzweig A.. 2000. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature. 404:510&#x2013;514. 10.1038/35006670</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35006670</ArticleId><ArticleId IdType="pmc">PMC4721590</ArticleId><ArticleId IdType="pubmed">10761921</ArticleId></ArticleIdList></Reference><Reference><Citation>Downing, J.R., Roussel M.F., and Sherr C.J.. 1989. Ligand and protein kinase C downmodulate the colony-stimulating factor 1 receptor by independent mechanisms. Mol. Cell Biol. 9(7):2890&#x2013;2896. 10.1128/mcb.9.7.2890-2896.1989</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.9.7.2890-2896.1989</ArticleId><ArticleId IdType="pmc">PMC362755</ArticleId><ArticleId IdType="pubmed">2528680</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichler, F., Duncan C., Musolino P.L., Orchard P.J., De Oliveira S., Thrasher A.J., Armant M., Dansereau C., Lund T.C., Miller W.P., et al. . 2017. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 377:1630&#x2013;1638. 10.1056/NEJMoa1700554</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1700554</ArticleId><ArticleId IdType="pmc">PMC5708849</ArticleId><ArticleId IdType="pubmed">28976817</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore, M.R.P., Najafi A.R., Koike M.A., Dagher N.N., Spangenberg E.E., Rice R.A., Kitazawa M., Matusow B., Nguyen H., West B.L., and Green K.N.. 2014. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 82:380&#x2013;397. 10.1016/j.neuron.2014.02.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Escolar, M.L., Poe M.D., Provenzale J.M., Richards K.C., Allison J., Wood S., Wenger D.A., Pietryga D., Wall D., Champagne M., et al. . 2005. Transplantation of umbilical-cord blood in babies with infantile Krabbe&#x2019;s disease. N. Engl. J. Med. 352:2069&#x2013;2081. 10.1056/NEJMoa042604</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa042604</ArticleId><ArticleId IdType="pubmed">15901860</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck, A.V., Blanchard T., Roselle C.P., Golinelli G., and June C.H.. 2022. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28:678&#x2013;689. 10.1038/s41591-022-01765-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01765-8</ArticleId><ArticleId IdType="pmc">PMC9305718</ArticleId><ArticleId IdType="pubmed">35440724</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson, E.M., Nagaraja S., Ocampo A., Tam L.T., Wood L.S., Pallegar P.N., Greene J.J., Geraghty A.C., Goldstein A.K., Ni L., et al. . 2019. Methotrexate chemotherapy induces persistent Tri-glial Dysregulation that underlies chemotherapy-related cognitive impairment. Cell. 176:43&#x2013;55.e13. 10.1016/j.cell.2018.10.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.049</ArticleId><ArticleId IdType="pmc">PMC6329664</ArticleId><ArticleId IdType="pubmed">30528430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux, F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R., et al. . 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 330:841&#x2013;845. 10.1126/science.1194637</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194637</ArticleId><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gow, D.J., Garceau V., Kapetanovic R., Sester D.P., Fici G.J., Shelly J.A., Wilson T.L., and Hume D.A.. 2012. Cloning and expression of porcine colony stimulating factor-1 (CSF-1) and colony stimulating factor-1 receptor (CSF-1R) and analysis of the species specificity of stimulation by CSF-1 and interleukin 34. Cytokine. 60:793&#x2013;805. 10.1016/j.cyto.2012.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2012.08.008</ArticleId><ArticleId IdType="pmc">PMC3500696</ArticleId><ArticleId IdType="pubmed">22974529</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, J., Sarlus H., Wszolek Z.K., Karrenbauer V.D., and Harris R.A.. 2020. Microglial replacement therapy: A potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy. Acta Neuropathol. Commun. 8:217. 10.1186/s40478-020-01093-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01093-3</ArticleId><ArticleId IdType="pmc">PMC7720517</ArticleId><ArticleId IdType="pubmed">33287883</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmann, J., Coburn M.A., England W., Figueroa Velez D.X., Kiani Shabestari S., Tu C.H., McQuade A., Kolahdouzan M., Echeverria K., Claes C., et al. . 2019. Development of a chimeric model to study and manipulate human microglia In Vivo. Neuron. 103:1016&#x2013;1033.e10. 10.1016/j.neuron.2019.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.002</ArticleId><ArticleId IdType="pmc">PMC7138101</ArticleId><ArticleId IdType="pubmed">31375314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, C.-T., Wu W.F., Deng Y.H., and Ge J.W.. 2020. Modulators of microglia activation and polarization in ischemic stroke (Review). Mol. Med. Rep. 21:2006&#x2013;2018. 10.3892/mmr.2020.11003</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11003</ArticleId><ArticleId IdType="pmc">PMC7115206</ArticleId><ArticleId IdType="pubmed">32323760</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M.. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:110&#x2013;119. 10.1107/S0108767390010224</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0108767390010224</ArticleId><ArticleId IdType="pubmed">2025413</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul, H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. . 2017. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 169:1276&#x2013;1290.e17. 10.1016/j.cell.2017.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, C., Beilina A., Smith N., Li Y., Kim M., Kumaran R., Kaganovich A., Mamais A., Adame A., Iba M., et al. . 2020. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci. Transl. Med. 12:eaay0399. 10.1126/scitranslmed.aay0399</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aay0399</ArticleId><ArticleId IdType="pmc">PMC8100991</ArticleId><ArticleId IdType="pubmed">33055242</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno, T., Kasanuki K., Ikeuchi T., Dickson D.W., and Wszolek Z.K.. 2018. -related leukoencephalopathy: A major player in primary microgliopathies. Neurology. 91:1092&#x2013;1104. 10.1212/WNL.0000000000006642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006642</ArticleId><ArticleId IdType="pmc">PMC6329328</ArticleId><ArticleId IdType="pubmed">30429277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlowski, C., and Weimer R.M.. 2012. An automated method to quantify microglia morphology and application to monitor activation state longitudinally in vivo. PLoS One. 7:e31814. 10.1371/journal.pone.0031814</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031814</ArticleId><ArticleId IdType="pmc">PMC3294422</ArticleId><ArticleId IdType="pubmed">22457705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft, S., Bollinger N., Bodenmann B., Heim D., Bucher C., Lengerke C., Kleber M., Tsakiris D.A., Passweg J., Tzankov A., and Medinger M.. 2019. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transpl. 54:540&#x2013;548. 10.1038/s41409-018-0293-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-018-0293-3</ArticleId><ArticleId IdType="pubmed">30108323</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalancette-H&#xe9;bert, M., Swarup V., Beaulieu J.M., Bohacek I., Abdelhamid E., Weng Y.C., Sato S., and Kriz J.. 2012. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J. Neurosci. 32:10383&#x2013;10395. 10.1523/JNEUROSCI.1498-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1498-12.2012</ArticleId><ArticleId IdType="pmc">PMC6703730</ArticleId><ArticleId IdType="pubmed">22836271</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Q., Cheng Z., Zhou L., Darmanis S., Neff N.F., Okamoto J., Gulati G., Bennett M.L., Sun L.O., Clarke L.E., et al. . 2019. Developmental heterogeneity of microglia and brain myeloid cells revealed by Deep single-cell RNA sequencing. Neuron. 101:207&#x2013;223.e10. 10.1016/j.neuron.2018.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.12.006</ArticleId><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y., Given K.S., Dickson E.L., Owens G.P., Macklin W.B., and Bennett J.L.. 2019. Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo. Exp. Neurol. 318:32&#x2013;41. 10.1016/j.expneurol.2019.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.04.011</ArticleId><ArticleId IdType="pmc">PMC6615458</ArticleId><ArticleId IdType="pubmed">31029597</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y., He X., Kawaguchi R., Zhang Y., Wang Q., Monavarfeshani A., Yang Z., Chen B., Shi Z., Meng H., et al. . 2020. Microglia-organized scar-free spinal cord repair in neonatal mice. Nature. 587:613&#x2013;618. 10.1038/s41586-020-2795-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2795-6</ArticleId><ArticleId IdType="pmc">PMC7704837</ArticleId><ArticleId IdType="pubmed">33029008</ArticleId></ArticleIdList></Reference><Reference><Citation>Love, M.I., Huber W., and Anders S.. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:550. 10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund, H., Pieber M., Parsa R., Han J., Grommisch D., Ewing E., Kular L., Needhamsen M., Espinosa A., Nilsson E., et al. . 2018. Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells. Nat. Commun. 9:4845. 10.1038/s41467-018-07295-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07295-7</ArticleId><ArticleId IdType="pmc">PMC6242869</ArticleId><ArticleId IdType="pubmed">30451869</ArticleId></ArticleIdList></Reference><Reference><Citation>Macintosh, J., Derksen A., Poulin C., Braverman N., Vanderver A., Thiffault I., Albrecht S., and Bernard G.. 2022. Novel biallelic variants in NRROS associated with a lethal microgliopathy, brain calcifications, and neurodegeneration. Neurogenetics. 23:151&#x2013;156. 10.1007/s10048-022-00683-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-022-00683-8</ArticleId><ArticleId IdType="pmc">PMC9289721</ArticleId><ArticleId IdType="pubmed">35099671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso, R., Fryatt G., Cleal M., Obst J., Pipi E., Monz&#xf3;n-Sandoval J., Ribe E., Winchester L., Webber C., Nevado A., et al. . 2019a. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain. 142:3243&#x2013;3264. 10.1093/brain/awz241</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz241</ArticleId><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso, R., Van Den Daele J., Fattorelli N., Wolfs L., Balusu S., Burton O., Liston A., Sierksma A., Fourne Y., Poovathingal S., et al. . 2019b. Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat. Neurosci. 22:2111&#x2013;2116. 10.1038/s41593-019-0525-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0525-x</ArticleId><ArticleId IdType="pmc">PMC7616913</ArticleId><ArticleId IdType="pubmed">31659342</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade, A., Coburn M., Tu C.H., Hasselmann J., Davtyan H., and Blurton-Jones M.. 2018. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener. 13:67. 10.1186/s13024-018-0297-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0297-x</ArticleId><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade, A., Kang Y.J., Hasselmann J., Jairaman A., Sotelo A., Coburn M., Shabestari S.K., Chadarevian J.P., Fote G., Tu C.H., et al. . 2020. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer&#x2019;s disease. Nat. Commun. 11:5370. 10.1038/s41467-020-19227-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19227-5</ArticleId><ArticleId IdType="pmc">PMC7584603</ArticleId><ArticleId IdType="pubmed">33097708</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade, A., and Blurton-Jones M.. 2019. Microglia in Alzheimer&#x2019;s disease: Exploring how genetics and phenotype influence risk. J. Mol. Biol. 431:1805&#x2013;1817. 10.1016/j.jmb.2019.01.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.01.045</ArticleId><ArticleId IdType="pmc">PMC6475606</ArticleId><ArticleId IdType="pubmed">30738892</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley, G.M., Uden M., Gullick W.J., and Dibb N.J.. 1999. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene. 18(20):3076&#x2013;3084. 10.1038/sj.onc.1202646</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1202646</ArticleId><ArticleId IdType="pubmed">10340379</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzio, L., Viotti A., and Martino G.. 2021. Microglia in neuroinflammation and neurodegeneration: From understanding to therapy. Front. Neurosci. 15:742065. 10.3389/fnins.2021.742065</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.742065</ArticleId><ArticleId IdType="pmc">PMC8497816</ArticleId><ArticleId IdType="pubmed">34630027</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva, J., Manninen T., Christman G., Hovanes K., Mandelin J., Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A., et al. . 2002. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71:656&#x2013;662. 10.1086/342259</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/342259</ArticleId><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Patir, A., Shih B., McColl B.W., and Freeman T.C.. 2019. A core transcriptional signature of human microglia: Derivation and utility in describing region-dependent alterations associated with Alzheimer&#x2019;s disease. Glia. 67:1240&#x2013;1253. 10.1002/glia.23572</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23572</ArticleId><ArticleId IdType="pubmed">30758077</ArticleId></ArticleIdList></Reference><Reference><Citation>Podle&#x15b;ny-Drabiniok, A., Marcora E., and Goate A.M.. 2020. Microglial phagocytosis: A disease-associated process emerging from Alzheimer&#x2019;s disease genetics. Trends Neurosci. 43:965&#x2013;979. 10.1016/j.tins.2020.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC9080913</ArticleId><ArticleId IdType="pubmed">33127097</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao, O., Ji H., Zhang Y., Zhang X., Zhang X., Liu N., Huang L., Liu C., and Gao W.. 2021. New insights in drug development for Alzheimer&#x2019;s disease based on microglia function. Biomed. Pharmacother. 140:111703. 10.1016/j.biopha.2021.111703</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111703</ArticleId><ArticleId IdType="pubmed">34083109</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts, A.W., Popov L.M., Mitchell G., Ching K.L., Licht D.J., Golovkine G., Barton G.M., and Cox J.S.. 2019. Cas9+ conditionally-immortalized macrophages as a tool for bacterial pathogenesis and beyond. Elife. 8:e45957. 10.7554/eLife.45957</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45957</ArticleId><ArticleId IdType="pmc">PMC6579556</ArticleId><ArticleId IdType="pubmed">31204998</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde, C.M., Schrum J., and Lee A.W.-M.. 2004. A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation. J. Biol. Chem. 279:43448&#x2013;43461. 10.1074/jbc.M314170200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M314170200</ArticleId><ArticleId IdType="pubmed">15297464</ArticleId></ArticleIdList></Reference><Reference><Citation>Rongvaux, A., Willinger T., Martinek J., Strowig T., Gearty S.V., Teichmann L.L., Saito Y., Marches F., Halene S., Palucka A.K., et al. . 2014. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32:364&#x2013;372. 10.1038/nbt.2858</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2858</ArticleId><ArticleId IdType="pmc">PMC4017589</ArticleId><ArticleId IdType="pubmed">24633240</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan, S., Besson-Girard S., Kaya T., Cantuti-Castelvetri L., Liu L., Ji H., Schifferer M., Gouna G., Usifo F., Kannaiyan N., et al. . 2021. White matter aging drives microglial diversity. Neuron. 109:1100&#x2013;1117.e10. 10.1016/j.neuron.2021.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.01.027</ArticleId><ArticleId IdType="pubmed">33606969</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailor, K.A., Agoranos G., L&#xf3;pez-Manzaneda S., Tada S., Gillet-Legrand B., Guerinot C., Masson J.B., Vestergaard C.L., Bonner M., Gagnidze K., et al. . 2022. Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain. Nat. Med. 28:517&#x2013;527. 10.1038/s41591-022-01691-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01691-9</ArticleId><ArticleId IdType="pubmed">35190726</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter, M.W., and Stevens B.. 2017. Microglia emerge as central players in brain disease. Nat. Med. 23:1018&#x2013;1027. 10.1038/nm.4397</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4397</ArticleId><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer, D.P., Lehrman E.K., Kautzman A.G., Koyama R., Mardinly A.R., Yamasaki R., Ransohoff R.M., Greenberg M.E., Barres B.A., and Stevens B.. 2012. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 74:691&#x2013;705. 10.1016/j.neuron.2012.03.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.026</ArticleId><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow, K., Monroe K.M., Kleinberger G., Cantuti-Castelvetri L., Parhizkar S., Xia D., Willem M., Werner G., Pettkus N., Brunner B., et al. . 2020. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 12:e11227. 10.15252/emmm.201911227</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, V.A., Graves-Lindsay T., Howe K., Bouk N., Chen H.C., Kitts P.A., Murphy T.D., Pruitt K.D., Thibaud-Nissen F., Albracht D., et al. . 2017. Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly. Genome Res. 27:849&#x2013;864. 10.1101/gr.213611.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.213611.116</ArticleId><ArticleId IdType="pmc">PMC5411779</ArticleId><ArticleId IdType="pubmed">28396521</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemer, A., Grozovski J., Tay T.L., Tao J., Volaski A., S&#xfc;&#xdf; P., Ardura-Fabregat A., Gross-Vered M., Kim J.S., David E., et al. . 2018. Engrafted parenchymal brain macrophages differ from microglia in transcriptome, chromatin landscape and response to challenge. Nat. Commun. 9:5206. 10.1038/s41467-018-07548-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07548-5</ArticleId><ArticleId IdType="pmc">PMC6284018</ArticleId><ArticleId IdType="pubmed">30523248</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya, Y., Kumar K.K., Mader M.M., Yoo Y., Ayala L.A., Zhou M., Mohr M.A., Neumayer G., Kumar I., Yamamoto R., et al. . 2022. Treatment of a genetic brain disease by CNS-wide microglia replacement. Sci. Transl. Med. 14:eabl9945. 10.1126/scitranslmed.abl9945</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abl9945</ArticleId><ArticleId IdType="pmc">PMC9618306</ArticleId><ArticleId IdType="pubmed">35294256</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, J.-Q., Wang B.R., Jiang T., Gao L., Zhang Y.D., and Xu J.. 2020. NLRP3 inflammasome: A potential therapeutic target in fine particulate matter-induced neuroinflammation in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 77:923&#x2013;934. 10.3233/JAD-200359</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200359</ArticleId><ArticleId IdType="pubmed">32804134</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., Perl A.E., Travers K.J., Wang S., Hunt J.P., et al. . 2012. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 485:260&#x2013;263. 10.1038/nature11016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11016</ArticleId><ArticleId IdType="pmc">PMC3390926</ArticleId><ArticleId IdType="pubmed">22504184</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson, C., Love M.I., and Robinson M.D.. 2015. Differential analyses for RNA-seq: Transcript-level estimates improve gene-level inferences. F1000 Res. 4:1521. 10.12688/f1000research.7563.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.7563.1</ArticleId><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg, E., Severson P.L., Hohsfield L.A., Crapser J., Zhang J., Burton E.A., Zhang Y., Spevak W., Lin J., Phan N.Y., et al. . 2019. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat. Commun. 10:3758. 10.1038/s41467-019-11674-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11674-z</ArticleId><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap, W.D., Wainberg Z.A., Anthony S.P., Ibrahim P.N., Zhang C., Healey J.H., Chmielowski B., Staddon A.P., Cohn A.L., Shapiro G.I., et al. . 2015. Structure-guided blockade of CSF1R kinase in Tenosynovial giant-cell tumor. N. Engl. J. Med. 373:428&#x2013;437. 10.1056/NEJMoa1411366</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1411366</ArticleId><ArticleId IdType="pubmed">26222558</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G.G., Calvo K.R., Pasillas M.P., Sykes D.B., H&#xe4;cker H., and Kamps M.P.. 2006. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat. Methods. 3:287&#x2013;293. 10.1038/nmeth865</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth865</ArticleId><ArticleId IdType="pubmed">16554834</ArticleId></ArticleIdList></Reference><Reference><Citation>Warmuth, M., Kim S., Gu X.J., Xia G., and Adri&#xe1;n F.. 2007. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19:55&#x2013;60. 10.1097/CCO.0b013e328011a25f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCO.0b013e328011a25f</ArticleId><ArticleId IdType="pubmed">17133113</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham, H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer International Publishing.</Citation></Reference><Reference><Citation>Wies Mancini, V.S.B., Di Pietro A.A., de Olmos S., Silva Pinto P., Vence M., Marder M., Igaz L.M., Marcora M.S., Pasquini J.M., Correale J.D., and Pasquini L.A.. 2022. Colony-stimulating factor-1 receptor inhibition attenuates microgliosis and myelin loss but exacerbates neurodegeneration in the chronic cuprizone model. J. Neurochem. 160:643&#x2013;661. 10.1111/jnc.15566</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15566</ArticleId><ArticleId IdType="pubmed">34935149</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Z., Rao Y., Huang Y., Zhou T., Feng R., Xiong S., Yuan T.F., Qin S., Lu Y., Zhou X., et al. . 2020. Efficient strategies for microglia replacement in the central nervous system. Cell Rep. 33:108443. 10.1016/j.celrep.2020.108443</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108443</ArticleId><ArticleId IdType="pubmed">33238120</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, Z., Raj D.D., Schaafsma W., van der Heijden R.A., Kooistra S.M., Reijne A.C., Zhang X., Moser J., Brouwer N., Heeringa P., et al. . 2018. Low-fat diet with caloric restriction reduces white matter microglia activation during aging. Front. Mol. Neurosci. 11:65. 10.3389/fnmol.2018.00065</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00065</ArticleId><ArticleId IdType="pmc">PMC5857900</ArticleId><ArticleId IdType="pubmed">29593493</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, W., Chen J., Xiong Y., Pixley F.J., Dai X.M., Yeung Y.G., and Stanley E.R.. 2008. CSF-1 receptor structure/function in MacCsf1r&#x2212;/&#x2212; macrophages: Regulation of proliferation, differentiation, and morphology. J. Leukoc. Biol. 84:852&#x2013;863. 10.1189/jlb.0308171</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0308171</ArticleId><ArticleId IdType="pmc">PMC2516905</ArticleId><ArticleId IdType="pubmed">18519746</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbino, D.R., Achuthan P., Akanni W., Amode M.R., Barrell D., Bhai J., Billis K., Cummins C., Gall A., Gir&#xf3;n C.G., et al. . 2018. Ensembl 2018. Nucleic Acids Res. 46:D754&#x2013;D761. 10.1093/nar/gkx1098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1098</ArticleId><ArticleId IdType="pmc">PMC5753206</ArticleId><ArticleId IdType="pubmed">29155950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan, L., Fan L., Kodama L., Sohn P.D., Wong M.Y., Mousa G.A., Zhou Y., Li Y., and Gan L.. 2020. A MAC2-positive progenitor-like microglial population is resistant to CSF1R inhibition in adult mouse brain. Elife. 9:e51796. 10.7554/eLife.51796</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.51796</ArticleId><ArticleId IdType="pmc">PMC7591254</ArticleId><ArticleId IdType="pubmed">33054973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36599061</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>388</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.</ArticleTitle><Pagination><StartPage>478</StartPage><EndPage>479</EndPage><MedlinePgn>478-479</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc2215148</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reish</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamshidi</LastName><ForeName>Pouya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamm</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugg</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Mengxuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Kelly L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCord</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumpelman</LastName><ForeName>Chase</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Rudolph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5414-3184</Identifier><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Sherry H-Y</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-5483-2908</Identifier><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG065463</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS113037</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG072080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12PYH0FTU9</RegistryNumber><NameOfSubstance UI="C000612089">lecanemab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.68</RegistryNumber><NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948.</RefSource><PMID Version="1">36449413</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2023 Feb 2;388(5):480. doi: 10.1056/NEJMc2215907.</RefSource><PMID Version="1">36599073</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="Y">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="Y">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020300" MajorTopicYN="N">Intracranial Hemorrhages</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010959" MajorTopicYN="Y">Tissue Plasminogen Activator</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>15</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36599061</ArticleId><ArticleId IdType="mid">NIHMS1897841</ArticleId><ArticleId IdType="pmc">PMC10228637</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2215148</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer&#x2019;s disease. N Engl J Med 2023;388:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">36449413</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36599073</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>388</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.</ArticleTitle><Pagination><StartPage>480</StartPage><MedlinePgn>480</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc2215907</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute, Phoenix, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT christopher.vandyck@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12PYH0FTU9</RegistryNumber><NameOfSubstance UI="C000612089">lecanemab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948.</RefSource><PMID Version="1">36449413</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148.</RefSource><PMID Version="1">36599061</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>15</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36599073</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2215907</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36608133</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Pathogenic tau-induced transposable element-derived dsRNA drives neuroinflammation.</ArticleTitle><Pagination><StartPage>eabq5423</StartPage><MedlinePgn>eabq5423</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabq5423</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abq5423</ELocationID><Abstract><AbstractText>Deposition of tau protein aggregates in the brain of affected individuals is a defining feature of "tauopathies," including Alzheimer's disease. Studies of human brain tissue and various model systems of tauopathy report that toxic forms of tau negatively affect nuclear and genomic architecture, identifying pathogenic tau-induced heterochromatin decondensation and consequent retrotransposon activation as a causal mediator of neurodegeneration. On the basis of their similarity to retroviruses, retrotransposons drive neuroinflammation via toxic intermediates, including double-stranded RNA (dsRNA). We find that dsRNA and dsRNA sensing machinery are elevated in astrocytes of postmortem brain tissue from patients with Alzheimer's disease and progressive supranuclear palsy and in brains of tau transgenic mice. Using a <i>Drosophila</i> model of tauopathy, we identify specific tau-induced retrotransposons that form dsRNA and find that pathogenic tau and heterochromatin decondensation causally drive dsRNA-mediated neurodegeneration and neuroinflammation. Our study suggests that pathogenic tau-induced heterochromatin decondensation and retrotransposon activation cause elevation of inflammatory, transposable element-derived dsRNA in the adult brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ochoa</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6765-0951</Identifier><AffiliationInfo><Affiliation>Sam and Ann Barshop Institute for Longevity and Aging Studies, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Paulino</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8532-9590</Identifier><AffiliationInfo><Affiliation>Sam and Ann Barshop Institute for Longevity and Aging Studies, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Elias</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1783-5664</Identifier><AffiliationInfo><Affiliation>Sam and Ann Barshop Institute for Longevity and Aging Studies, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Mange</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1830-207X</Identifier><AffiliationInfo><Affiliation>Sam and Ann Barshop Institute for Longevity and Aging Studies, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ray</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4491-167X</Identifier><AffiliationInfo><Affiliation>The Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieniek</LastName><ForeName>Kevin F</ForeName><Initials>KF</Initials><Identifier Source="ORCID">0000-0003-4922-864X</Identifier><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Bess</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1212-8138</Identifier><AffiliationInfo><Affiliation>Sam and Ann Barshop Institute for Longevity and Aging Studies, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS112391</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004251">DNA Transposable Elements</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018626">Retroelements</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006570">Heterochromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004251" MajorTopicYN="N">DNA Transposable Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018626" MajorTopicYN="N">Retroelements</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012330" MajorTopicYN="N">RNA, Double-Stranded</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006570" MajorTopicYN="N">Heterochromatin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>14</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36608133</ArticleId><ArticleId IdType="pmc">PMC9821943</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abq5423</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>V.&#xa0;Gorbunova, A.&#xa0;Seluanov, P.&#xa0;Mita, W.&#xa0;McKerrow, D.&#xa0;Feny&#xf6;, J. D.&#xa0;Boeke, S. B.&#xa0;Linker, F. H.&#xa0;Gage, J. A.&#xa0;Kreiling, A. P.&#xa0;Petrashen, T. A.&#xa0;Woodham, J. R.&#xa0;Taylor, S. L.&#xa0;Helfand, J. M.&#xa0;Sedivy, The role of retrotransposable elements in ageing and age-associated diseases. Nature 596, 43&#x2013;53 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8600649</ArticleId><ArticleId IdType="pubmed">34349292</ArticleId></ArticleIdList></Reference><Reference><Citation>S.&#xa0;Lanciano, G.&#xa0;Cristofari, Measuring and interpreting transposable element expression. Nat. Rev. Genet. 21, 721&#x2013;736 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32576954</ArticleId></ArticleIdList></Reference><Reference><Citation>H.&#xa0;Kaneko, S.&#xa0;Dridi, V.&#xa0;Tarallo, B. D.&#xa0;Gelfand, B. J.&#xa0;Fowler, W. G.&#xa0;Cho, M. E.&#xa0;Kleinman, S. L.&#xa0;Ponicsan, W. W.&#xa0;Hauswirth, V. A.&#xa0;Chiodo, K.&#xa0;Karik&#xf3;, J. W.&#xa0;Yoo, D. K.&#xa0;Lee, M.&#xa0;Hadziahmetovic, Y.&#xa0;Song, S.&#xa0;Misra, G.&#xa0;Chaudhuri, F. W.&#xa0;Buaas, R. E.&#xa0;Braun, D. R.&#xa0;Hinton, Q.&#xa0;Zhang, H. E.&#xa0;Grossniklaus, J. M.&#xa0;Provis, M. C.&#xa0;Madigan, A. H.&#xa0;Milam, N. L.&#xa0;Justice, R.&#xa0;J.&#xa0;C.&#xa0;Albuquerque, A. D.&#xa0;Blandford, S.&#xa0;Bogdanovich, Y.&#xa0;Hirano, J.&#xa0;Witta, E.&#xa0;Fuchs, D. R.&#xa0;Littman, B. K.&#xa0;Ambati, C. M.&#xa0;Rudin, M.&#xa0;M.&#xa0;W.&#xa0;Chong, P.&#xa0;Provost, J. F.&#xa0;Kugel, J. A.&#xa0;Goodrich, J. L.&#xa0;Dunaief, J. Z.&#xa0;Baffi, J.&#xa0;Ambati, DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325&#x2013;332 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077055</ArticleId><ArticleId IdType="pubmed">21297615</ArticleId></ArticleIdList></Reference><Reference><Citation>C.&#xa0;Guo, H.-H.&#xa0;Jeong, Y.-C.&#xa0;Hsieh, H.-U.&#xa0;Klein, D. A.&#xa0;Bennett, P. L.&#xa0;De Jager, Z.&#xa0;Liu, J. M.&#xa0;Shulman, Tau activates transposable elements in Alzheimer&#x2019;s disease. Cell Rep. 23, 2874&#x2013;2880 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181645</ArticleId><ArticleId IdType="pubmed">29874575</ArticleId></ArticleIdList></Reference><Reference><Citation>P.&#xa0;Ramirez, G.&#xa0;Zuniga, W.&#xa0;Sun, A.&#xa0;Beckmann, E.&#xa0;Ochoa, S. L.&#xa0;DeVos, B.&#xa0;Hyman, G.&#xa0;Chiu, E. R.&#xa0;Roy, W.&#xa0;Cao, M.&#xa0;Orr, V.&#xa0;Buggia-Prevot, W. J.&#xa0;Ray, B.&#xa0;Frost, Pathogenic tau accelerates aging-associated activation of transposable elements in the mouse central nervous system. Prog. Neurobiol. 208, 102181 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712387</ArticleId><ArticleId IdType="pubmed">34670118</ArticleId></ArticleIdList></Reference><Reference><Citation>W.&#xa0;Sun, H.&#xa0;Samimi, M.&#xa0;Gamez, H.&#xa0;Zare, B.&#xa0;Frost, Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. Nat. Neurosci. 21, 1038&#x2013;1048 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095477</ArticleId><ArticleId IdType="pubmed">30038280</ArticleId></ArticleIdList></Reference><Reference><Citation>J.&#xa0;Grundman, B.&#xa0;Spencer, F.&#xa0;Sarsoza, R. A.&#xa0;Rissman, Transcriptome analyses reveal tau isoform-driven changes in transposable element and gene expression. PLOS ONE 16, e0251611 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480850</ArticleId><ArticleId IdType="pubmed">34587152</ArticleId></ArticleIdList></Reference><Reference><Citation>T. L.&#xa0;Cuellar, A.-M.&#xa0;Herzner, X.&#xa0;Zhang, Y.&#xa0;Goyal, C.&#xa0;Watanabe, B. A.&#xa0;Friedman, V.&#xa0;Janakiraman, S.&#xa0;Durinck, J.&#xa0;Stinson, D.&#xa0;Arnott, T. K.&#xa0;Cheung, S.&#xa0;Chaudhuri, Z.&#xa0;Modrusan, J. M.&#xa0;Doerr, M.&#xa0;Classon, B.&#xa0;Haley, Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia. J. Cell Biol. 216, 3535&#x2013;3549 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674883</ArticleId><ArticleId IdType="pubmed">28887438</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;De Cecco, T.&#xa0;Ito, A. P.&#xa0;Petrashen, A. E.&#xa0;Elias, N. J.&#xa0;Skvir, S. W.&#xa0;Criscione, A.&#xa0;Caligiana, G.&#xa0;Brocculi, E. M.&#xa0;Adney, J. D.&#xa0;Boeke, O.&#xa0;Le, C.&#xa0;Beaus&#xe9;jour, J.&#xa0;Ambati, K.&#xa0;Ambati, M.&#xa0;Simon, A.&#xa0;Seluanov, V.&#xa0;Gorbunova, P. E.&#xa0;Slagboom, S. L.&#xa0;Helfand, N.&#xa0;Neretti, J. M.&#xa0;Sedivy, L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature 566, 73&#x2013;78 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6519963</ArticleId><ArticleId IdType="pubmed">30728521</ArticleId></ArticleIdList></Reference><Reference><Citation>C. A.&#xa0;Thomas, L.&#xa0;Tejwani, C. A.&#xa0;Trujillo, P. D.&#xa0;Negraes, R. H.&#xa0;Herai, P.&#xa0;Mesci, A.&#xa0;Macia, Y. J.&#xa0;Crow, A. R.&#xa0;Muotri, Modeling of TREX1-dependent autoimmune disease using human stem cells highlights L1 accumulation as a source of neuroinflammation. Cell Stem Cell 21, 319&#x2013;331.e8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5591075</ArticleId><ArticleId IdType="pubmed">28803918</ArticleId></ArticleIdList></Reference><Reference><Citation>K.&#xa0;Zhao, J.&#xa0;Du, Y.&#xa0;Peng, P.&#xa0;Li, S.&#xa0;Wang, Y.&#xa0;Wang, J.&#xa0;Hou, J.&#xa0;Kang, W.&#xa0;Zheng, S.&#xa0;Hua, X.-F.&#xa0;Yu, LINE1 contributes to autoimmunity through both RIG-I- and MDA5-mediated RNA sensing pathways. J. Autoimmun. 90, 105&#x2013;115 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29525183</ArticleId></ArticleIdList></Reference><Reference><Citation>H.&#xa0;Braak, E.&#xa0;Braak, Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>J.&#xa0;Sch&#xf6;nborn, J.&#xa0;Oberstas, E.&#xa0;Breyel, J.&#xa0;Tittgen, N.&#xa0;Schumacher, N.&#xa0;Lukacs, Monoclonal antibodies to double-stranded RNA as probes of RNA structure in crude nucleic acid extracts. Nucleic Acids Res. 19, 2993&#x2013;3000 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC328262</ArticleId><ArticleId IdType="pubmed">2057357</ArticleId></ArticleIdList></Reference><Reference><Citation>S.&#xa0;Ahmad, X.&#xa0;Mu, F.&#xa0;Yang, E.&#xa0;Greenwald, J. W.&#xa0;Park, E.&#xa0;Jacob, C.-Z.&#xa0;Zhang, S.&#xa0;Hur, Breaching self-tolerance to Alu duplex RNA underlies MDA5-mediated inflammation. Cell 172, 797&#x2013;810.e13 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807104</ArticleId><ArticleId IdType="pubmed">29395326</ArticleId></ArticleIdList></Reference><Reference><Citation>S.&#xa0;Hur, Double-stranded RNA sensors and modulators in innate immunity. Annu. Rev. Immunol. 37, 349&#x2013;375 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136661</ArticleId><ArticleId IdType="pubmed">30673536</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;Hong, V.&#xa0;Zhukareva, V.&#xa0;Vogelsberg-Ragaglia, Z.&#xa0;Wszolek, L.&#xa0;Reed, B. I.&#xa0;Miller, D. H.&#xa0;Geschwind, T. D.&#xa0;Bird, D.&#xa0;McKeel, A.&#xa0;Goate, J. C.&#xa0;Morris, K. C.&#xa0;Wilhelmsen, G. D.&#xa0;Schellenberg, J. Q.&#xa0;Trojanowski, V. M.-Y.&#xa0;Lee, Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282, 1914&#x2013;1917 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>K. J.&#xa0;Kopeikina, M.&#xa0;Polydoro, H. C.&#xa0;Tai, E.&#xa0;Yaeger, G. A.&#xa0;Carlson, R.&#xa0;Pitstick, B. T.&#xa0;Hyman, T. L.&#xa0;Spires-Jones, Synaptic alterations in the rTg4510 mouse model of tauopathy. J. Comp. Neurol. 521, 1334&#x2013;1353 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725804</ArticleId><ArticleId IdType="pubmed">23047530</ArticleId></ArticleIdList></Reference><Reference><Citation>T. L.&#xa0;Spires, J. D.&#xa0;Orne, K.&#xa0;SantaCruz, R.&#xa0;Pitstick, G. A.&#xa0;Carlson, K. H.&#xa0;Ashe, B. T.&#xa0;Hyman, Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am.&#xa0;J.&#xa0;Pathol. 168, 1598&#x2013;1607 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606598</ArticleId><ArticleId IdType="pubmed">16651626</ArticleId></ArticleIdList></Reference><Reference><Citation>K.&#xa0;Santacruz, J.&#xa0;Lewis, T.&#xa0;Spires, J.&#xa0;Paulson, L.&#xa0;Kotilinek, M.&#xa0;Ingelsson, A.&#xa0;Guimaraes, M.&#xa0;Deture, M.&#xa0;Ramsden, E.&#xa0;McGowan, C.&#xa0;Forster, M.&#xa0;Yue, J.&#xa0;Orne, C.&#xa0;Janus, A.&#xa0;Mariash, M.&#xa0;Kuskowski, B.&#xa0;Hyman, M.&#xa0;Hutton, K. H.&#xa0;Ashe, Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476&#x2013;481 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;Ramsden, L.&#xa0;Kotilinek, C.&#xa0;Forster, J.&#xa0;Paulson, E.&#xa0;McGowan, K.&#xa0;SantaCruz, A.&#xa0;Guimaraes, M.&#xa0;Yue, J.&#xa0;Lewis, G.&#xa0;Carlson, M.&#xa0;Hutton, K. H.&#xa0;Ashe, Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 25, 10637&#x2013;10647 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>I. J.&#xa0;Hartnell, D.&#xa0;Blum, J.&#xa0;A.&#xa0;R.&#xa0;Nicoll, G.&#xa0;Dorothee, D.&#xa0;Boche, Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain 144, 724&#x2013;745 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33527991</ArticleId></ArticleIdList></Reference><Reference><Citation>C. W.&#xa0;Wittmann, M. F.&#xa0;Wszolek, J. M.&#xa0;Shulman, P. M.&#xa0;Salvaterra, J.&#xa0;Lewis, M.&#xa0;Hutton, M. B.&#xa0;Feany, Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles. Science 293, 711&#x2013;714 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>V.&#xa0;Khurana, I.&#xa0;Elson-Schwab, T. A.&#xa0;Fulga, K. A.&#xa0;Sharp, C. A.&#xa0;Loewen, E.&#xa0;Mulkearns, J.&#xa0;Tyynel&#xe4;, C. R.&#xa0;Scherzer, M. B.&#xa0;Feany, Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLOS Genet. 6, 1&#x2013;11 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904797</ArticleId><ArticleId IdType="pubmed">20664788</ArticleId></ArticleIdList></Reference><Reference><Citation>B.&#xa0;Frost, M.&#xa0;Hemberg, J.&#xa0;Lewis, M. B.&#xa0;Feany, Tau promotes neurodegeneration through global chromatin relaxation. Nat. Neurosci. 17, 357&#x2013;366 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012297</ArticleId><ArticleId IdType="pubmed">24464041</ArticleId></ArticleIdList></Reference><Reference><Citation>M. R.&#xa0;Freeman, Drosophila central nervous system glia. Cold Spring Harb. Perspect. Biol. 7, a020552 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632667</ArticleId><ArticleId IdType="pubmed">25722465</ArticleId></ArticleIdList></Reference><Reference><Citation>V.&#xa0;Kis, B.&#xa0;Barti, M.&#xa0;Lippai, M.&#xa0;Sass, Specialized cortex glial cells accumulate lipid droplets in Drosophila melanogaster. PLOS ONE 10, e0131250 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493057</ArticleId><ArticleId IdType="pubmed">26148013</ArticleId></ArticleIdList></Reference><Reference><Citation>R.&#xa0;Hilu-Dadia, E.&#xa0;Kurant, Glial phagocytosis in developing and mature Drosophila CNS: Tight regulation for a healthy brain. Curr. Opin. Immunol. 62, 62&#x2013;68 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31862622</ArticleId></ArticleIdList></Reference><Reference><Citation>Y.-H.&#xa0;Chang, R. M.&#xa0;Keegan, L.&#xa0;Prazak, J.&#xa0;Dubnau, Cellular labeling of endogenous retrovirus replication (CLEVR) reveals de novo insertions of the gypsy retrotransposable element in cell culture and in both neurons and glial cells of aging fruit flies. PLOS Biol. 17, e3000278 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6541305</ArticleId><ArticleId IdType="pubmed">31095565</ArticleId></ArticleIdList></Reference><Reference><Citation>Y.-H.&#xa0;Chang, J.&#xa0;Dubnau, The gypsy endogenous retrovirus drives non-cell-autonomous propagation in a Drosophila TDP-43 model of neurodegeneration. Curr. Biol. 29, 3135&#x2013;3152.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783360</ArticleId><ArticleId IdType="pubmed">31495585</ArticleId></ArticleIdList></Reference><Reference><Citation>S.&#xa0;Deddouche, N.&#xa0;Matt, A.&#xa0;Budd, S.&#xa0;Mueller, C.&#xa0;Kemp, D.&#xa0;Galiana-Arnoux, C.&#xa0;Dostert, C.&#xa0;Antoniewski, J. A.&#xa0;Hoffmann, J.-L.&#xa0;Imler, The DExD/H-box helicase Dicer-2 mediates the induction of antiviral activity in Drosophila. Nat. Immunol. 9, 1425&#x2013;1432 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18953338</ArticleId></ArticleIdList></Reference><Reference><Citation>A.&#xa0;Mussabekova, L.&#xa0;Daeffler, J.-L.&#xa0;Imler, Innate and intrinsic antiviral immunity in Drosophila. Cell. Mol. Life Sci. 74, 2039&#x2013;2054 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419870</ArticleId><ArticleId IdType="pubmed">28102430</ArticleId></ArticleIdList></Reference><Reference><Citation>L.&#xa0;Fanti, M.&#xa0;Berloco, L.&#xa0;Piacentini, S.&#xa0;Pimpinelli, Chromosomal distribution of heterochromatin protein 1 (HP1) in Drosophila: A cytological map of euchromatic HP1 binding sites. Genetica 117, 135&#x2013;147 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12723693</ArticleId></ArticleIdList></Reference><Reference><Citation>A. B.&#xa0;Eberle, A.&#xa0;Jord&#xe1;n-Pla, A.&#xa0;Ga&#xf1;ez-Zapater, V.&#xa0;Hessle, G.&#xa0;Silberberg, A.&#xa0;von Euler, R. A.&#xa0;Silverstein, N.&#xa0;Visa, An Interaction between RRP6 and SU(VAR)3-9 targets RRP6 to heterochromatin and contributes to heterochromatin maintenance in Drosophila melanogaster. PLOS Genet. 11, e1005523 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4577213</ArticleId><ArticleId IdType="pubmed">26389589</ArticleId></ArticleIdList></Reference><Reference><Citation>C.&#xa0;Klattenhoff, H.&#xa0;Xi, C.&#xa0;Li, S.&#xa0;Lee, J.&#xa0;Xu, J. S.&#xa0;Khurana, F.&#xa0;Zhang, N.&#xa0;Schultz, B. S.&#xa0;Koppetsch, A.&#xa0;Nowosielska, H.&#xa0;Seitz, P. D.&#xa0;Zamore, Z.&#xa0;Weng, W. E.&#xa0;Theurkauf, The Drosophila HP1 homolog Rhino is required for transposon silencing and piRNA production by dual-strand clusters. Cell 138, 1137&#x2013;1149 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2770713</ArticleId><ArticleId IdType="pubmed">19732946</ArticleId></ArticleIdList></Reference><Reference><Citation>D.&#xa0;Vermaak, S.&#xa0;Henikoff, H. S.&#xa0;Malik, Positive selection drives the evolution of rhino, a member of the heterochromatin protein 1 family in Drosophila. PLOS Genet. 1, e9 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183528</ArticleId><ArticleId IdType="pubmed">16103923</ArticleId></ArticleIdList></Reference><Reference><Citation>T. K.&#xa0;Saldi, P. K.&#xa0;Gonzales, T. J.&#xa0;LaRocca, C. D.&#xa0;Link, Neurodegeneration, heterochromatin, and double-stranded RNA. J. Exp. Neurosci. 13, 1179069519830697 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376497</ArticleId><ArticleId IdType="pubmed">30792577</ArticleId></ArticleIdList></Reference><Reference><Citation>M. J.&#xa0;Heinrich, C. A.&#xa0;Purcell, A. J.&#xa0;Pruijssers, Y.&#xa0;Zhao, C. F.&#xa0;Spurlock III, S.&#xa0;Sriram, K. M.&#xa0;Ogden, T. S.&#xa0;Dermody, M. B.&#xa0;Scholz, P. S.&#xa0;Crooke III, J.&#xa0;Karijolich, T. M.&#xa0;Aune, Endogenous double-stranded Alu RNA elements stimulate IFN-responses in relapsing remitting multiple sclerosis. J. Autoimmun. 100, 40&#x2013;51 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513682</ArticleId><ArticleId IdType="pubmed">30826177</ArticleId></ArticleIdList></Reference><Reference><Citation>W.&#xa0;Li, L.&#xa0;Prazak, N.&#xa0;Chatterjee, S.&#xa0;Gr&#xfc;ninger, L.&#xa0;Krug, D.&#xa0;Theodorou, J.&#xa0;Dubnau, Activation of transposable elements during aging and neuronal decline in Drosophila. Nat. Neurosci. 16, 529&#x2013;531 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821974</ArticleId><ArticleId IdType="pubmed">23563579</ArticleId></ArticleIdList></Reference><Reference><Citation>J. G.&#xa0;Wood, B. C.&#xa0;Jones, N.&#xa0;Jiang, C.&#xa0;Chang, S.&#xa0;Hosier, P.&#xa0;Wickremesinghe, M.&#xa0;Garcia, D. A.&#xa0;Hartnett, L.&#xa0;Burhenn, N.&#xa0;Neretti, S. L.&#xa0;Helfand, Chromatin-modifying genetic interventions suppress age-associated transposable element activation and extend life span in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 113, 11277&#x2013;11282 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056045</ArticleId><ArticleId IdType="pubmed">27621458</ArticleId></ArticleIdList></Reference><Reference><Citation>S.&#xa0;Rodriguez, A.&#xa0;Sahin, B. R.&#xa0;Schrank, H.&#xa0;Al-Lawati, I.&#xa0;Costantino, E.&#xa0;Benz, D.&#xa0;Fard, A. D.&#xa0;Albers, L.&#xa0;Cao, A. C.&#xa0;Gomez, K.&#xa0;Evans, E.&#xa0;Ratti, M.&#xa0;Cudkowicz, M. P.&#xa0;Frosch, M.&#xa0;Talkowski, P. K.&#xa0;Sorger, B. T.&#xa0;Hyman, M. W.&#xa0;Albers, Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss. Sci. Transl. Med. 13, eaaz4699 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779652</ArticleId><ArticleId IdType="pubmed">34233951</ArticleId></ArticleIdList></Reference><Reference><Citation>T. J.&#xa0;LaRocca, A.&#xa0;Mariani, L. R.&#xa0;Watkins, C. D.&#xa0;Link, TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes. Neurobiol. Dis. 132, 104514 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6834892</ArticleId><ArticleId IdType="pubmed">31229690</ArticleId></ArticleIdList></Reference><Reference><Citation>A. B.&#xa0;Salmina, Y. K.&#xa0;Komleva, O. L.&#xa0;Lopatina, N. V.&#xa0;Kuvacheva, Y. V.&#xa0;Gorina, Y. A.&#xa0;Panina, Y. A.&#xa0;Uspenskaya, M. M.&#xa0;Petrova, I. V.&#xa0;Demko, A. S.&#xa0;Zamay, N. A.&#xa0;Malinovskaya, Astroglial control of neuroinflammation: TLR3-mediated dsRNA-sensing pathways are in the focus. Rev. Neurosci. 26, 143&#x2013;159 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25528762</ArticleId></ArticleIdList></Reference><Reference><Citation>F.&#xa0;Mouton-Liger, C.&#xa0;Paquet, J.&#xa0;Dumurgier, P.&#xa0;Lapalus, F.&#xa0;Gray, J.-L.&#xa0;Laplanche, J.&#xa0;Hugon; Groupe d&#x2019;Investigation du Liquide C&#xe9;phalorachidien Study Network , Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer&#x2019;s disease. Biol. Psychiatry 71, 829&#x2013;835 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22281122</ArticleId></ArticleIdList></Reference><Reference><Citation>J.&#xa0;Hugon, F.&#xa0;Mouton-Liger, J.&#xa0;Dumurgier, C.&#xa0;Paquet, PKR involvement in Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 9, 83 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5629792</ArticleId><ArticleId IdType="pubmed">28982375</ArticleId></ArticleIdList></Reference><Reference><Citation>G.&#xa0;Page, A.&#xa0;Rioux Bilan, S.&#xa0;Ingrand, C.&#xa0;Lafay-Chebassier, S.&#xa0;Pain, M. C.&#xa0;Perault Pochat, C.&#xa0;Bouras, T.&#xa0;Bayer, J.&#xa0;Hugon, Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer&#x2019;s disease. Neuroscience 139, 1343&#x2013;1354 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16581193</ArticleId></ArticleIdList></Reference><Reference><Citation>J. E.&#xa0;Rexach, D.&#xa0;Polioudakis, A.&#xa0;Yin, V.&#xa0;Swarup, T. S.&#xa0;Chang, T.&#xa0;Nguyen, A.&#xa0;Sarkar, L.&#xa0;Chen, J.&#xa0;Huang, L. C.&#xa0;Lin, W.&#xa0;Seeley, J. Q.&#xa0;Trojanowski, D.&#xa0;Malhotra, D. H.&#xa0;Geschwind, Tau pathology drives dementia risk-associated gene networks toward chronic inflammatory states and immunosuppression. Cell Rep. 33, 108398 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842189</ArticleId><ArticleId IdType="pubmed">33207193</ArticleId></ArticleIdList></Reference><Reference><Citation>G. G.&#xa0;Kovacs, Astroglia and tau: New perspectives. Front. Aging Neurosci. 12, 96 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160822</ArticleId><ArticleId IdType="pubmed">32327993</ArticleId></ArticleIdList></Reference><Reference><Citation>H.&#xa0;Scheiblich, M.&#xa0;Trombly, A.&#xa0;Ramirez, M. T.&#xa0;Heneka, Neuroimmune connections in aging and neurodegenerative diseases. Trends Immunol. 41, 300&#x2013;312 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32147113</ArticleId></ArticleIdList></Reference><Reference><Citation>M. T.&#xa0;Heneka, M. J.&#xa0;Carson, J.&#xa0;El Khoury, G. E.&#xa0;Landreth, F.&#xa0;Brosseron, D. L.&#xa0;Feinstein, A. H.&#xa0;Jacobs, T.&#xa0;Wyss-Coray, J.&#xa0;Vitorica, R. M.&#xa0;Ransohoff, K.&#xa0;Herrup, S. A.&#xa0;Frautschy, B.&#xa0;Finsen, G. C.&#xa0;Brown, A.&#xa0;Verkhratsky, K.&#xa0;Yamanaka, J.&#xa0;Koistinaho, E.&#xa0;Latz, A.&#xa0;Halle, G. C.&#xa0;Petzold, T.&#xa0;Town, D.&#xa0;Morgan, M. L.&#xa0;Shinohara, V. H.&#xa0;Perry, C.&#xa0;Holmes, N. G.&#xa0;Bazan, D. J.&#xa0;Brooks, S.&#xa0;Hunot, B.&#xa0;Joseph, N.&#xa0;Deigendesch, O.&#xa0;Garaschuk, E.&#xa0;Boddeke, C. A.&#xa0;Dinarello, J. C.&#xa0;Breitner, G. M.&#xa0;Cole, D. T.&#xa0;Golenbock, M. P.&#xa0;Kummer, Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 14, 388&#x2013;405 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>M. J.&#xa0;Reid, P.&#xa0;Beltran-Lobo, L.&#xa0;Johnson, B. G.&#xa0;Perez-Nievas, W.&#xa0;Noble, Astrocytes in tauopathies. Front. Neurol. 11, 572850 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7542303</ArticleId><ArticleId IdType="pubmed">33071951</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;Sidoryk-Wegrzynowicz, Y. N.&#xa0;Gerber, M.&#xa0;Ries, M.&#xa0;Sastre, A. M.&#xa0;Tolkovsky, M. G.&#xa0;Spillantini, Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions. Acta Neuropathol. Commun. 5, 89 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389177</ArticleId><ArticleId IdType="pubmed">29187256</ArticleId></ArticleIdList></Reference><Reference><Citation>H.&#xa0;Kim, E.&#xa0;Yang, J.&#xa0;Lee, S.-H.&#xa0;Kim, J.-S.&#xa0;Shin, J. Y.&#xa0;Park, S. J.&#xa0;Choi, S. J.&#xa0;Kim, I.-H.&#xa0;Choi, Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes. Immunology 124, 480&#x2013;488 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2492940</ArticleId><ArticleId IdType="pubmed">18248388</ArticleId></ArticleIdList></Reference><Reference><Citation>T. J.&#xa0;McCullers, M.&#xa0;Steiniger, Transposable elements in Drosophila. Mob. Genet. Elements 7, 1&#x2013;18 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5443660</ArticleId><ArticleId IdType="pubmed">28580197</ArticleId></ArticleIdList></Reference><Reference><Citation>S.&#xa0;Cacchione, G.&#xa0;Cenci, G. D.&#xa0;Raffa, Silence at the end: How Drosophila regulates expression and transposition of telomeric retroelements. J. Mol. Biol. 432, 4305&#x2013;4321 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32512004</ArticleId></ArticleIdList></Reference><Reference><Citation>S.&#xa0;Sadeq, S.&#xa0;Al-Hashimi, C. M.&#xa0;Cusack, A.&#xa0;Werner, Endogenous double-stranded RNA. Non-Coding RNA 7, 15 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930956</ArticleId><ArticleId IdType="pubmed">33669629</ArticleId></ArticleIdList></Reference><Reference><Citation>T. K.&#xa0;Saldi, P.&#xa0;Gonzales, A.&#xa0;Garrido-Lecca, V.&#xa0;Dostal, C. M.&#xa0;Roberts, L.&#xa0;Petrucelli, C. D.&#xa0;Link, The Caenorhabditis elegans ortholog of TDP-43 regulates the chromatin localization of the heterochromatin protein 1 homolog HPL-2. Mol. Cell. Biol. 38, e00668-17 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048318</ArticleId><ArticleId IdType="pubmed">29760282</ArticleId></ArticleIdList></Reference><Reference><Citation>Y.-J.&#xa0;Zhang, L.&#xa0;Guo, P. K.&#xa0;Gonzales, T. F.&#xa0;Gendron, Y.&#xa0;Wu, K.&#xa0;Jansen-West, A. D.&#xa0;O&#x2019;Raw, S. R.&#xa0;Pickles, M.&#xa0;Prudencio, Y.&#xa0;Carlomagno, M. A.&#xa0;Gachechiladze, C.&#xa0;Ludwig, R.&#xa0;Tian, J.&#xa0;Chew, M.&#xa0;DeTure, W.-L.&#xa0;Lin, J.&#xa0;Tong, L. M.&#xa0;Daughrity, M.&#xa0;Yue, Y.&#xa0;Song, J. W.&#xa0;Andersen, M.&#xa0;Castanedes-Casey, A.&#xa0;Kurti, A.&#xa0;Datta, G.&#xa0;Antognetti, A.&#xa0;McCampbell, R.&#xa0;Rademakers, B.&#xa0;Oskarsson, D. W.&#xa0;Dickson, M.&#xa0;Kampmann, M. E.&#xa0;Ward, J. D.&#xa0;Fryer, C. D.&#xa0;Link, J.&#xa0;Shorter, L.&#xa0;Petrucelli, Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science 363, eaav2606 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>F.&#xa0;Mohn, G.&#xa0;Sienski, D.&#xa0;Handler, J.&#xa0;Brennecke, The rhino-deadlock-cutoff complex licenses noncanonical transcription of dual-strand piRNA clusters in Drosophila. Cell 157, 1364&#x2013;1379 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24906153</ArticleId></ArticleIdList></Reference><Reference><Citation>B.&#xa0;Brower-Toland, S. D.&#xa0;Findley, L.&#xa0;Jiang, L.&#xa0;Liu, H.&#xa0;Yin, M.&#xa0;Dus, P.&#xa0;Zhou, S.&#xa0;C.&#xa0;R.&#xa0;Elgin, H.&#xa0;Lin, Drosophila PIWI associates with chromatin and interacts directly with HP1a. Genes Dev. 21, 2300&#x2013;2311 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973144</ArticleId><ArticleId IdType="pubmed">17875665</ArticleId></ArticleIdList></Reference><Reference><Citation>G.&#xa0;Kassiotis, J. P.&#xa0;Stoye, Immune responses to endogenous retroelements: Taking the bad with the good. Nat. Rev. Immunol. 16, 207&#x2013;219 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27026073</ArticleId></ArticleIdList></Reference><Reference><Citation>E. Y.&#xa0;Liu, J.&#xa0;Russ, C. P.&#xa0;Cali, J. M.&#xa0;Phan, A.&#xa0;Amlie-Wolf, E. B.&#xa0;Lee, Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep. 27, 1409&#x2013;1421.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;Prudencio, P. K.&#xa0;Gonzales, C. N.&#xa0;Cook, T. F.&#xa0;Gendron, L. M.&#xa0;Daughrity, Y.&#xa0;Song, M.&#xa0;T.&#xa0;W.&#xa0;Ebbert, M.&#xa0;van Blitterswijk, Y.-J.&#xa0;Zhang, K.&#xa0;Jansen-West, M. C.&#xa0;Baker, M.&#xa0;DeTure, R.&#xa0;Rademakers, K. B.&#xa0;Boylan, D. W.&#xa0;Dickson, L.&#xa0;Petrucelli, C. D.&#xa0;Link, Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Hum. Mol. Genet. 26, 3421&#x2013;3431 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886204</ArticleId><ArticleId IdType="pubmed">28637276</ArticleId></ArticleIdList></Reference><Reference><Citation>G.&#xa0;Dietzl, D.&#xa0;Chen, F.&#xa0;Schnorrer, K.-C.&#xa0;Su, Y.&#xa0;Barinova, M.&#xa0;Fellner, B.&#xa0;Gasser, K.&#xa0;Kinsey, S.&#xa0;Oppel, S.&#xa0;Scheiblauer, A.&#xa0;Couto, V.&#xa0;Marra, K.&#xa0;Keleman, B. J.&#xa0;Dickson, A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448, 151&#x2013;156 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17625558</ArticleId></ArticleIdList></Reference><Reference><Citation>W. D.&#xa0;Arndt, S. D.&#xa0;White, B. P.&#xa0;Johnson, T.&#xa0;Huynh, J.&#xa0;Liao, H.&#xa0;Harrington, S.&#xa0;Cotsmire, K. V.&#xa0;Kibler, J.&#xa0;Langland, B. L.&#xa0;Jacobs, Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus. Virology 497, 125&#x2013;135 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026613</ArticleId><ArticleId IdType="pubmed">27467578</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;Bokarewa, A.&#xa0;Tarkowski, M.&#xa0;Lind, L.&#xa0;Dahlberg, M.&#xa0;Magnusson, Arthritogenic dsRNA is present in synovial fluid from rheumatoid arthritis patients with an erosive disease course. Eur.&#xa0;J.&#xa0;Immunol. 38, 3237&#x2013;3244 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18991285</ArticleId></ArticleIdList></Reference><Reference><Citation>Y.&#xa0;Gao, S.&#xa0;Chen, S.&#xa0;Halene, T.&#xa0;Tebaldi, Transcriptome-wide quantification of double-stranded RNAs in live mouse tissues by dsRIP-Seq. STAR Protoc. 2, e100366 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7982789</ArticleId><ArticleId IdType="pubmed">33778776</ArticleId></ArticleIdList></Reference><Reference><Citation>Y.&#xa0;Gao, R.&#xa0;Vasic, Y.&#xa0;Song, R.&#xa0;Teng, C.&#xa0;Liu, R.&#xa0;Gbyli, G.&#xa0;Biancon, R.&#xa0;Nelakanti, K.&#xa0;Lobben, E.&#xa0;Kudo, W.&#xa0;Liu, A.&#xa0;Ardasheva, X.&#xa0;Fu, X.&#xa0;Wang, P.&#xa0;Joshi, V.&#xa0;Lee, B.&#xa0;Dura, G.&#xa0;Viero, A.&#xa0;Iwasaki, R.&#xa0;Fan, A.&#xa0;Xiao, R. A.&#xa0;Flavell, H.-B.&#xa0;Li, T.&#xa0;Tebaldi, S.&#xa0;Halene, m6A modification prevents formation of endogenous double-stranded RNAs and deleterious innate immune responses during hematopoietic development. Immunity 52, 1007&#x2013;1021.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7408742</ArticleId><ArticleId IdType="pubmed">32497523</ArticleId></ArticleIdList></Reference><Reference><Citation>R.&#xa0;Mahoney, E.&#xa0;Ochoa, P.&#xa0;Ramirez, H. E.&#xa0;Miller, A.&#xa0;Beckmann, G.&#xa0;Zuniga, R.&#xa0;Dobrowolski, B.&#xa0;Frost, Pathogenic tau causes a toxic depletion of nuclear calcium. Cell Rep. 32, 107900 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7428851</ArticleId><ArticleId IdType="pubmed">32668249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36603070</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>379</Volume><Issue>6627</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>A mesothelium divides the subarachnoid space into functional compartments.</ArticleTitle><Pagination><StartPage>84</StartPage><EndPage>88</EndPage><MedlinePgn>84-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.adc8810</ELocationID><Abstract><AbstractText>The central nervous system is lined by meninges, classically known as dura, arachnoid, and pia mater. We show the existence of a fourth meningeal layer that compartmentalizes the subarachnoid space in the mouse and human brain, designated the subarachnoid lymphatic-like membrane (SLYM). SLYM is morpho- and immunophenotypically similar to the mesothelial membrane lining of peripheral organs and body cavities, and it encases blood vessels and harbors immune cells. Functionally, the close apposition of SLYM with the endothelial lining of the meningeal venous sinus permits direct exchange of small solutes between cerebrospinal fluid and venous blood, thus representing the mouse equivalent of the arachnoid granulations. The functional characterization of SLYM provides fundamental insights into brain immune barriers and fluid transport.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>M&#xf8;llg&#xe5;rd</LastName><ForeName>Kjeld</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6645-8626</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Beinlich</LastName><ForeName>Felix R M</ForeName><Initials>FRM</Initials><Identifier Source="ORCID">0000-0002-6411-0909</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kusk</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9759-0331</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Miyakoshi</LastName><ForeName>Leo M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0003-0423-6240</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delle</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2910-0024</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pl&#xe1;</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5501-0789</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauglund</LastName><ForeName>Natalie L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">0000-0002-2198-6329</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmail</LastName><ForeName>Tina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9512-103X</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Martin K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomolka</LastName><ForeName>Ryszard S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0001-9797-1062</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4208-0005</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedergaard</LastName><ForeName>Maiken</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6502-6031</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY 14642, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004388" MajorTopicYN="N">Dura Mater</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013346" MajorTopicYN="Y">Subarachnoid Space</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004848" MajorTopicYN="N">Epithelium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36603070</ArticleId><ArticleId IdType="doi">10.1126/science.adc8810</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36627208</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A Gating Mutation in Ryanodine Receptor Type 2 Rescues Phenotypes of Alzheimer's Disease Mouse Models by Upregulating Neuronal Autophagy.</ArticleTitle><Pagination><StartPage>1441</StartPage><EndPage>1454</EndPage><MedlinePgn>1441-1454</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1820-22.2022</ELocationID><Abstract><AbstractText>It is well established that ryanodine receptors (RyanRs) are overactive in Alzheimer's disease (AD), and it has been suggested that inhibition of RyanR is potentially beneficial for AD treatment. In the present study, we explored a potential connection between basal RyanR activity and autophagy in neurons. Autophagy plays an important role in clearing damaged organelles and long-lived protein aggregates, and autophagy dysregulation occurs in both AD patients and AD animal models. Autophagy is known to be regulated by intracellular calcium (Ca<sup>2+</sup>) signals, and our results indicated that basal RyanR2 activity in hippocampal neurons inhibited autophagy through activation of calcineurin and the resulting inhibition of the AMPK (AMP-activated protein kinase)-ULK1 (unc-51-like autophagy-activating kinase 1) pathway. Thus, we hypothesized that increased basal RyanR2 activity in AD may lead to the inhibition of neuronal autophagy and accumulation of &#x3b2;-amyloid. To test this hypothesis, we took advantage of the RyanR2-E4872Q knock-in mouse model (EQ) in which basal RyanR2 activity is reduced because of shortened channel open time. We discovered that crossing EQ mice with the APPKI and APPPS1 mouse models of AD (both males and females) rescued amyloid accumulation and LTP impairment in these mice. Our results revealed that reduced basal activity of RyanR2-EQ channels disinhibited the autophagic pathway and led to increased amyloid clearance in these models. These data indicated a potential pathogenic outcome of RyanR2 overactivation in AD and also provided additional targets for therapeutic intervention in AD. Basal activity of ryanodine receptors controls neuronal autophagy and contributes to development of the AD phenotype.<b>SIGNIFICANCE STATEMENT</b> It is well established that neuronal autophagy is impaired in Alzheimer's disease (AD). Our results suggest that supranormal calcium (Ca<sup>2+</sup>) release from endoplasmic reticulum contributes to the inhibition of autophagy in AD and that reduction in basal activity of type 2 ryanodine receptors disinhibits the neuronal autophagic pathway and leads to increased amyloid clearance in AD models. Our findings directly link neuronal Ca<sup>2+</sup> dysregulation with autophagy dysfunction in AD and point to additional targets for therapeutic intervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Caitlynn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>S R Wayne</ForeName><Initials>SRW</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta T2N 1N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezprozvanny</LastName><ForeName>Ilya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center, Dallas, Texas 75390 Ilya.Bezprozvanny@UTSouthwestern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Neurodegeneration, St. Petersburg State Polytechnical Universty, St. Petersburg 195251, Russian Federation.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG071310</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PJT-152914</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="Y">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="Y">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">calcium</Keyword><Keyword MajorTopicYN="N">ryanodine receptor</Keyword><Keyword MajorTopicYN="N">transgenic</Keyword></KeywordList><CoiStatement>I.B. is a member of the scientific advisory board of Neurodon, LLC. S.R.W.C. filed a Patent Cooperation Treaty application for &#x201c;Methods of Treating and/or Preventing Alzheimer&#x2019;s Disease with R-carvedilol.&#x201d; The authors declare no other competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36627208</ArticleId><ArticleId IdType="pmc">PMC9987572</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1820-22.2022</ArticleId><ArticleId IdType="pii">JNEUROSCI.1820-22.2022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Bari MAA, Xu PY (2020) Molecular regulation of autophagy machinery by mTOR-dependent and -independent pathways. Ann N&#xa0;Y Acad Sci 1467:3&#x2013;20. 10.1111/nyas.14305</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14305</ArticleId><ArticleId IdType="pubmed">31985829</ArticleId></ArticleIdList></Reference><Reference><Citation>Amidfar M, de Oliveira J, Kucharska E, Budni J, Kim YK (2020) The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease. Life Sci 257:118020. 10.1016/j.lfs.2020.118020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118020</ArticleId><ArticleId IdType="pubmed">32603820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I (2012) Presenilins: a novel link between intracellular calcium signaling and lysosomal function? J Cell Biol 198:7&#x2013;10. 10.1083/jcb.201206003</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201206003</ArticleId><ArticleId IdType="pmc">PMC3392935</ArticleId><ArticleId IdType="pubmed">22778275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 31:454&#x2013;463. 10.1016/j.tins.2008.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2008.06.005</ArticleId><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci 28:6926&#x2013;6937. 10.1523/JNEUROSCI.0800-08.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0800-08.2008</ArticleId><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="pubmed">18596167</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239&#x2013;259. 10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K (2015) The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain 138:2814&#x2013;2833. 10.1093/brain/awv236</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv236</ArticleId><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs CA, Chakroborty S, Stutzmann GE (2017) Emerging pathways driving early synaptic pathology in Alzheimer's disease. Biochem Biophys Res Commun 483:988&#x2013;997. 10.1016/j.bbrc.2016.09.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.09.088</ArticleId><ArticleId IdType="pmc">PMC5303639</ArticleId><ArticleId IdType="pubmed">27659710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno AM, Huang JY, Bennett DA, Marr RA, Hastings ML, Stutzmann GE (2012) Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 33:e1001.e1&#x2013;1001.e6. 10.1016/j.neurobiolaging.2011.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.03.011</ArticleId><ArticleId IdType="pmc">PMC3160507</ArticleId><ArticleId IdType="pubmed">21531043</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G, Moser EI (2013) Memory, navigation and theta rhythm in the hippocampal-entorhinal system. Nat Neurosci 16:130&#x2013;138. 10.1038/nn.3304</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3304</ArticleId><ArticleId IdType="pmc">PMC4079500</ArticleId><ArticleId IdType="pubmed">23354386</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe1;rdenas C, Miller RA, Smith I, Bui T, Molg&#xf3; J, M&#xfc;ller M, Vais H, Cheung KH, Yang J, Parker I, Thompson CB,&#xa0;Birnbaum MJ,&#xa0;Hallows KR,&#xa0;Foskett JK (2010) Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell 142:270&#x2013;283. 10.1016/j.cell.2010.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.007</ArticleId><ArticleId IdType="pmc">PMC2911450</ArticleId><ArticleId IdType="pubmed">20655468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M, Mathews PM, Nixon RA (2004) Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol 63:821&#x2013;830. 10.1093/jnen/63.8.821</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/63.8.821</ArticleId><ArticleId IdType="pubmed">15330337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Goussakov I, Miller MB, Stutzmann GE (2009) Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci 29:9458&#x2013;9470. 10.1523/JNEUROSCI.2047-09.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2047-09.2009</ArticleId><ArticleId IdType="pmc">PMC6666542</ArticleId><ArticleId IdType="pubmed">19641109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J, Wicks J, Richardson JC, Conklin V, Cameransi BG, Stutzmann GE (2012) Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease. PLoS One 7:e52056. 10.1371/journal.pone.0052056</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052056</ArticleId><ArticleId IdType="pmc">PMC3528716</ArticleId><ArticleId IdType="pubmed">23284867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, He HJ, Ye QQ, Feng FF, Wang WW, Gu YY, Han RY, Xie CL (2021) Defective autophagy and mitophagy in Alzheimer's disease: mechanisms and translational implications. Mol Neurobiol 58:5289&#x2013;5302. 10.1007/s12035-021-02487-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02487-7</ArticleId><ArticleId IdType="pubmed">34279771</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WQ, et al.. (2014) The ryanodine receptor store-sensing gate controls Ca2+ waves and Ca2+-triggered arrhythmias. Nat Med 20:184&#x2013;192. 10.1038/nm.3440</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3440</ArticleId><ArticleId IdType="pmc">PMC4269524</ArticleId><ArticleId IdType="pubmed">24441828</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung KM, Jeong EJ, Park H, An HK, Yu SW (2016) Mediation of autophagic cell death by type 3 ryanodine receptor (RyR3) in adult hippocampal neural stem cells. Front Cell Neurosci 10:116. 10.3389/fncel.2016.00116</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00116</ArticleId><ArticleId IdType="pmc">PMC4858590</ArticleId><ArticleId IdType="pubmed">27199668</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen K, Flannagan RS, Baron S, Carraro-Lacroix LR, Wang D, Vermeire W, Michiels C, Munck S, Baert V, Sugita S, Wuytack F,&#xa0;Hiesinger PR,&#xa0;Grinstein S,&#xa0;Annaert W (2012) Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J Cell Biol 198:23&#x2013;35. 10.1083/jcb.201201076</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201201076</ArticleId><ArticleId IdType="pmc">PMC3392942</ArticleId><ArticleId IdType="pubmed">22753898</ArticleId></ArticleIdList></Reference><Reference><Citation>Colino A, Malenka RC (1993) Mechanisms underlying induction of long-term potentiation in rat medial and lateral perforant paths in vitro. J Neurophysiol 69:1150&#x2013;1159. 10.1152/jn.1993.69.4.1150</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.1993.69.4.1150</ArticleId><ArticleId IdType="pubmed">8492154</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S,&#xa0;Bacci A,&#xa0;Ammassari-Teule M,&#xa0;Marie H,&#xa0;Cecconi F (2011) Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 14:69&#x2013;76. 10.1038/nn.2709</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2709</ArticleId><ArticleId IdType="pubmed">21151119</ArticleId></ArticleIdList></Reference><Reference><Citation>Decuypere JP, Bultynck G, Parys JB (2011a) A dual role for Ca(2+) in autophagy regulation. Cell Calcium 50:242&#x2013;250. 10.1016/j.ceca.2011.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2011.04.001</ArticleId><ArticleId IdType="pubmed">21571367</ArticleId></ArticleIdList></Reference><Reference><Citation>Decuypere JP, Welkenhuyzen K, Luyten T, Ponsaerts R, Dewaele M, Molgo J, Agostinis P, Missiaen L, De Smedt H, Parys JB, Bultynck G (2011b) Ins(1,4,5)P3 receptor-mediated Ca2+ signaling and autophagy induction are interrelated. Autophagy 7:1472&#x2013;1489. 10.4161/auto.7.12.17909</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.7.12.17909</ArticleId><ArticleId IdType="pmc">PMC3327615</ArticleId><ArticleId IdType="pubmed">22082873</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Hogan D, Zhang WR, Taglialatela G (2007) Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 88:217&#x2013;224. 10.1016/j.nlm.2007.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2007.03.010</ArticleId><ArticleId IdType="pmc">PMC2031869</ArticleId><ArticleId IdType="pubmed">17521929</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Kayed R, Neugebauer V, Fu Y, Zhang W, Reese LC, Taglialatela G (2010) Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res 88:2923&#x2013;2932. 10.1002/jnr.22445</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22445</ArticleId><ArticleId IdType="pmc">PMC2919647</ArticleId><ArticleId IdType="pubmed">20544830</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, Asara JM,&#xa0;Fitzpatrick J,&#xa0;Dillin A,&#xa0;Viollet B,&#xa0;Kundu M,&#xa0;Hansen M,&#xa0;Shaw RJ (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331:456&#x2013;461. 10.1126/science.1196371</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1196371</ArticleId><ArticleId IdType="pmc">PMC3030664</ArticleId><ArticleId IdType="pubmed">21205641</ArticleId></ArticleIdList></Reference><Reference><Citation>Evrard C, Kienlen-Campard P, Coevoet M, Opsomer R, Tasiaux B, Melnyk P, Octave JN, Bu&#xe9;e L, Sergeant N, Vingtdeux V (2018) Contribution of the endosomal-lysosomal and proteasomal systems in amyloid-&#x3b2; precursor protein derived fragments processing. Front Cell Neurosci 12:435. 10.3389/fncel.2018.00435</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00435</ArticleId><ArticleId IdType="pmc">PMC6263093</ArticleId><ArticleId IdType="pubmed">30524243</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, Lautrup S, Hasan-Olive MM, Caponio D, Dan X, Rockt&#xe4;schel P,&#xa0;Croteau DL,&#xa0;Akbari M,&#xa0;Greig NH,&#xa0;Fladby T,&#xa0;Nilsen H,&#xa0;Cader MZ,&#xa0;Mattson MP,&#xa0;Tavernarakis N,&#xa0;Bohr VA (2019) Mitophagy inhibits amyloid-&#x3b2; and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci 22:401&#x2013;412. 10.1038/s41593-018-0332-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0332-9</ArticleId><ArticleId IdType="pmc">PMC6693625</ArticleId><ArticleId IdType="pubmed">30742114</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedeli C, Filadi R, Rossi A, Mammucari C, Pizzo P (2019) PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca2+ homeostasis. Autophagy 15:2044&#x2013;2062. 10.1080/15548627.2019.1596489</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1596489</ArticleId><ArticleId IdType="pmc">PMC6844518</ArticleId><ArticleId IdType="pubmed">30892128</ArticleId></ArticleIdList></Reference><Reference><Citation>Filadi R, Pizzo P (2019) Defective autophagy and Alzheimer's disease: is calcium the key? Neural Regen Res 14:2081&#x2013;2082. 10.4103/1673-5374.262584</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.262584</ArticleId><ArticleId IdType="pmc">PMC6788238</ArticleId><ArticleId IdType="pubmed">31397341</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuichi T, Furutama D, Hakamata Y, Nakai J, Takeshima H, Mikoshiba K (1994) Multiple types of ryanodine receptor/Ca2+ release channels are differentially expressed in rabbit brain. J Neurosci 14:4794&#x2013;4805. 10.1523/JNEUROSCI.14-08-04794.1994</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.14-08-04794.1994</ArticleId><ArticleId IdType="pmc">PMC6577160</ArticleId><ArticleId IdType="pubmed">8046450</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini G, Conti A, Mammarella S, Scrobogna M, Sorrentino V (1995) The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J Cell Biol 128:893&#x2013;904. 10.1083/jcb.128.5.893</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.128.5.893</ArticleId><ArticleId IdType="pmc">PMC2120385</ArticleId><ArticleId IdType="pubmed">7876312</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Capell A, Citron M, Teplow DB, Selkoe DJ (1995) The vacuolar H(+)-ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type beta-amyloid precursor protein. J Biol Chem 270:6186&#x2013;6192. 10.1074/jbc.270.11.6186</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.11.6186</ArticleId><ArticleId IdType="pubmed">7890753</ArticleId></ArticleIdList></Reference><Reference><Citation>He H, Liu X, Lv L, Liang H, Leng B, Zhao D, Zhang Y, Du Z, Chen X, Li S, Lu Y, Shan H (2014) Calcineurin suppresses AMPK-dependent cytoprotective autophagy in cardiomyocytes under oxidative stress. Cell Death Dis 5:e997. 10.1038/cddis.2013.533</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.533</ArticleId><ArticleId IdType="pmc">PMC4040710</ArticleId><ArticleId IdType="pubmed">24434520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, Sorrentino V, O'Neill C (1999) Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience 92:499&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408600</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MT, Joseph SK (2010) Role of inositol trisphosphate receptors in autophagy in DT40 cells. J Biol Chem 285:16912&#x2013;16920. 10.1074/jbc.M110.114207</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.114207</ArticleId><ArticleId IdType="pmc">PMC2878024</ArticleId><ArticleId IdType="pubmed">20308071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Violette CJ, Ziff EB (2015) Reduction of increased calcineurin activity rescues impaired homeostatic synaptic plasticity in presenilin 1 M146V mutant. Neurobiol Aging 36:3239&#x2013;3246. 10.1016/j.neurobiolaging.2015.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.09.007</ArticleId><ArticleId IdType="pmc">PMC4641803</ArticleId><ArticleId IdType="pubmed">26455952</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, et al. (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17:1&#x2013;382. 10.1080/15548627.2020.1797280</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2020.1797280</ArticleId><ArticleId IdType="pmc">PMC7996087</ArticleId><ArticleId IdType="pubmed">33634751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang H, Tan CY, Tian HZ, Liu LH, Yang MW, Hong FF, Yang SL (2020) Exploring the bi-directional relationship between autophagy and Alzheimer's disease. Cns Neurosci Ther 26:155&#x2013;166. 10.1111/cns.13216</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13216</ArticleId><ArticleId IdType="pmc">PMC6978262</ArticleId><ArticleId IdType="pubmed">31503421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacampagne A, Liu XP, Reiken S, Bussiere R, Meli AC, Lauritzen I, Teich AF, Zalk R, Saint N, Arancio O, Bauer C,&#xa0;Duprat F,&#xa0;Briggs CA,&#xa0;Chakroborty S,&#xa0;Stutzmann GE,&#xa0;Shelanski ML,&#xa0;Checler F,&#xa0;Chami M,&#xa0;Marks AR (2017) Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer's disease-like pathologies and cognitive deficits. Acta Neuropathol 134:749&#x2013;767. 10.1007/s00401-017-1733-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1733-7</ArticleId><ArticleId IdType="pubmed">28631094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam D, Kosta A, Luciani MF, Golstein P (2008) The inositol 1,4,5-trisphosphate receptor is required to signal autophagic cell death. Mol Biol Cell 19:691&#x2013;700. 10.1091/mbc.e07-08-0823</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e07-08-0823</ArticleId><ArticleId IdType="pmc">PMC2230578</ArticleId><ArticleId IdType="pubmed">18077554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I, Pardossi-Piquard R, Bourgeois A, Pagnotta S, Biferi MG, Barkats M, Lacor P, Klein W, Bauer C, Checler F (2016) Intraneuronal aggregation of the &#x3b2;-CTF fragment of APP (C99) induces A&#x3b2;-independent lysosomal-autophagic pathology. Acta Neuropathol 132:257&#x2013;276. 10.1007/s00401-016-1577-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1577-6</ArticleId><ArticleId IdType="pmc">PMC4947121</ArticleId><ArticleId IdType="pubmed">27138984</ArticleId></ArticleIdList></Reference><Reference><Citation>Law BYK, Michelangeli F, Qu YQ, Xu SW, Han Y, Mok SWFA, Dias IRDR, Javed MU, Chan WK, Xue WW, Yao X-J, Zeng W, Zhang H, Wang J-R, Liu L, Wong&#xa0; VKW (2019) Neferine induces autophagy-dependent cell death in apoptosis-resistant cancers via ryanodine receptor and Ca2+-dependent mechanism. Sci Rep 9:20034. 10.1038/s41598-019-56675-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56675-6</ArticleId><ArticleId IdType="pmc">PMC6934498</ArticleId><ArticleId IdType="pubmed">31882989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y,&#xa0;Westaway D,&#xa0;Cuervo AM,&#xa0;Nixon RA (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141:1146&#x2013;1158. 10.1016/j.cell.2010.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.05.008</ArticleId><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, McBrayer MK, Wolfe DM, Haslett LJ, Kumar A, Sato Y, Lie PP, Mohan P, Coffey EE, Kompella U, Mitchell CH,&#xa0;Lloyd-Evans E,&#xa0;Nixon RA (2015) Presenilin 1 maintains lysosomal Ca(2+) homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep 12:1430&#x2013;1444. 10.1016/j.celrep.2015.07.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.07.050</ArticleId><ArticleId IdType="pmc">PMC4558203</ArticleId><ArticleId IdType="pubmed">26299959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yang DS, Goulbourne CN, Im E, Stavrides P, Pensalfini A, Chan H, Bouchet-Marquis C, Bleiwas C, Berg MJ, Huo C,&#xa0;Peddy J,&#xa0;Pawlik M,&#xa0;Levy E,&#xa0;Rao M,&#xa0;Staufenbiel M,&#xa0;Nixon RA (2022) Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of A&#x3b2; in neurons, yielding senile plaques. Nat Neurosci 25:688&#x2013;701. 10.1038/s41593-022-01084-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01084-8</ArticleId><ArticleId IdType="pmc">PMC9174056</ArticleId><ArticleId IdType="pubmed">35654956</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeman DS, Hebestreit K, Ruetz T, Webb AE, McKay A, Pollina EA, Dulken BW, Zhao X, Yeo RW, Ho TT, Mahmoudi S,&#xa0;Devarajan K,&#xa0;Passegu&#xe9; E,&#xa0;Rando TA,&#xa0;Frydman J,&#xa0;Brunet A (2018) Lysosome activation clears aggregates and enhances quiescent neural stem cell activation during aging. Science 359:1277&#x2013;1283. 10.1126/science.aag3048</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag3048</ArticleId><ArticleId IdType="pmc">PMC5915358</ArticleId><ArticleId IdType="pubmed">29590078</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li L (2019) Targeting autophagy for the treatment of Alzheimer&#x2019;s disease: challenges and opportunities. Front Mol Neurosci 12:203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713911</ArticleId><ArticleId IdType="pubmed">31507373</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Supnet C, Sun S, Zhang H, Good L, Popugaeva E, Bezprozvanny I (2014) The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Channels (Austin) 8:230&#x2013;242. 10.4161/chan.27471</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/chan.27471</ArticleId><ArticleId IdType="pmc">PMC4203752</ArticleId><ArticleId IdType="pubmed">24476841</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yao J, Song Z, Guo W, Sun B, Wei J, Estillore JP, Back TG, Chen SRW (2021) Limiting RyR2 open time prevents Alzheimer's disease-related deficits in the 3xTG-AD mouse model. J Neurosci Res 99:2906&#x2013;2921. 10.1002/jnr.24936</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24936</ArticleId><ArticleId IdType="pubmed">34352124</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Z, Chen J, Zhao Y, Zhou W, Yao Q, Wang Y, He G (2020) Dynamic changes of autophagic flux induced by Abeta in the brain of postmortem Alzheimer's disease patients, animal models and cell models. Aging (Albany NY) 12:10912&#x2013;10930. 10.18632/aging.103305</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103305</ArticleId><ArticleId IdType="pmc">PMC7346050</ArticleId><ArticleId IdType="pubmed">32535554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Akinwumi BC, Shao Z, Anderson HD (2014) Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes. J Cardiovasc Pharmacol 64:420&#x2013;430. 10.1097/FJC.0000000000000134</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000000134</ArticleId><ArticleId IdType="pubmed">24979612</ArticleId></ArticleIdList></Reference><Reference><Citation>Malampati S, Song JX, Tong BCK, Nalluri A, Yang CB, Wang ZY, Sreenivasmurthy SG, Zhu Z, Liu J, Su CF, Krishnamoorthi S, Iyaswamy A, Cheung K-H, Lu J-H, Li M (2020) Targeting aggrephagy for the treatment of Alzheimer's disease. Cells 9:311. 10.3390/cells9020311</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020311</ArticleId><ArticleId IdType="pmc">PMC7072705</ArticleId><ArticleId IdType="pubmed">32012902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mary A, Eysert F, Checler F, Chami M (2023) Mitophagy in Alzheimer's disease: molecular defects and therapeutic approaches. Mol Psychiatry 28:202&#x2013;216. 10.1038/s41380-022-01631-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01631-6</ArticleId><ArticleId IdType="pmc">PMC9812780</ArticleId><ArticleId IdType="pubmed">35665766</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaid J, Mustaly-Kalimi S, Stutzmann GE (2020) Ca2+ dyshomeostasis disrupts neuronal and synaptic function in Alzheimer&#x2019;s disease. Cells 9:2655. 10.3390/cells9122655</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9122655</ArticleId><ArticleId IdType="pmc">PMC7763805</ArticleId><ArticleId IdType="pubmed">33321866</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, Montefusco S, Scotto-Rosato A, Prezioso C, Forrester A, Settembre C,&#xa0;Wang W,&#xa0;Gao Q,&#xa0;Xu H,&#xa0;Sandri M,&#xa0;Rizzuto R,&#xa0;De Matteis MA,&#xa0;Ballabio A (2015) Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol 17:288&#x2013;299. 10.1038/ncb3114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3114</ArticleId><ArticleId IdType="pmc">PMC4801004</ArticleId><ArticleId IdType="pubmed">25720963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustaly-Kalimi S, Stutzmann GE (2022) Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer's disease. Proc Natl Acad Sci U&#xa0;S&#xa0;A 119:e2211999119. 10.1073/pnas.2211999119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2211999119</ArticleId><ArticleId IdType="pmc">PMC9894236</ArticleId><ArticleId IdType="pubmed">36442130</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y, Yamamoto T, Xu XJ, Kobayashi S, Tanaka S, Tamitani M, Saito T, Saido TC, Yano M (2021) Enhancing calmodulin binding to ryanodine receptor is crucial to limit neuronal cell loss in Alzheimer disease. Sci Rep 11:7289. 10.1038/s41598-021-86822-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86822-x</ArticleId><ArticleId IdType="pmc">PMC8012710</ArticleId><ArticleId IdType="pubmed">33790404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 64:113&#x2013;122. 10.1093/jnen/64.2.113</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/64.2.113</ArticleId><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Oul&#xe8;s B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Br&#xe9;chot P, Trebak M, Checler F, Benfenati F,&#xa0;Chami M (2012) Ryanodine receptor blockade reduces amyloid-&#x3b2; load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci 32:11820&#x2013;11834. 10.1523/JNEUROSCI.0875-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0875-12.2012</ArticleId><ArticleId IdType="pmc">PMC3458216</ArticleId><ArticleId IdType="pubmed">22915123</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Liang G, Inan S, Wu Z, Joseph DJ, Meng QC, Peng Y, Eckenhoff MF, Wei HF (2012) Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett 516:274&#x2013;279. 10.1016/j.neulet.2012.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2012.04.008</ArticleId><ArticleId IdType="pmc">PMC3351794</ArticleId><ArticleId IdType="pubmed">22516463</ArticleId></ArticleIdList></Reference><Reference><Citation>Popugaeva E, Vlasova OL, Bezprozvanny I (2015) Restoring calcium homeostasis to treat Alzheimer's disease: a future perspective. Neurodegener Dis Manag 5:395&#x2013;398. 10.2217/nmt.15.36</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.15.36</ArticleId><ArticleId IdType="pmc">PMC5558533</ArticleId><ArticleId IdType="pubmed">26477700</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao H, Li Y, Xu ZD, Li WX, Fu ZJ, Wang YZ, King A, Wei HF (2017) Propofol affects neurodegeneration and neurogenesis by regulation of autophagy via effects on intracellular calcium homeostasis. Anesthesiology 127:490&#x2013;501. 10.1097/ALN.0000000000001730</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000001730</ArticleId><ArticleId IdType="pmc">PMC5561483</ArticleId><ArticleId IdType="pubmed">28614084</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C,&#xa0;Ghetti B,&#xa0;Czech C,&#xa0;H&#xf6;lscher C,&#xa0;Mathews PM,&#xa0;Jucker M (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7:940&#x2013;946. 10.1038/sj.embor.7400784</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MA, Rahman MS, Rahman MH, Rasheduzzaman M, Mamun-Or-Rashid ANM, Uddin MJ, Rahman MR, Hwang H, Pang MG, Rhim H (2021) Modulatory effects of autophagy on APP processing as a potential treatment target for Alzheimer's disease. Biomedicines 9:5. 10.3390/biomedicines9010005</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9010005</ArticleId><ArticleId IdType="pmc">PMC7824196</ArticleId><ArticleId IdType="pubmed">33374126</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozkalne A, Hyman BT, Spires-Jones TL (2011) Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. Neurobiol Dis 41:650&#x2013;654. 10.1016/j.nbd.2010.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.11.014</ArticleId><ArticleId IdType="pmc">PMC3031746</ArticleId><ArticleId IdType="pubmed">21134458</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Cuervo AM, Ravikumar B, Sarkar S, Korolchuk V, Kaushik S, Klionsky DJ (2009) In search of an &#x201c;autophagomometer&#x201d;. Autophagy 5:585&#x2013;589. 10.4161/auto.5.5.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.5.5.8823</ArticleId><ArticleId IdType="pubmed">19411822</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC (2014) Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci 17:661&#x2013;663. 10.1038/nn.3697</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3697</ArticleId><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I, De Castro V, Jimenez S, Ruano D, Vizuete M, Davila JC,&#xa0;Garcia-Verdugo JM,&#xa0;Jimenez AJ,&#xa0;Vitorica J,&#xa0;Gutierrez A (2012) Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. Acta Neuropathol 123:53&#x2013;70. 10.1007/s00401-011-0896-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0896-x</ArticleId><ArticleId IdType="pmc">PMC3249205</ArticleId><ArticleId IdType="pubmed">22020633</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, Banfi S,&#xa0;Parenti G,&#xa0;Cattaneo E,&#xa0;Ballabi A (2009) A gene network regulating lysosomal biogenesis and function. Science 325:473&#x2013;477. 10.1126/science.1174447</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1174447</ArticleId><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Saucerman JJ, Bers DM (2008) Calmodulin mediates differential sensitivity of CaMKII and calcineurin to local Ca2+ in cardiac myocytes. Biophys J 95:4597&#x2013;4612. 10.1529/biophysj.108.128728</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.108.128728</ArticleId><ArticleId IdType="pmc">PMC2576378</ArticleId><ArticleId IdType="pubmed">18689454</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Valero J (2011) The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev Neurosci 22:153&#x2013;169. 10.1515/RNS.2011.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/RNS.2011.018</ArticleId><ArticleId IdType="pubmed">21476939</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, Huynh T, Ferron M, Karsenty G, Vellard MC, Facchinetti V,&#xa0;Sabatini DM,&#xa0;Ballabio A (2012) A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J 31:1095&#x2013;1108. 10.1038/emboj.2012.32</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.32</ArticleId><ArticleId IdType="pmc">PMC3298007</ArticleId><ArticleId IdType="pubmed">22343943</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM (2005) Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem 94:1711&#x2013;1718. 10.1111/j.1471-4159.2005.03332.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03332.x</ArticleId><ArticleId IdType="pubmed">16156741</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings NR, O'Neal MA, Hu J, Kavalali ET, Bezprozvanny I, Malter JS (2018) Pin1 mediates A&#x3b2;42-induced dendritic spine loss. Sci Signal 11:aap8734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6136423</ArticleId><ArticleId IdType="pubmed">29559586</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan MI, Edelstein SJ, Le Nov&#xe8;re N (2008) An allosteric model of calmodulin explains differential activation of PP2B and CaMKII. Proc Natl Acad Sci U&#xa0;S&#xa0;A 105:10768&#x2013;10773. 10.1073/pnas.0804672105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804672105</ArticleId><ArticleId IdType="pmc">PMC2504824</ArticleId><ArticleId IdType="pubmed">18669651</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I (2006) Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci 26:5180&#x2013;5189. 10.1523/JNEUROSCI.0739-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0739-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Suire CN, Abdul-Hay SO, Sahara T, Kang D, Brizuela MK, Saftig P, Dickson DW, Rosenberry TL, Leissring MA (2020) Cathepsin D regulates cerebral A&#x3b2;42/40 ratios via differential degradation of A&#x3b2;42 and A&#x3b2;40. Alzheimers Res Ther 12:80. 10.1186/s13195-020-00649-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00649-8</ArticleId><ArticleId IdType="pmc">PMC7339583</ArticleId><ArticleId IdType="pubmed">32631408</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukumaran P, Da Conceicao VN, Sun YY, Ahamad N, Saraiva LR, Selvaraj S, Singh BB (2021) Calcium signaling regulates autophagy and apoptosis. Cells 10:2125. 10.3390/cells10082125</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10082125</ArticleId><ArticleId IdType="pmc">PMC8394685</ArticleId><ArticleId IdType="pubmed">34440894</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Yao J, Chen AW, Estillore JP, Wang R, Back TG, Chen SRW (2021) Genetically and pharmacologically limiting RyR2 open time prevents neuronal hyperactivity of hippocampal CA1 neurons in brain slices of 5xFAD mice. Neurosci Lett 758:136011. 10.1016/j.neulet.2021.136011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.136011</ArticleId><ArticleId IdType="pubmed">34090936</ArticleId></ArticleIdList></Reference><Reference><Citation>Supnet C, Grant J, Kong H, Westaway D, Mayne M (2006) Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. J Biol Chem 281:38440&#x2013;38447. 10.1074/jbc.M606736200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M606736200</ArticleId><ArticleId IdType="pubmed">17050533</ArticleId></ArticleIdList></Reference><Reference><Citation>Taglialatela G, Hogan D, Zhang WR, Dineley KT (2009) Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res 200:95&#x2013;99. 10.1016/j.bbr.2008.12.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2008.12.034</ArticleId><ArticleId IdType="pmc">PMC2663011</ArticleId><ArticleId IdType="pubmed">19162087</ArticleId></ArticleIdList></Reference><Reference><Citation>Taglialatela G, Rastellini C, Cicalese L (2015) Reduced incidence of dementia in solid organ transplant patients treated with calcineurin inhibitors. J Alzheimers Dis 47:329&#x2013;333. 10.3233/JAD-150065</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150065</ArticleId><ArticleId IdType="pmc">PMC4923720</ArticleId><ArticleId IdType="pubmed">26401556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaillant-Beuchot L,. et al.. (2021) Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer's disease models and human brains. Acta Neuropathol 141:39&#x2013;65. 10.1007/s00401-020-02234-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02234-7</ArticleId><ArticleId IdType="pmc">PMC7785558</ArticleId><ArticleId IdType="pubmed">33079262</ArticleId></ArticleIdList></Reference><Reference><Citation>Valladares D, Utreras-Mendoza Y, Campos C, Morales C, Diaz-Vegas A, Contreras-Ferrat A, Westermeier F, Jaimovich E, Marchi S, Pinton P, Lavandero S (2018) IP3 receptor blockade restores autophagy and mitochondrial function in skeletal muscle fibers of dystrophic mice. Biochim Biophys Acta Mol Basis Dis 1864:3685&#x2013;3695. 10.1016/j.bbadis.2018.08.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.08.042</ArticleId><ArticleId IdType="pubmed">30251688</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervliet T (2018) Ryanodine receptors in autophagy: implications for neurodegenerative diseases? Front Cell Neurosci 12:89. 10.3389/fncel.2018.00089</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00089</ArticleId><ArticleId IdType="pmc">PMC5880912</ArticleId><ArticleId IdType="pubmed">29636667</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervliet T, Pintelon I, Welkenhuyzen K, Bootman MD, Bannai H, Mikoshiba K, Martinet W, Kasri NN, Parys JB, Bultynck G (2017) Basal ryanodine receptor activity suppresses autophagic flux. Biochem Pharmacol 132:133&#x2013;142. 10.1016/j.bcp.2017.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2017.03.011</ArticleId><ArticleId IdType="pubmed">28322744</ArticleId></ArticleIdList></Reference><Reference><Citation>Vingtdeux V, Hamdane M, B&#xe9;gard S, Loyens A, Delacourte A, Beauvillain JC, Bu&#xe9;e L, Marambaud P, Sergeant N (2007) Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiol Dis 25:686&#x2013;696. 10.1016/j.nbd.2006.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.09.019</ArticleId><ArticleId IdType="pubmed">17207630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones T, Xie H, Arbel-Ornath M, Grosskreutz CL, Bacskai BJ,&#xa0;Hyman BT (2010) Amyloid &#x3b2; induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 30:2636&#x2013;2649. 10.1523/JNEUROSCI.4456-09.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4456-09.2010</ArticleId><ArticleId IdType="pmc">PMC2841957</ArticleId><ArticleId IdType="pubmed">20164348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, Pawlik M, Peterhoff CM, Yang AJ, Wilson DA, St George-Hyslop P, Westaway D, Mathews PM, Levy E, Cuervo AM, Nixon RA (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 134:258&#x2013;277. 10.1093/brain/awq341</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq341</ArticleId><ArticleId IdType="pmc">PMC3009842</ArticleId><ArticleId IdType="pubmed">21186265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Sun B, Institoris A, Zhan X, Guo W, Song Z, Liu Y, Hiess F, Boyce AKJ, Ni M, Wang R,&#xa0;Ter Keurs H,&#xa0;Back TG,&#xa0;Fill M,&#xa0;Thompson RJ,&#xa0;Turner RW,&#xa0;Gordon GR,&#xa0;Chen SRW (2020) Limiting RyR2 open time prevents Alzheimer's disease-related neuronal hyperactivity and memory loss but not &#x3b2;-amyloid accumulation. Cell Rep 32:108169. 10.1016/j.celrep.2020.108169</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108169</ArticleId><ArticleId IdType="pmc">PMC7532726</ArticleId><ArticleId IdType="pubmed">32966798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Sun X, Starovoytov V, Cai Q (2015) Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. Hum Mol Genet 24:2938&#x2013;2951. 10.1093/hmg/ddv056</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv056</ArticleId><ArticleId IdType="pmc">PMC4406302</ArticleId><ArticleId IdType="pubmed">25678552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, N&#xe4;slund J, Mathews PM, Cataldo AM, Nixon RA (2005) Macroautophagy&#x2014;a novel &#x3b2;-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171:87&#x2013;98. 10.1083/jcb.200505082</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200505082</ArticleId><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I (2010) Role of presenilins in neuronal calcium homeostasis. J Neurosci 30:8566&#x2013;8580. 10.1523/JNEUROSCI.1554-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1554-10.2010</ArticleId><ArticleId IdType="pmc">PMC2906098</ArticleId><ArticleId IdType="pubmed">20573903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Sun S, Wu L, Pchitskaya E, Zakharova O, Fon Tacer K, Bezprozvanny I (2016) Store-operated calcium channel complex in postsynaptic spines: a new therapeutic target for Alzheimer&#x2019;s disease treatment. J Neurosci 36:11837&#x2013;11850. 10.1523/JNEUROSCI.1188-16.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1188-16.2016</ArticleId><ArticleId IdType="pmc">PMC5125243</ArticleId><ArticleId IdType="pubmed">27881772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZG, Yang XF, Song YQ, Tu J (2021) Autophagy in Alzheimer's disease pathogenesis: therapeutic potential and future perspectives. Ageing Res Rev 72:101464. 10.1016/j.arr.2021.101464</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2021.101464</ArticleId><ArticleId IdType="pubmed">34551326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36634180</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>379</Volume><Issue>6628</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy.</ArticleTitle><Pagination><StartPage>eadd1236</StartPage><MedlinePgn>eadd1236</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.add1236</ELocationID><Abstract><AbstractText>Tau-mediated neurodegeneration is a hallmark of Alzheimer's disease. Primary tauopathies are characterized by pathological tau accumulation and neuronal and synaptic loss. Apolipoprotein E (ApoE)-mediated neuroinflammation is involved in the progression of tau-mediated neurodegeneration, and emerging evidence suggests that the gut microbiota regulates neuroinflammation in an APOE genotype-dependent manner. However, evidence of a causal link between the microbiota and tau-mediated neurodegeneration is lacking. In this study, we characterized a genetically engineered mouse model of tauopathy expressing human ApoE isoforms reared under germ-free conditions or after perturbation of their gut microbiota with antibiotics. Both of these manipulations reduced gliosis, tau pathology, and neurodegeneration in a sex- and ApoE isoform-dependent manner. The findings reveal mechanistic and translationally relevant interrelationships between the microbiota, neuroinflammation, and tau-mediated neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Dong-Oh</ForeName><Initials>DO</Initials><Identifier Source="ORCID">0000-0003-0315-4489</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6239-7988</Identifier><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Nimansha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5360-5466</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-4743-926X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2413-0937</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemieux</LastName><ForeName>Mackenzie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6015-8668</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jiye</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0266-3997</Identifier><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Javier R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-5937-0212</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0887-957X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Su</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Chandani</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3708-3634</Identifier><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodiya</LastName><ForeName>Hemraj</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-0908-0014</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lelwala-Guruge</LastName><ForeName>Janaki</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handley</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-2143-6570</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3714-517X</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-4039-8864</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Jeffrey I</ForeName><Initials>JI</Initials><Identifier Source="ORCID">0000-0001-8304-3548</Identifier><AffiliationInfo><Affiliation>The Edison Family Center for Genome Sciences and Systems Biology and the Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK030292</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007200</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK042086</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2023 Jan;613(7944):417. doi: 10.1038/d41586-023-00038-9.</RefSource><PMID Version="1">36639438</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2023 Feb;614(7949):629-630. doi: 10.1038/d41586-023-00261-4.</RefSource><PMID Version="1">36747101</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2023 Mar;24(3):133. doi: 10.1038/s41583-023-00681-1.</RefSource><PMID Version="1">36782051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="Y">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="Y">Neuroinflammatory Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36634180</ArticleId><ArticleId IdType="mid">NIHMS1870181</ArticleId><ArticleId IdType="pmc">PMC9901565</ArticleId><ArticleId IdType="doi">10.1126/science.add1236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long J, Holtzman DM, Alzheimer Disease: An Update on Pathobiology and Treatment Strategies, Cell, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo DO, Holtzman DM, Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer&#x2019;s Disease., J Gerontol A Biol Sci Med Sci, 75, 1232 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302187</ArticleId><ArticleId IdType="pubmed">31738402</ArticleId></ArticleIdList></Reference><Reference><Citation>Harach T et al., Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota., Sci Rep, 7, 41802 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5297247</ArticleId><ArticleId IdType="pubmed">28176819</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodiya HB et al., Sex-specific effects of microbiome perturbations on cerebral A&#x3b2; amyloidosis and microglia phenotypes., J Exp Med, 216, 1542 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605759</ArticleId><ArticleId IdType="pubmed">31097468</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh IJ et al., Murine Gut Microbiome Association With APOE Alleles, Front Immunol, 11, 200 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7034241</ArticleId><ArticleId IdType="pubmed">32117315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran TTT et al., genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer&#x2019;s disease pathophysiology, FASEB j, 33, 8221 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593891</ArticleId><ArticleId IdType="pubmed">30958695</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C et al., Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia., Neuron, 109, 1657 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141024</ArticleId><ArticleId IdType="pubmed">33831349</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al., ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy., Nature, 549, 523 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al., Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model., J Exp Med, 216, 2546 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R et al., CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice., Brain, 142, 3243 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann CN et al., Astrocytic a2-Na /K ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model, Sci Transl Med, 14, eabm4107 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161722</ArticleId><ArticleId IdType="pubmed">35171651</ArticleId></ArticleIdList></Reference><Reference><Citation>Erny D et al., Host microbiota constantly control maturation and function of microglia in the CNS., Nat Neurosci, 18, 965 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Spichak S et al., Microbially-derived short-chain fatty acids impact astrocyte gene expression in a sex-specific manner., Brain Behav Immun Health, 16, 100318 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474187</ArticleId><ArticleId IdType="pubmed">34589808</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR et al., Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson&#x2019;s Disease., Cell, 167, 1469 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirkof P, Burrowing and nest building behavior as indicators of well-being in mice., J Neurosci Methods, 234, 139 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24525328</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainchtein ID, Molofsky AV, Astrocytes and Microglia: In Sickness and in Health., Trends Neurosci, 43, 144 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472912</ArticleId><ArticleId IdType="pubmed">32044129</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Marco Barros R, Fitzpatrick Z, Clatworthy MR, The gut-meningeal immune axis: Priming brain defense against the most likely invaders., J Exp Med, 219, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8932540</ArticleId><ArticleId IdType="pubmed">35195681</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves de Lima K et al., Meningeal &#x3b3;&#x3b4; T cells regulate anxiety-like behavior via IL-17a signaling in neurons., Nat Immunol, 21, 1421 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496952</ArticleId><ArticleId IdType="pubmed">32929273</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Trinchieri G, Liu YJ, Plasmacytoid dendritic cells in immunity., Nat Immunol, 5, 1219 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15549123</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuijt TJ et al., The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia., Gut, 65, 575 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4819612</ArticleId><ArticleId IdType="pubmed">26511795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y et al., The Gut Microbiome as a Therapeutic Target for Cognitive Impairment., J Gerontol A Biol Sci Med Sci, 75, 1242 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302188</ArticleId><ArticleId IdType="pubmed">31811292</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo DO, Boros BD, Holtzman DM, The microbiome: A target for Alzheimer disease, Cell Res, 29, 779 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796832</ArticleId><ArticleId IdType="pubmed">31488883</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV et al., Lack of hepatic apoE does not influence early A&#x3b2; deposition: observations from a new APOE knock-in model., Mol Neurodegener, 14, 37 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796484</ArticleId><ArticleId IdType="pubmed">31623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefka AT et al., Commensal bacteria protect against food allergen sensitization., Proc Natl Acad Sci U S A, 111, 13145 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246970</ArticleId><ArticleId IdType="pubmed">25157157</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM, Assessing nest building in mice., Nat Protoc, 1, 1117 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares G et al., Employing an open-source tool to assess astrocyte tridimensional structure, Brain Struct Funct, 222, 1989 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5406431</ArticleId><ArticleId IdType="pubmed">27696155</ArticleId></ArticleIdList></Reference><Reference><Citation>SHOLL DA, Dendritic organization in the neurons of the visual and motor cortices of the cat., J Anat, 87, 387 (1953).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1244622</ArticleId><ArticleId IdType="pubmed">13117757</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto-Oliveira M et al., Plasticity of microglia., Biol Rev Camb Philos Soc, 97, 217 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34549510</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S, WGCNA: an R package for weighted correlation network analysis., BMC Bioinformatics, 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al., Metascape provides a biologist-oriented resource for the analysis of systems-level datasets., Nat Commun, 10, 1523 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R, Integrating single-cell transcriptomic data across different conditions, technologies, and species., Nat Biotechnol, 36, 411 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al., Comprehensive Integration of Single-Cell Data., Cell, 177, 1888 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Young MD, Behjati S, SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data., Gigascience, 9, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7763177</ArticleId><ArticleId IdType="pubmed">33367645</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G et al., MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data., Genome Biol, 16, 278 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C, Satija R, Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression., Genome Biol, 20, 296 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan BJ et al., DADA2: High-resolution sample inference from Illumina amplicon data., Nat Methods, 13, 581 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927377</ArticleId><ArticleId IdType="pubmed">27214047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JR et al., Ribosomal Database Project: data and tools for high throughput rRNA analysis., Nucleic Acids Res, 42, D633 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965039</ArticleId><ArticleId IdType="pubmed">24288368</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurdie PJ, Holmes S, phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data., PLoS One, 8, e61217 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632530</ArticleId><ArticleId IdType="pubmed">23630581</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2., Genome Biol, 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Yu G, MicrobiotaProcess: An R Package for Analysis, Visualization and Biomarker Discovery of Microbiome, Version 0.84, 3.12, (2021).</Citation></Reference><Reference><Citation>Wei T, Simko VR, R package &#x201c;corrplot&#x201d;: Visualization of a Correlation Matrix, WWW document, (2021).</Citation></Reference><Reference><Citation>Rey FE et al., Metabolic niche of a prominent sulfate-reducing human gut bacterium., Proc Natl Acad Sci U S A, 110, 13582 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746858</ArticleId><ArticleId IdType="pubmed">23898195</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data., Bioinformatics, 26, 139 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME et al., limma powers differential expression analyses for RNA-sequencing and microarray studies., Nucleic Acids Res, 43, e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R et al., Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses., Nucleic Acids Res, 43, e97 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551905</ArticleId><ArticleId IdType="pubmed">25925576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36635496</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models.</ArticleTitle><Pagination><StartPage>416</StartPage><EndPage>429</EndPage><MedlinePgn>416-429</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01240-0</ELocationID><Abstract><AbstractText>Loss-of-function variants of TREM2 are associated with increased risk of Alzheimer's disease (AD), suggesting that activation of this innate immune receptor may be a useful therapeutic strategy. Here we describe a high-affinity human TREM2-activating antibody engineered with a monovalent transferrin receptor (TfR) binding site, termed antibody transport vehicle (ATV), to facilitate blood-brain barrier transcytosis. Upon peripheral delivery in mice, ATV:TREM2 showed improved brain biodistribution and enhanced signaling compared to a standard anti-TREM2 antibody. In human induced pluripotent stem cell (iPSC)-derived microglia, ATV:TREM2 induced proliferation and improved mitochondrial metabolism. Single-cell RNA sequencing and morphometry revealed that ATV:TREM2 shifted microglia to metabolically responsive states, which were distinct from those induced by amyloid pathology. In an AD mouse model, ATV:TREM2 boosted brain microglial activity and glucose metabolism. Thus, ATV:TREM2 represents a promising approach to improve microglial function and treat brain hypometabolism found in patients with AD.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>van Lengerich</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhan</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7772-9340</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xia</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Darren</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joy</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9941-9538</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Joshua I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatarakis</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvert</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hummel</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lianoglou</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0924-1754</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzo</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prorok</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Elliot</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartos</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beumers</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonnet S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Weerd</LastName><ForeName>Lis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugas</LastName><ForeName>Jason C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duque</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earr</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadkar</LastName><ForeName>Kapil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giese</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gn&#xf6;rich</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kannuswamy</LastName><ForeName>Malavika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Do Jin</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunte</LastName><ForeName>Sebastian T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunze</LastName><ForeName>Lea H</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0003-4669-2113</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lac</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lechtenberg</LastName><ForeName>Kendra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Amy Wing-Sze</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chun-Chi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceutical Company, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modi</LastName><ForeName>Anuja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Vanessa O</ForeName><Initials>VO</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hoang N</ForeName><Initials>HN</Initials><Identifier Source="ORCID">0000-0001-6608-7581</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pes&#xe4;maa</LastName><ForeName>Ida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neurosciences, Ludwig Maximilians University Munich, Planegg-Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Propson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Marvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neurosciences, Ludwig Maximilians University Munich, Planegg-Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robles-Colmenares</LastName><ForeName>Yaneth</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlepckow</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slemann</LastName><ForeName>Luna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanoy</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Jung H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorne</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Chandler</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wind-Mark</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Ken</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0334-7512</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuchero</LastName><ForeName>Y Joy Yu</ForeName><Initials>YJY</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Dolo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Fen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0568-802X</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewcock</LastName><ForeName>Joseph W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1032-1265</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9247-2843</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Pascal E</ForeName><Initials>PE</Initials><Identifier Source="ORCID">0000-0002-2620-5165</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA. sanchez@dnli.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monroe</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-6901-1176</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., South San Francisco, CA, USA. monroe@dnli.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors, except P.M.Q., S.H., P.B., A.C., J.G., S.T.K., L.H.K., I.P., K.S., L.S., L.D.W., K.W.-M., M.R., L.M.B., M.B. and C.H., are full-time employees and/or shareholders of Denali Therapeutics. C.H. is a collaborator of Denali Therapeutics, participated on one advisory board meeting of Biogen and received a speaker honorarium from Novartis and Roche. C.H. is chief advisor of ISAR Bioscience and a member of the advisory board of AviadoBio. P.M.Q. is a full-time employee of Takeda Pharmaceuticals, Inc., a clinical development partner of Denali Therapeutics. This work has been described, in part, in pending patent applications.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635496</ArticleId><ArticleId IdType="pmc">PMC9991924</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01240-0</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01240-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wightman DP, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer&#x2019;s disease. Nat. Genet. 2021;53:1276&#x2013;1282. doi: 10.1038/s41588-021-00921-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00921-z</ArticleId><ArticleId IdType="pmc">PMC10243600</ArticleId><ArticleId IdType="pubmed">34493870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewcock, J. W. et al. Emerging microglia biology defines novel therapeutic approaches for Alzheimer&#x2019;s disease. Neuron108, 801&#x2013;821 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33096024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071. doi: 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Colonna M. TREM2&#x2014;a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 2018;14:667&#x2013;675. doi: 10.1038/s41582-018-0072-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0072-1</ArticleId><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerbach D, et al. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Neurosci. Lett. 2017;660:109&#x2013;114. doi: 10.1016/j.neulet.2017.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.09.034</ArticleId><ArticleId IdType="pubmed">28923481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, et al. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and &#x3b3;-secretase-dependent intramembranous cleavage. J. Biol. Chem. 2013;288:33027&#x2013;33036. doi: 10.1074/jbc.M113.517540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.517540</ArticleId><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 2014;6:243ra286. doi: 10.1126/scitranslmed.3009093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009093</ArticleId><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 2005;201:647&#x2013;657. doi: 10.1084/jem.20041611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18:1186&#x2013;1198. doi: 10.15252/embr.201743922.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201743922</ArticleId><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105:837&#x2013;854. doi: 10.1016/j.neuron.2019.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.12.007</ArticleId><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, et al. Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the A&#x3b2;42:A&#x3b2;40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer&#x2019;s mouse model. J. Neurosci. 2020;40:1956&#x2013;1974. doi: 10.1523/JNEUROSCI.1871-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1871-19.2019</ArticleId><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch-Queralt M, et al. Diet-dependent regulation of TGF&#x3b2; impairs reparative innate immune responses after demyelination. Nat. Metab. 2021;3:211&#x2013;227. doi: 10.1038/s42255-021-00341-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00341-7</ArticleId><ArticleId IdType="pmc">PMC7610359</ArticleId><ArticleId IdType="pubmed">33619376</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, et al. Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. Nat. Neurosci. 2021;24:489&#x2013;503. doi: 10.1038/s41593-021-00801-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00801-z</ArticleId><ArticleId IdType="pubmed">33603230</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 2019;51:414&#x2013;430. doi: 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, et al. Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 2017;13:381&#x2013;387. doi: 10.1016/j.jalz.2016.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.004</ArticleId><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis JC, et al. Whole exome sequencing study identifies novel rare and common Alzheimer&#x2019;s-associated variants involved in immune response and transcriptional regulation. Mol. Psychiatry. 2020;25:1859&#x2013;1875. doi: 10.1038/s41380-018-0112-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0112-7</ArticleId><ArticleId IdType="pmc">PMC6375806</ArticleId><ArticleId IdType="pubmed">30108311</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, et al. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol. Med. 2017;9:1356&#x2013;1365. doi: 10.15252/emmm.201707672.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707672</ArticleId><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton P, et al. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer&#x2019;s disease-associated H157Y variant. EMBO Mol. Med. 2017;9:1366&#x2013;1378. doi: 10.15252/emmm.201707673.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707673</ArticleId><ArticleId IdType="pmc">PMC5623839</ArticleId><ArticleId IdType="pubmed">28855301</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 2017;49:1373&#x2013;1384. doi: 10.1038/ng.3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Magno L, et al. Alzheimer&#x2019;s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res. Ther. 2019;11:16. doi: 10.1186/s13195-019-0469-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0469-0</ArticleId><ArticleId IdType="pmc">PMC6359863</ArticleId><ArticleId IdType="pubmed">30711010</ArticleId></ArticleIdList></Reference><Reference><Citation>Takalo M, et al. The Alzheimer&#x2019;s disease-associated protective Plc&#x3b3;2-P522R variant promotes immune functions. Mol. Neurodegener. 2020;15:52. doi: 10.1186/s13024-020-00402-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00402-7</ArticleId><ArticleId IdType="pmc">PMC7488484</ArticleId><ArticleId IdType="pubmed">32917267</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreone BJ, et al. Alzheimer&#x2019;s-associated PLC&#x3b3;2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat. Neurosci. 2020;23:927&#x2013;938. doi: 10.1038/s41593-020-0650-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0650-6</ArticleId><ArticleId IdType="pubmed">32514138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer&#x2019;s disease. Sci. Transl. Med. 2019;11:eaav6221. doi: 10.1126/scitranslmed.aav6221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav6221</ArticleId><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Morenas-Rodriguez E, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer&#x2019;s disease: a longitudinal observational study. Lancet Neurol. 2022;21:329&#x2013;341. doi: 10.1016/S1474-4422(22)00027-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00027-8</ArticleId><ArticleId IdType="pmc">PMC8926925</ArticleId><ArticleId IdType="pubmed">35305339</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q, et al. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer&#x2019;s disease variant Trem2R47H on murine myeloid cell function. J. Biol. Chem. 2018;293:12620&#x2013;12633. doi: 10.1074/jbc.RA118.001848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.001848</ArticleId><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cignarella F, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol. 2020;140:513&#x2013;534. doi: 10.1007/s00401-020-02193-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02193-z</ArticleId><ArticleId IdType="pmc">PMC7498497</ArticleId><ArticleId IdType="pubmed">32772264</ArticleId></ArticleIdList></Reference><Reference><Citation>Price BR, et al. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5&#xd7;FAD model of amyloid deposition. J. Neuroinflammation. 2020;17:238. doi: 10.1186/s12974-020-01915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01915-0</ArticleId><ArticleId IdType="pmc">PMC7427742</ArticleId><ArticleId IdType="pubmed">32795308</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 2020;12:e11227. doi: 10.15252/emmm.201911227.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x2019;s disease model. J. Exp. Med. 2020;217:e20200785. doi: 10.1084/jem.20200785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200785</ArticleId><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger DC, et al. Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2021;118:e2017742118. doi: 10.1073/pnas.2017742118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2017742118</ArticleId><ArticleId IdType="pmc">PMC7826333</ArticleId><ArticleId IdType="pubmed">33446504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassler M, Rappaport MS, Cuno CB, George J. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer&#x2019;s disease models. J. Neuroinflammation. 2021;18:19. doi: 10.1186/s12974-020-01980-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01980-5</ArticleId><ArticleId IdType="pmc">PMC7796541</ArticleId><ArticleId IdType="pubmed">33422057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariolis MS, et al. Brain delivery of therapeutic proteins using an Fc fragment blood&#x2013;brain barrier transport vehicle in mice and monkeys. Sci. Transl. Med. 2020;12:eaay1359. doi: 10.1126/scitranslmed.aay1359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aay1359</ArticleId><ArticleId IdType="pubmed">32461332</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184:4651&#x2013;4668. doi: 10.1016/j.cell.2021.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.08.002</ArticleId><ArticleId IdType="pmc">PMC8489356</ArticleId><ArticleId IdType="pubmed">34450028</ArticleId></ArticleIdList></Reference><Reference><Citation>Arguello A, et al. Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme. J. Exp. Med. 2022;219:e20211057. doi: 10.1084/jem.20211057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211057</ArticleId><ArticleId IdType="pmc">PMC8932535</ArticleId><ArticleId IdType="pubmed">35226042</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, et al. Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol. Neurodegeneration. 2022;17:41. doi: 10.1186/s13024-022-00547-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00547-7</ArticleId><ArticleId IdType="pmc">PMC9188195</ArticleId><ArticleId IdType="pubmed">35690868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 2017;21:366&#x2013;380. doi: 10.1016/j.celrep.2017.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Colonna M. Microglia in Alzheimer&#x2019;s disease at single-cell level. Are there common patterns in humans and mice? J. Exp. Med. 2021;218:e20202717. doi: 10.1084/jem.20202717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202717</ArticleId><ArticleId IdType="pmc">PMC8302448</ArticleId><ArticleId IdType="pubmed">34292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappel MS, et al. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl Acad. Sci. USA. 1991;88:9036&#x2013;9040. doi: 10.1073/pnas.88.20.9036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.20.9036</ArticleId><ArticleId IdType="pmc">PMC52646</ArticleId><ArticleId IdType="pubmed">1833770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DI, et al. An improved smaller biotin ligase for BioID proximity labeling. Mol. Biol. Cell. 2016;27:1188&#x2013;1196. doi: 10.1091/mbc.E15-12-0844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E15-12-0844</ArticleId><ArticleId IdType="pmc">PMC4831873</ArticleId><ArticleId IdType="pubmed">26912792</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94:278&#x2013;293. doi: 10.1016/j.neuron.2017.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397. doi: 10.1016/j.neuron.2014.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, et al. AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Sci. Transl. Med. 2021;13:eabe3947. doi: 10.1126/scitranslmed.abe3947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe3947</ArticleId><ArticleId IdType="pmc">PMC9345574</ArticleId><ArticleId IdType="pubmed">34851693</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai T, et al. In-vivo evaluation of indium-111-diethylenetriaminepentaacetic acid-labelling for determining the sites and rates of protein catabolism in mice. J. Pharm. Pharmacol. 1999;51:15&#x2013;20. doi: 10.1211/0022357991772033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/0022357991772033</ArticleId><ArticleId IdType="pubmed">10197412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni C, et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol. 2015;129:429&#x2013;447. doi: 10.1007/s00401-015-1388-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1388-1</ArticleId><ArticleId IdType="pmc">PMC4667728</ArticleId><ArticleId IdType="pubmed">25631124</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell Biol. 2019;20:137&#x2013;155. doi: 10.1038/s41580-018-0085-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0085-z</ArticleId><ArticleId IdType="pmc">PMC6746329</ArticleId><ArticleId IdType="pubmed">30523332</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat. Neurosci. 2020;23:194&#x2013;208. doi: 10.1038/s41593-019-0566-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0566-1</ArticleId><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Loving BA, Bruce KD. Lipid and lipoprotein metabolism in microglia. Front. Physiol. 2020;11:393. doi: 10.3389/fphys.2020.00393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.00393</ArticleId><ArticleId IdType="pmc">PMC7198855</ArticleId><ArticleId IdType="pubmed">32411016</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;17:491&#x2013;506. doi: 10.1016/j.cmet.2013.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.03.002</ArticleId><ArticleId IdType="pmc">PMC5967396</ArticleId><ArticleId IdType="pubmed">23562075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambold AS, Pearce EL. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol. 2018;39:6&#x2013;18. doi: 10.1016/j.it.2017.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2017.08.006</ArticleId><ArticleId IdType="pubmed">28923365</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci. Transl. Med. 2021;13:eabe5640. doi: 10.1126/scitranslmed.abe5640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe5640</ArticleId><ArticleId IdType="pubmed">34644146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, et al. The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J. 2017;36:1837&#x2013;1853. doi: 10.15252/embj.201796516.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201796516</ArticleId><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="pubmed">28559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, et al. Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. EMBO Mol. Med. 2019;11:e9711. doi: 10.15252/emmm.201809711.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201809711</ArticleId><ArticleId IdType="pmc">PMC6554672</ArticleId><ArticleId IdType="pubmed">31122931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216. doi: 10.1016/S1474-4422(12)70291-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou YN, et al. FDG-PET as an independent biomarker for Alzheimer&#x2019;s biological diagnosis: a longitudinal study. Alzheimers Res. Ther. 2019;11:57. doi: 10.1186/s13195-019-0512-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0512-1</ArticleId><ArticleId IdType="pmc">PMC6599313</ArticleId><ArticleId IdType="pubmed">31253185</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K/AKT/FoxO3a signaling pathway in Alzheimer&#x2019;s disease mice. Aging (Albany NY) 2020;12:20862&#x2013;20879. doi: 10.18632/aging.104104.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.104104</ArticleId><ArticleId IdType="pmc">PMC7655179</ArticleId><ArticleId IdType="pubmed">33065553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullman JC, et al. Brain delivery and activity of a lysosomal enzyme using a blood&#x2013;brain barrier transport vehicle in mice. Sci. Transl. Med. 2020;12:eaay1163. doi: 10.1126/scitranslmed.aay1163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aay1163</ArticleId><ArticleId IdType="pubmed">32461331</ArticleId></ArticleIdList></Reference><Reference><Citation>Reifschneider A, et al. Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO J. 2022;41:e109108. doi: 10.15252/embj.2021109108.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021109108</ArticleId><ArticleId IdType="pmc">PMC8844989</ArticleId><ArticleId IdType="pubmed">35019161</ArticleId></ArticleIdList></Reference><Reference><Citation>Piers TM, et al. A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia. FASEB J. 2020;34:2436&#x2013;2450. doi: 10.1096/fj.201902447R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201902447R</ArticleId><ArticleId IdType="pmc">PMC7027848</ArticleId><ArticleId IdType="pubmed">31907987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, et al. TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell. 2017;170:649&#x2013;663. doi: 10.1016/j.cell.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at https://www.biorxiv.org/content/10.1101/060012v3 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012v3</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417&#x2013;425. doi: 10.1016/j.cels.2015.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2015.12.004</ArticleId><ArticleId IdType="pmc">PMC4707969</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573&#x2013;3587. doi: 10.1016/j.cell.2021.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.048</ArticleId><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Branon TC, et al. Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 2018;36:880&#x2013;887. doi: 10.1038/nbt.4201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4201</ArticleId><ArticleId IdType="pmc">PMC6126969</ArticleId><ArticleId IdType="pubmed">30125270</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 2016;19:995&#x2013;998. doi: 10.1038/nn.4325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4325</ArticleId><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhoff F, et al. Automated spatial brain normalization and hindbrain white matter reference tissue give improved [18F]-florbetaben PET quantitation in Alzheimer&#x2019;s model mice. Front. Neurosci. 2016;10:45. doi: 10.3389/fnins.2016.00045.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00045</ArticleId><ArticleId IdType="pmc">PMC4770021</ArticleId><ArticleId IdType="pubmed">26973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, et al. Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple-tracer PET study. J. Nucl. Med. 2016;57:954&#x2013;960. doi: 10.2967/jnumed.115.167858.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.167858</ArticleId><ArticleId IdType="pubmed">26912428</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36641604</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2426-0266</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The journal of prevention of Alzheimer's disease</Title><ISOAbbreviation>J Prev Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Editorial: Usefulness of Anchor Based Methods for Determining Clinically Meaningful Change in MCI due to AD.</ArticleTitle><Pagination><StartPage>7</StartPage><EndPage>8</EndPage><MedlinePgn>7-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14283/jpad.2022.104</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hendrix</LastName><ForeName>S B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Suzanne B. Hendrix Pentara Corporation, Salt Lake City, UT, USA, shendrix@pentaracorp.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Prev Alzheimers Dis</MedlineTA><NlmUniqueID>101638820</NlmUniqueID><ISSNLinking>2274-5807</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102.</RefSource><PMID Version="1">36641605</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>SBH is owner and employee of Pentara Corporation and SPD is an employee of Pentara Corporation. Pentara performs statistical analyses for dozens of companies as a paid consultant in the Alzheimer&#x2019;s disease space.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>15</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36641604</ArticleId><ArticleId IdType="doi">10.14283/jpad.2022.104</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36641603</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2426-0266</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The journal of prevention of Alzheimer's disease</Title><ISOAbbreviation>J Prev Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Editorial: Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness.</ArticleTitle><Pagination><StartPage>5</StartPage><EndPage>6</EndPage><MedlinePgn>5-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14283/jpad.2022.103</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jeffrey Cummings, MD, ScD, 1380 Opal Valley Street, Henderson, NV 89052, jcummings@cnsinnovations.com, T: 702-902-3939.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM109025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Prev Alzheimers Dis</MedlineTA><NlmUniqueID>101638820</NlmUniqueID><ISSNLinking>2274-5807</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102.</RefSource><PMID Version="1">36641605</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>JC has provided consultation to Acadia, Actinogen, Alkahest, AlphaCognition, AriBio, Biogen, BioVie, Cassava, Cerecin, Corium, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, GAP Innovations, Grifols, Janssen, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Sage Therapeutics, Signant Health, Simcere, Sunbird Bio, Suven, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. JC is supported by NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053; NIA grant P30AG072959; NIA grant R35AG71476; Alzheimer&#x2019;s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; and the Joy Chambers-Grundy Endowment.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>15</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36641603</ArticleId><ArticleId IdType="doi">10.14283/jpad.2022.103</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36646701</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2373-8057</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>NPJ Parkinson's disease</Title><ISOAbbreviation>NPJ Parkinsons Dis</ISOAbbreviation></Journal><ArticleTitle>Dynamic physiological &#x3b1;-synuclein S129 phosphorylation is driven by neuronal activity.</ArticleTitle><Pagination><StartPage>4</StartPage><MedlinePgn>4</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41531-023-00444-w</ELocationID><Abstract><AbstractText>In Parkinson's disease and other synucleinopathies, the elevation of &#x3b1;-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined. Here we use multiple approaches to show for the first time that pS129 functions as a physiological regulator of neuronal activity. Neuronal activity triggers a sustained increase of pS129 in cultured neurons (200% within 4&#x2009;h). In accord, brain pS129 is elevated in environmentally enriched mice exhibiting enhanced long-term potentiation. Activity-dependent &#x3b1;-synuclein phosphorylation is S129-specific, reversible, confers no cytotoxicity, and accumulates at synapsin-containing presynaptic boutons. Mechanistically, our findings are consistent with a model in which neuronal stimulation enhances Plk2 kinase activity via a calcium/calcineurin pathway to counteract PP2A phosphatase activity for efficient phosphorylation of membrane-bound &#x3b1;-synuclein. Patch clamping of rat SNCA<sup>-/-</sup> neurons expressing exogenous wild-type or phospho-incompetent (S129A) &#x3b1;-synuclein suggests that pS129 fine-tunes the balance between excitatory and inhibitory neuronal currents. Consistently, our novel S129A knock-in (S129A<sup>KI</sup>) mice exhibit impaired hippocampal plasticity. The discovery of a key physiological function for pS129 has implications for understanding the role of &#x3b1;-synuclein in neurotransmission and adds nuance to the interpretation of pS129 as a synucleinopathy biomarker.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramalingam</LastName><ForeName>Nagendran</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9459-3593</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. nramalingam@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jin</LastName><ForeName>Shan-Xue</ForeName><Initials>SX</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Moors</LastName><ForeName>Tim E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonseca-Ornelas</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7810-5564</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimanaka</LastName><ForeName>Kazuma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Shi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Leveragen, Inc., 17 Briden Street, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cam</LastName><ForeName>Hugh P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Leveragen, Inc., 17 Briden Street, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Aurelia Hays</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brontesi</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Lai</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hacibaloglu</LastName><ForeName>Dinc Yasat</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Haiyang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0192-3889</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Joon</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanter</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4604-4629</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuber</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sulzer</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7632-0439</Identifier><AffiliationInfo><Affiliation>Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Therapeutics and Pharmacology, Columbia University Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosharov</LastName><ForeName>Eugene V</ForeName><Initials>EV</Initials><Identifier Source="ORCID">0000-0002-0229-7114</Identifier><AffiliationInfo><Affiliation>Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weisheng V</ForeName><Initials>WV</Initials><AffiliationInfo><Affiliation>Leveragen, Inc., 17 Briden Street, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9451-2151</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0001-8846-9767</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dettmer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-6676-0107</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. udettmer@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS109510</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS099328</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA007418</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>NPJ Parkinsons Dis</MedlineTA><NlmUniqueID>101675390</NlmUniqueID><ISSNLinking>2373-8057</ISSNLinking></MedlineJournalInfo><CoiStatement>D.J.S. is a director and consultant to Prothena Biosciences. W.V.C. is the CEO of Leveragen. The other authors declare no competing financial or non-financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36646701</ArticleId><ArticleId IdType="pmc">PMC9842642</ArticleId><ArticleId IdType="doi">10.1038/s41531-023-00444-w</ArticleId><ArticleId IdType="pii">10.1038/s41531-023-00444-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fujiwara H, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002;4:160&#x2013;164. doi: 10.1038/ncb748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb748</ArticleId><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleologou KE, et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 2008;283:16895&#x2013;16905. doi: 10.1074/jbc.M800747200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800747200</ArticleId><ArticleId IdType="pmc">PMC2423264</ArticleId><ArticleId IdType="pubmed">18343814</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, et al. Changes in properties of serine 129 phosphorylated &#x3b1;-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol. 2013;240:190&#x2013;204. doi: 10.1016/j.expneurol.2012.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.11.020</ArticleId><ArticleId IdType="pmc">PMC3720241</ArticleId><ArticleId IdType="pubmed">23201181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma MR, Hu ZW, Zhao YF, Chen YX, Li YM. Phosphorylation induces distinct alpha-synuclein strain formation. Sci. Rep. 2016;6:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112567</ArticleId><ArticleId IdType="pubmed">27853185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S. et al. LK6/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration. Sci. Rep. 10.1038/srep12564 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518213</ArticleId><ArticleId IdType="pubmed">26220523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. &#x3b1;-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc. Natl Acad. Sci. USA. 2012;109:16119&#x2013;16124. doi: 10.1073/pnas.1206286109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206286109</ArticleId><ArticleId IdType="pmc">PMC3479570</ArticleId><ArticleId IdType="pubmed">22988096</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silveira SA, et al. Phosphorylation does not prompt, nor prevent, the formation of &#x3b1;-synuclein toxic species in a rat model of Parkinson&#x2019;s disease. Hum. Mol. Genet. 2009;18:872&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">19074459</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland NR, et al. &#x3b1;-Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of parkinson disease. J. Neuropathol. Exp. Neurol. 2009;68:515&#x2013;524. doi: 10.1097/NEN.0b013e3181a24b53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181a24b53</ArticleId><ArticleId IdType="pmc">PMC2753269</ArticleId><ArticleId IdType="pubmed">19525899</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck K, et al. Ser129 phosphorylation of endogenous &#x3b1;-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. Neurobiol. Dis. 2015;78:100&#x2013;114. doi: 10.1016/j.nbd.2015.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.03.008</ArticleId><ArticleId IdType="pubmed">25818009</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiya Y, et al. Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J. Biol. Chem. 2010;285:40732&#x2013;40744. doi: 10.1074/jbc.M110.141952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.141952</ArticleId><ArticleId IdType="pmc">PMC3003373</ArticleId><ArticleId IdType="pubmed">20959456</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati A, Schneider BL, Aebischer P, Lashuel HA. Polo-like kinase 2 regulates selective autophagic &#x3b1;-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl Acad. Sci. USA. 2013;110:E3945&#x2013;3954. doi: 10.1073/pnas.1309991110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1309991110</ArticleId><ArticleId IdType="pmc">PMC3799334</ArticleId><ArticleId IdType="pubmed">23983262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenreiro S, et al. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson&#x2019;s disease. PLoS Genet. 2014;10:e1004302. doi: 10.1371/journal.pgen.1004302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004302</ArticleId><ArticleId IdType="pmc">PMC4014446</ArticleId><ArticleId IdType="pubmed">24810576</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinho R, et al. Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. Hum. Mol. Genet. 2019;28:31&#x2013;50. doi: 10.1093/hmg/ddy326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy326</ArticleId><ArticleId IdType="pubmed">30219847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai Y, Fujita SC, Iwatsubo T, Hasegawa M. Phosphorylated alpha-synuclein in normal mouse brain. FEBS Lett. 2004;572:227&#x2013;232. doi: 10.1016/j.febslet.2004.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2004.07.046</ArticleId><ArticleId IdType="pubmed">15304353</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntan&#xe9; G, Ferrer I, Martinez-Vicente M. &#x3b1;-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience. 2012;200:106&#x2013;119. doi: 10.1016/j.neuroscience.2011.10.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.10.042</ArticleId><ArticleId IdType="pubmed">22079575</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000;20:3214&#x2013;3220. doi: 10.1523/JNEUROSCI.20-09-03214.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-09-03214.2000</ArticleId><ArticleId IdType="pmc">PMC6773130</ArticleId><ArticleId IdType="pubmed">10777786</ArticleId></ArticleIdList></Reference><Reference><Citation>Berretta S, Parthasarathy HB, Graybiel AM. Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J. Neurosci. 1997;17:4752&#x2013;4763. doi: 10.1523/JNEUROSCI.17-12-04752.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-12-04752.1997</ArticleId><ArticleId IdType="pmc">PMC6573341</ArticleId><ArticleId IdType="pubmed">9169535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron. 2000;28:511&#x2013;525. doi: 10.1016/S0896-6273(00)00129-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00129-X</ArticleId><ArticleId IdType="pubmed">11144360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton AM, et al. Activity-dependent growth of new dendritic spines is regulated by the proteasome. Neuron. 2012;74:1023&#x2013;1030. doi: 10.1016/j.neuron.2012.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.04.031</ArticleId><ArticleId IdType="pmc">PMC3500563</ArticleId><ArticleId IdType="pubmed">22726833</ArticleId></ArticleIdList></Reference><Reference><Citation>Heubl M, et al. GABAA receptor dependent synaptic inhibition rapidly tunes KCC2 activity via the Cl&#x2013;sensitive WNK1 kinase. Nat. Commun. 2017;8:1776. doi: 10.1038/s41467-017-01749-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01749-0</ArticleId><ArticleId IdType="pmc">PMC5701213</ArticleId><ArticleId IdType="pubmed">29176664</ArticleId></ArticleIdList></Reference><Reference><Citation>Konietzny A, et al. Caldendrin and myosin V regulate synaptic spine apparatus localization via ER stabilization in dendritic spines. EMBO J. 2022;41:e106523. doi: 10.15252/embj.2020106523.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106523</ArticleId><ArticleId IdType="pmc">PMC8844991</ArticleId><ArticleId IdType="pubmed">34935159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hille B. Ionic channels in nerve membranes. Prog. Biophys. Mol. Biol. 1970;21:1&#x2013;32. doi: 10.1016/0079-6107(70)90022-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0079-6107(70)90022-2</ArticleId><ArticleId IdType="pubmed">4913288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak DTS, Sheng M. Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science. 2003;302:1368&#x2013;1373. doi: 10.1126/science.1082475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1082475</ArticleId><ArticleId IdType="pubmed">14576440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatavarty V, Sun Q, Turrigiano GG. How to scale down postsynaptic strength. J. Neurosci. 2013;33:13179&#x2013;13189. doi: 10.1523/JNEUROSCI.1676-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1676-13.2013</ArticleId><ArticleId IdType="pmc">PMC3735890</ArticleId><ArticleId IdType="pubmed">23926271</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HL, Queenan BN, Huganir RL. GRIP1 is required for homeostatic regulation of AMPAR trafficking. Proc. Natl Acad. Sci. USA. 2015;112:10026&#x2013;10031. doi: 10.1073/pnas.1512786112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1512786112</ArticleId><ArticleId IdType="pmc">PMC4538612</ArticleId><ArticleId IdType="pubmed">26216979</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, et al. Environmental novelty activates &#x3b2;2-adrenergic signaling to prevent the impairment of hippocampal LTP by A&#x3b2; oligomers. Neuron. 2013;77:929&#x2013;941. doi: 10.1016/j.neuron.2012.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.12.040</ArticleId><ArticleId IdType="pmc">PMC3596823</ArticleId><ArticleId IdType="pubmed">23473322</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JP, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006;281:29739&#x2013;29752. doi: 10.1074/jbc.M600933200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600933200</ArticleId><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Inglis KJ, et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 2009;284:2598&#x2013;2602. doi: 10.1074/jbc.C800206200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C800206200</ArticleId><ArticleId IdType="pmc">PMC2631975</ArticleId><ArticleId IdType="pubmed">19004816</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-W, et al. Enhanced phosphatase activity attenuates &#x3b1;-synucleinopathy in a mouse model. J. Neurosci. 2011;31:6963&#x2013;6971. doi: 10.1523/JNEUROSCI.6513-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6513-10.2011</ArticleId><ArticleId IdType="pmc">PMC5038983</ArticleId><ArticleId IdType="pubmed">21562258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara H, et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun. 1989;159:871&#x2013;877. doi: 10.1016/0006-291X(89)92189-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(89)92189-X</ArticleId><ArticleId IdType="pubmed">2539153</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburg DP, Feliu-Mojer M, Gaiottino J, Pak DTS, Sheng M. Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron. 2008;58:571&#x2013;583. doi: 10.1016/j.neuron.2008.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.03.021</ArticleId><ArticleId IdType="pmc">PMC2488274</ArticleId><ArticleId IdType="pubmed">18498738</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998;273:9443&#x2013;9449. doi: 10.1074/jbc.273.16.9443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.16.9443</ArticleId><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, et al. The N-terminus of the intrinsically disordered protein &#x3b1;-synuclein triggers membrane binding and helix folding. Biophys. J. 2010;99:2116&#x2013;2124. doi: 10.1016/j.bpj.2010.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2010.06.035</ArticleId><ArticleId IdType="pmc">PMC3042581</ArticleId><ArticleId IdType="pubmed">20923645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalingam, N. &amp; Dettmer, U. Temperature is a key determinant of alpha- and beta-synuclein membrane interactions in neurons. J. Biol. Chem. 10.1016/j.jbc.2021.100271 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7949061</ArticleId><ArticleId IdType="pubmed">33428933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. &#x3b1;-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 2014;24:2319&#x2013;2326. doi: 10.1016/j.cub.2014.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2014.08.027</ArticleId><ArticleId IdType="pmc">PMC4190006</ArticleId><ArticleId IdType="pubmed">25264250</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas KJ, et al. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci. 2014;34:9364&#x2013;9376. doi: 10.1523/JNEUROSCI.4787-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4787-13.2014</ArticleId><ArticleId IdType="pmc">PMC4087213</ArticleId><ArticleId IdType="pubmed">25009269</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T, Bendor J, Toupin C, Thorn K, Edwards RH. &#x3b1;-Synuclein promotes dilation of the exocytotic fusion pore. Nat. Neurosci. 2017;20:681&#x2013;689. doi: 10.1038/nn.4529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4529</ArticleId><ArticleId IdType="pmc">PMC5404982</ArticleId><ArticleId IdType="pubmed">28288128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S, Banker G. Culturing hippocampal neurons. Nat. Protoc. 2006;1:2406&#x2013;2415. doi: 10.1038/nprot.2006.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.356</ArticleId><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>King SO, Williams CL. Novelty-induced arousal enhances memory for cued classical fear conditioning: interactions between peripheral adrenergic and brainstem glutamatergic systems. Learn. Mem. Cold Spring Harb. N. 2009;16:625&#x2013;634. doi: 10.1101/lm.1513109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.1513109</ArticleId><ArticleId IdType="pubmed">19794188</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzanza N, de O, Sedlackova L, Kalaria RN. Alpha-synuclein post-translational modifications: implications for pathogenesis of lewy body disorders. Front. Aging Neurosci. 2021;13:690293. doi: 10.3389/fnagi.2021.690293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.690293</ArticleId><ArticleId IdType="pmc">PMC8267936</ArticleId><ArticleId IdType="pubmed">34248606</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, et al. Constitutive phosphorylation of the Parkinson&#x2019;s disease associated alpha-synuclein. J. Biol. Chem. 2000;275:390&#x2013;397. doi: 10.1074/jbc.275.1.390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.1.390</ArticleId><ArticleId IdType="pubmed">10617630</ArticleId></ArticleIdList></Reference><Reference><Citation>Theillet, F.-X. et al. Structural disorder of monomeric &#x3b1;-synuclein persists in mammalian cells. Nature10.1038/nature16531 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26808899</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca-Ornelas L, et al. Altered conformation of &#x3b1;-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson&#x2019;s disease. Cell Rep. 2021;36:109333. doi: 10.1016/j.celrep.2021.109333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109333</ArticleId><ArticleId IdType="pmc">PMC8552450</ArticleId><ArticleId IdType="pubmed">34233191</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston LJ, et al. Genetic deletion of Polo-like kinase 2 reduces alpha-synuclein serine-129 phosphorylation in presynaptic terminals but not Lewy bodies. J. Biol. Chem. 2021;296:100273. doi: 10.1016/j.jbc.2021.100273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100273</ArticleId><ArticleId IdType="pmc">PMC7948797</ArticleId><ArticleId IdType="pubmed">33428941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautenschl&#xe4;ger J, et al. C-terminal calcium binding of &#x3b1;-synuclein modulates synaptic vesicle interaction. Nat. Commun. 2018;9:712. doi: 10.1038/s41467-018-03111-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03111-4</ArticleId><ArticleId IdType="pmc">PMC5818535</ArticleId><ArticleId IdType="pubmed">29459792</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart AA, Ingebritsen TS, Cohen P. The protein phosphatases involved in cellular regulation. 5. Purification and properties of a Ca2+/calmodulin-dependent protein phosphatase (2B) from rabbit skeletal muscle. Eur. J. Biochem. 1983;132:289&#x2013;295. doi: 10.1111/j.1432-1033.1983.tb07361.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-1033.1983.tb07361.x</ArticleId><ArticleId IdType="pubmed">6301828</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart AA, Ingebritsen TS, Manalan A, Klee CB, Cohen P. Discovery of a Ca2+- and calmodulin-dependent protein phosphatase: probable identity with calcineurin (CaM-BP80) FEBS Lett. 1982;137:80&#x2013;84. doi: 10.1016/0014-5793(82)80319-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(82)80319-0</ArticleId><ArticleId IdType="pubmed">6279434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucker RS, Regehr WG. Short-term synaptic plasticity. Annu. Rev. Physiol. 2002;64:355&#x2013;405. doi: 10.1146/annurev.physiol.64.092501.114547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.physiol.64.092501.114547</ArticleId><ArticleId IdType="pubmed">11826273</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA, Leal K, Nanou E. Calcium channels and short-term synaptic plasticity. J. Biol. Chem. 2013;288:10742&#x2013;10749. doi: 10.1074/jbc.R112.411645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R112.411645</ArticleId><ArticleId IdType="pmc">PMC3624454</ArticleId><ArticleId IdType="pubmed">23400776</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas KJ, et al. Synucleins have multiple effects on presynaptic architecture. Cell Rep. 2017;18:161&#x2013;173. doi: 10.1016/j.celrep.2016.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.023</ArticleId><ArticleId IdType="pmc">PMC5510332</ArticleId><ArticleId IdType="pubmed">28052246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n-Vendrell C, et al. Effects of excess brain-derived human &#x3b1;-synuclein on synaptic vesicle trafficking. Front. Neurosci. 2021;15:639414. doi: 10.3389/fnins.2021.639414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.639414</ArticleId><ArticleId IdType="pmc">PMC7890186</ArticleId><ArticleId IdType="pubmed">33613189</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemani VM, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66&#x2013;79. doi: 10.1016/j.neuron.2009.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.12.023</ArticleId><ArticleId IdType="pmc">PMC3119527</ArticleId><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouke KE, et al. Synuclein regulates synaptic vesicle clustering and docking at a vertebrate synapse. Front. Cell Dev. Biol. 2021;9:774650. doi: 10.3389/fcell.2021.774650.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.774650</ArticleId><ArticleId IdType="pmc">PMC8660973</ArticleId><ArticleId IdType="pubmed">34901020</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, S&#xfc;dhof TC. &#x3b1;-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl Acad. Sci. USA. 2014;111:E4274&#x2013;4283. doi: 10.1073/pnas.1416598111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1416598111</ArticleId><ArticleId IdType="pmc">PMC4210039</ArticleId><ArticleId IdType="pubmed">25246573</ArticleId></ArticleIdList></Reference><Reference><Citation>Somayaji M, et al. A dual role for &#x3b1;-synuclein in facilitation and depression of dopamine release from substantia nigra neurons in vivo. Proc. Natl Acad. Sci. USA. 2020;117:32701&#x2013;32710. doi: 10.1073/pnas.2013652117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2013652117</ArticleId><ArticleId IdType="pmc">PMC7768743</ArticleId><ArticleId IdType="pubmed">33273122</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburg DP, Sheng M. Activity-induced Polo-like kinase 2 is required for homeostatic plasticity of hippocampal neurons during epileptiform activity. J. Neurosci. 2008;28:6583&#x2013;6591. doi: 10.1523/JNEUROSCI.1853-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1853-08.2008</ArticleId><ArticleId IdType="pmc">PMC3844828</ArticleId><ArticleId IdType="pubmed">18579731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KJ, et al. Requirement for Plk2 in orchestrated ras and rap signaling, homeostatic structural plasticity, and memory. Neuron. 2011;69:957&#x2013;973. doi: 10.1016/j.neuron.2011.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.02.004</ArticleId><ArticleId IdType="pmc">PMC3073828</ArticleId><ArticleId IdType="pubmed">21382555</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano GG. The self-tuning neuron: synaptic scaling of excitatory synapses. Cell. 2008;135:422&#x2013;435. doi: 10.1016/j.cell.2008.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.10.008</ArticleId><ArticleId IdType="pmc">PMC2834419</ArticleId><ArticleId IdType="pubmed">18984155</ArticleId></ArticleIdList></Reference><Reference><Citation>Diering GH, Huganir RL. The AMPA receptor code of synaptic plasticity. Neuron. 2018;100:314&#x2013;329. doi: 10.1016/j.neuron.2018.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.10.018</ArticleId><ArticleId IdType="pmc">PMC6214363</ArticleId><ArticleId IdType="pubmed">30359599</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, et al. Changes in the solubility and phosphorylation of &#x3b1;-synuclein over the course of Parkinson&#x2019;s disease. Acta Neuropathol. 2011;121:695&#x2013;704. doi: 10.1007/s00401-011-0815-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0815-1</ArticleId><ArticleId IdType="pubmed">21400129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanem SS, et al. &#x3b1;-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl Acad. Sci. USA. 2022;119:e2109617119. doi: 10.1073/pnas.2109617119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109617119</ArticleId><ArticleId IdType="pmc">PMC9169642</ArticleId><ArticleId IdType="pubmed">35353605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall H, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson&#x2019;s disease. Brain J. Neurol. 2014;137:2493&#x2013;2508. doi: 10.1093/brain/awu193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu193</ArticleId><ArticleId IdType="pubmed">25062696</ArticleId></ArticleIdList></Reference><Reference><Citation>Moors TE, et al. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol. Commun. 2022;10:82. doi: 10.1186/s40478-022-01382-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-022-01382-z</ArticleId><ArticleId IdType="pmc">PMC9164351</ArticleId><ArticleId IdType="pubmed">35659116</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RL, et al. Quantifying regional &#x3b1; -synuclein, amyloid &#x3b2;, and tau accumulation in lewy body dementia. Ann. Clin. Transl. Neurol. 2022;9:106&#x2013;121. doi: 10.1002/acn3.51482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51482</ArticleId><ArticleId IdType="pmc">PMC8862415</ArticleId><ArticleId IdType="pubmed">35060360</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabresi P, Castrioto A, Di Filippo M, Picconi B. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson&#x2019;s disease. Lancet Neurol. 2013;12:811&#x2013;821. doi: 10.1016/S1474-4422(13)70118-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70118-2</ArticleId><ArticleId IdType="pubmed">23867199</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone P, Erro R, Picillo M. Quality of life and nonmotor symptoms in Parkinson&#x2019;s disease. Int. Rev. Neurobiol. 2017;133:499&#x2013;516. doi: 10.1016/bs.irn.2017.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.irn.2017.05.023</ArticleId><ArticleId IdType="pubmed">28802930</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa C, et al. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson&#x2019;s disease. Brain J. Neurol. 2012;135:1884&#x2013;1899. doi: 10.1093/brain/aws101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws101</ArticleId><ArticleId IdType="pubmed">22561640</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendolino V, et al. l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via &#x3b2;-adrenergic receptors. Exp. Neurol. 2014;261:377&#x2013;385. doi: 10.1016/j.expneurol.2014.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.07.006</ArticleId><ArticleId IdType="pubmed">25058044</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x2019;s disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA. 1998;95:6469&#x2013;6473. doi: 10.1073/pnas.95.11.6469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6469</ArticleId><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahmoradian SH, et al. Lewy pathology in Parkinson&#x2019;s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 2019;22:1099&#x2013;1109. doi: 10.1038/s41593-019-0423-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0423-2</ArticleId><ArticleId IdType="pubmed">31235907</ArticleId></ArticleIdList></Reference><Reference><Citation>Moors TE, et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson&#x2019;s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol. 2021;142:423&#x2013;448. doi: 10.1007/s00401-021-02329-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02329-9</ArticleId><ArticleId IdType="pmc">PMC8357756</ArticleId><ArticleId IdType="pubmed">34115198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Biernat J, Mandelkow E. A current view on Tau protein phosphorylation in Alzheimer&#x2019;s disease. Curr. Opin. Neurobiol. 2021;69:131&#x2013;138. doi: 10.1016/j.conb.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2021.03.003</ArticleId><ArticleId IdType="pubmed">33892381</ArticleId></ArticleIdList></Reference><Reference><Citation>Dana H, et al. Sensitive red protein calcium indicators for imaging neural activity. eLife. 2016;5:e12727. doi: 10.7554/eLife.12727.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.12727</ArticleId><ArticleId IdType="pmc">PMC4846379</ArticleId><ArticleId IdType="pubmed">27011354</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovere, M., Sanderson, J. B., Fonseca-Ornelas, L., Patel, D. S. &amp; Bartels, T. Refolding of helical soluble &#x3b1;-synuclein through transient interaction with lipid interfaces. FEBS Lett. 10.1002/1873-3468.13047 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29633780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, et al. Environmental enrichment prevents A&#x3b2; oligomer-induced synaptic dysfunction through mirna-132 and hdac3 signaling pathways. Neurobiol. Dis. 2020;134:104617. doi: 10.1016/j.nbd.2019.104617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104617</ArticleId><ArticleId IdType="pmc">PMC7243177</ArticleId><ArticleId IdType="pubmed">31669733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36646931</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Droplet-based transcriptome profiling of individual synapses.</ArticleTitle><Pagination><StartPage>1332</StartPage><EndPage>1344</EndPage><MedlinePgn>1332-1344</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41587-022-01635-1</ELocationID><Abstract><AbstractText>Synapses are crucial structures that mediate signal transmission between neurons in complex neural circuits and display considerable morphological and electrophysiological heterogeneity. So far we still lack a high-throughput method to profile the molecular heterogeneity among individual synapses. In the present study, we develop a droplet-based single-cell (sc) total-RNA-sequencing platform, called Multiple-Annealing-and-Tailing-based Quantitative scRNA-seq in Droplets, for transcriptome profiling of individual neurites, primarily composed of synaptosomes. In the synaptosome transcriptome, or 'synaptome', profiling of both mouse and human brain samples, we detect subclusters among synaptosomes that are associated with neuronal subtypes and characterize the landscape of transcript splicing that occurs within synapses. We extend synaptome profiling to synaptopathy in an Alzheimer's disease (AD) mouse model and discover AD-associated synaptic gene expression changes that cannot be detected by single-nucleus transcriptome profiling. Overall, our results show that this platform provides a high-throughput, single-synaptosome transcriptome profiling tool that will facilitate future discoveries in neuroscience.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Muchun</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3221-3695</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrative Molecular and Biomedical Sciences Graduate Program, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Wenjian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics and Genomics Graduate Program, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Analytical Instrumentation, Institute of Cyber-Systems and Control, State Key Laboratory of Industrial Control Technology, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yongcheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute of Bioinspired Engineering, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Qiangyuan</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-4148-442X</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Analytical Instrumentation, Institute of Cyber-Systems and Control, State Key Laboratory of Industrial Control Technology, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer and Cell Biology Graduate Program, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baiping</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weitz</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-6678-5208</Identifier><AffiliationInfo><Affiliation>Wyss Institute of Bioinspired Engineering, Harvard University, Cambridge, MA, USA. weitz@seas.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physics and School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA. weitz@seas.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Chenghang</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8337-8038</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. czong@bcm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. czong@bcm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McNair Medical Institute, Baylor College of Medicine, Houston, TX, USA. czong@bcm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS093652</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA125123</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR024574</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025251</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 EB020399</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066606</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Biotechnol. 2023 Sep;41(9):1221-1224. doi: 10.1038/s41587-023-01877-7.</RefSource><PMID Version="1">37500915</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Biotechnol. 2023 Sep;41(9):1225-1228. doi: 10.1038/s41587-023-01878-6.</RefSource><PMID Version="1">37500916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="Y">Synapses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36646931</ArticleId><ArticleId IdType="doi">10.1038/s41587-022-01635-1</ArticleId><ArticleId IdType="pii">10.1038/s41587-022-01635-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gupta, A., Wang, Y. &amp; Markram, H. Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex. Science 287, 273&#x2013;278 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10634775</ArticleId><ArticleId IdType="doi">10.1126/science.287.5451.273</ArticleId></ArticleIdList></Reference><Reference><Citation>Husi, H., Ward, M. A., Choudhary, J. S., Blackstock, W. P. &amp; Grant, S. G. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 3, 661&#x2013;669 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10862698</ArticleId><ArticleId IdType="doi">10.1038/76615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez-Sandoval, O. et al. Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J. Neurosci. 30, 6999&#x2013;7016 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20484642</ArticleId><ArticleId IdType="pmc">4447206</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5996-09.2010</ArticleId></ArticleIdList></Reference><Reference><Citation>Cizeron, M. et al. A brainwide atlas of synapses across the mouse life span. Science 369, 270&#x2013;275 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32527927</ArticleId><ArticleId IdType="pmc">7115813</ArticleId><ArticleId IdType="doi">10.1126/science.aba3163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, F. et al. Architecture of the mouse brain synaptome. Neuron 99, 781&#x2013;799 e710 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30078578</ArticleId><ArticleId IdType="pmc">6117470</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng, K., Cao, W., Niu, Y., Deng, Q. &amp; Zong, C. Effective detection of variation in single-cell transcriptomes using MATQ-seq. Nat. Methods 14, 267&#x2013;270 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092691</ArticleId><ArticleId IdType="doi">10.1038/nmeth.4145</ArticleId></ArticleIdList></Reference><Reference><Citation>Macosko, E. Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202&#x2013;1214 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26000488</ArticleId><ArticleId IdType="pmc">4481139</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib, N. et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955&#x2013;958 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28846088</ArticleId><ArticleId IdType="pmc">5623139</ArticleId><ArticleId IdType="doi">10.1038/nmeth.4407</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28091601</ArticleId><ArticleId IdType="pmc">5241818</ArticleId><ArticleId IdType="doi">10.1038/ncomms14049</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, A. M. et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161, 1187&#x2013;1201 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26000487</ArticleId><ArticleId IdType="pmc">4441768</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.04.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramskold, D. et al. Full-length mRNA-seq from single-cell levels of RNA and individual circulating tumor cells. Nat. Biotechnol. 30, 777&#x2013;782 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22820318</ArticleId><ArticleId IdType="pmc">3467340</ArticleId><ArticleId IdType="doi">10.1038/nbt.2282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong, C., Lu, S., Chapman, A. R. &amp; Xie, X. S. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science 338, 1622&#x2013;1626 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23258894</ArticleId><ArticleId IdType="pmc">3600412</ArticleId><ArticleId IdType="doi">10.1126/science.1229164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, P. et al. Dissecting cell-type composition and activity-dependent transcriptional state in mammalian brains by massively parallel single-nucleus RNA-Seq. Mol. Cell 68, 1006&#x2013;1015.e1007 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29220646</ArticleId><ArticleId IdType="pmc">5743496</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2017.11.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafner, A. S., Donlin-Asp, P. G., Leitch, B., Herzog, E. &amp; Schuman, E. M. Local protein synthesis is a ubiquitous feature of neuronal pre- and postsynaptic compartments. Science 364, eaau3644 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31097639</ArticleId><ArticleId IdType="doi">10.1126/science.aau3644</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajigas, I. J. et al. The local transcriptome in the synaptic neuropil revealed by deep sequencing and high-resolution imaging. Neuron 74, 453&#x2013;466 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22578497</ArticleId><ArticleId IdType="pmc">3627340</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2012.02.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart, T. et al. Comprehensive Integration of single-cell data. Cell 177, 1888&#x2013;1902 e1821 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31178118</ArticleId><ArticleId IdType="pmc">6687398</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, K. A. et al. Neurodevelopmental disorder-associated ZBTB20 gene variants affect dendritic and synaptic structure. PLoS ONE 13, e0203760 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30281617</ArticleId><ArticleId IdType="pmc">6169859</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0203760</ArticleId></ArticleIdList></Reference><Reference><Citation>Frese, C. K. et al. Quantitative map of proteome dynamics during neuronal differentiation. Cell Rep. 18, 1527&#x2013;1542 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28178528</ArticleId><ArticleId IdType="pmc">5316641</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.01.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty, M. K. et al. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol. Cell 34, 652&#x2013;662 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19560418</ArticleId><ArticleId IdType="pmc">2737517</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2009.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery, J. M. &amp; Madison, D. V. Discrete synaptic states define a major mechanism of synapse plasticity. Trends Neurosci. 27, 744&#x2013;750 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15541515</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2004.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery, J. M. &amp; Madison, D. V. State-dependent heterogeneity in synaptic depression between pyramidal cell pairs. Neuron 33, 765&#x2013;777 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11879653</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(02)00606-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley, P. T. et al. Cytoplasmic intron sequence-retaining transcripts can be dendritically targeted via ID element retrotransposons. Neuron 69, 877&#x2013;884 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21382548</ArticleId><ArticleId IdType="pmc">3065018</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.02.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanzer, J. et al. RNA splicing capability of live neuronal dendrites. Proc. Natl Acad. Sci. USA 102, 16859&#x2013;16864 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16275927</ArticleId><ArticleId IdType="pmc">1277967</ArticleId><ArticleId IdType="doi">10.1073/pnas.0503783102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell, T. J. et al. Cytoplasmic BK(Ca) channel intron-containing mRNAs contribute to the intrinsic excitability of hippocampal neurons. Proc. Natl Acad. Sci. USA 105, 1901&#x2013;1906 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18250327</ArticleId><ArticleId IdType="pmc">2538856</ArticleId><ArticleId IdType="doi">10.1073/pnas.0711796105</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell, T. J. et al. Intron retention facilitates splice variant diversity in calcium-activated big potassium channel populations. Proc. Natl Acad. Sci. USA 107, 21152&#x2013;21157 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21078998</ArticleId><ArticleId IdType="pmc">3000244</ArticleId><ArticleId IdType="doi">10.1073/pnas.1015264107</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoto, J., Martinelli, D. C., Malenka, R. C., Tabuchi, K. &amp; Sudhof, T. C. Presynaptic neurexin-3 alternative splicing trans-synaptically controls postsynaptic AMPA receptor trafficking. Cell 154, 75&#x2013;88 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23827676</ArticleId><ArticleId IdType="pmc">3756801</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.05.060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, A. N. &amp; Appel, B. Oligodendrocytes express synaptic proteins that modulate myelin sheath formation. Nat. Commun. 10, 4125 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31511515</ArticleId><ArticleId IdType="pmc">6739339</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12059-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans, F. et al. SynGO: an evidence-based, expert-curated knowledge base for the synapse. Neuron 103, 217&#x2013;234.e214 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31171447</ArticleId><ArticleId IdType="pmc">6764089</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres, A., Banker, G., Steward, O., Binder, L. &amp; Payne, M. MAP2 is localized to the dendrites of hippocampal neurons which develop in culture. Brain Res. 315, 314&#x2013;318 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6722593</ArticleId><ArticleId IdType="doi">10.1016/0165-3806(84)90167-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Naisbitt, S. et al. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23, 569&#x2013;582 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10433268</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(00)80809-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Awasthi, A. et al. Synaptotagmin-3 drives AMPA receptor endocytosis, depression of synapse strength, and forgetting. Science 363, eaav1483 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30545844</ArticleId><ArticleId IdType="doi">10.1126/science.aav1483</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines, J. H., Ravanelli, A. M., Schwindt, R., Scott, E. K. &amp; Appel, B. Neuronal activity biases axon selection for myelination in vivo. Nat. Neurosci. 18, 683&#x2013;689 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25849987</ArticleId><ArticleId IdType="pmc">4414883</ArticleId><ArticleId IdType="doi">10.1038/nn.3992</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensch, S. et al. Synaptic vesicle release regulates myelin sheath number of individual oligodendrocytes in vivo. Nat. Neurosci. 18, 628&#x2013;630 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25849985</ArticleId><ArticleId IdType="pmc">4427868</ArticleId><ArticleId IdType="doi">10.1038/nn.3991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wake, H. et al. Nonsynaptic junctions on myelinating glia promote preferential myelination of electrically active axons. Nat. Commun. 6, 7844 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26238238</ArticleId><ArticleId IdType="doi">10.1038/ncomms8844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakers, K. et al. Astrocytes locally translate transcripts in their peripheral processes. Proc. Natl Acad. Sci. USA 114, E3830&#x2013;E3838 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28439016</ArticleId><ArticleId IdType="pmc">5441704</ArticleId><ArticleId IdType="doi">10.1073/pnas.1617782114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake, B. B. et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352, 1586&#x2013;1590 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27339989</ArticleId><ArticleId IdType="pmc">5038589</ArticleId><ArticleId IdType="doi">10.1126/science.aaf1204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27033548</ArticleId><ArticleId IdType="pmc">5094372</ArticleId><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy, E. R. et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J. Clin. Invest 130, 1912&#x2013;1930 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31917687</ArticleId><ArticleId IdType="pmc">7108898</ArticleId><ArticleId IdType="doi">10.1172/JCI133737</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar, G. M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866&#x2013;2875 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17360908</ArticleId><ArticleId IdType="pmc">6672572</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4970-06.2007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31042697</ArticleId><ArticleId IdType="pmc">6865822</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib, N. et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 23, 701&#x2013;706 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32341542</ArticleId><ArticleId IdType="pmc">9262034</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0624-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31932797</ArticleId><ArticleId IdType="pmc">6980793</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalcman, G., Federman, N. &amp; Romano, A. CaMKII isoforms in learning and memory: localization and function. Front. Mol. Neurosci. 11, 445 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30564099</ArticleId><ArticleId IdType="pmc">6288437</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2018.00445</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S. J. et al. Single-cell analysis of long non-coding RNAs in the developing human neocortex. Genome Biol. 17, 67 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27081004</ArticleId><ArticleId IdType="pmc">4831157</ArticleId><ArticleId IdType="doi">10.1186/s13059-016-0932-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilionis, R. et al. Single-cell barcoding and sequencing using droplet microfluidics. Nat. Protoc. 12, 44&#x2013;73 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27929523</ArticleId><ArticleId IdType="doi">10.1038/nprot.2016.154</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnaswami, S. R. et al. Using single nuclei for RNA-seq to capture the transcriptome of postmortem neurons. Nat. Protoc. 11, 499&#x2013;524 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26890679</ArticleId><ArticleId IdType="pmc">4941947</ArticleId><ArticleId IdType="doi">10.1038/nprot.2016.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 3 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.14806/ej.17.1.200</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, T., Heger, A. &amp; Sudbery, I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 27, 491&#x2013;499 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28100584</ArticleId><ArticleId IdType="pmc">5340976</ArticleId><ArticleId IdType="doi">10.1101/gr.209601.116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23104886</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, Y., Smyth, G. K. &amp; Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923&#x2013;930 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587 e3529 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34062119</ArticleId><ArticleId IdType="pmc">8238499</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.04.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister, C. &amp; Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31870423</ArticleId><ArticleId IdType="pmc">6927181</ArticleId><ArticleId IdType="doi">10.1186/s13059-019-1874-1</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis, C. S., Murrow, L. M. &amp; Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329&#x2013;337 e324 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30954475</ArticleId><ArticleId IdType="pmc">6853612</ArticleId><ArticleId IdType="doi">10.1016/j.cels.2019.03.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26653891</ArticleId><ArticleId IdType="pmc">4676162</ArticleId><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, M. D., McCarthy, D. J. &amp; Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19910308</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36652482</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Dimerization of the Alzheimer's disease pathogenic receptor SORLA regulates its association with retromer.</ArticleTitle><Pagination><StartPage>e2212180120</StartPage><MedlinePgn>e2212180120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2212180120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2212180120</ELocationID><Abstract><AbstractText><i>SORL1</i>, the gene encoding the large multidomain SORLA protein, has emerged as only the fourth gene that when mutated can by itself cause Alzheimer's disease (AD), and as a gene reliably linked to both the early- and late-onset forms of the disease. SORLA is known to interact with the endosomal trafficking regulatory complex called retromer in regulating the recycling of endosomal cargo, including the amyloid precursor protein (APP) and the glutamate receptor GluA1. Nevertheless, SORLA's precise structural-functional relationship in endosomal recycling tubules remains unknown. Here, we address these outstanding questions by relying on crystallographic and artificial-intelligence evidence to generate a structural model for how SORLA folds and fits into retromer-positive endosomal tubules, where it is found to dimerize via both SORLA's fibronectin-type-III (3Fn)- and VPS10p-domains. Moreover, we identify a SORLA fragment comprising the 3Fn-, transmembrane, and cytoplasmic domains that has the capacity to form a dimer, and to enhance retromer-dependent recycling of APP by decreasing its amyloidogenic processing. Collectively, these observations generate a model for how SORLA dimer (and possibly polymer) formation can function in stabilizing and enhancing retromer function at endosome tubules. These findings can inform investigation of the many AD-associated <i>SORL1</i> variants for evidence of pathogenicity and can guide discovery of novel drugs for the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Anne Mette G</ForeName><Initials>AMG</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Danish Research Institute of Translational Neuroscience, Aarhus University, Aarhus, 8000 Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitago</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazeli</LastName><ForeName>Elnaz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Danish Research Institute of Translational Neuroscience, Aarhus University, Aarhus, 8000 Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe6;gter</LastName><ForeName>Christian B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0001-6573-146X</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, Danish Research Institute of Translational Neuroscience, Aarhus University, Aarhus, 8000 Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY 10032.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petsko</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0003-3668-3694</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Olav M</ForeName><Initials>OM</Initials><Identifier Source="ORCID">0000-0003-4226-3354</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, Danish Research Institute of Translational Neuroscience, Aarhus University, Aarhus, 8000 Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="Y">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="Y">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">SORL1</Keyword><Keyword MajorTopicYN="N">dimerization</Keyword><Keyword MajorTopicYN="N">minigene</Keyword><Keyword MajorTopicYN="N">pathogenicity</Keyword></KeywordList><CoiStatement>The authors have organizational affiliations, stock ownership, and patent filings to disclose. G.A.P., S.A.S., and O.M.A. have financial interest in Retromer Therapeutics, Inc., but none of the research was funded by or influenced by the company. Aarhus University (A.M.G.J. and O.M.A.) holds a patent to the use of the SORLA minereceptor for AD gene-therapy.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>13</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36652482</ArticleId><ArticleId IdType="pmc">PMC9942828</ArticleId><ArticleId IdType="doi">10.1073/pnas.2212180120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jansen I. E., et al. , Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet. 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wightman D. P., et al. , A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer&#x2019;s disease. Nat. Genet. 53, 1276&#x2013;1282 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243600</ArticleId><ArticleId IdType="pubmed">34493870</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C., et al. , New insights into the genetic etiology of Alzheimer&#x2019;s disease and related dementias. Nat. Genet. 54, 412&#x2013;436 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005347</ArticleId><ArticleId IdType="pubmed">35379992</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H., et al. , Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer&#x2019;s disease. <i>Nat. Genet.</i>
54, 1786&#x2013;1794 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729101</ArticleId><ArticleId IdType="pubmed">36411364</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., et al. , Alzheimer&#x2019;s disease. Lancet 397, 1577&#x2013;1590 (2021), 10.1016/S0140-6736(20)32205-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32205-4</ArticleId><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H., et al. , Characterization of pathogenic SORL1 genetic variants for association with Alzheimer&#x2019;s disease: A clinical interpretation strategy. Eur. J. Hum. Genet. 25, 973&#x2013;981 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan N. S., et al. , Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol. 5, 832&#x2013;842 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043775</ArticleId><ArticleId IdType="pubmed">30009200</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjorback A. W., et al. , Retromer binds the FANSHY sorting motif in sorLA to regulate amyloid precursor protein sorting and processing. J. Neurosci. 32, 1467&#x2013;1480 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796259</ArticleId><ArticleId IdType="pubmed">22279231</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T. Y., et al. , SNX27 and SORLA interact to reduce amyloidogenic subcellular distribution and processing of amyloid precursor protein. J. Neurosci. 36, 7996&#x2013;8011 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961782</ArticleId><ArticleId IdType="pubmed">27466343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovtun O., et al. , Structure of the membrane-assembled retromer coat determined by cryo-electron tomography. Nature 561, 561&#x2013;564 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6173284</ArticleId><ArticleId IdType="pubmed">30224749</ArticleId></ArticleIdList></Reference><Reference><Citation>Leneva N., Kovtun O., Morado D. R., Briggs J. A. G., Owen D. J., Architecture and mechanism of metazoan retromer:SNX3 tubular coat assembly. Sci. Adv. 7, eabf8598 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990337</ArticleId><ArticleId IdType="pubmed">33762348</ArticleId></ArticleIdList></Reference><Reference><Citation>Caglayan S., et al. , Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer&#x2019;s disease mutation. Sci. Transl. Med. 6, 223ra220 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24523320</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen O. M., et al. , A genetically modified minipig model for Alzheimer&#x2019;s disease with SORL1 haploinsufficiency Cell Rep. Med. 3, 100740, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9512670</ArticleId><ArticleId IdType="pubmed">36099918</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes S., et al. , Alzheimer&#x2019;s vulnerable brain region relies on a distinct retromer core dedicated to endosomal recycling. Cell Rep. 37, 110182 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8792909</ArticleId><ArticleId IdType="pubmed">34965419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S., et al. , The Alzheimer&#x2019;s gene SORL1 is a regulator of endosomal traffic and recycling in human neurons. Cell. Mol. Life Sci. 79, 162 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8885486</ArticleId><ArticleId IdType="pubmed">35226190</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen S. K., et al. , Endosomal trafficking is required for glycosylation and normal maturation of the Alzheimer&#x2019;s-associated protein sorLA. bioRxiv [Preprint] (2020), 10.1101/2020.07.12.199885 Accessed 1 August 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.12.199885</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A., et al. , Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease. Acta Neuropathol. Commun. 9, 196 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8684260</ArticleId><ArticleId IdType="pubmed">34922638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen P. J., Steinberg F., To degrade or not to degrade: Mechanisms and significance of endocytic recycling. Nat. Rev. Mol. Cell Biol. 19, 679&#x2013;696 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30194414</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S. A., Petsko G. A., Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 16, 126&#x2013;132 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25669742</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S. A., Simoes-Spassov S., Mayeux R., Petsko G. A., Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer&#x2019;s disease. Trends Neurosci. 40, 592&#x2013;602 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5654621</ArticleId><ArticleId IdType="pubmed">28962801</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S. A., Petsko G. A., Endosomal recycling reconciles the Alzheimer&#x2019;s disease paradox. Sci. Transl. Med. 12, eabb1717 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8025181</ArticleId><ArticleId IdType="pubmed">33268506</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow T. E., Petersen C. M., Nykjaer A., VPS10P-domain receptors&#x2013;Regulators of neuronal viability and function. Nat. Rev. Neurosci. 9, 899&#x2013;909 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19002190</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermey G., The Vps10p-domain receptor family. Cell. Mol. Life Sci. 66, 2677&#x2013;2689 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115710</ArticleId><ArticleId IdType="pubmed">19434368</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti G., Andersen O. M., 20 years anniversary for SORLA/SORL1 (1996&#x2013;2016). Recept. Clin. Invest. 4, e1611 (2017).</Citation></Reference><Reference><Citation>Verheijen J., et al. , A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer&#x2019;s disease. Acta Neuropathol. 132, 213&#x2013;224 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947104</ArticleId><ArticleId IdType="pubmed">27026413</ArticleId></ArticleIdList></Reference><Reference><Citation>Leloup N., et al. , Low pH-induced conformational change and dimerization of sortilin triggers endocytosed ligand release. Nat. Commun. 8, 1708 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700061</ArticleId><ArticleId IdType="pubmed">29167428</ArticleId></ArticleIdList></Reference><Reference><Citation>Januliene D., et al. , Acidic environment induces dimerization and ligand binding site collapse in the Vps10p domain of sortilin. Structure 25, 1809&#x2013;1819.e3 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29107483</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabe-Wada T., Matsuba S., Unno M., Onai N., Crystal structure of the ligand-free form of the Vps10 ectodomain of dimerized Sortilin at acidic pH. FEBS Lett. 592, 2647&#x2013;2657 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29972886</ArticleId></ArticleIdList></Reference><Reference><Citation>Januliene D., et al. , Hidden twins: SorCS neuroreceptors form stable dimers. J. Mol. Biol. 429, 2907&#x2013;2917 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28827148</ArticleId></ArticleIdList></Reference><Reference><Citation>Leloup N., Chataigner L. M. P., Janssen B. J. C., Structural insights into SorCS2-nerve growth factor complex formation. Nat. Commun. 9, 2979 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065357</ArticleId><ArticleId IdType="pubmed">30061605</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., et al. , Cryo-EM structures reveal distinct apo conformations of sortilin-related receptor SORLA. Biochem. Biophys. Res. Commun. 600, 75&#x2013;79 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35196630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A., et al. , The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol. Dis. 47, 126&#x2013;134 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="pubmed">22516235</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Akhrass H., et al. , A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance. Oncogene 40, 1300&#x2013;1317 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892347</ArticleId><ArticleId IdType="pubmed">33420373</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz J. H., et al. , GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-beta production. Mol. Biol. Cell 23, 2645&#x2013;2657 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3395654</ArticleId><ArticleId IdType="pubmed">22621900</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgert T., et al. , SORLA-dependent and -independent functions for PACS1 in control of amyloidogenic processes. Mol. Cell. Biol. 33, 4308&#x2013;4320 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811889</ArticleId><ArticleId IdType="pubmed">24001769</ArticleId></ArticleIdList></Reference><Reference><Citation>Croucher D. R., et al. , Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers. Sci. Signal. 9, ra69 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27405979</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen O. M., et al. , SorLA/LR11, a neuronal sorting receptor that regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 102, 13461&#x2013;13466 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson S. E., et al. , Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: Evidence for a proximal role in Alzheimer&#x2019;s disease. J. Neurosci. 28, 12877&#x2013;12886 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehmedbasic A., et al. , SorLA complement-type repeat domains protect the amyloid precursor protein against processing. J. Biol. Chem. 290, 3359&#x2013;3376 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319007</ArticleId><ArticleId IdType="pubmed">25525276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitago Y., et al. , Structural basis for amyloidogenic peptide recognition by sorLA. Nat. Struct. Mol. Biol. 22, 199&#x2013;206 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25643321</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi V. J., et al. , Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10, 443&#x2013;449 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii Y., et al. , PA tag: A versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. Protein Expr. Purif. 95, 240&#x2013;247 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24480187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J., et al. , Highly accurate protein structure prediction with AlphaFold. Nature 596, 583&#x2013;589 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunyasuvunakool K., et al. , Highly accurate protein structure prediction for the human proteome. Nature 596, 590&#x2013;596 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387240</ArticleId><ArticleId IdType="pubmed">34293799</ArticleId></ArticleIdList></Reference><Reference><Citation>Willingham M. C., Hanover J. A., Dickson R. B., Pastan I., Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc. Natl. Acad. Sci. U.S.A. 81, 175&#x2013;179 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC344633</ArticleId><ArticleId IdType="pubmed">6141558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierro A., et al. , Functional architecture of the retromer cargo-recognition complex. Nature 449, 1063&#x2013;1067 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377034</ArticleId><ArticleId IdType="pubmed">17891154</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoelgen R., et al. , Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and b-secretase b-site APP-cleaving enzyme. J. Neurosci. 26, 418&#x2013;428 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674411</ArticleId><ArticleId IdType="pubmed">16407538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A., et al. , Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: Role of the intracellular adapter protein Fe65. J. Neurosci. 21, 8354&#x2013;8361 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762817</ArticleId><ArticleId IdType="pubmed">11606623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones D. T., Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol. 292, 195&#x2013;202 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10493868</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J., Randall A. Z., Sweredoski M. J., Baldi P., SCRATCH: A protein structure and structural feature prediction server. Nucleic Acids Res. 33, W72&#x2013;76 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160157</ArticleId><ArticleId IdType="pubmed">15980571</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K., Simossis V. A., Taylor W. R., Heringa J., A simple and fast secondary structure prediction method using hidden neural networks. Bioinformatics 21, 152&#x2013;159 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15377504</ArticleId></ArticleIdList></Reference><Reference><Citation>Manders E. M. M., Verbeek F. J., Aten J. A., Measurement of co-localization of objects in dual-colour confocal images. J. Microsc. 169, 375&#x2013;382 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">33930978</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider C. A., Rasband W. S., Eliceiri K. W., NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671&#x2013;675 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S., Cordelieres F. P., A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213&#x2013;232 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J. C., et al. , Scalable molecular dynamics on CPU and GPU architectures with NAMD. J. Chem. Phys. 153, 044130 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395834</ArticleId><ArticleId IdType="pubmed">32752662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner D. E., Chan K. Y., Phillips J. C., Schulten K., Parallel generalized born implicit solvent calculations with NAMD. J. Chem. Theory Comput. 7, 3635&#x2013;3642 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222955</ArticleId><ArticleId IdType="pubmed">22121340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner D. E., Phillips J. C., Schulten K., GPU/CPU algorithm for generalized born/solvent-accessible surface area implicit solvent calculations. J. Chem. Theory Comput. 8, 2521&#x2013;2530 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464051</ArticleId><ArticleId IdType="pubmed">23049488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitago Y., Andersen O. M., Petsko G. A., AlphaFold2prediction of hSORLA extracelluar domain. ModelArchive.
https://modelarchive.org/doi/10.5452/ma-zgbg4. Deposited 30 December 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.5452/ma-zgbg4</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36658241</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>Human early-onset dementia caused by DAP12 deficiency reveals a unique signature of dysregulated microglia.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>557</EndPage><MedlinePgn>545-557</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-022-01403-y</ELocationID><Abstract><AbstractText>The TREM2-DAP12 receptor complex sustains microglia functions. Heterozygous hypofunctional TREM2 variants impair microglia, accelerating late-onset Alzheimer's disease. Homozygous inactivating variants of TREM2 or TYROBP-encoding DAP12 cause Nasu-Hakola disease (NHD), an early-onset dementia characterized by cerebral atrophy, myelin loss and gliosis. Mechanisms underpinning NHD are unknown. Here, single-nucleus RNA-sequencing analysis of brain specimens from DAP12-deficient NHD individuals revealed a unique microglia signature indicating heightened RUNX1, STAT3 and transforming growth factor-&#x3b2; signaling pathways that mediate repair responses to injuries. This profile correlated with a wound healing signature in astrocytes and impaired myelination in oligodendrocytes, while pericyte profiles indicated vascular abnormalities. Conversely, single-nuclei signatures in mice lacking DAP12 signaling reflected very mild microglial defects that did not recapitulate NHD. We envision that DAP12 signaling in microglia attenuates wound healing pathways that, if left unchecked, interfere with microglial physiological functions, causing pathology in human. The identification of a dysregulated NHD microglia signature sparks potential therapeutic strategies aimed at resetting microglia signaling pathways.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yingyue</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0923-1046</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tada</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Zhangying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andhey</LastName><ForeName>Prabhakar S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swain</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>10x Genomics, Pleasanton, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deepcell, Menlo Park, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1672-0996</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artyomov</LastName><ForeName>Maxim N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0002-1133-4212</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takao</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry (NCNP), National Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain Bank, Mihara Memorial Hospital, Isesaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakita</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5222-4987</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. mcolonna@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG077244</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059082</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG078106</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110546">TYROBP protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536329">Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Immunol. 2023 Mar;24(3):558. doi: 10.1038/s41590-023-01465-6.</RefSource><PMID Version="1">36807644</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Immunol. 2023 Mar;24(3):379-381. doi: 10.1038/s41590-023-01440-1.</RefSource><PMID Version="1">36823406</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010009" MajorTopicYN="N">Osteochondrodysplasias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013344" MajorTopicYN="Y">Subacute Sclerosing Panencephalitis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008060" MajorTopicYN="N">Lipodystrophy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests Statement. M.C. is a member of the Vigil Neuro scientific advisory board (SAB), is consultant for Cell Signaling Technology, has received research grants from Vigil Neuro during the conduct of the study and has a patent to TREM2 pending. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>19</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36658241</ArticleId><ArticleId IdType="mid">NIHMS1867024</ArticleId><ArticleId IdType="pmc">PMC9992145</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01403-y</ArticleId><ArticleId IdType="pii">10.1038/s41590-022-01403-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ulland TK &amp; Colonna M TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14, 667&#x2013;675 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R-Y et al. TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. Molecular Neurodegeneration 17, 40 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166437</ArticleId><ArticleId IdType="pubmed">35658903</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG &amp; Goate AM Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Molecular Neurodegeneration 12, 43 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. Journal of Experimental Medicine jem.20171529 (2018) doi:10.1084/jem.20171529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171529</ArticleId><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nature Medicine 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y &amp; Colonna M Microglia in Alzheimer&#x2019;s disease at single-cell level. Are there common patterns in humans and mice? Journal of Experimental Medicine 218, e20202717 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302448</ArticleId><ArticleId IdType="pubmed">34292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J et al. Mutations in Two Genes Encoding Different Subunits of a Receptor Signaling Complex Result in an Identical Disease Phenotype. The American Journal of Human Genetics 71, 656&#x2013;662 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouery E et al. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Human Mutation 29, E194&#x2013;E204 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18546367</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J et al. CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts. Neurology 56, 1552&#x2013;1558 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11402114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A et al. Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease. Neurogenetics 16, 265&#x2013;276 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26001891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaifu T et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 111, 323&#x2013;332 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151867</ArticleId><ArticleId IdType="pubmed">12569157</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S et al. Brain and Bone Damage in KARAP/DAP12 Loss-of-Function Mice Correlate with Alterations in Microglia and Osteoclast Lineages. The American Journal of Pathology 166, 275&#x2013;286 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602283</ArticleId><ArticleId IdType="pubmed">15632019</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliani PL et al. TREM2 sustains microglial expansion during aging and response to demyelination. J. Clin. Invest. 125, 2161&#x2013;2170 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463196</ArticleId><ArticleId IdType="pubmed">25893602</ArticleId></ArticleIdList></Reference><Reference><Citation>Roumier A et al. Impaired Synaptic Function in the Microglial KARAP/DAP12-Deficient Mouse. J. Neurosci. 24, 11421&#x2013;11428 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730361</ArticleId><ArticleId IdType="pubmed">15601948</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasello E et al. Combined Natural Killer Cell and Dendritic Cell Functional Deficiency in KARAP/DAP12 Loss-of-Function Mutant Mice. Immunity 13, 355&#x2013;364 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11021533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T et al. Heterogeneity of presenile dementia with bone cysts (Nasu-Hakola disease): three genetic forms. Neurology 59, 1105&#x2013;1107 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12370476</ArticleId></ArticleIdList></Reference><Reference><Citation>Zusso M et al. Regulation of Postnatal Forebrain Amoeboid Microglial Cell Proliferation and Development by the Transcription Factor Runx1. J Neurosci 32, 11285&#x2013;11298 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621177</ArticleId><ArticleId IdType="pubmed">22895712</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths EK &amp; Penninger JM ADAP-ting TCR signaling to integrins. Sci STKE 2002, re3 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11943877</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B et al. VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways. Front Oncol 10, 543562 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7509134</ArticleId><ArticleId IdType="pubmed">33014879</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML &amp; McGlade CJ The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol 12, 446&#x2013;453 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11909529</ArticleId></ArticleIdList></Reference><Reference><Citation>Matak P et al. Activated macrophages induce hepcidin expression in HuH7 hepatoma cells. Haematologica 94, 773&#x2013;780 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688568</ArticleId><ArticleId IdType="pubmed">19454498</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh M &amp; Katoh M STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int J Mol Med 19, 273&#x2013;278 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17203201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K et al. Alzheimer&#x2019;s Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. Cell Rep 31, 107843 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7422733</ArticleId><ArticleId IdType="pubmed">32610143</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay EC et al. Peri-Infarct Upregulation of the Oxytocin Receptor in Vascular Dementia. J Neuropathol Exp Neurol 78, 436&#x2013;452 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467199</ArticleId><ArticleId IdType="pubmed">30990880</ArticleId></ArticleIdList></Reference><Reference><Citation>Absinta M et al. A lymphocyte&#x2013;microglia&#x2013;astrocyte axis in chronic active multiple sclerosis. Nature 597, 709&#x2013;714 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719282</ArticleId><ArticleId IdType="pubmed">34497421</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FO, Sica A, Mantovani A &amp; Locati M Macrophage activation and polarization. Front Biosci 13, 453&#x2013;461 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17981560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohradanova-Repic A et al. Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. Front Immunol 9, 852 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5946032</ArticleId><ArticleId IdType="pubmed">29780382</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda M et al. FGF-2 released from degenerating neurons exerts microglial-induced neuroprotection via FGFR3-ERK signaling pathway. J Neuroinflammation 11, 76 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022102</ArticleId><ArticleId IdType="pubmed">24735639</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia FJ et al. Single-cell dissection of the human brain vasculature. Nature 603, 893&#x2013;899 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9680899</ArticleId><ArticleId IdType="pubmed">35158371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley C, D&#x2019;Amore P, Hechtman HB &amp; Shepro D Vasoactive hormones and cAMP affect pericyte contraction and stress fibres in vitro. J Muscle Res Cell Motil 9, 184&#x2013;194 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2458383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerthoffer WT, Solway J &amp; Camoretti-Mercado B Emerging targets for novel therapy of asthma. Curr Opin Pharmacol 13, 324&#x2013;330 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686997</ArticleId><ArticleId IdType="pubmed">23639507</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy S &amp; Fehr AR PARP14: A key ADP-ribosylating protein in host&#x2013;virus interactions? PLOS Pathogens 18, e1010535 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9182250</ArticleId><ArticleId IdType="pubmed">35679255</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddleston M et al. Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. J Clin Invest 92, 349&#x2013;358 (1993).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC293611</ArticleId><ArticleId IdType="pubmed">8326003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiese S, Karus M &amp; Faissner A Astrocytes as a Source for Extracellular Matrix Molecules and Cytokines. Frontiers in Pharmacology 3, (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382726</ArticleId><ArticleId IdType="pubmed">22740833</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthies AM, Low QEH, Lingen MW &amp; DiPietro LA Neuropilin-1 Participates in Wound Angiogenesis. Am J Pathol 160, 289&#x2013;296 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867138</ArticleId><ArticleId IdType="pubmed">11786422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39, 779&#x2013;792.e11 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8366750</ArticleId><ArticleId IdType="pubmed">34087162</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulson AJ, Squair JW, Franklin RJM, Tetzlaff W &amp; Assinck P Diversity of Reactive Astrogliosis in CNS Pathology: Heterogeneity or Plasticity? Frontiers in Cellular Neuroscience 15, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8349991</ArticleId><ArticleId IdType="pubmed">34381334</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J-I et al. Immunohistochemical characterization of microglia in Nasu-Hakola disease brains. Neuropathology 31, 363&#x2013;375 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21118401</ArticleId></ArticleIdList></Reference><Reference><Citation>Erwig MS et al. Anillin facilitates septin assembly to prevent pathological outfoldings of central nervous system myelin. Elife 8, e43888 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344079</ArticleId><ArticleId IdType="pubmed">30672734</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel S et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543&#x2013;547 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Ximerakis M et al. Single-cell transcriptomic profiling of the aging mouse brain. Nature Neuroscience 22, 1696&#x2013;1708 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31551601</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S et al. White matter aging drives microglial diversity. Neuron 109, 1100&#x2013;1117.e10 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33606969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger DC et al. Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 118, e2017742118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826333</ArticleId><ArticleId IdType="pubmed">33446504</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherneck S et al. Role of Zinc Finger Transcription Factor Zfp69 in Body Fat Storage and Diabetes Susceptibility of Mice. in Sensory and Metabolic Control of Energy Balance (eds. Meyerhof W., Beisiegel U. &amp; Joost H-G.) 57&#x2013;68 (Springer, 2010). doi:10.1007/978-3-642-14426-4_6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-14426-4_6</ArticleId><ArticleId IdType="pubmed">20865372</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques S et al. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science 352, 1326&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221728</ArticleId><ArticleId IdType="pubmed">27284195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe Y et al. The myelin proteolipid plasmolipin forms oligomers and induces liquid-ordered membranes in the Golgi complex. J. Cell. Sci. 128, 2293&#x2013;2302 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26002055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu T &amp; Lieberman AP Npc1 acting in neurons and glia is essential for the formation and maintenance of CNS myelin. PLoS Genet. 9, e1003462 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623760</ArticleId><ArticleId IdType="pubmed">23593041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenigsbuch M et al. A shared disease-associated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25, 876&#x2013;886 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724210</ArticleId><ArticleId IdType="pubmed">35760863</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Long CL, Malhotra S &amp; Humphrey MB A Physical Interaction Between the Adaptor Proteins DOK3 and DAP12 Is Required to Inhibit Lipopolysaccharide Signaling in Macrophages. Sci. Signal. 6, (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923308</ArticleId><ArticleId IdType="pubmed">23962980</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR &amp; Colonna M Activating and inhibitory functions of DAP12. Nat Rev Immunol 7, 155&#x2013;161 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17220916</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S et al. TREM2 drives microglia response to amyloid-&#x3b2; via SYK-dependent and -independent pathways. Cell 185, 4153&#x2013;4169.e19 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9625082</ArticleId><ArticleId IdType="pubmed">36306735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapenna A, De Palma M &amp; Lewis CE Perivascular macrophages in health and disease. Nat Rev Immunol 18, 689&#x2013;702 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30127389</ArticleId></ArticleIdList></Reference><Reference><Citation>Haure-Mirande J-V et al. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer&#x2019;s pathology. Acta Neuropathol 134, 769&#x2013;788 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645450</ArticleId><ArticleId IdType="pubmed">28612290</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods-only References</Title><Reference><Citation>Fonseka CY et al. Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis. Sci Transl Med 10, eaaq0305 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448773</ArticleId><ArticleId IdType="pubmed">30333237</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature Biotechnology 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C &amp; Satija R Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biology 20, 296 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biology 16, 278 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreatta M &amp; Carmona SJ UCell: Robust and scalable single-cell gene signature scoring. Comput Struct Biotechnol J 19, 3796&#x2013;3798 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8271111</ArticleId><ArticleId IdType="pubmed">34285779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications 10, 1523 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Browaeys R, Saelens W &amp; Saeys Y NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods 17, 159&#x2013;162 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31819264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenkova D et al. phantasus: Visual and interactive gene expression analysis. (2022) doi:10.18129/B9.bioc.phantasus.</Citation><ArticleIdList><ArticleId IdType="doi">10.18129/B9.bioc.phantasus</ArticleId><ArticleId IdType="pmc">PMC11147506</ArticleId><ArticleId IdType="pubmed">38742735</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R et al. Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: Evidence for clinico-pathologic subtypes. Acta Neuropathologica Communications 4, 61 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918136</ArticleId><ArticleId IdType="pubmed">27338935</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36669485</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Virus exposure and neurodegenerative disease risk across national biobanks.</ArticleTitle><Pagination><StartPage>1086</StartPage><EndPage>1093.e2</EndPage><MedlinePgn>1086-1093.e2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2022.12.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(22)01147-3</ELocationID><Abstract><AbstractText>With recent findings connecting the Epstein-Barr virus to an increased risk of multiple sclerosis and growing concerns regarding the neurological impact of the coronavirus pandemic, we examined potential links between viral exposures and neurodegenerative disease risk. Using time series data from FinnGen for discovery and cross-sectional data from the UK Biobank for replication, we identified 45 viral exposures significantly associated with increased risk of neurodegenerative disease and replicated 22 of these associations. The largest effect association was between viral encephalitis exposure and Alzheimer's disease. Influenza with pneumonia was significantly associated with five of the six neurodegenerative diseases studied. We also replicated the Epstein-Barr/multiple sclerosis association. Some of these exposures were associated with an increased risk of neurodegeneration up to 15 years after infection. As vaccines are currently available for some of the associated viruses, vaccination may be a way to reduce some risk of neurodegenerative disease.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Kristin S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonard</LastName><ForeName>Hampton L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington DC, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; University of Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blauwendraat</LastName><ForeName>Cornelis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwaki</LastName><ForeName>Hirotaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington DC, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandres-Ciga</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Longitudinal Studies Section, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faghri</LastName><ForeName>Faraz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington DC, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International LLC, Washington DC, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. Electronic address: nallsm@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 May;19(5):259-260. doi: 10.1038/s41582-023-00790-6.</RefSource><PMID Version="1">36864169</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="N">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">encephalitis</Keyword><Keyword MajorTopicYN="N">generalized dementia</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">varicella-zoster</Keyword><Keyword MajorTopicYN="N">vascular dementia</Keyword><Keyword MajorTopicYN="N">viral exposure</Keyword></KeywordList><CoiStatement>Declaration of interests K.S.L., H.L.L., H.I., N.J., F.F., and M.A.N.&#x2019;s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>20</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36669485</ArticleId><ArticleId IdType="mid">NIHMS1861159</ArticleId><ArticleId IdType="pmc">PMC10079561</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2022.12.029</ArticleId><ArticleId IdType="pii">S0896-6273(22)01147-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, et al. (2022). Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, and Nath A (2022). Nervous system consequences of COVID-19. Science 375, 267&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotz SK, Blackhurst BM, Reagin KL, and Funk KE (2021). Microbial Infections Are a Risk Factor for Neurodegenerative Diseases. Front. Cell. Neurosci. 15, 691136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8292681</ArticleId><ArticleId IdType="pubmed">34305533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjan R, Abhinay A, and Mishra M (2018). Can oral microbial infections be a risk factor for neurodegeneration? A review of the literature. Neurol. India 66, 344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">29547153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurki MI, Karjalainen J, Palta P, Sipil&#xe4; TP, Kristiansson K, Donner K, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, et al. (2022). FinnGen: Unique genetic insights from combining isolated population and national health register data. medRxiv, 2022.03.03.22271360.</Citation></Reference><Reference><Citation>Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. (2015). UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, et al. (2015). Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 72, 31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391035</ArticleId><ArticleId IdType="pubmed">25419615</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, and Tabet N (2017). Herpes simplex encephalitis and Alzheimer&#x2019;s disease: Is there a link? J. Neurol. Sci. 380, 20&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">28870568</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcocci ME, Napoletani G, Protto V, Kolesova O, Piacentini R, Li Puma DD, Lomonte P, Grassi C, Palamara AT, and De Chiara G (2020). Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. Trends Microbiol. 28, 808&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">32386801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassendine MF, Taylor-Robinson SD, Fertleman M, Khan M, and Neely D (2020). Is Alzheimer&#x2019;s Disease a Liver Disease of the Brain? J. Alzheimers. Dis. 75, 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7306895</ArticleId><ArticleId IdType="pubmed">32250293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H-C, Xirasagar S, Lee H-C, Huang C-C, and Chen C-H (2017). Association of Alzhemier&#x2019;s disease with hepatitis C among patients with bipolar disorder. PLoS One 12, e0179312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5473552</ArticleId><ArticleId IdType="pubmed">28622343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C-H, Chien W-C, Chung C-H, Chiang C-P, Wang W-M, Chang H-A, Kao Y-C, and Tzeng N-S (2020). Increased risk of dementia in patients with genital warts: A nationwide cohort study in Taiwan. J. Dermatol. 47, 503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">32189395</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S-Y, Yang Y-X, Kuo K, Li H-Q, Shen X-N, Chen S-D, Cui M, Tan L, Dong Q, and Yu J-T (2021). Herpesvirus infections and Alzheimer&#x2019;s disease: a Mendelian randomization study. Alzheimers. Res. Ther. 13, 158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8464096</ArticleId><ArticleId IdType="pubmed">34560893</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Zhang L-J, Yang L, Yang C-S, Yi M, Zhang S-N, Wang N, Huang C-N, and Liu M-Q (2021). Positive association of herpes simplex virus-IgG with multiple sclerosis: A systematic review and meta-analysis. Mult. Scler. Relat. Disord. 47, 102633.</Citation><ArticleIdList><ArticleId IdType="pubmed">33254090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman LA, and Vilensky JA (2017). Encephalitis lethargica: 100 years after the epidemic. Brain 140, 2246&#x2013;2251.</Citation><ArticleIdList><ArticleId IdType="pubmed">28899018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocoros NM, Svensson E, Sz&#xe9;pligeti SK, Vestergaard SV, Szentk&#xfa;ti P, Thomsen RW, Borghammer P, S&#xf8;rensen HT, and Henderson VW (2021). Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurol. 78, 1461&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546623</ArticleId><ArticleId IdType="pubmed">34694344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhbinder AS, Ling Y, Hasan O, Jiang X, Kim Y, Phelps KN, Schmandt RE, Amran A, Coburn R, Ramesh S, et al. (2022). Risk of Alzheimer&#x2019;s Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching. J. Alzheimers. Dis. 88, 1061&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484126</ArticleId><ArticleId IdType="pubmed">35723106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrer S, and Rheinstein PH (2022). Vaccination Reduces Risk of Alzheimer&#x2019;s Disease, Parkinson&#x2019;s Disease and Other Neurodegenerative Disorders. Discov. Med. 34, 97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9608336</ArticleId><ArticleId IdType="pubmed">36281030</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnier C, Janbek J, Lathe R, and Haas J (2022). Reduced dementia incidence after varicella zoster vaccination in Wales 2013&#x2013;2020. Alzheimers. Dement. 8, e12293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006884</ArticleId><ArticleId IdType="pubmed">35434253</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherrer JF, Salas J, Wiemken TL, Hoft DF, Jacobs C, and Morley JE (2021). Impact of herpes zoster vaccination on incident dementia: A retrospective study in two patient cohorts. PLoS One 16, e0257405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597989</ArticleId><ArticleId IdType="pubmed">34788293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrer S, and Rheinstein PH (2021). Herpes Zoster Vaccination Reduces Risk of Dementia. In Vivo 35, 3271&#x2013;3275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627719</ArticleId><ArticleId IdType="pubmed">34697158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lophatananon A, Mekli K, Cant R, Burns A, Dobson C, Itzhaki R, and Muir K (2021). Shingles, Zostavax vaccination and risk of developing dementia: a nested case&#x2013;control study&#x2014;results from the UK Biobank cohort. BMJ Open 11, e045871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504358</ArticleId><ArticleId IdType="pubmed">34625411</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P-J, Hung M-C, Srivastav A, Grohskopf LA, Kobayashi M, Harris AM, Dooling KL, Markowitz LE, Rodriguez-Lainz A, and Williams WW (2021). Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill. Summ. 70, 1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162796</ArticleId><ArticleId IdType="pubmed">33983910</ArticleId></ArticleIdList></Reference><Reference><Citation>Terlizzi EP, and Black LI (2020). Shingles Vaccination Among Adults Aged 60 and Over: United States, 2018. NCHS Data Brief, 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32730737</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng N-S, Chung C-H, Lin F-H, Chiang C-P, Yeh C-B, Huang S-Y, Lu R-B, Chang H-A, Kao Y-C, Yeh H-W, et al. (2018). Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics 15, 417&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935641</ArticleId><ArticleId IdType="pubmed">29488144</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VC-H, Wu S-I, Huang K-Y, Yang Y-H, Kuo T-Y, Liang H-Y, Huang K-L, and Gossop M (2018). Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study. J. Clin. Psychiatry 79. 10.4088/JCP.16m11312.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.16m11312</ArticleId><ArticleId IdType="pubmed">29244265</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, Day-Williams AG, Stone DJ, Singleton AB, Nalls MA, et al. (2020). Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson&#x2019;s disease. J. Med. Genet. 57. 10.1136/jmedgenet-2019-106283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2019-106283</ArticleId><ArticleId IdType="pmc">PMC8474559</ArticleId><ArticleId IdType="pubmed">31784483</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutshumba J, Nikolajczyk BS, and Bachstetter AD (2021). Dysregulation of Systemic Immunity in Aging and Dementia. Front. Cell. Neurosci. 15. 10.3389/fncel.2021.652111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.652111</ArticleId><ArticleId IdType="pmc">PMC8258160</ArticleId><ArticleId IdType="pubmed">34239415</ArticleId></ArticleIdList></Reference><Reference><Citation>Piekut T, Hur&#x142;a M, Banaszek N, Szejn P, Dorszewska J, Kozubski W, and Prendecki M (2022). Infectious agents and Alzheimer&#x2019;s disease. J. Integr. Neurosci. 21, 73.</Citation><ArticleIdList><ArticleId IdType="pubmed">35364661</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldeeb MA, Hussain FS, and Siddiqi ZA (2020). COVID-19 infection may increase the risk of parkinsonism - Remember the Spanish flu? Cytokine Growth Factor Rev. 54, 6&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276126</ArticleId><ArticleId IdType="pubmed">32563553</ArticleId></ArticleIdList></Reference><Reference><Citation>Badrfam R, and Zandifar A (2020). From encephalitis lethargica to COVID-19: Is there another epidemic ahead? Clin. Neurol. Neurosurg. 196, 106065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347327</ArticleId><ArticleId IdType="pubmed">32659638</ArticleId></ArticleIdList></Reference><Reference><Citation>Satheesh NJ, Salloum-Asfar S, and Abdulla SA (2021). The Potential Role of COVID-19 in the Pathogenesis of Multiple Sclerosis-A Preliminary Report. Viruses 13. 10.3390/v13102091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13102091</ArticleId><ArticleId IdType="pmc">PMC8540806</ArticleId><ArticleId IdType="pubmed">34696521</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, and Hochberg Y (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 57, 289&#x2013;300. 10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend P, Phillimore P, and Beattie A (1988). Health and Deprivation: Inequality and the North (Routledge; ).</Citation></Reference><Reference><Citation>Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, et al. (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, and Lindgren CM (2018). GWAS identifies 14 loci for device-measured physical activity and sleep duration. Nat. Commun. 9, 5257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288145</ArticleId><ArticleId IdType="pubmed">30531941</ArticleId></ArticleIdList></Reference><Reference><Citation>Meddens SFW, de Vlaming R, Bowers P, Burik CAP, Linn&#xe9;r RK, Lee C, Okbay A, Turley P, Rietveld CA, Fontana MA, et al. (2021). Genomic analysis of diet composition finds novel loci and associations with health and lifestyle. Mol. Psychiatry 26, 2056&#x2013;2069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767645</ArticleId><ArticleId IdType="pubmed">32393786</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36696128</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>219</EndPage><MedlinePgn>211-219</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2022.4448</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Concerns have been raised that the use of antipsychotic medication for people living with dementia might have increased during the COVID-19 pandemic.</AbstractText><AbstractText Label="OBJECTIVE">To examine multinational trends in antipsychotic drug prescribing for people living with dementia before and during the COVID-19 pandemic.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This multinational network cohort study used electronic health records and claims data from 8 databases in 6 countries (France, Germany, Italy, South Korea, the UK, and the US) for individuals aged 65 years or older between January 1, 2016, and November 30, 2021. Two databases each were included for South Korea and the US.</AbstractText><AbstractText Label="EXPOSURES">The introduction of population-wide COVID-19 restrictions from April 2020 to the latest available date of each database.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The main outcomes were yearly and monthly incidence of dementia diagnosis and prevalence of people living with dementia who were prescribed antipsychotic drugs in each database. Interrupted time series analyses were used to quantify changes in prescribing rates before and after the introduction of population-wide COVID-19 restrictions.</AbstractText><AbstractText Label="RESULTS">A total of 857&#x202f;238 people with dementia aged 65 years or older (58.0% female) were identified in 2016. Reductions in the incidence of dementia were observed in 7 databases in the early phase of the pandemic (April, May, and June 2020), with the most pronounced reduction observed in 1 of the 2 US databases (rate ratio [RR], 0.30; 95% CI, 0.27-0.32); reductions were also observed in the total number of people with dementia prescribed antipsychotic drugs in France, Italy, South Korea, the UK, and the US. Rates of antipsychotic drug prescribing for people with dementia increased in 6 databases representing all countries. Compared with the corresponding month in 2019, the most pronounced increase in 2020 was observed in May in South Korea (Kangwon National University database) (RR, 2.11; 95% CI, 1.47-3.02) and June in the UK (RR, 1.96; 95% CI, 1.24-3.09). The rates of antipsychotic drug prescribing in these 6 databases remained high in 2021. Interrupted time series analyses revealed immediate increases in the prescribing rate in Italy (RR, 1.31; 95% CI, 1.08-1.58) and in the US Medicare database (RR, 1.43; 95% CI, 1.20-1.71) after the introduction of COVID-19 restrictions.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This cohort study found converging evidence that the rate of antipsychotic drug prescribing to people with dementia increased in the initial months of the COVID-19 pandemic in the 6 countries studied and did not decrease to prepandemic levels after the acute phase of the pandemic had ended. These findings suggest that the pandemic disrupted the care of people living with dementia and that the development of intervention strategies is needed to ensure the quality of care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Social Work and Social Administration, Faculty of Social Sciences, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sau Po Centre on Ageing, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Hong Kong Jockey Club Centre for Suicide Research and Prevention, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Wallis C Y</ForeName><Initials>WCY</Initials><AffiliationInfo><Affiliation>Research Department of Practice and Policy, UCL School of Pharmacy, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Carmen Olga</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Real World Data Enabling Platform, Roche, Welwyn Garden City, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Science and Engineering, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, Faculty of Brain Science, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kathy Y</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, Faculty of Brain Science, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Horsham, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Jae-Won</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Celine S L</ForeName><Initials>CSL</Initials><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><AffiliationInfo><Affiliation>Research Department of Practice and Policy, UCL School of Pharmacy, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian C K</ForeName><Initials>ICK</Initials><AffiliationInfo><Affiliation>Research Department of Practice and Policy, UCL School of Pharmacy, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine and Musketeers Foundation Institute of Data Science, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S021418/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2023 Mar 1;80(3):199-201. doi: 10.1001/jamapsychiatry.2022.4435.</RefSource><PMID Version="1">36696134</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2023 Jul 1;80(7):752-753. doi: 10.1001/jamapsychiatry.2023.1247.</RefSource><PMID Version="1">37195683</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2023 Jul 1;80(7):753-754. doi: 10.1001/jamapsychiatry.2023.1250.</RefSource><PMID Version="1">37195707</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012018" MajorTopicYN="N">Reflex</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Luo reported receiving grants from the Research Grants Council of Hong Kong outside the submitted work. Dr Lau reported receiving grants from AIR@InnoHK administered by the Innovation and Technology Commission of Hong Kong outside the submitted work. Dr Liu reported receiving grants from the UK Medical Research Council during the conduct of the study and outside the submitted work. Dr Fortin reported holding stock in Johnson &amp; Johnson. Dr Kern reported holding stock in Johnson &amp; Johnson. Dr Man reported receiving grants from the Hong Kong Research Grant Council during the conduct of the study and receiving grants from the CW Maplethorpe Fellowship, UK National Institute for Health and Care Research, European Commission Framework Horizon 2020, Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, Amgen, and GSK and personal fees from IQVIA Ltd outside the submitted work. Dr Wong reported receiving grants from the Hong Kong Health and Medical Research Fund and research funding from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, the UK National Institute for Health and Care Research, the European Commission, and the National Health and Medical Research Council in Australia outside the submitted work; receiving consulting fees from IQVIA outside the submitted work; and serving as a nonexecutive director of Jacobson Medical in Hong Kong and a consultant to the World Health Organization. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36696128</ArticleId><ArticleId IdType="pmc">PMC9878427</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2022.4448</ArticleId><ArticleId IdType="pii">2800310</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N&#xf8;rgaard A, Jensen-Dahm C, Gasse C, Hansen ES, Waldemar G. Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimers Dis. 2017;56(2):707-716. doi:10.3233/JAD-160828</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160828</ArticleId><ArticleId IdType="pubmed">28035931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kales HC, Kim HM, Zivin K, et al. . Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2011.11030347</ArticleId><ArticleId IdType="pmc">PMC4269551</ArticleId><ArticleId IdType="pubmed">22193526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pink J, O&#x2019;Brien J, Robinson L, Longson D; Guideline Committee . Dementia: assessment, management and support: summary of updated NICE guidance. BMJ. 2018;361:k2438. doi:10.1136/bmj.k2438</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k2438</ArticleId><ArticleId IdType="pubmed">29925626</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes EA, O&#x2019;Connor RC, Perry VH, et al. . Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020;7(6):547-560. doi:10.1016/S2215-0366(20)30168-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30168-1</ArticleId><ArticleId IdType="pmc">PMC7159850</ArticleId><ArticleId IdType="pubmed">32304649</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferbaum B, North CS. Mental health and the COVID-19 pandemic. N Engl J Med. 2020;383(6):510-512. doi:10.1056/NEJMp2008017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2008017</ArticleId><ArticleId IdType="pubmed">32283003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gedde MH, Husebo BS, Vahia IV, et al. . Impact of COVID-19 restrictions on behavioural and psychological symptoms in home-dwelling people with dementia: a prospective cohort study (PAN.DEM). BMJ Open. 2022;12(1):e050628. doi:10.1136/bmjopen-2021-050628</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-050628</ArticleId><ArticleId IdType="pmc">PMC8787843</ArticleId><ArticleId IdType="pubmed">35074810</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, Burns A, Schneider L. Antipsychotic prescribing to people with dementia during COVID-19. Lancet Neurol. 2020;19(11):892. doi:10.1016/S1474-4422(20)30370-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30370-7</ArticleId><ArticleId IdType="pmc">PMC7577650</ArticleId><ArticleId IdType="pubmed">33098796</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SL, Buckley BJR, Lane DA, Underhill P, Lip GYH. Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. Pharmacol Res. 2021;167:105534. doi:10.1016/j.phrs.2021.105534</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105534</ArticleId><ArticleId IdType="pmc">PMC9759831</ArticleId><ArticleId IdType="pubmed">33677103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sizoo EM, Thunnissen JA, van Loon AM, et al. . The course of neuropsychiatric symptoms and psychotropic drug use in Dutch nursing home patients with dementia during the first wave of COVID-19: a longitudinal cohort study. Int J Geriatr Psychiatry. 2022;37(3). doi:10.1002/gps.5693</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.5693</ArticleId><ArticleId IdType="pmc">PMC9087381</ArticleId><ArticleId IdType="pubmed">35191093</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen G, Russo MJ, Campos JA, Allegri RF. COVID-19 epidemic in Argentina: worsening of behavioral symptoms in elderly subjects with dementia living in the community. Front Psychiatry. 2020;11:866. doi:10.3389/fpsyt.2020.00866</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.00866</ArticleId><ArticleId IdType="pmc">PMC7485090</ArticleId><ArticleId IdType="pubmed">33005158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Schuemie MJ, Madigan D, Ryan PB, Suchard MA. Drawing reproducible conclusions from observational clinical data with OHDSI. Yearb Med Inform. 2021;30(1):283-289. doi:10.1055/s-0041-1726481</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1726481</ArticleId><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="pubmed">33882595</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Chai Y. CERVELLOPrevalence GitHub
repository. Accessed November 29, 2022. https://github.com/ohdsi-studies/CervelloPrevalence</Citation></Reference><Reference><Citation>Jouaville S, Miotti H, Coffin G, Sarfati B, Meihoc A. Validity and limitations of the Longitudinal Patient Database France for use in pharmacoepidemiological and pharmacoeconomics studies. Value Health. 2015;18(3):A18. doi:10.1016/j.jval.2015.03.115</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.03.115</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, et al. . Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435. doi:10.1136/bmj.n1435</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, Li X, Kostka K, et al. . Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf. 2022;31(5):495-510. doi:10.1002/pds.5419</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5419</ArticleId><ArticleId IdType="pmc">PMC9088543</ArticleId><ArticleId IdType="pubmed">35191114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et al. . Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329-7336. doi:10.1073/pnas.1510502113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SI, Cooper J, Fenton A, et al. . Decreased renal function is associated with incident dementia: an IMRD-THIN retrospective cohort study in the UK. Alzheimers Dement. 2022;18(10):1943-1956. doi:10.1002/alz.12539</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12539</ArticleId><ArticleId IdType="pubmed">34978143</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte-Salles T, Vizcaya D, Pistillo A, et al. . Thirty-day outcomes of children and adolescents with COVID-19: an international experience. Pediatrics. 2021;148(3):e2020042929. doi:10.1542/peds.2020-042929</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-042929</ArticleId><ArticleId IdType="pubmed">34049958</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale T, Angrist N, Goldszmidt R, et al. . A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021;5(4):529-538. doi:10.1038/s41562-021-01079-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41562-021-01079-8</ArticleId><ArticleId IdType="pubmed">33686204</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348-355. doi:10.1093/ije/dyw098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw098</ArticleId><ArticleId IdType="pmc">PMC5407170</ArticleId><ArticleId IdType="pubmed">27283160</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JSH, Peng C, Luo H, Zhang J, Oh H. Containment, health, and social policies in the time of COVID-19&#x2014;determinants and outcomes of initial responses across 120 countries. Health Policy Plan. 2021;36(10):1613-1624. doi:10.1093/heapol/czab115</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapol/czab115</ArticleId><ArticleId IdType="pubmed">34536271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li T, Barbarino P, et al. . Dementia care during COVID-19. Lancet. 2020;395(10231):1190-1191. doi:10.1016/S0140-6736(20)30755-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30755-8</ArticleId><ArticleId IdType="pmc">PMC7146671</ArticleId><ArticleId IdType="pubmed">32240625</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic: interim report&#x2014;November-December 2021. February 7, 2022. Accessed May 9, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2022.1</Citation></Reference><Reference><Citation>Brown A, Kirichek O, Balkwill A, et al. . Comparison of dementia recorded in routinely collected hospital admission data in England with dementia recorded in primary care. Emerg Themes Epidemiol. 2016;13(1):11. doi:10.1186/s12982-016-0053-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12982-016-0053-z</ArticleId><ArticleId IdType="pmc">PMC5084368</ArticleId><ArticleId IdType="pubmed">27800007</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DH Jr, &#xd8;stbye T, Langa KM, Weir D, Plassman BL. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009;17(4):807-815. doi:10.3233/JAD-2009-1099</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1099</ArticleId><ArticleId IdType="pmc">PMC3697480</ArticleId><ArticleId IdType="pubmed">19542620</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr MJ, Steeg S, Webb RT, et al. . Effects of the COVID-19 pandemic on primary care-recorded mental illness and self-harm episodes in the UK: a population-based cohort study. Lancet Public Health. 2021;6(2):e124-e135. doi:10.1016/S2468-2667(20)30288-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30288-7</ArticleId><ArticleId IdType="pmc">PMC7843955</ArticleId><ArticleId IdType="pubmed">33444560</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36724228</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Chaperoning of specific tau structure by immunophilin FKBP12 regulates the neuronal resilience to extracellular stress.</ArticleTitle><Pagination><StartPage>eadd9789</StartPage><MedlinePgn>eadd9789</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eadd9789</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.add9789</ELocationID><Abstract><AbstractText>Alzheimer's disease and related tauopathies are characterized by the pathogenic misfolding and aggregation of the microtubule-associated protein tau. Understanding how endogenous chaperones modulate tau misfolding could guide future therapies. Here, we show that the immunophilin FKBP12, the 12-kDa FK506-binding protein (also known as FKBP prolyl isomerase 1A), regulates the neuronal resilience by chaperoning a specific structure in monomeric tau. Using a combination of mouse and cell experiments, in vitro aggregation experiments, nuclear magnetic resonance-based structural analysis of monomeric tau, site-specific phosphorylation and mutation, as well as structure-based analysis using the neural network-based structure prediction program AlphaFold, we define the molecular factors that govern the binding of FKBP12 to tau and its influence on tau-induced neurotoxicity. We further demonstrate that tyrosine phosphorylation of tau blocks the binding of FKBP12 to two highly specific structural motifs in tau. Our data together with previous results demonstrating FKBP12/tau colocalization in neurons and neurofibrillary tangles support a critical role of FKBP12 in regulating tau pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lulu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6918-6777</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakraborty</LastName><ForeName>Pijush</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1749-5225</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lushuang</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2782-4088</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2549-9621</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Shannon E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-6410-1156</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webber</LastName><ForeName>Chelsea Joy</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libera</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1845-1742</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0002-4981-5564</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolozin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2068-1475</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurophotonics, Boston University, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Systems Neuroscience, Boston University, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zweckstetter</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2536-6581</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for NMR-based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, Am Fa&#xdf;berg 11, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG064932</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073899</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056318</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050471</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089544</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074591</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG072577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D022061">Tacrolimus Binding Protein 1A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D022021">Tacrolimus Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022061" MajorTopicYN="N">Tacrolimus Binding Protein 1A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022021" MajorTopicYN="N">Tacrolimus Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36724228</ArticleId><ArticleId IdType="pmc">PMC9891691</ArticleId><ArticleId IdType="doi">10.1126/sciadv.add9789</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>P.&#xa0;Scheltens, K.&#xa0;Blennow, M.&#xa0;M.&#xa0;B.&#xa0;Breteler, B.&#xa0;de Strooper, G. B.&#xa0;Frisoni, S.&#xa0;Salloway, W. M.&#xa0;van der Flier, Alzheimer&#x2019;s disease. Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Y.&#xa0;Wang, E.&#xa0;Mandelkow, Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5&#x2013;21 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>P.&#xa0;Scheltens, B.&#xa0;de Strooper, M.&#xa0;Kivipelto, H.&#xa0;Holstege, G.&#xa0;Ch&#xe9;telat, C. E.&#xa0;Teunissen, J.&#xa0;Cummings, W. M.&#xa0;van der Flier, Alzheimer&#x2019;s disease. Lancet 397, 1577&#x2013;1590 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>J.&#xa0;Koren III, U. K.&#xa0;Jinwal, Z.&#xa0;Davey, J.&#xa0;Kiray, K.&#xa0;Arulselvam, C. A.&#xa0;Dickey, Bending tau into shape: The emerging role of peptidyl-prolyl isomerases in tauopathies. Mol. Neurobiol. 44, 65&#x2013;70 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3260650</ArticleId><ArticleId IdType="pubmed">21523562</ArticleId></ArticleIdList></Reference><Reference><Citation>H.&#xa0;Shimura, Y.&#xa0;Miura-Shimura, K. S.&#xa0;Kosik, Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem. 279, 17957&#x2013;17962 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14963027</ArticleId></ArticleIdList></Reference><Reference><Citation>L.&#xa0;Petrucelli, D.&#xa0;Dickson, K.&#xa0;Kehoe, J.&#xa0;Taylor, H.&#xa0;Snyder, A.&#xa0;Grover, M.&#xa0;de Lucia, E.&#xa0;McGowan, J.&#xa0;Lewis, G.&#xa0;Prihar, J.&#xa0;Kim, W. H.&#xa0;Dillmann, S. E.&#xa0;Browne, A.&#xa0;Hall, R.&#xa0;Voellmy, Y.&#xa0;Tsuboi, T. M.&#xa0;Dawson, B.&#xa0;Wolozin, J.&#xa0;Hardy, M.&#xa0;Hutton, CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703&#x2013;714 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>F.&#xa0;Dou, W. J.&#xa0;Netzer, K.&#xa0;Tanemura, F.&#xa0;Li, F. U.&#xa0;Hartl, A.&#xa0;Takashima, G. K.&#xa0;Gouras, P.&#xa0;Greengard, H.&#xa0;Xu, Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. U.S.A. 100, 721&#x2013;726 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141063</ArticleId><ArticleId IdType="pubmed">12522269</ArticleId></ArticleIdList></Reference><Reference><Citation>U. K.&#xa0;Jinwal, J.&#xa0;Koren, S. I.&#xa0;Borysov, A. B.&#xa0;Schmid, J. F.&#xa0;Abisambra, L. J.&#xa0;Blair, A. G.&#xa0;Johnson, J. R.&#xa0;Jones, C. L.&#xa0;Shults, J. C.&#xa0;O&#x2019;Leary, Y.&#xa0;Jin, J.&#xa0;Buchner, M. B.&#xa0;Cox, C. A.&#xa0;Dickey, The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J. Neurosci. 30, 591&#x2013;599 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830818</ArticleId><ArticleId IdType="pubmed">20071522</ArticleId></ArticleIdList></Reference><Reference><Citation>K. P.&#xa0;Lu, X. Z.&#xa0;Zhou, The prolyl isomerase PIN1: A pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. 8, 904&#x2013;916 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17878917</ArticleId></ArticleIdList></Reference><Reference><Citation>P. J.&#xa0;Lu, G.&#xa0;Wulf, X. Z.&#xa0;Zhou, P.&#xa0;Davies, K. P.&#xa0;Lu, The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399, 784&#x2013;788 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10391244</ArticleId></ArticleIdList></Reference><Reference><Citation>B.&#xa0;Aghdasi, K.&#xa0;Ye, A.&#xa0;Resnick, A.&#xa0;Huang, H. C.&#xa0;Ha, X.&#xa0;Guo, T. M.&#xa0;Dawson, V. L.&#xa0;Dawson, S. H.&#xa0;Snyder, FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 98, 2425&#x2013;2430 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30154</ArticleId><ArticleId IdType="pubmed">11226255</ArticleId></ArticleIdList></Reference><Reference><Citation>C. J.&#xa0;Sabers, M. M.&#xa0;Martin, G. J.&#xa0;Brunn, J. M.&#xa0;Williams, F. J.&#xa0;Dumont, G.&#xa0;Wiederrecht, R. T.&#xa0;Abraham, Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270, 815&#x2013;822 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7822316</ArticleId></ArticleIdList></Reference><Reference><Citation>L. B.&#xa0;Shelton, J.&#xa0;Koren III, L. J.&#xa0;Blair, Imbalances in the Hsp90 chaperone machinery: implications for tauopathies. Front. Neurosci. 11, 724 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5744016</ArticleId><ArticleId IdType="pubmed">29311797</ArticleId></ArticleIdList></Reference><Reference><Citation>K.&#xa0;Nakamura, A.&#xa0;Greenwood, L.&#xa0;Binder, E. H.&#xa0;Bigio, S.&#xa0;Denial, L.&#xa0;Nicholson, X. Z.&#xa0;Zhou, K. P.&#xa0;Lu, Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer&#x2019;s disease. Cell 149, 232&#x2013;244 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601591</ArticleId><ArticleId IdType="pubmed">22464332</ArticleId></ArticleIdList></Reference><Reference><Citation>T.&#xa0;Ikura, N.&#xa0;Ito, Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating. Protein Eng. Des. Sel. 26, 539&#x2013;546 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23832849</ArticleId></ArticleIdList></Reference><Reference><Citation>L. J.&#xa0;Blair, B. A.&#xa0;Nordhues, S. E.&#xa0;Hill, K. M.&#xa0;Scaglione, J. C.&#xa0;O&#x2019;Leary III, S. N.&#xa0;Fontaine, L.&#xa0;Breydo, B.&#xa0;Zhang, P.&#xa0;Li, L.&#xa0;Wang, C.&#xa0;Cotman, H. L.&#xa0;Paulson, M.&#xa0;Muschol, V. N.&#xa0;Uversky, T.&#xa0;Klengel, E. B.&#xa0;Binder, R.&#xa0;Kayed, T. E.&#xa0;Golde, N.&#xa0;Berchtold, C. A.&#xa0;Dickey, Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J. Clin. Invest. 123, 4158&#x2013;4169 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784538</ArticleId><ArticleId IdType="pubmed">23999428</ArticleId></ArticleIdList></Reference><Reference><Citation>C. A.&#xa0;Hoeffer, W.&#xa0;Tang, H.&#xa0;Wong, A.&#xa0;Santillan, R. J.&#xa0;Patterson, L. A.&#xa0;Martinez, M. V.&#xa0;Tejada-Simon, R.&#xa0;Paylor, S. L.&#xa0;Hamilton, E.&#xa0;Klann, Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 60, 832&#x2013;845 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630531</ArticleId><ArticleId IdType="pubmed">19081378</ArticleId></ArticleIdList></Reference><Reference><Citation>H.&#xa0;Sugata, K.&#xa0;Matsuo, T.&#xa0;Nakagawa, M.&#xa0;Takahashi, H.&#xa0;Mukai, Y.&#xa0;Ono, K.&#xa0;Maeda, H.&#xa0;Akiyama, T.&#xa0;Kawamata, A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles. Neurosci. Lett. 459, 96&#x2013;99 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19414059</ArticleId></ArticleIdList></Reference><Reference><Citation>L. J.&#xa0;Blair, J. D.&#xa0;Baker, J. J.&#xa0;Sabbagh, C. A.&#xa0;Dickey, The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer&#x2019;s disease. J. Neurochem. 133, 1&#x2013;13 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4361273</ArticleId><ArticleId IdType="pubmed">25628064</ArticleId></ArticleIdList></Reference><Reference><Citation>A. P.&#xa0;Wingo, Y.&#xa0;Liu, E. S.&#xa0;Gerasimov, J.&#xa0;Gockley, B. A.&#xa0;Logsdon, D. M.&#xa0;Duong, E. B.&#xa0;Dammer, C.&#xa0;Robins, T. G.&#xa0;Beach, E. M.&#xa0;Reiman, M. P.&#xa0;Epstein, P. L.&#xa0;de Jager, J. J.&#xa0;Lah, D. A.&#xa0;Bennett, N. T.&#xa0;Seyfried, A. I.&#xa0;Levey, T. S.&#xa0;Wingo, Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer&#x2019;s disease pathogenesis. Nat. Genet. 53, 143&#x2013;146 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8130821</ArticleId><ArticleId IdType="pubmed">33510477</ArticleId></ArticleIdList></Reference><Reference><Citation>Y. N.&#xa0;Ou, Y. X.&#xa0;Yang, Y. T.&#xa0;Deng, C.&#xa0;Zhang, H.&#xa0;Hu, B. S.&#xa0;Wu, Y.&#xa0;Liu, Y. J.&#xa0;Wang, Y.&#xa0;Zhu, J.&#xa0;Suckling, L.&#xa0;Tan, J. T.&#xa0;Yu, Identification of novel drug targets for Alzheimer&#x2019;s disease by integrating genetics and proteomes from brain and blood. Mol. Psychiatry 26, 6065&#x2013;6073 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34381170</ArticleId></ArticleIdList></Reference><Reference><Citation>J.&#xa0;Jumper, R.&#xa0;Evans, A.&#xa0;Pritzel, T.&#xa0;Green, M.&#xa0;Figurnov, O.&#xa0;Ronneberger, K.&#xa0;Tunyasuvunakool, R.&#xa0;Bates, A.&#xa0;&#x17d;&#xed;dek, A.&#xa0;Potapenko, A.&#xa0;Bridgland, C.&#xa0;Meyer, S.&#xa0;A.&#xa0;A.&#xa0;Kohl, A. J.&#xa0;Ballard, A.&#xa0;Cowie, B.&#xa0;Romera-Paredes, S.&#xa0;Nikolov, R.&#xa0;Jain, J.&#xa0;Adler, T.&#xa0;Back, S.&#xa0;Petersen, D.&#xa0;Reiman, E.&#xa0;Clancy, M.&#xa0;Zielinski, M.&#xa0;Steinegger, M.&#xa0;Pacholska, T.&#xa0;Berghammer, S.&#xa0;Bodenstein, D.&#xa0;Silver, O.&#xa0;Vinyals, A. W.&#xa0;Senior, K.&#xa0;Kavukcuoglu, P.&#xa0;Kohli, D.&#xa0;Hassabis, Highly accurate protein structure prediction with AlphaFold. Nature 596, 583&#x2013;589 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>L.&#xa0;Jiang, P.&#xa0;E.&#xa0;A.&#xa0;Ash, B. F.&#xa0;Maziuk, H. I.&#xa0;Ballance, S.&#xa0;Boudeau, A. A.&#xa0;Abdullatif, M.&#xa0;Orlando, L.&#xa0;Petrucelli, T.&#xa0;Ikezu, B.&#xa0;Wolozin, TIA1 regulates the generation and response to toxic tau oligomers. Acta Neuropathol. 137, 259&#x2013;277 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377165</ArticleId><ArticleId IdType="pubmed">30465259</ArticleId></ArticleIdList></Reference><Reference><Citation>L.&#xa0;Jiang, J.&#xa0;Zhao, J. X.&#xa0;Cheng, B.&#xa0;Wolozin, Tau oligomers and fibrils exhibit differential patterns of seeding and association with RNA binding proteins. Front. Neurol. 11, 579434 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554625</ArticleId><ArticleId IdType="pubmed">33101187</ArticleId></ArticleIdList></Reference><Reference><Citation>P. D.&#xa0;Sohn, C. T.-L.&#xa0;Huang, R.&#xa0;Yan, L.&#xa0;Fan, T. E.&#xa0;Tracy, C. M.&#xa0;Camargo, K. M.&#xa0;Montgomery, T.&#xa0;Arhar, S.-A.&#xa0;Mok, R.&#xa0;Freilich, J.&#xa0;Baik, M.&#xa0;He, S.&#xa0;Gong, E. D.&#xa0;Roberson, C. M.&#xa0;Karch, J. E.&#xa0;Gestwicki, K.&#xa0;Xu, K. S.&#xa0;Kosik, L.&#xa0;Gan, Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis. Neuron 104, 458&#x2013;470.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880876</ArticleId><ArticleId IdType="pubmed">31542321</ArticleId></ArticleIdList></Reference><Reference><Citation>M. D.&#xa0;Mukrasch, S.&#xa0;Bibow, J.&#xa0;Korukottu, S.&#xa0;Jeganathan, J.&#xa0;Biernat, C.&#xa0;Griesinger, E.&#xa0;Mandelkow, M.&#xa0;Zweckstetter, Structural polymorphism of 441-residue tau at single residue resolution. PLOS Biol. 7, e34 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2642882</ArticleId><ArticleId IdType="pubmed">19226187</ArticleId></ArticleIdList></Reference><Reference><Citation>J. Ko, J.&#xa0;Lee, Can AlphaFold2 predict protein-peptide complex structures accurately. bioRxiv 2021.07.27.453972 [Preprint]. 27 July 2021. 10.1101/2021.07.27.453972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.27.453972</ArticleId></ArticleIdList></Reference><Reference><Citation>T. Tsaban, J.&#xa0;K.&#xa0;Varga, O.&#xa0;Avraham, Z.&#xa0;Ben-Aharon, A.&#xa0;Khramushin, O.&#xa0;Schueler-Furman, Harnessing protein folding neural networks for peptide-protein docking. bioRxiv 2021.08.01.454656 [Preprint]. 2 August 2021. 10.1101/2021.08.01.454656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.01.454656</ArticleId><ArticleId IdType="pmc">PMC8748686</ArticleId><ArticleId IdType="pubmed">35013344</ArticleId></ArticleIdList></Reference><Reference><Citation>K. P.&#xa0;Wilson, M. M.&#xa0;Yamashita, M. D.&#xa0;Sintchak, S. H.&#xa0;Rotstein, M. A.&#xa0;Murcko, J.&#xa0;Boger, J. A.&#xa0;Thomson, M. J.&#xa0;Fitzgibbon, J. R.&#xa0;Black, M. A.&#xa0;Navia, Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin. Acta Crystallogr. D Biol. Crystallogr. 51(Pt 4), 511&#x2013;521 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">15299838</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;Tong, Y.&#xa0;Jiang, FK506-binding proteins and their diverse functions. Curr. Mol. Pharmacol. 9, 48&#x2013;65 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6611466</ArticleId><ArticleId IdType="pubmed">25986568</ArticleId></ArticleIdList></Reference><Reference><Citation>V.&#xa0;Philip, J.&#xa0;Harris, R.&#xa0;Adams, D.&#xa0;Nguyen, J.&#xa0;Spiers, J.&#xa0;Baudry, E. E.&#xa0;Howell, R. J.&#xa0;Hinde, A survey of aspartate-phenylalanine and glutamate-phenylalanine interactions in the protein data bank: Searching for Anion&#x2212;&#x3c0; pairs. Biochemistry 50, 2939&#x2013;2950 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21366334</ArticleId></ArticleIdList></Reference><Reference><Citation>C.&#xa0;H.&#xa0;M.&#xa0;Rodrigues, D.&#xa0;E.&#xa0;V.&#xa0;Pires, D. B.&#xa0;Ascher, DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations. Protein Sci. 30, 60&#x2013;69 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737773</ArticleId><ArticleId IdType="pubmed">32881105</ArticleId></ArticleIdList></Reference><Reference><Citation>D. P.&#xa0;Hanger, B. H.&#xa0;Anderton, W.&#xa0;Noble, Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112&#x2013;119 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19246243</ArticleId></ArticleIdList></Reference><Reference><Citation>G. I.&#xa0;Cancino, K.&#xa0;Perez de Arce, P. U.&#xa0;Castro, E. M.&#xa0;Toledo, R.&#xa0;von Bernhardi, A. R.&#xa0;Alvarez, c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice. Neurobiol. Aging 32, 1249&#x2013;1261 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">19700222</ArticleId></ArticleIdList></Reference><Reference><Citation>A.&#xa0;Savastano, D.&#xa0;Flores, H.&#xa0;Kadavath, J.&#xa0;Biernat, E.&#xa0;Mandelkow, M.&#xa0;Zweckstetter, Disease-associated tau phosphorylation hinders tubulin assembly within tau condensates. Angew. Chem. Int. Ed. Engl. 60, 726&#x2013;730 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7839466</ArticleId><ArticleId IdType="pubmed">33017094</ArticleId></ArticleIdList></Reference><Reference><Citation>F.&#xa0;Clavaguera, M.&#xa0;Tolnay, M.&#xa0;Goedert, The prion-like behavior of assembled tau in transgenic mice. Cold Spring Harb. Perspect. Med. 7, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5629990</ArticleId><ArticleId IdType="pubmed">27940600</ArticleId></ArticleIdList></Reference><Reference><Citation>P.&#xa0;Chakraborty, G.&#xa0;Rivi&#xe8;re, S.&#xa0;Liu, A. I.&#xa0;de Opakua, R.&#xa0;Dervi&#x15f;o&#x11f;lu, A.&#xa0;Hebestreit, L. B.&#xa0;Andreas, I. M.&#xa0;Vorberg, M.&#xa0;Zweckstetter, Co-factor-free aggregation of tau into seeding-competent RNA-sequestering amyloid fibrils. Nat. Commun. 12, 4231 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270918</ArticleId><ArticleId IdType="pubmed">34244499</ArticleId></ArticleIdList></Reference><Reference><Citation>E.&#xa0;Galfre, S. J.&#xa0;Pitt, E.&#xa0;Venturi, M.&#xa0;Sitsapesan, N. R.&#xa0;Zaccai, K.&#xa0;Tsaneva-Atanasova, S.&#xa0;O&#x2019;Neill, R.&#xa0;Sitsapesan, FKBP12 activates the cardiac ryanodine receptor Ca2+&#x2212;release channel and is antagonised by FKBP12.6. PLOS ONE 7, e31956 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283708</ArticleId><ArticleId IdType="pubmed">22363773</ArticleId></ArticleIdList></Reference><Reference><Citation>Y. Shi, W.&#xa0;Zhang, Y.&#xa0;Yang, A.&#xa0;G.&#xa0;Murzin, B.&#xa0;Falcon, A.&#xa0;Kotecha, M.&#xa0;van Beers, A.&#xa0;Tarutani, F.&#xa0;Kametani, H.&#xa0;J.&#xa0;Garringer, R.&#xa0;Vidal, G.&#xa0;I.&#xa0;Hallinan, T.&#xa0;Lashley, Y.&#xa0;Saito, S.&#xa0;Murayama, M.&#xa0;Yoshida, H.&#xa0;Tanaka, A.&#xa0;Kakita, T.&#xa0;Ikeuchi, A.&#xa0;C.&#xa0;Robinson, D.&#xa0;M.&#xa0;A. Mann, G.&#xa0;G.&#xa0;Kovacs, T.&#xa0;Revesz, B.&#xa0;Ghetti, M.&#xa0;Hasegawa, M.&#xa0;Goedert, S.&#xa0;H.&#xa0;W. Scheres, Structure-based classification of tauopathies. bioRxiv 2021.05.28.446130 [Preprint]. 28 May 2021. 10.1101/2021.05.28.446130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.28.446130</ArticleId></ArticleIdList></Reference><Reference><Citation>W.&#xa0;Zhang, A.&#xa0;Tarutani, K. L.&#xa0;Newell, A. G.&#xa0;Murzin, T.&#xa0;Matsubara, B.&#xa0;Falcon, R.&#xa0;Vidal, H. J.&#xa0;Garringer, Y.&#xa0;Shi, T.&#xa0;Ikeuchi, S.&#xa0;Murayama, B.&#xa0;Ghetti, M.&#xa0;Hasegawa, M.&#xa0;Goedert, S.&#xa0;H.&#xa0;W.&#xa0;Scheres, Novel tau filament fold in corticobasal degeneration. Nature 580, 283&#x2013;287 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>W.&#xa0;Zhang, B.&#xa0;Falcon, A. G.&#xa0;Murzin, J.&#xa0;Fan, R. A.&#xa0;Crowther, M.&#xa0;Goedert, S.&#xa0;H.&#xa0;W.&#xa0;Scheres, Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife 8, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>B.&#xa0;Falcon, J.&#xa0;Zivanov, W.&#xa0;Zhang, A. G.&#xa0;Murzin, H. J.&#xa0;Garringer, R.&#xa0;Vidal, R. A.&#xa0;Crowther, K. L.&#xa0;Newell, B.&#xa0;Ghetti, M.&#xa0;Goedert, S.&#xa0;H.&#xa0;W.&#xa0;Scheres, Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>B.&#xa0;Falcon, W.&#xa0;Zhang, A. G.&#xa0;Murzin, G.&#xa0;Murshudov, H. J.&#xa0;Garringer, R.&#xa0;Vidal, R. A.&#xa0;Crowther, B.&#xa0;Ghetti, S.&#xa0;H.&#xa0;W.&#xa0;Scheres, M.&#xa0;Goedert, Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>A.&#xa0;W.&#xa0;P.&#xa0;Fitzpatrick, B.&#xa0;Falcon, S.&#xa0;He, A. G.&#xa0;Murzin, G.&#xa0;Murshudov, H. J.&#xa0;Garringer, R. A.&#xa0;Crowther, B.&#xa0;Ghetti, M.&#xa0;Goedert, S.&#xa0;H.&#xa0;W.&#xa0;Scheres, Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>H. D.&#xa0;Rickner, L.&#xa0;Jiang, R.&#xa0;Hong, N. K.&#xa0;O&#x2019;Neill, C. A.&#xa0;Mojica, B. J.&#xa0;Snyder, L.&#xa0;Zhang, D.&#xa0;Shaw, M.&#xa0;Medalla, B.&#xa0;Wolozin, C. S.&#xa0;Cheng, Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model. Nat. Commun. 13, 6275 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587045</ArticleId><ArticleId IdType="pubmed">36271092</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;Gerard, A.&#xa0;Deleersnijder, V.&#xa0;Daniels, S.&#xa0;Schreurs, S.&#xa0;Munck, V.&#xa0;Reumers, H.&#xa0;Pottel, Y.&#xa0;Engelborghs, C.&#xa0;van den Haute, J. M.&#xa0;Taymans, Z.&#xa0;Debyser, V.&#xa0;Baekelandt, Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson&#x2019;s disease-like pathology. J. Neurosci. 30, 2454&#x2013;2463 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634531</ArticleId><ArticleId IdType="pubmed">20164329</ArticleId></ArticleIdList></Reference><Reference><Citation>Y.&#xa0;Manabe, H.&#xa0;Warita, T.&#xa0;Murakami, M.&#xa0;Shiote, T.&#xa0;Hayashi, N.&#xa0;Omori, I.&#xa0;Nagano, M.&#xa0;Shoji, K.&#xa0;Abe, Early decrease of the immunophilin FKBP 52 in the spinal cord of a transgenic model for amyotrophic lateral sclerosis. Brain Res. 935, 124&#x2013;128 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12062482</ArticleId></ArticleIdList></Reference><Reference><Citation>T.&#xa0;Jayaraman, A. M.&#xa0;Brillantes, A. P.&#xa0;Timerman, S.&#xa0;Fleischer, H.&#xa0;Erdjument-Bromage, P.&#xa0;Tempst, A. R.&#xa0;Marks, FK506 binding protein associated with the calcium release channel (ryanodine receptor). J. Biol. Chem. 267, 9474&#x2013;9477 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1374404</ArticleId></ArticleIdList></Reference><Reference><Citation>G. E.&#xa0;Karagoz, A.&#xa0;M.&#xa0;S.&#xa0;Duarte, E.&#xa0;Akoury, H.&#xa0;Ippel, J.&#xa0;Biernat, T. M.&#xa0;Luengo, M.&#xa0;Radli, T.&#xa0;Didenko, B. A.&#xa0;Nordhues, D. B.&#xa0;Veprintsev, C. A.&#xa0;Dickey, E.&#xa0;Mandelkow, M.&#xa0;Zweckstetter, R.&#xa0;Boelens, T.&#xa0;Madl, S.&#xa0;G.&#xa0;D.&#xa0;R&#xfc;diger, Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell 156, 963&#x2013;974 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263503</ArticleId><ArticleId IdType="pubmed">24581495</ArticleId></ArticleIdList></Reference><Reference><Citation>U. K.&#xa0;Jinwal, E.&#xa0;Akoury, J. F.&#xa0;Abisambra, J. C.&#xa0;O&#x2019;Leary III, A. D.&#xa0;Thompson, L. J.&#xa0;Blair, Y.&#xa0;Jin, J.&#xa0;Bacon, B. A.&#xa0;Nordhues, M.&#xa0;Cockman, J.&#xa0;Zhang, P.&#xa0;Li, B.&#xa0;Zhang, S.&#xa0;Borysov, V. N.&#xa0;Uversky, J.&#xa0;Biernat, E.&#xa0;Mandelkow, J. E.&#xa0;Gestwicki, M.&#xa0;Zweckstetter, C. A.&#xa0;Dickey, Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J. 27, 1450&#x2013;1459 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606536</ArticleId><ArticleId IdType="pubmed">23271055</ArticleId></ArticleIdList></Reference><Reference><Citation>J.&#xa0;Oroz, B. J.&#xa0;Chang, P.&#xa0;Wysoczanski, C. T.&#xa0;Lee, &#xc1;.&#xa0;P&#xe9;rez-Lara, P.&#xa0;Chakraborty, R. V.&#xa0;Hofele, J. D.&#xa0;Baker, L. J.&#xa0;Blair, J.&#xa0;Biernat, H.&#xa0;Urlaub, E.&#xa0;Mandelkow, C. A.&#xa0;Dickey, M.&#xa0;Zweckstetter, Structure and pro-toxic mechanism of the human Hsp90/PPIase/tau complex. Nat. Commun. 9, 4532 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208366</ArticleId><ArticleId IdType="pubmed">30382094</ArticleId></ArticleIdList></Reference><Reference><Citation>J. D.&#xa0;Baker, L. B.&#xa0;Shelton, D.&#xa0;Zheng, F.&#xa0;Favretto, B. A.&#xa0;Nordhues, A.&#xa0;Darling, L. E.&#xa0;Sullivan, Z.&#xa0;Sun, P. K.&#xa0;Solanki, M. D.&#xa0;Martin, A.&#xa0;Suntharalingam, J. J.&#xa0;Sabbagh, S.&#xa0;Becker, E.&#xa0;Mandelkow, V. N.&#xa0;Uversky, M.&#xa0;Zweckstetter, C. A.&#xa0;Dickey, J.&#xa0;Koren, L. J.&#xa0;Blair, Human cyclophilin 40 unravels neurotoxic amyloids. PLOS Biol. 15, e2001336 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5486962</ArticleId><ArticleId IdType="pubmed">28654636</ArticleId></ArticleIdList></Reference><Reference><Citation>F.&#xa0;Favretto, D.&#xa0;Flores, J. D.&#xa0;Baker, T.&#xa0;Stroh&#xe4;ker, L. B.&#xa0;Andreas, L. J.&#xa0;Blair, S.&#xa0;Becker, M.&#xa0;Zweckstetter, Catalysis of proline isomerization and molecular chaperone activity in a tug-of-war. Nat. Commun. 11, 6046 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695863</ArticleId><ArticleId IdType="pubmed">33247146</ArticleId></ArticleIdList></Reference><Reference><Citation>P.&#xa0;Varnai, B.&#xa0;Thyagarajan, T.&#xa0;Rohacs, T.&#xa0;Balla, Rapidly inducible changes in phosphatidylinositol 4,5-bisphosphate levels influence multiple regulatory functions of the lipid in intact living cells. J. Cell Biol. 175, 377&#x2013;382 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064515</ArticleId><ArticleId IdType="pubmed">17088424</ArticleId></ArticleIdList></Reference><Reference><Citation>Z. G.&#xa0;Levine, S. C.&#xa0;Potter, C. M.&#xa0;Joiner, G. Q.&#xa0;Fei, B.&#xa0;Nabet, M.&#xa0;Sonnett, N. E.&#xa0;Zachara, N. S.&#xa0;Gray, J. A.&#xa0;Paulo, S.&#xa0;Walker, Mammalian cell proliferation requires noncatalytic functions of O-GlcNAc transferase. Proc. Natl. Acad. Sci. U.S.A. 118, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848692</ArticleId><ArticleId IdType="pubmed">33419956</ArticleId></ArticleIdList></Reference><Reference><Citation>L.&#xa0;Jiang, W.&#xa0;Lin, C.&#xa0;Zhang, P.&#xa0;E.&#xa0;A.&#xa0;Ash, M.&#xa0;Verma, J.&#xa0;Kwan, E.&#xa0;van Vliet, Z.&#xa0;Yang, A. L.&#xa0;Cruz, S.&#xa0;Boudeau, B. F.&#xa0;Maziuk, S.&#xa0;Lei, J.&#xa0;Song, V. E.&#xa0;Alvarez, S.&#xa0;Hovde, J. F.&#xa0;Abisambra, M.-H.&#xa0;Kuo, N.&#xa0;Kanaan, M. E.&#xa0;Murray, J. F.&#xa0;Crary, J.&#xa0;Zhao, J.-X.&#xa0;Cheng, L.&#xa0;Petrucelli, H.&#xa0;Li, A.&#xa0;Emili, B.&#xa0;Wolozin, Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. Mol. Cell 81, 4209&#x2013;4227.e12 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8541906</ArticleId><ArticleId IdType="pubmed">34453888</ArticleId></ArticleIdList></Reference><Reference><Citation>W. F.&#xa0;Vranken, W.&#xa0;Boucher, T. J.&#xa0;Stevens, R. H.&#xa0;Fogh, A.&#xa0;Pajon, M.&#xa0;Llinas, E. L.&#xa0;Ulrich, J. L.&#xa0;Markley, J.&#xa0;Ionides, E. D.&#xa0;Laue, The CCPN data model for NMR spectroscopy: Development of a software pipeline. Proteins 59, 687&#x2013;696 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15815974</ArticleId></ArticleIdList></Reference><Reference><Citation>M.&#xa0;P.&#xa0;Akdel, D.&#xa0;E.&#xa0;V. Pires, E.&#xa0;P.&#xa0;Pardo, J.&#xa0;J&#xe4;nes, A.&#xa0;O.&#xa0;Zalevsky, B.&#xa0;M&#xe9;sz&#xe1;ros, P.&#xa0;Bryant, L.&#xa0;L.&#xa0;Good, R.&#xa0;A.&#xa0;Laskowski, G.&#xa0;Pozzati, A.&#xa0;Shenoy, W.&#xa0;Zhu, P.&#xa0;Kundrotas, V.&#xa0;R.&#xa0;Serra, C.&#xa0;H.&#xa0;M. Rodrigues, A.&#xa0;S.&#xa0;Dunham, D.&#xa0;Burke, N.&#xa0;Borkakoti, S.&#xa0;Velankar, A.&#xa0;Frost, J.&#xa0;Basquin, K.&#xa0;Lindorff-Larsen, A.&#xa0;Bateman, A.&#xa0;V.&#xa0;Kajava, A.&#xa0;Valencia, S.&#xa0;Ovchinnikov, J.&#xa0;Durairaj, D.&#xa0;B.&#xa0;Ascher, J.&#xa0;M.&#xa0;Thornton, N.&#xa0;E.&#xa0;Davey, A.&#xa0;Stein, A.&#xa0;Elofsson, T.&#xa0;I.&#xa0;Croll, P.&#xa0;Beltrao, A structural biology community assessment of AlphaFold2 applications. bioRxiv 2021.09.26.461876 [Preprint]. 26 September 2021. 10.1101/2021.09.26.461876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.26.461876</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36732333</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system.</ArticleTitle><Pagination><StartPage>560</StartPage><MedlinePgn>560</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">560</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-36058-2</ELocationID><Abstract><AbstractText>Amyloid-like aggregates of the microtubule-associated protein Tau are associated with several neurodegenerative disorders including Alzheimer's disease. The existence of cellular machinery for the removal of such aggregates has remained unclear, as specialized disaggregase chaperones are thought to be absent in mammalian cells. Here we show in cell culture and in neurons that the hexameric ATPase valosin-containing protein (VCP) is recruited to ubiquitylated Tau fibrils, resulting in their efficient disaggregation. Aggregate clearance depends on the functional cooperation of VCP with heat shock 70&#x2009;kDa protein (Hsp70) and the ubiquitin-proteasome machinery. While inhibition of VCP activity stabilizes large Tau aggregates, disaggregation by VCP generates seeding-active Tau species as byproduct. These findings identify VCP as a core component of the machinery for the removal of neurodegenerative disease aggregates and suggest that its activity can be associated with enhanced aggregate spreading in tauopathies.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saha</LastName><ForeName>Itika</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuste-Checa</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1056-3849</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Silva Padilha</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Neurodegeneration Group, Max Planck Institute for Biological Intelligence, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecules - Signaling - Development, Max Planck Institute for Biological Intelligence, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Anatomy, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-3520-5439</Identifier><AffiliationInfo><Affiliation>Department of Structural Molecular Biology, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences and Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rner</LastName><ForeName>Roman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holthusen</LastName><ForeName>Hauke</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2050-413X</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinkaus</LastName><ForeName>Victoria A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Structural Molecular Biology, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudanova</LastName><ForeName>Irina</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-1052-8485</Identifier><AffiliationInfo><Affiliation>Molecular Neurodegeneration Group, Max Planck Institute for Biological Intelligence, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecules - Signaling - Development, Max Planck Institute for Biological Intelligence, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Anatomy, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Busnadiego</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8366-7622</Identifier><AffiliationInfo><Affiliation>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Structural Molecular Biology, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center G&#xf6;ttingen, 37099, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumeister</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-8154-8809</Identifier><AffiliationInfo><Affiliation>Department of Structural Molecular Biology, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, 75390, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08544, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautam</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0366-6169</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boehringer Ingelheim International GmbH, 55216, Ingelheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ViraTherapeutics GmbH, 6063, Rum, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0002-8085-7770</Identifier><AffiliationInfo><Affiliation>Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, 75390, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartl</LastName><ForeName>F Ulrich</ForeName><Initials>FU</Initials><Identifier Source="ORCID">0000-0002-7941-135X</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany. uhartl@biochem.mpg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA. uhartl@biochem.mpg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. uhartl@biochem.mpg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hipp</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-0497-3016</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany. m.s.hipp@umcg.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. m.s.hipp@umcg.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany. m.s.hipp@umcg.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan, 1, 9713 AV, Groningen, The Netherlands. m.s.hipp@umcg.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="D000074405">Valosin Containing Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="C000614178">VCP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074405" MajorTopicYN="N">Valosin Containing Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36732333</ArticleId><ArticleId IdType="pmc">PMC9894937</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-36058-2</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-36058-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Eisenberg DS, Crowther RA. Propagation of Tau aggregates and neurodegeneration. Annu. Rev. Neurosci. 2017;40:189&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab. Investig. 2019;99:912&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289372</ArticleId><ArticleId IdType="pubmed">30742061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) Tau protein. Nat. Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, et al. Abundant Tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S Tau protein. J. Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 2018;21:1341&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375686</ArticleId><ArticleId IdType="pubmed">30258241</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquer-Alicea J, Diamond MI. Propagation of protein aggregation in neurodegenerative diseases. Annu. Rev. Biochem. 2019;88:785&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">30917002</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, et al. Tau reduction prevents neuronal loss and reverses pathological Tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 2017;9:374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, et al. Reversal of neurofibrillary tangles and Tau-associated phenotype in the rTgTauEC model of early Alzheimer&#x2019;s disease. J. Neurosci. 2013;33:13300&#x2013;13311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742920</ArticleId><ArticleId IdType="pubmed">23946388</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle SM, Genest O, Wickner S. Protein rescue from aggregates by powerful molecular chaperone machines. Nat. Rev. Mol. Cell Biol. 2013;14:617&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24061228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogk A, Bukau B, Kampinga HH. Cellular handling of protein aggregates by disaggregation machines. Mol. Cell. 2018;69:214&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">29351843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nillegoda NB, Wentink AS, Bukau B. Protein disaggregation in multicellular organisms. Trends Biochem. Sci. 2018;43:285&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">29501325</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust O, et al. HSP40 proteins use class-specific regulation to drive HSP70 functional diversity. Nature. 2020;587:489&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">33177718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wentink AS, et al. Molecular dissection of amyloid disaggregation by human HSP70. Nature. 2020;587:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">33177717</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One. 2011;6:e26319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3194798</ArticleId><ArticleId IdType="pubmed">22022600</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachman E, et al. Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery generates small seeding-competent species. J. Biol. Chem. 2020;295:9676&#x2013;9690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363153</ArticleId><ArticleId IdType="pubmed">32467226</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider MM, et al. The Hsc70 disaggregation machinery removes monomer units directly from &#x3b1;-synuclein fibril ends. Nat. Commun. 2021;12:5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516981</ArticleId><ArticleId IdType="pubmed">34650037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, et al. Human Hsp70 disaggregase reverses Parkinson&#x2019;s-linked alpha-Synuclein amyloid fibrils. Mol. Cell. 2015;59:781&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5072489</ArticleId><ArticleId IdType="pubmed">26300264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodnar NO, Rapoport TA. Molecular mechanism of substrate processing by the Cdc48 ATPase complex. Cell. 2017;169:722&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5751438</ArticleId><ArticleId IdType="pubmed">28475898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Z, et al. Translocation of polyubiquitinated protein substrates by the hexameric Cdc48 ATPase. Mol. Cell. 2021;82:570&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8818041</ArticleId><ArticleId IdType="pubmed">34951965</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwich NF, et al. Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau. Science. 2020;370:eaay8826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818661</ArticleId><ArticleId IdType="pubmed">33004675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Manno A, Kakizuka A. Involvement of valosin-containing protein (VCP)/p97 in the formation and clearance of abnormal protein aggregates. Genes Cells. 2007;12:889&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">17584300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwon Y, et al. Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner. Science. 2021;372:eabf6548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574224</ArticleId><ArticleId IdType="pubmed">34739333</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan JR, Kolaitis R-M, Taylor JP, Parker R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP Function. Cell. 2013;153:1461&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760148</ArticleId><ArticleId IdType="pubmed">23791177</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Boom J, Meyer H. VCP/p97-mediated unfolding as a principle in protein homeostasis and signaling. Mol. Cell. 2018;69:182&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">29153394</ArticleId></ArticleIdList></Reference><Reference><Citation>Olszewski MM, Williams C, Dong KC, Martin A. The Cdc48 unfoldase prepares well-folded protein substrates for degradation by the 26S proteasome. Commun. Biol. 2019;2:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340886</ArticleId><ArticleId IdType="pubmed">30675527</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer H, Weihl CC. The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J. Cell Sci. 2014;127:3877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163641</ArticleId><ArticleId IdType="pubmed">25146396</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder R, et al. Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann. Neurol. 2005;57:457&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15732117</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GD, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 2004;36:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Blythe EE, Olson KC, Chau V, Deshaies RJ. Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP*NPLOC4*UFD1L is enhanced by a mutation that causes multisystem proteinopathy. Proc. Natl Acad. Sci. USA. 2017;114:E4380&#x2013;E4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465906</ArticleId><ArticleId IdType="pubmed">28512218</ArticleId></ArticleIdList></Reference><Reference><Citation>Manno A, Noguchi M, Fukushi J, Motohashi Y, Kakizuka A. Enhanced ATPase activities as a primary defect of mutant valosin-containing proteins that cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Genes Cells. 2010;15:911&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">20604808</ArticleId></ArticleIdList></Reference><Reference><Citation>Blythe EE, Gates SN, Deshaies RJ, Martin A. Multisystem Proteinopathy mutations in VCP/p97 increase NPLOC4&#xb7;UFD1L binding and substrate processing. Structure. 2019;27:1820&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929323</ArticleId><ArticleId IdType="pubmed">31623962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritz D, et al. Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations. Nat. Cell Biol. 2011;13:1116&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246400</ArticleId><ArticleId IdType="pubmed">21822278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tresse E, et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy. 2010;6:217&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929010</ArticleId><ArticleId IdType="pubmed">20104022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, et al. Proteomic landscape of Alzheimer&#x2019;s Disease: novel insights into pathogenesis and biomarker discovery. Mol. Neurodegener. 2021;16:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8359598</ArticleId><ArticleId IdType="pubmed">34384464</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Davies P, Mandelkow E. Tau paired helical filaments from Alzheimer&#x2019;s disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry. 2004;43:1694&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pubmed">14769047</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther T, Goedert M, Wischik CM. The repeat region of microtubule-associated protein Tau forms part of the core of the paired helical filament of Alzheimer&#x2019;s disease. Ann. Med. 1989;21:127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">2504257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct Tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J. Biol. Chem. 2009;284:3546&#x2013;3551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmued L, et al. Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J. Neurosci. Methods. 2012;209:120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">22705750</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature. 2018;561:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc. Natl Acad. Sci. USA. 1997;94:4113&#x2013;4118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20577</ArticleId><ArticleId IdType="pubmed">9108114</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Novel tau filament fold in corticobasal degeneration. Nature. 2020;580:283&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004;13:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun DH, Lee M, Halliwell B, Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J. Neurochem. 2003;86:363&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">12871577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjerpe R, et al. UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome. Cell. 2016;166:935&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003816</ArticleId><ArticleId IdType="pubmed">27477512</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey EC, et al. Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding. Science. 2019;365:eaax1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980381</ArticleId><ArticleId IdType="pubmed">31249135</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnaghi P, et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 2013;9:548&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">23892893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H-J, et al. Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083) J. Med. Chem. 2015;58:9480&#x2013;9497.</Citation><ArticleIdList><ArticleId IdType="pubmed">26565666</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;uerlein FJB, et al. In situ architecture and cellular interactions of polyq inclusions. Cell. 2017;171:179&#x2013;187.e110.</Citation><ArticleIdList><ArticleId IdType="pubmed">28890085</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinkaus VA, et al. In situ architecture of neuronal &#x3b1;-Synuclein inclusions. Nat. Commun. 2021;12:2110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8046968</ArticleId><ArticleId IdType="pubmed">33854052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace MC, et al. Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease. Acta Neuropathol. 2018;136:919&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411038</ArticleId><ArticleId IdType="pubmed">30140941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyer ML, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat. Med. 2018;24:186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">29334375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, et al. Firefly luciferase mutants as sensors of proteome stress. Nat. Methods. 2011;8:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">21892152</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlecht R, et al. Functional analysis of Hsp70 inhibitors. PLoS One. 2013;8:e78443&#x2013;e78443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3827032</ArticleId><ArticleId IdType="pubmed">24265689</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J. Neuropathol. Exp. Neurol. 2006;65:571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783167</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Dalal S, Pestronk A, Hanson PI. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum. Mol. Genet. 2005;15:189&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">16321991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalal S, Rosser MF, Cyr DM, Hanson PI. Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. Mol. Biol. Cell. 2004;15:637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC329284</ArticleId><ArticleId IdType="pubmed">14617820</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. VCP suppresses proteopathic seeding in neurons. Mol. Neurodegener. 2022;17:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9004082</ArticleId><ArticleId IdType="pubmed">35414105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuste-Checa P, et al. The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model. Nat. Commun. 2021;12:4863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357826</ArticleId><ArticleId IdType="pubmed">34381050</ArticleId></ArticleIdList></Reference><Reference><Citation>Erives AJ, Fassler JS. Metabolic and chaperone gene loss marks the origin of animals: evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients. PLoS One. 2015;10:e0117192&#x2013;e0117192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339202</ArticleId><ArticleId IdType="pubmed">25710177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag EM, Samant RS, Frydman J. Mechanisms and functions of spatial protein quality control. Annu. Rev. Biochem. 2017;86:97&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">28489421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cliffe R, et al. Filamentous aggregates are fragmented by the proteasome holoenzyme. Cell Rep. 2019;26:2140&#x2013;2149.e2143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6381791</ArticleId><ArticleId IdType="pubmed">30784595</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NamC, et al. VCP is essential for mitochondrial quality control by pink1/parkin and this function is impaired by VCP mutations. Neuron. 2013;78:65&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683300</ArticleId><ArticleId IdType="pubmed">23498974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolome F, et al. Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron. 2013;78:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843114</ArticleId><ArticleId IdType="pubmed">23498975</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashiyama H, et al. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration. Cell Death Differ. 2002;9:264&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">11859409</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, et al. Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD. EMBO J. 2020;39:e102811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156967</ArticleId><ArticleId IdType="pubmed">32175624</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME, et al. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell. 2014;156:170&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3909490</ArticleId><ArticleId IdType="pubmed">24439375</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Engineering therapeutic protein disaggregases. Mol. Biol. Cell. 2016;27:1556&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865313</ArticleId><ArticleId IdType="pubmed">27255695</ArticleId></ArticleIdList></Reference><Reference><Citation>VerPlank JJS, Tyrkalska SD, Fleming A, Rubinsztein DC, Goldberg AL. cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. Proc. Natl Acad. Sci. USA. 2020;117:14220&#x2013;14230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321992</ArticleId><ArticleId IdType="pubmed">32513741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, et al. SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway. Science. 2017;358:813&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747364</ArticleId><ArticleId IdType="pubmed">29123071</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, et al. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008;3:1101&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, et al. In situ structure of neuronal C9orf72 Poly-GA aggregates reveals proteasome recruitment. Cell. 2018;172:696&#x2013;705.e612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035389</ArticleId><ArticleId IdType="pubmed">29398115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigort A, et al. Focused ion beam micromachining of eukaryotic cells for cryoelectron tomography. Proc. Natl Acad. Sci. USA. 2012;109:4449&#x2013;4454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3311327</ArticleId><ArticleId IdType="pubmed">22392984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastronarde DN. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 2005;152:36&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16182563</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda Y, Laugks U, Lu&#x10d;i&#x107; V, Baumeister W, Danev R. Electron cryotomography of vitrified cells with a Volta phase plate. J. Struct. Biol. 2015;190:143&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">25770733</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat. Methods. 2013;10:584&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684049</ArticleId><ArticleId IdType="pubmed">23644547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer JR, Mastronarde DN, McIntosh JR. Computer visualization of three-dimensional image data using IMOD. J. Struct. Biol. 1996;116:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742726</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigort A, et al. Automated segmentation of electron tomograms for a quantitative description of actin filament networks. J. Struct. Biol. 2012;177:135&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">21907807</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Sanchez A, Garcia I, Asano S, Lucic V, Fernandez JJ. Robust membrane detection based on tensor voting for electron tomography. J. Struct. Biol. 2014;186:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24625523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SE, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteom. 2002;1:376&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">12118079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#x15b;niewski JR, Zielinska DF, Mann M. Comparison of ultrafiltration units for proteomic and N-glycoproteomic analysis by the filter-aided sample preparation method. Anal. Biochem. 2011;410:307&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">21144814</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychaudhuri S, et al. Interplay of acetyltransferase EP300 and the proteasome system in regulating heat shock transcription factor 1. Cell. 2014;156:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">24581496</ArticleId></ArticleIdList></Reference><Reference><Citation>Banning C, et al. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One. 2010;5:e9344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825263</ArticleId><ArticleId IdType="pubmed">20179761</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47:D442&#x2013;d450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36732642</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>430</StartPage><EndPage>446</EndPage><MedlinePgn>430-446</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01251-x</ELocationID><Abstract><AbstractText>Complex diseases are characterized by spatiotemporal cellular and molecular changes that may be difficult to comprehensively capture. However, understanding the spatiotemporal dynamics underlying pathology can shed light on disease mechanisms and progression. Here we introduce STARmap PLUS, a method that combines high-resolution spatial transcriptomics with protein detection in the same tissue section. As proof of principle, we analyze brain tissues of a mouse model of Alzheimer's disease at 8 and 13 months of age. Our approach provides a comprehensive cellular map of disease progression. It reveals a core-shell structure where disease-associated microglia (DAM) closely contact amyloid-&#x3b2; plaques, whereas disease-associated astrocyte-like (DAA-like) cells and oligodendrocyte precursor cells (OPCs) are enriched in the outer shells surrounding the plaque-DAM complex. Hyperphosphorylated tau emerges mainly in excitatory neurons in the CA1 region and correlates with the local enrichment of oligodendrocyte subtypes. The STARmap PLUS method bridges single-cell gene expression profiles with tissue histopathology at subcellular resolution, providing a tool to pinpoint the molecular and cellular changes underlying pathology.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zeng</LastName><ForeName>Hu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Jiahao</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6349-9799</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Haowen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meilandt</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dejanovic</LastName><ForeName>Borislav</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4191-5808</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohlen</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Hye</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Zefang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7477-7830</Identifier><AffiliationInfo><Affiliation>John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2217-6982</Identifier><AffiliationInfo><Affiliation>John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8703-5366</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA. msheng@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. msheng@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA. msheng@broadinstitute.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3090-9894</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA. wangxiao@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. wangxiao@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. wangxiao@broadinstitute.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 GM146245</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. X.W., H.Z. and J.R. are inventors on pending patent applications related to STARmap PLUS. X.W. is a scientific cofounder of Stellaromics. M.S. is a scientific cofounder of Neumora and a former employee of Genentech. W.J.M., C. J. B. and S.-H.L. are present employees of Genentech. All the other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36732642</ArticleId><ArticleId IdType="mid">NIHMS1963897</ArticleId><ArticleId IdType="pmc">PMC11332722</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01251-x</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01251-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masters CL et al. Alzheimer&#x2019;s disease. Nat. Rev. Dis. Prim. 1, 15056 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H. &amp; Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA &amp; Hyman BT Synergy between amyloid-&#x3b2; and tau in Alzheimer&#x2019;s disease. Nat. Neurosci. 23, 1183&#x2013;1193 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11831977</ArticleId><ArticleId IdType="pubmed">32778792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. &amp; Selkoe DJ The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Walker R. &amp; McGeer EG Patterns of gliosis in Alzheimer&#x2019;s disease and aging cerebrum. Glia 2, 420&#x2013;436 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2531723</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AM, De La Rocha IC &amp; Rivera A. Oligodendroglial cells in Alzheimer&#x2019;s disease. Adv. Exp. Med. Biol. 1175, 325&#x2013;333 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31583593</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Hyman BT &amp; Spires-Jones TL Beyond the neuron&#x2013;cellular interactions early in Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 20, 94&#x2013;108 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545070</ArticleId><ArticleId IdType="pubmed">30643230</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A. et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N. et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 23, 701&#x2013;706 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H. et al. Unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau S-F, Cao H, Fu AKY &amp; Ip NY Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 117, 25800&#x2013;25809 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568283</ArticleId><ArticleId IdType="pubmed">32989152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H. et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, Friedman BA, Dejanovic B. &amp; Sheng M. Microglia in brain development, homeostasis, and neurodegeneration. Annu. Rev. Genet. 53, 263&#x2013;288 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31518519</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A. et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173, 1073&#x2013;1081 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Rep. 22, 832&#x2013;847 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE &amp; Sheng M. Microglia in Alzheimer&#x2019;s disease. J. Cell Biol. 217, 459&#x2013;472 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewcock JW et al. Emerging microglia biology defines novel therapeutic approaches for Alzheimer&#x2019;s disease. Neuron 108, 801&#x2013;821 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33096024</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sankowski R, Staszewski O. &amp; Prinz M. Microglia heterogeneity in the single-cell era. Cell Rep. 30, 1271&#x2013;1281 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32023447</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE et al. Normal aging induces A1-like astrocyte reactivity. Proc. Natl Acad. Sci. USA 115, E1896&#x2013;E1905 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA &amp; Barres BA Reactive astrocytes: production, function, and therapeutic potential. Immunity 46, 957&#x2013;967 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV Astrocyte reactivity: subtypes, states, and functions in CNS innate immunity. Trends Immunol. 41, 758&#x2013;770 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484257</ArticleId><ArticleId IdType="pubmed">32819810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun SP et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson&#x2019;s disease. Nat. Med. 24, 931&#x2013;938 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039259</ArticleId><ArticleId IdType="pubmed">29892066</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Brink SC et al. Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. Nat. Methods 14, 935&#x2013;936 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28960196</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrupp N. et al. Single-nucleus RNA-seq is not suitable for detection of microglial activation genes in humans. Cell Rep. 32, 108189 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527779</ArticleId><ArticleId IdType="pubmed">32997994</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SE et al. Dissection of artifactual and confounding glial signatures by single-cell sequencing of mouse and human brain. Nat. Neurosci. 25, 306&#x2013;316 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11645269</ArticleId><ArticleId IdType="pubmed">35260865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett FC et al. A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98, 1170&#x2013;1183 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023731</ArticleId><ArticleId IdType="pubmed">29861285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KH, Boettiger AN, Moffitt JR, Wang S. &amp; Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 348, aaa6090 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662681</ArticleId><ArticleId IdType="pubmed">25858977</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriques SG et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science 363, 1463&#x2013;1467 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927209</ArticleId><ArticleId IdType="pubmed">30923225</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hl PL et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science 353, 78&#x2013;82 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27365449</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T. &amp; Satija R. Integrative single-cell analysis. Nat. Rev. Genet. 20, 257&#x2013;272 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30696980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. et al. Three-dimensional intact-tissue sequencing of single-cell transcriptional states. Science 361, eaat5691 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339868</ArticleId><ArticleId IdType="pubmed">29930089</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X. et al. Probabilistic cell typing enables fine mapping of closely related cell types in situ. Nat. Methods 17, 101&#x2013;106 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949128</ArticleId><ArticleId IdType="pubmed">31740815</ArticleId></ArticleIdList></Reference><Reference><Citation>Alon S. et al. Expansion sequencing: spatially precise in situ transcriptomics in intact biological systems. Science 371, eaax2656 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900882</ArticleId><ArticleId IdType="pubmed">33509999</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S. et al. Barcoded oligonucleotides ligated on RNA amplified for multiplexed and parallel in situ analyses. Nucleic Acids Res. 49, e58 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8191787</ArticleId><ArticleId IdType="pubmed">33693773</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W-T et al. Spatial transcriptomics and in situ sequencing to study Alzheimer&#x2019;s disease. Cell 182, 976&#x2013;991 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32702314</ArticleId></ArticleIdList></Reference><Reference><Citation>Grueninger F. et al. Phosphorylation of tau at S422 is enhanced by A&#x3b2; in tauPS2APP triple transgenic mice. Neurobiol. Dis. 37, 294&#x2013;306 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19781645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by &#x3b2;-amyloid pathology. Neuron 109, 1283&#x2013;1301 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein E, Borm LE &amp; Linnarsson S. The promise of spatial transcriptomics for neuroscience in the era of molecular cell typing. Science 358, 64&#x2013;69 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28983044</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans F. et al. SynGO: an evidence-based, expert-curated knowledge base for the synapse. Neuron 103, 217&#x2013;234 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764089</ArticleId><ArticleId IdType="pubmed">31171447</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A. et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015&#x2013;1030 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Z. et al. A taxonomy of transcriptomic cell types across the isocortex and hippocampal formation. Cell 184, 3222&#x2013;3241 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195859</ArticleId><ArticleId IdType="pubmed">34004146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL et al. Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391&#x2013;6410 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A. et al. Molecular architecture of the mouse nervous system. Cell 174, 999&#x2013;1014 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J. et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496&#x2013;502 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6434952</ArticleId><ArticleId IdType="pubmed">30787437</ArticleId></ArticleIdList></Reference><Reference><Citation>Feregrino C. &amp; Tschopp P. Assessing evolutionary and developmental transcriptome dynamics in homologous cell types. Dev. Dyn. 251, 1472&#x2013;1489 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9545966</ArticleId><ArticleId IdType="pubmed">34114716</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jim&#xe9;nez EP Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer&#x2019;s disease. Nat. Med. 25, 554&#x2013;560 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Raudvere U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191&#x2013;W198 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602461</ArticleId><ArticleId IdType="pubmed">31066453</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498&#x2013;2504 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pease-Raissi SE &amp; Chan JR Building a (w)rapport between neurons and oligodendroglia: reciprocal interactions underlying adaptive myelination. Neuron 109, 1258&#x2013;1273 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8068592</ArticleId><ArticleId IdType="pubmed">33621477</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B. et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer&#x2019;s disease mouse models. Nat. Aging 2, 837&#x2013;850 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154216</ArticleId><ArticleId IdType="pubmed">37118504</ArticleId></ArticleIdList></Reference><Reference><Citation>Cain A. et al. Multi-cellular communities are perturbed in the aging human brain and with Alzheimer&#x2019;s disease. Preprint at bioRxiv. 10.1101/2020.12.22.424084 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.22.424084</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt U, Weigert M, Broaddus C. &amp; Myers G. Medical Image Computing and Computer Assisted Intervention&#x2014;MICCAI 2018 265&#x2013;273 (Springer International Publishing, 2018).</Citation></Reference><Reference><Citation>Schindelin J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Angerer P. &amp; Theis FJ SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WE, Li C. &amp; Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118&#x2013;127 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16632515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Pau G, Fuchs F, Sklyar O, Boutros M. &amp; Huber W. EBImage&#x2013;an R package for image processing with applications to cellular phenotypes. Bioinformatics 26, 979&#x2013;981 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844988</ArticleId><ArticleId IdType="pubmed">20338898</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Eils R. &amp; Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847&#x2013;2849 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico D, Isserlin R, Stueker O, Emili A. &amp; Bader GD Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5, e13984 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981572</ArticleId><ArticleId IdType="pubmed">21085593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36745413</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.</ArticleTitle><Pagination><StartPage>360</StartPage><EndPage>369</EndPage><MedlinePgn>360-369</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.5272</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Alzheimer disease (AD) pathology starts with a prolonged phase of &#x3b2;-amyloid (A&#x3b2;) accumulation without symptoms. The duration of this phase differs greatly among individuals. While this disease phase has high relevance for clinical trial designs, it is currently unclear how to best predict the onset of clinical progression.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate combinations of different plasma biomarkers for predicting cognitive decline in A&#x3b2;-positive cognitively unimpaired (CU) individuals.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This prospective population-based prognostic study evaluated data from 2 prospective longitudinal cohort studies (the Swedish BioFINDER-1 and the Wisconsin Registry for Alzheimer Prevention [WRAP]), with data collected from February 8, 2010, to October 21, 2020, for the BioFINDER-1 cohort and from August 11, 2011, to June 27, 2021, for the WRAP cohort. Participants were CU individuals recruited from memory clinics who had brain A&#x3b2; pathology defined by cerebrospinal fluid (CSF) A&#x3b2;42/40 in the BioFINDER-1 study and by Pittsburgh Compound B (PiB) positron emission tomography (PET) in the WRAP study. A total of 564 eligible A&#x3b2;-positive and A&#x3b2;-negative CU participants with available relevant data from the BioFINDER-1 and WRAP cohorts were included in the study; of those, 171 A&#x3b2;-positive participants were included in the main analyses.</AbstractText><AbstractText Label="EXPOSURES">Baseline P-tau181, P-tau217, P-tau231, glial fibrillary filament protein, and neurofilament light measured in plasma; CSF biomarkers in the BioFINDER-1 cohort, and PiB PET uptake in the WRAP cohort.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was longitudinal measures of cognition (using the Mini-Mental State Examination [MMSE] and the modified Preclinical Alzheimer Cognitive Composite [mPACC]) over a median of 6 years (range, 2-10 years). The secondary outcome was conversion to AD dementia. Baseline biomarkers were used in linear regression models to predict rates of longitudinal cognitive change (calculated separately). Models were adjusted for age, sex, years of education, apolipoprotein E &#x3b5;4 allele status, and baseline cognition. Multivariable models were compared based on model R2 coefficients and corrected Akaike information criterion.</AbstractText><AbstractText Label="RESULTS">Among 171 A&#x3b2;-positive CU participants included in the main analyses, 119 (mean [SD] age, 73.0 [5.4] years; 60.5% female) were from the BioFINDER-1 study, and 52 (mean [SD] age, 64.4 [4.6] years; 65.4% female) were from the WRAP study. In the BioFINDER-1 cohort, plasma P-tau217 was the best marker to predict cognitive decline in the mPACC (model R2&#x2009;=&#x2009;0.41) and the MMSE (model R2&#x2009;=&#x2009;0.34) and was superior to the covariates-only models (mPACC: R2&#x2009;=&#x2009;0.23; MMSE: R2&#x2009;=&#x2009;0.04; P&#x2009;&lt;&#x2009;.001 for both comparisons). Results were validated in the WRAP cohort; for example, plasma P-tau217 was associated with mPACC slopes (R2&#x2009;=&#x2009;0.13 vs 0.01 in the covariates-only model; P&#x2009;=&#x2009;.01) and MMSE slopes (R2&#x2009;=&#x2009;0.29 vs 0.24 in the covariates-only model; P&#x2009;=&#x2009;.046). Sparse models were identified with plasma P-tau217 as a predictor of cognitive decline. Power calculations for enrichment in hypothetical clinical trials revealed large relative reductions in sample sizes when using plasma P-tau217 to enrich for CU individuals likely to experience cognitive decline over time.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, plasma P-tau217 predicted cognitive decline in patients with preclinical AD. These findings suggest that plasma P-tau217 may be used as a complement to CSF or PET for participant selection in clinical trials of novel disease-modifying treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvad&#xf3;</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tideman</LastName><ForeName>Pontus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration Program, Amsterdam University Medical Centers, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betthauser</LastName><ForeName>Tobey J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cody</LastName><ForeName>Karly Alex</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonaitis</LastName><ForeName>Erin M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langhough</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068398</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Zetterberg reported receiving personal fees as a member of the scientific advisory boards of Abbvie, Acumen, Alector, ALZpath, Annexon Biosciences, Apellis Pharmaceuticals, Artery Therapeutics, AZTherapies, Cognition Therapeutics, Denali Therapeutics, Eisai, NervGen Pharma, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed (now Biosplice Therapeutics), Siemens Healthineers, Triplet Therapeutics, and Wave Life Sciences and lecture fees from AlzeCure Pharma, Biogen, Cellectricon, Fujirebio, and Roche outside the submitted work. Dr Betthauser reported receiving grants from the Alzheimer's Association and the National Institute on Aging during the conduct of the study. Dr Jonaitis reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Koscik reported receiving grants from National Institutes of Health during the conduct of the study. Ms Cody reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Palmqvist reported serving on the scientific advisory boards of and/or giving lectures at symposia sponsored by BioArctic, Biogen, Cytox, Eli Lilly and Company, Geras Solutions, and Roche. Dr Blennow reported serving as a consultant, member of the advisory board, or member of the data monitoring committee for Abcam, Axon Pharma, BioArctic, Biogen, Eli Lilly and Company, JOMDD/Shimadzu, Julius Clinical, MagQu, Novartis, Ono Pharmaceutical Company, Pharmatrophix, Prothena Corporation, Roche Diagnostics, and Siemens Healthineers and being a cofounder of Brain Biomarker Solutions, which is a part of the GU Ventures incubator program, outside the submitted work. Dr Johnson reported receiving grants from the National Institute on Aging during the conduct of the study and receiving grants from Cerveau Technologies (via his institution) and personal fees from Merck &amp; Co, Prothena Corporation, and Roche Diagnostics outside the submitted work. Dr Hansson reported receiving grants from the Swedish Alzheimer Foundation and the Swedish Research Council and nonfinancial support from Eli Lilly and Company during the conduct of the study and receiving personal fees from Biogen, Eli Lilly and Company, and Eisai outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36745413</ArticleId><ArticleId IdType="pmc">PMC10087054</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.5272</ArticleId><ArticleId IdType="pii">2801289</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jansen WJ, Janssen O, Tijms BM, et al. ; Amyloid Biomarker Study Group . Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 2022;79(3):228-243. doi:10.1001/jamaneurol.2021.5216</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.5216</ArticleId><ArticleId IdType="pubmed">35099509</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Li Y, Buckles VD, et al. . Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology. 2021;97(18):e1823-e1834. doi:10.1212/WNL.0000000000012775</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012775</ArticleId><ArticleId IdType="pmc">PMC8610624</ArticleId><ArticleId IdType="pubmed">34504028</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Bilgel M, Koscik RL, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain. 2022;145(11):4065-4079. doi:10.1093/brain/awac213</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac213</ArticleId><ArticleId IdType="pmc">PMC9679170</ArticleId><ArticleId IdType="pubmed">35856240</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Weiner M, Mackin RS, et al. . Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology. 2019;93(4):e322-e333. doi:10.1212/WNL.0000000000007831</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007831</ArticleId><ArticleId IdType="pmc">PMC6669933</ArticleId><ArticleId IdType="pubmed">31289148</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305-2316. doi:10.1001/jama.2017.6669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.6669</ArticleId><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer&#x2019;s disease. News release. Eisai. September 28, 2022. Accessed October 31, 2022. https://www.eisai.com/news/2022/news202271.html</Citation></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963. doi:10.1038/s41591-021-01382-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Koscik RL, Betthauser TJ, Jonaitis EM, et al. . Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement (Amst). 2020;12(1):e12007. doi:10.1002/dad2.12007</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12007</ArticleId><ArticleId IdType="pmc">PMC7085284</ArticleId><ArticleId IdType="pubmed">32211502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Therneau TM, Lundt ES, et al. . Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Commun. 2022;4(2):fcac017. doi:10.1093/braincomms/fcac017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac017</ArticleId><ArticleId IdType="pmc">PMC8924651</ArticleId><ArticleId IdType="pubmed">35310829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Smith R, Ohlsson T, et al. . Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601-e612. doi:10.1212/WNL.0000000000006875</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006875</ArticleId><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Donohue MC, Berron D, Hansson O, Mattsson-Carlgren N. Time between milestone events in the Alzheimer&#x2019;s disease amyloid cascade. Neuroimage. 2021;227:117676. doi:10.1016/j.neuroimage.2020.117676</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2020.117676</ArticleId><ArticleId IdType="pubmed">33359337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisconsin Registry for Alzheimer&#x2019;s Prevention. University of Wisconsin&#x2013;Madison; 2022. Accessed December 18, 2022. https://wrap.wisc.edu</Citation></Reference><Reference><Citation>Mattsson N, Insel PS, Palmqvist S, et al. . Increased amyloidogenic APP processing in APOE &#x25b;4&#x2013;negative individuals with cerebral &#x3b2;-amyloidosis. Nat Commun. 2016;7:10918. doi:10.1038/ncomms10918</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10918</ArticleId><ArticleId IdType="pmc">PMC4786682</ArticleId><ArticleId IdType="pubmed">26948379</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall S, &#xd6;hrfelt A, Constantinescu R, et al. . Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445-1452. doi:10.1001/archneurol.2012.1654</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.1654</ArticleId><ArticleId IdType="pubmed">22925882</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Koscik RL, Jonaitis EM, et al. . The Wisconsin Registry for Alzheimer&#x2019;s Prevention: a review of findings and current directions. Alzheimers Dement (Amst). 2017;10:130-142. doi:10.1016/j.dadm.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5755749</ArticleId><ArticleId IdType="pubmed">29322089</ArticleId></ArticleIdList></Reference><Reference><Citation>Langhough Koscik R, Hermann BP, Allison S, et al. . Validity evidence for the research category, &#x201c;cognitively unimpaired&#x2013;declining,&#x201d; as a risk marker for mild cognitive impairment and Alzheimer&#x2019;s disease. Front Aging Neurosci. 2021;13:688478. doi:10.3389/fnagi.2021.688478</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.688478</ArticleId><ArticleId IdType="pmc">PMC8350058</ArticleId><ArticleId IdType="pubmed">34381351</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. ; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Alzheimer&#x2019;s Disease Cooperative Study . The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970. doi:10.1001/jamaneurol.2014.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Tideman P, Cullen N, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Prediction of future Alzheimer&#x2019;s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034-1042. doi:10.1038/s41591-021-01348-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01348-z</ArticleId><ArticleId IdType="pubmed">34031605</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Palmqvist S, Leuzy A, et al. . Detecting amyloid positivity in early Alzheimer&#x2019;s disease using combinations of plasma A&#x3b2;42/A&#x3b2;40 and P-tau. Alzheimers Dement. 2022;18(2):283-293. doi:10.1002/alz.12395</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12395</ArticleId><ArticleId IdType="pubmed">34151519</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hulle C, Jonaitis EM, Betthauser TJ, et al. . An examination of a novel multipanel of CSF biomarkers in the Alzheimer&#x2019;s disease clinical and pathological continuum. Alzheimers Dement. 2021;17(3):431-445. doi:10.1002/alz.12204</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12204</ArticleId><ArticleId IdType="pmc">PMC8016695</ArticleId><ArticleId IdType="pubmed">33336877</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Stomrud E, Cullen N, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer&#x2019;s disease. Alzheimers Dement. Published online August 11, 2022. doi:10.1002/alz.12751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12751</ArticleId><ArticleId IdType="pmc">PMC9918613</ArticleId><ArticleId IdType="pubmed">35950735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Pascoal TA, Karikari TK, et al. . Plasma P-tau231: a new biomarker for incipient Alzheimer&#x2019;s disease pathology. Acta Neuropathol. 2021;141(5):709-724. doi:10.1007/s00401-021-02275-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02275-6</ArticleId><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Christian BT, Okonkwo OC, et al. . Amyloid burden and neural function in people at risk for Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35(3):576-584. doi:10.1016/j.neurobiolaging.2013.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.028</ArticleId><ArticleId IdType="pmc">PMC4018215</ArticleId><ArticleId IdType="pubmed">24269021</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Zhou J, Irizarry MC, et al. . AHEAD 3-45 study design: a global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer&#x2019;s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). Alzheimers Dement. 2020;16(S9):e044511. doi:10.1002/alz.044511</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.044511</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham KP, Anderson DR. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res. 2004;33(2):261-304. doi:10.1177/0049124104268644</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0049124104268644</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. . Longitudinal plasma P-tau217 is increased in early stages of Alzheimer&#x2019;s disease. Brain. 2020;143(11):3234-3241. doi:10.1093/brain/awaa286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa286</ArticleId><ArticleId IdType="pmc">PMC7719022</ArticleId><ArticleId IdType="pubmed">33068398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Edelmayer RM, Boxer AL, et al. . The Alzheimer&#x2019;s Association appropriate use recommendations for blood biomarkers in Alzheimer&#x2019;s disease. Alzheimers Dement. Published online July 31, 2022. doi:10.1002/alz.12756</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12756</ArticleId><ArticleId IdType="pmc">PMC10087669</ArticleId><ArticleId IdType="pubmed">35908251</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil&#xe0;-Alom&#xe0; M, Ashton NJ, Shekari M, et al. . Plasma P-tau231 and P-tau217 as state markers of amyloid-&#x3b2; pathology in preclinical Alzheimer&#x2019;s disease. Nat Med. 2022;28(9):1797-1801. doi:10.1038/s41591-022-01925-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01925-w</ArticleId><ArticleId IdType="pmc">PMC9499867</ArticleId><ArticleId IdType="pubmed">35953717</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. . Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022. doi:10.15252/emmm.202114022</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202114022</ArticleId><ArticleId IdType="pmc">PMC8185545</ArticleId><ArticleId IdType="pubmed">33949133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; eposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer&#x2019;s disease. Sci Adv. 2020;6(16):eaaz2387. doi:10.1126/sciadv.aaz2387</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. . Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915-924. doi:10.1001/jamaneurol.2019.1424</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1424</ArticleId><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. . Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78(8):961-971. doi:10.1001/jamaneurol.2021.1858</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.1858</ArticleId><ArticleId IdType="pmc">PMC8240013</ArticleId><ArticleId IdType="pubmed">34180956</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36748826</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Expectations and clinical meaningfulness of randomized controlled trials.</ArticleTitle><Pagination><StartPage>2730</StartPage><EndPage>2736</EndPage><MedlinePgn>2730-2736</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12959</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement. Introducing treatment strategies early in the disease and assessing meaningful change over the course of an 18-month clinical trial are critical to understanding the value to an effective intervention. With new clinical trial data expected soon on emerging therapeutics from several AD studies, the Alzheimer's Association convened a work group of experts to discuss key considerations for interpreting data from cognitive and functional measures and what is considered a clinically meaningful benefit or meaningful slowing of this fatal disease. Our expectations of outcomes from therapeutic interventions in AD may need to be modified.</AbstractText><CopyrightInformation>&#xa9; 2023 Alzheimer's Association. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>USC Alzheimer's Therapeutic Research Institute, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>J Scott</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atri</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Banner Health, Sun City, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Siemers Integration, LLC, Zionsville, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Alzheimer's Association, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Alzheimer's Association, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">MCI</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">clinical meaningfulness</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">cognitive impairment</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Ronald C. Petersen is a full-time employee of the Mayo Foundation for Education and Research, has received grants or contracts from the National Institute on Aging Alzheimer&#x2019;s Disease Research Centers (NIA ADRC), MCSA, Alzheimer&#x2019;s Disease Neuroimaging Inititative (ADNI), Alzheimer&#x2019;s Clinical Trials Consortium (ACTC), and National Institute of Neurological Disorders and Stroke (NINDS). MarkVCID (Vascular contributions to cognitive impairment &amp; dementia), royalties or licenses from Oxford University Press and UpToDate, consulting fees from Roche, Nestle, Merck, Biogen, Eisai, and Genentech, and participated on a Data Safety Monitoring Board (DSMB) or Advisory Board (AB) for Genentech. Paul S. Aisen has received grants or contracts from the National Institutes of Health (NIH), Alzheimer&#x2019;s Association, Foundation for NIH (FNIH), Lilly, Janssen, and Eisai and consulting fees from Merck, Biogen, AbbVie, Roche, and Immunobrain Checkpoint. J. Scott Andrews is a full-time employee and minor shareholder of Takeda Pharmaceuticals. Alireza Atri has received consulting fees from Roche/Genentech, Novo Nordisk, Eisai, Acadia, AZ Therapies, Biogen, Japanese Organization for Medical Device Development, Inc. (JOMDD), Mundbeck, Qynapse, and Suven, grants from Alzheon, Athira, Biohaven (with Alzheimer&#x2019;s Disease Cooperative Study), Eisai (with Alzheimer&#x2019;s Therapeutic Research Institute/ Alzheimer&#x2019;s Clinical Trials Consortium), Lilly (with ATRI/ACTC), Vivoryon (with ADCS), ACTC, ADCS, AZ Alzheimer&#x2019;s Research Consortium, ATRI, Global Alzheimer&#x2019;s Platform (GAP), University of Southern California (USC), Indiana University, Johns Hopkins, Washington University St. Louis, Gates Ventures, Arizona Department of Health Services (AZ DHS), NIA/NIH, and the FNIH, royalties from Oxford University Press, educational presentation fees from AbbVie, Acadia, Biogen, Eisai, and Lundbeck, and travel compensation from the Alzheimer&#x2019;s Association, Alzheimer&#x2019;s Disease International (ADI), American Academy of Neurology (AAN). Brandy R. Matthews is a full-time employee and minor shareholder at Eli Lilly &amp; Co. Dorene M. Rentz has received consulting fees from the Dana Foundation, payment or honoraria from USC, Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) course 2021, Grand Rounds, and External Scientific Advisory Boards, and support for travel to ACTC meetings and University of California-Davis Advisory Board meetings. Eric R. Siemers has received consulting fees from Biogen, Cogstate, Cortexyme, Partner Therapeutics, Pinteon Therapeutics, Vaccinex, Acumen Pharmaceuticals, Gates Ventures, and Hoffman LaRoche, has participated on an advisory board for Hoffman LaRoche, has held leadership roles at the Alzheimer&#x2019;s Association and Bright Focus Foundation, and holds stock or stock options in Acumen Pharmaceuticals. Christopher J. Weber and Maria C. Carrillo are full-time employees of the Alzheimer&#x2019;s Association. Author disclosures are available in the supporting information.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36748826</ArticleId><ArticleId IdType="mid">NIHMS1997356</ArticleId><ArticleId IdType="pmc">PMC11156248</ArticleId><ArticleId IdType="doi">10.1002/alz.12959</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Food and Drug Administration. Peripheral and central nervous system drugs advisory committee meeting, July 7, 1989. Rockville, MD: Department of Health and Human Services, Public Heath Service; 1989. p. 227.</Citation></Reference><Reference><Citation>Hansson O Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer&#x2019;s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">34838239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535&#x2013;562. doi:10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. Plasma p-Tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26:379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer&#x2019;s disease neuroimaging initiative. Mol Psychiatry. 2021;26:429&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">33106600</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Janelidze S, Stomrud E, et al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain. 2021;144:2826&#x2013;2836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557344</ArticleId><ArticleId IdType="pubmed">34077494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer&#x2019;s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12:3555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196018</ArticleId><ArticleId IdType="pubmed">34117234</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer&#x2019;s disease. J Prev Alzheimers Dis 2022;9(2):197&#x2013;210. doi:10.14283/jpad.2022.30</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2022.30</ArticleId><ArticleId IdType="pubmed">35542991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2021;384(18):1691&#x2013;1704. doi:10.1056/NEJMoa2100708. Epub 2021 Mar 13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer&#x2019;s disease. Nat Med. 2021;27(7):1187&#x2013;1196. doi:10.1038/s41591-021-01369-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01369-8</ArticleId><ArticleId IdType="pmc">PMC8988051</ArticleId><ArticleId IdType="pubmed">34155411</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer&#x2019;s disease with Lecanemab, an anti-A&#x3b2; protofibril antibody. Alzheimers Res Ther. 2021;13(1):80. doi:10.1186/s13195-021-00813-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00813-8</ArticleId><ArticleId IdType="pmc">PMC8053280</ArticleId><ArticleId IdType="pubmed">33865446</ArticleId></ArticleIdList></Reference><Reference><Citation>DiBenedetti DB, Slota C, Wronski SL, et al. Assessing what matters most to patients with or at risk for Alzheimer&#x2019;s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90. doi:10.1186/s13195-020-00659-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00659-6</ArticleId><ArticleId IdType="pmc">PMC7393916</ArticleId><ArticleId IdType="pubmed">32731886</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansfield C, Bullok K, Fuhs JV, et al. The patient voice: exploring treatment preferences in participants with mild cognitive concerns to inform regulatory decision making. Patient. 2022;15(5):551&#x2013;564. doi:10.1007/s40271-022-00576-w. Epub 2022 Apr 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40271-022-00576-w</ArticleId><ArticleId IdType="pmc">PMC9365745</ArticleId><ArticleId IdType="pubmed">35435572</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JS, Desai U, Kirson N, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer&#x2019;s disease clinical trials. Alzheimers Dement (NY). 2019;5:354&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6690415</ArticleId><ArticleId IdType="pubmed">31417957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansdall CJ, McDougall F, Butler LM, et al. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer&#x2019;s disease. J Prev Alzheimers Dis. 2023;10(1):9&#x2013;18. doi:10.14283/jpad.2022.102</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2022.102</ArticleId><ArticleId IdType="pubmed">36641605</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration, Discussion Document for Patient-Focused Drug Development (PFDD) Public Workshop on Guidance 4: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making, December 6, 2019. https://www.fda.gov/drugs/development-approval-process-drugs/public-workshop-patient-focused-drug-development-guidance-4-incorporating-clinical-outcome</Citation></Reference><Reference><Citation>Cummings J Editorial: Change on clinical trial outcome assessments: the search for meaningfulness. J Prev Alzheimers Dis. 2023;10(1):5&#x2013;6. doi:10.14283/jpad.2022.103</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2022.103</ArticleId><ArticleId IdType="pubmed">36641603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels AM, Siemers ER, Yu P, et al. A combined measure of cognition and function for clinical trials: the integrated Alzheimer&#x2019;s disease rating scale (iADRS). J Prev Alzheimers Dis. 2015;2:227&#x2013;241. doi:10.14283/jpad.2015.82</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2015.82</ArticleId><ArticleId IdType="pmc">PMC4806404</ArticleId><ArticleId IdType="pubmed">27019841</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer&#x2019;s disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993&#x2013;999. doi:10.1136/jnnp-2015-312383</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312383</ArticleId><ArticleId IdType="pmc">PMC5013117</ArticleId><ArticleId IdType="pubmed">27010616</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Clinical Dementia rating: current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Kruse C, Maier F, et al. What matters to patients with Alzheimer&#x2019;s disease and their care partners? Implications for understanding the value of future interventions. J Prev Alz Dis. 2022;3(9):550&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">35841256</ArticleId></ArticleIdList></Reference><Reference><Citation>Staunton H, Willgoss T, Nelsen L, et al. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399361</ArticleId><ArticleId IdType="pubmed">30830492</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Buckley R, Mormino E, et al. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020;16(3):552&#x2013;560. doi:10.1016/j.jalz.2019.09.074. Epub 2020 Jan 4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.09.074</ArticleId><ArticleId IdType="pmc">PMC7067681</ArticleId><ArticleId IdType="pubmed">31759879</ArticleId></ArticleIdList></Reference><Reference><Citation>Raket LL. Progression models for repeated measures: estimating novel treatment effects in progressive diseases. Stat Med. 2022;41(28):5537&#x2013;5557. doi:10.1002/sim.9581. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.9581</ArticleId><ArticleId IdType="pubmed">36114798</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Weiner M, Mackin RS, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology. 2019;93(4):e322&#x2013;e333. doi:10.1212/WNL.0000000000007831. Epub 2019 Jul 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007831</ArticleId><ArticleId IdType="pmc">PMC6669933</ArticleId><ArticleId IdType="pubmed">31289148</ArticleId></ArticleIdList></Reference><Reference><Citation>Assun&#xe7;&#xe3;o SS, Sperling RA, Ritchie C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer&#x2019;s disease. Alz Res Therapy. 2022;14:54. doi:10.1186/s13195-022-00984-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-022-00984-y</ArticleId><ArticleId IdType="pmc">PMC9017027</ArticleId><ArticleId IdType="pubmed">35440022</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Seifert H, Andersen SW, Lipkovich I, Holdridge KC, Siemers E. A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer&#x2019;s disease. PLoS One. 2015;10(3):e0119632. doi:10.1371/journal.pone.0119632. Erratum in: PLoS One. 2015;10(6):e0131338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0119632</ArticleId><ArticleId IdType="pmc">PMC4363486</ArticleId><ArticleId IdType="pubmed">25781335</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawe RJ, Yu L, Arfanakis K, Schneider JA, Bennett DA, Boyle PA. Late-life cognitive decline is associated with hippocampal volume, above and beyond its associations with traditional neuropathologic indices. Alzheimers Dement. 2020;16(1):209&#x2013;218. doi:10.1002/alz.12009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12009</ArticleId><ArticleId IdType="pmc">PMC6953608</ArticleId><ArticleId IdType="pubmed">31914231</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Head E, Schmitt FA, et al. Alzheimer&#x2019;s disease is not &#x201c;brain aging&#x201d;: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571&#x2013;587. doi:10.1007/s00401-011-0826-y. Epub 2011 Apr 24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0826-y</ArticleId><ArticleId IdType="pmc">PMC3179861</ArticleId><ArticleId IdType="pubmed">21516511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171&#x2013;186. doi:10.1007/s00401-017-1717-7. Epub 2017 May 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1717-7</ArticleId><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. Neurology. 2018;91(9):395&#x2013;402. doi:10.1212/WNL.0000000000006088. Epub 2018 Aug 8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006088</ArticleId><ArticleId IdType="pmc">PMC6133623</ArticleId><ArticleId IdType="pubmed">30089620</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrix JA, Bateman RJ, Brashear HR, et al. Challenges, solutions, and recommendations for Alzheimer&#x2019;s disease combination therapy. Alzheimers Dement. 2016;12(5):623&#x2013;630. doi:10.1016/j.jalz.2016.02.007. Epub 2016 Mar 24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.02.007</ArticleId><ArticleId IdType="pubmed">27017906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Alam J, Fillit H, et al. Combination therapy for Alzheimer&#x2019;s disease: perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2019;6(3):164&#x2013;168. doi:10.14283/jpad.2019.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2019.12</ArticleId><ArticleId IdType="pubmed">31062826</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36747024</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>406</StartPage><EndPage>415</EndPage><MedlinePgn>406-415</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-023-01257-z</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by synaptic loss, which can result from dysfunctional microglial phagocytosis and complement activation. However, what signals drive aberrant microglia-mediated engulfment of synapses in AD is unclear. Here we report that secreted phosphoprotein 1 (SPP1/osteopontin) is upregulated predominantly by perivascular macrophages and, to a lesser extent, by perivascular fibroblasts. Perivascular SPP1 is required for microglia to engulf synapses and upregulate phagocytic markers including C1qa, Grn and Ctsb in presence of amyloid-&#x3b2; oligomers. Absence of Spp1 expression in AD mouse models results in prevention of synaptic loss. Furthermore, single-cell RNA sequencing and putative cell-cell interaction analyses reveal that perivascular SPP1 induces microglial phagocytic states in the hippocampus of a mouse model of AD. Altogether, we suggest a functional role for SPP1 in perivascular cells-to-microglia crosstalk, whereby SPP1 modulates microglia-mediated synaptic engulfment in mouse models of AD.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Schepper</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0640-2417</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Judy Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowley</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0436-1332</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>La&#xed;s S S</ForeName><Initials>LSS</Initials><Identifier Source="ORCID">0000-0002-0152-459X</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garceau</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toomey</LastName><ForeName>Christina E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-5146-3326</Identifier><AffiliationInfo><Affiliation>The Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokolova</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueda-Carrasco</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9280-6612</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Sun-Hye</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Immunology and Regenerative Biology (IRB), Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung-Seok</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-0284-1658</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Regenerative Biology (IRB), Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Childs</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burden</LastName><ForeName>Jemima J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-5894-7043</Identifier><AffiliationInfo><Affiliation>Laboratory for Molecular Cell Biology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6612-6111</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala Frigerio</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4290-5716</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Regenerative Biology (IRB), Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Soyon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5744-4871</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute, Institute of Neurology, University College London, London, UK. soyon.hong@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506896">Spp1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36747024</ArticleId><ArticleId IdType="pmc">PMC9991912</ArticleId><ArticleId IdType="doi">10.1038/s41593-023-01257-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-023-01257-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arandjelovic, S. &amp; Ravichandran, K. S. Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol.16, 907&#x2013;917 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826466</ArticleId><ArticleId IdType="pubmed">26287597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf, K., Masuda, T., Jord&#xe3;o, M. J. C. &amp; Prinz, M. Macrophages at CNS interfaces: ontogeny and function in health and disease. Nat. Rev. Neurosci.20, 547&#x2013;562 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31358892</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron74, 691&#x2013;705 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cser&#xe9;p, C. et al. Microglia monitor and protect neuronal function through specialized somatic purinergic junctions. Science367, 528&#x2013;537 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31831638</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science1456, 10&#x2013;13 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt, B., Vajkoczy, P. &amp; Weller, R. O. The movers and shapers in immune privilege of the CNS. Nat. Immunol.18, 123&#x2013;131 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapenna, A. M., De Palma, M. &amp; Lewis, C. E. Perivascular macrophages in health and disease. Nat. Rev. Immunol.18, 689&#x2013;702 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30127389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science330, 841&#x2013;845 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Utz, S. G. et al. Early fate defines microglia and non-parenchymal brain macrophage development. Cell181, 557&#x2013;573 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32259484</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann, T. et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol.17, 797&#x2013;805 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. S. et al. 2021 A binary Cre transgenic approach dissects microglia and CNS border-associated macrophages. Immunity54, 176&#x2013;190 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33333014</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda, T. et al. Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature604, 740&#x2013;748 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35444273</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove, H. et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci.22, 1021&#x2013;1035 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Podle&#x15b;ny-Drabiniok, A., Marcora, E. &amp; Goate, A. M. Microglial phagocytosis: a disease-associated process emerging from Alzheimer&#x2019;s disease genetics. Trends Neurosci.43, 965&#x2013;979 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9080913</ArticleId><ArticleId IdType="pubmed">33127097</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirakawa, K. et al. IL (interleukin)-10-STAT3-galectin-3 axis is essential for osteopontin-producing reparative macrophage polarization after myocardial infarction. Circulation138, 2021&#x2013;2035 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29967195</ArticleId></ArticleIdList></Reference><Reference><Citation>Remmerie, A. et al. Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver. Immunity53, 641&#x2013;657 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501731</ArticleId><ArticleId IdType="pubmed">32888418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittling, S. R. Osteopontin in macrophage function. Expert Rev. Mol. Med.13, e15 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21545755</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaitin, D. A. et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell178, 686&#x2013;698 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7068689</ArticleId><ArticleId IdType="pubmed">31257031</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaw, L. et al. Altered wound healing in mice lacking a functional osteopontin gene (Spp1). J. Clin. Invest.101, 1468&#x2013;1478 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508725</ArticleId><ArticleId IdType="pubmed">9525990</ArticleId></ArticleIdList></Reference><Reference><Citation>Comi, C. et al. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer&#x2019;s disease and its levels correlate with cognitive decline. J. Alzheimers Dis.19, 1143&#x2013;1148 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20308780</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson, R. W. et al. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer&#x2019;s disease pathology. Transl. Psychiatry6, e952 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5314115</ArticleId><ArticleId IdType="pubmed">27845782</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai, Y. L. et al. Plasma osteopontin as a biomarker of Alzheimer&#x2019;s disease and vascular cognitive impairment. Sci. Rep.11, 4010 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889621</ArticleId><ArticleId IdType="pubmed">33597603</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, E. C. B. et al. Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med.26, 769&#x2013;780 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio, C. et al. The major risk factors for Alzheimer&#x2019;s disease: age, sex, and genes modulate the microglia response to A&#x3b2; plaques. Cell Rep.27, 1293&#x2013;1306(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska, A. et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell173, 1073&#x2013;1081 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvin, A. et al. Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration. Immunity55, 1448&#x2013;1465 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35931085</ArticleId></ArticleIdList></Reference><Reference><Citation>Browaeys, R., Saelens, W. &amp; Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods17, 159&#x2013;162 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31819264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze, M. et al. Impact of TREM2R47Hvariant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest.130, 4954&#x2013;4968 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, T. et al. Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat. Neurosci.17, 661&#x2013;664 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell131, 1164&#x2013;1178 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca, M. I. et al. Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J. Neuroinflammation14, 48 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340039</ArticleId><ArticleId IdType="pubmed">28264694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. B. et al. Targeting amyloid-&#x3b2; peptide (A&#x3b2;) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A&#x3b2; precursor protein (APP) transgenic mice. J. Biol. Chem.281, 4292&#x2013;4299 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie, R. M. et al. Oligomeric amyloid &#x3b2; associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA106, 4012&#x2013;4017 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, T., Guo, R. &amp; Zhang, F. Brain perivascular macrophages: recent advances and implications in health and diseases. CNS Neurosci. Ther.25, 1318&#x2013;1328 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154594</ArticleId><ArticleId IdType="pubmed">31749316</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell10.1016/j.cell.2017.05.018 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel, A. et al. Molecular architecture of the mouse nervous system. Cell174, 999&#x2013;1014 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz, E. et al. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc. Natl Acad. Sci. USA106, 13939&#x2013;13944 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728999</ArticleId><ArticleId IdType="pubmed">19666516</ArticleId></ArticleIdList></Reference><Reference><Citation>Haimon, Z. et al. Re-evaluating microglia expression profiles using RiboTag and cell isolation strategies. Nat. Immunol.19, 636&#x2013;644 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986066</ArticleId><ArticleId IdType="pubmed">29777220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin, D. et al. An environment-dependent transcriptional network specifies human microglia identity. Science356, 1248&#x2013;1259 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramerova, I. et al. Spp1 (osteopontin) promotes TGF&#x3b2; processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases. Hum. Mol. Genet.28, 3431&#x2013;3442 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7345878</ArticleId><ArticleId IdType="pubmed">31411676</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky, O. et al. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat. Neurosci.17, 131&#x2013;143 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Krysko, D. V., Ravichandran, K. S. &amp; Vandenabeele, P. Macrophages regulate the clearance of living cells by calreticulin. Nat. Commun.9, 4644 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220184</ArticleId><ArticleId IdType="pubmed">30405101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, D. D., Lin, E. C. K., Kovach, N. L., Hoyer, J. R. &amp; Smith, J. W. A biochemical characterization of the binding of osteopontin to integrins &#x3b1;v&#x3b2;1 and &#x3b1;v&#x3b2;5. J. Biol. Chem.270, 26232&#x2013;26238 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7592829</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xf6;ller, T. et al. Silencing of TGF&#x3b2; signalling in microglia results in impaired homeostasis. Nat. Commun.9, 4011 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6167353</ArticleId><ArticleId IdType="pubmed">30275444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman, S. M. et al. Human Alzheimer&#x2019;s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of A&#x3b2; plaque pathology. J. Neuroinflammation15, 1&#x2013;15 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127905</ArticleId><ArticleId IdType="pubmed">30189875</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellgren, C. M. et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat. Neurosci.22, 374&#x2013;385 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410571</ArticleId><ArticleId IdType="pubmed">30718903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar, A. et al. Schizophrenia risk from complex variation of complement component 4. Nature530, 177&#x2013;183 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752392</ArticleId><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic, B. et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron100, 1322&#x2013;1336 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, T. et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep.28, 2111&#x2013;2123 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui, H. et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell165, 925&#x2013;935 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasek, M. J. et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature534, 538&#x2013;543 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452615</ArticleId><ArticleId IdType="pubmed">27337340</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden, S. S. et al. Complement factor C1q mediates sleep spindle loss and epileptic spikes after mild brain injury. Science373, eabj2685 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8750918</ArticleId><ArticleId IdType="pubmed">34516796</ArticleId></ArticleIdList></Reference><Reference><Citation>Absinta, M. et al. A lymphocyte&#x2013;microglia&#x2013;astrocyte axis in chronic active multiple sclerosis. Nature597, 709&#x2013;714 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719282</ArticleId><ArticleId IdType="pubmed">34497421</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmer, L. et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature573, 75&#x2013;82 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6731122</ArticleId><ArticleId IdType="pubmed">31316211</ArticleId></ArticleIdList></Reference><Reference><Citation>Werneburg, S. et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity52, 167&#x2013;182 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996144</ArticleId><ArticleId IdType="pubmed">31883839</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber, G. F. &amp; Cantor, H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev.7, 241&#x2013;248 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8971479</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Q. et al. Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron101, 207&#x2013;223 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, X., Qiu, Y., Wight, A., Kim, H. J. &amp; Cantor, H. Definition of a mouse microglial subset that regulates neuronal development and proinflammatory responses in the brain. Proc. Natl Acad. Sci. USA119, e2116241119 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8872761</ArticleId><ArticleId IdType="pubmed">35177477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond, T. R. et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes resource single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell. Immunity50, 253&#x2013;271 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nberg, A. et al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat. Med.27, 640&#x2013;646 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, A. C. et al. A human brain vascular atlas reveals diverse mediators of Alzheimer&#x2019;s risk. Nature603, 885&#x2013;892 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9635042</ArticleId><ArticleId IdType="pubmed">35165441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes, C. A. et al. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol.121, 431&#x2013;443 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21259015</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney, M. D., Sagare, A. P. &amp; Zlokovic, B. V. Blood&#x2013;brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol.14, 133&#x2013;150 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation, D. A. et al. Blood&#x2013;brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med.25, 270&#x2013;276 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367058</ArticleId><ArticleId IdType="pubmed">30643288</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo, J. B. et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer&#x2019;s Coordinating Centre. Brain136, 2697&#x2013;2706 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858112</ArticleId><ArticleId IdType="pubmed">23842566</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy, J. &amp; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer&#x2019;s disease. Trends Pharmacol. Sci.12, 383&#x2013;388 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentsendorj, A. et al. A novel role for osteopontin in macrophage-mediated amyloid-&#x3b2; clearance in Alzheimer&#x2019;s models. Brain. Behav. Immun.67, 163&#x2013;180 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865478</ArticleId><ArticleId IdType="pubmed">28860067</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, Q. et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci. Transl. Med.9, 6295 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami, S. S. et al. Progranulin protects against amyloid &#x3b2; 2 deposition and toxicity in Alzheimer&#x2019;s disease mouse models. Nat. Med.20, 1157&#x2013;1164 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196723</ArticleId><ArticleId IdType="pubmed">25261995</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara, M. L., Kim, H. J., Kim, J. H., Garcia, V. A. &amp; Cantor, H. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc. Natl Acad. Sci. USA105, 7235&#x2013;7239 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438233</ArticleId><ArticleId IdType="pubmed">18480255</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyonaga, T. et al. Osteopontin deficiency accelerates spontaneous colitis in mice with disrupted gut microbiota and macrophage phagocytic activity. PLoS ONE10, e0135552 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537118</ArticleId><ArticleId IdType="pubmed">26274807</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, Y. J. et al. Osteopontin: correlation with phagocytosis by brain macrophages in a rat model of stroke. Glia59, 413&#x2013;423 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21264948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray, T. et al. TGF-&#x3b2;1 promotes microglial amyloid-&#x3b2; clearance and reduces plaque burden in transgenic mice. Nat. Med.7, 612&#x2013;618 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur, I. et al. Deficiency in neuronal TGF-&#x3b2; signaling promotes neurodegeneration and Alzheimer&#x2019;s pathology. J. Clin. Invest.116, 3060&#x2013;3069 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1626127</ArticleId><ArticleId IdType="pubmed">17080199</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilliams, M., Thierry, G. R., Bonnardel, J. &amp; Bajenoff, M. Establishment and maintenance of the macrophage niche. Immunity52, 434&#x2013;451 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32187515</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin, W. et al. Efficient CRISPR/Cas9-mediated genome editing in mice by zygote electroporation of nuclease. Genetics200, 423&#x2013;430 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492369</ArticleId><ArticleId IdType="pubmed">25819794</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt, M., Nicholas, F. W., James, J. W., Moran, C. &amp; Martin, I. C. A. Development of a highly fecund inbred strain of mice. Mamm. Genome15, 951&#x2013;959 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15599553</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine, T. J. et al. National institute on aging-Alzheimer&#x2019;s association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol.123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao, S., Qin, M. &amp; Wang, H. Analysis of knee infrared image based on sample entropy algorithm. Proceedings of 2015 8th International Conference on Intelligent Networks and Intelligent Systems (ICINIS) 1&#x2013;4 (IEEE, 2016).</Citation></Reference><Reference><Citation>Emi, M. et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics3, 373&#x2013;379 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3243553</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Deerinck, T. J., Bushong, E. A., Thor, A. &amp; Ellisman, M. H. NCMIR methods for 3D EM: a new protocol for preparation of biological specimens for serial block face scanning electron microscopy. Microscopy1, 6&#x2013;8 (2010).</Citation></Reference><Reference><Citation>Cardona, A. et al. TrakEM2 software for neural circuit reconstruction. PLoS ONE1, e38011 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378562</ArticleId><ArticleId IdType="pubmed">22723842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohen, R. et al. UTAP: user-friendly transcriptome analysis pipeline. BMC Bioinf.20, 154&#x2013;157 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6434621</ArticleId><ArticleId IdType="pubmed">30909881</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, S. et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol.20, 4106&#x2013;4114 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36750096</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>186</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Structures of LRP2 reveal a molecular machine for endocytosis.</ArticleTitle><Pagination><StartPage>821</StartPage><EndPage>836.e13</EndPage><MedlinePgn>821-836.e13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2023.01.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(23)00046-6</ELocationID><Abstract><AbstractText>The low-density lipoprotein (LDL) receptor-related protein 2 (LRP2 or megalin) is representative of the phylogenetically conserved subfamily of giant LDL receptor-related proteins, which function in endocytosis and are implicated in diseases of the kidney and brain. Here, we report high-resolution cryoelectron microscopy structures of LRP2 isolated from mouse kidney, at extracellular and endosomal pH. The structures reveal LRP2 to be a molecular machine that adopts a conformation for ligand binding at the cell surface and for ligand shedding in the endosome. LRP2 forms a homodimer, the conformational transformation of which is governed by pH-sensitive sites at both homodimer and intra-protomer interfaces. A subset of LRP2 deleterious missense variants in humans appears to impair homodimer assembly. These observations lay the foundation for further understanding the function and mechanism of LDL receptors and implicate homodimerization as a conserved feature of the LRP receptor subfamily.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beenken</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerutti</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brasch</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Utah, Salt Lake City, UT 84112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yicheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Aaron Diamond AIDS Research Center, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Zizhang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Aaron Diamond AIDS Research Center, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdjument-Bromage</LastName><ForeName>Hediye</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, New York University Grossman School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Zainab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbins-Juarez</LastName><ForeName>Shelief Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavez</LastName><ForeName>Estefania Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahlsen</LastName><ForeName>Goran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsamba</LastName><ForeName>Phinikoula S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neubert</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, New York University Grossman School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Anthony W P</ForeName><Initials>AWP</Initials><AffiliationInfo><Affiliation>Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: anthony.fitzpatrick@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barasch</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Columbia University George M. O'Brien Urology Center, New York, NY 10032, USA. Electronic address: jmb4@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Aaron Diamond AIDS Research Center, Columbia University, New York, NY 10032, USA; Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. Electronic address: lss8@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 GM103310</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR027990</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS110435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK124667</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR001875</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 DK104309</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD019994</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK108741</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026561">Low Density Lipoprotein Receptor-Related Protein-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000597357">LRP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C055127">Lrp2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Kidney Int. 2024 Jan;105(1):11-14. doi: 10.1016/j.kint.2023.05.026.</RefSource><PMID Version="1">37380129</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="Y">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026561" MajorTopicYN="Y">Low Density Lipoprotein Receptor-Related Protein-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD91</Keyword><Keyword MajorTopicYN="N">LDL</Keyword><Keyword MajorTopicYN="N">LRP1</Keyword><Keyword MajorTopicYN="N">LRP2</Keyword><Keyword MajorTopicYN="N">cryo-EM</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">megalin</Keyword><Keyword MajorTopicYN="N">pH-sensitive</Keyword><Keyword MajorTopicYN="N">proteinuria</Keyword><Keyword MajorTopicYN="N">recycling</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36750096</ArticleId><ArticleId IdType="mid">NIHMS1875572</ArticleId><ArticleId IdType="pmc">PMC9993842</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2023.01.016</ArticleId><ArticleId IdType="pii">S0092-8674(23)00046-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nielsen R, Christensen EI, and Birn H (2016). Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int 89, 58&#x2013;67. 10.1016/j.kint.2015.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2015.11.007</ArticleId><ArticleId IdType="pubmed">26759048</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen EI, and Nielsen R (2007). Role of megalin and cubilin in renal physiology and pathophysiology. Rev Physiol Biochem Pharmacol 158, 1&#x2013;22. 10.1007/112_0604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/112_0604</ArticleId><ArticleId IdType="pubmed">17729440</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonias SL, and Campana WM (2014). LDL receptor-related protein-1: a regulator of inflammation in atherosclerosis, cancer, and injury to the nervous system. Am J Pathol 184, 18&#x2013;27. 10.1016/j.ajpath.2013.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2013.08.029</ArticleId><ArticleId IdType="pmc">PMC3873482</ArticleId><ArticleId IdType="pubmed">24128688</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium, C.e.S. (1998). Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 282, 2012&#x2013;2018. 10.1126/science.282.5396.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.282.5396.2012</ArticleId><ArticleId IdType="pubmed">9851916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yochem J, and Greenwald I (1993). A gene for a low density lipoprotein receptor-related protein in the nematode Caenorhabditis elegans. Proc Natl Acad Sci U S A 90, 4572&#x2013;4576. 10.1073/pnas.90.10.4572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.10.4572</ArticleId><ArticleId IdType="pmc">PMC46554</ArticleId><ArticleId IdType="pubmed">8506301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerjaschki D, and Farquhar MG (1982). The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 79, 5557&#x2013;5561. 10.1073/pnas.79.18.5557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.79.18.5557</ArticleId><ArticleId IdType="pmc">PMC346943</ArticleId><ArticleId IdType="pubmed">6752952</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychowdhury R, Niles JL, McCluskey RT, and Smith JA (1989). Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science 244, 1163&#x2013;1165. 10.1126/science.2786251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2786251</ArticleId><ArticleId IdType="pubmed">2786251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerjaschki D, and Farquhar MG (1983). Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157, 667&#x2013;686. 10.1084/jem.157.2.667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.157.2.667</ArticleId><ArticleId IdType="pmc">PMC2186920</ArticleId><ArticleId IdType="pubmed">6337231</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A, Pietromonaco S, Loo AK, and Farquhar MG (1994). Complete cloning and sequencing of rat gp330/&#x201d;megalin,&#x201d; a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci U S A 91, 9725&#x2013;9729. 10.1073/pnas.91.21.9725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.21.9725</ArticleId><ArticleId IdType="pmc">PMC44889</ArticleId><ArticleId IdType="pubmed">7937880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjalm G, Murray E, Crumley G, Harazim W, Lundgren S, Onyango I, Ek B, Larsson M, Juhlin C, Hellman P, et al. (1996). Cloning and sequencing of human gp330, a Ca(2+)-binding receptor with potential intracellular signaling properties. Eur J Biochem 239, 132&#x2013;137. 10.1111/j.1432-1033.1996.0132u.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-1033.1996.0132u.x</ArticleId><ArticleId IdType="pubmed">8706697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren S, Carling T, Hjalm G, Juhlin C, Rastad J, Pihlgren U, Rask L, Akerstrom G, and Hellman P (1997). Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 45, 383&#x2013;392. 10.1177/002215549704500306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215549704500306</ArticleId><ArticleId IdType="pubmed">9071320</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G, Bachinsky DR, Stamenkovic I, Strickland DK, Brown D, Andres G, and McCluskey RT (1994). Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem 42, 531&#x2013;542. 10.1177/42.4.7510321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/42.4.7510321</ArticleId><ArticleId IdType="pubmed">7510321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Haudenschild CC, Strickland DK, and Argraves WS (1994). Immunological localization of glycoprotein 330, low density lipoprotein receptor related protein and 39 kDa receptor associated protein in embryonic mouse tissues. In Vivo 8, 343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">7803716</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann KJ, Lange WP, Tangelder MM, and Koene RA (1986). The organ distribution of gp-330 (Heymann antigen) and gp-90 in the mouse and the rat. Virchows Arch A Pathol Anat Histopathol 408, 541&#x2013;553. 10.1007/BF00705307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00705307</ArticleId><ArticleId IdType="pubmed">3082068</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, and Jay G (1997). Neuronal cell death in Alzheimer&#x2019;s disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 100, 310&#x2013;320. 10.1172/JCI119536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI119536</ArticleId><ArticleId IdType="pmc">PMC508193</ArticleId><ArticleId IdType="pubmed">9218507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bento-Abreu A, Velasco A, Polo-Hernandez E, Perez-Reyes PL, Tabernero A, and Medina JM (2008). Megalin is a receptor for albumin in astrocytes and is required for the synthesis of the neurotrophic factor oleic acid. J Neurochem 106, 1149&#x2013;1159. 10.1111/j.1471-4159.2008.05462.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05462.x</ArticleId><ArticleId IdType="pubmed">18466341</ArticleId></ArticleIdList></Reference><Reference><Citation>Carro E, Spuch C, Trejo JL, Antequera D, and Torres-Aleman I (2005). Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 25, 10884&#x2013;10893. 10.1523/JNEUROSCI.2909-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2909-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725866</ArticleId><ArticleId IdType="pubmed">16306401</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun JT, Wang L, Pasinetti GM, Finch CE, and Zlokovic BV (1999). Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp Neurol 157, 194&#x2013;201. 10.1006/exnr.1999.7052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1999.7052</ArticleId><ArticleId IdType="pubmed">10222122</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvira-Botero X, Perez-Gonzalez R, Spuch C, Vargas T, Antequera D, Garzon M, Bermejo-Pareja F, and Carro E (2010). Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. Mol Cell Neurosci 45, 306&#x2013;315. 10.1016/j.mcn.2010.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2010.07.005</ArticleId><ArticleId IdType="pubmed">20637285</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ A, Christa A, Kur E, Lioubinski O, Bachmann S, Willnow TE, and Hammes A (2012). LRP2 is an auxiliary SHH receptor required to condition the forebrain ventral midline for inductive signals. Dev Cell 22, 268&#x2013;278. 10.1016/j.devcel.2011.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2011.11.023</ArticleId><ArticleId IdType="pubmed">22340494</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajera CR, Emich H, Lioubinski O, Christ A, Beckervordersandforth-Bonk R, Yoshikawa K, Bachmann S, Christensen EI, Gotz M, Kempermann G, et al. (2010). LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche. J Cell Sci 123, 1922&#x2013;1930. 10.1242/jcs.065912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.065912</ArticleId><ArticleId IdType="pubmed">20460439</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil SY, Youn BS, Byun K, Huang H, Namkoong C, Jang PG, Lee JY, Jo YH, Kang GM, Kim HK, et al. (2013). Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway. Nat Commun 4, 1862. 10.1038/ncomms2896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2896</ArticleId><ArticleId IdType="pubmed">23673647</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, and Herz J (1996). Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci U S A 93, 8460&#x2013;8464. 10.1073/pnas.93.16.8460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.16.8460</ArticleId><ArticleId IdType="pmc">PMC38693</ArticleId><ArticleId IdType="pubmed">8710893</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, and Christ A (2017). Endocytic receptor LRP2/megalin-of holoprosencephaly and renal Fanconi syndrome. Pflugers Arch 469, 907&#x2013;916. 10.1007/s00424-017-1992-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-017-1992-0</ArticleId><ArticleId IdType="pubmed">28497274</ArticleId></ArticleIdList></Reference><Reference><Citation>Moestrup SK, Nielsen S, Andreasen P, Jorgensen KE, Nykjaer A, Roigaard H, Gliemann J, and Christensen EI (1993). Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem 268, 16564&#x2013;16570.</Citation><ArticleIdList><ArticleId IdType="pubmed">8344937</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Goldstein JL, Orth K, Brown MS, and Herz J (1992). Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 267, 26172&#x2013;26180.</Citation><ArticleIdList><ArticleId IdType="pubmed">1464627</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen EI, Moskaug JO, Vorum H, Jacobsen C, Gundersen TE, Nykjaer A, Blomhoff R, Willnow TE, and Moestrup SK (1999). Evidence for an essential role of megalin in transepithelial transport of retinol. J Am Soc Nephrol 10, 685&#x2013;695. 10.1681/ASN.V104685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V104685</ArticleId><ArticleId IdType="pubmed">10203351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, and Willnow TE (1999). An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96, 507&#x2013;515. 10.1016/s0092-8674(00)80655-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)80655-8</ArticleId><ArticleId IdType="pubmed">10052453</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, and Farquhar MG (1998). Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 9, 1759&#x2013;1766. 10.1681/ASN.V9101759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V9101759</ArticleId><ArticleId IdType="pubmed">9773776</ArticleId></ArticleIdList></Reference><Reference><Citation>Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, and Borregaard N (2005). The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 579, 773&#x2013;777. 10.1016/j.febslet.2004.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2004.12.031</ArticleId><ArticleId IdType="pubmed">15670845</ArticleId></ArticleIdList></Reference><Reference><Citation>Barasch J, Hollmen M, Deng R, Hod EA, Rupert PB, Abergel RJ, Allred BE, Xu K, Darrah SF, Tekabe Y, et al. (2016). Disposal of iron by a mutant form of lipocalin 2. Nat Commun 7, 12973. 10.1038/ncomms12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12973</ArticleId><ArticleId IdType="pmc">PMC5095531</ArticleId><ArticleId IdType="pubmed">27796299</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber K, Hvidberg V, Moestrup SK, Dahlback B, and Nielsen LB (2006). Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol 20, 212&#x2013;218. 10.1210/me.2005-0209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2005-0209</ArticleId><ArticleId IdType="pubmed">16099815</ArticleId></ArticleIdList></Reference><Reference><Citation>Moestrup SK, Schousboe I, Jacobsen C, Leheste JR, Christensen EI, and Willnow TE (1998). beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J Clin Invest 102, 902&#x2013;909. 10.1172/JCI3772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI3772</ArticleId><ArticleId IdType="pmc">PMC508955</ArticleId><ArticleId IdType="pubmed">9727058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strickland DK, and Argraves WS (1995). Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem 270, 13070&#x2013;13075. 10.1074/jbc.270.22.13070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.22.13070</ArticleId><ArticleId IdType="pubmed">7768901</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson S, Chappell DA, Argraves KM, Strickland DK, and Argraves WS (1995). Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100. J Biol Chem 270, 19417&#x2013;19421. 10.1074/jbc.270.33.19417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.33.19417</ArticleId><ArticleId IdType="pubmed">7642623</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Bay AE, Schreiner R, Benedicto I, Paz Marzolo M, Banfelder J, Weinstein AM, and Rodriguez-Boulan EJ (2016). The fast-recycling receptor Megalin defines the apical recycling pathway of epithelial cells. Nat Commun 7, 11550. 10.1038/ncomms11550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11550</ArticleId><ArticleId IdType="pmc">PMC4873671</ArticleId><ArticleId IdType="pubmed">27180806</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M, Baterina OY Jr., Taupin V, and Farquhar MG (2013). ARH directs megalin to the endocytic recycling compartment to regulate its proteolysis and gene expression. J Cell Biol 202, 113&#x2013;127. 10.1083/jcb.201211110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201211110</ArticleId><ArticleId IdType="pmc">PMC3704979</ArticleId><ArticleId IdType="pubmed">23836931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerjaschki D, Miettinen A, and Farquhar MG (1987). Initial events in the formation of immune deposits in passive Heymann nephritis. gp330-anti-gp330 immune complexes form in epithelial coated pits and rapidly become attached to the glomerular basement membrane. J Exp Med 166, 109&#x2013;128. 10.1084/jem.166.1.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.166.1.109</ArticleId><ArticleId IdType="pmc">PMC2188651</ArticleId><ArticleId IdType="pubmed">2885390</ArticleId></ArticleIdList></Reference><Reference><Citation>Czekay RP, Orlando RA, Woodward L, Lundstrom M, and Farquhar MG (1997). Endocytic trafficking of megalin/RAP complexes: dissociation of the complexes in late endosomes. Mol Biol Cell 8, 517&#x2013;532. 10.1091/mbc.8.3.517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.8.3.517</ArticleId><ArticleId IdType="pmc">PMC276101</ArticleId><ArticleId IdType="pubmed">9188102</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers JC, Zhang W, Lord GM, van der Harst P, Lawlor DA, Sehmi JS, Gale DP, Wass MN, Ahmadi KR, Bakker SJ, et al. (2010). Genetic loci influencing kidney function and chronic kidney disease. Nat Genet 42, 373&#x2013;375. 10.1038/ng.566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.566</ArticleId><ArticleId IdType="pmc">PMC3748585</ArticleId><ArticleId IdType="pubmed">20383145</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasman DI, Fuchsberger C, Pattaro C, Teumer A, Boger CA, Endlich K, Olden M, Chen MH, Tin A, Taliun D, et al. (2012). Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum Mol Genet 21, 5329&#x2013;5343. 10.1093/hmg/dds369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds369</ArticleId><ArticleId IdType="pmc">PMC3607468</ArticleId><ArticleId IdType="pubmed">22962313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Lee Y, Park B, Won S, Han JS, and Heo NJ (2018). Genome-wide association analysis identifies multiple loci associated with kidney disease-related traits in Korean populations. PLoS One 13, e0194044. 10.1371/journal.pone.0194044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0194044</ArticleId><ArticleId IdType="pmc">PMC5860731</ArticleId><ArticleId IdType="pubmed">29558500</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsa A, Fuchsberger C, Kottgen A, O&#x2019;Seaghdha CM, Pattaro C, de Andrade M, Chasman DI, Teumer A, Endlich K, Olden M, et al. (2013). Common variants in Mendelian kidney disease genes and their association with renal function. J Am Soc Nephrol 24, 2105&#x2013;2117. 10.1681/ASN.2012100983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2012100983</ArticleId><ArticleId IdType="pmc">PMC3839542</ArticleId><ArticleId IdType="pubmed">24029420</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, Garnaas M, Tin A, Sorice R, Li Y, et al. (2016). Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun 7, 10023. 10.1038/ncomms10023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10023</ArticleId><ArticleId IdType="pmc">PMC4735748</ArticleId><ArticleId IdType="pubmed">26831199</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsakka EGE, Mokhtar MM, Hegazy M, Ismail A, and Doghish AS (2022). Megalin, a multi-ligand endocytic receptor, and its participation in renal function and diseases: A review. Life Sci 308, 120923. 10.1016/j.lfs.2022.120923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2022.120923</ArticleId><ArticleId IdType="pubmed">36049529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci S, Al-Gazali L, Hill RS, Donnai D, Black GC, Bieth E, Chassaing N, Lacombe D, Devriendt K, Teebi A, et al. (2007). Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet 39, 957&#x2013;959. 10.1038/ng2063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng2063</ArticleId><ArticleId IdType="pmc">PMC2891728</ArticleId><ArticleId IdType="pubmed">17632512</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, et al. (2020). LRP1 is a master regulator of tau uptake and spread. Nature 580, 381&#x2013;385. 10.1038/s41586-020-2156-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2156-5</ArticleId><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen EI, and Birn H (2002). Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 3, 256&#x2013;266. 10.1038/nrm778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm778</ArticleId><ArticleId IdType="pubmed">11994745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillis AP, Van Duyn LB, Murphy-Ullrich JE, and Strickland DK (2008). LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88, 887&#x2013;918. 10.1152/physrev.00033.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00033.2007</ArticleId><ArticleId IdType="pmc">PMC2744109</ArticleId><ArticleId IdType="pubmed">18626063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JM, Lathuiliere A, Migliorini M, Arai AL, Wani MM, Dujardin S, Muratoglu SC, Hyman BT, and Strickland DK (2021). Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. J Biol Chem 296, 100715. 10.1016/j.jbc.2021.100715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100715</ArticleId><ArticleId IdType="pmc">PMC8164048</ArticleId><ArticleId IdType="pubmed">33930462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridler C (2018). APOE4 transforms the transcriptome. Nat Rev Neurol 14, 450&#x2013;451. 10.1038/s41582-018-0034-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0034-7</ArticleId><ArticleId IdType="pubmed">29915370</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas T, Bullido MJ, Martinez-Garcia A, Antequera D, Clarimon J, Rosich-Estrago M, Martin-Requero A, Mateo I, Rodriguez-Rodriguez E, Vilella-Cuadrada E, et al. (2010). A megalin polymorphism associated with promoter activity and Alzheimer&#x2019;s disease risk. Am J Med Genet B Neuropsychiatr Genet 153B, 895&#x2013;902. 10.1002/ajmg.b.31056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.31056</ArticleId><ArticleId IdType="pubmed">20052685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LL, Pan XL, Wang Y, Tang HD, Deng YL, Ren RJ, Xu W, Ma JF, Wang G, and Chen SD (2011). A single nucleotide polymorphism in LRP2 is associated with susceptibility to Alzheimer&#x2019;s disease in the Chinese population. Clin Chim Acta 412, 268&#x2013;270. 10.1016/j.cca.2010.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2010.10.015</ArticleId><ArticleId IdType="pubmed">20971101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, and Zlokovic BV (2007). Transport pathways for clearance of human Alzheimer&#x2019;s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27, 909&#x2013;918. 10.1038/sj.jcbfm.9600419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600419</ArticleId><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, and Ghiso J (1996). Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93, 4229&#x2013;4234. 10.1073/pnas.93.9.4229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.9.4229</ArticleId><ArticleId IdType="pmc">PMC39517</ArticleId><ArticleId IdType="pubmed">8633046</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet 41, 1088&#x2013;1093. 10.1038/ng.440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.440</ArticleId><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet 41, 1094&#x2013;1099. 10.1038/ng.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.439</ArticleId><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Fass D, Blacklow S, Kim PS, and Berger JM (1997). Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module. Nature 388, 691&#x2013;693. 10.1038/41798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/41798</ArticleId><ArticleId IdType="pubmed">9262405</ArticleId></ArticleIdList></Reference><Reference><Citation>Downing AK, Knott V, Werner JM, Cardy CM, Campbell ID, and Handford PA (1996). Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders. Cell 85, 597&#x2013;605. 10.1016/s0092-8674(00)81259-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)81259-3</ArticleId><ArticleId IdType="pubmed">8653794</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehon RG, Kooh PJ, Rebay I, Regan CL, Xu T, Muskavitch MA, and Artavanis-Tsakonas S (1990). Molecular interactions between the protein products of the neurogenic loci Notch and Delta, two EGF-homologous genes in Drosophila. Cell 61, 523&#x2013;534. 10.1016/0092-8674(90)90534-l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(90)90534-l</ArticleId><ArticleId IdType="pubmed">2185893</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, and Stuart D (1995). The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell 82, 131&#x2013;141. 10.1016/0092-8674(95)90059-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90059-4</ArticleId><ArticleId IdType="pubmed">7606779</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer TA (1998). An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components. J Mol Biol 283, 837&#x2013;862. 10.1006/jmbi.1998.2115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1998.2115</ArticleId><ArticleId IdType="pubmed">9790844</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon H, Meng W, Takagi J, Eck MJ, Springer TA, and Blacklow SC (2001). Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat Struct Biol 8, 499&#x2013;504. 10.1038/88556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/88556</ArticleId><ArticleId IdType="pubmed">11373616</ArticleId></ArticleIdList></Reference><Reference><Citation>Croy JE, Brandon T, and Komives EA (2004). Two apolipoprotein E mimetic peptides, ApoE(130&#x2013;149) and ApoE(141&#x2013;155)2, bind to LRP1. Biochemistry 43, 7328&#x2013;7335. 10.1021/bi036208p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi036208p</ArticleId><ArticleId IdType="pubmed">15182176</ArticleId></ArticleIdList></Reference><Reference><Citation>Croy JE, Shin WD, Knauer MF, Knauer DJ, and Komives EA (2003). All three LDL receptor homology regions of the LDL receptor-related protein bind multiple ligands. Biochemistry 42, 13049&#x2013;13057. 10.1021/bi034752s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi034752s</ArticleId><ArticleId IdType="pubmed">14596620</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher C, Beglova N, and Blacklow SC (2006). Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Mol Cell 22, 277&#x2013;283. 10.1016/j.molcel.2006.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.02.021</ArticleId><ArticleId IdType="pubmed">16630895</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttman M, Prieto JH, Croy JE, and Komives EA (2010). Decoding of lipoprotein-receptor interactions: properties of ligand binding modules governing interactions with apolipoprotein E. Biochemistry 49, 1207&#x2013;1216. 10.1021/bi9017208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi9017208</ArticleId><ArticleId IdType="pmc">PMC2821871</ArticleId><ArticleId IdType="pubmed">20030366</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttman M, Prieto JH, Handel TM, Domaille PJ, and Komives EA (2010). Structure of the minimal interface between ApoE and LRP. J Mol Biol 398, 306&#x2013;319. 10.1016/j.jmb.2010.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2010.03.022</ArticleId><ArticleId IdType="pmc">PMC2880916</ArticleId><ArticleId IdType="pubmed">20303980</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen GA, Andersen OM, Bonvin AM, Bjerrum-Bohr I, Etzerodt M, Thogersen HC, O&#x2019;Shea C, Poulsen FM, and Kragelund BB (2006). Binding site structure of one LRP-RAP complex: implications for a common ligand-receptor binding motif. J Mol Biol 362, 700&#x2013;716. 10.1016/j.jmb.2006.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2006.07.013</ArticleId><ArticleId IdType="pubmed">16938309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CJ, De Biasio A, and Beglova N (2010). Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids. Structure 18, 366&#x2013;376. 10.1016/j.str.2009.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2009.12.013</ArticleId><ArticleId IdType="pubmed">20223219</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando RA, Exner M, Czekay RP, Yamazaki H, Saito A, Ullrich R, Kerjaschki D, and Farquhar MG (1997). Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions. Proc Natl Acad Sci U S A 94, 2368&#x2013;2373. 10.1073/pnas.94.6.2368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.6.2368</ArticleId><ArticleId IdType="pmc">PMC20094</ArticleId><ArticleId IdType="pubmed">9122201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf CA, Dancea F, Shi M, Bade-Noskova V, Ruterjans H, Kerjaschki D, and Lucke C (2007). Solution structure of the twelfth cysteine-rich ligand-binding repeat in rat megalin. Journal of biomolecular NMR 37, 321&#x2013;328. 10.1007/s10858-006-9129-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10858-006-9129-3</ArticleId><ArticleId IdType="pubmed">17245526</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagil R, O&#x2019;Shea C, Nykjaer A, Bonvin AM, and Kragelund BB (2013). Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin. The Journal of biological chemistry 288, 4424&#x2013;4435. 10.1074/jbc.M112.434159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.434159</ArticleId><ArticleId IdType="pmc">PMC3567692</ArticleId><ArticleId IdType="pubmed">23275343</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn IR, van den Berg BM, van der Meijden PZ, Pannekoek H, and van Zonneveld AJ (1997). Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding. J Biol Chem 272, 13608&#x2013;13613. 10.1074/jbc.272.21.13608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.21.13608</ArticleId><ArticleId IdType="pubmed">9153209</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer AB, Rohlena J, van der Zwaan C, van Zonneveld AJ, Boertjes RC, Lenting PJ, and Mertens K (2007). Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII. Biochim Biophys Acta 1774, 714&#x2013;722. 10.1016/j.bbapap.2007.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2007.04.003</ArticleId><ArticleId IdType="pubmed">17512806</ArticleId></ArticleIdList></Reference><Reference><Citation>Neels JG, van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, and van Zonneveld AJ (1999). The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 274, 31305&#x2013;31311. 10.1074/jbc.274.44.31305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.44.31305</ArticleId><ArticleId IdType="pubmed">10531329</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermoeller-McCormick LM, Li Y, Osaka H, FitzGerald DJ, Schwartz AL, and Bu G (2001). Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci 114, 899&#x2013;908. 10.1242/jcs.114.5.899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.114.5.899</ArticleId><ArticleId IdType="pubmed">11181173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottomley MJ, Cirillo A, Orsatti L, Ruggeri L, Fisher TS, Santoro JC, Cummings RT, Cubbon RM, Lo Surdo P, Calzetta A, et al. (2009). Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 284, 1313&#x2013;1323. 10.1074/jbc.M808363200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808363200</ArticleId><ArticleId IdType="pubmed">19001363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon HJ, Lagace TA, McNutt MC, Horton JD, and Deisenhofer J (2008). Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 105, 1820&#x2013;1825. 10.1073/pnas.0712064105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0712064105</ArticleId><ArticleId IdType="pmc">PMC2538846</ArticleId><ArticleId IdType="pubmed">18250299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, and Carfi A (2011). Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 12, 1300&#x2013;1305. 10.1038/embor.2011.205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2011.205</ArticleId><ArticleId IdType="pmc">PMC3245695</ArticleId><ArticleId IdType="pubmed">22081141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, and Hobbs HH (2007). Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282, 18602&#x2013;18612. 10.1074/jbc.M702027200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M702027200</ArticleId><ArticleId IdType="pubmed">17452316</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser V, Limbird LE, Brown MS, Goldstein JL, and Russell DW (1988). Mutational analysis of the ligand binding domain of the low density lipoprotein receptor. J Biol Chem 263, 13282&#x2013;13290.</Citation><ArticleIdList><ArticleId IdType="pubmed">3417658</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Henry L, Ho YK, Pownall HJ, and Rudenko G (2010). Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J Lipid Res 51, 297&#x2013;308. 10.1194/jlr.M000422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M000422</ArticleId><ArticleId IdType="pmc">PMC2803231</ArticleId><ArticleId IdType="pubmed">19674976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong Y, Zhang B, Gu S, Lee K, Zhou J, Yao G, Figueiredo D, Perry K, Mei L, and Jin R (2012). Structural basis of agrin-LRP4-MuSK signaling. Genes Dev 26, 247&#x2013;258. 10.1101/gad.180885.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.180885.111</ArticleId><ArticleId IdType="pmc">PMC3278892</ArticleId><ArticleId IdType="pubmed">22302937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Han W, Park T, Kim EJ, Bang I, Lee HS, Jeong Y, Roh K, Kim J, Kim JS, et al. (2020). Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains. Nat Commun 11, 5357. 10.1038/s41467-020-19155-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19155-4</ArticleId><ArticleId IdType="pmc">PMC7585440</ArticleId><ArticleId IdType="pubmed">33097721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Q, Chen J, and Liu Y (2021). LRP5 and LRP6 in Wnt Signaling: Similarity and Divergence. Front Cell Dev Biol 9, 670960. 10.3389/fcell.2021.670960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.670960</ArticleId><ArticleId IdType="pmc">PMC8134664</ArticleId><ArticleId IdType="pubmed">34026761</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, and He X (2000). LDL-receptor-related proteins in Wnt signal transduction. Nature 407, 530&#x2013;535. 10.1038/35035117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35035117</ArticleId><ArticleId IdType="pubmed">11029007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinson KI, Brennan J, Monkley S, Avery BJ, and Skarnes WC (2000). An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407, 535&#x2013;538. 10.1038/35035124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35035124</ArticleId><ArticleId IdType="pubmed">11029008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Bubeck D, MacDonald BT, Liang WX, Mao JH, Malinauskas T, Llorca O, Aricescu AR, Siebold C, He X, and Jones EY (2011). Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Dev Cell 21, 848&#x2013;861. 10.1016/j.devcel.2011.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2011.09.007</ArticleId><ArticleId IdType="pmc">PMC3564486</ArticleId><ArticleId IdType="pubmed">22000855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Z, Biechele T, Wei Z, Morrone S, Moon RT, Wang L, and Xu W (2011). Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat Struct Mol Biol 18, 1204&#x2013;1210. 10.1038/nsmb.2139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2139</ArticleId><ArticleId IdType="pmc">PMC3249237</ArticleId><ArticleId IdType="pubmed">21984209</ArticleId></ArticleIdList></Reference><Reference><Citation>Matoba K, Mihara E, Tamura-Kawakami K, Miyazaki N, Maeda S, Hirai H, Thompson S, Iwasaki K, and Takagi J (2017). Conformational Freedom of the LRP6 Ectodomain Is Regulated by N-glycosylation and the Binding of the Wnt Antagonist Dkk1. Cell Rep 18, 32&#x2013;40. 10.1016/j.celrep.2016.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.017</ArticleId><ArticleId IdType="pubmed">28052259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn VE, Chu ML, Choi HJ, Tran D, Abo A, and Weis WI (2011). Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. Dev Cell 21, 862&#x2013;873. 10.1016/j.devcel.2011.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2011.09.003</ArticleId><ArticleId IdType="pmc">PMC3215855</ArticleId><ArticleId IdType="pubmed">22000856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon H, and Blacklow SC (2005). Structure and physiologic function of the low-density lipoprotein receptor. Annu Rev Biochem 74, 535&#x2013;562. 10.1146/annurev.biochem.74.082803.133354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.74.082803.133354</ArticleId><ArticleId IdType="pubmed">15952897</ArticleId></ArticleIdList></Reference><Reference><Citation>Beglova N, Jeon H, Fisher C, and Blacklow SC (2004). Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor. Mol Cell 16, 281&#x2013;292. 10.1016/j.molcel.2004.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2004.09.038</ArticleId><ArticleId IdType="pubmed">15494314</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CG, Goldstein JL, Sudhof TC, Anderson RG, Russell DW, and Brown MS (1987). Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 326, 760&#x2013;765. 10.1038/326760a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/326760a0</ArticleId><ArticleId IdType="pubmed">3494949</ArticleId></ArticleIdList></Reference><Reference><Citation>Boswell EJ, Jeon H, Blacklow SC, and Downing AK (2004). Global defects in the expression and function of the low density lipoprotein receptor (LDLR) associated with two familial hypercholesterolemia mutations resulting in misfolding of the LDLR epidermal growth factor-AB pair. J Biol Chem 279, 30611&#x2013;30621. 10.1074/jbc.M401412200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M401412200</ArticleId><ArticleId IdType="pubmed">15100232</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, and Deisenhofer J (2002). Structure of the LDL receptor extracellular domain at endosomal pH. Science 298, 2353&#x2013;2358. 10.1126/science.1078124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1078124</ArticleId><ArticleId IdType="pubmed">12459547</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Goldstein JL, Strickland DK, Ho YK, and Brown MS (1991). 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem 266, 21232&#x2013;21238.</Citation><ArticleIdList><ArticleId IdType="pubmed">1718973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, and Strickland DK (1995). LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 82, 331&#x2013;340. 10.1016/0092-8674(95)90320-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90320-8</ArticleId><ArticleId IdType="pubmed">7543026</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita M, Bu G, Herz J, and Schwartz AL (1995). Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest 96, 1164&#x2013;1168. 10.1172/JCI118105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118105</ArticleId><ArticleId IdType="pmc">PMC185308</ArticleId><ArticleId IdType="pubmed">7635954</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Orth K, and Herz J (1994). Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein. J Biol Chem 269, 15827&#x2013;15832.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515061</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Rohlmann A, Horton J, Otani H, Braun JR, Hammer RE, and Herz J (1996). RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J 15, 2632&#x2013;2639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450198</ArticleId><ArticleId IdType="pubmed">8654360</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G, Geuze HJ, Strous GJ, and Schwartz AL (1995). 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J 14, 2269&#x2013;2280. 10.1002/j.1460-2075.1995.tb07221.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1995.tb07221.x</ArticleId><ArticleId IdType="pmc">PMC398334</ArticleId><ArticleId IdType="pubmed">7774585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokuno H, Brady S, Kotite L, Herz J, and Havel RJ (1994). Effect of the 39-kDa receptor-associated protein on the hepatic uptake and endocytosis of chylomicron remnants and low density lipoproteins in the rat. J Biol Chem 269, 13238&#x2013;13243.</Citation><ArticleIdList><ArticleId IdType="pubmed">7513700</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando RA, and Farquhar MG (1994). Functional domains of the receptor-associated protein (RAP). Proc Natl Acad Sci U S A 91, 3161&#x2013;3165. 10.1073/pnas.91.8.3161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.8.3161</ArticleId><ArticleId IdType="pmc">PMC43535</ArticleId><ArticleId IdType="pubmed">7512726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashcom JD, Tiller SE, Dickerson K, Cravens JL, Argraves WS, and Strickland DK (1990). The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin. J Cell Biol 110, 1041&#x2013;1048. 10.1083/jcb.110.4.1041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.110.4.1041</ArticleId><ArticleId IdType="pmc">PMC2116111</ArticleId><ArticleId IdType="pubmed">1691187</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorini MM, Behre EH, Brew S, Ingham KC, and Strickland DK (2003). Allosteric modulation of ligand binding to low density lipoprotein receptor-related protein by the receptor-associated protein requires critical lysine residues within its carboxyl-terminal domain. J Biol Chem 278, 17986&#x2013;17992. 10.1074/jbc.M212592200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M212592200</ArticleId><ArticleId IdType="pubmed">12637503</ArticleId></ArticleIdList></Reference><Reference><Citation>Beglov D, Lee CJ, De Biasio A, Kozakov D, Brenke R, Vajda S, and Beglova N (2009). Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors. Proteins 77, 940&#x2013;949. 10.1002/prot.22519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.22519</ArticleId><ArticleId IdType="pmc">PMC2767435</ArticleId><ArticleId IdType="pubmed">19676115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolic J, Belot L, Raux H, Legrand P, Gaudin Y, and A AA (2018). Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat Commun 9, 1029. 10.1038/s41467-018-03432-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03432-4</ArticleId><ArticleId IdType="pmc">PMC5847621</ArticleId><ArticleId IdType="pubmed">29531262</ArticleId></ArticleIdList></Reference><Reference><Citation>De Nardis C, Lossl P, van den Biggelaar M, Madoori PK, Leloup N, Mertens K, Heck AJ, and Gros P (2017). Recombinant Expression of the Full-length Ectodomain of LDL Receptor-related Protein 1 (LRP1) Unravels pH-dependent Conformational Changes and the Stoichiometry of Binding with Receptor-associated Protein (RAP). J Biol Chem 292, 912&#x2013;924. 10.1074/jbc.M116.758862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.758862</ArticleId><ArticleId IdType="pmc">PMC5247663</ArticleId><ArticleId IdType="pubmed">27956551</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PH, Moestrup SK, and Gliemann J (1989). Purification of the human placental alpha 2-macroglobulin receptor. FEBS Lett 255, 275&#x2013;280. 10.1016/0014-5793(89)81105-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(89)81105-6</ArticleId><ArticleId IdType="pubmed">2477279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanalas JJ, and Makker SP (1990). Isolation of a 330-kDa glycoprotein from human kidney similar to the Heymann nephritis autoantigen (gp330). J Am Soc Nephrol 1, 792&#x2013;798. 10.1681/ASN.V15792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V15792</ArticleId><ArticleId IdType="pubmed">2133428</ArticleId></ArticleIdList></Reference><Reference><Citation>Moestrup SK, and Gliemann J (1989). Purification of the rat hepatic alpha 2-macroglobulin receptor as an approximately 440-kDa single chain protein. J Biol Chem 264, 15574&#x2013;15577.</Citation><ArticleIdList><ArticleId IdType="pubmed">2475504</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando RA, Kerjaschki D, Kurihara H, Biemesderfer D, and Farquhar MG (1992). gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc Natl Acad Sci U S A 89, 6698&#x2013;6702. 10.1073/pnas.89.15.6698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.15.6698</ArticleId><ArticleId IdType="pmc">PMC49570</ArticleId><ArticleId IdType="pubmed">1495959</ArticleId></ArticleIdList></Reference><Reference><Citation>Biemesderfer D, Dekan G, Aronson PS, and Farquhar MG (1993). Biosynthesis of the gp330/44-kDa Heymann nephritis antigenic complex: assembly takes place in the ER. Am J Physiol 264, F1011&#x2013;1020. 10.1152/ajprenal.1993.264.6.F1011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.1993.264.6.F1011</ArticleId><ArticleId IdType="pubmed">8322889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstrom M, Orlando RA, Saedi MS, Woodward L, Kurihara H, and Farquhar MG (1993). Immunocytochemical and biochemical characterization of the Heymann nephritis antigenic complex in rat L2 yolk sac cells. Am J Pathol 143, 1423&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887159</ArticleId><ArticleId IdType="pubmed">8238258</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SE, Ashcom JD, Argraves WS, and Strickland DK (1992). A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem 267, 9035&#x2013;9040.</Citation><ArticleIdList><ArticleId IdType="pubmed">1374383</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A, Rubinstein JL, Fleet DJ, and Brubaker MA (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14, 290&#x2013;296. 10.1038/nmeth.4169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4169</ArticleId><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH (2012). RELION: implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol 180, 519&#x2013;530. 10.1016/j.jsb.2012.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2012.09.006</ArticleId><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH (2012). A Bayesian view on cryo-EM structure determination. J Mol Biol 415, 406&#x2013;418. 10.1016/j.jmb.2011.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.11.010</ArticleId><ArticleId IdType="pmc">PMC3314964</ArticleId><ArticleId IdType="pubmed">22100448</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong ED, Bepler T, Berger B, and Davis JH (2021). CryoDRGN: reconstruction of heterogeneous cryo-EM structures using neural networks. Nat Methods 18, 176&#x2013;185. 10.1038/s41592-020-01049-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-020-01049-4</ArticleId><ArticleId IdType="pmc">PMC8183613</ArticleId><ArticleId IdType="pubmed">33542510</ArticleId></ArticleIdList></Reference><Reference><Citation>Pober BR, Longoni M, and Noonan KM (2009). A review of Donnai-Barrow and facio-oculo-acoustico-renal (DB/FOAR) syndrome: clinical features and differential diagnosis. Birth Defects Res A Clin Mol Teratol 85, 76&#x2013;81. 10.1002/bdra.20534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdra.20534</ArticleId><ArticleId IdType="pmc">PMC2882234</ArticleId><ArticleId IdType="pubmed">19089858</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlton JR, Tan W, Daouk G, Teot L, Rosen S, Bennett KM, Cwiek A, Nam S, Emma F, Jouret F, et al. (2020). Beyond the tubule: pathological variants of LRP2, encoding the megalin receptor, result in glomerular loss and early progressive chronic kidney disease. Am J Physiol Renal Physiol 319, F988&#x2013;F999. 10.1152/ajprenal.00295.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00295.2020</ArticleId><ArticleId IdType="pmc">PMC7792689</ArticleId><ArticleId IdType="pubmed">33103447</ArticleId></ArticleIdList></Reference><Reference><Citation>Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, Megy K, Grozeva D, Dewhurst E, Malka S, et al. (2017). Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. Am J Hum Genet 100, 75&#x2013;90. 10.1016/j.ajhg.2016.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.12.003</ArticleId><ArticleId IdType="pmc">PMC5223092</ArticleId><ArticleId IdType="pubmed">28041643</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson KA, White M, Allen NM, Byrne S, Carton R, Comerford E, Costello D, Doherty C, Dunleavey B, El-Naggar H, et al. (2020). A comparison of genomic diagnostics in adults and children with epilepsy and comorbid intellectual disability. Eur J Hum Genet 28, 1066&#x2013;1077. 10.1038/s41431-020-0610-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-020-0610-3</ArticleId><ArticleId IdType="pmc">PMC7381648</ArticleId><ArticleId IdType="pubmed">32238909</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasli N, Ahmed I, Mittal K, Ohadi M, Mikhailov A, Rafiq MA, Bhatti A, Carter MT, Andrade DM, Ayub M, et al. (2016). Identification of a homozygous missense mutation in LRP2 and a hemizygous missense mutation in TSPYL2 in a family with mild intellectual disability. Psychiatr Genet 26, 66&#x2013;73. 10.1097/YPG.0000000000000114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YPG.0000000000000114</ArticleId><ArticleId IdType="pubmed">26529358</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarova A, Bercury KK, Adams KW, Joyner D, Deng M, Spoelgen R, Koker M, Strickland DK, and Hyman BT (2008). The LDL receptor-related protein can form homo-dimers in neuronal cells. Neurosci Lett 442, 91&#x2013;95. 10.1016/j.neulet.2008.06.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.06.070</ArticleId><ArticleId IdType="pmc">PMC2565777</ArticleId><ArticleId IdType="pubmed">18602448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Xia MQ, Strickland DK, Rebeck GW, and Hyman BT (2000). The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 97, 11551&#x2013;11556. 10.1073/pnas.200238297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.200238297</ArticleId><ArticleId IdType="pmc">PMC17238</ArticleId><ArticleId IdType="pubmed">11016955</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Preiser H, Maestracci D, Ghosh BK, Cerda JJ, and Crane RK (1973). Purification of the human intestinal brush border membrane. Biochim Biophys Acta 323, 98&#x2013;112. 10.1016/0005-2736(73)90434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-2736(73)90434-3</ArticleId><ArticleId IdType="pubmed">4356391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappsilber J, Mann M, and Ishihama Y (2007). Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2, 1896&#x2013;1906. 10.1038/nprot.2007.261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.261</ArticleId><ArticleId IdType="pubmed">17703201</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins DN, Pappin DJ, Creasy DM, and Cottrell JS (1999). Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551&#x2013;3567. 10.1002/(SICI)1522-2683(19991201)20:18&lt;3551::AID-ELPS3551&gt;3.0.CO;2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1522-2683(19991201)20:18&lt;3551::AID-ELPS3551&gt;3.0.CO;2-2</ArticleId><ArticleId IdType="pubmed">10612281</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, and Mann M (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10, 1794&#x2013;1805. 10.1021/pr101065j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr101065j</ArticleId><ArticleId IdType="pubmed">21254760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyanova S, Temu T, and Cox J (2016). The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc 11, 2301&#x2013;2319. 10.1038/nprot.2016.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.136</ArticleId><ArticleId IdType="pubmed">27809316</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuck P (2000). Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 78, 1606&#x2013;1619. 10.1016/S0006-3495(00)76713-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(00)76713-0</ArticleId><ArticleId IdType="pmc">PMC1300758</ArticleId><ArticleId IdType="pubmed">10692345</ArticleId></ArticleIdList></Reference><Reference><Citation>Young G, Hundt N, Cole D, Fineberg A, Andrecka J, Tyler A, Olerinyova A, Ansari A, Marklund EG, Collier MP, et al. (2018). Quantitative mass imaging of single biological macromolecules. Science 360, 423&#x2013;427. 10.1126/science.aar5839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar5839</ArticleId><ArticleId IdType="pmc">PMC6103225</ArticleId><ArticleId IdType="pubmed">29700264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigmundsson K, Masson G, Rice R, Beauchemin N, and Obrink B (2002). Determination of active concentrations and association and dissociation rate constants of interacting biomolecules: an analytical solution to the theory for kinetic and mass transport limitations in biosensor technology and its experimental verification. Biochemistry 41, 8263&#x2013;8276. 10.1021/bi020099h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi020099h</ArticleId><ArticleId IdType="pubmed">12081475</ArticleId></ArticleIdList></Reference><Reference><Citation>Suloway C, Pulokas J, Fellmann D, Cheng A, Guerra F, Quispe J, Stagg S, Potter CS, and Carragher B (2005). Automated molecular microscopy: the new Leginon system. J Struct Biol 151, 41&#x2013;60. 10.1016/j.jsb.2005.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2005.03.010</ArticleId><ArticleId IdType="pubmed">15890530</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, and Agard DA (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods 14, 331&#x2013;332. 10.1038/nmeth.4193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4193</ArticleId><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, and Grigorieff N (2015). CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol 192, 216&#x2013;221. 10.1016/j.jsb.2015.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2015.08.008</ArticleId><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A, and Fleet DJ (2021). 3D variability analysis: Resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. J Struct Biol 213, 107702. 10.1016/j.jsb.2021.107702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2021.107702</ArticleId><ArticleId IdType="pubmed">33582281</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A, Zhang H, and Fleet DJ (2020). Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat Methods 17, 1214&#x2013;1221. 10.1038/s41592-020-00990-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-020-00990-8</ArticleId><ArticleId IdType="pubmed">33257830</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Garcia R, Gomez-Blanco J, Cuervo A, Carazo JM, Sorzano COS, and Vargas J (2021). DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun Biol 4, 874. 10.1038/s42003-021-02399-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02399-1</ArticleId><ArticleId IdType="pmc">PMC8282847</ArticleId><ArticleId IdType="pubmed">34267316</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, and Cowtan K (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126&#x2013;2132. 10.1107/S0907444904019158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444904019158</ArticleId><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Croll TI (2018). ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr D Struct Biol 74, 519&#x2013;530. 10.1107/S2059798318002425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798318002425</ArticleId><ArticleId IdType="pmc">PMC6096486</ArticleId><ArticleId IdType="pubmed">29872003</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, and Adams PD (2018). Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol 74, 531&#x2013;544. 10.1107/S2059798318006551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798318006551</ArticleId><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelle W, Haslam SM, Ziak M, Roth J, Morris HR, and Dell A (2000). Characterization of the N-linked oligosaccharides of megalin (gp330) from rat kidney. Glycobiology 10, 295&#x2013;304. 10.1093/glycob/10.3.295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/10.3.295</ArticleId><ArticleId IdType="pubmed">10704528</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian E, Wang S, Zhang L, Zhang Y, Malicdan MC, Mao Y, Christoffersen C, Tabak LA, Schjoldager KT, and Ten Hagen KG (2019). Galnt11 regulates kidney function by glycosylating the endocytosis receptor megalin to modulate ligand binding. Proc Natl Acad Sci U S A 116, 25196&#x2013;25202. 10.1073/pnas.1909573116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1909573116</ArticleId><ArticleId IdType="pmc">PMC6911204</ArticleId><ArticleId IdType="pubmed">31740596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Mao Y, Narimatsu Y, Ye Z, Tian W, Goth CK, Lira-Navarrete E, Pedersen NB, Benito-Vicente A, Martin C, et al. (2018). Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions. J Biol Chem 293, 7408&#x2013;7422. 10.1074/jbc.M117.817981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.817981</ArticleId><ArticleId IdType="pmc">PMC5949982</ArticleId><ArticleId IdType="pubmed">29559555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano M, Totani K, Fukuda T, Gu J, and Suzuki A (2017). N-Glycoform-dependent interactions of megalin with its ligands. Biochim Biophys Acta Gen Subj 1861, 3106&#x2013;3118. 10.1016/j.bbagen.2016.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2016.10.015</ArticleId><ArticleId IdType="pubmed">27773703</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebschner D, Afonine PV, Baker ML, Bunkoczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ, et al. (2019). Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol 75, 861&#x2013;877. 10.1107/S2059798319011471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798319011471</ArticleId><ArticleId IdType="pmc">PMC6778852</ArticleId><ArticleId IdType="pubmed">31588918</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, Klaholz BP, Moriarty NW, Poon BK, Sobolev OV, Terwilliger TC, Adams PD, and Urzhumtsev A (2018). New tools for the analysis and validation of cryo-EM maps and atomic models. Acta Crystallogr D Struct Biol 74, 814&#x2013;840. 10.1107/S2059798318009324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798318009324</ArticleId><ArticleId IdType="pmc">PMC6130467</ArticleId><ArticleId IdType="pubmed">30198894</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis IW, Murray LW, Richardson JS, and Richardson DC (2004). MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 32, W615&#x2013;619. 10.1093/nar/gkh398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh398</ArticleId><ArticleId IdType="pmc">PMC441536</ArticleId><ArticleId IdType="pubmed">15215462</ArticleId></ArticleIdList></Reference><Reference><Citation>Terashi G, Wang X, Maddhuri Venkata Subramaniya SR, Tesmer JJG, and Kihara D (2022). Residue-wise local quality estimation for protein models from cryo-EM maps. Nat Methods 19, 1116&#x2013;1125. 10.1038/s41592-022-01574-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-022-01574-4</ArticleId><ArticleId IdType="pmc">PMC10024464</ArticleId><ArticleId IdType="pubmed">35953671</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, and Ferrin TE (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci 30, 70&#x2013;82. 10.1002/pro.3943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3943</ArticleId><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, and Ben-Tal N (2016). ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res 44, W344&#x2013;350. 10.1093/nar/gkw408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw408</ArticleId><ArticleId IdType="pmc">PMC4987940</ArticleId><ArticleId IdType="pubmed">27166375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkenazy H, Erez E, Martz E, Pupko T, and Ben-Tal N (2010). ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res 38, W529&#x2013;533. 10.1093/nar/gkq399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq399</ArticleId><ArticleId IdType="pmc">PMC2896094</ArticleId><ArticleId IdType="pubmed">20478830</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser F, Pupko T, Paz I, Bell RE, Bechor-Shental D, Martz E, and Ben-Tal N (2003). ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 19, 163&#x2013;164. 10.1093/bioinformatics/19.1.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/19.1.163</ArticleId><ArticleId IdType="pubmed">12499312</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, Pupko T, and Ben-Tal N (2005). ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucleic Acids Res 33, W299&#x2013;302. 10.1093/nar/gki370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki370</ArticleId><ArticleId IdType="pmc">PMC1160131</ArticleId><ArticleId IdType="pubmed">15980475</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A, et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature 596, 583&#x2013;589. 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010). Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486&#x2013;501. 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, Gopal K, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Pai RK, Read RJ, Romo TD, et al. (2004). Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat 11, 53&#x2013;55. 10.1107/s0909049503024130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/s0909049503024130</ArticleId><ArticleId IdType="pubmed">14646133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004). UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25, 1605&#x2013;1612. 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Laue TM (1997). Advances in sedimentation velocity analysis. Biophys J 72, 395&#x2013;396. 10.1016/S0006-3495(97)78679-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(97)78679-X</ArticleId><ArticleId IdType="pmc">PMC1184329</ArticleId><ArticleId IdType="pubmed">8994625</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36764301</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects.</ArticleTitle><Pagination><StartPage>1191</StartPage><EndPage>1204.e5</EndPage><MedlinePgn>1191-1204.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2023.01.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(23)00034-X</ELocationID><Abstract><AbstractText>Using induced pluripotent stem cells (iPSCs) to understand the mechanisms of neurological disease holds great promise; however, there is a lack of well-curated lines from a large array of participants. Answer ALS has generated over 1,000 iPSC lines from control and amyotrophic lateral sclerosis (ALS) patients along with clinical and whole-genome sequencing data. The current report summarizes cell marker and gene expression in motor neuron cultures derived from 92 healthy control and 341 ALS participants using a 32-day differentiation protocol. This is the largest set of iPSCs to be differentiated into motor neurons, and characterization suggests that cell composition and sex are significant sources of variability that need to be carefully controlled for in future studies. These data are reported as a resource for the scientific community that will utilize Answer ALS data for disease modeling using a wider array of omics being made available for these samples.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Workman</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Ryan G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ornelas</LastName><ForeName>Loren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panther</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galvez</LastName><ForeName>Erick</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meepe</LastName><ForeName>Imara</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valencia</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Emilda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>Ruby</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinedo</LastName><ForeName>Louis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsitkov</LastName><ForeName>Stanislav</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Ritchie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Center for Neural Science and Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Julia A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Systems and Therapeutics, Gladstone Institutes, University of California, San Francisco, San Francisco, CA, USA; Taube/Koret Center for Neurodegenerative Disease, Gladstone Institutes, University of California, San Francisco, San Francisco, CA, USA; Departments of Neurology and Physiology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Answer ALS Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Terri</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>On Point Scientific Inc., San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finkbeiner</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Systems and Therapeutics, Gladstone Institutes, University of California, San Francisco, San Francisco, CA, USA; Taube/Koret Center for Neurodegenerative Disease, Gladstone Institutes, University of California, San Francisco, San Francisco, CA, USA; Departments of Neurology and Physiology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraenkel</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sareen</LastName><ForeName>Dhruv</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: dhruv.sareen@cshs.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA; Department of Biological Chemistry, University of California, Irvine, CA, USA; Department of Neurobiology and Behavior, University of California, Irvine, CA, USA; Department of Psychiatry and Human Behavior and Sue and Bill Gross Stem Cell Center, University of California, Irvine, CA, USA. Electronic address: lmthomps@uci.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svendsen</LastName><ForeName>Clive N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Cedars-Sinai Biomanufacturing Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: clive.svendsen@cshs.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD021718</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR075047</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR025496</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA062203</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD010794</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA217378</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2025 May 28:S0896-6273(25)00393-9. doi: 10.1016/j.neuron.2025.05.022.</RefSource><PMID Version="1">40441139</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">motor neurons</Keyword><Keyword MajorTopicYN="N">sex differences</Keyword></KeywordList><CoiStatement>Declaration of interests US patent 10,221,395-B2 has been granted describing a method for reprogramming blood to induced pluripotent stem cells. Apart from this issued patent filing, the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36764301</ArticleId><ArticleId IdType="mid">NIHMS1930043</ArticleId><ArticleId IdType="pmc">PMC10557526</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2023.01.010</ArticleId><ArticleId IdType="pii">S0896-6273(23)00034-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giacomelli E, Vahsen BF, Calder EL, Xu Y, Scaber J, Gray E, Dafinca R, Talbot K, and Studer L (2022). Human stem cell models of neurodegeneration: from basic science of amyotrophic lateral sclerosis to clinical translation. Cell Stem Cell 29, 11&#x2013;35. 10.1016/j.stem.2021.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.12.008</ArticleId><ArticleId IdType="pmc">PMC8785905</ArticleId><ArticleId IdType="pubmed">34995492</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, Hendricks E, Linares GR, Wang Y, Son EY, et al. (2018). Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 24, 313&#x2013;325. 10.1038/nm.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, and Okano H (2018). Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 24, 1579&#x2013;1589. 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang EA, Tomov ML, Suhr ST, Luo J, Olmsted ZT, Paluh JL, and Cibelli J (2015). Derivation of ethnically diverse human induced pluripotent stem cell lines. Sci. Rep. 5, 15234. 10.1038/srep15234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15234</ArticleId><ArticleId IdType="pmc">PMC5388175</ArticleId><ArticleId IdType="pubmed">26482195</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, Thompson T, Li J, Kaye JA, Lim RG, Wu J, Ramamoorthy D, Lima L, Vaibhav V, Matlock A, et al. (2022). Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat. Neurosci. 25, 226&#x2013;237. 10.1038/s41593-021-01006-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-01006-0</ArticleId><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Sances S, Bruijn LI, Chandran S, Eggan K, Ho R, Klim JR, Livesey MR, Lowry E, Macklis JD, Rushton D, et al. (2016). Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat. Neurosci. 19, 542&#x2013;553. 10.1038/nn.4273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4273</ArticleId><ArticleId IdType="pmc">PMC5015775</ArticleId><ArticleId IdType="pubmed">27021939</ArticleId></ArticleIdList></Reference><Reference><Citation>Toombs J, Panther L, Ornelas L, Liu C, Gomez E, Mart&#xed;n-Ib&#xe1;&#xf1;ez R, Cox SR, Ritchie SJ, Harris SE, Taylor A, et al. (2020). Generation of twenty four induced pluripotent stem cell lines from twenty four members of the Lothian Birth Cohort 1936. Stem Cell Res. 46, 101851. 10.1016/j.scr.2020.101851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2020.101851</ArticleId><ArticleId IdType="pmc">PMC7347008</ArticleId><ArticleId IdType="pubmed">32450543</ArticleId></ArticleIdList></Reference><Reference><Citation>Michetti F, D&#x2019;Ambrosi N, Toesca A, Puglisi MA, Serrano A, Marchese E, Corvino V, and Geloso MC (2019). The S100B story: from biomarker to active factor in neural injury. J. Neurochem. 148, 168&#x2013;187. 10.1111/jnc.14574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14574</ArticleId><ArticleId IdType="pubmed">30144068</ArticleId></ArticleIdList></Reference><Reference><Citation>Panther L, Ornelas L, Jones MR, Gross AR, Gomez E, Liu C, Berman B, Svendsen CN, and Sareen D (2021). Generation of iPSC lines with high cytogenetic stability from peripheral blood mononuclear cells (PBMCs). 10.1101/2021.09.27.462082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.27.462082</ArticleId></ArticleIdList></Reference><Reference><Citation>ENCODE Consortium (2017). ENCODE experimental guidelines for ENCODE3 RNA-seq. https://www.encodeproject.org/about/experiment-guidelines/.</Citation></Reference><Reference><Citation>Schulze SK, Kanwar R, G&#xf6;lzenleuchter M, Therneau TM, and Beutler AS (2012). SERE: single-parameter quality control and sample comparison for RNA-Seq. BMC Genomics 13, 524. 10.1186/1471-2164-13-524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-13-524</ArticleId><ArticleId IdType="pmc">PMC3534338</ArticleId><ArticleId IdType="pubmed">23033915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman GE, and Schadt EE (2016). variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinformatics 17, 483. 10.1186/s12859-016-1323-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-016-1323-z</ArticleId><ArticleId IdType="pmc">PMC5123296</ArticleId><ArticleId IdType="pubmed">27884101</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256. 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, et al. (2013). RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428. 10.1016/jneuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/jneuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, B&#xe4;umer D, East S, Neal J, Morris HR, Ansorge O, and Blake DJ (2014). Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging 35, 1779.e5&#x2013;1779.e13. 10.1016/j.neurobiolaging.2014.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.01.016</ArticleId><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, Murray ME, Overstreet KK, Piazza-Johnston AE, Desaro P, et al. (2015). Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci. 18, 1175&#x2013;1182. 10.1038/nn.4065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4065</ArticleId><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar S, Seaton LR, Weissbein U, Eldar-Geva T, and Benvenisty N (2019). Global characterization of X chromosome inactivation in human pluripotent stem cells. Cell Rep. 27, 20&#x2013;29.e3. 10.1016/j.celrep.2019.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.03.019</ArticleId><ArticleId IdType="pubmed">30943402</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman P, Gubbay J, Vivian N, Goodfellow P, and Lovell-Badge R (1991). Male development of chromosomally female mice transgenic for Sry. Nature 351, 117&#x2013;121. 10.1038/351117a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/351117a0</ArticleId><ArticleId IdType="pubmed">2030730</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, et al. (2019). Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 22, 180&#x2013;190. 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, et al. (2019). ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 22, 167&#x2013;179. 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, Briner A, Rodriguez CM, Guo C, Akiyama T, et al. (2022). TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 603, 124&#x2013;130. 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, Bampton A, Lee FCY, Masino L, Qi YA, et al. (2022). TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131&#x2013;137. 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Saris CG, Horvath S, van Vught PW, van Es MA, Blauw HM, Fuller TF, Langfelder P, DeYoung J, Wokke JH, Veldink JH, et al. (2009). Weighted gene co-expression network analysis of the peripheral blood from amyotrophic lateral sclerosis patients. BMC Genomics 10, 405. 10.1186/1471-2164-10-405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-10-405</ArticleId><ArticleId IdType="pmc">PMC2743717</ArticleId><ArticleId IdType="pubmed">19712483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XS, Simmons Z, Liu W, Boyer PJ, and Connor JR (2006). Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph. Lateral Scler. 7, 201&#x2013;210. 10.1080/17482960600947689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600947689</ArticleId><ArticleId IdType="pubmed">17127558</ArticleId></ArticleIdList></Reference><Reference><Citation>Roczniak-Ferguson A, and Ferguson SM (2019). Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis. Life Sci. Alliance 2, 2. 10.26508/lsa.201900358.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201900358</ArticleId><ArticleId IdType="pmc">PMC6749094</ArticleId><ArticleId IdType="pubmed">31527135</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, et al. (2016). A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J. Neurol. Neurosurg. Psychiatry 87, 851&#x2013;858. 10.1136/jnnp-2015-311541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311541</ArticleId><ArticleId IdType="pubmed">26746183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Misawa K, Tohnai G, Nakatochi M, Furuhashi S, Atsuta N, Hayashi N, Yokoi D, Watanabe H, Watanabe H, et al. (2020). A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun. Biol. 3, 526. 10.1038/s42003-020-01251-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01251-2</ArticleId><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida A, Takahashi A, Kubo M, Saito S, Hosono N, Ohnishi Y, Kiyotani K, Mushiroda T, Nakajima M, Ozaki K, et al. (2011). A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum. Mol. Genet. 20, 3684&#x2013;3692. 10.1093/hmg/ddr268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr268</ArticleId><ArticleId IdType="pubmed">21665992</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack AA, Kroboth S, Rajesh D, and Wang WB (2011). Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors. PLoS One 6, e27956. 10.1371/journal.pone.0027956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027956</ArticleId><ArticleId IdType="pmc">PMC3222670</ArticleId><ArticleId IdType="pubmed">22132178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kytt&#xe4;l&#xe4; A, Moraghebi R, Valensisi C, Kettunen J, Andrus C, Pasumarthy KK, Nakanishi M, Nishimura K, Ohtaka M, Weltner J, et al. (2016). Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential. Stem Cell Rep. 6, 200&#x2013;212. 10.1016/j.stemcr.2015.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2015.12.009</ArticleId><ArticleId IdType="pmc">PMC4750096</ArticleId><ArticleId IdType="pubmed">26777058</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LR, Cho S, and Discher DE (2018). Stem cell differentiation is regulated by extracellular matrix mechanics. Physiology (Bethesda) 33, 16&#x2013;25. 10.1152/physiol.00026.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00026.2017</ArticleId><ArticleId IdType="pmc">PMC5866410</ArticleId><ArticleId IdType="pubmed">29212889</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, and Henderson RD (2010). Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 7, 557&#x2013;570. 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein LH, Janssen A, Dougherty A, Willey E, Stanton BR, et al. (2010). The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph. Lateral Scler. 11, 439&#x2013;442. 10.3109/17482961003610853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003610853</ArticleId><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, Tork C, Shelley B, McHugh J, Wallace K, Klein SM, Lindstrom MJ, and Svendsen CN (2007). Sexual dimorphism in disease onset and progression of a rat model of ALS. Amyotroph. Lateral Scler. 8, 20&#x2013;25. 10.1080/17482960600982447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600982447</ArticleId><ArticleId IdType="pubmed">17364431</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos D, Ram&#xed;rez-N&#xfa;&#xf1;ez O, Granado-Serrano AB, Torres P, Ayala V, Moiseeva V, Povedano M, Ferrer I, Pamplona R, Portero-Otin M, and Boada J (2016). Early and gender-specific differences in spinal cord mitochondrial function and oxidative stress markers in a mouse model of ALS. Acta Neuropathol. Commun. 4, 3. 10.1186/s40478-015-0271-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0271-6</ArticleId><ArticleId IdType="pmc">PMC4711180</ArticleId><ArticleId IdType="pubmed">26757991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf3; A, Mora G, Moglia C, Manera U, Canosa A, Cammarosano S, Ilardi A, Bertuzzo D, Bersano E, Cugnasco P, et al. (2017). Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d&#x2019;aosta register. JAMA Neurol. 74, 1097&#x2013;1104. 10.1001/jama-neurol.2017.1387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama-neurol.2017.1387</ArticleId><ArticleId IdType="pmc">PMC5710181</ArticleId><ArticleId IdType="pubmed">28692730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf3; A, Moglia C, Canosa A, Manera U, D&#x2019;Ovidio F, Vasta R, Grassano M, Brunetti M, Barberis M, Corrado L, et al. (2020). ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology 94, e802&#x2013;e810. 10.1212/WNL.0000000000008869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008869</ArticleId><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Janiszewski A, Talon I, Chappell J, Collombet S, Song J, De Geest N, To SK, Bervoets G, Marin-Bejar O, Provenzano C, et al. (2019). Dynamic reversal of random X-chromosome inactivation during iPSC reprogramming. Genome Res. 29, 1659&#x2013;1672. 10.1101/gr.249706.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.249706.119</ArticleId><ArticleId IdType="pmc">PMC6771397</ArticleId><ArticleId IdType="pubmed">31515287</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenes AJ, Yoshikawa H, Bensaddek D, Mirauta B, Seaton D, Hukelmann JL, Jiang H, Stegle O, and Lamond AI (2021). Erosion of human X chromosome inactivation causes major remodeling of the iPSC proteome. Cell Rep. 35, 109032. 10.1016/j.celrep.2021.109032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109032</ArticleId><ArticleId IdType="pmc">PMC8097692</ArticleId><ArticleId IdType="pubmed">33910018</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchieu J, Kuoy E, Chin MH, Trinh H, Patterson M, Sherman SP, Aimiuwu O, Lindgren A, Hakimian S, Zack JA, et al. (2010). Female human iPSCs retain an inactive X chromosome. Cell Stem Cell 7, 329&#x2013;342. 10.1016/j.stem.2010.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2010.06.024</ArticleId><ArticleId IdType="pmc">PMC2935700</ArticleId><ArticleId IdType="pubmed">20727844</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Evans S, Choudary P, Tomita H, Meador-Woodruff J, Molnar M, Li J, Lopez JF, Myers R, Cox D, et al. (2004). Gender-specific gene expression in post-mortem human brain: localization to sex chromosomes. Neuropsychopharmacology 29, 373&#x2013;384. 10.1038/sj.npp.1300337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1300337</ArticleId><ArticleId IdType="pmc">PMC3130534</ArticleId><ArticleId IdType="pubmed">14583743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukiainen T, Villani AC, Yen A, Rivas MA, Marshall JL, Satija R, Aguirre M, Gauthier L, Fleharty M, Kirby A, et al. (2017). Landscape of X chromosome inactivation across human tissues. Nature 550, 244&#x2013;248. 10.1038/nature24265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24265</ArticleId><ArticleId IdType="pmc">PMC5685192</ArticleId><ArticleId IdType="pubmed">29022598</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, and Morimoto S (2022). iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell 29, 189&#x2013;208. 10.1016/j.stem.2022.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2022.01.007</ArticleId><ArticleId IdType="pubmed">35120619</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, van den Berg LH, Genge A, Miller R, Baloh RH, Kern R, et al. (2020). Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve 62, 156&#x2013;166. 10.1002/mus.26801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26801</ArticleId><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho R, Workman MJ, Mathkar P, Wu K, Kim KJ, O&#x2019;Rourke JG, Kellogg M, Montel V, Banuelos MG, Arogundade OA, et al. (2021). Cross-comparison of human iPSC motor neuron models of familial and sporadic ALS reveals early and convergent transcriptomic disease signatures. Cell Syst. 12, 159&#x2013;175.e9. 10.1016/j.cels.2020.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7897311</ArticleId><ArticleId IdType="pubmed">33382996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, and Thomson JA (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797&#x2013;801. 10.1126/science.1172482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1172482</ArticleId><ArticleId IdType="pmc">PMC2758053</ArticleId><ArticleId IdType="pubmed">19325077</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409&#x2013;412. 10.1038/nmeth.1591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1591</ArticleId><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N, and Yamanaka S (2013). An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 31, 458&#x2013;466. 10.1002/stem.1293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1293</ArticleId><ArticleId IdType="pubmed">23193063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36787382</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>772</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Palmitoylation of the Parkinson's disease-associated protein synaptotagmin-11 links its turnover to &#x3b1;-synuclein homeostasis.</ArticleTitle><Pagination><StartPage>eadd7220</StartPage><MedlinePgn>eadd7220</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.add7220</ELocationID><Abstract><AbstractText>Synaptotagmin-11 (Syt11) is a vesicle-trafficking protein that is linked genetically to Parkinson's disease (PD). Likewise, the protein &#x3b1;-synuclein regulates vesicle trafficking, and its abnormal aggregation in neurons is the defining cytopathology of PD. Because of their functional similarities in the same disease context, we investigated whether the two proteins were connected. We found that Syt11 was palmitoylated in mouse and human brain tissue and in cultured cortical neurons and that this modification to Syt11 disrupted &#x3b1;-synuclein homeostasis in neurons. Palmitoylation of two cysteines adjacent to the transmembrane domain, Cys<sup>39</sup> and Cys<sup>40</sup>, localized Syt11 to digitonin-insoluble portions of intracellular membranes and protected it from degradation by the endolysosomal system. In neurons, palmitoylation of Syt11 increased its abundance and enhanced the binding of &#x3b1;-synuclein to intracellular membranes. As a result, the abundance of the physiologic tetrameric form of &#x3b1;-synuclein was decreased, and that of its aggregation-prone monomeric form was increased. These effects were replicated by overexpression of wild-type Syt11 but not a palmitoylation-deficient mutant. These findings suggest that palmitoylation-mediated increases in Syt11 amounts may promote pathological &#x3b1;-synuclein aggregation in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Gary P H</ForeName><Initials>GPH</Initials><Identifier Source="ORCID">0000-0001-7004-8630</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkie</LastName><ForeName>Erin C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0001-8846-9767</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS110876</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>134193-27-4</RegistryNumber><NameOfSubstance UI="D050857">Synaptotagmins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494265">SYT11 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2023 Jun;38(6):955-956. doi: 10.1002/mds.29418.</RefSource><PMID Version="1">37166399</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050857" MajorTopicYN="N">Synaptotagmins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054878" MajorTopicYN="N">Lipoylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> DJS is a director and consultant to Prothena Biosciences. The other authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36787382</ArticleId><ArticleId IdType="mid">NIHMS1889997</ArticleId><ArticleId IdType="pmc">PMC10150695</ArticleId><ArticleId IdType="doi">10.1126/scisignal.add7220</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Consortium IPDG, Imputation of sequence variants for identification of genetic risks for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet. 377, 641&#x2013;649 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, I. P. D. G. C. (IPDGC), P. S. G. (PSG) P. R. T. O. Gen. I. (PROGENI), 23andMe, GenePD, N. R. C. (NGRC), H. I. of H. G. (HIHG), A. J. D. Investigator, C. for H. and A. R. in G. E. (CHARGE), N. A. B. E. C. (NABEC), U. K. B. E. C. (UKBEC), G. P. D. Consortium, A. G. A. Group, Ikram MA, Ioannidis JPA, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat Genet. 46, 989&#x2013;993 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sesar A, Cacheiro P, L&#xf3;pez-L&#xf3;pez M, Cami&#xf1;a-Tato M, Quint&#xe1;ns B, Monroy-Jaramillo N, Alonso-Vilatela M-E, Cebri&#xe1;n E, Yescas-G&#xf3;mez P, Ares B, Rivas M-T, Castro A, Carracedo A, Sobrido M-J, Synaptotagmin XI in Parkinson&#x2019;s disease: New evidence from an association study in Spain and Mexico. J Neurol Sci. 362, 321&#x2013;325 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26944171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, Dauvilliers Y, Spiegelman D, Greenbaum L, Fahn S, Waters CH, Dupr&#xe9; N, Rouleau GA, Hassin-Baer S, Fon EA, Alcalay RN, Gan-Or Z, Targeted sequencing of Parkinson&#x2019;s disease loci genes highlights SYT11, FGF20 and other associations. Brain. 144, 462&#x2013;472 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940168</ArticleId><ArticleId IdType="pubmed">33349842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfes AC, Dean C, The diversity of synaptotagmin isoforms. Curr Opin Neurobiol. 63, 198&#x2013;209 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32663762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai H, Shin O-H, Machius M, Tomchick DR, S&#xfc;dhof TC, Rizo J, Structural basis for the evolutionary inactivation of Ca2+ binding to synaptotagmin 4. Nat Struct Mol Biol. 11, 844&#x2013;849 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15311271</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerberg L, Hallstr&#xf6;m BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sj&#xf6;stedt E, Lundberg E, Szigyarto CA-K, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson &#xc5;, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhl&#xe9;n M, Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics*. Mol Cell Proteomics. 13, 397&#x2013;406 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916642</ArticleId><ArticleId IdType="pubmed">24309898</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimojo M, Madara J, Pankow S, Liu X, Yates J, S&#xfc;dhof TC, Maximov A, Synaptotagmin-11 mediates a vesicle trafficking pathway that is essential for development and synaptic plasticity. Genes &amp; development. 33, 365&#x2013;376 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411015</ArticleId><ArticleId IdType="pubmed">30808661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Wang Y, Hu M, Chai Z, Wu Q, Huang R, Han W, Zhang CX, Zhou Z, Synaptotagmin-11 inhibits clathrin-mediated and bulk endocytosis. Embo Rep. 17, 47&#x2013;63 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718405</ArticleId><ArticleId IdType="pubmed">26589353</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Wang Y, Li C, Gao P, Zhang F, Hu M, Li J, Zhang S, Li R, Zhang CX, Synaptotagmin-11 inhibits spontaneous neurotransmission through vti1a. J Neurochem. 159, 729&#x2013;741 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34599505</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Kang X, Zhou L, Chai Z, Wu Q, Huang R, Xu H, Hu M, Sun X, Sun S, Li J, Jiao R, Zuo P, Zheng L, Yue Z, Zhou Z, Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson&#x2019;s disease-like pathology. Nat Commun. 9, 81 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758517</ArticleId><ArticleId IdType="pubmed">29311685</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M, Alpha-synuclein in Lewy bodies. Nature. 388, 839&#x2013;840 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM, Stabilization of &#x3b1;-Synuclein Secondary Structure upon Binding to Synthetic Membranes*. J Biol Chem. 273, 9443&#x2013;9449 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeliovich A, Gitler AD, Defects in trafficking bridge Parkinson&#x2019;s disease pathology and genetics. Nature. 539, 207&#x2013;216 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27830778</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n-Vendrell C, Medeiros AT, Sanderson JB, Jiang H, Bartels T, Morgan JR, Effects of Excess Brain-Derived Human &#x3b1;-Synuclein on Synaptic Vesicle Trafficking. Front Neurosci-switz. 15, 639414 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890186</ArticleId><ArticleId IdType="pubmed">33613189</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca-Ornelas L, Viennet T, Rovere M, Jiang H, Liu L, Nuber S, Ericsson M, Arthanari H, Selkoe DJ, Altered conformation of &#x3b1;-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson&#x2019;s disease. Cell Reports. 36, 109333 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8552450</ArticleId><ArticleId IdType="pubmed">34233191</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Casta&#xf1;o-D&#xed;ez D, Schweighauser G, Graff-Meyer A, Goldie KN, S&#xfc;tterlin R, Huisman E, Ingrassia A, de Gier Y, Rozemuller AJM, Wang J, Paepe AD, Erny J, Staempfli A, Hoernschemeyer J, Gro&#xdf;er&#xfc;schkamp F, Niedieker D, El-Mashtoly SF, Quadri M, IJcken WFJV, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, de Berg WDJV, Lauer ME, Lewy pathology in Parkinson&#x2019;s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 22, 1099&#x2013;1109 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31235907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang R, Swayze R, Lise MF, Gerrow K, Mullard A, Honer WG, El-Husseini A, Presynaptic trafficking of synaptotagmin I is regulated by protein palmitoylation. The Journal of biological chemistry. 279, 50524&#x2013;50536 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15355980</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery AR, Czibener C, Andrews NW, Palmitoylation-dependent association with CD63 targets the Ca2+ sensor synaptotagmin VII to lysosomes. J Cell Biology. 191, 599&#x2013;613 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003310</ArticleId><ArticleId IdType="pubmed">21041449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho GPH, Ramalingam N, Imberdis T, Wilkie EC, Dettmer U, Selkoe DJ, Upregulation of Cellular Palmitoylation Mitigates &#x3b1;-Synuclein Accumulation and Neurotoxicity. Movement Disord. 36, 348&#x2013;359 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8887921</ArticleId><ArticleId IdType="pubmed">33103814</ArticleId></ArticleIdList></Reference><Reference><Citation>Drisdel RC, Alexander JK, Sayeed A, Green WN, Assays of protein palmitoylation. Methods. 40, 127&#x2013;134 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17012024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan J, Roth AF, Bailey AO, Davis NG, Palmitoylated proteins: purification and identification. Nat Protoc. 2, 1573&#x2013;1584 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17585299</ArticleId></ArticleIdList></Reference><Reference><Citation>Craven SE, El-Husseini AE, Bredt DS, Synaptic Targeting of the Postsynaptic Density Protein PSD-95 Mediated by Lipid and Protein Motifs. Neuron. 22, 497&#x2013;509 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10197530</ArticleId></ArticleIdList></Reference><Reference><Citation>Heindel U, Schmidt MFG, Veit M, Palmitoylation sites and processing of synaptotagmin I, the putative calcium sensor for neurosecretion. Febs Lett. 544, 57&#x2013;62 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12782290</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins MO, Woodley KT, Choudhary JS, Global, site-specific analysis of neuronal protein S-acylation. Sci Rep-uk. 7, 4683 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5498535</ArticleId><ArticleId IdType="pubmed">28680068</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman J-W, Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T, Parkinson&#x2019;s disease induced pluripotent stem cells with triplication of the &#x3b1;-synuclein locus. Nat Commun. 2, 440 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265381</ArticleId><ArticleId IdType="pubmed">21863007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H-C, Schuman EM, Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci. 9, 826&#x2013;838 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18931696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalingam N, Dettmer U, Temperature is a key determinant of alpha- and beta-synuclein membrane interactions in neurons. J Biol Chem. 296, 100271 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7949061</ArticleId><ArticleId IdType="pubmed">33428933</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain LH, Shipston MJ, The Physiology of Protein S-acylation. Physiol Rev. 95, 341&#x2013;376 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551212</ArticleId><ArticleId IdType="pubmed">25834228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzakis NS, Bhatia VK, Larsen J, Madsen KL, Bolinger P-Y, Kunding AH, Castillo J, Gether U, Hedeg&#xe5;rd P, Stamou D, How curved membranes recruit amphipathic helices and protein anchoring motifs. Nat Chem Biol. 5, 835&#x2013;841 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19749743</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen JB, Jensen MB, Bhatia VK, Pedersen SL, Bj&#xf8;rnholm T, Iversen L, Uline M, Szleifer I, Jensen KJ, Hatzakis NS, Stamou D, Membrane curvature enables N-Ras lipid anchor sorting to liquid-ordered membrane phases. Nat Chem Biol. 11, 192&#x2013;194 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25622090</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros AT, Soll LG, Tessari I, Bubacco L, Morgan JR, &#x3b1;-Synuclein Dimers Impair Vesicle Fission during Clathrin-Mediated Synaptic Vesicle Recycling. Front Cell Neurosci. 11, 388 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732215</ArticleId><ArticleId IdType="pubmed">29321725</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter JD, Braun AR, Sachs JN, Curvature Dynamics of &#x3b1;-Synuclein Familial Parkinson Disease Mutants*. J Biol Chem. 284, 7177&#x2013;7189 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652287</ArticleId><ArticleId IdType="pubmed">19126542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Dolt KS, Kriek M, Baker T, Downey P, Drummond NJ, Canham MA, Natalwala A, Rosser S, Kunath T, Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. Eur J Neurosci. 49, 510&#x2013;524 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492083</ArticleId><ArticleId IdType="pubmed">30472757</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Rationally Designed Variants of &#x3b1;-Synuclein Illuminate Its in vivo Structural Properties in Health and Disease. Front Neurosci-switz. 12, 623 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6167557</ArticleId><ArticleId IdType="pubmed">30319334</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi A, Alnakhala H, Terry-Kantor E, Newman A, Liu L, Imberdis T, Fanning S, Nuber S, Ramalingam N, Selkoe D, Dettmer U, Pathogenic Mechanisms of Cytosolic and Membrane-Enriched &#x3b1;-Synuclein Converge on Fatty Acid Homeostasis. J Neurosci. 42, 2116&#x2013;2130 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8916762</ArticleId><ArticleId IdType="pubmed">35086904</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D, In Vivo Cross-linking Reveals Principally Oligomeric Forms of &#x3b1;-Synuclein and &#x3b2;-Synuclein in Neurons and Non-neural Cells. J Biol Chem. 288, 6371&#x2013;6385 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Soldner F, Luth ES, Kim NC, von Saucken VE, Sanderson JB, Jaenisch R, Bartels T, Selkoe D, Parkinson-causing &#x3b1;-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun. 6, 7314 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490410</ArticleId><ArticleId IdType="pubmed">26076669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Yun SP, Lee S, Umanah GE, Bandaru VVR, Yin X, Rhee P, Karuppagounder SS, Kwon S-H, Lee H, Mao X, Kim D, Pandey A, Lee G, Dawson VL, Dawson TM, Ko HS, GBA1 deficiency negatively affects physiological &#x3b1;-synuclein tetramers and related multimers. Proc National Acad Sci. 115, 798&#x2013;803 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5789900</ArticleId><ArticleId IdType="pubmed">29311330</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, Choi JG, Selkoe DJ, &#x3b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 477, 107&#x2013;110 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Das U, Scott DA, Tang Y, McLean PJ, Roy S, &#x3b1;-Synuclein Multimers Cluster Synaptic Vesicles and Attenuate Recycling. Curr Biol. 24, 2319&#x2013;2326 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190006</ArticleId><ArticleId IdType="pubmed">25264250</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntan&#xe9; G, Ferrer I, Martinez-Vicente M, &#x3b1;-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience. 200, 106&#x2013;119 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22079575</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ, &#x3b1;-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease. J Neuropathology Exp Neurology. 68, 515&#x2013;524 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753269</ArticleId><ArticleId IdType="pubmed">19525899</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati A, Schneider BL, Aebischer P, Lashuel HA, Polo-like kinase 2 regulates selective autophagic &#x3b1;-synuclein clearance and suppresses its toxicity in vivo. Proc National Acad Sci. 110, E3945&#x2013;E3954 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799334</ArticleId><ArticleId IdType="pubmed">23983262</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T, alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature cell biology. 4, 160&#x2013;164 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M-R, Hu Z-W, Zhao Y-F, Chen Y-X, Li Y-M, Phosphorylation induces distinct alpha-synuclein strain formation. Sci Rep-uk. 6, 37130 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112567</ArticleId><ArticleId IdType="pubmed">27853185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, Alegre J, G&#xf3;mez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atar&#xe9;s B, Llorens V, Tortosa EG, del Ser T, Mu&#xf1;oz DG, de Yebenes JG, The new mutation, E46K, of &#x3b1;-synuclein causes parkinson and Lewy body dementia. Ann Neurol. 55, 164&#x2013;173 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbefo MK, Fares M-B, Paleologou K, Oueslati A, Yin G, Tenreiro S, Pinto M, Outeiro T, Zweckstetter M, Masliah E, Lashuel HA, Parkinson Disease Mutant E46K Enhances &#x3b1;-Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo *. J Biol Chem. 290, 9412&#x2013;9427 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4392248</ArticleId><ArticleId IdType="pubmed">25657004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, LaBaer J, Rochet J-C, Bonini NM, Lindquist S, &#x3b1;-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson9s Models. Science. 313, 324&#x2013;328 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Scoles DR, Nguyen D, Pulst SM, The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Human molecular genetics. 12, 2587&#x2013;2597 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12925569</ArticleId></ArticleIdList></Reference><Reference><Citation>Narendra D, Walker JE, Youle R, Mitochondrial Quality Control Mediated by PINK1 and Parkin: Links to Parkinsonism. Csh Perspect Biol. 4, a011338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536340</ArticleId><ArticleId IdType="pubmed">23125018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordureau A, Paulo JA, Zhang W, Ahfeldt T, Zhang J, Cohn EF, Hou Z, Heo J-M, Rubin LL, Sidhu SS, Gygi SP, Harper JW, Dynamics of PARKIN-Dependent Mitochondrial Ubiquitylation in Induced Neurons and Model Systems Revealed by Digital Snapshot Proteomics. Mol Cell. 70, 211&#x2013;227.e8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5910199</ArticleId><ArticleId IdType="pubmed">29656925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordureau A, Paulo JA, Zhang J, An H, Swatek KN, Cannon JR, Wan Q, Komander D, Harper JW, Global Landscape and Dynamics of Parkin and USP30-Dependent Ubiquitylomes in iNeurons during Mitophagic Signaling. Mol Cell. 77, 1124&#x2013;1142.e10 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098486</ArticleId><ArticleId IdType="pubmed">32142685</ArticleId></ArticleIdList></Reference><Reference><Citation>Antico O, Ordureau A, Stevens M, Singh F, Nirujogi RS, Gierlinski M, Barini E, Rickwood ML, Prescott A, Toth R, Ganley IG, Harper JW, Muqit MMK, Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1. Sci Adv. 7, eabj0722 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589319</ArticleId><ArticleId IdType="pubmed">34767452</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ, Phosphorylation of Ser-129 Is the Dominant Pathological Modification of &#x3b1;-Synuclein in Familial and Sporadic Lewy Body Disease*. J Biol Chem. 281, 29739&#x2013;29752 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuber S, Rajsombath M, Minakaki G, Winkler J, M&#xfc;ller CP, Ericsson M, Caldarone B, Dettmer U, Selkoe DJ, Abrogating Native &#x3b1;-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson&#x2019;s Disease. Neuron. 100, 75&#x2013;90.e5 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211795</ArticleId><ArticleId IdType="pubmed">30308173</ArticleId></ArticleIdList></Reference><Reference><Citation>Imberdis T, Negri J, Ramalingam N, Terry-Kantor E, Ho GPH, Fanning S, Stirtz G, Kim T-E, Levy OA, Young-Pearse TL, Selkoe D, Dettmer U, Cell models of lipid-rich &#x3b1;-synuclein aggregation validate known modifiers of &#x3b1;-synuclein biology and identify stearoyl-CoA desaturase. Proc National Acad Sci. 116, 20760&#x2013;20769 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6789936</ArticleId><ArticleId IdType="pubmed">31548371</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanning S, Cirka H, Thies JL, Jeong J, Niemi SM, Yoon J, Ho GPH, Pacheco JA, Dettmer U, Liu L, Clish CB, Hodgetts KJ, Hutchinson JN, Muratore CR, Caldwell GA, Caldwell KA, Selkoe D, Lipase regulation of cellular fatty acid homeostasis as a Parkinson&#x2019;s disease therapeutic strategy. Npj Park Dis. 8, 74 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9184586</ArticleId><ArticleId IdType="pubmed">35680956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D, &#x3b1;-Synuclein&#x2013;induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc National Acad Sci. 113, 1931&#x2013;1936 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763774</ArticleId><ArticleId IdType="pubmed">26839413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme R, Zuccaro E, Ghosh SD, Li C, Sherwood JL, Pietilainen O, Barrett LE, Limone F, Worringer KA, Kommineni S, Zang Y, Cacchiarelli D, Meissner A, Adolfsson R, Haggarty S, Madison J, Muller M, Arlotta P, Fu Z, Feng G, Eggan K, Combining NGN2 Programming with Developmental Patterning Generates Human Excitatory Neurons with NMDAR-Mediated Synaptic Transmission. Cell Reports. 23, 2509&#x2013;2523 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003669</ArticleId><ArticleId IdType="pubmed">29791859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, Xu W, Yang N, Danko T, Chen L, Wernig M, S&#xfc;dhof TC, Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 78, 785&#x2013;798 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho GPH, Selvakumar B, Mukai J, Hester LD, Wang Y, Gogos JA, Snyder SH, S-Nitrosylation and S-Palmitoylation Reciprocally Regulate Synaptic Targeting of PSD-95. Neuron. 71, 131&#x2013;141 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181141</ArticleId><ArticleId IdType="pubmed">21745643</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36641605</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2426-0266</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The journal of prevention of Alzheimer's disease</Title><ISOAbbreviation>J Prev Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>18</EndPage><MedlinePgn>9-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14283/jpad.2022.102</ELocationID><Abstract><AbstractText Label="BACKGROUND">Consensus is lacking on what constitutes a meaningful score change for individual patients on clinical outcome assessments (COAs) that are commonly used in clinical trials of Alzheimer's disease. Such thresholds are one important approach to help contextualize trial results and demonstrate meaningful treatment benefit.</AbstractText><AbstractText Label="OBJECTIVES">To estimate meaningful within-patient change thresholds for the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog), and the Mini-Mental State Examination (MMSE) among participants with mild cognitive impairment (MCI).</AbstractText><AbstractText Label="DESIGN">Retrospective anchor- and distribution-based analyses of data from the ADC-008 (NCT00000173) study were used to estimate thresholds for meaningful within-patient change on the target measures.</AbstractText><AbstractText Label="SETTING">Analyses were conducted using data from ADC-008 a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study among participants with the amnestic subtype of MCI, which was conducted by the Alzheimer's Disease Cooperative Study (ADCS) between March 1999 and January 2004 in the United States and Canada.</AbstractText><AbstractText Label="PARTICIPANTS">Analyses were based on 769 eligible participants who completed the baseline assessment from 69 ADCS sites in the United States and Canada.</AbstractText><AbstractText Label="MEASUREMENTS">The target outcome measures for this analysis included the CDR-SB, the ADAS-Cog, and the MMSE. The anchor measures for this analysis included the Global Deterioration Scale and the MCI-Clinical Global Impression of Change.</AbstractText><AbstractText Label="RESULTS">Focusing on the 12-month time point, within-patient increases of 1-2.5 points in the CDR-SB and increases of 2-5 points on the 11-item ADAS-Cog and 13-item ADAS-Cog, on average, reflect minimal-to-moderate levels of deterioration, respectively.</AbstractText><AbstractText Label="CONCLUSIONS">These thresholds may be useful to aid the interpretation of Alzheimer's disease clinical trial data by illustrating meaningful within-patient progression over the course of a clinical trial via supplementary progressor analyses, which may in turn be informative for treatment decisions. Estimates generated via these methods are specifically intended to evaluate within-patient change and are not intended to assess the magnitude and meaningfulness of differences between group-level changes over time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lansdall</LastName><ForeName>C J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Claire Lansdall, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Email: Claire.lansdall@roche.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDougall</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Delmar</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pross</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McLeod</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Kerchner</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00000173</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Prev Alzheimers Dis</MedlineTA><NlmUniqueID>101638820</NlmUniqueID><ISSNLinking>2274-5807</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Prev Alzheimers Dis. 2023;10(1):5-6. doi: 10.14283/jpad.2022.103.</RefSource><PMID Version="1">36641603</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Prev Alzheimers Dis. 2023;10(1):7-8. doi: 10.14283/jpad.2022.104.</RefSource><PMID Version="1">36641604</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADC-008</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">clinical outcome assessment</Keyword><Keyword MajorTopicYN="N">clinically important</Keyword><Keyword MajorTopicYN="N">endpoint</Keyword><Keyword MajorTopicYN="N">meaningful change</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword></KeywordList><CoiStatement>This analysis was conducted under a research contract between RTI Health Solutions and F. Hoffmann-La Roche Ltd and was funded by F. Hoffmann-La Roche Ltd. CJL, FM, PD, NP, GAK, and RD are employees of F. Hoffmann-La Roche Ltd. LMB was an employee of F. Hoffmann-La Roche Ltd. during the authoring of the manuscript. CJL, FM, LMB, NP, and GAK are also shareholders of F. Hoffmann-La Roche Ltd. SQ, LM, and XZ are employees of RTI Health Solutions.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>15</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36641605</ArticleId><ArticleId IdType="doi">10.14283/jpad.2022.102</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36792830</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>614</Volume><Issue>7949</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A NPAS4-NuA4 complex couples synaptic activity to DNA repair.</ArticleTitle><Pagination><StartPage>732</StartPage><EndPage>741</EndPage><MedlinePgn>732-741</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-023-05711-7</ELocationID><Abstract><AbstractText>Neuronal activity is crucial for adaptive circuit remodelling but poses an inherent risk to the stability of the genome across the long lifespan of postmitotic neurons<sup>1-5</sup>. Whether neurons have acquired specialized genome protection mechanisms that enable them to withstand decades of potentially damaging stimuli during periods of heightened activity is unknown. Here we identify an activity-dependent DNA repair mechanism&#xa0;in which a new form of the NuA4-TIP60 chromatin modifier assembles in activated neurons around the inducible, neuronal-specific transcription factor NPAS4. We purify this complex from the brain and demonstrate its functions in eliciting activity-dependent changes to neuronal transcriptomes and circuitry. By characterizing the landscape of activity-induced DNA double-strand breaks in the brain, we show that NPAS4-NuA4 binds to recurrently damaged regulatory elements and recruits additional DNA repair machinery to stimulate their repair. Gene regulatory elements bound by NPAS4-NuA4 are partially protected against age-dependent accumulation of somatic mutations. Impaired NPAS4-NuA4 signalling leads to a cascade of cellular defects, including dysregulated activity-dependent transcriptional responses, loss of control over neuronal inhibition and genome instability, which all culminate to reduce organismal lifespan. In addition, mutations in several components of the NuA4 complex are reported to lead to neurodevelopmental and autism spectrum&#xa0;disorders. Together, these findings identify a neuronal-specific complex that couples neuronal activity directly to genome preservation, the disruption of which may contribute to developmental disorders, neurodegeneration and ageing.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Pollina</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Developmental Biology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gilliam</LastName><ForeName>Daniel T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajarillo</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmin</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yap</LastName><ForeName>Ee-Lynn</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0003-0428-3215</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>M Aurel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Emi</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5287-0284</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0002-7519-5098</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>Bernardo L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0003-0095-9177</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weitz</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-1380-2160</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA, USA. meg@hms.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS046579</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HD105351</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007473</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG064042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS112455</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS028829</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS072030</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D000074443">Lysine Acetyltransferase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mol Cell. 2023 Apr 20;83(8):1208-1209. doi: 10.1016/j.molcel.2023.03.019.</RefSource><PMID Version="1">37084713</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051792" MajorTopicYN="N">Basic Helix-Loop-Helix Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053903" MajorTopicYN="N">DNA Breaks, Double-Stranded</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="Y">DNA Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074443" MajorTopicYN="N">Lysine Acetyltransferase 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="Y">Multiprotein Complexes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="Y">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="Y">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36792830</ArticleId><ArticleId IdType="pmc">PMC9946837</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-05711-7</ArticleId><ArticleId IdType="pii">10.1038/s41586-023-05711-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yap EL, Greenberg ME. Activity-regulated transcription: bridging the gap between neural activity and behavior. Neuron. 2018;100:330&#x2013;348. doi: 10.1016/j.neuron.2018.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.10.013</ArticleId><ArticleId IdType="pmc">PMC6223657</ArticleId><ArticleId IdType="pubmed">30359600</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E, et al. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-&#x3b2;. Nat. Neurosci. 2013;16:613&#x2013;621. doi: 10.1038/nn.3356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3356</ArticleId><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabhushi R, et al. Activity-induced DNA breaks govern the expression of neuronal early-response genes. Cell. 2015;161:1592&#x2013;1605. doi: 10.1016/j.cell.2015.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.05.032</ArticleId><ArticleId IdType="pmc">PMC4886855</ArticleId><ArticleId IdType="pubmed">26052046</ArticleId></ArticleIdList></Reference><Reference><Citation>Delint-Ramirez I, et al. Calcineurin dephosphorylates topoisomerase II&#x3b2; and regulates the formation of neuronal-activity-induced DNA breaks. Mol. Cell. 2022;82:3794&#x2013;3809.e8. doi: 10.1016/j.molcel.2022.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2022.09.012</ArticleId><ArticleId IdType="pmc">PMC9990814</ArticleId><ArticleId IdType="pubmed">36206766</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe SL, Movsesyan VA, Jorgensen TJ, Kondratyev A. Rapid phosphorylation of histone H2A.X following ionotropic glutamate receptor activation. Eur. J. Neurosci. 2006;23:2351&#x2013;2361. doi: 10.1111/j.1460-9568.2006.04768.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2006.04768.x</ArticleId><ArticleId IdType="pmc">PMC1534119</ArticleId><ArticleId IdType="pubmed">16706843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap EL, et al. Bidirectional perisomatic inhibitory plasticity of a Fos neuronal network. Nature. 2021;590:115&#x2013;121. doi: 10.1038/s41586-020-3031-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-3031-0</ArticleId><ArticleId IdType="pmc">PMC7864877</ArticleId><ArticleId IdType="pubmed">33299180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloodgood BL, Sharma N, Browne HA, Trepman AZ, Greenberg ME. The activity-dependent transcription factor NPAS4 regulates domain-specific inhibition. Nature. 2013;503:121&#x2013;125. doi: 10.1038/nature12743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12743</ArticleId><ArticleId IdType="pmc">PMC4169177</ArticleId><ArticleId IdType="pubmed">24201284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891. doi: 10.1038/nature02661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02661</ArticleId><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunch H, et al. Transcriptional elongation requires DNA break-induced signalling. Nat. Commun. 2015;6:10191. doi: 10.1038/ncomms10191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10191</ArticleId><ArticleId IdType="pmc">PMC4703865</ArticleId><ArticleId IdType="pubmed">26671524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju BG, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006;312:1798&#x2013;1802. doi: 10.1126/science.1127196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1127196</ArticleId><ArticleId IdType="pubmed">16794079</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyama T, Wilson DM., 3rd DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst.) 2013;12:620&#x2013;636. doi: 10.1016/j.dnarep.2013.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2013.04.015</ArticleId><ArticleId IdType="pmc">PMC3720834</ArticleId><ArticleId IdType="pubmed">23684800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA, et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science. 2018;359:555&#x2013;559. doi: 10.1126/science.aao4426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao4426</ArticleId><ArticleId IdType="pmc">PMC5831169</ArticleId><ArticleId IdType="pubmed">29217584</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage in the ageing process. Nature. 2021;592:695&#x2013;703. doi: 10.1038/s41586-021-03307-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03307-7</ArticleId><ArticleId IdType="pmc">PMC9844150</ArticleId><ArticleId IdType="pubmed">33911272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, et al. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature. 2008;455:1198&#x2013;1204. doi: 10.1038/nature07319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07319</ArticleId><ArticleId IdType="pmc">PMC2637532</ArticleId><ArticleId IdType="pubmed">18815592</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyon Y, Cote J. The highly conserved and multifunctional NuA4 HAT complex. Curr. Opin. Genet. Dev. 2004;14:147&#x2013;154. doi: 10.1016/j.gde.2004.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2004.02.009</ArticleId><ArticleId IdType="pubmed">15196461</ArticleId></ArticleIdList></Reference><Reference><Citation>Galarneau L, et al. Multiple links between the NuA4 histone acetyltransferase complex and epigenetic control of transcription. Mol. Cell. 2000;5:927&#x2013;937. doi: 10.1016/S1097-2765(00)80258-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(00)80258-0</ArticleId><ArticleId IdType="pubmed">10911987</ArticleId></ArticleIdList></Reference><Reference><Citation>Allard S, et al. NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM-related cofactor Tra1p. EMBO J. 1999;18:5108&#x2013;5119. doi: 10.1093/emboj/18.18.5108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/18.18.5108</ArticleId><ArticleId IdType="pmc">PMC1171581</ArticleId><ArticleId IdType="pubmed">10487762</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen Brain Map, Cell Types Database: RNA-Seq Data. https://celltypes.brain-map.org/rnaseq/human_m1_10x (2020).</Citation></Reference><Reference><Citation>Skene PJ, Henikoff S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. eLife. 2017;6:e21856. doi: 10.7554/eLife.21856.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.21856</ArticleId><ArticleId IdType="pmc">PMC5310842</ArticleId><ArticleId IdType="pubmed">28079019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan SK, et al. EP400 deposits H3.3 into promoters and enhancers during gene activation. Mol. Cell. 2016;61:27&#x2013;38. doi: 10.1016/j.molcel.2015.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.10.039</ArticleId><ArticleId IdType="pmc">PMC4707986</ArticleId><ArticleId IdType="pubmed">26669263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird AW, et al. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature. 2002;419:411&#x2013;415. doi: 10.1038/nature01035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01035</ArticleId><ArticleId IdType="pubmed">12353039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikura T, et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell. 2000;102:463&#x2013;473. doi: 10.1016/S0092-8674(00)00051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)00051-9</ArticleId><ArticleId IdType="pubmed">10966108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat. Cell Biol. 2009;11:1376&#x2013;1382. doi: 10.1038/ncb1982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1982</ArticleId><ArticleId IdType="pmc">PMC2783526</ArticleId><ArticleId IdType="pubmed">19783983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusch T, et al. Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions. Science. 2004;306:2084&#x2013;2087. doi: 10.1126/science.1103455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1103455</ArticleId><ArticleId IdType="pubmed">15528408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, et al. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat. Struct. Mol. Biol. 2013;20:317&#x2013;325. doi: 10.1038/nsmb.2499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2499</ArticleId><ArticleId IdType="pmc">PMC3594358</ArticleId><ArticleId IdType="pubmed">23377543</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquet K, et al. The TIP60 complex regulates bivalent chromatin recognition by 53BP1 through direct H4K20me binding and H2AK15 acetylation. Mol. Cell. 2016;62:409&#x2013;421. doi: 10.1016/j.molcel.2016.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.03.031</ArticleId><ArticleId IdType="pmc">PMC4887106</ArticleId><ArticleId IdType="pubmed">27153538</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigidi GS, et al. Genomic decoding of neuronal depolarization by stimulus-specific NPAS4 heterodimers. Cell. 2019;179:373&#x2013;391.e27. doi: 10.1016/j.cell.2019.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.004</ArticleId><ArticleId IdType="pmc">PMC6800120</ArticleId><ArticleId IdType="pubmed">31585079</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma N, et al. ARNT2 tunes activity-dependent gene expression through NCoR2-nediated repression and NPAS4-mediated activation. Neuron. 2019;102:390&#x2013;406.e9. doi: 10.1016/j.neuron.2019.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.007</ArticleId><ArticleId IdType="pmc">PMC6504996</ArticleId><ArticleId IdType="pubmed">30846309</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellino GI, et al. Release of paused RNA polymerase II at specific loci favors DNA double-strand-break formation and promotes cancer translocations. Nat. Genet. 2019;51:1011&#x2013;1023. doi: 10.1038/s41588-019-0421-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0421-z</ArticleId><ArticleId IdType="pubmed">31110352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman BAM, et al. Genome-wide detection of DNA double-strand breaks by in-suspension BLISS. Nat. Protoc. 2020;15:3894&#x2013;3941. doi: 10.1038/s41596-020-0397-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0397-2</ArticleId><ArticleId IdType="pubmed">33139954</ArticleId></ArticleIdList></Reference><Reference><Citation>Canela A, et al. Genome organization drives chromosome fragility. Cell. 2017;170:507&#x2013;521.e18. doi: 10.1016/j.cell.2017.06.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.06.034</ArticleId><ArticleId IdType="pmc">PMC6133249</ArticleId><ArticleId IdType="pubmed">28735753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, et al. Neuronal enhancers are hotspots for DNA single-strand break repair. Nature. 2021;593:440&#x2013;444. doi: 10.1038/s41586-021-03468-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03468-5</ArticleId><ArticleId IdType="pmc">PMC9827709</ArticleId><ArticleId IdType="pubmed">33767446</ArticleId></ArticleIdList></Reference><Reference><Citation>Paull TT. 20 years of Mre11 biology: no end in sight. Mol. Cell. 2018;71:419&#x2013;427. doi: 10.1016/j.molcel.2018.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.06.033</ArticleId><ArticleId IdType="pubmed">30057197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoa NN, et al. Mre11 is essential for the removal of lethal topoisomerase 2 covalent cleavage complexes. Mol. Cell. 2016;64:1010. doi: 10.1016/j.molcel.2016.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.11.028</ArticleId><ArticleId IdType="pubmed">27912094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wienert B, et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq. Science. 2019;364:286&#x2013;289. doi: 10.1126/science.aav9023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav9023</ArticleId><ArticleId IdType="pmc">PMC6589096</ArticleId><ArticleId IdType="pubmed">31000663</ArticleId></ArticleIdList></Reference><Reference><Citation>Salifou K, et al. Chromatin-associated MRN complex protects highly transcribing genes from genomic instability. Sci. Adv. 2021;7:eabb2947. doi: 10.1126/sciadv.abb2947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb2947</ArticleId><ArticleId IdType="pmc">PMC8139584</ArticleId><ArticleId IdType="pubmed">34020942</ArticleId></ArticleIdList></Reference><Reference><Citation>Loonstra A, et al. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc. Natl Acad. Sci. USA. 2001;98:9209&#x2013;9214. doi: 10.1073/pnas.161269798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.161269798</ArticleId><ArticleId IdType="pmc">PMC55399</ArticleId><ArticleId IdType="pubmed">11481484</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahlberg A, et al. Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing. Nat. Protoc. 2017;12:664&#x2013;682. doi: 10.1038/nprot.2017.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2017.006</ArticleId><ArticleId IdType="pubmed">28253235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooe N, Motonaga K, Kobayashi K, Saito K, Kaneko H. Functional characterization of basic helix-loop-helix-PAS type transcription factor NXF in vivo: putative involvement in an &#x201c;on demand&#x201d; neuroprotection system. J. Biol. Chem. 2009;284:1057&#x2013;1063. doi: 10.1074/jbc.M805196200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805196200</ArticleId><ArticleId IdType="pubmed">19001414</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid DA, et al. Incorporation of a nucleoside analog maps genome repair sites in postmitotic human neurons. Science. 2021;372:91&#x2013;94. doi: 10.1126/science.abb9032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb9032</ArticleId><ArticleId IdType="pmc">PMC9179101</ArticleId><ArticleId IdType="pubmed">33795458</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PB, Chen HV, Acharya D, Rando OJ, Fazzio TG. R loops regulate promoter-proximal chromatin architecture and cellular differentiation. Nat. Struct. Mol. Biol. 2015;22:999&#x2013;1007. doi: 10.1038/nsmb.3122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.3122</ArticleId><ArticleId IdType="pmc">PMC4677832</ArticleId><ArticleId IdType="pubmed">26551076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, et al. RNA-driven genetic changes in bacteria and in human cells. Mutat. Res. 2011;717:91&#x2013;98. doi: 10.1016/j.mrfmmm.2011.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mrfmmm.2011.03.016</ArticleId><ArticleId IdType="pubmed">21515292</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin H, et al. Transcript-RNA-templated DNA recombination and repair. Nature. 2014;515:436&#x2013;439. doi: 10.1038/nature13682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13682</ArticleId><ArticleId IdType="pmc">PMC4899968</ArticleId><ArticleId IdType="pubmed">25186730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahrour MH, et al. Whole-exome sequencing and homozygosity analysis implicate depolarization-regulated neuronal genes in autism. PLoS Genet. 2012;8:e1002635. doi: 10.1371/journal.pgen.1002635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002635</ArticleId><ArticleId IdType="pmc">PMC3325173</ArticleId><ArticleId IdType="pubmed">22511880</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert J, et al. De novo KAT5 variants cause a syndrome with recognizable facial dysmorphisms, cerebellar atrophy, sleep disturbance, and epilepsy. Am. J. Hum. Genet. 2020;107:564&#x2013;574. doi: 10.1016/j.ajhg.2020.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2020.08.002</ArticleId><ArticleId IdType="pmc">PMC7477011</ArticleId><ArticleId IdType="pubmed">32822602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell S, et al. Mutations in ACTL6B cause neurodevelopmental deficits and epilepsy and lead to loss of dendrites in human neurons. Am. J. Hum. Genet. 2019;104:815&#x2013;834. doi: 10.1016/j.ajhg.2019.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2019.03.022</ArticleId><ArticleId IdType="pmc">PMC6507050</ArticleId><ArticleId IdType="pubmed">31031012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, et al. SIRT6 is responsible for more efficient DNA double-strand break repair in long-lived species. Cell. 2019;177:622&#x2013;638.e22. doi: 10.1016/j.cell.2019.03.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.03.043</ArticleId><ArticleId IdType="pmc">PMC6499390</ArticleId><ArticleId IdType="pubmed">31002797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zullo JM, et al. Regulation of lifespan by neural excitation and REST. Nature. 2019;574:359&#x2013;364. doi: 10.1038/s41586-019-1647-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1647-8</ArticleId><ArticleId IdType="pmc">PMC6893853</ArticleId><ArticleId IdType="pubmed">31619788</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher JB, et al. Depletion of Tip60 from in vivo cardiomyocytes increases myocyte density, followed by cardiac dysfunction, myocyte fallout and lethality. PLoS ONE. 2016;11:e0164855. doi: 10.1371/journal.pone.0164855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164855</ArticleId><ArticleId IdType="pmc">PMC5074524</ArticleId><ArticleId IdType="pubmed">27768769</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PB, et al. Hdac6 regulates Tip60-p400 function in stem cells. eLife. 2013;2:e01557. doi: 10.7554/eLife.01557.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.01557</ArticleId><ArticleId IdType="pmc">PMC3843111</ArticleId><ArticleId IdType="pubmed">24302573</ArticleId></ArticleIdList></Reference><Reference><Citation>Buis J, Stoneham T, Spehalski E, Ferguson DO. Mre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2. Nat. Struct. Mol. Biol. 2012;19:246&#x2013;252. doi: 10.1038/nsmb.2212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2212</ArticleId><ArticleId IdType="pmc">PMC3272152</ArticleId><ArticleId IdType="pubmed">22231403</ArticleId></ArticleIdList></Reference><Reference><Citation>Buis J, et al. Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation. Cell. 2008;135:85&#x2013;96. doi: 10.1016/j.cell.2008.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.08.015</ArticleId><ArticleId IdType="pmc">PMC2645868</ArticleId><ArticleId IdType="pubmed">18854157</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo A, et al. Epigenomic signatures of neuronal diversity in the mammalian brain. Neuron. 2015;86:1369&#x2013;1384. doi: 10.1016/j.neuron.2015.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.05.018</ArticleId><ArticleId IdType="pmc">PMC4499463</ArticleId><ArticleId IdType="pubmed">26087164</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth K, Bito H, Tsien RW. Signaling from synapse to nucleus: postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity. Neuron. 1996;16:89&#x2013;101. doi: 10.1016/S0896-6273(00)80026-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80026-4</ArticleId><ArticleId IdType="pubmed">8562094</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel-Sieler C, et al. Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proc. Natl Acad. Sci. USA. 2004;101:13648&#x2013;13653. doi: 10.1073/pnas.0405310101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0405310101</ArticleId><ArticleId IdType="pmc">PMC518807</ArticleId><ArticleId IdType="pubmed">15347806</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods. 2013;10:1213&#x2013;1218. doi: 10.1038/nmeth.2688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2688</ArticleId><ArticleId IdType="pmc">PMC3959825</ArticleId><ArticleId IdType="pubmed">24097267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hainer SJ, Fazzio TG. High-resolution chromatin profiling using CUT&amp;RUN. Curr. Protoc. Mol. Biol. 2019;126:e85. doi: 10.1002/cpmb.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpmb.85</ArticleId><ArticleId IdType="pmc">PMC6422702</ArticleId><ArticleId IdType="pubmed">30688406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong N, John S, Nussenzweig A, Canela A. END-seq: an unbiased, high-resolution, and genome-wide approach to map DNA double-strand breaks and resection in human cells. Methods Mol. Biol. 2021;2153:9&#x2013;31. doi: 10.1007/978-1-0716-0644-5_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0644-5_2</ArticleId><ArticleId IdType="pubmed">32840769</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57&#x2013;74. doi: 10.1038/nature11247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11247</ArticleId><ArticleId IdType="pmc">PMC3439153</ArticleId><ArticleId IdType="pubmed">22955616</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140. doi: 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114&#x2013;2120. doi: 10.1093/bioinformatics/btu170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene PJ, Henikoff JG, Henikoff S. Targeted in situ genome-wide profiling with high efficiency for low cell numbers. Nat. Protoc. 2018;13:1006&#x2013;1019. doi: 10.1038/nprot.2018.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2018.015</ArticleId><ArticleId IdType="pubmed">29651053</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923&#x2013;930. doi: 10.1093/bioinformatics/btt656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. &amp; Peterson, H. gprofiler2&#x2014;an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res10.12688/f1000research.24956.2 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859841</ArticleId><ArticleId IdType="pubmed">33564394</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888&#x2013;1902.e21. doi: 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 2014;32:381&#x2013;386. doi: 10.1038/nbt.2859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2859</ArticleId><ArticleId IdType="pmc">PMC4122333</ArticleId><ArticleId IdType="pubmed">24658644</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Systems. 2019;8:329&#x2013;337.e4. doi: 10.1016/j.cels.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2019.03.003</ArticleId><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr. Protoc. Mol. Biol. 2015;109:21.29.1&#x2013;21.29.9. doi: 10.1002/0471142727.mb2129s109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142727.mb2129s109</ArticleId><ArticleId IdType="pmc">PMC4374986</ArticleId><ArticleId IdType="pubmed">25559105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol. 2008;9:R137. doi: 10.1186/gb-2008-9-9-r137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2008-9-9-r137</ArticleId><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Meers MP, Tenenbaum D, Henikoff S. Peak calling by Sparse Enrichment Analysis for CUT&amp;RUN chromatin profiling. Epigenetics Chromatin. 2019;12:42. doi: 10.1186/s13072-019-0287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13072-019-0287-4</ArticleId><ArticleId IdType="pmc">PMC6624997</ArticleId><ArticleId IdType="pubmed">31300027</ArticleId></ArticleIdList></Reference><Reference><Citation>Machanick P, Bailey TL. MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics. 2011;27:1696&#x2013;1697. doi: 10.1093/bioinformatics/btr189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr189</ArticleId><ArticleId IdType="pmc">PMC3106185</ArticleId><ArticleId IdType="pubmed">21486936</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36797418</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2157-846X</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature biomedical engineering</Title><ISOAbbreviation>Nat Biomed Eng</ISOAbbreviation></Journal><ArticleTitle>Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease.</ArticleTitle><Pagination><StartPage>629</StartPage><EndPage>646</EndPage><MedlinePgn>629-646</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41551-023-01007-3</ELocationID><Abstract><AbstractText>The monogenic nature of Huntington's disease (HD) and other neurodegenerative diseases caused by the expansion of glutamine-encoding CAG repeats makes them particularly amenable to gene therapy. Here we show the feasibility of replacing expanded CAG repeats in the mutant HTT allele with a normal CAG repeat in genetically engineered pigs mimicking the selective neurodegeneration seen in patients with HD. A single intracranial or intravenous injection of adeno-associated virus encoding for Cas9, a single-guide RNA targeting the HTT gene, and donor DNA containing the normal CAG repeat led to the depletion of mutant HTT in the animals and to substantial reductions in the dysregulated expression and neurotoxicity of mutant HTT and in neurological symptoms. Our findings support the further translational development of virally delivered Cas9-based gene therapies for the treatment of genetic neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Sen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China. 231yansen@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yingqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Caijuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhaoming</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>China-New Zealand Joint Laboratory on Biomedicine and Health, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiawei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Zhuchi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>China-New Zealand Joint Laboratory on Biomedicine and Health, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chunhui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yizhi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xichen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Bofeng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-3362-3063</Identifier><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Weien</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Liangxue</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5256-6802</Identifier><AffiliationInfo><Affiliation>China-New Zealand Joint Laboratory on Biomedicine and Health, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China. lai_liangxue@gibh.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Jiang</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China. xjli33@jnu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shihua</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1775-6536</Identifier><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China. lishihualis@jnu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Biomed Eng</MedlineTA><NlmUniqueID>101696896</NlmUniqueID><ISSNLinking>2157-846X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36797418</ArticleId><ArticleId IdType="doi">10.1038/s41551-023-01007-3</ArticleId><ArticleId IdType="pii">10.1038/s41551-023-01007-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 1, 15005 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">27188817</ArticleId><ArticleId IdType="doi">10.1038/nrdp.2015.5</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman, J. M., De Jager, P. L. &amp; Feany, M. B. Parkinson&#x2019;s disease: genetics and pathogenesis. Annu. Rev. Pathol. 6, 193&#x2013;222 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21034221</ArticleId><ArticleId IdType="doi">10.1146/annurev-pathol-011110-130242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims, R., Hill, M. &amp; Williams, J. The multiplex model of the genetics of Alzheimer&#x2019;s disease. Nat. Neurosci. 23, 311&#x2013;322 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32112059</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0599-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray, T. Ageing, neurodegeneration and brain rejuvenation. Nature 539, 180&#x2013;186 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27830812</ArticleId><ArticleId IdType="pmc">5172605</ArticleId><ArticleId IdType="doi">10.1038/nature20411</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunting, E. L., Hamilton, J. &amp; Tabrizi, S. J. Polyglutamine diseases. Curr. Opin. Neurobiol. 72, 39&#x2013;47 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34488036</ArticleId><ArticleId IdType="doi">10.1016/j.conb.2021.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman, A. P., Shakkottai, V. G. &amp; Albin, R. L. Polyglutamine repeats in neurodegenerative diseases. Annu. Rev. Pathol. 14, 1&#x2013;27 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30089230</ArticleId><ArticleId IdType="doi">10.1146/annurev-pathmechdis-012418-012857</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr, H. T. &amp; Zoghbi, H. Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575&#x2013;621 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId><ArticleId IdType="doi">10.1146/annurev.neuro.29.051605.113042</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronin, N. &amp; DiFiglia, M. Huntingtin-lowering strategies in Huntington&#x2019;s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov. Disord. 29, 1455&#x2013;1461 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25164989</ArticleId><ArticleId IdType="doi">10.1002/mds.26020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, C. F., Krainer, A. R. &amp; Cleveland, D. W. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu. Rev. Neurosci. 42, 385&#x2013;406 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31283897</ArticleId><ArticleId IdType="pmc">7427431</ArticleId><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington&#x2019;s disease. N. Engl. J. Med. 380, 2307&#x2013;2316 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31059641</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1900907</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyfe, I. Antisense oligonucleotides improve cognitive function in HD model. Nat. Rev. Neurol. 14, 690&#x2013;691 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30356156</ArticleId><ArticleId IdType="doi">10.1038/s41582-018-0096-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington&#x2019;s disease by transient repression of huntingtin synthesis. Neuron 74, 1031&#x2013;1044 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22726834</ArticleId><ArticleId IdType="pmc">3383626</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2012.05.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell, A. L. et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington&#x2019;s disease. Sci. Transl. Med. 10, eaar3959 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30282695</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aar3959</ArticleId></ArticleIdList></Reference><Reference><Citation>Franich, N. R. et al. AAV vector&#x2013;mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington&#x2019;s disease. Mol. Ther. 16, 947&#x2013;956 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18388917</ArticleId><ArticleId IdType="doi">10.1038/mt.2008.50</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos, C. A. et al. in Polyglutamine Disorders (eds N&#xf3;brega, C. &amp; Pereira de Almeida, L.) 395&#x2013;438 (Springer, 2018).</Citation></Reference><Reference><Citation>McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington&#x2019;s disease. Mol. Ther. 19, 2152&#x2013;2162 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22031240</ArticleId><ArticleId IdType="pmc">3242667</ArticleId><ArticleId IdType="doi">10.1038/mt.2011.219</ArticleId></ArticleIdList></Reference><Reference><Citation>Spronck, E. A. et al. AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models. Mol. Ther. Methods Clin. Dev. 13, 334&#x2013;343 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30984798</ArticleId><ArticleId IdType="pmc">6446047</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2019.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Vall&#xe8;s, A. et al. Widespread and sustained target engagement in Huntington&#x2019;s disease minipigs upon intrastriatal microRNA-based gene therapy. Sci. Transl. Med. 13, eabb8920 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33827977</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abb8920</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert, M., Blandel, F., Leumann, C., Garcia, L. &amp; Goyenvalle, A. Lowering mutant huntingtin using tricyclo-DNA antisense oligonucleotides as a therapeutic approach for Huntington&#x2019;s disease. Nucleic Acid Ther. 29, 256&#x2013;265 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31184975</ArticleId><ArticleId IdType="doi">10.1089/nat.2018.0775</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, A. C. et al. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain 143, 407&#x2013;429 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31738395</ArticleId><ArticleId IdType="doi">10.1093/brain/awz328</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingwell, K. Double setback for ASO trials in Huntington disease. Nat. Rev. Drug Discov. 20, 412&#x2013;413 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34012000</ArticleId><ArticleId IdType="doi">10.1038/d41573-021-00088-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, Y. et al. Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer&#x2019;s disease alleviates amyloid-related pathologies in mice. Nat. Biomed. Eng. 6, 168&#x2013;180 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34312508</ArticleId><ArticleId IdType="doi">10.1038/s41551-021-00759-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekman, F. K. et al. CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington&#x2019;s disease mouse model. Mol. Ther. Nucleic Acids 17, 829&#x2013;839 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31465962</ArticleId><ArticleId IdType="pmc">6717077</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2019.07.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington&#x2019;s disease. J. Clin. Invest. 127, 2719&#x2013;2724 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28628038</ArticleId><ArticleId IdType="pmc">5490741</ArticleId><ArticleId IdType="doi">10.1172/JCI92087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, W., Li, S. &amp; Li, X.-J. A CRISPR monkey model unravels a unique function of PINK1 in primate brains. Mol. Neurodegener. 14, 17 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31046796</ArticleId><ArticleId IdType="pmc">6498691</ArticleId><ArticleId IdType="doi">10.1186/s13024-019-0321-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. et al. Atypical behaviour and connectivity in SHANK3-mutant macaques. Nature 570, 326&#x2013;331 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31189958</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1278-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedbrook, C. N., Deverman, B. E. &amp; Gradinaru, V. Viral strategies for targeting the central and peripheral nervous systems. Annu.Rev. Neurosci. 41, 323&#x2013;348 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29709207</ArticleId><ArticleId IdType="doi">10.1146/annurev-neuro-080317-062048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172&#x2013;1179 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28671695</ArticleId><ArticleId IdType="pmc">5529245</ArticleId><ArticleId IdType="doi">10.1038/nn.4593</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204&#x2013;209 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26829320</ArticleId><ArticleId IdType="pmc">5088052</ArticleId><ArticleId IdType="doi">10.1038/nbt.3440</ArticleId></ArticleIdList></Reference><Reference><Citation>Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106&#x2013;115 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34887588</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00969-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunney, J. K. et al. Importance of the pig as a human biomedical model. Sci. Transl. Med. 13, eabd5758 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34818055</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abd5758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind, N. M. et al. The use of pigs in neuroscience: modeling brain disorders. Neurosci. Biobehav. Rev. 31, 728&#x2013;751 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17445892</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2007.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti, A. et al. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat. Med. 26, 207&#x2013;214 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31988462</ArticleId><ArticleId IdType="pmc">7212064</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0738-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, S. et al. A Huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington&#x2019;s disease. Cell 173, 989&#x2013;1002.e13 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29606351</ArticleId><ArticleId IdType="pmc">5935586</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2018.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59&#x2013;65 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19098898</ArticleId><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredsson, F. P., Rising, A. C. &amp; Mandel, R. J. AAV9: a potential blood-brain barrier buster. Mol. Ther. 17, 403&#x2013;405 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19247366</ArticleId><ArticleId IdType="pmc">2835088</ArticleId><ArticleId IdType="doi">10.1038/mt.2009.15</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayton, R. D., Wang, D. B. &amp; Klein, R. L. The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin. Biol. Ther. 12, 757&#x2013;766 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22519910</ArticleId><ArticleId IdType="pmc">3361729</ArticleId><ArticleId IdType="doi">10.1517/14712598.2012.681463</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry, E. &amp; Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839&#x2013;862 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30844402</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir, J. et al. Targeted disruption of the Huntington&#x2019;s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811&#x2013;823 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7774020</ArticleId><ArticleId IdType="doi">10.1016/0092-8674(95)90542-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitlin, S., Liu, J.-P., Chapman, D. L., Papaioannou, V. E. &amp; Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington&#x2019;s disease gene homologue. Nat. Genet. 11, 155&#x2013;163 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7550343</ArticleId><ArticleId IdType="doi">10.1038/ng1095-155</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner, A., Dragatsis, I., Zeitlin, S. &amp; Goldowitz, D. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol. Neurobiol. 28, 259&#x2013;275 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14709789</ArticleId><ArticleId IdType="doi">10.1385/MN:28:3:259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G., Liu, X., Gaertig, M. A., Li, S. &amp; Li, X.-J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl Acad. Sci. USA 113, 3359&#x2013;3364 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26951659</ArticleId><ArticleId IdType="pmc">4812735</ArticleId><ArticleId IdType="doi">10.1073/pnas.1524575113</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi, S. J., Ghosh, R. &amp; Leavitt, B. R. Huntingtin lowering strategies for disease modification in Huntington&#x2019;s disease. Neuron 102, 899 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31121127</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaemmerer, W. F. &amp; Grondin, R. C. The effects of huntingtin-lowering: what do we know so far? Degener. Neurol. Neuromuscul. Dis. 9, 3&#x2013;17 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30881191</ArticleId><ArticleId IdType="pmc">6413743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox, D. B. T., Platt, R. J. &amp; Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121&#x2013;131 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25654603</ArticleId><ArticleId IdType="pmc">4492683</ArticleId><ArticleId IdType="doi">10.1038/nm.3793</ArticleId></ArticleIdList></Reference><Reference><Citation>Salsman, J. &amp; Dellaire, G. Precision genome editing in the CRISPR era. Biochem. Cell Biol. 95, 187&#x2013;201 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28177771</ArticleId><ArticleId IdType="doi">10.1139/bcb-2016-0137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, C.-E. et al. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol. 181, 803&#x2013;816 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18504298</ArticleId><ArticleId IdType="pmc">2396813</ArticleId><ArticleId IdType="doi">10.1083/jcb.200710158</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers, M. M. et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington&#x2019;s disease minipig model. Mol. Ther. 26, 2163&#x2013;2177 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30007561</ArticleId><ArticleId IdType="pmc">6127509</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.06.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder, P. et al. Integrated genomics and proteomics define huntingtin CAG length&#x2013;dependent networks in mice. Nat. Neurosci. 19, 623&#x2013;633 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26900923</ArticleId><ArticleId IdType="pmc">5984042</ArticleId><ArticleId IdType="doi">10.1038/nn.4256</ArticleId></ArticleIdList></Reference><Reference><Citation>Malla, B., Guo, X., Senger, G., Chasapopoulou, Z. &amp; Yildirim, F. A systematic review of transcriptional dysregulation in Huntington&#x2019;s disease studied by RNA sequencing. Front. Genet. 12, 751033 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34721539</ArticleId><ArticleId IdType="pmc">8554124</ArticleId><ArticleId IdType="doi">10.3389/fgene.2021.751033</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodman, B. et al. The HdhQ150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 72, 83&#x2013;97 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17352931</ArticleId><ArticleId IdType="doi">10.1016/j.brainresbull.2006.11.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi, C. &amp; Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9&#x2013;21 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29192260</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2017.148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch, K. M. &amp; Miller, T. M. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94, 1056&#x2013;1070 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28641106</ArticleId><ArticleId IdType="pmc">5821515</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.04.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Marxreiter, F., Stemick, J. &amp; Kohl, Z. Huntingtin lowering strategies. Int. J. Mol. Sci. 21, 2146 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32245050</ArticleId><ArticleId IdType="pmc">7139361</ArticleId><ArticleId IdType="doi">10.3390/ijms21062146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitler, B. et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington&#x2019;s disease. Nat. Med. 25, 1131&#x2013;1142 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31263285</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0478-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Menalled, L. B. Knock-in mouse models of Huntington&#x2019;s disease. Neurotherapeutics 2, 465&#x2013;470 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1602/neurorx.2.3.465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauleau, P., Lapouble, E., Val-Laillet, D. &amp; Malbert, C.-H. The pig model in brain imaging and neurosurgery. Animal 3, 1138&#x2013;1151 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">22444844</ArticleId><ArticleId IdType="doi">10.1017/S1751731109004649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez, K., Dicks, N., Glanzner, W., Agellon, L. &amp; Bordignon, V. Efficacy of the porcine species in biomedical research. Front. Genet. 6, 293 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26442109</ArticleId><ArticleId IdType="pmc">4584988</ArticleId><ArticleId IdType="doi">10.3389/fgene.2015.00293</ArticleId></ArticleIdList></Reference><Reference><Citation>Klymiuk, N. et al. Tailored pig models for preclinical efficacy and safety testing of targeted therapies. Toxicol. Pathol. 44, 346&#x2013;357 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26511847</ArticleId><ArticleId IdType="doi">10.1177/0192623315609688</ArticleId></ArticleIdList></Reference><Reference><Citation>Meurens, F., Summerfield, A., Nauwynck, H., Saif, L. &amp; Gerdts, V. The pig: a model for human infectious diseases. Trends Microbiol. 20, 50&#x2013;57 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22153753</ArticleId><ArticleId IdType="doi">10.1016/j.tim.2011.11.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabst, R. The pig as a model for immunology research. Cell Tissue Res. 380, 287&#x2013;304 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32356014</ArticleId><ArticleId IdType="pmc">7223737</ArticleId><ArticleId IdType="doi">10.1007/s00441-020-03206-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Swindle, M. M., Makin, A., Herron, A. J., Clubb, F. J. &amp; Frazier, K. S. Swine as models in biomedical research and toxicology testing. Vet. Pathol. 49, 344&#x2013;356 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21441112</ArticleId><ArticleId IdType="doi">10.1177/0300985811402846</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaranch, L. et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol. Ther. 22, 329&#x2013;337 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24419081</ArticleId><ArticleId IdType="pmc">3918916</ArticleId><ArticleId IdType="doi">10.1038/mt.2013.266</ArticleId></ArticleIdList></Reference><Reference><Citation>Marc&#xf3;, S. et al. Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal. Mol. Ther. Methods Clin. Dev. 23, 370&#x2013;389 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34761052</ArticleId><ArticleId IdType="pmc">8550992</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2021.09.017</ArticleId></ArticleIdList></Reference><Reference><Citation>West, J. &amp; Gill, W. W. Genome editing in large animals. J. Equine Vet. Sci. 41, 1&#x2013;6 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27766006</ArticleId><ArticleId IdType="pmc">5067081</ArticleId><ArticleId IdType="doi">10.1016/j.jevs.2016.03.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, J., Lai, L., Ji, W. &amp; Zhou, Q. Genome editing in large animals: current status and future prospects. Natl Sci. Rev. 6, 402&#x2013;420 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">34691891</ArticleId><ArticleId IdType="pmc">8291540</ArticleId><ArticleId IdType="doi">10.1093/nsr/nwz013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton, D. K. &amp; Stevens, B. The contribution of glial cells to Huntington&#x2019;s disease pathogenesis. Neurobiol. Dis. 143, 104963 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32593752</ArticleId><ArticleId IdType="pmc">7433320</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2020.104963</ArticleId></ArticleIdList></Reference><Reference><Citation>Simhadri, V. L. et al. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol. Ther. Methods Clin. Dev. 10, 105&#x2013;112 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30073181</ArticleId><ArticleId IdType="pmc">6070699</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2018.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224&#x2013;226 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30809026</ArticleId><ArticleId IdType="pmc">6533916</ArticleId><ArticleId IdType="doi">10.1038/s41587-019-0032-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger, A. M., Lohse, M. &amp; Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114&#x2013;2120 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24695404</ArticleId><ArticleId IdType="pmc">4103590</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23104886</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe, K. L. et al. Ensembl 2021. Nucleic Acids Res. 49, D884&#x2013;D891 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33137190</ArticleId><ArticleId IdType="doi">10.1093/nar/gkaa942</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078&#x2013;2079 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19505943</ArticleId><ArticleId IdType="pmc">2723002</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btp352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25690850</ArticleId><ArticleId IdType="pmc">4643835</ArticleId><ArticleId IdType="doi">10.1038/nbt.3122</ArticleId></ArticleIdList></Reference><Reference><Citation>Love, M. I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C. et al. TBtools: an integrative toolkit developed for interactive analyses of big biological data. Mol. Plant 13, 1194&#x2013;1202 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32585190</ArticleId><ArticleId IdType="doi">10.1016/j.molp.2020.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Head, S. R. et al. Library construction for next-generation sequencing: overviews and challenges. Biotechniques https://doi.org/10.2144/000114133 (2014).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36798226</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>MS4A4A modifies the risk of Alzheimer disease by regulating lipid metabolism and immune response in a unique microglia state.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.02.06.23285545</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.02.06.23285545</ELocationID><Abstract><AbstractText>Genome-wide association studies (GWAS) have identified many modifiers of Alzheimer disease (AD) risk enriched in microglia. Two of these modifiers are common variants in the <i>MS4A</i> locus (rs1582763: protective and rs6591561: risk) and serve as major regulators of CSF sTREM2 levels. To understand their functional impact on AD, we used single nucleus transcriptomics to profile brains from carriers of these variants. We discovered a "chemokine" microglial subpopulation that is altered in <i>MS4A</i> variant carriers and for which <i>MS4A4A</i> is the major regulator. The protective variant increases <i>MS4A4A</i> expression and shifts the chemokine microglia subpopulation to an interferon state, while the risk variant suppresses <i>MS4A4A</i> expression and reduces this subpopulation of microglia. Our findings provide a mechanistic explanation for the AD variants in the <i>MS4A</i> locus. Further, they pave the way for future mechanistic studies of AD variants and potential therapeutic strategies for enhancing microglia resilience in AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>You</LastName><ForeName>Shih-Feng</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brase</LastName><ForeName>Logan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filipello</LastName><ForeName>Fabia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Abhirami K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del-Aguila</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>June</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Oliveira Albanus</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budde</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentsch</LastName><ForeName>Jen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dr&#xe4;ger</LastName><ForeName>Nina M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattler</LastName><ForeName>Sydney M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccio</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles Perkins Centre and Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cashikar</LastName><ForeName>Anil G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis School of Medicine, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118146</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG067764</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062734</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS127211</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36798226</ArticleId><ArticleId IdType="pmc">PMC9934804</ArticleId><ArticleId IdType="doi">10.1101/2023.02.06.23285545</ArticleId><ArticleId IdType="pii">2023.02.06.23285545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Novikova G. et al. Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun 12, 1610 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955030</ArticleId><ArticleId IdType="pubmed">33712570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wightman D.P., et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 53, 1276&#x2013;1282 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243600</ArticleId><ArticleId IdType="pubmed">34493870</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C., et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 54, 412&#x2013;436 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005347</ArticleId><ArticleId IdType="pubmed">35379992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle B.W., et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A. et al. Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science 366, 1134&#x2013;1139 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen D.V., Hanson J.E. &amp; Sheng M. Microglia in Alzheimer's disease. J Cell Biol 217, 459&#x2013;472 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiola I., Mantovani A. &amp; Locati M. The tetraspan MS4A family in homeostasis, immunity, and disease. Trends Immunol 42, 764&#x2013;781 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34384709</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y. et al. The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk. bioRxiv (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697053</ArticleId><ArticleId IdType="pubmed">31413141</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L. et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131, 925&#x2013;933 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y. et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Sci Transl Med 11(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697053</ArticleId><ArticleId IdType="pubmed">31413141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature genetics (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj A.C., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature genetics 43, 436&#x2013;441 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M. et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J Clin Invest 130, 4954&#x2013;4968 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W.M., et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215, 745&#x2013;760 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A. et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631&#x2013;643 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P.B., et al. INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease. Alzheimers Dement (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36524682</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M. et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease. Nat Commun 11, 6129 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704703</ArticleId><ArticleId IdType="pubmed">33257666</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M. et al. A transcriptomic atlas of aged human microglia. Nat Commun 9, 539 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajab N. et al. An integrated analysis of human myeloid cells identifies gaps in in vitro models of in vivo biology. Stem Cell Reports 16, 1629&#x2013;1643 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8190595</ArticleId><ArticleId IdType="pubmed">33989517</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan A. &amp; Reiner O. Linking cytoplasmic dynein and transport of Rab8 vesicles to the midbody during cytokinesis by the doublecortin domain-containing 5 protein. J Cell Sci 124, 3989&#x2013;4000 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22159412</ArticleId></ArticleIdList></Reference><Reference><Citation>Garlanda C., Bottazzi B., Magrini E., Inforzato A. &amp; Mantovani A. PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. Physiol Rev 98, 623&#x2013;639 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985957</ArticleId><ArticleId IdType="pubmed">29412047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ham D.W., et al. Chronic Toxoplasma gondii Infection Alleviates Experimental Autoimmune Encephalomyelitis by the Immune Regulation Inducing Reduction in IL-17A/Th17 Via Upregulation of SOCS3. Neurotherapeutics 18, 430&#x2013;447 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116467</ArticleId><ArticleId IdType="pubmed">33205383</ArticleId></ArticleIdList></Reference><Reference><Citation>Stravalaci M. et al. Control of Complement Activation by the Long Pentraxin PTX3: Implications in Age-Related Macular Degeneration. Front Pharmacol 11, 591908 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725797</ArticleId><ArticleId IdType="pubmed">33324220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ummenthum K. et al. Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease. Eur J Immunol 46, 701&#x2013;711 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26576501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomaru H. et al. Fosb gene products contribute to excitotoxic microglial activation by regulating the expression of complement C5a receptors in microglia. Glia 62, 1284&#x2013;1298 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090226</ArticleId><ArticleId IdType="pubmed">24771617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M.Y., et al. 25-Hydroxycholesterol amplifies microglial IL-1beta production in an apoE isoform-dependent manner. J Neuroinflammation 17, 192 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298825</ArticleId><ArticleId IdType="pubmed">32552741</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond T.R., et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50, 253&#x2013;271 e256 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H. et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T., Sankowski R., Staszewski O. &amp; Prinz M. Microglia Heterogeneity in the Single-Cell Era. Cell Rep 30, 1271&#x2013;1281 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32023447</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H. et al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep 21, 366&#x2013;380 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila J.L., et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers Res Ther 11, 71 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Brase L. et al. A landscape of the genetic and cellular heterogeneity in Alzheimer disease. medRxiv, 2021.2011.2030.21267072 (2021).</Citation></Reference><Reference><Citation>Da Mesquita S. et al. Meningeal lymphatics affect microglia responses and anti-Abeta immunotherapy. Nature 593, 255&#x2013;260 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817786</ArticleId><ArticleId IdType="pubmed">33911285</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli R.C., et al. Microglia states and nomenclature: A field at its crossroads. Neuron 110, 3458&#x2013;3483 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9999291</ArticleId><ArticleId IdType="pubmed">36327895</ArticleId></ArticleIdList></Reference><Reference><Citation>Drager N.M., et al. A CRISPRi/a platform in human iPSC-derived microglia uncovers regulators of disease states. Nat Neurosci 25, 1149&#x2013;1162 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9448678</ArticleId><ArticleId IdType="pubmed">35953545</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaraju S. et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease. Mol Neurodegener 13, 24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963076</ArticleId><ArticleId IdType="pubmed">29784049</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J. et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496&#x2013;502 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6434952</ArticleId><ArticleId IdType="pubmed">30787437</ArticleId></ArticleIdList></Reference><Reference><Citation>La Manno G., , et al. RNA velocity of single cells. Nature 560, 494&#x2013;498 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6130801</ArticleId><ArticleId IdType="pubmed">30089906</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk D. et al. Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. Cell 174, 716&#x2013;729 e727 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771278</ArticleId><ArticleId IdType="pubmed">29961576</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan A.B., et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res 47, W212&#x2013;W224 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602523</ArticleId><ArticleId IdType="pubmed">31114921</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.L., et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nat Neurosci 20, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimenova A.A., et al. Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response. Neurobiol Dis 148, 105217 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808757</ArticleId><ArticleId IdType="pubmed">33301878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929&#x2013;1935 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171, 1437&#x2013;1452 e1417 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990023</ArticleId><ArticleId IdType="pubmed">29195078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal R. et al. MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells. Immunol Cell Biol 95, 611&#x2013;619 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28303902</ArticleId></ArticleIdList></Reference><Reference><Citation>Feringa F.M. &amp; van der Kant R. Cholesterol and Alzheimer's Disease; From Risk Genes to Pathological Effects. Front Aging Neurosci 13, 690372 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8264368</ArticleId><ArticleId IdType="pubmed">34248607</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A.M., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467&#x2013;1472 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W.J., et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 90, 8098&#x2013;8102 (1993).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L. et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science 359, 684&#x2013;688 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29301957</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing J., Titus A.R. &amp; Humphrey M.B. The TREM2-DAP12 signaling pathway in Nasu- Hakola disease: a molecular genetics perspective. Res Rep Biochem 5, 89&#x2013;100 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605443</ArticleId><ArticleId IdType="pubmed">26478868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland T.K., et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell 170, 649&#x2013;663 e613 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent A.A., et al. TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron 105, 837&#x2013;854 e839 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Adorni M.P., Ruscica M., Ferri N., Bernini F. &amp; Zimetti F. Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. Front Aging Neurosci 11, 120 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538876</ArticleId><ArticleId IdType="pubmed">31178716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimetti F. et al. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. J Alzheimers Dis 55, 315&#x2013;320 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27662294</ArticleId></ArticleIdList></Reference><Reference><Citation>Apaijai N. et al. Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation. J Am Heart Assoc 8, e010838 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497363</ArticleId><ArticleId IdType="pubmed">30636486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M. et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 11(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H. et al. Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactions. Atherosclerosis 237, 443&#x2013;452 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25463072</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold E.S., et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc Natl Acad Sci U S A 111, 10666&#x2013;10671 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115544</ArticleId><ArticleId IdType="pubmed">24994901</ArticleId></ArticleIdList></Reference><Reference><Citation>Koarai A. et al. 25-Hydroxycholesterol enhances cytokine release and Toll-like receptor 3 response in airway epithelial cells. Respir Res 13, 63 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460764</ArticleId><ArticleId IdType="pubmed">22849850</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosklint T., Ohlsson B.G., Wiklund O., Noren K. &amp; Hulten L.M. Oxysterols induce interleukin-1beta production in human macrophages. Eur J Clin Invest 32, 35&#x2013;42 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11851725</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. et al. 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an LXR-dependent mechanism. J Lipid Res 59, 439&#x2013;451 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832929</ArticleId><ArticleId IdType="pubmed">29298812</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams C.M., et al. Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J Biol Chem 279, 52772&#x2013;52780 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15452130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashikar A.G., et al. Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol. bioRxiv, 2022.2005.2003.490494 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10060115</ArticleId><ArticleId IdType="pubmed">36849076</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang E.V., McDonald J.G., Russell D.W. &amp; Cyster J.G. Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation. Cell 171, 1057&#x2013;1071 e1011 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5693620</ArticleId><ArticleId IdType="pubmed">29033131</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboldi A. et al. Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 345, 679&#x2013;684 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289637</ArticleId><ArticleId IdType="pubmed">25104388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang J. et al. 25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome. Nat Commun 7, 13129 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5093305</ArticleId><ArticleId IdType="pubmed">27779191</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmin F. et al. Oxysterols regulate encephalitogenic CD4(+) T cell trafficking during central nervous system autoimmunity. J Autoimmun 56, 45&#x2013;55 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25456971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Schneider J.A., Arvanitakis Z. &amp; Wilson R.S. Overview and findings from the religious orders study. Curr Alzheimer Res 9, 628&#x2013;645 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., et al. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 9, 646&#x2013;663 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M. et al. Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Sci Data 3, 160089 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., et al. Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10, 43 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5992755</ArticleId><ArticleId IdType="pubmed">29880032</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M.I., Huber W. &amp; Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz M. et al. GeneMANIA update 2018. Nucleic Acids Res 46, W60&#x2013;W64 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030815</ArticleId><ArticleId IdType="pubmed">29912392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov M.V., et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90&#x2013;97 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Bardes E.E., Aronow B.J. &amp; Jegga A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37, W305&#x2013;311 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703978</ArticleId><ArticleId IdType="pubmed">19465376</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W., Pant G., Bhavnasi Y.K., Blanchard S.G. Jr. &amp; Brouwer C. Pathview Web: user friendly pathway visualization and data integration. Nucleic Acids Res 45, W501&#x2013;W508 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570256</ArticleId><ArticleId IdType="pubmed">28482075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollie E. Brooks K.K., van Benthem Koen J., Magnusson Ami, Berg Casper W., Nielsen Anders, Skaug Hans J., Machler Martin and Bolker Benjamin M.. glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated Generalized Linear Mixed Modeling. The R Journal 9, 378&#x2013;400 (2017).</Citation></Reference><Reference><Citation>Li Z., et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol 139, 45&#x2013;61 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaujoux R. &amp; Seoighe C. CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics 29, 2211&#x2013;2212 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23825367</ArticleId></ArticleIdList></Reference><Reference><Citation>Luecken M.D. &amp; Theis F.J. Current best practices in single-cell RNA-seq analysis: a tutorial. Mol Syst Biol 15, e8746 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582955</ArticleId><ArticleId IdType="pubmed">31217225</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L., Lun A.T.L., Morgan M.D. &amp; Marioni J.C. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol 36, 421&#x2013;427 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152897</ArticleId><ArticleId IdType="pubmed">29608177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36805154</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Trends in Postmortem Neurodegenerative and Cerebrovascular Neuropathologies Over 25 Years.</ArticleTitle><Pagination><StartPage>370</StartPage><EndPage>376</EndPage><MedlinePgn>370-376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.5416</ELocationID><Abstract><AbstractText Label="IMPORTANCE">With rapid aging of the US population, understanding trends over time in dementia occurrence is essential to public health planning and intervention; this understanding includes trends in neuropathologies underlying clinical dementia.</AbstractText><AbstractText Label="OBJECTIVE">To characterize trends in pathways underlying dementia by examining prevalence of postmortem neuropathologies in birth cohorts across 25 years.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Two longitudinal cohorts, the Religious Orders Study and the Rush Memory and Aging Project, with autopsy data from 1997 to 2022 with up to 27 years follow-up were analyzed. Deceased individuals with complete postmortem neuropathology evaluations were included, and 177 individuals with most distant (&lt;1905) or recent (&gt;1930) years of birth were excluded.</AbstractText><AbstractText Label="EXPOSURES">Four categories of year of birth: 1905-1914, 1915-1919, 1920-1924, and 1925-1930.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Outcomes included pathologic diagnosis of Alzheimer disease (AD), global AD pathology, amyloid load, tau tangles, neocortical Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy neuropathological change, atherosclerosis, arteriolosclerosis, gross chronic infarcts, and chronic microinfarcts. For comparison, pathologies in each birth epoch were age-standardized to age distribution of the cohorts. &#x3c7;2 Tests were used for categorical outcomes, and analysis of variance was used to compare means across birth epochs.</AbstractText><AbstractText Label="RESULTS">Overall, 1554 participants were examined (510 [33%] male; median [range] age at death, 90 [66-108] years). Participants were distributed fairly evenly across birth epochs (1905-1914: n&#x2009;=&#x2009;374; 1915-1919: n&#x2009;=&#x2009;360; 1920-1924: n&#x2009;=&#x2009;466; 1925-1930: n&#x2009;=&#x2009;354). Across year of birth groups, no differences were found in prevalence of pathologic AD diagnosis; age-standardized prevalence fluctuated between 62% and 68% in the birth cohorts (&#x3c7;2 test: P&#x2009;=&#x2009;.76 across birth epochs). Similarly, no differences were found in mean levels of global AD pathology, although there was greater density specifically of tau tangles in later birth cohorts (eg, age-standardized mean [SD], 1.53 [1.20] years for the 1905-1914 cohort and 1.87 [1.47] years for the 1925-1930 cohort; analysis of variance test: P&#x2009;=&#x2009;.01 across birth cohorts). There were no differences over time in other neurodegenerative pathologies. In contrast, atherosclerosis and arteriosclerosis were dramatically lower over time; for example, age-standardized prevalence of moderate to severe atherosclerosis ranged from 54% among those born from 1905-1914 to 22% for 1925-1930 (&#x3c7;2 test: P&#x2009;&lt;&#x2009;.001 across birth epochs).</AbstractText><AbstractText Label="CONCLUSION AND RELEVANCE">In this study, few differences in neurodegenerative pathologies were found, but there may be worse levels of tau tangles across birth cohorts over 25 years. This indicates that any improvements over time in clinical dementia observed by cohorts are likely in part associated with improved resilience to pathology rather than reduced AD pathology. Finally, vessel pathologies were markedly lower over birth cohorts, indicating the assocation with brain health of populationwide improvements in several vascular risk factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grodstein</LastName><ForeName>Francine</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leurgans</LastName><ForeName>Sue E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capuano</LastName><ForeName>Ana W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000723354">limbic-predominant age-related TDP-43 encephalopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Jul;19(7):389-390. doi: 10.1038/s41582-023-00812-3.</RefSource><PMID Version="1">37173593</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Leurgans and Capuano reported grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36805154</ArticleId><ArticleId IdType="pmc">PMC9941972</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.5416</ArticleId><ArticleId IdType="pii">2801809</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Satizabal CL, Beiser AS, Chouraki V, Ch&#xea;ne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart study. N Engl J Med. 2016;374(6):523-532. doi:10.1056/NEJMoa1504327</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504327</ArticleId><ArticleId IdType="pmc">PMC4943081</ArticleId><ArticleId IdType="pubmed">26863354</ArticleId></ArticleIdList></Reference><Reference><Citation>Derby CA, Katz MJ, Lipton RB, Hall CB. Trends in dementia incidence in a birth cohort analysis of the Einstein Aging study. JAMA Neurol. 2017;74(11):1345-1351. doi:10.1001/jamaneurol.2017.1964</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1964</ArticleId><ArticleId IdType="pmc">PMC5710583</ArticleId><ArticleId IdType="pubmed">28873124</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom SE, Phadke M, Hubbard RA, Crane PK, Stern Y, Larson EB. Association of demographic and early-life socioeconomic factors by birth cohort with dementia incidence among US adults born between 1893 and 1949. JAMA Netw Open. 2020;3(7):e2011094. doi:10.1001/jamanetworkopen.2020.11094</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.11094</ArticleId><ArticleId IdType="pmc">PMC8794045</ArticleId><ArticleId IdType="pubmed">32716513</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer&#x2019;s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement. 2019;15(1):1-7. doi:10.1016/j.jalz.2018.07.216</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.216</ArticleId><ArticleId IdType="pmc">PMC6531287</ArticleId><ArticleId IdType="pubmed">30195482</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Bennett EE, Turner RW, et al. . Trends in relative incidence and prevalence of dementia across non-Hispanic Black and White individuals in the United States, 2000-2016. JAMA Neurol. 2021;78(3):275-284. doi:10.1001/jamaneurol.2020.4471</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4471</ArticleId><ArticleId IdType="pmc">PMC7953306</ArticleId><ArticleId IdType="pubmed">33252617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YT, Beiser AS, Breteler MMB, et al. . The changing prevalence and incidence of dementia over time: current evidence. Nat Rev Neurol. 2017;13(6):327-339. doi:10.1038/nrneurol.2017.63</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.63</ArticleId><ArticleId IdType="pubmed">28497805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Satizabal CL, Seshadri S. Role of improved vascular health in the declining incidence of dementia. Stroke. 2017;48(7):2013-2020. doi:10.1161/STROKEAHA.117.013369</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.117.013369</ArticleId><ArticleId IdType="pmc">PMC5505318</ArticleId><ArticleId IdType="pubmed">28596460</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: trends in dementia incidence since 1990 in the Rotterdam study. Neurology. 2012;78(19):1456-1463. doi:10.1212/WNL.0b013e3182553be6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553be6</ArticleId><ArticleId IdType="pubmed">22551732</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda H, Sasaki K, Hamasaki H, et al. . Trends in autopsy-verified dementia prevalence over 29 years of the Hisayama study. Neuropathology. 2016;36(4):383-387. doi:10.1111/neup.12298</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12298</ArticleId><ArticleId IdType="pubmed">26989005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamasaki H, Honda H, Okamoto T, et al. . Recent increases in hippocampal tau pathology in the aging Japanese population: the Hisayama study. J Alzheimers Dis. 2017;55(2):613-624. doi:10.3233/JAD-160521</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160521</ArticleId><ArticleId IdType="pubmed">27716666</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;vari E, Herrmann FR, Bouras C, Gold G. Amyloid deposition is decreasing in aging brains: an autopsy study of 1,599 older people. Neurology. 2014;82(4):326-331. doi:10.1212/WNL.0000000000000069</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000069</ArticleId><ArticleId IdType="pubmed">24363129</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wang T, Yu L, et al. . To what degree is late life cognitive decline driven by age-related neuropathologies? Brain. 2021;144(7):2166-2175. doi:10.1093/brain/awab092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab092</ArticleId><ArticleId IdType="pmc">PMC8370442</ArticleId><ArticleId IdType="pubmed">33742668</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83. doi:10.1002/ana.25123</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25123</ArticleId><ArticleId IdType="pmc">PMC5876116</ArticleId><ArticleId IdType="pubmed">29244218</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Keene CD, Flanagan ME, et al. . Resistance to Alzheimer disease neuropathologic changes and apparent cognitive resilience in the Nun and Honolulu-Asia aging studies. J Neuropathol Exp Neurol. 2017;76(6):458-466. doi:10.1093/jnen/nlx030</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx030</ArticleId><ArticleId IdType="pmc">PMC6334750</ArticleId><ArticleId IdType="pubmed">28499012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious orders study and rush memory and aging project. J Alzheimers Dis. 2018;64(s1):S161-S189. doi:10.3233/JAD-179939</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. . Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844. doi:10.1212/01.wnl.0000219668.47116.e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000219668.47116.e6</ArticleId><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. ; National Institute on Aging; Alzheimer&#x2019;s Association . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378-384. doi:10.1001/archneur.61.3.378</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.3.378</ArticleId><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al. . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-1124. doi:10.1212/WNL.47.5.1113</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.5.1113</ArticleId><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Yu L, Schneider JA, Arnold SE, Buchman AS, Bennett DA. Lewy bodies and olfactory dysfunction in old age. Chem Senses. 2011;36(4):367-373. doi:10.1093/chemse/bjq139</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/chemse/bjq139</ArticleId><ArticleId IdType="pmc">PMC3073534</ArticleId><ArticleId IdType="pubmed">21257733</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Wilson RS, Chen E-Y, Bennett DA, Schneider JA. TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology. 2017;88(7):653-660. doi:10.1212/WNL.0000000000003610</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003610</ArticleId><ArticleId IdType="pmc">PMC5317379</ArticleId><ArticleId IdType="pubmed">28087828</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Beckett LA, Barnes LL, et al. . Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging. 2002;17(2):179-193. doi:10.1037/0882-7974.17.2.179</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0882-7974.17.2.179</ArticleId><ArticleId IdType="pubmed">12061405</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944. doi:10.1212/WNL.34.7.939</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. GPE Discussion Series No. 31; World Health Organization. 2001.</Citation></Reference><Reference><Citation>Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. Int J Epidemiol. 2019;48(6):1815-1823. doi:10.1093/ije/dyz143</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz143</ArticleId><ArticleId IdType="pubmed">31378814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackland DT, Roccella EJ, Deutsch AF, et al. ; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Council on Functional Genomics and Translational Biology . Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45(1):315-353. doi:10.1161/01.str.0000437068.30550.cf</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.0000437068.30550.cf</ArticleId><ArticleId IdType="pmc">PMC5995123</ArticleId><ArticleId IdType="pubmed">24309587</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott CA, Li L, Rothwell PM. Diverging temporal trends in stroke incidence in younger vs older people: a systematic review and meta-analysis. JAMA Neurol. 2022;79(10):1036-1048. doi:10.1001/jamaneurol.2022.1520</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.1520</ArticleId><ArticleId IdType="pmc">PMC9364236</ArticleId><ArticleId IdType="pubmed">35943738</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol. 2012;11(3):272-282. doi:10.1016/S1474-4422(11)70307-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70307-6</ArticleId><ArticleId IdType="pmc">PMC3359329</ArticleId><ArticleId IdType="pubmed">22341035</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Leurgans SE, et al. . Attributable risk of Alzheimer&#x2019;s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85(1):114-124. doi:10.1002/ana.25380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25380</ArticleId><ArticleId IdType="pmc">PMC10128614</ArticleId><ArticleId IdType="pubmed">30421454</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge HH, Zhu J, Woltjer R, et al. ; SMART data consortium . Risk of incident clinical diagnosis of Alzheimer&#x2019;s disease-type dementia attributable to pathology-confirmed vascular disease. Alzheimers Dement. 2017;13(6):613-623. doi:10.1016/j.jalz.2016.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.11.003</ArticleId><ArticleId IdType="pmc">PMC5466467</ArticleId><ArticleId IdType="pubmed">28017827</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Crane PK, et al. . Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62(4):406-413. doi:10.1002/ana.21208</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21208</ArticleId><ArticleId IdType="pubmed">17879383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamar M, Leurgans S, Kapasi A, et al. . Complex profiles of cerebrovascular disease pathologies in the aging brain and their relationship with cognitive decline. Stroke. 2022;53(1):218-227. doi:10.1161/STROKEAHA.121.034814</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.121.034814</ArticleId><ArticleId IdType="pmc">PMC8712368</ArticleId><ArticleId IdType="pubmed">34601898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidney S, Quesenberry CP Jr, Jaffe MG, et al. . Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. 2016;1(5):594-599. doi:10.1001/jamacardio.2016.1326</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2016.1326</ArticleId><ArticleId IdType="pubmed">27438477</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Capuano AW, Lamar M, et al. . Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology. Neurology. 2018;91(6):e517-e525. doi:10.1212/WNL.0000000000005951</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005951</ArticleId><ArticleId IdType="pmc">PMC6105052</ArticleId><ArticleId IdType="pubmed">29997190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, Leurgans SE, Arvanitakis Z, Barnes LL, Bennett DA, Schneider JA. A&#x3b2; (amyloid beta) and tau tangle pathology modifies the association between small vessel disease and cortical microinfarcts. Stroke. 2021;52(3):1012-1021. doi:10.1161/STROKEAHA.120.031073</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.120.031073</ArticleId><ArticleId IdType="pmc">PMC7902459</ArticleId><ArticleId IdType="pubmed">33567873</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewster P, Barnes L, Haan M, et al. . Progress and future challenges in aging and diversity research in the United States. Alzheimers Dement. 2019;15(7):995-1003. doi:10.1016/j.jalz.2018.07.221</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.221</ArticleId><ArticleId IdType="pmc">PMC7021489</ArticleId><ArticleId IdType="pubmed">30240574</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . Stroke facts. Accessed June 6, 2022. https://www.cdc.gov/stroke/facts.htm</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36809323</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>329</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.</ArticleTitle><Pagination><StartPage>551</StartPage><EndPage>560</EndPage><MedlinePgn>551-560</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2023.0268</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Numerous studies have established the association of the common APOE &#x3b5;2 and APOE &#x3b5;4 alleles with Alzheimer disease (AD) risk across ancestries. Studies of the interaction of these alleles with other amino acid changes on APOE in non-European ancestries are lacking and may improve ancestry-specific risk prediction.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether APOE amino acid changes specific to individuals of African ancestry modulate AD risk.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Case-control study including 31&#x202f;929 participants and using a sequenced discovery sample (Alzheimer Disease Sequencing Project; stage 1) followed by 2 microarray imputed data sets derived from the Alzheimer Disease Genetic Consortium (stage 2, internal replication) and the Million Veteran Program (stage 3, external validation). This study combined case-control, family-based, population-based, and longitudinal AD cohorts, which recruited participants (1991-2022) in primarily US-based studies with 1 US/Nigerian study. Across all stages, individuals included in this study were of African ancestry.</AbstractText><AbstractText Label="EXPOSURES">Two APOE missense variants (R145C and R150H) were assessed, stratified by APOE genotype.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was AD case-control status, and secondary outcomes included age at AD onset.</AbstractText><AbstractText Label="RESULTS">Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male). In stage 2, across multiple cohorts, 1201 cases (median age, 75 [IQR, 69-81] years; 30.8% male) and 2744 controls (median age, 80 [IQR, 75-84] years; 31.4% male) were included. In stage 3, 733 cases (median age, 79.4 [IQR, 73.8-86.5] years; 97.0% male) and 19&#x202f;406 controls (median age, 71.9 [IQR, 68.4-75.8] years; 94.5% male) were included. In &#x3b5;3/&#x3b5;4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P&#x2009;=&#x2009;6.0&#x2009;&#xd7;&#x2009;10-6) and was associated with a reported younger age at AD onset (&#x3b2;, -5.87 years; 95% CI, -8.35 to -3.4 years; P&#x2009;=&#x2009;3.4&#x2009;&#xd7;&#x2009;10-6). Association with increased AD risk was replicated in stage 2 (R145C was present in 23 individuals with AD [4.7%] and 21 controls [2.7%]; OR, 2.20; 95% CI, 1.04-4.65; P&#x2009;=&#x2009;.04) and was concordant in stage 3 (R145C was present in 11 individuals with AD [3.8%] and 149 controls [2.7%]; OR, 1.90; 95% CI, 0.99-3.64; P&#x2009;=&#x2009;.051). Association with earlier AD onset was replicated in stage 2 (&#x3b2;, -5.23 years; 95% CI, -9.58 to -0.87 years; P&#x2009;=&#x2009;.02) and stage 3 (&#x3b2;, -10.15 years; 95% CI, -15.66 to -4.64 years; P&#x2009;=&#x2009;4.0&#x2009;&#xd7;&#x2009;10-4). No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this exploratory analysis, the APOE &#x3b5;3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the &#x3b5;3/&#x3b5;4 genotype. With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Guen</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut du Cerveau-Paris Brain Institute-ICM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raulin</LastName><ForeName>Ana-Caroline</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logue</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherva</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belloy</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eger</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Annabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuchenbecker</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Leary</LastName><ForeName>Justin P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merritt</LastName><ForeName>Victoria C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA San Diego Healthcare System, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panizzon</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauger</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaziano</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thornton</LastName><ForeName>Timothy A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napolioni</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zihuai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG058654</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048927</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060747</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066206</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG068753</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 CX001727</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG062602</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2020.15085</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamaneurol.2019.1456</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamaneurol.2022.1166</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="Y">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="Y">Black People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Ms Chen reported receipt of grants from Stanford Medical Scholars Research Program. Dr Merritt reported receipt of grants from Department of Veterans Affairs and salary support from the VA Clinical Science Research and Development Service. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36809323</ArticleId><ArticleId IdType="pmc">PMC9945061</ArticleId><ArticleId IdType="doi">10.1001/jama.2023.0268</ArticleId><ArticleId IdType="pii">2801680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921-923. doi:10.1126/science.8346443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, et al. . Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180-184. doi:10.1038/ng0694-180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Medway CW, Abdul-Hay S, Mims T, et al. . ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer&#x2019;s disease. Mol Neurodegener. 2014;9(1):11. doi:10.1186/1750-1326-9-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-11</ArticleId><ArticleId IdType="pmc">PMC3995879</ArticleId><ArticleId IdType="pubmed">24607147</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen Y, Belloy ME, Grenier-Boley B, et al. ; EADB, GR@ACE, DEGESCO, DemGene, GERAD, and EADI Groups . Association of rare APOE missense variants V236E and R251G with risk of Alzheimer disease. JAMA Neurol. 2022;79(7):652-663. doi:10.1001/jamaneurol.2022.1166</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.1166</ArticleId><ArticleId IdType="pmc">PMC9157381</ArticleId><ArticleId IdType="pubmed">35639372</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O&#x2019;Hare M, et al. . Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-1683. doi:10.1038/s41591-019-0611-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0611-3</ArticleId><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou Ziki MD, Strulovici-Barel Y, Hackett NR, et al. . Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations. Am J Cardiol. 2014;113(2):302-308. doi:10.1016/j.amjcard.2013.09.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2013.09.021</ArticleId><ArticleId IdType="pmc">PMC3943837</ArticleId><ArticleId IdType="pubmed">24239320</ArticleId></ArticleIdList></Reference><Reference><Citation>Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A. 1982;79(15):4696-4700. doi:10.1073/pnas.79.15.4696</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.79.15.4696</ArticleId><ArticleId IdType="pmc">PMC346743</ArticleId><ArticleId IdType="pubmed">6289314</ArticleId></ArticleIdList></Reference><Reference><Citation>de Villiers WJ, van der Westhuyzen DR, Coetzee GA, Henderson HE, Marais AD. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler Thromb Vasc Biol. 1997;17(5):865-872. doi:10.1161/01.ATV.17.5.865</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.17.5.865</ArticleId><ArticleId IdType="pubmed">9157949</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. ; Genome Aggregation Database Consortium . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Bis JC, Martin ER, et al. . The Alzheimer&#x2019;s Disease Sequencing Project: study design and sample selection. Neurol Genet. 2017;3(5):e194. doi:10.1212/NXG.0000000000000194</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000194</ArticleId><ArticleId IdType="pmc">PMC5646177</ArticleId><ArticleId IdType="pubmed">29184913</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR Jr, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202-211. doi:10.1016/j.jalz.2010.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.007</ArticleId><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646-663. doi:10.2174/156720512801322663</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322663</ArticleId><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, et al. ; Alzheimer Disease Genetics Consortium; European Alzheimer&#x2019;s Disease Initiative; Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium; Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium . Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Schmidt M, Klein HU, et al. ; Writing Group for the Alzheimer&#x2019;s Disease Genetics Consortium . Novel Alzheimer disease risk loci and pathways in African American individuals using the African Genome Resources Panel: a meta-analysis. JAMA Neurol. 2021;78(1):102-113. doi:10.1001/jamaneurol.2020.3536</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.3536</ArticleId><ArticleId IdType="pmc">PMC7573798</ArticleId><ArticleId IdType="pubmed">33074286</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaziano JM, Concato J, Brophy M, et al. . Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214-223. doi:10.1016/j.jclinepi.2015.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.09.016</ArticleId><ArticleId IdType="pubmed">26441289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherva R, Zhang R, Sahelijo N, et al. . African ancestry GWAS of dementia in a large military cohort identifies significant risk loci. Published online December 22, 2022. doi:10.1038/s41380-022-01890-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01890-3</ArticleId><ArticleId IdType="pmc">PMC10066923</ArticleId><ArticleId IdType="pubmed">36543923</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL. Improved ancestry inference using weights from external reference panels. Bioinformatics. 2013;29(11):1399-1406. doi:10.1093/bioinformatics/btt144</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt144</ArticleId><ArticleId IdType="pmc">PMC3661048</ArticleId><ArticleId IdType="pubmed">23539302</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A, Brooks LD, Durbin RM, et al. ; 1000 Genomes Project Consortium . A global reference for human genetic variation. Nature. 2015;526(7571):68-74. doi:10.1038/nature15393</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15393</ArticleId><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen Y, Belloy ME, Napolioni V, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . A novel age-informed approach for genetic association analysis in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2021;13(1):72. doi:10.1186/s13195-021-00808-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00808-5</ArticleId><ArticleId IdType="pmc">PMC8017764</ArticleId><ArticleId IdType="pubmed">33794991</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen Y, Napolioni V, Belloy ME, et al. . Common X-chromosome variants are associated with Parkinson disease risk. Ann Neurol. 2021;90(1):22-34. doi:10.1002/ana.26051</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26051</ArticleId><ArticleId IdType="pmc">PMC8601399</ArticleId><ArticleId IdType="pubmed">33583074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H, Hui Q, Lynch J, et al. ; VA Million Veteran Program . Harmonizing genetic ancestry and self-identified race/ethnicity in genome-wide association studies. Am J Hum Genet. 2019;105(4):763-772. doi:10.1016/j.ajhg.2019.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2019.08.012</ArticleId><ArticleId IdType="pmc">PMC6817526</ArticleId><ArticleId IdType="pubmed">31564439</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliun D, Harris DN, Kessler MD, et al. ; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium . Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021;590(7845):290-299. doi:10.1038/s41586-021-03205-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03205-y</ArticleId><ArticleId IdType="pmc">PMC7875770</ArticleId><ArticleId IdType="pubmed">33568819</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer&#x2019;s disease clinical trials. Alzheimers Dement (N Y). 2019;5:354-363. doi:10.1016/j.trci.2019.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.06.005</ArticleId><ArticleId IdType="pmc">PMC6690415</ArticleId><ArticleId IdType="pubmed">31417957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels AM, Rentz DM, Case M, Lauzon S, Sims JR. Integrated Alzheimer&#x2019;s Disease Rating Scale: clinically meaningful change estimates. Alzheimers Dement (N Y). 2022;8(1):e12312. doi:10.1002/trc2.12312</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12312</ArticleId><ArticleId IdType="pmc">PMC9169866</ArticleId><ArticleId IdType="pubmed">35676941</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al. ; IGAP Consortium . A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21(1):108-117. doi:10.1038/mp.2015.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.23</ArticleId><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal DB, Baumbach J, Hoffmann M, Kacprowski T, List M. A framework for modeling epistatic interaction. Bioinformatics. 2021;37(12):1708-1716. doi:10.1093/bioinformatics/btaa990</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa990</ArticleId><ArticleId IdType="pubmed">33252645</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogarten SM, Sofer T, Chen H, et al. . Genetic association testing using the GENESIS R/Bioconductor package. Bioinformatics. 2019;35(24):5346-5348. doi:10.1093/bioinformatics/btz567</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz567</ArticleId><ArticleId IdType="pmc">PMC7904076</ArticleId><ArticleId IdType="pubmed">31329242</ArticleId></ArticleIdList></Reference><Reference><Citation>Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. Genet Epidemiol. 2015;39(4):276-293. doi:10.1002/gepi.21896</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21896</ArticleId><ArticleId IdType="pmc">PMC4836868</ArticleId><ArticleId IdType="pubmed">25810074</ArticleId></ArticleIdList></Reference><Reference><Citation>Conomos MP, Laurie CA, Stilp AM, et al. . Genetic diversity and association studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet. 2016;98(1):165-184. doi:10.1016/j.ajhg.2015.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2015.12.001</ArticleId><ArticleId IdType="pmc">PMC4716704</ArticleId><ArticleId IdType="pubmed">26748518</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48. doi:10.18637/jss.v036.i03</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1-48. doi:10.18637/jss.v067.i01</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Chen JJ, Sorum AW, et al. . Tau internalization is regulated by 6-O sulfation on heparan sulfate proteoglycans (HSPGs). Sci Rep. 2018;8(1):6382. doi:10.1038/s41598-018-24904-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24904-z</ArticleId><ArticleId IdType="pmc">PMC5913225</ArticleId><ArticleId IdType="pubmed">29686391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Lopez C, Tariot PN, Caputo A, et al. . The Alzheimer&#x2019;s Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer&#x2019;s disease. Alzheimers Dement (N Y). 2019;5:216-227. doi:10.1016/j.trci.2019.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.02.005</ArticleId><ArticleId IdType="pmc">PMC6562315</ArticleId><ArticleId IdType="pubmed">31211217</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312. doi:10.1101/cshperspect.a006312</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006312</ArticleId><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz J, Kouiavskaia D, Migliorini M, et al. . The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46(8):1721-1731. doi:10.1194/jlr.M500114-JLR200</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M500114-JLR200</ArticleId><ArticleId IdType="pubmed">15863833</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott DA, Halliday GM, Garner B. Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neurosci. 2010;11:23. doi:10.1186/1471-2202-11-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-11-23</ArticleId><ArticleId IdType="pmc">PMC2837047</ArticleId><ArticleId IdType="pubmed">20170526</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagawa H, Gong JS, Jung CG, et al. . Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. J Neurosci Res. 2009;87(11):2498-2508. doi:10.1002/jnr.22073</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22073</ArticleId><ArticleId IdType="pmc">PMC3065888</ArticleId><ArticleId IdType="pubmed">19326444</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res. 1999;40(11):1933-1949. doi:10.1016/S0022-2275(20)32417-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)32417-2</ArticleId><ArticleId IdType="pubmed">10552997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36827976</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology.</ArticleTitle><Pagination><StartPage>706</StartPage><EndPage>719</EndPage><MedlinePgn>706-719</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2023.01.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(23)00015-2</ELocationID><Abstract><AbstractText>Loss of function (LoF) of TAR-DNA binding protein 43 (TDP-43) and mis-localization, together with TDP-43-positive and hyperphosphorylated inclusions, are found in post-mortem tissue of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients, including those carrying LoF variants in the progranulin gene (GRN). Modeling TDP-43 pathology has been challenging in&#xa0;vivo and in&#xa0;vitro. We present a three-dimensional induced pluripotent stem cell (iPSC)-derived paradigm-mature brain organoids (mbOrg)-composed of cortical-like-astrocytes (iA) and neurons. When devoid of GRN, mbOrgs spontaneously recapitulate TDP-43 mis-localization, hyperphosphorylation, and LoF phenotypes. Mixing and matching genotypes in mbOrgs showed that GRN<sup>-/-</sup> iA are drivers for TDP-43 pathology. Finally, we rescued TDP-43 LoF by adding exogenous progranulin, demonstrating a link between TDP-43 LoF and progranulin expression. In conclusion, we present an iPSC-derived platform that shows striking features of human TDP-43 proteinopathy and provides a tool for the mechanistic modeling of TDP-43 pathology and patient-tailored therapeutic screening for FTD and ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Majo</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA; Synapticure Inc, Chicago, IL 60612, USA. Electronic address: martina@synapticure.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koontz</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA; Synapticure Inc, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsan</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsey</LastName><ForeName>Arren</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Yien-Ming</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Kyounghee</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huinan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dr&#xe4;ger</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA; Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzales</LastName><ForeName>Santiago L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurnellas</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alector, Inc, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyaoka</LastName><ForeName>Yuichiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Regenerative Medicine Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya, Tokyo 156-8506, Japan; Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klim</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA; Neuroscience Graduate Program, University of California San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullian</LastName><ForeName>Erik M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA; Neuroscience Graduate Program, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: erik.ullian@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 EY002162</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062359</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neurons</Keyword><Keyword MajorTopicYN="N">strocyte-neuronal signaling</Keyword></KeywordList><CoiStatement>Conflict of interests M.dM. and M.Koontz are full-time employees and equity holders of Synapticure Inc. E.M.U. is an equity holder of Synapticure Inc. M. Kampmann is an inventor on U.S. Patent 11,254,933 related to CRISPRi and CRISPRa screening, serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, and Alector, and is an advisor to Modulo Bio and Recursion Therapeutics. J.R.K. is a shareholder of Faze Medicines and QurAlis, and is an author on patent that describes surfaces for the long-term culture of pluripotent cells (U.S. patent 8,648,170) as well as a patent application that describes methods and compositions for restoring STMN2 levels (U.S. patent application 20,220,133,848). M.Kurnellas is a full-time employee and has equity interest in Alector, Inc. N.M.Dr&#xe4;ger is a full time employee at Modulo Bio, Inc. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>18</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36827976</ArticleId><ArticleId IdType="pmc">PMC10031303</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2023.01.012</ArticleId><ArticleId IdType="pii">S2213-6711(23)00015-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z., Sheng H., Xu Y., Lin W.-L., Innes A.E., Gass J., Yu X., Hou H., Chiba S., Yamanouchi K., et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 2010;177:311&#x2013;324. doi: 10.2353/ajpath.2010.090915.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.090915</ArticleId><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama T., Koike Y., Petrucelli L., Gitler A.D. Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: towards therapeutic targets and biomarkers. Clin. Transl. Med. 2022;12 doi: 10.1002/ctm2.818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.818</ArticleId><ArticleId IdType="pmc">PMC9098226</ArticleId><ArticleId IdType="pubmed">35567447</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S., Zhang Z., Coppola G., Mao W., Futai K., Karydas A., Geschwind M.D., Tartaglia M.C., Gao F., Gianni D., et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012;2:789&#x2013;798. doi: 10.1016/j.celrep.2012.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.09.007</ArticleId><ArticleId IdType="pmc">PMC3532907</ArticleId><ArticleId IdType="pubmed">23063362</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M., Mackenzie I.R., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., Snowden J., Adamson J., Sadovnick A.D., Rollinson S., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006 doi: 10.1038/nature05016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05016</ArticleId><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C., Grenier-Boley B., Lambert J.-C. Genetics of Alzheimer&#x2019;s disease: where we are, and where we are going. Curr. Opin. Neurobiol. 2020;61:40&#x2013;48. doi: 10.1016/j.conb.2019.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.11.024</ArticleId><ArticleId IdType="pubmed">31863938</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard J.W., Bula M., Davila-Velderrain J., Akay L.A., Zhu L., Frank A., Victor M.B., Bonner J.M., Mathys H., Lin Y.-T., et al. Author Correction: reconstruction of the human blood&#x2013;brain barrier in&#xa0;vitro reveals a pathogenic mechanism of APOE4 in pericytes. Nat. Med. 2021;27:356. doi: 10.1038/s41591-021-01250-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01250-8</ArticleId><ArticleId IdType="pubmed">33514950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossolasco P., Cimini S., Maderna E., Bardelli D., Canafoglia L., Cavallaro T., Ricci M., Silani V., Marucci G., Rossi G. GRN&#x2212;/&#x2212; iPSC-derived cortical neurons recapitulate the pathological findings of both frontotemporal lobar degeneration and neuronal ceroidolipofuscinosis. Neurobiol. Dis. 2022:105891. doi: 10.1016/j.nbd.2022.105891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105891</ArticleId><ArticleId IdType="pubmed">36220610</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A.-L., Wilkins O.G., Keuss M.J., Hill S.E., Zanovello M., Lee W.C., Bampton A., Lee F.C.Y., Masino L., Qi Y.A., et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;13:16. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br. J. Pharmacol. 2020 doi: 10.1111/bph.15148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15148</ArticleId><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell J.R., Halliday G.M., Kril J.J., Ittner L.M., G&#xf6;tz J., Kiernan M.C., Hodges J.R. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016 doi: 10.1016/S0140-6736(15)60684-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60684-5</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Logroscino G., Traynor B.J., Collins J., Simeone J.C., Goldstein L.A., White L.A. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung W.-S., Clarke L.E., Wang G.X., Stafford B.K., Sher A., Chakraborty C., Joung J., Foo L.C., Thompson A., Chen C., et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504:394&#x2013;400. doi: 10.1038/nature12776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12776</ArticleId><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne A.N., Baskerville V., Zaepfel B.L., Dickson D.W., Rigo F., Bennett F., Patrick Lusk C., Rothstein J.D. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci. Transl. Med. 2021;13 doi: 10.1126/scitranslmed.abe1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe1923</ArticleId><ArticleId IdType="pmc">PMC9022198</ArticleId><ArticleId IdType="pubmed">34321318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Gijselinck I., van der Zee J., Engelborghs S., Wils H., Pirici D., Rademakers R., Vandenberghe R., Dermaut B., Martin J.J., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006 doi: 10.1038/nature05017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05017</ArticleId><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai M.K., Mastrangelo M.A., Ryan D.A., Sudol K.L., Narrow W.C., Bowers W.J. Early oligodendrocyte/myelin pathology in Alzheimer&#x2019;s disease mice constitutes a novel therapeutic target. Am. J. Pathol. 2010;177:1422&#x2013;1435. doi: 10.2353/ajpath.2010.100087.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.100087</ArticleId><ArticleId IdType="pmc">PMC2928974</ArticleId><ArticleId IdType="pubmed">20696774</ArticleId></ArticleIdList></Reference><Reference><Citation>Dr&#xe4;ger N.M., Sattler S.M., Huang C.T.-L., Teter O.M., Leng K., Hashemi S.H., Hong J., Aviles G., Clelland C.D., Zhan L., et al. A CRISPRi/a platform in human iPSC-derived microglia uncovers regulators of disease states. Nat. Neurosci. 2022 doi: 10.1038/s41593-022-01131-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01131-4</ArticleId><ArticleId IdType="pmc">PMC9448678</ArticleId><ArticleId IdType="pubmed">35953545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandopulle M.S., Prestil R., Grunseich C., Wang C., Gan L., Michael E. Transcription-factor mediated differentiation of human iPSCs into neurons Running Title Rapid differentiation of iPSCs into neurons. Current Protocols in Cell Biology. 2018 doi: 10.1002/cpcb.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpcb.51</ArticleId><ArticleId IdType="pmc">PMC6993937</ArticleId><ArticleId IdType="pubmed">29924488</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Z., Chen Z., Fu S., Dai L., Shen Y. Progranulin administration attenuates &#x3b2;-amyloid deposition in the Hippocampus of 5xFAD mice through modulating BACE1 expression and microglial phagocytosis. Front. Cell. Neurosci. 2020;14 doi: 10.3389/fncel.2020.00260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00260</ArticleId><ArticleId IdType="pmc">PMC7461932</ArticleId><ArticleId IdType="pubmed">32973454</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen D.v., Hanson J.E., Sheng M. JCB (J. Cell Biol.) Vol. 217. Rockefeller University Press; 2018. Microglia in Alzheimer&#x2019;s disease; pp. 459&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201709069</ArticleId><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Li C., Shang H. Astrocytes in neurodegeneration: inspiration from genetics. Front. Neurosci. 2022;16 doi: 10.3389/fnins.2022.882316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.882316</ArticleId><ArticleId IdType="pmc">PMC9268899</ArticleId><ArticleId IdType="pubmed">35812232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley K.W., Nakao-Inoue H., Molofsky A.v., Oldham M.C. Variation among intact tissue samples reveals the core transcriptional features of human CNS cell classes. Nat. Neurosci. 2018;21:1171&#x2013;1184. doi: 10.1038/s41593-018-0216-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0216-z</ArticleId><ArticleId IdType="pmc">PMC6192711</ArticleId><ArticleId IdType="pubmed">30154505</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim J.R., Williams L.A., Limone F., San Juan I.G., Davis-Dusenbery B.N., Mordes D.A., Butberry A., Steinbaugh M.J., Gamage K.K., Kirchner R., et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. 2019;22 doi: 10.1038/s41593-018-0300-4.ALS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4.ALS</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D.S., Roberts R.O. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J.&#xa0;Mol. Neurosci. 2011;45:330&#x2013;335. doi: 10.1007/s12031-011-9538-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9538-y</ArticleId><ArticleId IdType="pmc">PMC3208074</ArticleId><ArticleId IdType="pubmed">21584654</ArticleId></ArticleIdList></Reference><Reference><Citation>Krencik R., Hokanson K.C., Narayan A.R., Dvornik J., Rooney G.E., Rauen K.A., Weiss L.A., Rowitch D.H., Ullian E.M. Dysregulation of astrocyte extracellular signaling in Costello syndrome. Sci. Transl. Med. 2015;7:1&#x2013;12. doi: 10.1126/scitranslmed.aaa5645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa5645</ArticleId><ArticleId IdType="pmc">PMC4474402</ArticleId><ArticleId IdType="pubmed">25947161</ArticleId></ArticleIdList></Reference><Reference><Citation>Krencik R., Seo K., van Asperen J.v., Basu N., Cvetkovic C., Barlas S., Chen R., Ludwig C., Wang C., Ward M.E., et al. Systematic three-dimensional coculture rapidly recapitulates interactions between human neurons and astrocytes. Stem Cell Rep. 2017;9:1745&#x2013;1753. doi: 10.1016/j.stemcr.2017.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.10.026</ArticleId><ArticleId IdType="pmc">PMC5785708</ArticleId><ArticleId IdType="pubmed">29198827</ArticleId></ArticleIdList></Reference><Reference><Citation>Krencik R., Zhang S.-C. Directed differentiation of functional astroglial subtypes from human pluripotent stem cells. Nat. Protoc. 2011;6:1710&#x2013;1717. doi: 10.1038/nprot.2011.405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2011.405</ArticleId><ArticleId IdType="pmc">PMC3198813</ArticleId><ArticleId IdType="pubmed">22011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., D&#x2019;Souza S.S., Moskvin O.V., Toh H., Wang B., Zhang J., Swanson S., Guo L.-W., Thomson J.A., Slukvin I.I. Specification and diversification of pericytes and smooth muscle cells from mesenchymoangioblasts. Cell Rep. 2017;19:1902&#x2013;1916. doi: 10.1016/j.celrep.2017.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.05.019</ArticleId><ArticleId IdType="pmc">PMC6428685</ArticleId><ArticleId IdType="pubmed">28564607</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E., Chung W.-S. Glial control of synapse number in healthy and diseased brain. Front. Cell. Neurosci. 2019;0:42. doi: 10.3389/FNCEL.2019.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FNCEL.2019.00042</ArticleId><ArticleId IdType="pmc">PMC6381066</ArticleId><ArticleId IdType="pubmed">30814931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Huang E.J. Brain Res. Vol. 1656. Elsevier B.V; 2017. Modeling ALS and FTD with iPSC-derived neurons; pp. 88&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.10.003</ArticleId><ArticleId IdType="pmc">PMC4833714</ArticleId><ArticleId IdType="pubmed">26462653</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K., Rose I.V.L., Kim H., Xia W., Romero-Fernandez W., Rooney B., Koontz M., Li E., Ao Y., Wang S., et al. CRISPRi screens in human iPSC-derived astrocytes elucidate regulators of distinct inflammatory reactive states. Nat Neurosci. 2022;25:1528&#x2013;1542. doi: 10.1038/s41593-022-01180-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01180-9</ArticleId><ArticleId IdType="pmc">PMC9633461</ArticleId><ArticleId IdType="pubmed">36303069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., M&#xfc;nch A.E., Chung W.S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017 doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.-C., Polymenidou M., Cleveland D.W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033. Converging.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S.J., Malatesta M., Lien B.V., Saha P., Thombare S.S., Hong S.J., Pedraza L., Koontz M., Seo K., Horlbeck M.A., et al. CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biol. 2020;21:83. doi: 10.1186/s13059-020-01995-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-020-01995-4</ArticleId><ArticleId IdType="pmc">PMC7110660</ArticleId><ArticleId IdType="pubmed">32234056</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T., Simon M.J., Rana A., Cherf G.M., Srivastava A., Davis S.S., Low R.L.Y., Chiu C.L., Fang M., Huang F., et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184:4651&#x2013;4668.e25. doi: 10.1016/j.cell.2021.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.08.002</ArticleId><ArticleId IdType="pmc">PMC8489356</ArticleId><ArticleId IdType="pubmed">34450028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H., Zhang J., Makinson S.R., Cahill M.K., Kelley K.W., Huang H.Y., Shang Y., Oldham M.C., Martens L.H., Gao F., et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165:921&#x2013;935. doi: 10.1016/j.cell.2016.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.04.001</ArticleId><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R.A. Acta Neuropathologica. 2007. The neuropathology and clinical phenotype of FTD with progranulin mutations.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0223-8</ArticleId><ArticleId IdType="pubmed">17458552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantle J.L., Lee K.H. A differentiating neural stem cell-derived astrocytic population mitigates the inflammatory effects of TNF-&#x3b1; and IL-6 in an iPSC-based blood-brain barrier model. Neurobiol. Dis. 2018;119:113&#x2013;120. doi: 10.1016/j.nbd.2018.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.07.030</ArticleId><ArticleId IdType="pubmed">30075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z., L&#xf3;pez-Erauskin J., Baughn M.W., Zhang O., Drenner K., Sun Y., Freyermuth F., McMahon M.A., Beccari M.S., Artates J.W., et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka Y., Chan A.H., Judge L.M., Yoo J., Huang M., Nguyen T.D., Lizarraga P.P., So P.-L., Conklin B.R. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods. 2014;11:291&#x2013;293. doi: 10.1038/nmeth.2840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2840</ArticleId><ArticleId IdType="pmc">PMC4063274</ArticleId><ArticleId IdType="pubmed">24509632</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Brayne C., Flanagan M.E., Abner E.L., Agrawal S., Attems J., Castellani R.J., Corrada M.M., Cykowski M.D., Di J., et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer&#x2019;s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022 doi: 10.1007/s00401-022-02444-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02444-1</ArticleId><ArticleId IdType="pmc">PMC9552938</ArticleId><ArticleId IdType="pubmed">35697880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Dickson D.W., Trojanowski J.Q., Jack C.R., Boyle P.A., Arfanakis K., Rademakers R., Alafuzoff I., Attems J., Brayne C., et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (New York, N.Y.) 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V., Tosat-Bitrian C., Nozal V., Nagaraj S., Martin-Requero A., Martinez A. TDP-43: a key therapeutic target beyond amyotrophic lateral sclerosis. ACS Chem. Neurosci. 2019;10:1183&#x2013;1196. doi: 10.1021/acschemneuro.9b00026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00026</ArticleId><ArticleId IdType="pubmed">30785719</ArticleId></ArticleIdList></Reference><Reference><Citation>Petoukhov E., Fernando S., Mills F., Shivji F., Hunter D., Krieger C., Silverman M.A., Bamji S.X. Activity-dependent secretion of progranulin from synapses. J.&#xa0;Cell Sci. 2013;126:5412&#x2013;5421. doi: 10.1242/jcs.132076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.132076</ArticleId><ArticleId IdType="pubmed">24046442</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Humphrey J., Pickles S., Brown A.-L., Hill S.E., Kachergus J., Shi J., Heckman M., Spiegel M., Cook C., et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J.&#xa0;Clin. Invest. 2020 doi: 10.1172/jci139741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci139741</ArticleId><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek H., Cun&#xed;-L&#xf3;pez C., Stewart R., Colletti T., Notaro A., Nguyen T.H., Sun Y., Guo C.C., Lupton M.K., Roberts T.L., et al. ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression. J.&#xa0;Neuroinflammation. 2022;19 doi: 10.1186/s12974-022-02421-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02421-1</ArticleId><ArticleId IdType="pmc">PMC8887023</ArticleId><ArticleId IdType="pubmed">35227277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H., Tatton N., McCaughey S., Kurnellas M., Rosenthal A. Trends in Pharmacological Sciences. Elsevier Ltd; 2022. Progranulin as a therapeutic target in neurodegenerative diseases.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2021.11.015</ArticleId><ArticleId IdType="pubmed">35039149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen E.Y., Wexler E.M., Versano R., Coppola G., Gao F., Winden K.D., Oldham M.C., Martens L.H., Zhou P., Farese R.V., Jr., Geschwind D.H. Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating wnt signaling. Neuron. 2011;71:1030&#x2013;1042. doi: 10.1016/j.neuron.2011.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.07.021</ArticleId><ArticleId IdType="pmc">PMC3633414</ArticleId><ArticleId IdType="pubmed">21943601</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H., Kamphorst W., Rosso S.M., Azmani A., Masdjedi R., de Koning I., Maat-Kievit J.A., Anar B., Kaat L.D., Breedveld G.J., et al. Distinct genetic forms of frontotemporal dementia. Neurology. 2008;71:1220. doi: 10.1212/01.wnl.0000319702.37497.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000319702.37497.72</ArticleId><ArticleId IdType="pubmed">18703462</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha D.M., Clarke B.E., Hall C.E., Tyzack G.E., Ziff O.J., Greensmith L., Kalmar B., Ahmed M., Alam A., Thelin E.P., et al. Astrocytes display cell autonomous and diverse early reactive states in familial amyotrophic lateral sclerosis. Brain. 2022 doi: 10.1093/brain/awab328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab328</ArticleId><ArticleId IdType="pmc">PMC9014746</ArticleId><ArticleId IdType="pubmed">35042241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia L., Milnerwood A., Guo A., Mills F., Yoshida E., Vasuta C., Mackenzie I.R., Raymond L., Cynader M., Jia W., Bamji S.X. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J.&#xa0;Neurosci. 2011;31:11126. doi: 10.1523/JNEUROSCI.6244-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6244-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623368</ArticleId><ArticleId IdType="pubmed">21813674</ArticleId></ArticleIdList></Reference><Reference><Citation>Uesaka N., Abe M., Konno K., Yamazaki M., Sakoori K., Watanabe T., Kao T.-H., Mikuni T., Watanabe M., Sakimura K., Kano M. Retrograde signaling from progranulin to Sort1 counteracts synapse elimination in the developing cerebellum. Neuron. 2018;97:796&#x2013;805.e5. doi: 10.1016/j.neuron.2018.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.01.018</ArticleId><ArticleId IdType="pubmed">29398357</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A., Olabarria M., Noristani H.N., Yeh C.-Y., Rodriguez J.J. Astrocytes in Alzheimer&#x2019;s disease. Neurotherapeutics. 2010;7:399&#x2013;412. doi: 10.1016/j.nurt.2010.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurt.2010.05.017</ArticleId><ArticleId IdType="pmc">PMC5084302</ArticleId><ArticleId IdType="pubmed">20880504</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan J., M&#xe4;kinen P., Helisalmi S., Haapasalo A., Soininen H., Hiltunen M. An association study between granulin gene polymorphisms and Alzheimer&#x2019;s disease in Finnish population. Am. J. Med. Genet. Part B: Neuropsychiatric Genetics. 2009;150B5:747&#x2013;750. doi: 10.1002/ajmg.b.30889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.30889</ArticleId><ArticleId IdType="pubmed">19016491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Ward M.E., Chen R., Liu K., Tracy T.E., Chen X., Xie M., Sohn P.D., Ludwig C., Meyer-Franke A., et al. Scalable production of iPSC-derived human neurons to identify tau-lowering compounds by high-content screening. Stem Cell Rep. 2017;9:1221&#x2013;1233. doi: 10.1016/j.stemcr.2017.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.08.019</ArticleId><ArticleId IdType="pmc">PMC5639430</ArticleId><ArticleId IdType="pubmed">28966121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Chen J., Hu Y., Liao A., Zheng W., Wang X., Lan J., Shen J., Wang S., Yang F., et al. Progranulin improves neural development via the PI3K/Akt/GSK-3&#x3b2; pathway in the cerebellum of a VPA-induced rat model of ASD. Transl. Psychiatry. 2022;12:114. doi: 10.1038/s41398-022-01875-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-022-01875-4</ArticleId><ArticleId IdType="pmc">PMC8941112</ArticleId><ArticleId IdType="pubmed">35318322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward M.E., Taubes A., Chen R., Miller B.L., Sephton C.F., Gelfand J.M., Minami S., Boscardin J., Martens L.H., Seeley W.W., et al. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J.&#xa0;Exp. Med. 2014;211:1937&#x2013;1945. doi: 10.1084/jem.20140214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20140214</ArticleId><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Velmeshev D., Hashimoto K., Huang Y.H., Hofmann J.W., Shi X., Chen J., Leidal A.M., Dishart J.G., Cahill M.K., et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature. 2020 doi: 10.1038/s41586-020-2709-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2709-7</ArticleId><ArticleId IdType="pmc">PMC7746606</ArticleId><ArticleId IdType="pubmed">32866962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen K., Sloan S.A., Bennett M.L., Scholze A.R., O'Keeffe S., Phatnani H.P., Guarnieri P., Caneda C., Ruderisch N., et al. An rna-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. The J. of Neuroscience. 2014;34:11929. doi: 10.1523/JNEUROSCI.1860-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Sloan S.A., Clarke L.E., Caneda C., Plaza C.A., Blumenthal P.D., Vogel H., Steinberg G.K., Edwards M.S.B., Li G., et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron. 2016;89:37&#x2013;53. doi: 10.1016/j.neuron.2015.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36848111</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Prevalence, Timing, and Network Localization of Emergent Visual Creativity in Frontotemporal Dementia.</ArticleTitle><Pagination><StartPage>377</StartPage><EndPage>387</EndPage><MedlinePgn>377-387</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2023.0001</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The neurological substrates of visual artistic creativity (VAC) are unknown. VAC is demonstrated here to occur early in frontotemporal dementia (FTD), and multimodal neuroimaging is used to generate a novel mechanistic hypothesis involving dorsomedial occipital cortex enhancement. These findings may illuminate a novel mechanism underlying human visual creativity.</AbstractText><AbstractText Label="OBJECTIVE">To determine the anatomical and physiological underpinnings of VAC in FTD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This case-control study analyzed records of 689 patients who met research criteria for an FTD spectrum disorder between 2002 and 2019. Individuals with FTD and emergence of visual artistic creativity (VAC-FTD) were matched to 2 control groups based on demographic and clinical parameters: (1) not visually artistic FTD (NVA-FTD) and (2) healthy controls (HC). Analysis took place between September 2019 to December 2021.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Clinical, neuropsychological, genetic, and neuroimaging data were analyzed to characterize VAC-FTD and compare VAC-FTD with control groups.</AbstractText><AbstractText Label="RESULTS">Of 689 patients with FTD, 17 (2.5%) met VAC-FTD inclusion criteria (mean [SD] age, 65 [9.7] years; 10 [58.8%] female). NVA-FTD (n&#x2009;=&#x2009;51; mean [SD] age, 64.8 [7] years; 25 [49.0%] female) and HC (n&#x2009;=&#x2009;51; mean [SD] age, 64.5 [7.2] years; 25 [49%] female) groups were well matched to VAC-FTD demographically. Emergence of VAC occurred around the time of onset of symptoms and was disproportionately seen in patients with temporal lobe predominant degeneration (8 of 17 [47.1%]). Atrophy network mapping identified a dorsomedial occipital region whose activity inversely correlated, in healthy brains, with activity in regions found within the patient-specific atrophy patterns in VAC-FTD (17 of 17) and NVA-FTD (45 of 51 [88.2%]). Structural covariance analysis revealed that the volume of this dorsal occipital region was strongly correlated in VAC-FTD, but not in NVA-FTD or HC, with a volume in the primary motor cortex corresponding to the right-hand representation.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study generated a novel hypothesis about the mechanisms underlying the emergence of VAC in FTD. These findings suggest that early lesion-induced activation of dorsal visual association areas may predispose some patients to the emergence of VAC under certain environmental or genetic conditions. This work sets the stage for further exploration of enhanced capacities arising early in the course of neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Friedberg</LastName><ForeName>Adit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, and Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquini</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscape, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diggs</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaubitz</LastName><ForeName>Erika A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ill&#xe1;n-Gala</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, and Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>now with Eli Lilly and Company, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mundada</LastName><ForeName>Nidhi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knudtson</LastName><ForeName>Marguerite</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neylan</LastName><ForeName>Kyra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Isabel Elaine</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, and Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Katherine P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, and Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonham</LastName><ForeName>Luke W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Eliana M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Center for Autism Research and Treatment Semel Institute for Neuroscience and Human Behavior, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Precision Health, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorno-Tempini</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Associate Editor, JAMA Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, and Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062588</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG053435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG065501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG048291</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG065457</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DC015544</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG065457</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="N">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Friedberg reported grants from The Larry L. Hillblom Foundation, the Global Brain Health Institute, Alzheimer&#x2019;s Association, and Alzheimer&#x2019;s Society Pilot Awards for Global Brain Health Leaders during the conduct of the study. Dr Illan-Gala reported personal fees from Esteve S.L, KRKA farmac&#xe9;utica S.L, Nutricia, and Sociedad Espa&#xf1;ola de Neurolog&#xed;a and grants from Instituto de Salud Carlos III, Global Brain Health Institute, and Alzheimer&#x2019;s Association outside the submitted work. Dr Iaccarino is a minor shareholder of Eli Lilly and Company. Dr Rankin reported grants from the National Institutes of Health and the National Science Foundation and serves on the advisory board of Eli Lilly and Company outside the submitted work. Dr Yokoyama reported grants from the National Institute on Aging, Rainwater Charitable Foundation, and the Alzheimer's Association and serves as the endowed chair for the Mary Oakley Foundation outside the submitted work. Drs Ramos, Grinberg, Gorno-Tempini, and Rabinovici reported grants from the National Institutes of Health during the conduct of the study. Dr Rosen reported grants from National Institutes of Health during the conduct of the study and personal fees from Genentech Pharmaceuticals, Eisai Pharmaceuticals, Takeda Pharmaceuticals, Biogen Pharmaceuticals, and Wave Pharmaceuticals outside the submitted work. Dr B. Miller reported grants from the National Institute on Aging during the conduct of the study; serves as medical advisor for the John Douglas French Foundation; serves as scientific advisor for the Larry L. Hillblom Foundation, Association for Frontotemporal Degeneration, National Institute for Health Research Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia, and the Buck Institute for Research on Aging; serves as external advisor for University of Washington ADRC, Stanford University ADRC, Arizona Alzheimer&#x2019;s Disease Center, and Massachusetts Alzheimer Disease Research Center; and serves on the external advisory committee for University of Southern California P01 Urban Air Pollution and Alzheimer&#x2019;s Disease: Risk, Heterogeneity and Mechanisms. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>27</Day><Hour>11</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36848111</ArticleId><ArticleId IdType="pmc">PMC9972248</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2023.0001</ArticleId><ArticleId IdType="pii">2802050</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jung RE, Segall JM, Jeremy Bockholt H, et al. . Neuroanatomy of creativity. Hum Brain Mapp. 2010;31(3):398-409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826582</ArticleId><ArticleId IdType="pubmed">19722171</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Beaty RE, Qiu J. Mapping the artistic brain: common and distinct neural activations associated with musical, drawing, and literary creativity. Hum Brain Mapp. 2020;41(12):3403-3419. doi:10.1002/hbm.25025</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.25025</ArticleId><ArticleId IdType="pmc">PMC7375056</ArticleId><ArticleId IdType="pubmed">32472741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidel DW. Creativity, brain, and art: biological and neurological considerations. Front Hum Neurosci. 2014;8:389. doi:10.3389/fnhum.2014.00389</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnhum.2014.00389</ArticleId><ArticleId IdType="pmc">PMC4041074</ArticleId><ArticleId IdType="pubmed">24917807</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaty RE, Seli P, Schacter DL. Network neuroscience of creative cognition: mapping cognitive mechanisms and individual differences in the creative brain. Curr Opin Behav Sci. 2019;27:22-30. doi:10.1016/j.cobeha.2018.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cobeha.2018.08.013</ArticleId><ArticleId IdType="pmc">PMC6428436</ArticleId><ArticleId IdType="pubmed">30906824</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pisapia N, Bacci F, Parrott D, Melcher D. Brain networks for visual creativity: a functional connectivity study of planning a visual artwork. Sci Rep. 2016;6:39185. doi:10.1038/srep39185</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39185</ArticleId><ArticleId IdType="pmc">PMC5171814</ArticleId><ArticleId IdType="pubmed">27991592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenett YN, Kraemer DJM, Alfred KL, Colaizzi GA, Cortes RA, Green AE. Developing a neurally informed ontology of creativity measurement. Neuroimage. 2020;221:117166. doi:10.1016/j.neuroimage.2020.117166</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2020.117166</ArticleId><ArticleId IdType="pubmed">32682097</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee A. The neuropsychology of visual art: conferring capacity. Int Rev Neurobiol. 2006;74:39-49. doi:10.1016/S0074-7742(06)74003-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0074-7742(06)74003-X</ArticleId><ArticleId IdType="pubmed">16730504</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MH, Carton AM, Hardy CJ, et al. . Processing emotion from abstract art in frontotemporal lobar degeneration. Neuropsychologia. 2016;81:245-254. doi:10.1016/j.neuropsychologia.2015.12.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2015.12.031</ArticleId><ArticleId IdType="pmc">PMC4749539</ArticleId><ArticleId IdType="pubmed">26748236</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BL, Cummings J, Mishkin F, et al. . Emergence of artistic talent in frontotemporal dementia. Neurology. 1998;51(4):978-982. doi:10.1212/WNL.51.4.978</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.4.978</ArticleId><ArticleId IdType="pubmed">9781516</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Matthews BR, Crawford RK, et al. . Unravelling Bol&#xe9;ro: progressive aphasia, transmodal creativity and the right posterior neocortex. Brain. 2008;131(pt 1):39-49. doi:10.1093/brain/awm270</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm270</ArticleId><ArticleId IdType="pubmed">18057074</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Jellinger KA, Fellner L, Wenning GK, Yilmazer-Hanke D, Haybaeck J. Emergent creativity in frontotemporal dementia. J Neural Transm (Vienna). 2021;128(3):279-293. doi:10.1007/s00702-021-02325-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-021-02325-z</ArticleId><ArticleId IdType="pubmed">33709181</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BL, Ponton M, Benson DF, Cummings JL, Mena I. Enhanced artistic creativity with temporal lobe degeneration. Lancet. 1996;348(9043):1744-1745. doi:10.1016/S0140-6736(05)65881-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)65881-3</ArticleId><ArticleId IdType="pubmed">8973469</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas-Anterion C, Creac&#x2019;h C, Dionet E, et al. . De novo artistic activity following insular-SII ischemia. Pain. 2010;150(1):121-127. doi:10.1016/j.pain.2010.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2010.04.010</ArticleId><ArticleId IdType="pubmed">20447767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunadia A, Aughtman S, Hoffmann M, Rossi F. Superlative artistic abilities in a patient with post-traumatic brain injury. Cureus. 2021;13(7):e16697. doi:10.7759/cureus.16697</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.16697</ArticleId><ArticleId IdType="pmc">PMC8389864</ArticleId><ArticleId IdType="pubmed">34462704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayseless N, Aharon-Peretz J, Shamay-Tsoory S. Unleashing creativity: the role of left temporoparietal regions in evaluating and inhibiting the generation of creative ideas. Neuropsychologia. 2014;64:157-168. doi:10.1016/j.neuropsychologia.2014.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2014.09.022</ArticleId><ArticleId IdType="pubmed">25261613</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Brown JA, Possin KL, et al. . Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140(12):3329-3345. doi:10.1093/brain/awx254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx254</ArticleId><ArticleId IdType="pmc">PMC5841140</ArticleId><ArticleId IdType="pubmed">29053860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos EM, Dokuru DR, Van Berlo V, et al. ; ARTFL/LEFFTDS consortium . Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimers Dement. 2020;16(1):118-130. doi:10.1002/alz.12011</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12011</ArticleId><ArticleId IdType="pmc">PMC7199807</ArticleId><ArticleId IdType="pubmed">31914217</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, et al. . Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. doi:10.1212/WNL.0b013e31827f0fd1</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f0fd1</ArticleId><ArticleId IdType="pmc">PMC3590050</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Respondek G, Stamelou M, et al. ; Movement Disorder Society-endorsed PSP Study Group . Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26987</ArticleId><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554. doi:10.1212/WNL.51.6.1546</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Bhatia KP, Burn DJ, et al. ; Movement Disorders Society Scientific Issues Committee . Movement disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18(5):467-486. doi:10.1002/mds.10459</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.10459</ArticleId><ArticleId IdType="pubmed">12722160</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Agid Y, Calne D, et al. . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9. doi:10.1212/WNL.47.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.1.1</ArticleId><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572. doi:10.1192/bjp.140.6.566</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.140.6.566</ArticleId><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neuroimage. 2000;11(6 Pt 1):805-821. doi:10.1006/nimg.2000.0582</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2000.0582</ArticleId><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Petersen RC, Xu YC, et al. . Medial temporal atrophy on MRI in normal aging and very mild Alzheimer&#x2019;s disease. Neurology. 1997;49(3):786-794. doi:10.1212/WNL.49.3.786</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.49.3.786</ArticleId><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barr&#xe9; L, et al. . Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer&#x2019;s disease dementia. J Neurosci. 2012;32(46):16265-16273. doi:10.1523/JNEUROSCI.2170-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2170-12.2012</ArticleId><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD. Mapping symptoms to brain networks with the human connectome. N Engl J Med. 2018;379(23):2237-2245. doi:10.1056/NEJMra1706158</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1706158</ArticleId><ArticleId IdType="pubmed">30575457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetreault AM, Phan T, Orlando D, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Network localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Brain. 2020;143(4):1249-1260. doi:10.1093/brain/awaa058</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa058</ArticleId><ArticleId IdType="pmc">PMC7174048</ArticleId><ArticleId IdType="pubmed">32176777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetreault AM, Phan T, Petersen KJ, et al. ; 4 Repeat Tau Neuroimaging Initiative . Network localization of alien limb in patients with corticobasal syndrome. Ann Neurol. 2020;88(6):1118-1131. doi:10.1002/ana.25901</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25901</ArticleId><ArticleId IdType="pubmed">32935385</ArticleId></ArticleIdList></Reference><Reference><Citation>Boes AD, Prasad S, Liu H, et al. . Network localization of neurological symptoms from focal brain lesions. Brain. 2015;138(pt 10):3061-3075. doi:10.1093/brain/awv228</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv228</ArticleId><ArticleId IdType="pmc">PMC4671478</ArticleId><ArticleId IdType="pubmed">26264514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AL, Fox MD. Reply: the influence of sample size and arbitrary statistical thresholds in lesion-network mapping. Brain. 2020;143(5):e41. doi:10.1093/brain/awaa095</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa095</ArticleId><ArticleId IdType="pmc">PMC7241951</ArticleId><ArticleId IdType="pubmed">32365379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli A, Friston KJ, Frackowiak RS, Price CJ. Structural covariance in the human cortex. J Neurosci. 2005;25(36):8303-8310. doi:10.1523/JNEUROSCI.0357-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0357-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725541</ArticleId><ArticleId IdType="pubmed">16148238</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42-52. doi:10.1016/j.neuron.2009.03.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.03.024</ArticleId><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan L, Li H, Zhuo J, et al. . The Human Brainnetome Atlas: a new brain atlas based on connectional architecture. Cereb Cortex. 2016;26(8):3508-3526. doi:10.1093/cercor/bhw157</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhw157</ArticleId><ArticleId IdType="pmc">PMC4961028</ArticleId><ArticleId IdType="pubmed">27230218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314. doi:10.1212/WNL.44.12.2308</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.12.2308</ArticleId><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu A, Werner K, Roy S, et al. . A case study of an emerging visual artist with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurocase. 2009;15(3):235-247. doi:10.1080/13554790802633213</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13554790802633213</ArticleId><ArticleId IdType="pmc">PMC2829114</ArticleId><ArticleId IdType="pubmed">19274573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Perryman KM. Disrupted facial empathy in drawings from artists with frontotemporal dementia. Neurocase. 2003;9(1):44-50. doi:10.1076/neur.9.1.44.14375</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/neur.9.1.44.14375</ArticleId><ArticleId IdType="pubmed">16210224</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodale MA, Milner AD. Separate visual pathways for perception and action. Trends Neurosci. 1992;15(1):20-25. doi:10.1016/0166-2236(92)90344-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-2236(92)90344-8</ArticleId><ArticleId IdType="pubmed">1374953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishai A, Sagi D. Common mechanisms of visual imagery and perception. Science. 1995;268(5218):1772-1774. doi:10.1126/science.7792605</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7792605</ArticleId><ArticleId IdType="pubmed">7792605</ArticleId></ArticleIdList></Reference><Reference><Citation>Popal H, Quimby M, Hochberg D, Dickerson BC, Collins JA. Altered functional connectivity of cortical networks in semantic variant primary progressive aphasia. Neuroimage Clin. 2020;28:102494. doi:10.1016/j.nicl.2020.102494</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102494</ArticleId><ArticleId IdType="pmc">PMC7708956</ArticleId><ArticleId IdType="pubmed">33395985</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander-Bloch A, Giedd JN, Bullmore E. Imaging structural co-variance between human brain regions. Nat Rev Neurosci. 2013;14(5):322-336. doi:10.1038/nrn3465</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3465</ArticleId><ArticleId IdType="pmc">PMC4043276</ArticleId><ArticleId IdType="pubmed">23531697</ArticleId></ArticleIdList></Reference><Reference><Citation>Draganski B, Gaser C, Busch V, Schuierer G, Bogdahn U, May A. Neuroplasticity: changes in grey matter induced by training. Nature. 2004;427(6972):311-312. doi:10.1038/427311a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/427311a</ArticleId><ArticleId IdType="pubmed">14737157</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaser C, Schlaug G. Brain structures differ between musicians and non-musicians. J Neurosci. 2003;23(27):9240-9245. doi:10.1523/JNEUROSCI.23-27-09240.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-27-09240.2003</ArticleId><ArticleId IdType="pmc">PMC6740845</ArticleId><ArticleId IdType="pubmed">14534258</ArticleId></ArticleIdList></Reference><Reference><Citation>Calmels C. Neural correlates of motor expertise: Extensive motor training and cortical changes. Brain Res. 2020;1739:146323. doi:10.1016/j.brainres.2019.146323</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146323</ArticleId><ArticleId IdType="pubmed">31278937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36879142</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Forty-hertz light stimulation does not entrain native gamma oscillations in Alzheimer's disease model mice.</ArticleTitle><Pagination><StartPage>570</StartPage><EndPage>578</EndPage><MedlinePgn>570-578</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-023-01270-2</ELocationID><Abstract><AbstractText>There is a demand for noninvasive methods to ameliorate disease. We investigated whether 40-Hz flickering light entrains gamma oscillations and suppresses amyloid-&#x3b2; in the brains of APP/PS1 and 5xFAD mouse models of Alzheimer's disease. We used multisite silicon probe recording in the visual cortex, entorhinal cortex or the hippocampus and found that 40-Hz flickering simulation did not engage native gamma oscillations in these regions. Additionally, spike responses in the hippocampus were weak, suggesting 40-Hz light does not effectively entrain deep structures. Mice avoided 40-Hz flickering light, associated with elevated cholinergic activity in the hippocampus. We found no reliable changes in plaque count or microglia morphology by either immunohistochemistry or in vivo two-photon imaging following 40-Hz stimulation, nor reduced levels of amyloid-&#x3b2; 40/42. Thus, visual flicker stimulation may not be a viable mechanism for modulating activity in deep structures.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soula</LastName><ForeName>Marisol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-&#xc1;vila</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0343-1685</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Skirball Institute of Biomolecular Medicine, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yiyao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitzan</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadowski</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-3830-1779</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Wen-Biao</ForeName><Initials>WB</Initials><Identifier Source="ORCID">0000-0002-5620-7276</Identifier><AffiliationInfo><Affiliation>Skirball Institute of Biomolecular Medicine, Langone Medical Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buzs&#xe1;ki</LastName><ForeName>Gy&#xf6;rgy</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3100-4800</Identifier><AffiliationInfo><Affiliation>Neuroscience Institute, Langone Medical Center, New York University, New York, NY, USA. gyorgy.buzsaki@nyulangone.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Langone Medical Center, New York University, New York, NY, USA. gyorgy.buzsaki@nyulangone.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Langone Medical Center, New York University, New York, NY, USA. gyorgy.buzsaki@nyulangone.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG075840</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH122391</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR001447</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 NS107616</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>6</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36879142</ArticleId><ArticleId IdType="mid">NIHMS1955139</ArticleId><ArticleId IdType="pmc">PMC10839995</ArticleId><ArticleId IdType="doi">10.1038/s41593-023-01270-2</ArticleId><ArticleId IdType="pii">10.1038/s41593-023-01270-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Llin&#xe1;s RR, Ribary U, Jeanmonod D, Kronberg E &amp; Mitra PP. Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc. Natl Acad. Sci. USA 96, 15222&#x2013; 15227 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24801</ArticleId><ArticleId IdType="pubmed">10611366</ArticleId></ArticleIdList></Reference><Reference><Citation>Krook-Magnuson E, Gelinas JN, Soltesz I &amp; Buzs&#xe1;ki G. Neuroelectronics and biooptics: closed-loop technologies in neurological disorders. JAMA Neurol. 72, 823&#x2013;829 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501886</ArticleId><ArticleId IdType="pubmed">25961887</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino HF et al. Author correction: gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 562, E1 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30046102</ArticleId></ArticleIdList></Reference><Reference><Citation>Adaikkan C et al. Gamma entrainment binds higher-order brain regions and offers neuroprotection. Neuron 102, 929&#x2013;943.e8 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697125</ArticleId><ArticleId IdType="pubmed">31076275</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorell AJ et al. Multi-sensory gamma stimulation ameliorates Alzheimer&#x2019;s-associated pathology and improves cognition. Cell 177, 256&#x2013;271.e22 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774262</ArticleId><ArticleId IdType="pubmed">30879788</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q et al. Gamma frequency light flicker regulates amyloid precursor protein trafficking for reducing &#x3b2;-amyloid load in Alzheimer&#x2019;s disease model. Aging Cell 21, e13573 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920449</ArticleId><ArticleId IdType="pubmed">35199454</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SS et al. Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer&#x2019;s disease of 3&#xd7;Tg mice. J. Appl. Physiol. 132, 1054&#x2013;1068 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35201933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y et al. Non-invasive 40-Hz light flicker ameliorates Alzheimer&#x2019;s-associated rhythm disorder via regulating central circadian clock in mice. Front. Physiol. 11, 294 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7193101</ArticleId><ArticleId IdType="pubmed">32390857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW et al. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat. Neurosci. 14, 750&#x2013;756 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D et al. Gamma frequency sensory timulation in probable mild Alzheimer&#x2019;s dementia patients: results of a preliminary clinical trial. PLoS ONE 17, e0278412 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714926</ArticleId><ArticleId IdType="pubmed">36454969</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SS et al. Physical exercise during exposure to 40-Hz light flicker improves cognitive functions in the 3xTg mouse model of Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 12, 62 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240923</ArticleId><ArticleId IdType="pubmed">32434556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L et al. Rhythmic light flicker rescues hippocampal low gamma and protects ischemic neurons by enhancing presynaptic plasticity. Nat. Commun. 11, 3012 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296037</ArticleId><ArticleId IdType="pubmed">32541656</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter G et al. Optogenetic gamma stimulation rescues memory impairments in an Alzheimer&#x2019;s disease mouse model. Nat. Commun. 10, 5322 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6876640</ArticleId><ArticleId IdType="pubmed">31757962</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronov D, Nevers R &amp; Tank DW. Mapping of a non-spatial dimension by the hippocampal-entorhinal circuit. Nature 543, 719&#x2013;722 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5492514</ArticleId><ArticleId IdType="pubmed">28358077</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RF. The neurobiology of learning and memory. Science 233, 941&#x2013;947 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3738519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiitinen H et al. Selective attention enhances the auditory 40-Hz transient response in humans. Nature 364, 59&#x2013;60 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8316297</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer AC et al. Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load. Nat. Protoc. 13, 1850&#x2013; 1868 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30072722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S &amp; Cordeli&#xe8;res FP. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213&#x2013;232 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Forner S et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer&#x2019;s disease. Sci. Data 8, 270 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8519958</ArticleId><ArticleId IdType="pubmed">34654824</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacker JS et al. Unlocking the brain: a new method for western blot protein detection from fixed brain tissue. J. Neurosci. Methods 348, 108995 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33202258</ArticleId></ArticleIdList></Reference><Reference><Citation>Senzai Y, Fernandez-Ruiz A &amp; Buzs&#xe1;ki G. Layer-specific physiological features and interlaminar interactions in the primary visual cortex of the mouse. Neuron 101, 500&#x2013;513.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367010</ArticleId><ArticleId IdType="pubmed">30635232</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein MC, Polack PO, Tran DT &amp; Golshani P. Visually evoked 3&#x2013;5 Hz membrane potential oscillations reduce the responsiveness of visual cortex neurons in awake behaving mice. J. Neurosci. 37, 5084&#x2013;5098 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444194</ArticleId><ArticleId IdType="pubmed">28432140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitzan N, Swanson R, Schmitz D &amp; Buzs&#xe1;ki G. Brain-wide interactions during hippocampal sharp wave ripples. Proc. Natl Acad. Sci. USA 119, e2200931119 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9171920</ArticleId><ArticleId IdType="pubmed">35561219</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz NA, Zatka-Haas P, Carandini M &amp; Harris KD. Distributed coding of choice, action and engagement across the mouse brain. Nature 576, 266&#x2013;273 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913580</ArticleId><ArticleId IdType="pubmed">31776518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyskov E, Ponomarev V, Sandstr&#xf6;m M, Mild KH &amp; Medvedev S. Steady-state visual evoked potentials to computer monitor flicker. Int. J. Psychophysiol. 28, 285&#x2013;290 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9545663</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams PE, Mechler F, Gordon J, Shapley R &amp; Hawken MJ. Entrainment to video displays in primary visual cortex of macaque and humans. J. Neurosci. 24, 8278&#x2013;8288 (2004); erratum 24, 10034 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729686</ArticleId><ArticleId IdType="pubmed">15385611</ArticleId></ArticleIdList></Reference><Reference><Citation>Krolak-Salmon P et al. Human lateral geniculate nucleus and visual cortex respond to screen flicker. Ann. Neurol. 53, 73&#x2013;80 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12509850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K et al. Optimal flickering light stimulation for entraining gamma waves in the human brain. Sci. Rep. 11, 16206 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8355349</ArticleId><ArticleId IdType="pubmed">34376723</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing M et al. An optimized acetylcholine sensor for monitoring in vivo cholinergic activity. Nat. Methods 17, 1139&#x2013;1146 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606762</ArticleId><ArticleId IdType="pubmed">32989318</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva A, Fern&#xe1;ndez-Ruiz A, Fermino de Oliveira E &amp; Buzs&#xe1;ki G. Origin of gamma frequency power during hippocampal sharp-wave ripples. Cell Rep. 25, 1693&#x2013;1700.e4 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310484</ArticleId><ArticleId IdType="pubmed">30428340</ArticleId></ArticleIdList></Reference><Reference><Citation>Duecker K, Gutteling TP, Herrmann CS &amp; Jensen O. No evidence for entrainment: endogenous gamma oscillations and rhythmic flicker responses coexist in visual cortex. J. Neurosci. 41, 6684&#x2013;6698 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8336697</ArticleId><ArticleId IdType="pubmed">34230106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XJ &amp; Buzs&#xe1;ki G. Gamma oscillation by synaptic inhibition in a hippocampal interneuronal network model. J. Neurosci. 16, 6402&#x2013;6413 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578902</ArticleId><ArticleId IdType="pubmed">8815919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz A et al. Gamma rhythm communication between entorhinal cortex and dentate gyrus neuronal assemblies. Science 372, eabf3119 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285088</ArticleId><ArticleId IdType="pubmed">33795429</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman SM, Greenhouse DS, Bailey IL, Clear RD &amp; Raasch TW. Human electroretinogram responses to video displays, fluorescent lighting, and other high frequency sources. Optom. Vis. Sci. 68, 645&#x2013;662 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1923343</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann CS. Human EEG responses to 1&#x2013;100 Hz flicker: resonance phenomena in visual cortex and their potential correlation to cognitive phenomena. Exp. Brain Res. 137, 346&#x2013;353 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11355381</ArticleId></ArticleIdList></Reference><Reference><Citation>Fylan F &amp; Harding GF. The effect of television frame rate on EEG abnormalities in photosensitive and pattern-sensitive epilepsy. Epilepsia 38, 1124&#x2013;1131 (1997); erratum 39, 453 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9579959</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur M &amp; Snodderly DM. A dissociation between brain activity and perception: chromatically opponent cortical neurons signal chromatic flicker that is not perceived. Vis. Res. 37, 377&#x2013;382 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9156168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghose GM &amp; Freeman RD. Oscillatory discharge in the visual system: does it have a functional role? J. Neurophysiol. 68, 1558&#x2013;1574 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1479430</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin PR &amp; Teoh HJ. Effects of visual stimuli and a stressor on head pain. Headache 39, 705&#x2013;715 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">11279946</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray CM &amp; Singer W. Stimulus-specific neuronal oscillations in orientation columns of cat visual cortex. Proc. Natl Acad. Sci. USA 86, 1698&#x2013;1702 (1989).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC286768</ArticleId><ArticleId IdType="pubmed">2922407</ArticleId></ArticleIdList></Reference><Reference><Citation>Britten KH, Shadlen MN, Newsome WT &amp; Movshon JA. Responses of neurons in macaque MT to stochastic motion signals. Vis. Neurosci. 10, 1157&#x2013;1169 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8257671</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesaran B et al. Investigating large-scale brain dynamics using field potential recordings: analysis and interpretation. Nat. Neurosci. 21, 903&#x2013;919 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386068</ArticleId><ArticleId IdType="pubmed">29942039</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 11, 1006&#x2013;1012 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Moe KE, Vitiello MV, Larsen LH &amp; Prinz PN. Symposium: cognitive processes and sleep disturbances: sleep/wake patterns in Alzheimer&#x2019;s disease: relationships with cognition and function. J. Sleep Res. 4, 15&#x2013;20 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">10607136</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA et al. Prefrontal atrophy, disrupted NREM slow waves and impaired hippocampal-dependent memory in aging. Nat. Neurosci. 16, 357&#x2013;364 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286370</ArticleId><ArticleId IdType="pubmed">23354332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP et al. Associations between &#x3b2;-amyloid kinetics and the &#x3b2;-amyloid diurnal pattern in the central nervous system. JAMA Neurol. 74, 207&#x2013;215 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305432</ArticleId><ArticleId IdType="pubmed">27992627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastanenka KV et al. Frequency-dependent exacerbation of Alzheimer&#x2019;s disease neuropathophysiology. Sci. Rep. 9, 8964 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6586873</ArticleId><ArticleId IdType="pubmed">31221985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastanenka KV et al. Optogenetic restoration of disrupted slow oscillations halts amyloid deposition and restores calcium homeostasis in an animal model of Alzheimer&#x2019;s disease. PLoS ONE 12, e0170275 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5257003</ArticleId><ArticleId IdType="pubmed">28114405</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannetti EA et al. Restoring memory by optogenetic synchronization of hippocampus oscillations in an Alzheimer&#x2019;s disease mouse model. Preprint at bioRxiv 10.1101/363820 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/363820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085&#x2013;1092 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Venturino A et al. Microglia enable mature perineuronal nets disassembly upon anesthetic ketamine exposure or 60-Hz light entrainment in the healthy brain. Cell Rep. 36, 109313 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284881</ArticleId><ArticleId IdType="pubmed">34233180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail R et al. The effect of 40-Hz light therapy on amyloid load in patients with prodromal and clinical Alzheimer&#x2019;s disease. Int. J. Alzheimers Dis. 30, 6852303 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091362</ArticleId><ArticleId IdType="pubmed">30155285</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke D, Crombag HS &amp; Hall CN. An open-source pipeline for analysing changes in microglial morphology. Open Biol. 11, 210045 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354754</ArticleId><ArticleId IdType="pubmed">34375551</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik SH, Kang S, Son SM &amp; Mook-Jung I. Microglia contributes to plaque growth by cell death due to uptake of amyloid &#x3b2; in the brain of Alzheimer&#x2019;s disease mouse model. Glia 64, 2274&#x2013;2290 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27658617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Pan F, Parkhurst CN, Grutzendler J &amp; Gan WB. Thinned-skull cranial window technique for long-term imaging of the cortex in live mice. Nat. Protoc. 5, 201&#x2013;208 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690457</ArticleId><ArticleId IdType="pubmed">20134419</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachitariu M, Steinmetz N, Kadir S, Carandini M &amp; Harris KD Fast and accurate spike sorting of high-channel count probes with KiloSort. in Advances in Neural Information Processing Systems 29 (eds Lee D et al.) (NIPS, 2016).</Citation></Reference><Reference><Citation>Petersen PC, Siegle JH, Steinmetz NA, Mahallati S &amp; Buzs&#xe1;ki G. CellExplorer: a framework for visualizing and characterizing single neurons. Neuron. 109, 3594&#x2013;3608.e2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8602784</ArticleId><ArticleId IdType="pubmed">34592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Zar JH Biostatistical Analysis 4th edn (Prentice Hall, 1999).</Citation></Reference><Reference><Citation>Zhang Y et al. Cholinergic suppression of hippocampal sharp-wave ripples impairs working memory. Proc. Natl Acad. Sci. USA 118, e2016432118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054002</ArticleId><ArticleId IdType="pubmed">33833054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36890231</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>615</Volume><Issue>7953</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy.</ArticleTitle><Pagination><StartPage>668</StartPage><EndPage>677</EndPage><MedlinePgn>668-677</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-023-05788-0</ELocationID><Abstract><AbstractText>Extracellular deposition of amyloid-&#x3b2; as neuritic plaques and intracellular accumulation of hyperphosphorylated, aggregated tau as neurofibrillary tangles are two of the characteristic hallmarks of Alzheimer's disease<sup>1,2</sup>. The regional progression of brain atrophy in Alzheimer's disease highly correlates with tau accumulation but not amyloid deposition<sup>3-5</sup>, and the mechanisms of tau-mediated neurodegeneration remain elusive. Innate immune responses represent a common pathway for the initiation and progression of some neurodegenerative diseases. So far, little is known about the extent or role of the adaptive immune response and its interaction with the innate immune response in the presence of amyloid-&#x3b2; or tau pathology<sup>6</sup>. Here we systematically compared the immunological milieux in the brain of mice with amyloid deposition or tau aggregation and neurodegeneration. We found that mice with tauopathy but not those with amyloid deposition developed a unique innate and adaptive immune response and that depletion of microglia or T cells blocked tau-mediated neurodegeneration. Numbers of T cells, especially those of cytotoxic T cells, were markedly increased in areas with tau pathology in mice with tauopathy and in the Alzheimer's disease brain. T cell numbers correlated with the extent of neuronal loss, and the cells dynamically transformed their cellular characteristics from activated to exhausted states along with unique TCR clonal expansion. Inhibition of interferon-&#x3b3; and PDCD1 signalling both significantly ameliorated brain atrophy. Our results thus reveal a tauopathy- and neurodegeneration-related immune hub involving activated microglia and T cell responses, which could serve as therapeutic targets for preventing neurodegeneration in Alzheimer's disease and primary tauopathies.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6710-3798</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firulyova</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Almazov National Medical Research Centre, St Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6325-863X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aladyeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3483-6944</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chanung</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shchukina</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Woo</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuede</LastName><ForeName>Carla M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3714-517X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artyomov</LastName><ForeName>Maxim N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0002-1133-4212</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-4743-926X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA. holtzman@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University School of Medicine, St Louis, MO, USA. holtzman@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000611649">IFNG protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491383">Pdcd1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2023 Mar;615(7953):588-589. doi: 10.1038/d41586-023-00600-5.</RefSource><PMID Version="1">36890310</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2024 Oct;634(8036):E15. doi: 10.1038/s41586-024-08200-7.</RefSource><PMID Version="1">39415023</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="Y">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of Interest. D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali and Cajal Neuroscience and consults for Genentech and Alector. J.K. is a member of a scientific advisory group for PureTech. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36890231</ArticleId><ArticleId IdType="mid">NIHMS1898299</ArticleId><ArticleId IdType="pmc">PMC10258627</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-05788-0</ArticleId><ArticleId IdType="pii">10.1038/s41586-023-05788-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duyckaerts C, Delatour B &amp; Potier MC Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118, 5&#x2013;36, doi:10.1007/s00401-009-0532-1 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0532-1</ArticleId><ArticleId IdType="pubmed">19381658</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL et al. Alzheimer&#x2019;s disease. Nat Rev Dis Primers 1, 15056, doi:10.1038/nrdp.2015.56 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.56</ArticleId><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr. &amp; Holtzman DM Biomarker modeling of Alzheimer&#x2019;s disease. Neuron 80, 1347&#x2013;1358, doi:10.1016/j.neuron.2013.12.003 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES &amp; Holtzman DM Three dimensions of the amyloid hypothesis: time, space and &#x2018;wingmen&#x2019;. Nat Neurosci 18, 800&#x2013;806, doi:10.1038/nn.4018 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4018</ArticleId><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x2019;s disease. Neurology 60, 1495&#x2013;1500, doi:10.1212/01.wnl.0000063311.58879.01 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000063311.58879.01</ArticleId><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X &amp; Holtzman DM Emerging roles of innate and adaptive immunity in Alzheimer&#x2019;s disease. Immunity 55, 2236&#x2013;2254, doi:10.1016/j.immuni.2022.10.016 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.10.016</ArticleId><ArticleId IdType="pmc">PMC9772134</ArticleId><ArticleId IdType="pubmed">36351425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD et al. Altered microglial response to Abeta plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol Neurodegener 9, 20, doi:10.1186/1750-1326-9-20 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong M et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med 13, doi:10.1126/scitranslmed.abd7522 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd7522</ArticleId><ArticleId IdType="pmc">PMC8128342</ArticleId><ArticleId IdType="pubmed">33597265</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupp NJ, Wegenast-Braun BM, Radde R, Calhoun ME &amp; Jucker M Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol Aging 32, 2324 e2321&#x2013;2326, doi:10.1016/j.neurobiolaging.2010.08.014 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.08.014</ArticleId><ArticleId IdType="pubmed">20970889</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoni P et al. Cerebrovascular pathology during the progression of experimental Alzheimer&#x2019;s disease. Neurobiol Dis 88, 107&#x2013;117, doi:10.1016/j.nbd.2016.01.001 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.01.001</ArticleId><ArticleId IdType="pubmed">26774030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351, doi:10.1016/j.neuron.2007.01.010 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM &amp; Holtzman DM Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312&#x2013;339, doi:10.1016/j.cell.2019.09.001 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Marsh SE &amp; Stevens B Immune Signaling in Neurodegeneration. Immunity 50, 955&#x2013;974, doi:10.1016/j.immuni.2019.03.016 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.016</ArticleId><ArticleId IdType="pmc">PMC6822103</ArticleId><ArticleId IdType="pubmed">30995509</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP &amp; Latz E Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14, 463&#x2013;477, doi:10.1038/nri3705 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3705</ArticleId><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569, doi:10.1016/j.immuni.2017.08.008 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 48, 380&#x2013;395 e386, doi:10.1016/j.immuni.2018.01.011 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.01.011</ArticleId><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J, Sisodia SS &amp; Ransohoff RM Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 14, 1227&#x2013;1235, doi:10.1038/nn.2923 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2923</ArticleId><ArticleId IdType="pubmed">21952260</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer HG &amp; Reichmann G Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 166, 2717&#x2013;2726, doi:10.4049/jimmunol.166.4.2717 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.4.2717</ArticleId><ArticleId IdType="pubmed">11160337</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D et al. CD4(+) T cells contribute to neurodegeneration in Lewy body dementia. Science 374, 868&#x2013;874, doi:10.1126/science.abf7266 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7266</ArticleId><ArticleId IdType="pmc">PMC9122025</ArticleId><ArticleId IdType="pubmed">34648304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E et al. Neutrophils promote Alzheimer&#x2019;s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med 21, 880&#x2013;886, doi:10.1038/nm.3913 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3913</ArticleId><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbarayan MS, Hudson C, Moss LD, Nash KR &amp; Bickford PC T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an alpha-synuclein rat model of Parkinson&#x2019;s disease. J Neuroinflammation 17, 242, doi:10.1186/s12974-020-01911-4 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01911-4</ArticleId><ArticleId IdType="pmc">PMC7429710</ArticleId><ArticleId IdType="pubmed">32799878</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber C et al. T cells promote microglia-mediated synaptic elimination and cognitive dysfunction during recovery from neuropathogenic flaviviruses. Nat Neurosci 22, 1276&#x2013;1288, doi:10.1038/s41593-019-0427-y (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0427-y</ArticleId><ArticleId IdType="pmc">PMC6822175</ArticleId><ArticleId IdType="pubmed">31235930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer&#x2019;s disease. Nature 577, 399&#x2013;404, doi:10.1038/s41586-019-1895-7 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1895-7</ArticleId><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini M, Kirabali T, Kulic L, Nitsch RM &amp; Ferretti MT Extravascular CD3+ T Cells in Brains of Alzheimer Disease Patients Correlate with Tau but Not with Amyloid Pathology: An Immunohistochemical Study. Neurodegener Dis 18, 49&#x2013;56, doi:10.1159/000486200 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000486200</ArticleId><ArticleId IdType="pubmed">29402847</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent C et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain 140, 184&#x2013;200, doi:10.1093/brain/aww270 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww270</ArticleId><ArticleId IdType="pmc">PMC5382942</ArticleId><ArticleId IdType="pubmed">27818384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH et al. TREM2-independent oligodendrocyte, astrocyte, and T cell responses to tau and amyloid pathology in mouse models of Alzheimer disease. Cell Rep 37, 110158, doi:10.1016/j.celrep.2021.110158 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110158</ArticleId><ArticleId IdType="pubmed">34965428</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris GT &amp; Kipnis J Immune cells and CNS physiology: Microglia and beyond. J Exp Med 216, 60&#x2013;70, doi:10.1084/jem.20180199 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180199</ArticleId><ArticleId IdType="pmc">PMC6314530</ArticleId><ArticleId IdType="pubmed">30504438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X et al. Transcriptomic mapping uncovers Purkinje neuron plasticity driving learning. Nature 605, 722&#x2013;727, doi:10.1038/s41586-022-04711-3 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04711-3</ArticleId><ArticleId IdType="pmc">PMC9887520</ArticleId><ArticleId IdType="pubmed">35545673</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S, Fu Z &amp; Kipnis J The Meningeal Lymphatic System: A New Player in Neurophysiology. Neuron 100, 375&#x2013;388, doi:10.1016/j.neuron.2018.09.022 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.022</ArticleId><ArticleId IdType="pmc">PMC6268162</ArticleId><ArticleId IdType="pubmed">30359603</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al. Meningeal lymphatics affect microglia responses and anti-Abeta immunotherapy. Nature 593, 255&#x2013;260, doi:10.1038/s41586-021-03489-0 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03489-0</ArticleId><ArticleId IdType="pmc">PMC8817786</ArticleId><ArticleId IdType="pubmed">33911285</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J &amp; Kipnis J Bypassing the blood-brain barrier. Science 366, 1448&#x2013;1449, doi:10.1126/science.aay0479 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay0479</ArticleId><ArticleId IdType="pubmed">31857468</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell 184, 1000&#x2013;1016 e1027, doi:10.1016/j.cell.2020.12.040 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.040</ArticleId><ArticleId IdType="pmc">PMC8487654</ArticleId><ArticleId IdType="pubmed">33508229</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn T &amp; Kallies A T cell responses in the central nervous system. Nat Rev Immunol 17, 179&#x2013;194, doi:10.1038/nri.2016.144 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.144</ArticleId><ArticleId IdType="pubmed">28138136</ArticleId></ArticleIdList></Reference><Reference><Citation>Siller-Farfan JA &amp; Dushek O Molecular mechanisms of T cell sensitivity to antigen. Immunol Rev 285, 194&#x2013;205, doi:10.1111/imr.12690 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12690</ArticleId><ArticleId IdType="pubmed">30129204</ArticleId></ArticleIdList></Reference><Reference><Citation>Loetscher M et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184, 963&#x2013;969, doi:10.1084/jem.184.3.963 (1996).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.3.963</ArticleId><ArticleId IdType="pmc">PMC2192763</ArticleId><ArticleId IdType="pubmed">9064356</ArticleId></ArticleIdList></Reference><Reference><Citation>Madore C, Yin Z, Leibowitz J &amp; Butovsky O Microglia, Lifestyle Stress, and Neurodegeneration. Immunity 52, 222&#x2013;240, doi:10.1016/j.immuni.2019.12.003 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.12.003</ArticleId><ArticleId IdType="pmc">PMC7234821</ArticleId><ArticleId IdType="pubmed">31924476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J Clin Invest 130, 4954&#x2013;4968, doi:10.1172/JCI138179 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138179</ArticleId><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y et al. Microglia use TAM receptors to detect and engulf amyloid beta plaques. Nat Immunol 22, 586&#x2013;594, doi:10.1038/s41590-021-00913-5 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00913-5</ArticleId><ArticleId IdType="pmc">PMC8102389</ArticleId><ArticleId IdType="pubmed">33859405</ArticleId></ArticleIdList></Reference><Reference><Citation>Neefjes J, Jongsma ML, Paul P &amp; Bakke O Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11, 823&#x2013;836, doi:10.1038/nri3084 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3084</ArticleId><ArticleId IdType="pubmed">22076556</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217, doi:10.1016/j.cell.2017.05.018 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep 21, 366&#x2013;380, doi:10.1016/j.celrep.2017.09.039 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ et al. Unexpected role of interferon-gamma in regulating neuronal connectivity and social behaviour. Nature 535, 425&#x2013;429, doi:10.1038/nature18626 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18626</ArticleId><ArticleId IdType="pmc">PMC4961620</ArticleId><ArticleId IdType="pubmed">27409813</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14, 577&#x2013;589, doi:10.1038/s41582-018-0058-z (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252&#x2013;264, doi:10.1038/nrc3239 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3239</ArticleId><ArticleId IdType="pmc">PMC4856023</ArticleId><ArticleId IdType="pubmed">22437870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpe AH &amp; Pauken KE The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18, 153&#x2013;167, doi:10.1038/nri.2017.108 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.108</ArticleId><ArticleId IdType="pubmed">28990585</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenzweig N et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun 10, 465, doi:10.1038/s41467-019-08352-5 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-08352-5</ArticleId><ArticleId IdType="pmc">PMC6349941</ArticleId><ArticleId IdType="pubmed">30692527</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer&#x2019;s disease. Nat Med 22, 135&#x2013;137, doi:10.1038/nm.4022 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4022</ArticleId><ArticleId IdType="pubmed">26779813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumagai S et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21, 1346&#x2013;1358, doi:10.1038/s41590-020-0769-3 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0769-3</ArticleId><ArticleId IdType="pubmed">32868929</ArticleId></ArticleIdList></Reference><Reference><Citation>Turley SJ, Fletcher AL &amp; Elpek KG The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat Rev Immunol 10, 813&#x2013;825, doi:10.1038/nri2886 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2886</ArticleId><ArticleId IdType="pubmed">21088682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG &amp; Keane RW Pattern recognition receptors and central nervous system repair. Exp Neurol 258, 5&#x2013;16, doi:10.1016/j.expneurol.2014.01.001 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.01.001</ArticleId><ArticleId IdType="pmc">PMC4974939</ArticleId><ArticleId IdType="pubmed">25017883</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV et al. Lack of hepatic apoE does not influence early Abeta deposition: observations from a new APOE knock-in model. Mol Neurodegener 14, 37, doi:10.1186/s13024-019-0337-1 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0337-1</ArticleId><ArticleId IdType="pmc">PMC6796484</ArticleId><ArticleId IdType="pubmed">31623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi T et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res 5, 106&#x2013;117, doi:10.1158/2326-6066.CIR-16-0391 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0391</ArticleId><ArticleId IdType="pmc">PMC5510474</ArticleId><ArticleId IdType="pubmed">28073774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak DF et al. Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. PLoS One 8, e66024, doi:10.1371/journal.pone.0066024 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0066024</ArticleId><ArticleId IdType="pmc">PMC3677926</ArticleId><ArticleId IdType="pubmed">23762458</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuede CM et al. Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain. PLoS One 5, e11374, doi:10.1371/journal.pone.0011374 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011374</ArticleId><ArticleId IdType="pmc">PMC2894063</ArticleId><ArticleId IdType="pubmed">20613880</ArticleId></ArticleIdList></Reference><Reference><Citation>Khuchua Z et al. Deletion of the N-terminus of murine map2 by gene targeting disrupts hippocampal ca1 neuron architecture and alters contextual memory. Neuroscience 119, 101&#x2013;111, doi:10.1016/s0306-4522(03)00094-0 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0306-4522(03)00094-0</ArticleId><ArticleId IdType="pubmed">12763072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50, 253&#x2013;271 e256, doi:10.1016/j.immuni.2018.11.004 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.11.004</ArticleId><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36894565</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>09</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults.</ArticleTitle><Pagination><StartPage>3967</StartPage><MedlinePgn>3967</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3967</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-30167-0</ELocationID><Abstract><AbstractText>Slow paced breathing via heart rate variability (HRV) biofeedback stimulates vagus-nerve pathways that counter noradrenergic stress and arousal pathways that can influence production and clearance of Alzheimer's disease (AD)-related proteins. Thus, we examined whether HRV biofeedback intervention affects plasma &#x391;&#x3b2;40, &#x391;&#x3b2;42, total tau (tTau), and phosphorylated tau-181 (pTau-181) levels. We randomized healthy adults (N&#x2009;=&#x2009;108) to use slow-paced breathing with HRV biofeedback to increase heart rate oscillations (Osc+) or to use personalized strategies with HRV biofeedback to decrease heart rate oscillations (Osc-). They practiced 20-40&#xa0;min daily. Four weeks of practicing the Osc+&#x2009;and Osc- conditions produced large effect size differences in change in plasma A&#x3b2;40 and A&#x3b2;42 levels. The Osc+&#x2009;condition decreased plasma &#x391;&#x3b2; while the Osc- condition increased &#x391;&#x3b2;. Decreases in &#x391;&#x3b2; were associated with decreases in gene transcription indicators of &#x3b2;-adrenergic signaling, linking effects to the noradrenergic system. There were also opposing effects of the Osc+&#x2009;and Osc- interventions on tTau for younger adults and pTau-181 for older adults. These results provide novel data supporting a causal role of autonomic activity in modulating plasma AD-related biomarkers.Trial registration: NCT03458910 (ClinicalTrials.gov); first posted on 03/08/2018.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Jungwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouanet</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Alessandra Cadete</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nashiro</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Hyun Joo</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porat</LastName><ForeName>Shai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Junxiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Steve W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nation</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thayer</LastName><ForeName>Julian F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mather</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA. mara.mather@usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03458910</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057184</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG080652</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG057184</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001341" MajorTopicYN="N">Autonomic Nervous System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014630" MajorTopicYN="N">Vagus Nerve</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>9</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36894565</ArticleId><ArticleId IdType="pmc">PMC9998394</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-30167-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-30167-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer&#x2019;s disease incidence rates. Alzheimer&#x2019;s Dement. 2008;4(5):316&#x2013;323. doi: 10.1016/j.jalz.2008.05.2479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2008.05.2479</ArticleId><ArticleId IdType="pubmed">18790458</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnemeier H, Wiegand UKH, Brandes A, et al. Circadian profile of cardiac autonomic nervous modulation in healthy subjects. J. Cardiovasc. Electrophysiol. 2003;14(8):791&#x2013;799. doi: 10.1046/j.1540-8167.2003.03078.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1540-8167.2003.03078.x</ArticleId><ArticleId IdType="pubmed">12890036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukusaki C, Kawakubo K, Yamamoto Y. Assessment of the primary effect of aging on heart rate variability in humans. Clin. Auton. Res. 2000;10(3):123&#x2013;130. doi: 10.1007/BF02278016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02278016</ArticleId><ArticleId IdType="pubmed">10954070</ArticleId></ArticleIdList></Reference><Reference><Citation>Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J. Physiol. 2000;528(3):407&#x2013;417. doi: 10.1111/j.1469-7793.2000.00407.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7793.2000.00407.x</ArticleId><ArticleId IdType="pmc">PMC2270159</ArticleId><ArticleId IdType="pubmed">11060120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PY, Yun AJ, Bazar KA. Conditions of aging as manifestations of sympathetic bias unmasked by loss of parasympathetic function. Med. Hypotheses. 2004;62(6):868&#x2013;870. doi: 10.1016/j.mehy.2003.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2003.11.024</ArticleId><ArticleId IdType="pubmed">15142638</ArticleId></ArticleIdList></Reference><Reference><Citation>Mather M. Noradrenaline in the aging brain: Promoting cognitive reserve or accelerating Alzheimer&#x2019;s disease? Semin. Cell Dev. Biol. 2021;116:108&#x2013;124. doi: 10.1016/j.semcdb.2021.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC8292227</ArticleId><ArticleId IdType="pubmed">34099360</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G, Li QX. Platelets and Alzheimer&#x2019;s disease: Potential of APP as a biomarker. World J. Psychiatry. 2012;2(6):102&#x2013;113. doi: 10.5498/wjp.v2.i6.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.5498/wjp.v2.i6.102</ArticleId><ArticleId IdType="pmc">PMC3782192</ArticleId><ArticleId IdType="pubmed">24175176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobarro M, Gerenu G, Ram&#xed;rez MJ. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer&#x2019;s transgenic mice. Int. J. Neuropsychopharmacol. 2013;16(10):2245&#x2013;2257. doi: 10.1017/S1461145713000631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1461145713000631</ArticleId><ArticleId IdType="pubmed">23768694</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y, Zhao X, Bao G, et al. Activation of &#x3b2;2-adrenergic receptor stimulates &#x3b3;-secretase activity and accelerates amyloid plaque formation. Nat. Med. 2006;12(12):1390&#x2013;1396. doi: 10.1038/nm1485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1485</ArticleId><ArticleId IdType="pubmed">17115048</ArticleId></ArticleIdList></Reference><Reference><Citation>Justice NJ. The relationship between stress and Alzheimer&#x2019;s disease. Neurobiol. Stress. 2018;8:127&#x2013;133. doi: 10.1016/j.ynstr.2018.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ynstr.2018.04.002</ArticleId><ArticleId IdType="pmc">PMC5991350</ArticleId><ArticleId IdType="pubmed">29888308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Hussaini SA, Bastille IM, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 2016;19(8):1085&#x2013;1092. doi: 10.1038/nn.4328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4328</ArticleId><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14(4):389&#x2013;394. doi: 10.1038/embor.2013.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 2014;211(3):387&#x2013;393. doi: 10.1084/jem.20131685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20131685</ArticleId><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA. Stress-induced tau phosphorylation: Functional neuroplasticity or neuronal vulnerability? J. Alzheimers Dis. 2009;18(2):453&#x2013;457. doi: 10.3233/JAD-2009-1153.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1153</ArticleId><ArticleId IdType="pmc">PMC2906152</ArticleId><ArticleId IdType="pubmed">19584431</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Bretteville A, Liu L, et al. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 2009;23(8):2595&#x2013;2604. doi: 10.1096/fj.08-122424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-122424</ArticleId><ArticleId IdType="pmc">PMC2717763</ArticleId><ArticleId IdType="pubmed">19279139</ArticleId></ArticleIdList></Reference><Reference><Citation>Papon MA, Whittington R, El Khoury N, Planel E. Alzheimer&#x2019;s disease and anesthesia. Front. Neurosci. 2011 doi: 10.3389/fnins.2010.00272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2010.00272</ArticleId><ArticleId IdType="pmc">PMC3034231</ArticleId><ArticleId IdType="pubmed">21344011</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittington RA, Vir&#xe1;g L, Gratuze M, et al. Dexmedetomidine increases tau phosphorylation under normothermic conditions in vivo and in vitro. Neurobiol. Aging. 2015;36(8):2414&#x2013;2428. doi: 10.1016/j.neurobiolaging.2015.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.05.002</ArticleId><ArticleId IdType="pmc">PMC4465078</ArticleId><ArticleId IdType="pubmed">26058840</ArticleId></ArticleIdList></Reference><Reference><Citation>Benveniste H, Liu X, Koundal S, Sanggaard S, Lee H, Wardlaw J. The glymphatic system and waste clearance with brain aging: A review. GER. 2019;65(2):106&#x2013;119. doi: 10.1159/000490349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000490349</ArticleId><ArticleId IdType="pmc">PMC6329683</ArticleId><ArticleId IdType="pubmed">29996134</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373&#x2013;377. doi: 10.1126/science.1241224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241224</ArticleId><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Benveniste H, Lee H, Ding F, et al. Anesthesia with dexmedetomidine and low-dose isoflurane increases solute transport via the glymphatic pathway in rat brain when compared with high-dose isoflurane. Anesthesiology. 2017;127(6):976&#x2013;988. doi: 10.1097/ALN.0000000000001888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000001888</ArticleId><ArticleId IdType="pmc">PMC5685871</ArticleId><ArticleId IdType="pubmed">28938276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng KP, Brodnick SK, Blanz SL, et al. Clinically-derived vagus nerve stimulation enhances cerebrospinal fluid penetrance. Brain Stimul. 2020;13(4):1024&#x2013;1030. doi: 10.1016/j.brs.2020.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2020.03.012</ArticleId><ArticleId IdType="pubmed">32388045</ArticleId></ArticleIdList></Reference><Reference><Citation>Eide PK, Vatnehol SAS, Emblem KE, Ringstad G. Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes. Sci. Rep. 2018;8(1):7194. doi: 10.1038/s41598-018-25666-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25666-4</ArticleId><ArticleId IdType="pmc">PMC5940793</ArticleId><ArticleId IdType="pubmed">29740121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohr T, Hjorth PG, Holst SC, et al. The glymphatic system: Current understanding and modeling. iScience. 2022;25(9):104987. doi: 10.1016/j.isci.2022.104987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104987</ArticleId><ArticleId IdType="pmc">PMC9460186</ArticleId><ArticleId IdType="pubmed">36093063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JAHR. Effect of 1 night of total sleep deprivation on cerebrospinal fluid &#x3b2;-amyloid 42 in healthy middle-aged men: A randomized clinical trial. JAMA Neurol. 2014;71(8):971&#x2013;977. doi: 10.1001/jamaneurol.2014.1173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1173</ArticleId><ArticleId IdType="pubmed">24887018</ArticleId></ArticleIdList></Reference><Reference><Citation>Blattner MS, Panigrahi SK, Toedebusch CD, et al. Increased cerebrospinal fluid amyloid-&#x3b2; during sleep deprivation in healthy middle-aged adults is not due to stress or circadian disruption (Naismith S, ed.) JAD. 2020;75(2):471&#x2013;482. doi: 10.3233/JAD-191122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-191122</ArticleId><ArticleId IdType="pmc">PMC7246155</ArticleId><ArticleId IdType="pubmed">32250301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, McCullough A, Landsness EC, et al. Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer&#x2019;s disease. Sci. Transl. Med. 2019;11(474):6550. doi: 10.1126/scitranslmed.aau6550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6550</ArticleId><ArticleId IdType="pmc">PMC6342564</ArticleId><ArticleId IdType="pubmed">30626715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey, B. P. et al. Effect of sleep on overnight cerebrospinal fluid amyloid &#x3b2; kinetics. Ann. Neurol.83(1), 197&#x2013;204. 10.1002/ana.25117 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="pubmed">29220873</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrer PM, Gevirtz R. Heart rate variability biofeedback: How and why does it work? Front. Psychol. 2014;5:756. doi: 10.3389/fpsyg.2014.00756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2014.00756</ArticleId><ArticleId IdType="pmc">PMC4104929</ArticleId><ArticleId IdType="pubmed">25101026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mather M, Thayer JF. How heart rate variability affects emotion regulation brain networks. Curr. Opin. Behav. Sci. 2018;19:98&#x2013;104. doi: 10.1016/j.cobeha.2017.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cobeha.2017.12.017</ArticleId><ArticleId IdType="pmc">PMC5761738</ArticleId><ArticleId IdType="pubmed">29333483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nashiro K, Min J, Yoo HJ, et al. Increasing coordination and responsivity of emotion-related brain regions with a heart rate variability biofeedback randomized trial. Cognit. Affect. Behav. Neurosci. 2022 doi: 10.3758/s13415-022-01032-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/s13415-022-01032-w</ArticleId><ArticleId IdType="pmc">PMC9931635</ArticleId><ArticleId IdType="pubmed">36109422</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Esh CL, Kokjohn TA, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2009;5(1):18&#x2013;29. doi: 10.1016/j.jalz.2008.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2008.10.004</ArticleId><ArticleId IdType="pmc">PMC2663406</ArticleId><ArticleId IdType="pubmed">19118806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Martins RN, Rumble B, et al. The amyloid precursor protein of Alzheimer&#x2019;s disease is released by human platelets. J. Biol. Chem. 1990;265(26):15977&#x2013;15983. doi: 10.1016/S0021-9258(18)55493-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)55493-4</ArticleId><ArticleId IdType="pubmed">2118534</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann. Neurol. 2018;84(5):648&#x2013;658. doi: 10.1002/ana.25334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25334</ArticleId><ArticleId IdType="pmc">PMC6282982</ArticleId><ArticleId IdType="pubmed">30196548</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Palmqvist S, et al. Plasma &#x3b2;-amyloid in Alzheimer&#x2019;s disease and vascular disease. Sci. Rep. 2016;6:26801. doi: 10.1038/srep26801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26801</ArticleId><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Deters KD, Risacher SL, Kim S, et al. Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2017;58(4):1245&#x2013;1254. doi: 10.3233/JAD-161114.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161114</ArticleId><ArticleId IdType="pmc">PMC5523909</ArticleId><ArticleId IdType="pubmed">28550246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fossati S, Ramos Cejudo J, Debure L, et al. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. Diagn. Assess. Dis. Monit. 2019;11:483&#x2013;492. doi: 10.1016/j.dadm.2019.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.05.001</ArticleId><ArticleId IdType="pmc">PMC6624242</ArticleId><ArticleId IdType="pubmed">31334328</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J. Exp. Med. 2020;217(11):e20200861. doi: 10.1084/jem.20200861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200861</ArticleId><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat. Med. 2020;26(3):387&#x2013;397. doi: 10.1038/s41591-020-0762-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark C, Lewczuk P, Kornhuber J, et al. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer&#x2019;s disease pathology and clinical disease progression. Alz. Res. Therapy. 2021;13:65. doi: 10.1186/s13195-021-00805-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00805-8</ArticleId><ArticleId IdType="pmc">PMC7995778</ArticleId><ArticleId IdType="pubmed">33766131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SW. Elevating the perspective on human stress genomics. Psychoneuroendocrinology. 2010;35(7):955&#x2013;962. doi: 10.1016/j.psyneuen.2010.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2010.06.008</ArticleId><ArticleId IdType="pmc">PMC2917592</ArticleId><ArticleId IdType="pubmed">20630660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomara N, Bruno D, Plaska CR, et al. Plasma amyloid-&#x3b2; dynamics in late-life major depression: A longitudinal study. Transl. Psychiatry. 2022;12(1):1&#x2013;7. doi: 10.1038/s41398-022-02077-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-022-02077-8</ArticleId><ArticleId IdType="pmc">PMC9334636</ArticleId><ArticleId IdType="pubmed">35902554</ArticleId></ArticleIdList></Reference><Reference><Citation>do Nascimento KKF, Silva KP, Malloy-Diniz LF, Butters MA, Diniz BS. Plasma and cerebrospinal fluid amyloid-&#x3b2; levels in late-life depression: A systematic review and meta-analysis. J. Psychiatr. Res. 2015;69:35&#x2013;41. doi: 10.1016/j.jpsychires.2015.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2015.07.024</ArticleId><ArticleId IdType="pmc">PMC5102150</ArticleId><ArticleId IdType="pubmed">26343592</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard, K.S., Dudoit, S., &amp; van der Laan, M.J. Multiple Testing Procedures: The Multtest Package and Applications to Genomics. (Gentleman, R., Carey, V.J., Huber, W., Irizarry, R.A., Dudoit, S., eds.). 251&#x2013;272. 10.1007/0-387-29362-0_15 (Springer, 2005).</Citation></Reference><Reference><Citation>Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93(3):491&#x2013;507. doi: 10.1093/biomet/93.3.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/93.3.491</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: A controlled trial. Arch. Neurol. 2010;67(1):71&#x2013;79. doi: 10.1001/archneurol.2009.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.307</ArticleId><ArticleId IdType="pmc">PMC3056436</ArticleId><ArticleId IdType="pubmed">20065132</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederiksen KS, Madsen K, Andersen BB, et al. Moderate- to high-intensity exercise does not modify cortical &#x3b2;-amyloid in Alzheimer&#x2019;s disease. Alzheimers Dement. (N.Y.) 2019;5:208&#x2013;215. doi: 10.1016/j.trci.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.04.006</ArticleId><ArticleId IdType="pmc">PMC6556817</ArticleId><ArticleId IdType="pubmed">31198839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Jung YS, Kim JW, Ha MS, Ha SM, Kim DY. Effects of aquatic and land-based exercises on amyloid beta, heat shock protein 27, and pulse wave velocity in elderly women. Exp. Gerontol. 2018;108:62&#x2013;68. doi: 10.1016/j.exger.2018.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2018.03.024</ArticleId><ArticleId IdType="pubmed">29604402</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidoni ED, Morris JK, Watts A, et al. Effect of aerobic exercise on amyloid accumulation in preclinical Alzheimer&#x2019;s: A 1-year randomized controlled trial. PLoS ONE. 2021;16(1):e0244893. doi: 10.1371/journal.pone.0244893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244893</ArticleId><ArticleId IdType="pmc">PMC7808620</ArticleId><ArticleId IdType="pubmed">33444359</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-analysis of plasma amyloid-&#x3b2; levels in Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis. 2011;26(2):365&#x2013;375. doi: 10.3233/JAD-2011-101977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101977</ArticleId><ArticleId IdType="pmc">PMC5660871</ArticleId><ArticleId IdType="pubmed">21709378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid protein is elevated in late-onset Alzheimer disease families. Neurology. 2008;70(8):596&#x2013;606. doi: 10.1212/01.wnl.0000278386.00035.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000278386.00035.21</ArticleId><ArticleId IdType="pubmed">17914065</ArticleId></ArticleIdList></Reference><Reference><Citation>Stakos DA, Stamatelopoulos K, Bampatsias D, et al. The Alzheimer&#x2019;s disease amyloid-beta hypothesis in cardiovascular aging and disease. J. Am. Coll. Cardiol. 2020;75(8):952&#x2013;967. doi: 10.1016/j.jacc.2019.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.12.033</ArticleId><ArticleId IdType="pmc">PMC7042886</ArticleId><ArticleId IdType="pubmed">32130931</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabelle A, Schraen S, Gutierrez L, et al. Plasma &#x3b2;-amyloid 40 levels are positively associated with mortality risks in the elderly. Alzheimer&#x2019;s Dement. 2015;11(6):672&#x2013;680. doi: 10.1016/j.jalz.2014.04.515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.04.515</ArticleId><ArticleId IdType="pubmed">25022539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer&#x2019;s Dement. 2018;14(8):989&#x2013;997. doi: 10.1016/j.jalz.2018.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Omoluabi T, Torraville SE, Maziar A, et al. Novelty-like activation of locus coeruleus protects against deleterious human pretangle tau effects while stress-inducing activation worsens its effects. Alzheimer&#x2019;s Dement. Transl. Res. Clin. Intervent. 2021;7(1):e12231. doi: 10.1002/trc2.12231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12231</ArticleId><ArticleId IdType="pmc">PMC8719346</ArticleId><ArticleId IdType="pubmed">35005208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohmeier TE, Hildebrandt DA, Warren S, May PJ, Cunningham JT. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am. J. Physiol.-Regulat. Integr. Comp. Physiol. 2005;288(4):R828&#x2013;R836. doi: 10.1152/ajpregu.00591.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00591.2004</ArticleId><ArticleId IdType="pubmed">15793036</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian DY, Cheng Y, Zhuang ZQ, et al. Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer&#x2019;s disease. Mol. Psychiatry. 2021;26(10):6074&#x2013;6082. doi: 10.1038/s41380-021-01073-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01073-6</ArticleId><ArticleId IdType="pubmed">33828237</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y, Bu XL, Liu YH, et al. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer&#x2019;s disease. Acta Neuropathol. 2015;130(4):487&#x2013;499. doi: 10.1007/s00401-015-1477-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1477-1</ArticleId><ArticleId IdType="pmc">PMC4575389</ArticleId><ArticleId IdType="pubmed">26363791</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain&#x2014;Implications for Alzheimer disease. Nat. Rev. Neurol. 2015;11(8):457&#x2013;470. doi: 10.1038/nrneurol.2015.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.119</ArticleId><ArticleId IdType="pmc">PMC4694579</ArticleId><ArticleId IdType="pubmed">26195256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiviniemi V, Wang X, Korhonen V, et al. Ultra-fast magnetic resonance encephalography of physiological brain activity&#x2014;Glymphatic pulsation mechanisms? J. Cereb. Blood Flow Metab. 2016;36(6):1033&#x2013;1045. doi: 10.1177/0271678X15622047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X15622047</ArticleId><ArticleId IdType="pmc">PMC4908626</ArticleId><ArticleId IdType="pubmed">26690495</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques F, Sousa JC, Sousa N, Palha JA. Blood&#x2013;brain-barriers in aging and in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2013;8(1):38. doi: 10.1186/1750-1326-8-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-38</ArticleId><ArticleId IdType="pmc">PMC4015275</ArticleId><ArticleId IdType="pubmed">24148264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress BT, Iliff JJ, Xia M, et al. Impairment of paravascular clearance pathways in the aging brain. Ann. Neurol. 2014;76(6):845&#x2013;861. doi: 10.1002/ana.24271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24271</ArticleId><ArticleId IdType="pmc">PMC4245362</ArticleId><ArticleId IdType="pubmed">25204284</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010;6(3):131&#x2013;144. doi: 10.1038/nrneurol.2010.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.4</ArticleId><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Potter R, Sigurdson W, et al. &#x3b2;-Amyloid dynamics in human plasma. Arch. Neurol. 2012;69(12):1591&#x2013;1597. doi: 10.1001/archneurol.2012.18107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.18107</ArticleId><ArticleId IdType="pmc">PMC3808092</ArticleId><ArticleId IdType="pubmed">23229043</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LLB, Harp D, Jung WS. Reliability generalization of scores on the Spielberger State-Trait Anxiety Inventory. Educ. Psychol. Meas. 2002;62(4):603&#x2013;618. doi: 10.1177/0013164402062004005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0013164402062004005</ArticleId></ArticleIdList></Reference><Reference><Citation>Radloff LS. The CES-D Scale: A self-report depression scale for research in the general population. Appl. Psychol. Meas. 1977;1(3):385&#x2013;401. doi: 10.1177/014662167700100306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014662167700100306</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove JR, Prapavessis H. Preliminary evidence for the reliability and validity of an abbreviated profile of mood states. Int. J. Sport Psychol. 1992;23(2):93&#x2013;109.</Citation></Reference><Reference><Citation>Bellenger CR, Miller D, Halson SL, Roach G, Sargent C. Wrist-based photoplethysmography assessment of heart rate and heart rate variability: Validation of WHOOP. Sensors. 2021;21(10):3571. doi: 10.3390/s21103571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s21103571</ArticleId><ArticleId IdType="pmc">PMC8160717</ArticleId><ArticleId IdType="pubmed">34065516</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DJ, Roach GD, Lastella M, et al. A validation study of a commercial wearable device to automatically detect and estimate sleep. Biosensors. 2021;11(6):185. doi: 10.3390/bios11060185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bios11060185</ArticleId><ArticleId IdType="pmc">PMC8226553</ArticleId><ArticleId IdType="pubmed">34201016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SW, Yan W, Galic Z, Arevalo J, Zack JA. Expression-based monitoring of transcription factor activity: The TELiS database. Bioinformatics. 2005;21(6):803&#x2013;810. doi: 10.1093/bioinformatics/bti038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bti038</ArticleId><ArticleId IdType="pubmed">15374858</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SW, Shanahan MJ, Gaydosh L, Harris KM. Population-based RNA profiling in Add Health finds social disparities in inflammatory and antiviral gene regulation to emerge by young adulthood. PNAS. 2020;117(9):4601&#x2013;4608. doi: 10.1073/pnas.1821367117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1821367117</ArticleId><ArticleId IdType="pmc">PMC7060722</ArticleId><ArticleId IdType="pubmed">32041883</ArticleId></ArticleIdList></Reference><Reference><Citation>Glickman ME, Rao SR, Schultz MR. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J. Clin. Epidemiol. 2014;67(8):850&#x2013;857. doi: 10.1016/j.jclinepi.2014.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.03.012</ArticleId><ArticleId IdType="pubmed">24831050</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, 2022). https://www.r-project.org/. Accessed 18 Jan 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36927019</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>379</Volume><Issue>6637</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Mechanism of <i>STMN2</i> cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.</ArticleTitle><Pagination><StartPage>1140</StartPage><EndPage>1149</EndPage><MedlinePgn>1140-1149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abq5622</ELocationID><Abstract><AbstractText>Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration. We found that TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in <i>STMN2</i> pre-mRNA. Targeting dCasRx or antisense oligonucleotides (ASOs) suppressed cryptic splicing, which restored axonal regeneration and stathmin-2-dependent lysosome trafficking in TDP-43-deficient human motor neurons. In mice that were gene-edited to contain human <i>STMN2</i> cryptic splice-polyadenylation sequences, ASO injection into cerebral spinal fluid successfully corrected <i>Stmn2</i> pre-mRNA misprocessing and restored stathmin-2 expression levels independently of TDP-43 binding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baughn</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><Identifier Source="ORCID">0000-0001-8525-8024</Identifier><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melamed</LastName><ForeName>Ze'ev</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-3734-3926</Identifier><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Erauskin</LastName><ForeName>Jone</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beccari</LastName><ForeName>Melinda S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-1019-6388</Identifier><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5895-6684</Identifier><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuberi</LastName><ForeName>Aamir</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0252-9760</Identifier><AffiliationInfo><Affiliation>Rare Disease Translational Center, The Jackson Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Presa</LastName><ForeName>Maximilliano</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0160-6528</Identifier><AffiliationInfo><Affiliation>Rare Disease Translational Center, The Jackson Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalo-Gil</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rare Disease Translational Center, The Jackson Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maimon</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez-Sanchez</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8107-5850</Identifier><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Som</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bravo-Hern&#xe1;ndez</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8762-0357</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taupin</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artates</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acks</LastName><ForeName>Eitan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ndayambaje</LastName><ForeName>I Sandra</ForeName><Initials>IS</Initials><Identifier Source="ORCID">0000-0002-8099-2307</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agra de Almeida Quadros</LastName><ForeName>Ana R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-6909-2420</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar-Nejad</LastName><ForeName>Paayman</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5176-739X</Identifier><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>C Frank</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0001-9887-6251</Identifier><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutz</LastName><ForeName>Cathleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rare Disease Translational Center, The Jackson Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagier-Tourenne</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3058-8322</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard University and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0002-1934-3682</Identifier><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 NS124203</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG066596</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA034196</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U42 OD010921</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS112503</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012322">RNA Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050777">Stathmin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C063314">STMN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C512849">Stmn2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022821">RNA Splice Sites</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Jun;19(6):326. doi: 10.1038/s41582-023-00806-1.</RefSource><PMID Version="1">37012364</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2023 May;22(5):354. doi: 10.1038/d41573-023-00056-2.</RefSource><PMID Version="1">37041235</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2023 Jun;24(6):346. doi: 10.1038/s41576-023-00603-y.</RefSource><PMID Version="1">37069253</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2023 Jul 12;8(1):266. doi: 10.1038/s41392-023-01533-1.</RefSource><PMID Version="1">37433765</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026723" MajorTopicYN="Y">Polyadenylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012322" MajorTopicYN="N">RNA Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050777" MajorTopicYN="Y">Stathmin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="Y">RNA Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022821" MajorTopicYN="N">RNA Splice Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="Y">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071446" MajorTopicYN="N">Neuronal Outgrowth</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: A patent application has been filed describing composition and methods for restoring stathmin-2 expression; publication number US 2021-0252039. D.W.C. and Z.M. are inventors on the patent. CFB, KL, PJN, FR, are employees of Ionis Pharmaceuticals. DWC is a consultant for Ionis Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>8</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36927019</ArticleId><ArticleId IdType="mid">NIHMS1890463</ArticleId><ArticleId IdType="pmc">PMC10148063</ArticleId><ArticleId IdType="doi">10.1126/science.abq5622</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nussbacher JK, Tabet R, Yeo GW, Lagier-Tourenne C, Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions. Neuron 102, 294&#x2013;320 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545120</ArticleId><ArticleId IdType="pubmed">30998900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW, TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 19, R46&#x2013;64 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A et al., Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97, 1268&#x2013;1283 e1266 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Barmada SJ, RNA Degradation in Neurodegenerative Disease. Adv Neurobiol 20, 103&#x2013;142 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6498147</ArticleId><ArticleId IdType="pubmed">29916018</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, Shorter J, RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion 5, 179&#x2013;187 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226045</ArticleId><ArticleId IdType="pubmed">21847013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW, Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr., Cleveland DW, Decoding ALS: from genes to mechanism. Nature 539, 197&#x2013;206 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA et al., TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol 127, 811&#x2013;824 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS et al., TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284, 20329&#x2013;20339 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T et al., TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C et al., TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol 61, 435&#x2013;445 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y et al., TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. Acta Neuropathol 118, 359&#x2013;369 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19330339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima T et al., Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy. J Neuropathol Exp Neurol 76, 676&#x2013;682 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901076</ArticleId><ArticleId IdType="pubmed">28789478</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC et al., TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 69, 918&#x2013;929 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT et al., Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503&#x2013;1527 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL et al., Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol 137, 27&#x2013;46 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M et al., Cryptic exon incorporation occurs in Alzheimer&#x2019;s brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol 133, 923&#x2013;931 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444385</ArticleId><ArticleId IdType="pubmed">28332094</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR et al., Characterising the RNA targets and position-dependent splicing regulation by TDP-43; implications for neurodegenerative diseases. Nat Neurosci, (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M et al., Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14, 459&#x2013;468 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C et al., Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 15, 1488&#x2013;1497 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A-L et al., TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131&#x2013;137 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR et al., TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature 603, 124&#x2013;130 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC, TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650&#x2013;655 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH et al., Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener 12, 13 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289002</ArticleId><ArticleId IdType="pubmed">28153034</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z et al., Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration Nat. Neurosci. 22, 180&#x2013;190 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR et al., ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci 22, 167&#x2013;179 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvin S, Sobel A, Neuronal stathmins: a family of phosphoproteins cooperating for neuronal development, plasticity and regeneration. Prog Neurobiol 126, 1&#x2013;18 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25449700</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Geisler S, DiAntonio A, Dynamic regulation of SCG10 in regenerating axons after injury. Exp Neurol 252, 1&#x2013;11 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947015</ArticleId><ArticleId IdType="pubmed">24246279</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra San Juan I et al., Loss of mouse Stmn2 function causes motor neuropathy. Neuron, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119928</ArticleId><ArticleId IdType="pubmed">35294901</ArticleId></ArticleIdList></Reference><Reference><Citation>Krus KL et al., Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. bioRxiv, 2022.2003.2013.484188 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9327139</ArticleId><ArticleId IdType="pubmed">35767949</ArticleId></ArticleIdList></Reference><Reference><Citation>Krach F et al., Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol 136, 405&#x2013;423 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215775</ArticleId><ArticleId IdType="pubmed">29881994</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M et al., Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest 130, 6080&#x2013;6092 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Belmont LD, Mitchison TJ, Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84, 623&#x2013;631 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8598048</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein R, Mori N, Matthews K, Lo LC, Anderson DJ, The NGF-inducible SCG10 mRNA encodes a novel membrane-bound protein present in growth cones and abundant in developing neurons. Neuron 1, 463&#x2013;476 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3272176</ArticleId></ArticleIdList></Reference><Reference><Citation>Morii H, Shiraishi-Yamaguchi Y, Mori N, SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons. J Neurobiol 66, 1101&#x2013;1114 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16838365</ArticleId></ArticleIdList></Reference><Reference><Citation>Riederer BM et al., Regulation of microtubule dynamics by the neuronal growth-associated protein SCG10. Proc Natl Acad Sci U S A 94, 741&#x2013;745 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19584</ArticleId><ArticleId IdType="pubmed">9012855</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan JE, Lytle NK, Zuniga A, Goldstein LS, The Microtubule Regulatory Protein Stathmin Is Required to Maintain the Integrity of Axonal Microtubules in Drosophila. PLoS One 8, e68324 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694009</ArticleId><ArticleId IdType="pubmed">23840848</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf ER, Heerssen HM, Wright CM, Davis GW, DiAntonio A, Stathmin is required for stability of the Drosophila neuromuscular junction. J Neurosci 31, 15026&#x2013;15034 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207242</ArticleId><ArticleId IdType="pubmed">22016536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM et al., Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol 348, 575&#x2013;588 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim F, Spingola M, Peabody DS, Altering the RNA binding specificity of a translational repressor. J Biol Chem 269, 9006&#x2013;9010 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8132638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rot G et al., High-Resolution RNA Maps Suggest Common Principles of Splicing and Polyadenylation Regulation by TDP-43. Cell Rep 19, 1056&#x2013;1067 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437728</ArticleId><ArticleId IdType="pubmed">28467899</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R et al., Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol Cell 56, 311&#x2013;322 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224598</ArticleId><ArticleId IdType="pubmed">25263597</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Tang L, Mechano-regulation of alternative splicing. Curr Genomics 14, 49&#x2013;55 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580779</ArticleId><ArticleId IdType="pubmed">23997650</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda A et al., Position-specific binding of FUS to nascent RNA regulates mRNA length. Genes Dev 29, 1045&#x2013;1057 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441052</ArticleId><ArticleId IdType="pubmed">25995189</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin G, Gruber AR, Keller W, Zavolan M, Genome-wide analysis of pre-mRNA 3&#x2019; end processing reveals a decisive role of human cleavage factor I in the regulation of 3&#x2019; UTR length. Cell Rep 1, 753&#x2013;763 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22813749</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giammartino DC, Nishida K, Manley JL, Mechanisms and consequences of alternative polyadenylation. Mol Cell 43, 853&#x2013;866 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3194005</ArticleId><ArticleId IdType="pubmed">21925375</ArticleId></ArticleIdList></Reference><Reference><Citation>So BR et al., A Complex of U1 snRNP with Cleavage and Polyadenylation Factors Controls Telescripting, Regulating mRNA Transcription in Human Cells. Molecular Cell 76, 590&#x2013;599.e594 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6874754</ArticleId><ArticleId IdType="pubmed">31522989</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon R, Ugalde AP, Agami R, Alternative cleavage and polyadenylation: extent, regulation and function. Nature reviews 14, 496&#x2013;506 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23774734</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian B, Graber JH, Signals for pre-mRNA cleavage and polyadenylation. Wiley Interdiscip Rev RNA 3, 385&#x2013;396 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451228</ArticleId><ArticleId IdType="pubmed">22012871</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S et al., Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell 173, 665&#x2013;676 e614 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5910255</ArticleId><ArticleId IdType="pubmed">29551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS et al., Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017&#x2013;3026 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Kordasiewicz HB, Cleveland DW, Antisense Drugs Make Sense for Neurological Diseases. Annual Review of Pharmacology and Toxicology 61, 831&#x2013;852 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8682074</ArticleId><ArticleId IdType="pubmed">33035446</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH et al., Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536&#x2013;543 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes-Dias P, Holzbaur ELF, Axonal transport: Driving synaptic function. Science 366, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996143</ArticleId><ArticleId IdType="pubmed">31601744</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlson E, Maday S, Fu MM, Moughamian AJ, Holzbaur EL, Retrograde axonal transport: pathways to cell death? Trends Neurosci 33, 335&#x2013;344 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902719</ArticleId><ArticleId IdType="pubmed">20434225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN et al., Mice Carrying ALS Mutant TDP-43, but Not Mutant FUS, Display In Vivo Defects in Axonal Transport of Signaling Endosomes. Cell Reports 30, 3655&#x2013;3662.e3652 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090381</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES et al., ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A 110, E736&#x2013;745 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H et al., TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA et al., Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367&#x2013;371 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR et al., Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61, 427&#x2013;434 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al., Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigo F, Martinson HG, Functional coupling of last-intron splicing and 3&#x2019;-end processing to transcription in vitro: the poly(A) signal couples to splicing before committing to cleavage. Mol Cell Biol 28, 849&#x2013;862 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2223410</ArticleId><ArticleId IdType="pubmed">17967872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyburz A, Friedlein A, Langen H, Keller W, Direct interactions between subunits of CPSF and the U2 snRNP contribute to the coupling of pre-mRNA 3&#x2019; end processing and splicing. Mol Cell 23, 195&#x2013;205 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16857586</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T et al., Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 383, 109&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA, Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nature Medicine 28, 104&#x2013;116 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros BD, Schoch KM, Kreple CJ, Miller TM, Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics 19, 1145&#x2013;1158 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587169</ArticleId><ArticleId IdType="pubmed">35653060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM et al., TDP-43 regulates its mRNA levels through a negative feedback loop. Embo J, (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Avendano-Vazquez SE et al., Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev 26, 1679&#x2013;1684 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418585</ArticleId><ArticleId IdType="pubmed">22855830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR, Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82, 834&#x2013;848 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427210</ArticleId><ArticleId IdType="pubmed">18371932</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Krainer AR, Cleveland DW, Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu Rev Neurosci 42, 385&#x2013;406 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL et al., TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131&#x2013;137 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR et al., TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 603, 124&#x2013;130 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson DG et al., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6, 343&#x2013;345 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W et al., An optimized method for high-titer lentivirus preparations without ultracentrifugation. Sci Rep 5, 13875 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562269</ArticleId><ArticleId IdType="pubmed">26348152</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FJ et al., Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System. Neuron 92, 780&#x2013;795 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123850</ArticleId><ArticleId IdType="pubmed">27773581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36945515</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Novel method for collecting hippocampal interstitial fluid extracellular vesicles (EV-ISF) reveals sex-dependent changes in microglial EV proteome in response to A&#x3b2; pathology.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.03.10.532133</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.03.10.532133</ELocationID><Abstract><AbstractText>Brain-derived extracellular vesicles (EVs) play an active role in Alzheimer's disease (AD), relaying important physiological information about their host tissues. Circulating EVs are protected from degradation, making them attractive AD biomarkers. However, it is unclear how circulating EVs relate to EVs isolated from disease-vulnerable brain regions. We developed a novel method for collecting EVs from the hippocampal interstitial fluid (ISF) of live mice. EVs (EVISF) were isolated via ultracentrifugation and characterized by nanoparticle tracking analysis, immunogold labeling, and flow cytometry. Mass spectrometry and proteomic analyses were performed on EVISF cargo. EVISF were 40-150 nm in size and expressed CD63, CD9, and CD81. Using a model of cerebral amyloidosis (e.g. APPswe,PSEN1dE9 mice), we found protein concentration increased but protein diversity decreased with A deposition. Genotype, age, and A&#x3b2; deposition modulated proteostasis- and immunometabolic-related pathways. Changes in the microglial EVISF proteome were sexually dimorphic and associated with a differential response of plaque associated microglia. We found that female APP/PS1 mice have more amyloid plaques, less plaque associated microglia, and a less robust- and diverse- EVISF microglial proteome. Thus, in vivo microdialysis is a novel technique for collecting EVISF and offers a unique opportunity to explore the role of EVs in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pait</LastName><ForeName>Morgan C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Sarah D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yixin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ashish</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Sangeeta</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gironda</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Anwar</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Caitlin M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0003-1572-7360</Identifier></Author><Author ValidYN="Y"><LastName>Snipes</LastName><ForeName>J Andy</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jingyun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Furdui</LastName><ForeName>Cristina M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Deep</LastName><ForeName>Gagan</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Macauley</LastName><ForeName>Shannon L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG072947</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061805</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068330</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>J Extracell Vesicles. 2024 Jan;13(1):e12398. doi: 10.1002/jev2.12398.</RefSource><PMID Version="1">38191961</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36945515</ArticleId><ArticleId IdType="pmc">PMC10029004</ArticleId><ArticleId IdType="doi">10.1101/2023.03.10.532133</ArticleId><ArticleId IdType="pii">2023.03.10.532133</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37117788</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2662-8465</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature aging</Title><ISOAbbreviation>Nat Aging</ISOAbbreviation></Journal><ArticleTitle>CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>391</StartPage><EndPage>401</EndPage><MedlinePgn>391-401</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s43587-023-00380-7</ELocationID><Abstract><AbstractText>Cerebrospinal fluid (CSF) amyloid-&#x3b2; peptide (A&#x3b2;)42/A&#x3b2;40 and the concentration of tau phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's disease (AD). The present study used mass spectrometry to measure concentrations of nine phosphorylated and five nonphosphorylated tau species and phosphorylation occupancies (percentage phosphorylated/nonphosphorylated) at ten sites. In the present study we show that, in 750 individuals with a median age of 71.2&#x2009;years, CSF pT217/T217 predicted the presence of brain amyloid by positron emission tomography (PET) slightly better than A&#x3b2;42/A&#x3b2;40 (P&#x2009;=&#x2009;0.02). Furthermore, for individuals with positive brain amyloid by PET (n&#x2009;=&#x2009;263), CSF pT217/T217 was more strongly correlated with the amount of amyloid (Spearman's &#x3c1;&#x2009;=&#x2009;0.69) than A&#x3b2;42/A&#x3b2;40 (&#x3c1;&#x2009;=&#x2009;-0.42, P&#x2009;&lt;&#x2009;0.0001). In two independent cohorts of participants with symptoms of AD dementia (n&#x2009;=&#x2009;55 and n&#x2009;=&#x2009;90), CSF pT217/T217 and pT205/T205 were better correlated with tau PET measures than CSF p-tau181 concentration. These findings suggest that CSF pT217/T217 and pT205/T205 represent improved CSF biomarkers of amyloid and tau pathology in AD.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><Identifier Source="ORCID">0000-0003-4937-2860</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. barthelemy.nicolas@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA. barthelemy.nicolas@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saef</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-2109-2955</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yingxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horie</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7736-2614</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvad&#xf3;</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henson</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-1680-1465</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. schindler.s.e@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. schindler.s.e@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG070941</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Aging</MedlineTA><NlmUniqueID>101773306</NlmUniqueID><ISSNLinking>2662-8465</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>N.R.B., K.H., C.S., V.O. and R.J.B. are coinventors on the following US patent applications: &#x2018;Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimer&#x2019;s disease and other tauopathies&#x2019; (PCT/US2020/046224, N.R.B., K.H., C.S. and R.J.B.); &#x2018;CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies&#x2019; (PCT/US2022/022906, N.R.B., C.S. and R.J.B.); &#x2018;Plasma based methods for detecting CNS amyloid deposition&#x2019; (PCT/UC2018/030518, V.O. and R.J.B.); and &#x2018;Methods of diagnosing and treating based on site-specific tau phosphorylation&#x2019; (PCT/US2019/030725, N.R.B. and R.J.B.). N.R.B., K.H., C.S., V.O. and R.J.B. may receive a royalty income based on technology licensed by Washington University to C2N Diagnostics. K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received a salary from Eisai. A.M.F. has received research funding from Biogen, Centene, Fujirebio and Roche Diagnostics. She is a member of the scientific advisory boards for Roche Diagnostics, Genentech and Diadem. She consults for DiamiR and Seimens Healthcare Diagnostics Inc. T.L.S.B. has investigator-initiated research funding from the NIH, the Alzheimer&#x2019;s Association, the Barnes-Jewish Hospital Foundation and Siemens. She participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Janssen and Roche, and serves as a consultant to Biogen, Eli Lilly, Eisai and Siemens. C.X. consulted for DIADEM and has used funding from the NIH to hire C2N Diagnostics as a vendor in another independent NIH-funded project. He received no funding from C2N Diagnostics. Neither J.C.M. nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2&#x2009;years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Fujirebio, Genentech, Novartis, Novo Nordisk, Roche and Siemens. R.J.B. cofounded C2N Diagnostics. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive a royalty income based on technology (stable isotope labeling kinetics, blood plasma assay and methods of diagnosing AD with phosphorylation changes) licensed by Washington University to C2N Diagnostics. R.J.B. receives an income from C2N Diagnostics for serving on the scientific advisory board, and has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. S.E.S. has analyzed data provided by C2N Diagnostics to Washington University, but she has not received any research funding or personal compensation from C2N Diagnostics or any other for-profit organizations. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37117788</ArticleId><ArticleId IdType="pmc">PMC10154225</ArticleId><ArticleId IdType="doi">10.1038/s43587-023-00380-7</ArticleId><ArticleId IdType="pii">10.1038/s43587-023-00380-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol. 2018;14:225&#x2013;236. doi: 10.1038/nrneurol.2018.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2018.9</ArticleId><ArticleId IdType="pubmed">29449700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Tau PET correlates with different Alzheimer&#x2019;s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol. Med. 2021;13:e14398. doi: 10.15252/emmm.202114398.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202114398</ArticleId><ArticleId IdType="pmc">PMC8350902</ArticleId><ArticleId IdType="pubmed">34254442</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol. 2015;78:439&#x2013;453. doi: 10.1002/ana.24454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24454</ArticleId><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2022;98:e1137&#x2013;e1150. doi: 10.1212/WNL.0000000000200040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200040</ArticleId><ArticleId IdType="pmc">PMC8935438</ArticleId><ArticleId IdType="pubmed">35173015</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, et al. Preclinical Alzheimer&#x2019;s disease biomarkers accurately predict cognitive and neuropathological outcomes. Brain. 2022;145:4506&#x2013;4518. doi: 10.1093/brain/awac250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac250</ArticleId><ArticleId IdType="pmc">PMC10200309</ArticleId><ArticleId IdType="pubmed">35867858</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139:2249&#x2013;2260. doi: 10.1093/brain/aww139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww139</ArticleId><ArticleId IdType="pmc">PMC4958902</ArticleId><ArticleId IdType="pubmed">27286736</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, et al. Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer&#x2019;s disease. Sci. Adv. 2020;6:eaaz2387. doi: 10.1126/sciadv.aaz2387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, et al. Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J. Proteome Res. 2016;15:667&#x2013;676. doi: 10.1021/acs.jproteome.5b01001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b01001</ArticleId><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer&#x2019;s disease. Acta Neuropathol. 2019;137:279&#x2013;296. doi: 10.1007/s00401-018-1948-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1948-2</ArticleId><ArticleId IdType="pmc">PMC6514201</ArticleId><ArticleId IdType="pubmed">30547227</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE, Jr., et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer&#x2019;s disease. PLoS ONE. 2013;8:e76523. doi: 10.1371/journal.pone.0076523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076523</ArticleId><ArticleId IdType="pmc">PMC3792042</ArticleId><ArticleId IdType="pubmed">24116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;98:861&#x2013;864. doi: 10.1016/j.neuron.2018.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.04.035</ArticleId><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772&#x2013;781. doi: 10.1001/jama.2020.12134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer&#x2019;s disease pathology. Acta Neuropathol. 2021;141:709&#x2013;724. doi: 10.1007/s00401-021-02275-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02275-6</ArticleId><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J. Exp. Med. 2020;217:e20200861. doi: 10.1084/jem.20200861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200861</ArticleId><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78:1108&#x2013;1117. doi: 10.1001/jamaneurol.2021.2293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2293</ArticleId><ArticleId IdType="pmc">PMC8314178</ArticleId><ArticleId IdType="pubmed">34309632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mila-Aloma M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer&#x2019;s disease. Nat. Med. 2022;28:1797&#x2013;1801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9499867</ArticleId><ArticleId IdType="pubmed">35953717</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer&#x2019;s disease. Brain10.1093/brain/awac333 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10115176</ArticleId><ArticleId IdType="pubmed">36087307</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet. Neurol. 2021;20:739&#x2013;752. doi: 10.1016/S1474-4422(21)00214-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00214-3</ArticleId><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat. Commun. 2020;11:1683. doi: 10.1038/s41467-020-15436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther. 2020;12:26. doi: 10.1186/s13195-020-00596-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. Neurology. 2021;97:e1681&#x2013;e1694. doi: 10.1212/WNL.0000000000012727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012727</ArticleId><ArticleId IdType="pmc">PMC8605616</ArticleId><ArticleId IdType="pubmed">34493616</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer&#x2019;s disease diagnosis. Alzheimer&#x2019;s Dement. 2021;17:755&#x2013;767. doi: 10.1002/alz.12236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12236</ArticleId><ArticleId IdType="pmc">PMC8246793</ArticleId><ArticleId IdType="pubmed">33252199</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer&#x2019;s disease. Front. Aging Neurosci. 2019;11:121. doi: 10.3389/fnagi.2019.00121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00121</ArticleId><ArticleId IdType="pmc">PMC6537657</ArticleId><ArticleId IdType="pubmed">31178717</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie K, Barthelemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer&#x2019;s disease. Brain. 2021;144:515&#x2013;527. doi: 10.1093/brain/awaa373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa373</ArticleId><ArticleId IdType="pmc">PMC7940175</ArticleId><ArticleId IdType="pubmed">33283854</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, et al. Site-specific cerebrospinal fluid tau hyperphosphorylation in response to Alzheimer&#x2019;s disease brain pathology: not all tau phospho-sites are hyperphosphorylated. Alzheimer&#x2019;s Dement. 2022;85:415&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8842784</ArticleId><ArticleId IdType="pubmed">34806603</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat. Med. 2020;26:398&#x2013;407. doi: 10.1038/s41591-020-0781-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer&#x2019;s disease. EBioMedicine. 2022;76:103836. doi: 10.1016/j.ebiom.2022.103836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103836</ArticleId><ArticleId IdType="pmc">PMC8850760</ArticleId><ArticleId IdType="pubmed">35158308</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer&#x2019;s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol. Med. 2020;12:e12921. doi: 10.15252/emmm.202012921.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202012921</ArticleId><ArticleId IdType="pmc">PMC7721364</ArticleId><ArticleId IdType="pubmed">33169916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, et al. Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer&#x2019;s trial selection and disease monitoring. Nat. Med. 2022;28:2555&#x2013;2562. doi: 10.1038/s41591-022-02074-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02074-w</ArticleId><ArticleId IdType="pmc">PMC9800279</ArticleId><ArticleId IdType="pubmed">36456833</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2022;80:188&#x2013;199. doi: 10.1001/jamaneurol.2022.4485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.4485</ArticleId><ArticleId IdType="pmc">PMC9856704</ArticleId><ArticleId IdType="pubmed">36508198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobom J, et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer&#x2019;s disease continuum. Mol. Neurodegen. 2022;17:81. doi: 10.1186/s13024-022-00586-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00586-0</ArticleId><ArticleId IdType="pmc">PMC9743664</ArticleId><ArticleId IdType="pubmed">36510321</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Karikari TK. Comorbidities confound Alzheimer&#x2019;s blood tests. Nat. Med. 2022;28:1349&#x2013;1351. doi: 10.1038/s41591-022-01875-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01875-3</ArticleId><ArticleId IdType="pubmed">35788176</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichet Binette, A. et al. Confounding factors of Alzheimer&#x2019;s disease plasma biomarkers and their impact on clinical performance. Alzheimer&#x2019;s Dement.10.1002/alz.12787 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10499000</ArticleId><ArticleId IdType="pubmed">36152307</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76:264&#x2013;273. doi: 10.1001/jamaneurol.2018.4249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4249</ArticleId><ArticleId IdType="pmc">PMC6439726</ArticleId><ArticleId IdType="pubmed">30615028</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett SL, et al. Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw. Open. 2019;2:e1917363. doi: 10.1001/jamanetworkopen.2019.17363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.17363</ArticleId><ArticleId IdType="pmc">PMC6991300</ArticleId><ArticleId IdType="pubmed">31834392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology. Ann. Clin. Transl. Neurol. 2021;8:1817&#x2013;1830. doi: 10.1002/acn3.51435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51435</ArticleId><ArticleId IdType="pmc">PMC8419397</ArticleId><ArticleId IdType="pubmed">34342183</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie K, et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat. Med. 2022;28:2547&#x2013;2554. doi: 10.1038/s41591-022-02075-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02075-9</ArticleId><ArticleId IdType="pmc">PMC9800273</ArticleId><ArticleId IdType="pubmed">36424467</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414. doi: 10.1212/WNL.43.11.2412-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis. Assoc. Disord. 2006;20:210&#x2013;216. doi: 10.1097/01.wad.0000213865.09806.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wad.0000213865.09806.92</ArticleId><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, et al. Apolipoprotein Eepsilon4 modifies Alzheimer&#x2019;s disease onset in an E280A PS1 kindred. Ann. Neurol. 2003;54:163&#x2013;169. doi: 10.1002/ana.10636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10636</ArticleId><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Boerwinkle AH, et al. Temporal correlation of CSF and neuroimaging in the amyloid-tau-neurodegeneration model of Alzheimer disease. Neurology. 2021;97:e76&#x2013;e87. doi: 10.1212/WNL.0000000000012123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012123</ArticleId><ArticleId IdType="pmc">PMC8312859</ArticleId><ArticleId IdType="pubmed">33931538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, et al. CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer&#x2019;s Dement. 2018;14:1470&#x2013;1481. doi: 10.1016/j.jalz.2018.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Partial volume correction in quantitative amyloid imaging. NeuroImage. 2015;107:55&#x2013;64. doi: 10.1016/j.neuroimage.2014.11.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2014.11.058</ArticleId><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimer&#x2019;s Dement. 2019;11:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389727</ArticleId><ArticleId IdType="pubmed">30847382</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin. 2018;19:406&#x2013;416. doi: 10.1016/j.nicl.2018.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.04.022</ArticleId><ArticleId IdType="pmc">PMC6051499</ArticleId><ArticleId IdType="pubmed">30035025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. NeuroImage. 2017;161:171&#x2013;178. doi: 10.1016/j.neuroimage.2017.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.07.050</ArticleId><ArticleId IdType="pmc">PMC5696044</ArticleId><ArticleId IdType="pubmed">28756238</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, et al. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:2295&#x2013;2305. doi: 10.1007/s00259-021-05401-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05401-4</ArticleId><ArticleId IdType="pmc">PMC8175317</ArticleId><ArticleId IdType="pubmed">34041562</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837&#x2013;845. doi: 10.2307/2531595.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate&#x2014;a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 1995;57:289&#x2013;300.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36973044</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>20</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Accelerated Brain Volume Loss Caused by Anti-&#x3b2;-Amyloid Drugs: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>e2114</StartPage><EndPage>e2124</EndPage><MedlinePgn>e2114-e2124</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000207156</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">To evaluate brain volume changes caused by different subclasses of anti-&#x3b2;-amyloid (A&#x3b2;) drugs trailed in patients with Alzheimer disease.</AbstractText><AbstractText Label="METHODS">PubMed, Embase, and ClinicalTrials.gov databases were searched for clinical trials of anti-A&#x3b2; drugs. This systematic review and meta-analysis included adults enrolled in randomized controlled trials of anti-A&#x3b2; drugs (n = 8,062-10,279). The inclusion criteria were as follows: (1) randomized controlled trials of patients treated with anti-A&#x3b2; drugs that have demonstrated to favorably change at least one biomarker of pathologic A&#x3b2; and (2) detailed MRI data sufficient to assess the volumetric changes in at least one brain region. MRI brain volumes were used as the primary outcome measure; brain regions commonly reported include hippocampus, lateral ventricle, and whole brain. Amyloid-related imaging abnormalities (ARIAs) were investigated when reported in clinical trials. Of the 145 trials reviewed, 31 were included in the final analyses.</AbstractText><AbstractText Label="RESULTS">A meta-analysis on the highest dose of each trial on hippocampus, ventricle, and whole brain revealed drug-induced acceleration of volume changes that varied by anti-A&#x3b2; drug class. Secretase inhibitors accelerated atrophy to the hippocampus (&#x394; placebo - &#x394; drug: -37.1 &#xb5;L [19.6% more than placebo]; 95% CI -47.0 to -27.1) and whole brain (&#x394; placebo - &#x394; drug: -3.3 mL [21.8% more than placebo]; 95% CI -4.1 to 2.5). Conversely, ARIA-inducing monoclonal antibodies accelerated ventricular enlargement (&#x394; placebo - &#x394; drug: +2.1 mL [38.7% more than placebo]; 95% CI 1.5-2.8) where a striking correlation between ventricular volume and ARIA frequency was observed (<i>r</i> = 0.86, <i>p</i> = 6.22 &#xd7; 10<sup>-7</sup>). Mild cognitively impaired participants treated with anti-A&#x3b2; drugs were projected to have a material regression toward brain volumes typical of Alzheimer dementia &#x223c;8 months earlier than if they were untreated.</AbstractText><AbstractText Label="DISCUSSION">These findings reveal the potential for anti-A&#x3b2; therapies to compromise long-term brain health by accelerating brain atrophy and provide new insight into the adverse impact of ARIA. Six recommendations emerge from these findings.</AbstractText><CopyrightInformation>&#xa9; 2023 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinowski</LastName><ForeName>Pawel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayton</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia. scott.ayton@florey.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2023 May 16;100(20):941-942. doi: 10.1212/WNL.0000000000207268.</RefSource><PMID Version="1">36973045</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>F. Alves and P. Kalinowski declare support from the NIH National Institute on Aging for the submitted work. S. Ayton declares support from the NIH National Institute on Aging for the submitted work and reports acting as a consultant for Eisai in the past 3 years; no other relationships or activities that could appear to have influenced the submitted work. Go to Neurology.org/N for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36973044</ArticleId><ArticleId IdType="pmc">PMC10186239</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000207156</ArticleId><ArticleId IdType="pii">WNL.0000000000207156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ackley SF, Zimmerman SC, Brenowitz WD, et al. . Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905687</ArticleId><ArticleId IdType="pubmed">33632704</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe D. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? PLoS Biol. 2022;20(7):e3001694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302755</ArticleId><ArticleId IdType="pubmed">35862308</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH, Swanson CJ, Aisen P, et al. . Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">36449413</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Chalkias S, Barkhof F, et al. . Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609465</ArticleId><ArticleId IdType="pubmed">34807243</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S, Aisen PS, Barkhof F, et al. . Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197-210.</Citation><ArticleIdList><ArticleId IdType="pubmed">35542991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-1704.</Citation><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G, Streffer JR, Timmers M, et al. . Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimers Res Ther. 2020;12(1):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227237</ArticleId><ArticleId IdType="pubmed">32410694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Henley D, Aisen PS, et al. . Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b/3 clinical trial. JAMA Neurol. 2021;78(3):293-301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816119</ArticleId><ArticleId IdType="pubmed">33464300</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson CJ, Zhang Y, Dhadda S, et al. . A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A&#x3b2; protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053280</ArticleId><ArticleId IdType="pubmed">33865446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sur C, Kost J, Scott D, et al. . BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain. 2020;143(12):3816-3826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453290</ArticleId><ArticleId IdType="pubmed">33253354</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G, Fox N, Clegg S, et al. . Changes in brain volume with bapineuzumab in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2016;49(4):1123-1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">26639957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels AM, Tariot PN, Zimmer JA, et al. . Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 2020;77(2):199-209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902191</ArticleId><ArticleId IdType="pubmed">31764959</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, Lind M, Wagen AZ, et al. . Biochemically-defined pools of amyloid-&#x3b2; in sporadic Alzheimer's disease: correlation with amyloid PET. Brain. 2017;140(5):1486-1498.</Citation><ArticleIdList><ArticleId IdType="pubmed">28383676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayton S. Brain volume loss due to donanemab. Eur J Neurol. 2021;28(9):e67-e68.</Citation><ArticleIdList><ArticleId IdType="pubmed">34224184</ArticleId></ArticleIdList></Reference><Reference><Citation>Krudys K. BLA761178: Aduhelm (Aducanumab) Clincal Review(s). FDA Center for Drug Evaluation and Research; 2021.</Citation></Reference><Reference><Citation>Park HY, Suh CH, Woo S, Kim PH, Kim KW. Quality reporting of systematic review and meta-analysis according to PRISMA 2020 guidelines: results from recently published papers in the Korean Journal of Radiology. Korean J Radiol. 2022;23(3):355-369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8876652</ArticleId><ArticleId IdType="pubmed">35213097</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008539</ArticleId><ArticleId IdType="pubmed">33781348</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48.</Citation></Reference><Reference><Citation>Borenstein M, ed. Effect Sizes for Continuous Data. Russell Sage Foundation; 2009.</Citation></Reference><Reference><Citation>Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC. Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging. 2010;31(8):1452-1462.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947486</ArticleId><ArticleId IdType="pubmed">20620665</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E, Wang D, Sperling R, et al. . Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. 2018;90(10):e877-e886.</Citation><ArticleIdList><ArticleId IdType="pubmed">29429971</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir RD, Tanzi RE. Low evolutionary selection pressure in senescence does not explain the persistence of A&#x3b2; in the vertebrate genome. Front Aging Neurosci. 2019;11:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447958</ArticleId><ArticleId IdType="pubmed">30983989</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Agboola F, Grant E, et al. . Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. Brain. 2022;145(12):4459-4473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10200301</ArticleId><ArticleId IdType="pubmed">35925685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc Natl Acad Sci USA. 2017;114(4):E476-E485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulisano W, Melone M, Ripoli C, et al. . Neuromodulatory action of picomolar extracellular A&#x3b2;42 oligomers on presynaptic and postsynaptic mechanisms underlying synaptic function and memory. J Neurosci. 2019;39(30):5986-6000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6650983</ArticleId><ArticleId IdType="pubmed">31127002</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmeri A, Ricciarelli R, Gulisano W, et al. . Amyloid-beta peptide is needed for cGMP-induced long-term potentiation and memory. J Neurosci. 2017;37(29):6926-6937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518421</ArticleId><ArticleId IdType="pubmed">28626017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayton S, Lei P, Hare DJ, et al. . Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J Neurosci. 2015;35(8):3591-3597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605561</ArticleId><ArticleId IdType="pubmed">25716857</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Tariot PN, et al. . Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018;378(18):1691-1703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="pubmed">29719179</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease. N Engl J Med. 2019;380(15):1483-1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">30970197</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Raman R, Farlow M, et al. . A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(4):341-350.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Lu M, Burnham SC, et al. . Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9577883</ArticleId><ArticleId IdType="pubmed">36251300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36973045</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>20</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Brain Shrinkage in Anti-&#x3b2;-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy?</ArticleTitle><Pagination><StartPage>941</StartPage><EndPage>942</EndPage><MedlinePgn>941-942</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000207268</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Department of Radiology and Nuclear Medicine (F.B.), Amsterdam University Medical Center, VU Medical Center, Amsterdam, Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London, UK; Department of Neurology (D.S.K.) and Mayo Clinic Alzheimer Research Center, Mayo Clinic, Rochester MN. f.barkhof@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>From the Department of Radiology and Nuclear Medicine (F.B.), Amsterdam University Medical Center, VU Medical Center, Amsterdam, Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London, UK; Department of Neurology (D.S.K.) and Mayo Clinic Alzheimer Research Center, Mayo Clinic, Rochester MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurology. 2023 May 16;100(20):e2114-e2124. doi: 10.1212/WNL.0000000000207156.</RefSource><PMID Version="1">36973044</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006257" MajorTopicYN="N">Head</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36973045</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000207268</ArticleId><ArticleId IdType="pii">WNL.0000000000207268</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36989373</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>689</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration.</ArticleTitle><Pagination><StartPage>eadf0141</StartPage><MedlinePgn>eadf0141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.adf0141</ELocationID><Abstract><AbstractText>Complement overactivation mediates microglial synapse elimination in neurological diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), but how complement activity is regulated in the brain remains largely unknown. We identified that the secreted neuronal pentraxin Nptx2 binds complement C1q and thereby regulates its activity in the brain. Nptx2-deficient mice show increased complement activity, C1q-dependent microglial synapse engulfment, and loss of excitatory synapses. In a neuroinflammation culture model and in aged TauP301S mice, adeno-associated virus (AAV)-mediated neuronal overexpression of Nptx2 was sufficient to restrain complement activity and ameliorate microglia-mediated synapse loss. Analysis of human cerebrospinal fluid (CSF) samples from a genetic FTD cohort revealed reduced concentrations of Nptx2 and Nptx2-C1q protein complexes in symptomatic patients, which correlated with elevated C1q and activated C3. Together, these results show that Nptx2 regulates complement activity and microglial synapse elimination in the brain and that diminished Nptx2 concentrations might exacerbate complement-mediated neurodegeneration in patients with FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiechao</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7879-0757</Identifier><AffiliationInfo><Affiliation>Solomon H.&#xa0;Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>Sarah D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-5746-5111</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graykowski</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Mei-Fang</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0003-1681-2161</Identifier><AffiliationInfo><Affiliation>Solomon H.&#xa0;Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Binhui</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9390-3660</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>Lucia A A</ForeName><Initials>LAA</Initials><Identifier Source="ORCID">0000-0002-3521-3693</Identifier><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Jesse E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-3059-5132</Identifier><AffiliationInfo><Affiliation>Genentech, Neuroscience, South San&#xa0;Francisco, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8703-5366</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worley</LastName><ForeName>Paul F</ForeName><Initials>PF</Initials><Identifier Source="ORCID">0000-0002-5086-614X</Identifier><AffiliationInfo><Affiliation>Solomon H.&#xa0;Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dejanovic</LastName><ForeName>Borislav</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4191-5808</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, 02142, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG009973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG072643</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097966</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG065169</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092775">neuronal pentraxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> M.S. is a scientific cofounder and senior advisory board member of Neumora Therapeutics and a senior advisory board member of Biogen, Vanqua Bio, ArcLight Therapeutics, and Cerevel Therapeutics. P.F.W. and M.-F.X. are cofounders of CogNext. J.E.H. is employed by Genentech. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36989373</ArticleId><ArticleId IdType="mid">NIHMS1924034</ArticleId><ArticleId IdType="pmc">PMC10467038</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adf0141</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Volk L, Chiu S-L, Sharma K, Huganir RL, Glutamate synapses in human cognitive disorders. Annu. Rev. Neurosci 38, 127&#x2013;149 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25897873</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton DK, Dissing-Olesen L, Stevens B, Neuron-glia signaling in synapse elimination. Annu. Rev. Neurosci 42, 107&#x2013;127 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31283900</ArticleId></ArticleIdList></Reference><Reference><Citation>Neniskyte U, Gross CT, Errant gardeners: Glial-cell-dependent synaptic pruning and neurodevelopmental disorders. Nat. Rev. Neurosci 18, 658&#x2013;670 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28931944</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SWM, Barres BA, The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, Friedman BA, Dejanovic B, Sheng M, Microglia in brain development, homeostasis, and neurodegeneration. Annu. Rev. Genet 53, 263&#x2013;288(2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31518519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, Huntley MA, Mazi&#xe8;re AD, Meilandt WJ, Wu T, Srinivasan K, Jiang Z, Gandham V, Friedman BA, Ngu H, Foreman O, Carano RAD, Chih B, Klumperman J, Bakalarski C, Hanson JE, Sheng M, Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron 100, 1322&#x2013;1336.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, Wu T, Tsai M-C, Graykowski D, Gandham VD, Rose CM, Bakalarski CE, Ngu H, Wang Y, Pandey S, Rezzonico MG, Friedman BA, Edmonds R, Mazi&#xe8;re AD, Rakosi-Schmidt R, Singh T, Klumperman J, Foreman O, Chang MC, Xie L, Sheng M, Hanson JE, Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer&#x2019;s disease mouse models. Nat. Aging 2, 837&#x2013;850 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154216</ArticleId><ArticleId IdType="pubmed">37118504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley MA, Wang Y, Wang T-M, Hedehus M, Barck KH, Stark M, Ngu H, Foreman O, Meilandt WJ, Elstrott J, Chang MC, Hansen DV, Carano RAD, Sheng M, Hanson JE, Complement C3 is activated in human AD Brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 28, 2111&#x2013;2123.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Comer AL, Jinadasa T, Sriram B, Phadke RA, Kretsge LN, Nguyen TPH, Antognetti G, Gilbert JP, Lee J, Newmark ER, Hausmann FS, Rosenthal S, Kot KL, Liu Y, Yen WW, Dejanovic B, Cruz-Mart&#xed;n A, Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. PLOS Biol. 18, e3000604 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6959572</ArticleId><ArticleId IdType="pubmed">31935214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B, Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasek MJ, Garber C, Dorsey D, Durrant DM, Bollman B, Soung A, Yu J, Perez-Torres C, Frouin A, Wilton DK, Funk K, DeMasters BK, Jiang X, Bowen JR, Mennerick S, Robinson JK, Garbow JR, Tyler KL, Suthar MS, Schmidt RE, Stevens B, Klein RS, A complement&#x2013;Microglial axis drives synapse loss during virus-induced memory impairment. Nature 534, 538&#x2013;543 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452615</ArticleId><ArticleId IdType="pubmed">27337340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton DK, Mastro K, Heller MD, Gergits FW, Willing CR, Frouin A, Daggett A, Gu X, Kim AY, Faull R, Jayadev S, Yednock T, Yang XW, Stevens B, Microglia mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington&#x2019;s disease through complement-dependent mechanisms. bioRxiv 471180.4 December 2021. 10.1101/2021.12.03.471180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.03.471180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong Q, Soteros BM, Wollet M, Kim JH, Sia G-M, The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development. Nat. Neurosci 23, 1067&#x2013;1078(2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7483802</ArticleId><ArticleId IdType="pubmed">32661396</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein H-H, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR, ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat. Med 25, 496&#x2013;506 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420126</ArticleId><ArticleId IdType="pubmed">30692699</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J, Tijsma O, Hack EC, Daha MR, Roos A, Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur. J. Immunol 33, 465&#x2013;473 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12645945</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Hopf C, Reddy R, Cho RW, Guo L, Lanahan A, Petralia RS, Wenthold RJ, O&#x2019;Brien RJ, Worley P, Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. Neuron 39, 513&#x2013;528 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-J, Wei M, Zhang C, Maxeiner S, Pak C, Botelho SC, Trotter J, Sterky FH, S&#xfc;dhof TC, Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses. J. Neurosci 37, 1062&#x2013;1080 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5296791</ArticleId><ArticleId IdType="pubmed">27986928</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho RW, Park JM, Wolff SBE, Xu D, Hopf C, Kim J, Reddy RC, Petralia RS, Perin MS, Linden DJ, Worley PF, mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. Neuron 57, 858&#x2013;871 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701195</ArticleId><ArticleId IdType="pubmed">18367087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Park JM, Pelkey KA, Grabenstatter HL, Xu D, Linden DJ, Sutula TP, McBain CJ, Worley PF, Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons. Nat. Neurosci 13, 1090&#x2013;1097 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949072</ArticleId><ArticleId IdType="pubmed">20729843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelkey KA, Barksdale E, Craig MT, Yuan X, Sukumaran M, Vargish GA, Mitchell RM, Wyeth MS, Petralia RS, Chittajallu R, Karlsson R-M, Cameron HA, Murata Y, Colonnese MT, Worley PF, McBain CJ, Pentraxins coordinate excitatory synapse maturation and circuit integration of parvalbumin interneurons. Neuron 85, 1257&#x2013;1272 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4368480</ArticleId><ArticleId IdType="pubmed">25754824</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien RJ, Xu D, Petralia RS, Steward O, Huganir RL, Worley P, Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp. Neuron 23, 309&#x2013;323 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10399937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sia G-M, B&#xe9;&#xef;que J-C, Rumbaugh G, Cho R, Worley PF, Huganir RL, Interaction of the N-Terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron 55, 87&#x2013;102 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17610819</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M-F, Roh S-E, Zhou J, Chien C-C, Lucey BP, Craig MT, Hayes LN, Coughlin JM, Leweke FM, Jia M, Xu D,Zhou W, Talbot CC Jr., Arnold DB, Staley M, Jiang C, Reti IM, Sawa A, Pelkey KA, McBain CJ, Savonenko A, Worley PF, A biomarker-authenticated model of schizophrenia implicating NPTX2 loss of function. Sci. Adv 7, eabf6935 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8612534</ArticleId><ArticleId IdType="pubmed">34818031</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M-F, Xu D, Craig MT, Pelkey KA, Chien C-C, Shi Y, Zhang J, Resnick S, Pletnikova O, Salmon D, Brewer J, Edland S, Wegiel J, Tycko B, Savonenko A, Reeves RH, Troncoso JC, McBain CJ, Galasko D, Worley PF, NPTX2 and cognitive dysfunction in Alzheimer&#x2019;s disease. eLife 6, e23798 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404919</ArticleId><ArticleId IdType="pubmed">28440221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Huang S, Chang MC, Worley P, Kirkwood A, Quinlan EM, Obligatory role for the immediate early gene NARP in critical period plasticity. Neuron 79, 335&#x2013;346 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804028</ArticleId><ArticleId IdType="pubmed">23889936</ArticleId></ArticleIdList></Reference><Reference><Citation>Severin D, Hong SZ, Roh S-E, Huang S, Zhou J, Bridi MCD, Hong I, Murase S, Robertson S, Haberman RP, Huganir RL, Gallagher M, Quinlan EM, Worley P, Kirkwood A, All-or-none disconnection of pyramidal inputs onto parvalbumin-positive interneurons gates ocular dominance plasticity. Proc. Nat. Acad. Sci. U.S.A 118, e2105388118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449314</ArticleId><ArticleId IdType="pubmed">34508001</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, Meeter LH, Dopper EG, Papma JM, Heller C, Convery R, Moore K, Bocchetta M, Neason M, Peakman G, Cash DM, Teunissen CE, Graff C, Synofzik M, Moreno F, Finger E, S&#xe1;nchez-Valle R, Vandenberghe R, Jr RL, Masellis M, Tartaglia MC, Rowe JB, Butler CR, Ducharme S, Gerhard A, Danek A, Levin J, Pijnenburg YA, Otto M, Borroni B, Tagliavini F, de Mendonca A, Santana I, Galimberti D, Seelaar H, Rohrer JD, Worley PF, van Swieten JC; Genetic Frontotemporal Dementia Initiative (GENFI), Neuronal pentraxin 2: A synapse-derived CSF biomarker in genetic frontotemporal dementia. J. Neuro. Neurosurg. Psychiatry 91, 612&#x2013;621 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279197</ArticleId><ArticleId IdType="pubmed">32273328</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, Vanbrabant J, Jacobs D, Vanderstichele H, Vanmechelen E; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI), P. Worley, Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dementia Transl. Res. Clin. Interventions 5, 871&#x2013;882 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6911971</ArticleId><ArticleId IdType="pubmed">31853477</ArticleId></ArticleIdList></Reference><Reference><Citation>Belbin O, Xiao M-F, Xu D, Carmona-Iragui M, Pegueroles J, Benejam B, Videla L, Fern&#xe1;ndez S, Barroeta I, Nu&#xf1;ez-Llaves R, Montal V, Vilaplana E, Altuna M, Clarim&#xf3;n J, Alcolea D, Blesa R, Lle&#xf3; A, Worley PF, Fortea J, Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer&#x2019;s disease-related inhibitory circuit dysfunction in adults with Down syndrome. Mol. Neurodegener 15, 46 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7433053</ArticleId><ArticleId IdType="pubmed">32807227</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steenoven I, Koel-Simmelink MJA, Vergouw LJM, Tijms BM, Piersma SR, Pham TV, Bridel C, Ferri G-L, Cocco C, Noli B, Worley PF, Xiao M-F, Xu D, Oeckl P, Otto M, van der Flier WM, de Jong FJ, Jimenez CR, Lemstra AW, Teunissen CE, Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: A proteomic approach. Mol. Neurodegener 15, 36 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301448</ArticleId><ArticleId IdType="pubmed">32552841</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Moghekar A, Walker KA, Pettigrew C, Hou X, Lu H, Miller MI, Alfini A, Albert M, Xu D, Xiao M-F, Worley P, Csernansky J, Holtzman D, Knopman D, Kukull W, Grimm K, Hsiao J, Ryan L, Lyketsos C, Pardo C, Schellenberg G, Shaw L, Thambisetty M, Trojanowski J, Resting-state functional connectivity is associated with cerebrospinal fluid levels of the synaptic protein NPTX2 in non-demented older adults. Front. Aging Neurosci 11, 132 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568192</ArticleId><ArticleId IdType="pubmed">31231205</ArticleId></ArticleIdList></Reference><Reference><Citation>Styr B, Slutsky I, Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer&#x2019;s disease. Nat. Neurosci 21, 463&#x2013;473 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533171</ArticleId><ArticleId IdType="pubmed">29403035</ArticleId></ArticleIdList></Reference><Reference><Citation>Inforzato A, Peri G, Doni A, Garlanda C, Mantovani A, Bastone A, Carpentieri A, Amoresano A, Pucci P, Roos A, Daha MR, Vincenti S, Gallo G, Carminati P, Santis RD, Salvatori G, Structure and function of the long pentraxin PTX3 glycosidic moiety: Finetuning of the interaction with C1q and complement activation. Biochemistry 45, 11540&#x2013;11551 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16981714</ArticleId></ArticleIdList></Reference><Reference><Citation>Favuzzi E, Huang S, Saldi GA, Binan L, Ibrahim LA, Fern&#xe1;ndez-Otero M, Cao Y, Zeine A, Sefah A, Zheng K, Xu Q, Khlestova E, Farhi SL, Bonneau R, Datta SR, Stevens B, Fishell G, GABA-receptive microglia selectively sculpt developing inhibitory circuits. Cell 184, 5686 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122269</ArticleId><ArticleId IdType="pubmed">34715023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang H-Y, Shang Y, Oldham MC, Martens LH, Gao F, Coppola G, Sloan SA, Hsieh CL, Kim CC, Bigio EH, Weintraub S, Mesulam M-M, Rademakers R, Mackenzie IR, Seeley WW, Karydas A, Miller BL, Borroni B, Ghidoni R, Farese RV, Paz JT, Barres BA, Huang EJ, Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 165, 921&#x2013;935 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido-Salgado M, Vidal-Taboada JM, Barriga GG-D, Sol&#xe0; C, Saura J, RNA-Seq transcriptomic profiling of primary murine microglia treated with LPS or LPS + IFN&#x3b3;. Sci. Rep 8, 16096 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208373</ArticleId><ArticleId IdType="pubmed">30382133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndoja A, Reja R, Lee S-H, Webster JD, Ngu H, Rose CM, Kirkpatrick DS, Modrusan Z, Chen Y-JJ, Dugger DL, Gandham V, Xie L, Newton K, Dixit VM, Ubiquitin ligase COP1 suppresses neuroinflammation by degrading c/EBP&#x3b2; in microglia. Cell 182, 1156&#x2013;1169.e12 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32795415</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum ML, Wilton DK, Muthukumar A, Fox RG, Carey A, Crotty W, Scott-Hewitt N, Bien E, Sabatini DA, Lanser T, Frouin A, Gergits F, H&#xe5;vik B, Gialeli C, Nacu E, Blom AM, Eggan K, Johnson MB, McCarroll SA, Stevens B, CUB and sushi multiple domains 1 (CSMD1) opposes the complement cascade in neural tissues. bioRxiv 291427. 12 September 2020. 10.1101/2020.09.11.291427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.11.291427</ArticleId></ArticleIdList></Reference><Reference><Citation>Vad&#xe1;szi H, Kiss B, Micsonai A, Schlosser G, Szaniszl&#xf3; T, Kov&#xe1;cs R&#xc1;, Gy&#xf6;rffy BA, K&#xe9;kesi KA, Goto Y, Uzonyi B, Liliom K, Kardos J, Competitive inhibition of the classical complement pathway using exogenous single-chain C1q recognition proteins. J. Biol. Chem 298, 102113 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9270254</ArticleId><ArticleId IdType="pubmed">35690144</ArticleId></ArticleIdList></Reference><Reference><Citation>Vukojicic A, Delestr&#xe9;e N, Fletcher EV, Pagiazitis JG, Sankaranarayanan S, Yednock TA, Barres BA, Mentis GZ, The classical complement pathway mediates microglia-dependent remodeling of spinal motor circuits during development and in SMA. Cell Rep. 29, 3087&#x2013;3100.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937140</ArticleId><ArticleId IdType="pubmed">31801075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansita JA, Mease KM, Qiu H, Yednock T, Sankaranarayanan S, Kramer S, Nonclinical development of ANX005: A humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int. J. Toxicol 36, 449&#x2013;462 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29202623</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, Kim L, Tsai H-H, Huang EJ, Rowitch DH, Berns DS, Tenner AJ, Shamloo M, Barres BA, A dramatic increase of C1q protein in the CNS during normal aging. J. Neurosci 33, 13460&#x2013;13474 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamitaki N, Sekar A, Handsaker RE, de Rivera H, Tooley K, Morris DL, Taylor KE, Whelan CW, Tombleson P, Loohuis LMO; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Kimberly RP, Kaufman KM, Harley JB, Langefeld CD, Seidman CE, Pato MT, Pato CN, Ophoff RA, Graham RR, Criswell LA, Vyse TJ, McCarroll SA, Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 582, 577&#x2013;581 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319891</ArticleId><ArticleId IdType="pubmed">32499649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Doren VV, Genovese G, Rose SA, Handsaker RE, Daly MJ, Carroll MC, Stevens B, McCarroll SA; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Schizophrenia risk from complex variation of complement component 4. Nature 530, 177&#x2013;183 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752392</ArticleId><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz M, Yalcin E, Presumey J, Aw E, Ma M, Whelan CW, Stevens B, McCarroll SA, Carroll MC, Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice. Nat. Neurosci 24, 214&#x2013;224 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086435</ArticleId><ArticleId IdType="pubmed">33353966</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, Stevens B, Lemere CA, Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci. Transl. Med 9, eaaf6295 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez MX, Jiang S, Cole TA, Chu S-H, Fonseca MI, Fang MJ, Hohsfield LA, Torres MD, Green KN, Wetsel RA, Mortazavi A, Tenner AJ, Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss. Mol. Neurodegener 12, 66 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604420</ArticleId><ArticleId IdType="pubmed">28923083</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpanini SM, Torvell M, Bevan RJ, Byrne RAJ, Daskoulidou N, Saito T, Saido TC, Taylor PR, Hughes TR, Zelek WM, Morgan BP, Terminal complement pathway activation drives synaptic loss in Alzheimer&#x2019;s disease models. Acta Neuropathologica Commun. 10, 99 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258209</ArticleId><ArticleId IdType="pubmed">35794654</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Heller C, Sogorb-Esteve A, Swift IJ, McFall D, Peakman G, Bouzigues A, Poos JM, Jiskoot LC, Panman JL, Papma JM, Meeter LH, Dopper EGP, Bocchetta M, Todd E, Cash D, Graff C, Synofzik M, Moreno F, Finger E, Sanchez-Valle R, Vandenberghe R, Laforce R Jr, Masellis M, Tartaglia MC, Rowe JB, Butler C, Ducharme S, Gerhard A, Danek A, Levin J, Pijnenburg YAL, Otto M, Borroni B, Tagliavini F, de Mendon&#xe7;a A, Santana I, Galimberti D, Sorbi S, Zetterberg H, Huang E, van Swieten JC, Rohrer JD, Seelaar H; Genetic Frontotemporal Dementia Initiative (GENFI), Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: Results from the GENFI study. J. Neuroinflamm 19, 217 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9446850</ArticleId><ArticleId IdType="pubmed">36064709</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Bron EE, Poos JM, Jiskoot LC, Panman JL, Papma JM, Meeter LH, Dopper EGP, Wilke C, Synofzik M, Heller C, Swift IJ, Sogorb-Esteve A, Bouzigues A, Borroni B, Sanchez-Valle R, Moreno F, Graff C, Laforce R, Galimberti D, Masellis M, Tartaglia MC, Finger E, Vandenberghe R, Rowe JB, de Mendon&#xe7;a A, Tagliavini F, Santana I, Ducharme S, Butler CR, Gerhard A, Levin J, Danek A, Otto M, Pijnenburg YAL, Sorbi S, Zetterberg H, Niessen WJ, Rohrer JD, Klein S, van Swieten JC, Venkatraghavan V, Seelaar H; GENFI consortium A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain 145, 1805&#x2013;1817 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166533</ArticleId><ArticleId IdType="pubmed">34633446</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36996217</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>379</Volume><Issue>6639</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.</ArticleTitle><Pagination><StartPage>1336</StartPage><EndPage>1341</EndPage><MedlinePgn>1336-1341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abn1366</ELocationID><Abstract><AbstractText>Aggregates of the protein tau are proposed to drive pathogenesis in neurodegenerative diseases. Tau can be targeted by using passively transferred antibodies (Abs), but the mechanisms of Ab protection are incompletely understood. In this work, we used a variety of cell and animal model systems and showed that the cytosolic Ab receptor and E3 ligase TRIM21 (T21) could play a role in Ab protection against tau pathology. Tau-Ab complexes were internalized to the cytosol of neurons, which enabled T21 engagement and protection against seeded aggregation. Ab-mediated protection against tau pathology was lost in mice that lacked T21. Thus, the cytosolic compartment provides a site of immunotherapeutic protection, which may help in the design of Ab-based therapies in neurodegenerative disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mukadam</LastName><ForeName>Aamir S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-3363-7636</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Miller</LastName><ForeName>Lauren V C</ForeName><Initials>LVC</Initials><Identifier Source="ORCID">0000-0002-0612-494X</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Smith</LastName><ForeName>Annabel E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0001-5837-6121</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaysburd</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakya</LastName><ForeName>Siri A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-5893-6771</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, N-0424 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine and Department of Pharmacology, University of Oslo and Oslo University Hospital, N-0372 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanford</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7712-0575</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keeling</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6413-2550</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuck</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0002-8148-542X</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsinelos</LastName><ForeName>Taxiarchis</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6951-3216</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Chris</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4690-7594</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skov</LastName><ForeName>Lise</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7142-7728</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaalund</LastName><ForeName>Sanne S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-8975-1825</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foss</LastName><ForeName>Stian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6527-051X</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, N-0424 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine and Department of Pharmacology, University of Oslo and Oslo University Hospital, N-0372 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayes</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wing</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knox</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banbury</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avezov</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2894-0585</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0001-7216-8679</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cambridge University Hospitals NHS Trust, Cambridge CB2 0SZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5214-7886</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Jan Terje</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-1710-1628</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, N-0424 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine and Department of Pharmacology, University of Oslo and Oslo University Hospital, N-0372 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Leo C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0003-2131-0334</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEwan</LastName><ForeName>William A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0002-4408-0407</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>206248</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105181010</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011961">Receptors, Fc</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C035401">SS-A antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070584">Tripartite Motif Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011961" MajorTopicYN="N">Receptors, Fc</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012261" MajorTopicYN="Y">Ribonucleoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070584" MajorTopicYN="Y">Tripartite Motif Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="Y">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests</b>
. WAM, LCJ, ASM, LVCM, SK, AES, and BJT are listed as inventors on a patent related to this study. WAM has acted as consultant to Ahren Innovation Capital.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>14</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36996217</ArticleId><ArticleId IdType="mid">EMS174787</ArticleId><ArticleId IdType="pmc">PMC7614512</ArticleId><ArticleId IdType="doi">10.1126/science.abn1366</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M. Tau filaments in neurodegenerative diseases. FEBS Lett. 2018;592:2383&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">29790176</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Chen JJ, Sorum AW, Miller GM, Sharf T, See SK, Hsieh-Wilson LC, Kampmann M, Kosik KS. Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) Sci Rep. 2018;8:6382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5913225</ArticleId><ArticleId IdType="pubmed">29686391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, Gradinaru V, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JM, Lathuiliere A, Migliorini M, Arai AL, Wani MM, Dujardin S, Muratoglu SC, Hyman BT, Strickland DK. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. Journal of Biological Chemistry. 2021;296:100715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164048</ArticleId><ArticleId IdType="pubmed">33930462</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110:E3138&#x2013;3147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O&#x2019;Neill MJ, Hutton ML, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457&#x2013;34467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M, Ittner A, Ke YD, G&#xf6;tz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6:e26860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234245</ArticleId><ArticleId IdType="pubmed">22174735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, Solanoy H, Brendza R, Ngu H, Foreman O, Chan R, et al. Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement. Cell Rep. 2016;16:1690&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">27475227</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Liu W, Hu X, Hanna M, Caravaca A, Paul SM. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep. 2015;5:11161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="pubmed">26057852</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake. J Biol Chem. 2015;290:21652&#x2013;21662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4571888</ArticleId><ArticleId IdType="pubmed">26126828</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcy-receptor binding and functional lysosomes. Sci Rep. 2019;9:4658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420568</ArticleId><ArticleId IdType="pubmed">30874605</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans LD, Wassmer T, Fraser G, Smith J, Perkinton M, Billinton A, Livesey FJ. Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways. Cell Rep. 2018;22:3612&#x2013;3624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896171</ArticleId><ArticleId IdType="pubmed">29590627</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, Skrobala E, Landrieu I, Michel A, Schmitt M, Citron M, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019;142:1736&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536853</ArticleId><ArticleId IdType="pubmed">31038156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem. 2013;288:33081&#x2013;33095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829157</ArticleId><ArticleId IdType="pubmed">24089520</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Gu J, Sait HBR, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcy receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288:35452&#x2013;35465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853292</ArticleId><ArticleId IdType="pubmed">24163366</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin L, Bohrmann B, G&#xf6;pfert U, Oroszlan-Szovik K, Ozmen L, Gr&#xfc;ninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer&#x2019;s disease. Brain. 2014;137:2834&#x2013;2846.</Citation><ArticleIdList><ArticleId IdType="pubmed">25085375</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsinelos T, Tuck BJ, Mukadam AS, McEwan WA. The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration. Front Immunol. 2019;10:1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554282</ArticleId><ArticleId IdType="pubmed">31214163</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21) Proc Natl Acad Sci U S A. 2010;107:19985&#x2013;19990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993423</ArticleId><ArticleId IdType="pubmed">21045130</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, Hauler F, Williams CR, Bidgood SR, Mallery DL, Crowther RA, James LC. Regulation of Virus Neutralization and the Persistent Fraction by TRIM21. J Virol. 2012;86:8482&#x2013;8491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421726</ArticleId><ArticleId IdType="pubmed">22647693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher AJ, Mallery DL, Watkinson RE, Dickson CF, James LC. Sequential ubiquitination and deubiquitination enzymes synchronize the dual sensor and effector functions of TRIM21. Proc Natl Acad Sci U S A. 2015;112:10014&#x2013;10019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4538650</ArticleId><ArticleId IdType="pubmed">26150489</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, Schuh M. A Method for the Acute and Rapid Degradation of Endogenous Proteins. Cell. 2017;171:1692&#x2013;1706.:e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5733393</ArticleId><ArticleId IdType="pubmed">29153837</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, Falcon B, Vaysburd M, Clift D, Oblak AL, Ghetti B, Goedert M, James LC. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci U S A. 2017;114:574&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen C-H, Yao Y, Lin Y-M, Driver JA, Sun Y, Wei S, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523:431&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718588</ArticleId><ArticleId IdType="pubmed">26176913</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuck BJ, Miller LVC, Katsinelos T, Smith AE, Wilson EL, Keeling S, Cheng S, Vaysburd MJ, Knox C, Tredgett L, Metzakopian E, et al. Cholesterol determines the cytosolic entry and seeded aggregation of tau. Cell Rep. 2022;39:110776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108550</ArticleId><ArticleId IdType="pubmed">35508140</ArticleId></ArticleIdList></Reference><Reference><Citation>James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A. 2007;104:6200&#x2013;6205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851072</ArticleId><ArticleId IdType="pubmed">17400754</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LVC, Mukadam AS, Durrant CS, Vaysburd MJ, Katsinelos T, Tuck BJ, Sanford S, Sheppard O, Knox C, Cheng S, James LC, et al. Tau assemblies do not behave like independently acting prion-like particles in mouse neuraltissue. Acta Neuropathol Commun. 2021;9:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953780</ArticleId><ArticleId IdType="pubmed">33712082</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimi R, Chang T-H, Wang H, Atsumi T, Morse HC, Ozato K. Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts. J Immunol. 2009;182:7527&#x2013;7538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803686</ArticleId><ArticleId IdType="pubmed">19494276</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, et al. Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein. J Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, Huck J, Shi J, Gavin J, Brownell J, Yang Y, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018;24:186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">29334375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Jakes R, Crowther RA, Lee VM-Y, Ihara Y, Goedert M. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Letters. 1996;384:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes J-M, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJY, Watts RJ, et al. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. J Biol Chem. 2017;292:3900&#x2013;3908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339770</ArticleId><ArticleId IdType="pubmed">28077575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O&#x2019;Connell K, Clark J, Mayes K, Higginson K, Hirst JC, McAdam MB, et al. TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination. Proc Natl Acad Sci U S A. 2018;115:10440&#x2013;10445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187179</ArticleId><ArticleId IdType="pubmed">30209217</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, Tam JCH, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14:327&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672961</ArticleId><ArticleId IdType="pubmed">23455675</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss S, Watkinson RE, Grevys A, McAdam MB, Bern M, Hoydahl LS, Dalhus B, Michaelsen TE, Sandlie I, James LC, Andersen JT, et al. TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity. J Immunol. 2016;196:3452&#x2013;3459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977002</ArticleId><ArticleId IdType="pubmed">26962230</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald JA, Bronner IF, Drynan L, Fan J, Curry A, Fraser G, Lavenir I, Goedert M. Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord. Acta Neuropathologica Communications. 2019;7:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421678</ArticleId><ArticleId IdType="pubmed">30885267</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Santos AF, Mukadam AS, Osswald M, Jacques DA, Dickson CF, McLaughlin SH, Johnson CM, Kiss L, Luptak J, Renner N, et al. Target-induced clustering activates Trim-Away of pathogens and proteins. Nat Struct Mol Biol. 2021;28:278&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611929</ArticleId><ArticleId IdType="pubmed">33633400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Z, Chen D, Ryder BD, Joachimiak LA. Biophysical properties of a tau seed. Sci Rep. 2021;11:13602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245522</ArticleId><ArticleId IdType="pubmed">34193922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Chen D, Morazova OA, Ruff KM, Sharma AM, Liu X, Goodarzi M, Pappu RV, Colby DW, Mirzaei H, Joachimiak LA, et al. Inert and seed-competent tau monomers suggest structural origins of aggregation. Elife. 2018;7:e36584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039173</ArticleId><ArticleId IdType="pubmed">29988016</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin GMJ, Lee S-H, Singh D, Yuan Y, Ng Y-G, Reichardt LF, Arikkath J. Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat Protoc. 2012;7:1741&#x2013;1754.</Citation><ArticleIdList><ArticleId IdType="pubmed">22936216</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods. 1997;204:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202712</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990;9:4225&#x2013;4230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552204</ArticleId><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, Ward ME. Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol. 2018;79:e51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993937</ArticleId><ArticleId IdType="pubmed">29924488</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, Gathagan RJ, Iba M, McBride JD, Trojanowski JQ, Lee VMY, et al. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology innontransgenic mice. J Exp Med. 2016;213:2635&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36973359</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2397-3374</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature human behaviour</Title><ISOAbbreviation>Nat Hum Behav</ISOAbbreviation></Journal><ArticleTitle>An umbrella review of randomized control trials on the effects of physical exercise on cognition.</ArticleTitle><Pagination><StartPage>928</StartPage><EndPage>941</EndPage><MedlinePgn>928-941</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41562-023-01554-4</ELocationID><Abstract><AbstractText>Extensive research links regular physical exercise to an overall enhancement of cognitive function across the lifespan. Here we assess the causal evidence supporting this relationship in the healthy population, using an umbrella review of meta-analyses limited to randomized controlled trials (RCTs). Despite most of the 24 reviewed meta-analyses reporting a positive overall effect, our assessment reveals evidence of low statistical power in the primary RCTs, selective inclusion of studies, publication bias and large variation in combinations of pre-processing and analytic decisions. In addition, our meta-analysis of all the primary RCTs included in the revised meta-analyses shows small exercise-related benefits (d&#x2009;=&#x2009;0.22, 95% confidence interval 0.16 to 0.28) that became substantially smaller after accounting for key moderators (that is, active control and baseline differences; d&#x2009;=&#x2009;0.13, 95% confidence interval 0.07 to 0.20), and negligible after correcting for publication bias (d&#x2009;=&#x2009;0.05, 95% confidence interval -0.09 to 0.14). These findings suggest caution in claims and recommendations linking regular physical exercise to cognitive benefits in the healthy human population until more reliable causal evidence accumulates.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ciria</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0001-7067-5060</Identifier><AffiliationInfo><Affiliation>Mind, Brain and Behavior Research Center (CIMCYC), University of Granada, Granada, Spain. lciria@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Psychology, University of Granada, Granada, Spain. lciria@ugr.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rom&#xe1;n-Caballero</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0943-6217</Identifier><AffiliationInfo><Affiliation>Mind, Brain and Behavior Research Center (CIMCYC), University of Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Psychology, University of Granada, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vadillo</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-8421-816X</Identifier><AffiliationInfo><Affiliation>Department of Basic Psychology, Autonomous University of Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holgado</LastName><ForeName>Darias</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3211-8006</Identifier><AffiliationInfo><Affiliation>Department of Experimental Psychology, University of Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Sport Sciences, University of Lausanne, Quartier UNIL-Centre, B&#xe2;timent Synathlon, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luque-Casado</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9293-637X</Identifier><AffiliationInfo><Affiliation>Center for Sport Studies, Rey Juan Carlos University, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perakakis</LastName><ForeName>Pandelis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Social, Work, and Differential Psychology, Complutense University of Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanabria</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4164-7607</Identifier><AffiliationInfo><Affiliation>Mind, Brain and Behavior Research Center (CIMCYC), University of Granada, Granada, Spain. daniel@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Psychology, University of Granada, Granada, Spain. daniel@ugr.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Hum Behav</MedlineTA><NlmUniqueID>101697750</NlmUniqueID><ISSNLinking>2397-3374</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36973359</ArticleId><ArticleId IdType="doi">10.1038/s41562-023-01554-4</ArticleId><ArticleId IdType="pii">10.1038/s41562-023-01554-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sallis, J. F. et al. Physical activity in relation to urban environments in 14 cities worldwide: a cross-sectional study. Lancet 387, 2207&#x2013;2217 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27045735</ArticleId><ArticleId IdType="pmc">10833440</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(15)01284-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiney, H. &amp; Machado, L. Benefits of regular aerobic exercise for executive functioning in healthy populations. Psychon. Bull. Rev. 20, 73&#x2013;86 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23229442</ArticleId><ArticleId IdType="doi">10.3758/s13423-012-0345-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, D. et al. Physical activity guidelines 2020: comprehensive and inclusive recommendations to activate populations. Lancet 396, 1780&#x2013;1782 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33248019</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)32229-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull, F. C. et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med. 54, 1451&#x2013;1462 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsports-2020-102955</ArticleId><ArticleId IdType="pubmed">33239350</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso, J. C. &amp; Suzuki, W. A. The effects of acute exercise on mood, cognition, neurophysiology, and neurochemical pathways: a review. Brain Plast. 2, 127&#x2013;152 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29765853</ArticleId><ArticleId IdType="pmc">5928534</ArticleId><ArticleId IdType="doi">10.3233/BPL-160040</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomporowski, P. D. &amp; Pesce, C. Exercise, sports, and performance arts benefit cognition via a common process. Psychol. Bull. 145, 929 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31192623</ArticleId><ArticleId IdType="doi">10.1037/bul0000200</ArticleId></ArticleIdList></Reference><Reference><Citation>Angevaren, M., Aufdemkampe, G., Verhaar, H., Aleman, A. &amp; Vanhees, L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD005381.pub3 (2008).</Citation></Reference><Reference><Citation>Young, J., Angevaren, M., Rusted, J. &amp; Tabet, N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst. Rev. 4, 1&#x2013;117 (2015).</Citation></Reference><Reference><Citation>Ludyga, S., Gerber, M., P&#xfc;hse, U., Looser, V. N. &amp; Kamijo, K. Systematic review and meta-analysis investigating moderators of long-term effects of exercise on cognition in healthy individuals. Nat. Hum. Behav. 4, 603&#x2013;612 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32231280</ArticleId><ArticleId IdType="doi">10.1038/s41562-020-0851-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Verburgh, L., Konigs, M., Scherder, E. J. A. &amp; Oosterlaan, J. Physical exercise and executive functions in preadolescent children, adolescents and young adults: a meta-analysis. Br. J. Sports Med. 48, 973&#x2013;979 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23467962</ArticleId><ArticleId IdType="doi">10.1136/bjsports-2012-091441</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, A. S. et al. Effects of physical activity interventions on cognitive and academic performance in children and adolescents: a novel combination of a systematic review and recommendations from an expert panel. Br. J. Sports Med. 53, 640&#x2013;647 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30061304</ArticleId><ArticleId IdType="doi">10.1136/bjsports-2017-098136</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond, A. &amp; Ling, D. S. Aerobic-exercise and resistance-training interventions have been among the least effective ways to improve executive functions of any method tried thus far. Dev. Cogn. Neurosci. 37, 100572 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">29909061</ArticleId><ArticleId IdType="doi">10.1016/j.dcn.2018.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson, K. I. et al. Physical activity, cognition, and brain outcomes: a review of the 2018 physical activity guidelines. Med. Sci. Sports Exerc. 51, 1242&#x2013;1251 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31095081</ArticleId><ArticleId IdType="pmc">6527141</ArticleId><ArticleId IdType="doi">10.1249/MSS.0000000000001936</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe, S. &amp; Kramer, A. F. Fitness effects on the cognitive function of older adults a meta-analytic study. Psychol. Sci. 14, 125&#x2013;130 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12661673</ArticleId><ArticleId IdType="doi">10.1111/1467-9280.t01-1-01430</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, P. J. et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom. Med. 72, 239&#x2013;252 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20223924</ArticleId><ArticleId IdType="pmc">2897704</ArticleId><ArticleId IdType="doi">10.1097/PSY.0b013e3181d14633</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherder, E. et al. Executive functions of sedentary elderly may benefit from walking: a systematic review and meta-analysis. Am. J. Geriatr. Psychiatry 22, 782&#x2013;791 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23636004</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2012.12.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindheimer, J. B., O&#x2019;Connor, P. J. &amp; Dishman, R. K. Quantifying the placebo effect in psychological outcomes of exercise training: a meta-analysis of randomized trials. Sports Med. 45, 693&#x2013;711 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25762083</ArticleId><ArticleId IdType="doi">10.1007/s40279-015-0303-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, W. M., Davis, N., Sands, S. A., Whittington, R. A. &amp; Sun, L. S. Physical activity and cognitive development: a meta-analysis. J. Neurosurg. Anesthesiol. 28, 373&#x2013;380 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27768674</ArticleId><ArticleId IdType="doi">10.1097/ANA.0000000000000349</ArticleId></ArticleIdList></Reference><Reference><Citation>Barha, C. K., Davis, J. C., Falck, R. S., Nagamatsu, L. S. &amp; Liu-Ambrose, T. Sex differences in exercise efficacy to improve cognition: a systematic review and meta-analysis of randomized controlled trials in older humans. Front. Neuroendocrinol. 46, 71&#x2013;85 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28442274</ArticleId><ArticleId IdType="doi">10.1016/j.yfrne.2017.04.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore, A. &amp; Lom, B. The effects of chronic and acute physical activity on working memory performance in healthy participants: a systematic review with meta-analysis of randomized controlled trials. Syst. Rev. 6, 1&#x2013;16 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-017-0514-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Northey, J. M., Cherbuin, N., Pumpa, K. L., Smee, D. J. &amp; Rattray, B. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br. J. Sports Med. 52, 154&#x2013;160 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28438770</ArticleId><ArticleId IdType="doi">10.1136/bjsports-2016-096587</ArticleId></ArticleIdList></Reference><Reference><Citation>Falck, R. S., Davis, J. C., Best, J. R., Crockett, R. A. &amp; Liu-Ambrose, T. Impact of exercise training on physical and cognitive function among older adults: a systematic review and meta-analysis. Neurobiol. Aging 79, 119&#x2013;130 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31051329</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders, L. M., Hortobagyi, T., la Bastide-van Gemert, S., van der Zee, E. A. &amp; van Heuvelen, M. J. Dose&#x2013;response relationship between exercise and cognitive function in older adults with and without cognitive impairment: a systematic review and meta-analysis. PLoS ONE 14, e0210036 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30629631</ArticleId><ArticleId IdType="pmc">6328108</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0210036</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue, Y., Yang, Y. &amp; Huang, T. Effects of chronic exercise interventions on executive function among children and adolescents: a systematic review with meta-analysis. Br. J. Sports Med. 53, 1397&#x2013;1404 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30737201</ArticleId><ArticleId IdType="doi">10.1136/bjsports-2018-099825</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasquoine, P. G. &amp; Chen, P.-Y. Effect of physical exercise on popular measures of executive function in older, nonclinical, participants of randomized controlled trials: a meta-analytic review. Appl. Neuropsychol. Adult. 29, 203&#x2013;211 (2020).</Citation></Reference><Reference><Citation>Xiong, J., Ye, M., Wang, L. &amp; Zheng, G. Effects of physical exercise on executive function in cognitively healthy older adults: a systematic review and meta-analysis of randomized controlled trials. Int. J. Nurs. Stud. 114, 103810 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33248291</ArticleId><ArticleId IdType="doi">10.1016/j.ijnurstu.2020.103810</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, F.-T. et al. Effects of exercise training interventions on executive function in older adults: a systematic review and meta-analysis. Sports Med. 50, 1451&#x2013;1467 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32447717</ArticleId><ArticleId IdType="pmc">7376513</ArticleId><ArticleId IdType="doi">10.1007/s40279-020-01292-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp, B. F. et al. Effects of physical activity interventions on cognitive outcomes and academic performance in adolescents and young adults: a meta-analysis. J. Sports Sci. 38, 2637&#x2013;2660 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32783695</ArticleId><ArticleId IdType="doi">10.1080/02640414.2020.1794763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, C. M., Petrov, M. E. &amp; Lee, R. E. Aerobic physical activity to improve memory and executive function in sedentary adults without cognitive impairment: a systematic review and meta-analysis. Prev. Med. Rep. 23, 101496 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34377632</ArticleId><ArticleId IdType="pmc">8327129</ArticleId><ArticleId IdType="doi">10.1016/j.pmedr.2021.101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhidong, C., Wang, X., Yin, J., Song, D. &amp; Chen, Z. Effects of physical exercise on working memory in older adults: a systematic and meta-analytic review. Eur. Rev. Aging Phys. Act. 18, 1&#x2013;15 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11556-021-00272-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Amatriain-Fern&#xe1;ndez, S., Ezquerro Garc&#xed;a-Noblejas, M. &amp; Budde, H. Effects of chronic exercise on the inhibitory control of children and adolescents: a systematic review and meta-analysis. Scand. J. Med. Sci. Sports 31, 1196&#x2013;1208 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33559271</ArticleId><ArticleId IdType="doi">10.1111/sms.13934</ArticleId></ArticleIdList></Reference><Reference><Citation>Meli, A. M., Ali, A., Mhd Jalil, A. M., Mohd Yusof, H. &amp; Tan, M. M. Effects of physical activity and micronutrients on cognitive performance in children aged 6 to 11 years: a systematic review and meta-analysis of randomized controlled trials. Medicina 58, 57 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">35056365</ArticleId><ArticleId IdType="pmc">8781636</ArticleId><ArticleId IdType="doi">10.3390/medicina58010057</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, Y. et al. Physical activity and cognition in sedentary older adults: a systematic review and meta-analysis. J. Alzheimers Dis. 87, 957&#x2013;968 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35431253</ArticleId><ArticleId IdType="pmc">9198743</ArticleId><ArticleId IdType="doi">10.3233/JAD-220073</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghjayan, S. L. et al. Aerobic exercise improves episodic memory in late adulthood: a systematic review and meta-analysis. Commun. Med. 2, 1&#x2013;11 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-022-00079-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe, S. J. et al. Cardiovascular fitness, cortical plasticity, and aging. Proc. Natl Acad. Sci. USA 101, 3316&#x2013;3321 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14978288</ArticleId><ArticleId IdType="pmc">373255</ArticleId><ArticleId IdType="doi">10.1073/pnas.0400266101</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakes, K. D. &amp; Hoyt, W. T. Promoting self-regulation through school-based martial arts training. J. Appl. Dev. Psychol. 25, 283&#x2013;302 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.appdev.2004.04.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscari, A. et al. Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial. Int. J. Geriatr. Psychiatry 25, 1055&#x2013;1064 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20033904</ArticleId><ArticleId IdType="doi">10.1002/gps.2462</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss, M. W. et al. Plasticity of brain networks in a randomized intervention trial of exercise training in older adults. Front. Aging Neurosci. 2, 32 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20890449</ArticleId><ArticleId IdType="pmc">2947936</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss, M. W. et al. The influence of aerobic fitness on cerebral white matter integrity and cognitive function in older adults: results of a one-year exercise intervention. Hum. Brain Mapp. 34, 2972&#x2013;2985 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22674729</ArticleId><ArticleId IdType="doi">10.1002/hbm.22119</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidoni, E. D. et al. Effect of aerobic exercise on amyloid accumulation in preclinical Alzheimer&#x2019;s: a 1-year randomized controlled trial. PLoS ONE 16, e0244893 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33444359</ArticleId><ArticleId IdType="pmc">7808620</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0244893</ArticleId></ArticleIdList></Reference><Reference><Citation>Le&#xf3;n, J., Ure&#xf1;a, A., Bola&#xf1;os, M. J., Bilbao, A. &amp; O&#xf1;a, A. A combination of physical and cognitive exercise improves reaction time in persons 61&#x2013;84 years old. J. Aging Phys. Act. 23, 72&#x2013;77 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">24413071</ArticleId><ArticleId IdType="doi">10.1123/JAPA.2012-0313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouaziz, W. et al. Effects of a short-term interval aerobic training programme with active recovery bouts (IATP-R) on cognitive and mental health, functional performance and quality of life: a randomised controlled trial in sedentary seniors. Int. J. Clin. Pract. 73, e13219 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">29963733</ArticleId><ArticleId IdType="doi">10.1111/ijcp.13219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink, K. M. et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial. JAMA 314, 781&#x2013;790 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26305648</ArticleId><ArticleId IdType="pmc">4698980</ArticleId><ArticleId IdType="doi">10.1001/jama.2015.9617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind, R. R. et al. Improved cognitive performance in preadolescent Danish children after the school-based physical activity programme &#x201c;FIFA 11 for Health&#x201d; for Europe&#x2014;a cluster-randomised controlled trial. Eur. J. Sport Sci. 18, 130&#x2013;139 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29161988</ArticleId><ArticleId IdType="doi">10.1080/17461391.2017.1394369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansai, J. H. &amp; Rebelatto, J. R. Effect of two physical exercise protocols on cognition and depressive symptoms in oldest-old people: a randomized controlled trial. Geriatrics Gerontol. Int. 15, 1127&#x2013;1134 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ggi.12411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne, J. A. &amp; Egger, M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 54, 1046&#x2013;1055 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11576817</ArticleId><ArticleId IdType="doi">10.1016/S0895-4356(01)00377-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Vevea, J. L. &amp; Hedges, L. V. A general linear model for estimating effect size in the presence of publication bias. Psychometrika 60, 419&#x2013;435 (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02294384</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley, T. D., Doucouliagos, H., Ioannidis, J. P. &amp; Carter, E. C. Detecting publication selection bias through excess statistical significance. Res. Synth. Methods 12, 776&#x2013;795 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34196473</ArticleId><ArticleId IdType="doi">10.1002/jrsm.1512</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley, T. D. &amp; Doucouliagos, H. Meta-regression approximations to reduce publication selection bias. Res. Synth. Methods 5, 60&#x2013;78 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">26054026</ArticleId><ArticleId IdType="doi">10.1002/jrsm.1095</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger, M., Smith, G. D., Schneider, M. &amp; Minder, C. Bias in meta-analysis detected by a simple, graphical test. B. Med. J. 315, 629&#x2013;634 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers, M. A. &amp; Pustejovsky, J. E. Evaluating meta-analytic methods to detect selective reporting in the presence of dependent effect sizes. Psychol. Methods 26, 141 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/met0000300</ArticleId></ArticleIdList></Reference><Reference><Citation>Barto&#x161;, F., Maier, M., Wagenmakers, E.-J., Doucouliagos, H. &amp; Stanley, T. D. Robust Bayesian meta-analysis: model-averaging across complementary publication bias adjustment methods. Res. Synth. Methods 14, 99&#x2013;116 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1594</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsohn, U., Simmons, J. P. &amp; Nelson, L. D. Specification curve analysis. Nat. Hum. Behav. 4, 1208&#x2013;1214 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32719546</ArticleId><ArticleId IdType="doi">10.1038/s41562-020-0912-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen, R. F., Lawlor, B. A. &amp; Kenny, R. Failure to demonstrate that memory improvement is due either to aerobic exercise or increased hippocampal volume. Proc. Natl Acad. Sci. USA 108, E89&#x2013;E89 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21504947</ArticleId><ArticleId IdType="pmc">3088586</ArticleId><ArticleId IdType="doi">10.1073/pnas.1102593108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, J. S. &amp; Evans, J. A. Slowed canonical progress in large fields of science. Proc. Natl Acad. Sci. USA 118, e2021636118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34607941</ArticleId><ArticleId IdType="pmc">8522281</ArticleId><ArticleId IdType="doi">10.1073/pnas.2021636118</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Science Collaboration. Estimating the reproducibility of psychological science. Science 349, aac4716 (2015).</Citation></Reference><Reference><Citation>Errington, T. M. et al. Investigating the replicability of preclinical cancer biology. eLife 10, e71601 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34874005</ArticleId><ArticleId IdType="pmc">8651293</ArticleId><ArticleId IdType="doi">10.7554/eLife.71601</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerer, C. F. et al. Evaluating replicability of laboratory experiments in economics. Science 351, 1433&#x2013;1436 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26940865</ArticleId><ArticleId IdType="doi">10.1126/science.aaf0918</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerer, C. F. et al. Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015. Nat. Hum. Behav. 2, 637&#x2013;644 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">31346273</ArticleId><ArticleId IdType="doi">10.1038/s41562-018-0399-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Zotcheva, E. et al. Effects of 5 years aerobic exercise on cognition in older adults: the generation 100 study: a randomized controlled trial. Sports Med. 52, 1689&#x2013;1699 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34878637</ArticleId><ArticleId IdType="doi">10.1007/s40279-021-01608-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvarven, A., Str&#xf8;mland, E. &amp; Johannesson, M. Comparing meta-analyses and preregistered multiple-laboratory replication projects. Nat. Hum. Behav. 4, 423&#x2013;434 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31873200</ArticleId><ArticleId IdType="doi">10.1038/s41562-019-0787-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood, K. &amp; Middleton, L. Physical activity and the maintenance of cognitive function. Alzheimers Dement. 3, S38&#x2013;S44 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">19595973</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2007.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Belsky, D. W. et al. Cardiorespiratory fitness and cognitive function in midlife: neuroprotection or neuroselection?: fitness and cognitive function. Ann. Neurol. 77, 607&#x2013;617 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25601795</ArticleId><ArticleId IdType="pmc">4376580</ArticleId><ArticleId IdType="doi">10.1002/ana.24356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau, J., Ioannidis, J. P. &amp; Schmid, C. H. Summing up evidence: one answer is not always enough. Lancet 351, 123&#x2013;127 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9439507</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(97)08468-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogue, J. &amp; Yusuf, S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351, 47&#x2013;52 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9433436</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(97)08461-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter, J. E. &amp; Schmidt, F. L. Methods of Meta-analysis: Correcting Error and Bias in Research Findings (Sage, 2004).</Citation></Reference><Reference><Citation>Simonsohn, U., Simmons, J. &amp; Nelson, L. D. Above averaging in literature reviews. Nat. Rev. Psychol. 1, 551&#x2013;552 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44159-022-00101-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter, E. C., Sch&#xf6;nbrodt, F. D., Gervais, W. M. &amp; Hilgard, J. Correcting for bias in psychology: a comparison of meta-analytic methods. Adv. Methods Pract. Psychol. Sci. 2, 115&#x2013;144 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2515245919847196</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass, A. et al. Relationships of peripheral IGF-1, VEGF and BDNF levels to exercise-related changes in memory, hippocampal perfusion and volumes in older adults. Neuroimage 131, 142&#x2013;154 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26545456</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2015.10.084</ArticleId></ArticleIdList></Reference><Reference><Citation>Gow, A. J. et al. Neuroprotective lifestyles and the aging brain: activity, atrophy, and white matter integrity. Neurology 79, 1802&#x2013;1808 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23091073</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182703fd2</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranahan, A. M. et al. Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus 19, 951&#x2013;961 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19280661</ArticleId><ArticleId IdType="pmc">2755651</ArticleId><ArticleId IdType="doi">10.1002/hipo.20577</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie, B. R. et al. Exercising our brains: how physical activity impacts synaptic plasticity in the dentate gyrus. Neuromol. Med. 10, 47&#x2013;58 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-008-8033-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Stummer, W., Weber, K., Tranmer, B., Baethmann, A. &amp; Kempski, O. Reduced mortality and brain damage after locomotor activity in gerbil forebrain ischemia. Stroke 25, 1862&#x2013;1869 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8073470</ArticleId><ArticleId IdType="doi">10.1161/01.STR.25.9.1862</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman, C. W., Berchtold, N. C. &amp; Christie, L.-A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 30, 464&#x2013;472 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17765329</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2007.06.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer, J. et al. Effects of voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague&#x2013;Dawley rats in vivo. Neuroscience 124, 71&#x2013;79 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14960340</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2003.09.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarumi, T. &amp; Zhang, R. The role of exercise-induced cardiovascular adaptation in brain health. Exerc. Sport Sci. Rev. 43, 181&#x2013;189 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26196870</ArticleId><ArticleId IdType="doi">10.1249/JES.0000000000000063</ArticleId></ArticleIdList></Reference><Reference><Citation>McMorris, T. (ed.) Exercise&#x2013;Cognition Interaction: Neuroscience Perspectives (Academic Press, 2016).</Citation></Reference><Reference><Citation>Mann, D. T., Williams, A. M., Ward, P. &amp; Janelle, C. M. Perceptual-cognitive expertise in sport: a meta-analysis. J. Sport Exerc. Psychol. 29, 457&#x2013;478 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17968048</ArticleId><ArticleId IdType="doi">10.1123/jsep.29.4.457</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons, D. J. et al. Do &#x201c;brain-training&#x201d; programs work? Psychol. Sci. Public Interest 17, 103&#x2013;186 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27697851</ArticleId><ArticleId IdType="doi">10.1177/1529100616661983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n-Caballero, R., Sanabria, D. &amp; Ciria, L. F. Let&#x2019;s go beyond &#x201c;the effect of&#x201d;: reappraising the impact of ordinary activities on cognition. Psicol&#xf3;gica 44, e15144 (2023).</Citation></Reference><Reference><Citation>Gavelin, H. M. et al. Combined physical and cognitive training for older adults with and without cognitive impairment: a systematic review and network meta-analysis of randomized controlled trials. Ageing Res. Rev. 66, 101232 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33249177</ArticleId><ArticleId IdType="doi">10.1016/j.arr.2020.101232</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekkekakis, P. Why is exercise underutilized in clinical practice despite evidence it is effective? Lessons in pragmatism from the inclusion of exercise in guidelines for the treatment of depression in the British National Health Service. Kinesiol. Rev. 10, 29&#x2013;50 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/kr.2020-0036</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. &amp; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).</Citation></Reference><Reference><Citation>Morris, S. B. Estimating effect sizes from pretest-posttest-control group designs. Organ. Res. Methods 11, 364&#x2013;386 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1094428106291059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedges, L. V., Tipton, E. &amp; Johnson, M. C. Robust variance estimation in meta-regression with dependent effect size estimates. Res. Synth. Methods 1, 39&#x2013;65 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">26056092</ArticleId><ArticleId IdType="doi">10.1002/jrsm.5</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher, Z., Tipton, E., Zhipeng, H. &amp; Fisher, M. Z. Package &#x2018;robumeta&#x2019; (2017).</Citation></Reference><Reference><Citation>Borenstein, M., Hedges, L. V., Higgins, J. P. &amp; Rothstein, H. R. Introduction to Meta-analysis (John Wiley &amp; Sons, 2021).</Citation></Reference><Reference><Citation>Pustejovsky, J. E. &amp; Rodgers, M. A. Testing for funnel plot asymmetry of standardized mean differences. Res. Synth. Methods 10, 57&#x2013;71 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30506832</ArticleId><ArticleId IdType="doi">10.1002/jrsm.1332</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37010830</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Age at Menopause and Hormone Therapy Use With Tau and &#x3b2;-Amyloid Positron Emission Tomography.</ArticleTitle><Pagination><StartPage>462</StartPage><EndPage>473</EndPage><MedlinePgn>462-473</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2023.0455</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Postmenopausal females represent around 70% of all individuals with Alzheimer disease. Previous literature shows elevated levels of tau in cognitively unimpaired postmenopausal females compared with age-matched males, particularly in the setting of high &#x3b2;-amyloid (A&#x3b2;). The biological mechanisms associated with higher tau deposition in female individuals remain elusive.</AbstractText><AbstractText Label="OBJECTIVE">To examine the extent to which sex, age at menopause, and hormone therapy (HT) use are associated with regional tau at a given level of A&#x3b2;, both measured with positron emission tomography (PET).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study included participants enrolled in the Wisconsin Registry for Alzheimer Prevention. Cognitively unimpaired males and females with at least 1 18F-MK-6240 and 11C-Pittsburgh compound B PET scan were analyzed. Data were collected between November 2006 and May 2021.</AbstractText><AbstractText Label="EXPOSURES">Premature menopause (menopause at younger than 40 years), early menopause (menopause at age 40-45 years), and regular menopause (menopause at older than 45 years) and HT user (current/past use) and HT nonuser (no current/past use). Exposures were self-reported.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Seven tau PET regions that show sex differences across temporal, parietal, and occipital lobes. Primary analyses examined the interaction of sex, age at menopause or HT, and A&#x3b2; PET on regional tau PET in a series of linear regressions. Secondary analyses investigated the influence of HT timing in association with age at menopause on regional tau PET.</AbstractText><AbstractText Label="RESULTS">Of 292 cognitively unimpaired individuals, there were 193 females (66.1%) and 99 males (33.9%). The mean (range) age at tau scan was 67 (49-80) years, 52 (19%) had abnormal A&#x3b2;, and 106 (36.3%) were APOE&#x3b5;4 carriers. There were 98 female HT users (52.2%) (past/current). Female sex (standardized &#x3b2;&#x2009;=&#x2009;-0.41; 95% CI, -0.97 to -0.32; P&#x2009;&lt;&#x2009;.001), earlier age at menopause (standardized &#x3b2;&#x2009;=&#x2009;-0.38; 95% CI, -0.14 to -0.09; P&#x2009;&lt;&#x2009;.001), and HT use (standardized &#x3b2;&#x2009;=&#x2009;0.31; 95% CI, 0.40-1.20; P&#x2009;=&#x2009;.008) were associated with higher regional tau PET in individuals with elevated A&#x3b2; compared with male sex, later age at menopause, and HT nonuse. Affected regions included medial and lateral regions of the temporal and occipital lobes. Late initiation of HT (&gt;5 years following age at menopause) was associated with higher tau PET compared with early initiation (&#x3b2;&#x2009;=&#x2009;0.49; 95% CI, 0.27-0.43; P&#x2009;=&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, females exhibited higher tau compared with age-matched males, particularly in the setting of elevated A&#x3b2;. In females, earlier age at menopause and late initiation of HT were associated with increased tau vulnerability especially when neocortical A&#x3b2; elevated. These observational findings suggest that subgroups of female individuals may be at higher risk of pathological burden.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coughlan</LastName><ForeName>Gillian T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betthauser</LastName><ForeName>Tobey J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Rory</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koscik</LastName><ForeName>Rebecca L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klinger</LastName><ForeName>Hannah M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Harvard T.H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonaitis</LastName><ForeName>Erin M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yau</LastName><ForeName>Wai-Ying Wendy</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenzel</LastName><ForeName>Allen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christian</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gleason</LastName><ForeName>Carey E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saelzler</LastName><ForeName>Ursula G</ForeName><Initials>UG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Properzi</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanseeuw</LastName><ForeName>Bernard J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>JoAnn E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Harvard T.H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin-Madison, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Rachel F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 HD090256</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025245</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG061238</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062285</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053798</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG057437</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006728">Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008593" MajorTopicYN="N">Menopause</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006728" MajorTopicYN="N">Hormones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Betthauser, Koscik, Jonaitis, and Wenzel reported grants from the National Institutes of Health during the conduct of the study. Dr Hanseeuw reported grants from Fonds National de la Recherche Scientifique and WelBio and personal fees from Biogen and Roche outside the submitted work. Dr Manson reported grants from the National Institutes of Health during the conduct of the study and outside the submitted work and grants from Mars Edge outside the submitted work. Dr Rentz reported grants from the National Institute of Aging during the conduct of the study. Dr Sperling reported consulting fees from AC Immune, Alector, Genentech, Janssen, Neuraly, Oligomerix, Prothena, Renew, Alnylam, Cytox, JOMDD, Nervgen, Neurocentria, Shionogi, Vigil Neuroscience, Ionis, Acumen, and Vaxxinity and grants from Eisai, Eli Lilly, National Institute on Aging, and Alzheimer's Association outside the submitted work. Dr S.C. Johnson reported consulting for Roche Diagnostics and grants from Cerveau Technologies to their institution during the conduct of the study and consulting for Prothena and Eisai outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37010830</ArticleId><ArticleId IdType="pmc">PMC10071399</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2023.0455</ArticleId><ArticleId IdType="pii">2802791</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>2022 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s Association . Accessed February 22, 2023. https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf</Citation><ArticleIdList><ArticleId IdType="pubmed">35289055</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Scott MR, Jacobs HIL, et al. . Sex mediates relationships between regional tau pathology and cognitive decline. Ann Neurol. 2020;88(5):921-932. doi:10.1002/ana.25878</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25878</ArticleId><ArticleId IdType="pmc">PMC7581543</ArticleId><ArticleId IdType="pubmed">32799367</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Rabin JS, et al. . Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 2019;76(5):542-551. doi:10.1001/jamaneurol.2018.4693</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4693</ArticleId><ArticleId IdType="pmc">PMC6515599</ArticleId><ArticleId IdType="pubmed">30715078</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62(6):685-691. doi:10.1001/archpsyc.62.6.685</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.62.6.685</ArticleId><ArticleId IdType="pubmed">15939846</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Harrison TM, La Joie R, Baker SL, Jagust WJ. Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. Eur J Nucl Med Mol Imaging. 2020;47(9):2155-2164. doi:10.1007/s00259-019-04669-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04669-x</ArticleId><ArticleId IdType="pmc">PMC7338820</ArticleId><ArticleId IdType="pubmed">31915896</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesinger AM, Graff-Radford NR, Duara R, et al. . Sex and age interact to determine clinicopathologic differences in Alzheimer&#x2019;s disease. Acta Neuropathol. 2018;136(6):873-885. doi:10.1007/s00401-018-1908-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1908-x</ArticleId><ArticleId IdType="pmc">PMC6280837</ArticleId><ArticleId IdType="pubmed">30219939</ArticleId></ArticleIdList></Reference><Reference><Citation>Shifren JL, Gass MLS; NAMS Recommendations for Clinical Care of Midlife Women Working Group . The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038-1062. doi:10.1097/GME.0000000000000319</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GME.0000000000000319</ArticleId><ArticleId IdType="pubmed">25225714</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbo RM, Gambina G, Broggio E, Scacchi R. Influence of variation in the follicle-stimulating hormone receptor gene (FSHR) and age at menopause on the development of Alzheimer&#x2019;s disease in women. Dement Geriatr Cogn Disord. 2011;32(1):63-69. doi:10.1159/000330472</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000330472</ArticleId><ArticleId IdType="pubmed">21865747</ArticleId></ArticleIdList></Reference><Reference><Citation>Phung TKT, Waltoft BL, Laursen TM, et al. . Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord. 2010;30(1):43-50. doi:10.1159/000314681</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000314681</ArticleId><ArticleId IdType="pubmed">20689282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove R, Secor E, Chibnik LB, et al. . Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222-229. doi:10.1212/WNL.0000000000000033</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000033</ArticleId><ArticleId IdType="pmc">PMC3902759</ArticleId><ArticleId IdType="pubmed">24336141</ArticleId></ArticleIdList></Reference><Reference><Citation>Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47-63. doi:10.1016/0091-7435(91)90006-p</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0091-7435(91)90006-p</ArticleId><ArticleId IdType="pubmed">1826173</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson VW. Estrogen, cognition, and a woman&#x2019;s risk of Alzheimer&#x2019;s disease. Am J Med. 1997;103(3A):11S-18S. doi:10.1016/S0002-9343(97)00261-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(97)00261-1</ArticleId><ArticleId IdType="pubmed">9344402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkura T, Teshima Y, Isse K, et al. . Estrogen increase cerebral and cerebellar blood flows in postmenopausal women. Menopause. 1995;2(1):13-18.</Citation></Reference><Reference><Citation>Manson JE, Chlebowski RT, Stefanick ML, et al. . Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women&#x2019;s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.278040</ArticleId><ArticleId IdType="pmc">PMC3963523</ArticleId><ArticleId IdType="pubmed">24084921</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Rapp SR, Shumaker SA, et al. . Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291(24):2959-2968. doi:10.1001/jama.291.24.2959</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.24.2959</ArticleId><ArticleId IdType="pubmed">15213207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp SR, Espeland MA, Shumaker SA, et al. . Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2002;289(20):2663-2672. doi:10.1001/jama.289.20.2663</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.20.2663</ArticleId><ArticleId IdType="pubmed">12771113</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA, Legault C, Rapp SR, et al. . Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651-2662. doi:10.1001/jama.289.20.2651</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.20.2651</ArticleId><ArticleId IdType="pubmed">12771112</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA; MIRAGE Study Group . Postmenopausal hormone therapy and Alzheimer&#x2019;s disease risk: interaction with age. J Neurol Neurosurg Psychiatry. 2005;76(1):103-105. doi:10.1136/jnnp.2003.024927</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.024927</ArticleId><ArticleId IdType="pmc">PMC1739309</ArticleId><ArticleId IdType="pubmed">15608005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodis HN, Mack WJ, Henderson VW, et al. ; ELITE Research Group . Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231. doi:10.1056/NEJMoa1505241</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1505241</ArticleId><ArticleId IdType="pmc">PMC4921205</ArticleId><ArticleId IdType="pubmed">27028912</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol. 2011;69(1):163-169. doi:10.1002/ana.22239</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22239</ArticleId><ArticleId IdType="pmc">PMC3058824</ArticleId><ArticleId IdType="pubmed">21280086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung YF, Tsai CT, Kuo CY, et al. . Use of hormone replacement therapy and risk of dementia: a nationwide cohort study. Neurology. 2022;99:e1835-e1842. doi:10.1212/WNL.0000000000200960</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200960</ArticleId><ArticleId IdType="pubmed">36240091</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, Breitner JCS, Whitmer RA, et al. . Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology. 2012;79(18):1846-1852. doi:10.1212/WNL.0b013e318271f823</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318271f823</ArticleId><ArticleId IdType="pmc">PMC3525314</ArticleId><ArticleId IdType="pubmed">23100399</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLennan AH, Henderson VW, Paine BJ, et al. . Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause. 2006;13(1):28-36. doi:10.1097/01.gme.0000191204.38664.61</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.gme.0000191204.38664.61</ArticleId><ArticleId IdType="pubmed">16607096</ArticleId></ArticleIdList></Reference><Reference><Citation>Buist DS, Newton KM, Miglioretti DL, et al. . Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004;104(5 Pt 1):1042-1050. doi:10.1097/01.AOG.0000143826.38439.af</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.AOG.0000143826.38439.af</ArticleId><ArticleId IdType="pubmed">15516400</ArticleId></ArticleIdList></Reference><Reference><Citation>Faubion S, Crandall C, Davis L, et al. ; &#x201c;The 2022 Hormone Therapy Position Statement of The North American Menopause Society&#x201d; Advisory Panel . The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GME.0000000000002028</ArticleId><ArticleId IdType="pubmed">35797481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee . American Association of Clinical Endocrinologists and American College of Endocrinology: position statement on menopause: 2017 update. Endocr Pract. 2017;23(7):869-880. doi:10.4158/EP171828.PS</Citation><ArticleIdList><ArticleId IdType="doi">10.4158/EP171828.PS</ArticleId><ArticleId IdType="pubmed">28703650</ArticleId></ArticleIdList></Reference><Reference><Citation>Menopause: diagnosis and management. National Institute for Health and Care Excellence . Updated December 5, 2019. Accessed February 22, 2023. http://www.nice.org.uk/guidance/ng23</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, O&#x2019;Donnell A, McGrath ER, et al. . Menopause status moderates sex differences in tau burden: a Framingham PET study. Ann Neurol. 2022;92(1):11-22. doi:10.1002/ana.26382</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26382</ArticleId><ArticleId IdType="pmc">PMC9233144</ArticleId><ArticleId IdType="pubmed">35471588</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Koscik RL, Jonaitis EM, et al. . The Wisconsin Registry for Alzheimer&#x2019;s Prevention: a review of findings and current directions. Alzheimers Dement (Amst). 2017;10:130-142. doi:10.1016/j.dadm.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5755749</ArticleId><ArticleId IdType="pubmed">29322089</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, La Rue A, Hermann BP, et al. . The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE &#x3b5;3/&#x3b5;3 genotype. Alzheimers Dement. 2011;7(4):456-465. doi:10.1016/j.jalz.2010.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.11.012</ArticleId><ArticleId IdType="pmc">PMC3143375</ArticleId><ArticleId IdType="pubmed">21784354</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlow SD, Gass M, Hall JE, et al. ; STRAW + 10 Collaborative Group . Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168. doi:10.1210/jc.2011-3362</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2011-3362</ArticleId><ArticleId IdType="pmc">PMC3319184</ArticleId><ArticleId IdType="pubmed">22344196</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Christian BT, Okonkwo OC, et al. . Amyloid burden and neural function in people at risk for Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35(3):576-584. doi:10.1016/j.neurobiolaging.2013.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.028</ArticleId><ArticleId IdType="pmc">PMC4018215</ArticleId><ArticleId IdType="pubmed">24269021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273-289. doi:10.1006/nimg.2001.0978</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2001.0978</ArticleId><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, Bendlin BB, Racine AM, et al. . Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging. 2015;36(9):2568-2576. doi:10.1016/j.neurobiolaging.2015.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.05.004</ArticleId><ArticleId IdType="pmc">PMC4523445</ArticleId><ArticleId IdType="pubmed">26059712</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Bilgel M, Koscik RL, et al. . Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain. 2022;145(11):4065-4079. doi:10.1093/brain/awac213</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac213</ArticleId><ArticleId IdType="pmc">PMC9679170</ArticleId><ArticleId IdType="pubmed">35856240</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Cody KA, Zammit MD, et al. . In vivo characterization and quantification of neurofibrillary tau PET radioligand 18 F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93-99. doi:10.2967/jnumed.118.209650</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.209650</ArticleId><ArticleId IdType="pmc">PMC6354223</ArticleId><ArticleId IdType="pubmed">29777006</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonaitis EM, Koscik RL, Clark LR, et al. . Measuring longitudinal cognition: Individual tests versus composites. Alzheimers Dement (Amst). 2019;11:74-84. doi:10.1016/j.dadm.2018.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2018.11.006</ArticleId><ArticleId IdType="pmc">PMC6816509</ArticleId><ArticleId IdType="pubmed">31673596</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. ; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Alzheimer&#x2019;s Disease Cooperative Study . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970. doi:10.1001/jamaneurol.2014.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc. 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenaker DAJM, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014;43(5):1542-1562. doi:10.1093/ije/dyu094</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyu094</ArticleId><ArticleId IdType="pmc">PMC4190515</ArticleId><ArticleId IdType="pubmed">24771324</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller VM, Naftolin F, Asthana S, et al. . The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071-1084. doi:10.1097/GME.0000000000001326</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GME.0000000000001326</ArticleId><ArticleId IdType="pmc">PMC6738629</ArticleId><ArticleId IdType="pubmed">31453973</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino RB Sr, Vasan RS, Pencina MJ, et al. . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. doi:10.1161/CIRCULATIONAHA.107.699579</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.699579</ArticleId><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller S, Hann Y, Jhang JH, et al. . Spotlights, floodlights, and the magic number zero: simple effects tests in moderated regression. J Mark Res. 2013;L:277-288. doi:10.1509/jmr.12.0420</Citation><ArticleIdList><ArticleId IdType="doi">10.1509/jmr.12.0420</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1-15.e1, 4. doi:10.1016/j.jalz.2014.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Seco&#x219;an C, Balint O, Pirtea L, Grigora&#x219; D, B&#x103;lulescu L, Ilina R. Surgically induced menopause&#x2014;a practical review of literature. Medicina (Kaunas). 2019;55(8):482. doi:10.3390/medicina55080482</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina55080482</ArticleId><ArticleId IdType="pmc">PMC6722518</ArticleId><ArticleId IdType="pubmed">31416275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Schelbaum E, Hoffman K, et al. . Sex-driven modifiers of Alzheimer risk: a multimodality brain imaging study. Neurology. 2020;95(2):e166-e178. doi:10.1212/WNL.0000000000009781</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009781</ArticleId><ArticleId IdType="pmc">PMC7455325</ArticleId><ArticleId IdType="pubmed">32580974</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinogradova Y, Dening T, Hippisley-Cox J, Taylor L, Moore M, Coupland C. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ. 2021;374:n2182. doi:10.1136/bmj.n2182</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2182</ArticleId><ArticleId IdType="pmc">PMC8479814</ArticleId><ArticleId IdType="pubmed">34588168</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J, Kaunitz A. Menopause management&#x2014; getting clinical care back on track. N Engl J Med. 2016;374(9):801-803. doi:10.1056/NEJMp1514242</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1514242</ArticleId><ArticleId IdType="pubmed">26962899</ArticleId></ArticleIdList></Reference><Reference><Citation>Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. . Use of postmenopausal hormone therapy and risk of Alzheimer&#x2019;s disease in Finland: nationwide case-control study. BMJ. 2019;364:l665. doi:10.1136/bmj.l665</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l665</ArticleId><ArticleId IdType="pmc">PMC6402043</ArticleId><ArticleId IdType="pubmed">30842086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Aggarwal NT, Vila-Castelar C, et al. . Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. Alzheimers Dement. 2022;18(12):2707-2724. doi:10.1002/alz.12662</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12662</ArticleId><ArticleId IdType="pmc">PMC9547039</ArticleId><ArticleId IdType="pubmed">35394117</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Waller M, Masters CL, Dobson A. To what extent does age at death account for sex differences in rates of mortality from Alzheimer disease? Am J Epidemiol. 2019;188(7):1213-1223. doi:10.1093/aje/kwz048</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwz048</ArticleId><ArticleId IdType="pubmed">30824901</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER. Invited commentary: examining sex/gender differences in risk of Alzheimer disease and related dementias: challenges and future directions. Am J Epidemiol. 2019;188(7):1224-1227. doi:10.1093/aje/kwz047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwz047</ArticleId><ArticleId IdType="pmc">PMC6601521</ArticleId><ArticleId IdType="pubmed">30824902</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw C, Hayes-Larson E, Glymour MM, et al. . Evaluation of selective survival and sex/gender differences in dementia incidence using a simulation model. JAMA Netw Open. 2021;4(3):e211001. doi:10.1001/jamanetworkopen.2021.1001</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.1001</ArticleId><ArticleId IdType="pmc">PMC7944377</ArticleId><ArticleId IdType="pubmed">33687445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahuja M. Age of menopause and determinants of menopause age: a PAN India survey by IMS. J Midlife Health. 2016;7(3):126-131. doi:10.4103/0976-7800.191012</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0976-7800.191012</ArticleId><ArticleId IdType="pmc">PMC5051232</ArticleId><ArticleId IdType="pubmed">27721640</ArticleId></ArticleIdList></Reference><Reference><Citation>Legorreta D, Monta&#xf1;o JA, Hern&#xe1;ndez I, Salinas C, Hern&#xe1;ndez-Bueno JA; AMEC Research Committee . Age at menopause, motives for consultation and symptoms reported by 40-59-year-old Mexican women. Climacteric. 2013;16(4):417-425. doi:10.3109/13697137.2012.696288</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13697137.2012.696288</ArticleId><ArticleId IdType="pubmed">22888911</ArticleId></ArticleIdList></Reference><Reference><Citation>Brett KM, Reuben CA. Prevalence of estrogen or estrogen-progestin hormone therapy use. Obstet Gynecol. 2003;102(6):1240-1249. doi:10.1016/j.obstetgynecol.2003.09.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.obstetgynecol.2003.09.024</ArticleId><ArticleId IdType="pubmed">14662210</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly MT, Richardson M, Platt R. Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995. J Gen Intern Med. 2000;15(8):542-550. doi:10.1046/j.1525-1497.2000.03499.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2000.03499.x</ArticleId><ArticleId IdType="pmc">PMC1495583</ArticleId><ArticleId IdType="pubmed">10940145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13(4):220-231. doi:10.1038/nrendo.2016.164</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2016.164</ArticleId><ArticleId IdType="pubmed">27716751</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett W, Stampfer MJ, Bain C, et al. . Cigarette smoking, relative weight, and menopause. Am J Epidemiol. 1983;117(6):651-658. doi:10.1093/oxfordjournals.aje.a113598</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a113598</ArticleId><ArticleId IdType="pubmed">6859020</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, von Sanden C, Salim A, O&#x2019;Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007;166(4):367-378. doi:10.1093/aje/kwm116</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwm116</ArticleId><ArticleId IdType="pubmed">17573335</ArticleId></ArticleIdList></Reference><Reference><Citation>Honigberg MC, Zekavat SM, Aragam K, et al. . Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411-2421. doi:10.1001/jama.2019.19191</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.19191</ArticleId><ArticleId IdType="pmc">PMC7231649</ArticleId><ArticleId IdType="pubmed">31738818</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37059509</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using &#x3b1;-synuclein seed amplification: a cross-sectional study.</ArticleTitle><Pagination><StartPage>407</StartPage><EndPage>417</EndPage><MedlinePgn>407-417</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(23)00109-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(23)00109-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Emerging evidence shows that &#x3b1;-synuclein seed amplification assays (SAAs) have the potential to differentiate people with Parkinson's disease from healthy controls. We used the well characterised, multicentre Parkinson's Progression Markers Initiative (PPMI) cohort to further assess the diagnostic performance of the &#x3b1;-synuclein SAA and to examine whether the assay identifies heterogeneity among patients and enables the early identification of at-risk groups.</AbstractText><AbstractText Label="METHODS">This cross-sectional analysis is based on assessments done at enrolment for PPMI participants (including people with sporadic Parkinson's disease from LRRK2 and GBA variants, healthy controls, prodromal individuals with either rapid eye movement sleep behaviour disorder (RBD) or hyposmia, and non-manifesting carriers of LRRK2 and GBA variants) from 33 participating academic neurology outpatient practices worldwide (in Austria, Canada, France, Germany, Greece, Israel, Italy, the Netherlands, Norway, Spain, the UK, and the USA). &#x3b1;-synuclein SAA analysis of CSF was performed using previously described methods. We assessed the sensitivity and specificity of the &#x3b1;-synuclein SAA in participants with Parkinson's disease and healthy controls, including subgroups based on genetic and clinical features. We established the frequency of positive &#x3b1;-synuclein SAA results in prodromal participants (RBD and hyposmia) and non-manifesting carriers of genetic variants associated with Parkinson's disease, and compared &#x3b1;-synuclein SAA to clinical measures and other biomarkers. We used odds ratio estimates with 95% CIs to measure the association between &#x3b1;-synuclein SAA status and categorical measures, and two-sample 95% CIs from the resampling method to assess differences in medians between &#x3b1;-synuclein SAA positive and negative participants for continuous measures. A linear regression model was used to control for potential confounders such as age and sex.</AbstractText><AbstractText Label="FINDINGS">This analysis included 1123 participants who were enrolled between July 7, 2010, and July 4, 2019. Of these, 545 had Parkinson's disease, 163 were healthy controls, 54 were participants with scans without evidence of dopaminergic deficit, 51 were prodromal participants, and 310 were non-manifesting carriers. Sensitivity for Parkinson's disease was 87&#xb7;7% (95% CI 84&#xb7;9-90&#xb7;5), and specificity for healthy controls was 96&#xb7;3% (93&#xb7;4-99&#xb7;2). The sensitivity of the &#x3b1;-synuclein SAA in sporadic Parkinson's disease with the typical olfactory deficit was 98&#xb7;6% (96&#xb7;4-99&#xb7;4). The proportion of positive &#x3b1;-synuclein SAA was lower than this figure in subgroups including LRRK2 Parkinson's disease (67&#xb7;5% [59&#xb7;2-75&#xb7;8]) and participants with sporadic Parkinson's disease without olfactory deficit (78&#xb7;3% [69&#xb7;8-86&#xb7;7]). Participants with LRRK2 variant and normal olfaction had an even lower &#x3b1;-synuclein SAA positivity rate (34&#xb7;7% [21&#xb7;4-48&#xb7;0]). Among prodromal and at-risk groups, 44 (86%) of 51 of participants with RBD or hyposmia had positive &#x3b1;-synuclein SAA (16 of 18 with hyposmia, and 28 of 33 with RBD). 25 (8%) of 310 non-manifesting carriers (14 of 159 [9%] LRRK2 and 11 of 151 [7%] GBA) were positive.</AbstractText><AbstractText Label="INTERPRETATION">This study represents the largest analysis so far of the &#x3b1;-synuclein SAA for the biochemical diagnosis of Parkinson's disease. Our results show that the assay classifies people with Parkinson's disease with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals before diagnosis. These findings suggest a crucial role for the &#x3b1;-synuclein SAA in therapeutic development, both to identify pathologically defined subgroups of people with Parkinson's disease and to establish biomarker-defined at-risk cohorts.</AbstractText><AbstractText Label="FUNDING">PPMI is funded by the Michael J Fox Foundation for Parkinson's Research and funding partners, including: Abbvie, AcureX, Aligning Science Across Parkinson's, Amathus Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biohaven, Biogen, BioLegend, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel, Coave, DaCapo Brainscience, 4D Pharma, Denali, Edmond J Safra Foundation, Eli Lilly, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, VanquaBio, Verily, Voyager Therapeutics, and Yumanity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siderowf</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: andrew.siderowf@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Concha-Marambio</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research and Development Unit, Amprion, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafontant</LastName><ForeName>David-Erick</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farris</LastName><ForeName>Carly M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Research and Development Unit, Amprion, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yihua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research and Development Unit, Amprion, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urenia</LastName><ForeName>Paula A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Research and Development Unit, Amprion, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hieu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research and Development Unit, Amprion, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcalay</LastName><ForeName>Roy N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chahine</LastName><ForeName>Lana M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kieburtz</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Rochester Medical Center, University of Rochester, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchant</LastName><ForeName>Kalpana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany; Paracelsus-Elena Klinik, Kassel, and German Center for Neurodegenerative Diseases, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poston</LastName><ForeName>Kathleen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seibyl</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disorders, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simuni</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanner</LastName><ForeName>Caroline M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Parkinson's Disease Research, Education and Clinical Center, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Videnovic</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seung Ho</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurth</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caspell-Garcia</LastName><ForeName>Chelsea</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffey</LastName><ForeName>Christopher S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frasier</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Luis M A</ForeName><Initials>LMA</Initials><AffiliationInfo><Affiliation>The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutten</LastName><ForeName>Samantha J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherer</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marek</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disorders, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research and Development Unit, Amprion, San Diego, CA, USA; Department of Neurology, University of Texas McGovern Medical School at Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Parkinson's Progression Markers Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055053</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG079685</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061069</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059321</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2023 May;22(5):369-371. doi: 10.1016/S1474-4422(23)00124-2.</RefSource><PMID Version="1">37059498</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Jun;19(6):324. doi: 10.1038/s41582-023-00814-1.</RefSource><PMID Version="1">37100894</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Chem. 2023 Nov 2;69(11):1209-1211. doi: 10.1093/clinchem/hvad111.</RefSource><PMID Version="1">37688494</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2023 Nov;22(11):983-984. doi: 10.1016/S1474-4422(23)00372-1.</RefSource><PMID Version="1">37863602</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2023 Nov;22(11):984-985. doi: 10.1016/S1474-4422(23)00374-5.</RefSource><PMID Version="1">37863603</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2023 Nov;22(11):985. doi: 10.1016/S1474-4422(23)00373-3.</RefSource><PMID Version="1">37863604</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="N">Anosmia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020187" MajorTopicYN="Y">REM Sleep Behavior Disorder</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests AS declares consultancy for Merck, Parkinson Study Group; and honoraria from Bial. LC-M declares employment for Amprion; stock ownership (employee stock options) for Amprion; and patent or patent applications numbers US 20210277076A1, US 20210311077A1, US 20190353669A1, and US 20210223268A1. CMF declares employment for Amprion; stock ownership (employee stock options) for Amprion; and patent or patent applications numbers US 20210277076A1 and US 20210311077A1. YM declares employment for Amprion; stock ownership (employee stock options) for Amprion; and patent or patent applications number US 20210277076A1. PAU declares employment for Amprion; and stock ownership (employee stock options) for Amprion. HN declares employment for Amprion; and stock ownership (employee stock options) for Amprion. RNA declares consultancies for Janssen, Sanofi, Ono Therapuetics, Avrobio, Takeda, Gain Therapuetics, Merck, GlaxoSmithKline, and Caraway. LMC declares honoraria (royalties) from Elsevier and Wolters Kluwel. TF declares travel grants from the Michael J Fox Foundation. KMe declares consultancies for the Michael J Fox Foundation, AcuRx, Caraway, Cerebral Therapeutics, NRG Therapeutics (scientific advisory board), Nurabio, Retromer Therapeutics (director on the board, part-time chief scientific officer), Schrodinger, Sinopia Biosciences (scientific advisory board), and Vanqua Biosciences (scientific advisory board); stock ownership for Cognition Therapeutics, Eli Lilly (retiree stock holder), Envisagenics, and Retromer Therapeutics; honoraria for the University of Utah; patents or patent applications for Retromer Therapeutics (planned patent); and travel grants from the University of Utah. BM declares consultancies from Roche, Biogen, and the Michael J Fox Foundation; honoraria for Abbvie; and travel grants for Abbvie. KLP declares consultancies for Curasen; was on a scientific advisory board for Curasen and Amprion; honoraria from invited scientific presentations to universities and professional societies not exceeding $5000 per year from California Congress of Clinical Neurology, California Neurological Society, and Johns Hopkins University; and patents or patent applications numbers 17/314,979 and 63/377,293. JS declares consultancies from Invicro, Biogen, and Abbvie; and stock ownership from RealmIDX, MNI Holdings, and LikeMinds. TSi declares consultancies for 4D Pharma, Acadia, AcureX, AskBio, Amneal, Blue Rock Therapeutics, Caraway, Critical Path for Parkinson's Consortium, Denali, Michael J Fox Foundation, Neuroderm, Roche, Sanofi, Sinopia, Sunovion, Takeda, UCB, Vanqua Bio, and Voyager. CMT declares consultancies for CNS Ratings, Australian Parkinson's Mission, Biogen, Evidera, Cadent (data safety monitoring board), Adamas (steering committee), Biogen (via the Parkinson Study Group steering committee), Kyowa Kirin (advisory board), Lundbeck (advisory board), Jazz/Cavion (steering committee), and Acorda (advisory board). DW declares receiving salary support from Michael J Fox Foundation for serving on an Executive Steering Committee for the PPMI. AV declares consultancies for CoA Therapeutics, XW Pharma, and Biogen. MF declares employment for the Michael J Fox Foundation. LMAO declares employment for the Michael J Fox Foundation. SJH declares employment for the Michael J Fox Foundation. TSh declares employment for the Michael J Fox Foundation. KMa declares consultancies for Invicro, MJFF, Roche, Calico, Coave, Neuron23, Orbimed, Neuroderm, Sanofi, Takeda, Merck, Lilly, Inhibikase, and Neuramedy. CS declares employment for Amprion; stock ownership for Amprion; honoraria (will receive royalties for the sale of seed amplification assay [SAA]) from Amprion; and patents or patent applications, awarded and amplified in conjunction with Amprion for the SAA assay.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>20</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37059509</ArticleId><ArticleId IdType="mid">NIHMS1937442</ArticleId><ArticleId IdType="pmc">PMC10627170</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(23)00109-6</ArticleId><ArticleId IdType="pii">S1474-4422(23)00109-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson&#x2019;s disease. Lancet Neurol 2019; 18: 573&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">30981640</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, R&#xfc;b U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol Aging 2003; 24: 197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866090</ArticleId><ArticleId IdType="pubmed">20306269</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadio V, Incensi A, Leta V, et al. Skin nerve &#x3b1;-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014; 82: 1362&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">24634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001; 411: 810&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459061</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of &#x3b1;-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 2017; 74: 163&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">27918765</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 2016; 3: 812&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048391</ArticleId><ArticleId IdType="pubmed">27752516</ArticleId></ArticleIdList></Reference><Reference><Citation>Groveman BR, Orr&#xf9; CD, Hughson AG, et al. Rapid and ultra-sensitive quantitation of disease-associated &#x3b1;-synuclein seeds in brain and cerebrospinal fluid by &#x3b1;Syn RT-QuIC. Acta Neuropathol Commun 2018; 6: 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806364</ArticleId><ArticleId IdType="pubmed">29422107</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating &#x3b1;-synuclein strains in Parkinson&#x2019;s disease and multiple system atrophy. Nature 2020; 578: 273&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066875</ArticleId><ArticleId IdType="pubmed">32025029</ArticleId></ArticleIdList></Reference><Reference><Citation>Concha-Marambio L, Farris CM, Holguin B, et al. Seed amplification assay to diagnose early Parkinson&#x2019;s and predict dopaminergic deficit progression. Mov Disord 2021; 36: 2444&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530949</ArticleId><ArticleId IdType="pubmed">34236720</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo MJ, Orru CD, Concha-Marambio L, et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson&#x2019;s disease. Acta Neuropathol Commun 2021; 9: 179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8572469</ArticleId><ArticleId IdType="pubmed">34742348</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 2020; 140: 49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299922</ArticleId><ArticleId IdType="pubmed">32342188</ArticleId></ArticleIdList></Reference><Reference><Citation>Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of &#x3b1;-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 2021; 20: 203&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">33609478</ArticleId></ArticleIdList></Reference><Reference><Citation>Brumm MC, Pierz KA, Lafontant D-E, et al. Updated percentiles for the University of Pennsylvania smell identification test in adults 50 years of age and older. Neurology 2023; published online Feb 27. 10.1212/WNL.0000000000207077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000207077</ArticleId><ArticleId IdType="pmc">PMC10115503</ArticleId><ArticleId IdType="pubmed">36849448</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek K, Chowdhury S, Siderowf A, et al. The Parkinson&#x2019;s progression markers initiative (PPMI)&#x2014;establishing a PD biomarker cohort. Ann Clin Transl Neurol 2018; 5: 1460&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6292383</ArticleId><ArticleId IdType="pubmed">30564614</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol 2012; 123: 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Fedler J, Coffey CS, et al. Evolution of Alzheimer&#x2019;s disease cerebrospinal fluid biomarkers in early Parkinson&#x2019;s disease. Ann Neurol 2020; 88: 574&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497251</ArticleId><ArticleId IdType="pubmed">32542885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, Dakna M, Kruse N, et al. Validation of serum neurofilament light chain as a biomarker of Parkinson&#x2019;s disease progression. Mov Disord 2020; 35: 1999&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017468</ArticleId><ArticleId IdType="pubmed">32798333</ArticleId></ArticleIdList></Reference><Reference><Citation>Simuni T, Uribe L, Cho HR, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson&#x2019;s Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol 2020; 19: 71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6956652</ArticleId><ArticleId IdType="pubmed">31678032</ArticleId></ArticleIdList></Reference><Reference><Citation>Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C. Seed Amplification Assay (SAA) for detection of pathologic &#x3b1;Synuclein aggregates in CSF as biomarker for Parkinson&#x2019;s disease and related synucleinopathies. Nat Protoc 2023; published online Jan 18. 10.1038/s41596-022-00787-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-022-00787-3</ArticleId><ArticleId IdType="pmc">PMC10561622</ArticleId><ArticleId IdType="pubmed">36653527</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek K, Seibyl J, Eberly S, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014; 82: 1791&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035714</ArticleId><ArticleId IdType="pubmed">24759846</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings D, Siderowf A, Stern M, et al. Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter&#x2013;deficit prodromal cohort. JAMA Neurol 2017; 74: 933&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710321</ArticleId><ArticleId IdType="pubmed">28595287</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido A, Fairfoul G, Tolosa ES, Mart&#xed; MJ, Green A. &#x3b1;-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson&#x2019;s disease. Ann Clin Transl Neurol 2019; 6: 1024&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6562027</ArticleId><ArticleId IdType="pubmed">31211166</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015; 72: 100&#x2013;05.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399368</ArticleId><ArticleId IdType="pubmed">25401511</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider SA, Alcalay RN. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov Disord 2017; 32: 1504&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726430</ArticleId><ArticleId IdType="pubmed">29124790</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Yan X, Lv H, Liu Y, He Z, Luo X. Gender differences in prevalence of LRRK2-associated Parkinson disease: a meta-analysis of observational studies. Neurosci Lett 2020; 715: 134609.</Citation><ArticleIdList><ArticleId IdType="pubmed">31698024</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 2015; 77: 830&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5769479</ArticleId><ArticleId IdType="pubmed">25767079</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller A, M&#xfc;ngersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9: 521&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383407</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L. &#x3b1;-synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology 2022; 99: 195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">35914941</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana HQ, Balwani M, Bier L, Alcalay RN. Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med 2013; 15: 146&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519952</ArticleId><ArticleId IdType="pubmed">22935721</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy DG, Falchi M, O&#x2019;Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson&#x2019;s disease: a case-control study. Lancet Neurol 2008; 7: 583&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder K, Wang Y, Alcalay RN, et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 2015; 85: 89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501942</ArticleId><ArticleId IdType="pubmed">26062626</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010; 67: 798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">20625084</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockmann K, Quadalti C, Lerche S, et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol Commun 2021; 9: 175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556894</ArticleId><ArticleId IdType="pubmed">34717775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37059498</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>&#x3b1;-synuclein seed amplification and its uses in Parkinson's disease.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>371</EndPage><MedlinePgn>369-371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(23)00124-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(23)00124-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Christian Albrechts-University and University Hospital Schleswig-Holstein (Campus Kiel), Kiel, Germany. Electronic address: daniela.berg@uksh.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neurogenetics, University of L&#xfc;beck and University Hospital Schleswig-Holstein (Campus L&#xfc;beck), L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet Neurol. 2023 May;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6.</RefSource><PMID Version="1">37059509</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="Y">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>20</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37059498</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(23)00124-2</ArticleId><ArticleId IdType="pii">S1474-4422(23)00124-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37095396</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resilience.</ArticleTitle><Pagination><StartPage>737</StartPage><EndPage>750</EndPage><MedlinePgn>737-750</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-023-01315-6</ELocationID><Abstract><AbstractText>Pathological hallmarks of Alzheimer's disease (AD) precede clinical symptoms by years, indicating a period of cognitive resilience before the onset of dementia. Here, we report that activation of cyclic GMP-AMP synthase (cGAS) diminishes cognitive resilience by decreasing the neuronal transcriptional network of myocyte enhancer factor 2c (MEF2C) through type I interferon (IFN-I) signaling. Pathogenic tau activates cGAS and IFN-I responses in microglia, in part mediated by cytosolic leakage of mitochondrial DNA. Genetic ablation of Cgas in mice with tauopathy diminished the microglial IFN-I response, preserved synapse integrity and plasticity and protected against cognitive impairment without affecting the pathogenic tau load. cGAS ablation increased, while activation of IFN-I decreased, the neuronal MEF2C expression network linked to cognitive resilience in AD. Pharmacological inhibition of cGAS in mice with tauopathy enhanced the neuronal MEF2C transcriptional network and restored synaptic integrity, plasticity and memory, supporting the therapeutic potential of targeting the cGAS-IFN-MEF2C axis to improve resilience against AD-related pathological insults.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Udeochu</LastName><ForeName>Joe C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Amin</LastName><ForeName>Sadaf</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3758-6485</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. saa2044@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Yige</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-4925-7865</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1780-6919</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Eileen Ruth S</ForeName><Initials>ERS</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carling</LastName><ForeName>Gillian K</ForeName><Initials>GK</Initials><Identifier Source="ORCID">0000-0002-1504-1716</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bangyan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGurran</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coronas-Samano</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9114-3546</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>Grant</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mousa</LastName><ForeName>Gergey Alzaem</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Man Ying</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Pearly</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagiri</LastName><ForeName>Ravi Kumar</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0002-4531-8288</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corona</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Burke Neurological Institute at Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarahmady</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>The Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raju</LastName><ForeName>Ravikiran M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>The Picower Institute of Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Sue-Ann</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-4593-3368</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Shiaoching</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-3752-8266</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Mingrui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>Tara E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0003-3356-4091</Identifier><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratan</LastName><ForeName>Rajiv R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Burke Neurological Institute at Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0003-1262-0592</Identifier><AffiliationInfo><Affiliation>The Picower Institute of Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Subhash C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4600-275X</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. lig2033@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 HD052896</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD098061</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG074541</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG057862</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG072758</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054214</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064239</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064326">MEF2 Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578041">Mef2c protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D009713">Nucleotidyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Immunol. 2023 May;24(5):741-742. doi: 10.1038/s41590-023-01485-2.</RefSource><PMID Version="1">37095376</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064326" MajorTopicYN="N">MEF2 Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009713" MajorTopicYN="Y">Nucleotidyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>L.G. is founder and equity holder of Aeton Therapeutics, Inc. S.C.S. is an equity holder and a consultant of Aeton Therapeutics, Inc. R.R.R. is a stakeholder and Chair of the Scientific Advisory Board for Neuronasal, which develops treatments for concussion. R.R.R. is on the Scientific Advisory Board for Elevian Therapeutics, which develops antiaging therapies for stroke. All other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37095396</ArticleId><ArticleId IdType="mid">NIHMS1897713</ArticleId><ArticleId IdType="pmc">PMC10166855</ArticleId><ArticleId IdType="doi">10.1038/s41593-023-01315-6</ArticleId><ArticleId IdType="pii">10.1038/s41593-023-01315-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol. Neurodegener. 2019;14:32. doi: 10.1186/s13024-019-0333-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0333-5</ArticleId><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, et al. On the path to 2025: understanding the Alzheimer&#x2019;s disease continuum. Alzheimers Res. Ther. 2017;9:60. doi: 10.1186/s13195-017-0283-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0283-5</ArticleId><ArticleId IdType="pmc">PMC5549378</ArticleId><ArticleId IdType="pubmed">28793924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 2019;51:414&#x2013;430. doi: 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer&#x2019;s disease. Nat. Neurosci. 2020;23:311&#x2013;322. doi: 10.1038/s41593-020-0599-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0599-5</ArticleId><ArticleId IdType="pubmed">32112059</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JM, et al. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer&#x2019;s disease. Neurobiol. Aging. 2014;35:1012&#x2013;1023. doi: 10.1016/j.neurobiolaging.2013.10.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.10.089</ArticleId><ArticleId IdType="pubmed">24262201</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer&#x2019;s disease. Nat. Commun. 2020;11:6129. doi: 10.1038/s41467-020-19737-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19737-2</ArticleId><ArticleId IdType="pmc">PMC7704703</ArticleId><ArticleId IdType="pubmed">33257666</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy ER, et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J. Clin. Invest. 2020;130:1912&#x2013;1930. doi: 10.1172/JCI133737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI133737</ArticleId><ArticleId IdType="pmc">PMC7108898</ArticleId><ArticleId IdType="pubmed">31917687</ArticleId></ArticleIdList></Reference><Reference><Citation>Rexach JE, et al. Tau pathology drives dementia risk-associated gene networks toward chronic inflammatory states and immunosuppression. Cell Rep. 2020;33:108398. doi: 10.1016/j.celrep.2020.108398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108398</ArticleId><ArticleId IdType="pmc">PMC7842189</ArticleId><ArticleId IdType="pubmed">33207193</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS&#x2013;STING pathway of cytosolic DNA sensing. Nat. Immunol. 2016;17:1142&#x2013;1149. doi: 10.1038/ni.3558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3558</ArticleId><ArticleId IdType="pubmed">27648547</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, Rajendrarao S, Shahani N, Ramirez-Jarquin UN, Subramaniam S. Cyclic GMP&#x2013;AMP synthase promotes the inflammatory and autophagy responses in Huntington disease. Proc. Natl Acad. Sci. USA. 2020;117:15989&#x2013;15999. doi: 10.1073/pnas.2002144117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002144117</ArticleId><ArticleId IdType="pmc">PMC7354937</ArticleId><ArticleId IdType="pubmed">32581130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliter DA, et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561:258&#x2013;262. doi: 10.1038/s41586-018-0448-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0448-9</ArticleId><ArticleId IdType="pmc">PMC7362342</ArticleId><ArticleId IdType="pubmed">30135585</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, et al. Activation of innate immune cGAS&#x2013;STING pathway contributes to Alzheimer&#x2019;s pathogenesis in 5xFAD mice. Nat. Aging. 2023;3:202&#x2013;212. doi: 10.1038/s43587-022-00337-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-022-00337-2</ArticleId><ArticleId IdType="pubmed">37118112</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, et al. Tau activates microglia via the PQBP1&#x2013;cGAS&#x2013;STING pathway to promote brain inflammation. Nat. Commun. 2021;12:6565. doi: 10.1038/s41467-021-26851-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26851-2</ArticleId><ArticleId IdType="pmc">PMC8592984</ArticleId><ArticleId IdType="pubmed">34782623</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker SJ, et al. MEF2 is a key regulator of cognitive potential and confers resilience to neurodegeneration. Sci. Transl. Med. 2021;13:eabd7695. doi: 10.1126/scitranslmed.abd7695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd7695</ArticleId><ArticleId IdType="pmc">PMC9258338</ArticleId><ArticleId IdType="pubmed">34731014</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nat. Med. 2019;25:152&#x2013;164. doi: 10.1038/s41591-018-0223-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0223-3</ArticleId><ArticleId IdType="pmc">PMC6602064</ArticleId><ArticleId IdType="pubmed">30510257</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. doi: 10.1186/1471-2105-9-559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi K, Zhang-Akiyama QM. Establishment of human cell lines lacking mitochondrial DNA. Methods Mol. Biol. 2009;554:383&#x2013;391. doi: 10.1007/978-1-59745-521-3_23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-521-3_23</ArticleId><ArticleId IdType="pubmed">19513686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaguni LS. DNA polymerase &#x3b3;, the mitochondrial replicase. Annu. Rev. Biochem. 2004;73:293&#x2013;320. doi: 10.1146/annurev.biochem.72.121801.161455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.72.121801.161455</ArticleId><ArticleId IdType="pubmed">15189144</ArticleId></ArticleIdList></Reference><Reference><Citation>Rongvaux A, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell. 2014;159:1563&#x2013;1577. doi: 10.1016/j.cell.2014.11.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.11.037</ArticleId><ArticleId IdType="pmc">PMC4272443</ArticleId><ArticleId IdType="pubmed">25525875</ArticleId></ArticleIdList></Reference><Reference><Citation>White MJ, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell. 2014;159:1549&#x2013;1562. doi: 10.1016/j.cell.2014.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.11.036</ArticleId><ArticleId IdType="pmc">PMC4520319</ArticleId><ArticleId IdType="pubmed">25525874</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou Z, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature. 2017;550:402&#x2013;406. doi: 10.1038/nature24050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24050</ArticleId><ArticleId IdType="pmc">PMC5850938</ArticleId><ArticleId IdType="pubmed">28976970</ArticleId></ArticleIdList></Reference><Reference><Citation>Lama L, et al. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression. Nat. Commun. 2019;10:2261. doi: 10.1038/s41467-019-08620-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-08620-4</ArticleId><ArticleId IdType="pmc">PMC6529454</ArticleId><ArticleId IdType="pubmed">31113940</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019;8:329&#x2013;337. doi: 10.1016/j.cels.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2019.03.003</ArticleId><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, et al. AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Sci. Transl. Med. 2021;13:eabe3947. doi: 10.1126/scitranslmed.abe3947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe3947</ArticleId><ArticleId IdType="pmc">PMC9345574</ArticleId><ArticleId IdType="pubmed">34851693</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 2014;32:381&#x2013;386. doi: 10.1038/nbt.2859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2859</ArticleId><ArticleId IdType="pmc">PMC4122333</ArticleId><ArticleId IdType="pubmed">24658644</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 2017;21:366&#x2013;380. doi: 10.1016/j.celrep.2017.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy TE, et al. Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss. Neuron. 2016;90:245&#x2013;260. doi: 10.1016/j.neuron.2016.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.03.005</ArticleId><ArticleId IdType="pmc">PMC4859346</ArticleId><ArticleId IdType="pubmed">27041503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cembrowski MS, Wang L, Sugino K, Shields BC, Spruston N. Hipposeq: a comprehensive RNA-seq database of gene expression in hippocampal principal neurons. eLife. 2016;5:e14997. doi: 10.7554/eLife.14997.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.14997</ArticleId><ArticleId IdType="pmc">PMC4846374</ArticleId><ArticleId IdType="pubmed">27113915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar A, et al. Efficient generation of CA3 neurons from human pluripotent stem cells enables modeling of hippocampal connectivity in vitro. Cell Stem Cell. 2018;22:684&#x2013;697. doi: 10.1016/j.stem.2018.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.04.009</ArticleId><ArticleId IdType="pmc">PMC6345574</ArticleId><ArticleId IdType="pubmed">29727680</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong HW, Swanson LW, Chen L, Fanselow MS, Toga AW. Genomic-anatomic evidence for distinct functional domains in hippocampal field CA1. Proc. Natl Acad. Sci. USA. 2009;106:11794&#x2013;11799. doi: 10.1073/pnas.0812608106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812608106</ArticleId><ArticleId IdType="pmc">PMC2710698</ArticleId><ArticleId IdType="pubmed">19561297</ArticleId></ArticleIdList></Reference><Reference><Citation>Arneson D, et al. Single cell molecular alterations reveal target cells and pathways of concussive brain injury. Nat. Commun. 2018;9:3894. doi: 10.1038/s41467-018-06222-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06222-0</ArticleId><ArticleId IdType="pmc">PMC6156584</ArticleId><ArticleId IdType="pubmed">30254269</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaitner C, et al. Satb2 determines miRNA expression and long-term memory in the adult central nervous system. eLife. 2016;5:e17361. doi: 10.7554/eLife.17361.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.17361</ArticleId><ArticleId IdType="pmc">PMC5207769</ArticleId><ArticleId IdType="pubmed">27897969</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. Proc. Natl Acad. Sci. USA. 2008;105:9397&#x2013;9402. doi: 10.1073/pnas.0802876105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802876105</ArticleId><ArticleId IdType="pmc">PMC2453715</ArticleId><ArticleId IdType="pubmed">18599437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. PCDH7 interacts with GluN1 and regulates dendritic spine morphology and synaptic function. Sci. Rep. 2020;10:10951. doi: 10.1038/s41598-020-67831-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67831-8</ArticleId><ArticleId IdType="pmc">PMC7331671</ArticleId><ArticleId IdType="pubmed">32616769</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. et al. Satb2 ablation impairs hippocampus-based long-term spatial memory and short-term working memory and immediate early genes (IEGs)-mediated hippocampal synaptic plasticity. Mol. Neurobiol, 10.1007/s12035-017-0531-5 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28421537</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149:708&#x2013;721. doi: 10.1016/j.cell.2012.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.046</ArticleId><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 2013;45:1452&#x2013;1458. doi: 10.1038/ng.2802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng S, et al. Inhibition of EphA/Ephrin-A signaling using genetic and pharmacologic approaches improves recovery following traumatic brain injury in mice. Brain Inj. 2019;33:1385&#x2013;1401. doi: 10.1080/02699052.2019.1641622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02699052.2019.1641622</ArticleId><ArticleId IdType="pubmed">31319723</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettwig M, et al. Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy. Nat. Commun. 2021;12:6530. doi: 10.1038/s41467-021-26880-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26880-x</ArticleId><ArticleId IdType="pmc">PMC8586222</ArticleId><ArticleId IdType="pubmed">34764281</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10:e1004606. doi: 10.1371/journal.pgen.1004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004606</ArticleId><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Sniekers S, et al. Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence. Nat. Genet. 2017;49:1107&#x2013;1112. doi: 10.1038/ng.3869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3869</ArticleId><ArticleId IdType="pmc">PMC5665562</ArticleId><ArticleId IdType="pubmed">28530673</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavell SW, et al. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron. 2008;60:1022&#x2013;1038. doi: 10.1016/j.neuron.2008.11.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.11.029</ArticleId><ArticleId IdType="pmc">PMC2630178</ArticleId><ArticleId IdType="pubmed">19109909</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 2009;66:435&#x2013;440. doi: 10.1001/archneurol.2009.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.15</ArticleId><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, et al. Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner. Nat. Commun. 2017;8:717. doi: 10.1038/s41467-017-00769-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00769-0</ArticleId><ArticleId IdType="pmc">PMC5620041</ArticleId><ArticleId IdType="pubmed">28959042</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue F, Tian J, Yu C, Du H, Guo L. Type I interferon response-related microglial Mef2c deregulation at the onset of Alzheimer&#x2019;s pathology in 5xFAD mice. Neurobiol. Dis. 2021;152:105272. doi: 10.1016/j.nbd.2021.105272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105272</ArticleId><ArticleId IdType="pmc">PMC7956132</ArticleId><ArticleId IdType="pubmed">33540048</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelamanchili SV, Chaudhuri AD, Chen LN, Xiong H, Fox HS. MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis. 2010;1:e77. doi: 10.1038/cddis.2010.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2010.56</ArticleId><ArticleId IdType="pmc">PMC3002786</ArticleId><ArticleId IdType="pubmed">21170291</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford HA, Kasher PR, Hamilton N. Dirty fish versus squeaky clean mice: dissecting interspecies differences between animal models of interferonopathy. Front. Immunol. 2020;11:623650. doi: 10.3389/fimmu.2020.623650.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.623650</ArticleId><ArticleId IdType="pmc">PMC7843416</ArticleId><ArticleId IdType="pubmed">33519829</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CR, et al. STING controls nociception via type I interferon signalling in sensory neurons. Nature. 2021;591:275&#x2013;280. doi: 10.1038/s41586-020-03151-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03151-1</ArticleId><ArticleId IdType="pmc">PMC7977781</ArticleId><ArticleId IdType="pubmed">33442058</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 2019;22:2087&#x2013;2097. doi: 10.1038/s41593-019-0539-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods. 2017;14:955&#x2013;958. doi: 10.1038/nmeth.4407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4407</ArticleId><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888&#x2013;1902. doi: 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol. 2018;36:70&#x2013;80. doi: 10.1038/nbt.4038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4038</ArticleId><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, et al. Comprehensive functional genomic resource and integrative model for the human brain. Science. 2018;362:eaat8464. doi: 10.1126/science.aat8464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat8464</ArticleId><ArticleId IdType="pmc">PMC6413328</ArticleId><ArticleId IdType="pubmed">30545857</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015;16:278. doi: 10.1186/s13059-015-0844-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739&#x2013;1740. doi: 10.1093/bioinformatics/btr260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr260</ArticleId><ArticleId IdType="pmc">PMC3106198</ArticleId><ArticleId IdType="pubmed">21546393</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods. 2017;14:979&#x2013;982. doi: 10.1038/nmeth.4402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4402</ArticleId><ArticleId IdType="pmc">PMC5764547</ArticleId><ArticleId IdType="pubmed">28825705</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566:496&#x2013;502. doi: 10.1038/s41586-019-0969-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0969-x</ArticleId><ArticleId IdType="pmc">PMC6434952</ArticleId><ArticleId IdType="pubmed">30787437</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;966. doi: 10.1016/j.neuron.2010.08.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.044</ArticleId><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttikonda SR, et al. Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer&#x2019;s disease. Nat. Neurosci. 2021;24:343&#x2013;354. doi: 10.1038/s41593-020-00796-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00796-z</ArticleId><ArticleId IdType="pmc">PMC8382543</ArticleId><ArticleId IdType="pubmed">33558694</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. Microglial NF-&#x3ba;B drives tau spreading and toxicity in a mouse model of tauopathy. Nat. Commun. 2022;13:1969. doi: 10.1038/s41467-022-29552-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29552-6</ArticleId><ArticleId IdType="pmc">PMC9005658</ArticleId><ArticleId IdType="pubmed">35413950</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37095250</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>1437</StartPage><EndPage>1447</EndPage><MedlinePgn>1437-1447</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-023-02326-3</ELocationID><Abstract><AbstractText>Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting antisense oligonucleotide (MAPT<sub>Rx</sub>) and reduce tau levels in patients with mild AD. A randomized, double-blind, placebo-controlled, multiple-ascending dose phase 1b trial evaluated the safety, pharmacokinetics and target engagement of MAPT<sub>Rx</sub>. Four ascending dose cohorts were enrolled sequentially and randomized 3:1 to intrathecal bolus administrations of MAPT<sub>Rx</sub> or placebo every 4 or 12&#x2009;weeks during the 13-week treatment period, followed by a 23&#x2009;week post-treatment period. The primary endpoint was safety. The secondary endpoint was MAPT<sub>Rx</sub> pharmacokinetics in cerebrospinal fluid (CSF). The prespecified key exploratory outcome was CSF total-tau protein concentration. Forty-six patients enrolled in the trial, of whom 34 were randomized to MAPT<sub>Rx</sub> and 12 to placebo. Adverse events were reported in 94% of MAPT<sub>Rx</sub>-treated patients and 75% of placebo-treated patients; all were mild or moderate. No serious adverse events were reported in MAPT<sub>Rx</sub>-treated patients. Dose-dependent reduction in the CSF total-tau concentration was observed with greater than 50% mean reduction from baseline at 24&#x2009;weeks post-last dose in the 60&#x2009;mg (four doses) and 115&#x2009;mg (two doses) MAPT<sub>Rx</sub> groups. Clinicaltrials.gov registration number: NCT03186989 .</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mummery</LastName><ForeName>Catherine J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-6739-0803</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London, London, UK. c.mummery@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;rjesson-Hanson</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska University Hospital, ME Aging, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijverberg</LastName><ForeName>Everard G B</ForeName><Initials>EGB</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>University Medical Center Groningen / RUG, Alzheimer Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducharme</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7309-1113</Identifier><AffiliationInfo><Affiliation>Douglas Mental Health University Institute and McConnell Brain Imaging Centre of the Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic, Psychiatry - Cognition and Geriatric Psychiatry, Sahlgrenska University Hospital, Gothenburg/Molndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, DZNE, and Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials><Identifier Source="ORCID">0000-0001-6369-0764</Identifier><AffiliationInfo><Affiliation>CRST Oy; Turku PET Centre University of Turku and Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology University of Ulm and DZNE, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodenschatz</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pharmakologisches Studienzentrum Chemnitz GmbH Mittweida, Mittweida, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kordasiewicz</LastName><ForeName>Holly</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Swayze</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0001-6430-6576</Identifier><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fitzsimmons</LastName><ForeName>Bethany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mignon</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Moore</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yun</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Baumann</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Norris</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0003-2074-5862</Identifier><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Crean</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Graham</LastName><ForeName>Danielle L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ratti</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bennett</LastName><ForeName>C Frank</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junge</LastName><ForeName>Candice</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Roger M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03186989</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2024 Jan;30(1):304. doi: 10.1038/s41591-023-02639-3.</RefSource><PMID Version="1">37845513</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>C.J.M. reports advisory board membership for Roche, Lilly, Biogen and Ionis; research grants from Biogen; seminar chair for Biogen; chair of data safety monitoring board for AD trial led by Imperial College; supported by the NIHR Biomedical Research Centre dementia subtheme at UCLH. M.J. reports advisory board membership for Biogen Sweden AB and BioArctic AB. S.D. reports salary support from the Fonds de recherche du Qu&#xe9;bec &#x2013; Sant&#xe9;; consultancies from Biogen, Wave Life Sciences, AZTherapies and Janssen Pharmaceuticals; advisory board membership and/or speaker fees from Eisai, Biogen, Sunovion, Innodem Neurosciences, HealthTech Connex and QurAlis; cofounder of AFX Medical Inc. E.G.B.V. reports consultancies from New Amsterdam Pharma, Treeway, ReMynd, Vivoryon, Biogen, Vigil Neuroscience, ImmunoBrain Checkpoint and Brainstorm Therapeutics. PI of studies with AC immune, CogRX therapeutics, New Amsterdam Pharma, Janssen, UCB, Roche, GreenValley, Vivoryon, ImmunoBrain, Alector and Alzheon and sub-I from DIAN-TU, Alzheon, Eli Lilly, Cortexyme, Biogen en Fuij Film Toyama. L.M., K.M.M., C.Y., D.L., D.A.N., R.C., C.F.B., C.J. and R.M.L. are employees of, and hold stock in, Ionis. D.L.G., E.H. and E.R. are employees of, and hold stock in, Biogen. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37095250</ArticleId><ArticleId IdType="pmc">PMC10287562</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02326-3</ArticleId><ArticleId IdType="pii">10.1038/s41591-023-02326-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lane CA, Hardy J, Schott JM. Alzheimer&#x2019;s disease. Eur. J. Neurol. 2018;25:59&#x2013;70. doi: 10.1111/ene.13439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13439</ArticleId><ArticleId IdType="pubmed">28872215</ArticleId></ArticleIdList></Reference><Reference><Citation>2021 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement.17, 327&#x2013;406 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>2020 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement.10.1002/alz.12068 (2020).</Citation></Reference><Reference><Citation>McKhann GM, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269. doi: 10.1016/j.jalz.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:1505&#x2013;1521. doi: 10.1016/j.jalz.2018.07.220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.220</ArticleId><ArticleId IdType="pmc">PMC10013957</ArticleId><ArticleId IdType="pubmed">30316776</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011;70:960&#x2013;969. doi: 10.1097/NEN.0b013e318232a379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Disease International, G.M., Prince M, Prina M. Numbers of people with dementia worldwide. An update to the estimates in the World Alzheimer Report 2015. Alzheimer&#x2019;s Disease Internationalhttps://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/ (2020).</Citation></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE, Holzbaur ELF. Differential regulation of dynein and kinesin motor proteins by tau. Science. 2008;319:1086&#x2013;1089. doi: 10.1126/science.1152993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1152993</ArticleId><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:915&#x2013;924. doi: 10.1001/jamaneurol.2019.1424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1424</ArticleId><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74:427&#x2013;436. doi: 10.1001/jamaneurol.2016.5755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5755</ArticleId><ArticleId IdType="pmc">PMC5470368</ArticleId><ArticleId IdType="pubmed">28241163</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, et al. Synaptic tau seeding precedes tau pathology in human Alzheimer&#x2019;s disease brain. Front. Neurosci. 2018;12:267. doi: 10.3389/fnins.2018.00267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00267</ArticleId><ArticleId IdType="pmc">PMC5928393</ArticleId><ArticleId IdType="pubmed">29740275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, et al. Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 2013;288:1856&#x2013;1870. doi: 10.1074/jbc.M112.394528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.394528</ArticleId><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 2015;11:1176&#x2013;1183. doi: 10.1016/j.celrep.2015.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.04.043</ArticleId><ArticleId IdType="pubmed">25981034</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat. Commun. 2015;6:8490. doi: 10.1038/ncomms9490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9490</ArticleId><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipton OA, et al. Tau protein is required for amyloid &#x3b2;-induced impairment of hippocampal long-term potentiation. J. Neurosci. 2011;31:1688&#x2013;1692. doi: 10.1523/JNEUROSCI.2610-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2610-10.2011</ArticleId><ArticleId IdType="pmc">PMC3836238</ArticleId><ArticleId IdType="pubmed">21289177</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539. doi: 10.1038/416535a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754. doi: 10.1126/science.1141736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Dendritic function of tau mediates amyloid-&#x3b2; toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397. doi: 10.1016/j.cell.2010.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy K, et al. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am. J. Pathol. 2012;181:1928&#x2013;1940. doi: 10.1016/j.ajpath.2012.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.08.012</ArticleId><ArticleId IdType="pubmed">23026200</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 2017;9:eaag0481. doi: 10.1126/scitranslmed.aag0481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aag0481</ArticleId><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 2013;33:12887&#x2013;12897. doi: 10.1523/JNEUROSCI.2107-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2107-13.2013</ArticleId><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sud R, Geller ET, Schellenberg GD. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol. Ther. Nucleic Acids. 2014;3:e180. doi: 10.1038/mtna.2014.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2014.30</ArticleId><ArticleId IdType="pmc">PMC4121519</ArticleId><ArticleId IdType="pubmed">25072694</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch MK, et al. Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron. 2016;90:941&#x2013;947. doi: 10.1016/j.neuron.2016.04.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.042</ArticleId><ArticleId IdType="pmc">PMC5040069</ArticleId><ArticleId IdType="pubmed">27210553</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, et al. Tau reduction prevents A&#x3b2;-induced defects in axonal transport. Science. 2010;330:198. doi: 10.1126/science.1194653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194653</ArticleId><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang L, Yu W, Andreadis A, Luo M, Baas PW. Tau protects microtubules in the axon from severing by katanin. J. Neurosci. 2006;26:3120&#x2013;3129. doi: 10.1523/JNEUROSCI.5392-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5392-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674103</ArticleId><ArticleId IdType="pubmed">16554463</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 2001;114:1179&#x2013;1187. doi: 10.1242/jcs.114.6.1179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.114.6.1179</ArticleId><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujio K, et al. 14-3-3 proteins and protein phosphatases are not reduced in tau-deficient mice. NeuroReport. 2007;18:1049&#x2013;1052. doi: 10.1097/WNR.0b013e32818b2a0b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0b013e32818b2a0b</ArticleId><ArticleId IdType="pubmed">17558294</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, et al. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol. Aging. 2013;34:1523&#x2013;1529. doi: 10.1016/j.neurobiolaging.2012.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.003</ArticleId><ArticleId IdType="pmc">PMC3596503</ArticleId><ArticleId IdType="pubmed">23332171</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Hall AM, Kelinske M, Roberson ED. Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol. Aging. 2014;35:2617&#x2013;2624. doi: 10.1016/j.neurobiolaging.2014.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.05.001</ArticleId><ArticleId IdType="pmc">PMC4171213</ArticleId><ArticleId IdType="pubmed">24908165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, et al. Targeting Huntingtin expression in patients with Huntington&#x2019;s disease. N. Engl. J. Med. 2019;380:2307&#x2013;2316. doi: 10.1056/NEJMoa1900907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1900907</ArticleId><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;98:861&#x2013;864. doi: 10.1016/j.neuron.2018.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.04.035</ArticleId><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandusky-Beltran LA, Sigurdsson EM. Tau immunotherapies: lessons learned, current status and future considerations. Neuropharmacology. 2020;175:108104. doi: 10.1016/j.neuropharm.2020.108104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.108104</ArticleId><ArticleId IdType="pmc">PMC7492435</ArticleId><ArticleId IdType="pubmed">32360477</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, et al. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep. 2015;5:11161. doi: 10.1038/srep11161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep11161</ArticleId><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="pubmed">26057852</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol. Neurodegener. 2015;10:55. doi: 10.1186/s13024-015-0052-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0052-5</ArticleId><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron. 2017;94:1056&#x2013;1070. doi: 10.1016/j.neuron.2017.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.010</ArticleId><ArticleId IdType="pmc">PMC5821515</ArticleId><ArticleId IdType="pubmed">28641106</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G, et al. Changes in brain volume with bapineuzumab in mild to moderate Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2016;49:1123&#x2013;1134. doi: 10.3233/JAD-150448.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150448</ArticleId><ArticleId IdType="pubmed">26639957</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, et al. Effects of A&#x3b2; immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572. doi: 10.1212/01.WNL.0000159743.08996.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000159743.08996.99</ArticleId><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sur C, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer&#x2019;s disease brain. Brain. 2020;143:3816&#x2013;3826. doi: 10.1093/brain/awaa332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa332</ArticleId><ArticleId IdType="pmc">PMC8453290</ArticleId><ArticleId IdType="pubmed">33253354</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77:1253&#x2013;1262. doi: 10.1212/WNL.0b013e3182309fa5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182309fa5</ArticleId><ArticleId IdType="pmc">PMC3179648</ArticleId><ArticleId IdType="pubmed">21917766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nave S, et al. Sembragiline in moderate Alzheimer&#x2019;s disease: results of a randomized, double-blind, placebo-controlled phase II trial (MAyflOwer RoAD) J. Alzheimers Dis. 2017;58:1217&#x2013;1228. doi: 10.3233/JAD-161309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161309</ArticleId><ArticleId IdType="pmc">PMC5523913</ArticleId><ArticleId IdType="pubmed">28550255</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Farlow M, Aisen PS, Alzheimer&#x2019;s Disease Cooperative Study Data Analysis and Publication Committee Phase 3 trials of solanezumab and bapineuzumab for Alzheimer&#x2019;s disease. N. Engl. J. Med. 2014;370:1460. doi: 10.1056/NEJMoa1312889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1312889</ArticleId><ArticleId IdType="pubmed">24716687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquier F, et al. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2016;51:1131&#x2013;1143. doi: 10.3233/JAD-150376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150376</ArticleId><ArticleId IdType="pubmed">26967206</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer&#x2019;s disease patients. Alzheimers Dement. 2016;12:110&#x2013;120. doi: 10.1016/j.jalz.2015.06.1893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.06.1893</ArticleId><ArticleId IdType="pubmed">26238576</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, et al. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology. 2013;80:648&#x2013;654. doi: 10.1212/WNL.0b013e318281ccd3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318281ccd3</ArticleId><ArticleId IdType="pmc">PMC3590059</ArticleId><ArticleId IdType="pubmed">23303849</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor SM, et al. Ventricular enlargement as a possible measure of Alzheimer&#x2019;s disease progression validated using the Alzheimer&#x2019;s disease neuroimaging initiative database. Brain. 2008;131:2443&#x2013;2454. doi: 10.1093/brain/awn146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn146</ArticleId><ArticleId IdType="pmc">PMC2724905</ArticleId><ArticleId IdType="pubmed">18669512</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 2021;17:157&#x2013;172. doi: 10.1038/s41582-020-00435-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00435-y</ArticleId><ArticleId IdType="pubmed">33318676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivadinov R, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008;71:136&#x2013;144. doi: 10.1212/01.wnl.0000316810.01120.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000316810.01120.05</ArticleId><ArticleId IdType="pubmed">18606968</ArticleId></ArticleIdList></Reference><Reference><Citation>De Stefano N, Arnold DL. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult. Scler. 2015;21:675&#x2013;676. doi: 10.1177/1352458514564494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458514564494</ArticleId><ArticleId IdType="pubmed">25623248</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N. Engl. J. Med. 2014;370:322&#x2013;333. doi: 10.1056/NEJMoa1304839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning EN, et al. A comparison of accelerated and non-accelerated MRI scans for brain volume and boundary shift integral measures of volume change: evidence from the ADNI dataset. Neuroinformatics. 2017;15:215&#x2013;226. doi: 10.1007/s12021-017-9326-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-017-9326-0</ArticleId><ArticleId IdType="pmc">PMC5443885</ArticleId><ArticleId IdType="pubmed">28316055</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schobel, S. A. Preliminary results from GENERATION HD1, a phase III trial of tominersen in individuals with manifest HD. In CHDI 16th Annual HD Therapeutics Conference (2021).</Citation></Reference><Reference><Citation>Viglietta, V. A Ph1b/2a study of WVE-003, an investigational allele-selective, mHTT&#x2013;lowering oligonucleotide for the treatment of early manifest Huntington&#x2019;s disease, and review of PRECISION-HD results. In CHDI 16th Annual HDTherapeutics Conference (2021).</Citation></Reference><Reference><Citation>Biogen. SPINRAZA. Prescribing information https://www.spinrazahcp.com/content/dam/commercial/spinraza/hcp/en_us/pdf/spinraza-prescribing-information.pdf (2020).</Citation></Reference><Reference><Citation>Tabrizi SJ, et al. Potential disease-modifying therapies for Huntington&#x2019;s disease: lessons learned and future opportunities. Lancet Neurol. 2022;21:645&#x2013;658. doi: 10.1016/S1474-4422(22)00121-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00121-1</ArticleId><ArticleId IdType="pmc">PMC7613206</ArticleId><ArticleId IdType="pubmed">35716694</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer&#x2019;s Disease Cooperative Study experience. Neurology. 1997;48:1508&#x2013;1510. doi: 10.1212/WNL.48.6.1508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.48.6.1508</ArticleId><ArticleId IdType="pubmed">9191756</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;279. doi: 10.1016/j.jalz.2011.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 2010;50:259&#x2013;293. doi: 10.1146/annurev.pharmtox.010909.105654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.010909.105654</ArticleId><ArticleId IdType="pubmed">20055705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. [P4&#x2013;266]: application of a multi-atlas segmentation tool to hippocampus, ventricle and whole brain segmentation. Alzheimers Dement. 2017;13:P1385&#x2013;P1386.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37099634</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>693</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Sleep deprivation exacerbates microglial reactivity and A&#x3b2; deposition in a <i>TREM2</i>-dependent manner in mice.</ArticleTitle><Pagination><StartPage>eade6285</StartPage><MedlinePgn>eade6285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.ade6285</ELocationID><Abstract><AbstractText>Sleep loss is associated with cognitive decline in the aging population and is a risk factor for Alzheimer's disease (AD). Considering the crucial role of immunomodulating genes such as that encoding the triggering receptor expressed on myeloid cells type 2 (TREM2) in removing pathogenic amyloid-&#x3b2; (A&#x3b2;) plaques and regulating neurodegeneration in the brain, our aim was to investigate whether and how sleep loss influences microglial function in mice. We chronically sleep-deprived wild-type mice and the 5xFAD mouse model of cerebral amyloidosis, expressing either the humanized TREM2 common variant, the loss-of-function R47H AD-associated risk variant, or without TREM2 expression. Sleep deprivation not only enhanced TREM2-dependent A&#x3b2; plaque deposition compared with 5xFAD mice with normal sleeping patterns but also induced microglial reactivity that was independent of the presence of parenchymal A&#x3b2; plaques. We investigated lysosomal morphology using transmission electron microscopy and found abnormalities particularly in mice without A&#x3b2; plaques and also observed lysosomal maturation impairments in a TREM2-dependent manner in both microglia and neurons, suggesting that changes in sleep modified neuro-immune cross-talk. Unbiased transcriptome and proteome profiling provided mechanistic insights into functional pathways triggered by sleep deprivation that were unique to TREM2 and A&#x3b2; pathology and that converged on metabolic dyshomeostasis. Our findings highlight that sleep deprivation directly affects microglial reactivity, for which TREM2 is required, by altering the metabolic ability to cope with the energy demands of prolonged wakefulness, leading to further A&#x3b2; deposition, and underlines the importance of sleep modulation as a promising future therapeutic approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parhizkar</LastName><ForeName>Samira</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5807-190X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gent</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0547-9463</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rensing</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gratuze</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strout</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2027-6851</Identifier><AffiliationInfo><Affiliation>Washington University Center for Cellular Imaging, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sviben</LastName><ForeName>Sanja</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5918-4834</Identifier><AffiliationInfo><Affiliation>Washington University Center for Cellular Imaging, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tycksen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6362-0141</Identifier><AffiliationInfo><Affiliation>Genome Technology Access Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-7046-4378</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Washington University Medical School, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilmore</LastName><ForeName>Petra Erdmann</ForeName><Initials>PE</Initials><Identifier Source="ORCID">0000-0002-3949-9801</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Washington University Medical School, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprung</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2368-8859</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Washington University Medical School, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Jim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2199-0456</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Washington University Medical School, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remolina Serrano</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5937-0212</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Choonghee</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8907-5858</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chanung</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6418-3809</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landsness</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3227-1641</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7907-3602</Identifier><AffiliationInfo><Affiliation>Washington University Center for Cellular Imaging, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Reid</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0753-7594</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Washington University Medical School, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5222-4987</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-8334-5893</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD032186</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HD103525</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS109292</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. DMH is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies, US patent 9,834,596. DMH co-founded and is on the scientific advisory board of C2N Diagnostics. DMH is on the scientific advisory board of Denali, Genentech, and Cajal Neuroscience and consults for Alector and Asteroid</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37099634</ArticleId><ArticleId IdType="mid">NIHMS1923419</ArticleId><ArticleId IdType="pmc">PMC10449561</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.ade6285</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sabia S, Fayosse A, Dumurgier J, van Hees VT, Paquet C, Sommerlad A, Kivim&#xe4;ki M, Dugravot A, Singh-Manoux A, Association of sleep duration in middle and old age with incidence of dementia. Nat. Commun 12, 2289 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058039</ArticleId><ArticleId IdType="pubmed">33879784</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince T-M, Abel T, The impact of sleep loss on hippocampal function. Learn. Mem 20, 558&#x2013;69 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768199</ArticleId><ArticleId IdType="pubmed">24045505</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O&#x2019;Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M, Sleep Drives Metabolite Clearance from the Adult Brain. Science. 342, 373&#x2013;377 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R, Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol. Neurodegener 11, 74 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5146863</ArticleId><ArticleId IdType="pubmed">27931262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellesi M, de Vivo L, Chini M, Gilli F, Tononi G, Cirelli C, Sleep Loss Promotes Astrocytic Phagocytosis and Microglial Activation in Mouse Cerebral Cortex. J. Neurosci 37, 5263&#x2013;5273 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5456108</ArticleId><ArticleId IdType="pubmed">28539349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneshwaran K, Olah M, Tasaki S, Yu L, Bradshaw EM, Schneider JA, Buchman AS, Bennett DA, De Jager PL, Lim ASP, Sleep fragmentation, microglial aging, and cognitive impairment in adults with and without Alzheimer&#x2019;s dementia. Sci. Adv 5, eaax7331 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6905859</ArticleId><ArticleId IdType="pubmed">31844665</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Ba L, Wang M, Deng S-Y, Chen S-M, Huang L-F, Zhang M, Wang W, Ding F-F, Chronic sleep fragmentation shares similar pathogenesis with neurodegenerative diseases: Endosome-autophagosome-lysosome pathway dysfunction and microglia-mediated neuroinflammation. CNS Neurosci. Ther 26, 215&#x2013;227 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6978272</ArticleId><ArticleId IdType="pubmed">31549780</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 363, 880&#x2013;884 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="pubmed">30679382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM, Amyloid-&#x3b2; Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science. 326, 1005&#x2013;1007 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-ES, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM, Slow wave sleep disruption increases cerebrospinal fluid amyloid-&#x3b2; levels. Brain 140, 2104&#x2013;2111 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790144</ArticleId><ArticleId IdType="pubmed">28899014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D-W, Wang J, Zhang L-L, Wang Y-J, Gao C-Y, Cerebrospinal Fluid Amyloid-&#x3b2; Levels are Increased in Patients with Insomnia. J. Alzheimer&#x2019;s Dis 61, 645&#x2013;651 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29278891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma RA, Varga AW, Bubu OM, Pirraglia E, Kam K, Parekh A, Wohlleber M, Miller MD, Andrade A, Lewis C, Tweardy S, Buj M, Yau PL, Sadda R, Mosconi L, Li Y, Butler T, Glodzik L, Fieremans E, Babb JS, Blennow K, Zetterberg H, Lu SE, Badia SG, Romero S, Rosenzweig I, Gosselin N, Jean-Louis G, Rapoport DM, de Leon MJ, Ayappa I, Osorio RS, Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. Am. J. Respir. Crit. Care Med 197, 933&#x2013;943 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6020410</ArticleId><ArticleId IdType="pubmed">29125327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Hicks TJ, McLeland JS, Toedebusch CD, Boyd J, Elbert DL, Patterson BW, Baty J, Morris JC, Ovod V, Mawuenyega KG, Bateman RJ, Effect of sleep on overnight cerebrospinal fluid amyloid &#x3b2; kinetics. Ann. Neurol 83, 197&#x2013;204 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="pubmed">29220873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, Koscik RL, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Sager MA, Asthana S, Johnson SC, Benca RM, Bendlin BB, Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 89, 445&#x2013;453 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539733</ArticleId><ArticleId IdType="pubmed">28679595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP, &#x3b2;-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat. Neurosci 18, 1051&#x2013;1057 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="pubmed">26030850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-ES, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, Morris JC, Holtzman DM, Sleep Quality and Preclinical Alzheimer Disease. JAMA Neurol. 70, 587 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM, Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer&#x2019;s disease. Sci. Transl. Med 11 (2019), doi:10.1126/scitranslmed.aau6550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6550</ArticleId><ArticleId IdType="pmc">PMC6342564</ArticleId><ArticleId IdType="pubmed">30626715</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Gamaldo AA, An Y, Wu MN, Simonsick EM, Bilgel M, Zhou Y, Wong DF, Ferrucci L, Resnick SM, Self-reported Sleep and &#x3b2;-Amyloid Deposition in Community-Dwelling Older Adults. JAMA Neurol. 70, 1537&#x2013;43 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Local Sleep and Alzheimer&#x2019;s Disease Pathophysiology. Front. Neurosci 14, 525970 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538792</ArticleId><ArticleId IdType="pubmed">33071726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, It&#x2019;s complicated: The relationship between sleep and Alzheimer&#x2019;s disease in humans. Neurobiol. Dis 144, 105031 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484285</ArticleId><ArticleId IdType="pubmed">32738506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingiosi AM, Frank MG, Goodnight, astrocyte: waking up to astroglial mechanisms in sleep. FEBS J. (2022), doi:10.1111/febs.16424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16424</ArticleId><ArticleId IdType="pmc">PMC9463397</ArticleId><ArticleId IdType="pubmed">35271767</ArticleId></ArticleIdList></Reference><Reference><Citation>Haydon PG, Astrocytes and the Modulation of Sleep, doi:10.1016/j.conb.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2017.02.008</ArticleId><ArticleId IdType="pmc">PMC5511068</ArticleId><ArticleId IdType="pubmed">28284099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, How neuroinflammation contributes to neurodegeneration. Science 353, 777&#x2013;783 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Holtzman DM, Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, Holtzman DM, Serrano JR, Hoyle R, Holtzman DM, Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med 216, 2546&#x2013;2561 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullington JM, Simpson NS, Meier-Ewert HK, Haack M, Sleep loss and inflammation. Best Pract. Res. Clin. Endocrinol. Metab 24, 775&#x2013;84 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548567</ArticleId><ArticleId IdType="pubmed">21112025</ArticleId></ArticleIdList></Reference><Reference><Citation>Everson CA, Clinical assessment of blood leukocytes, serum cytokines, and serum immunoglobulins as responses to sleep deprivation in laboratory rats. Am. J. Physiol. Regul. Integr. Comp. Physiol 289, R1054&#x2013;63 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15947073</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M, Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med 215, 745&#x2013;760 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Colonna M, Holtzman DM, Elucidating the Role of TREM2 in Alzheimer&#x2019;s Disease. Neuron 94, 237&#x2013;248 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, M&#xfc;ller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertiirk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C, Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. 22, 191&#x2013;204 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, Holtzman DM, TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci 22, 1217&#x2013;1222 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, Sainouchi M, Kakita A, Bennett DA, Schneider JA, Nichols MR, Beausoleil SA, Ulrich JD, Holtzman DM, Artyomov MN, Colonna M, Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS, Ebbert MTW, Baker KE, Cook C, Wang X, Sens JP, Kocher J-P, Petrucelli L, Fryer JD, Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J. Exp. Med 215, 2235&#x2013;2245 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6122978</ArticleId><ArticleId IdType="pubmed">30082275</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O, The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M, Amit I, A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.el7 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM, Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of &#x3b2;-Amyloid in Mice with Alzheimer&#x2019;s Disease Pathology. Sci. Transl. Med 4 (2012), doi: 10.1126/scitranslmed.3004291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004291</ArticleId><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O, Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A&#x3b2; aggregation in the 5XFAD mouse model of Alzheimer&#x2019;s disease. Neurobiol. Aging 33, 196.e29&#x2013;196.e40 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">20619937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM, Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener 9, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC-C, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, Wang Y, Artyomov MN, Holtzman DM, Colonna M, TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell 170, 649&#x2013;663.el3 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi H, Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regen. Res 15, 25&#x2013;29 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6862407</ArticleId><ArticleId IdType="pubmed">31535638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustos V, Pulina MV, Bispo A, Lam A, Flajolet M, Gorelick FS, Greengard P, Phosphorylated Presenilin 1 decreases &#x3b2;-amyloid by facilitating autophagosome&#x2013;lysosome fusion. Proc. Natl. Acad. Sci 114, 7148&#x2013;7153 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502640</ArticleId><ArticleId IdType="pubmed">28533369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Shigeyama S, Minami S, Shima T, Akayama S, Matsuda T, Esposito A, Napolitano G, Kuma A, Namba-Hamano T, Nakamura J, Yamamoto K, Sasai M, Tokumura A, Miyamoto M, Oe Y, Fujita T, Terawaki S, Takahashi A, Hamasaki M, Yamamoto M, Okada Y, Komatsu M, Nagai T, Takabatake Y, Xu H, Isaka Y, Ballabio A, Yoshimori T, LC3 lipidation is essential for TFEB activation during the lysosomal damage response to kidney injury. Nat. Cell Biol. 2020 2210 22, 1252&#x2013;1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32989250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ, An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci 34, 11929&#x2013;47 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Snider BJ, Li M, Yanagisawa M, de Lecea L, Holtzman DM, Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer&#x2019;s disease. J. Exp. Med 211, 2487&#x2013;2496 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267230</ArticleId><ArticleId IdType="pubmed">25422493</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D, Lucas A, Baskaran S, Haddick PCG, Lenser M, Earr TK, Shi J, Dugas JC, Andreone BJ, Logan T, Solanoy HO, Chen H, Srivastava A, Poda SB, Sanchez PE, Watts RJ, Sandmann T, Astarita G, Lewcock JW, Monroe KM, Di Paolo G, TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron 105, 837&#x2013;854.e9 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon A, Strasburger HJ, Ayata P, Chen X, Nair A, Ikegami A, Hwang P, Chan AT, Graves SM, Uweru JO, Ledderose C, Kutlu MG, Wheeler MA, Kahan A, Ishikawa M, Wang YC, Loh YHE, Jiang JX, Surmeier DJ, Robson SC, Junger WG, Sebra R, Calipari ES, Kenny PJ, Eyo UB, Colonna M, Quintana FJ, Wake H, Gradinaru V, Schaefer A, Negative feedback control of neuronal activity by microglia. Nat. 2020 5867829 586, 417&#x2013;423 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577179</ArticleId><ArticleId IdType="pubmed">32999463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee J-M, Holtzman DM, Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat. Neurosci 14, 750&#x2013;756 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G, Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-&#x3b2; clearance and aggregation in Alzheimer&#x2019;s disease. Sci. Transl. Med 8, 332ra44 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512541</ArticleId><ArticleId IdType="pubmed">27030596</ArticleId></ArticleIdList></Reference><Reference><Citation>An Y, Varma VR, Varma S, Casanova R, Dammer E, Pletnikova O, Chia CW, Egan JM, Ferrucci L, Troncoso J, Levey AI, Lah J, Seyfried NT, Legido-Quigley C, O&#x2019;Brien R, Thambisetty M, Evidence for brain glucose dysregulation in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 14, 318&#x2013;329 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866736</ArticleId><ArticleId IdType="pubmed">29055815</ArticleId></ArticleIdList></Reference><Reference><Citation>Freude S, Hettich MM, Schumann C, St&#xf6;hr O, Koch L, K&#xf6;hler C, Udelhoven M, Leeser U, M&#xfc;ller M, Kubota N, Kadowaki T, Krone W, Schroder H, Br&#xfc;ning JC, Schubert M, Neuronal IGF-1 resistance reduces A&#x3b2; accumulation and protects against premature death in a model of Alzheimer&#x2019;s disease. FASEB J. 23, 3315&#x2013;3324 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19487308</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr O, Schilbach L, Moll L, Hettich MM, Freude S, Wunderlich FT, Ernst M, Zemva J, Br&#xfc;ning JC, Krone W, Udelhoven M, Schubert M, Insulin receptor signaling mediates APP processing and &#x3b2;-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer&#x2019;s disease. Age (Omaha). 35, 83&#x2013;101 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543743</ArticleId><ArticleId IdType="pubmed">22057897</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley M, Macauley SL, Holtzman DM, Changes in insulin and insulin signaling in Alzheimer&#x2019;s disease: cause or consequence? J. Exp. Med 213, 1375&#x2013;1385 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986537</ArticleId><ArticleId IdType="pubmed">27432942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn EA, Wang H-X, Andel R, Fratiglioni L, A Change in Sleep Pattern May Predict Alzheimer Disease. Am. J. Geriatr. Psychiatry 22, 1262&#x2013;1271 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23954041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M, TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160 (2015), doi:10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger Z, Frye CG, Liu D, Dan Y, Bouchard KE, Robust, automated sleep scoring by a compact neural network with distributional shift correction. PLoS One 14, e0224642 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6910668</ArticleId><ArticleId IdType="pubmed">31834897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaghouby F, Donohue KD, O&#x2019;Hara BF, Sunderam S, Noninvasive dissection of mouse sleep using a piezoelectric motion sensor. J. Neurosci. Methods 259, 90&#x2013;100 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715949</ArticleId><ArticleId IdType="pubmed">26582569</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jungbauer L, Yu C, Ladu MJ, Preparing Synthetic A&#x3b2; in Different Aggregation States. Methods Mol. Biol 670, 13 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752843</ArticleId><ArticleId IdType="pubmed">20967580</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Duff K, A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J. Vis. Exp (2008), doi:10.3791/960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/960</ArticleId><ArticleId IdType="pmc">PMC2762909</ArticleId><ArticleId IdType="pubmed">19066529</ArticleId></ArticleIdList></Reference><Reference><Citation>Erde J, Loo RRO, Loo JA, Enhanced FASP (eFASP) to increase proteome coverage and sample recovery for quantitative proteomic experiments. J. Proteome Res 13, 1885&#x2013;95 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3993969</ArticleId><ArticleId IdType="pubmed">24552128</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z-W, Fuchs K, Sieghart W, Townsend RR, Evers AS, Deep amino acid sequencing of native brain GABAA receptors using high-resolution mass spectrometry. Mol. Cell. Proteomics 11, M111.011445 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270104</ArticleId><ArticleId IdType="pubmed">22338125</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier F, Brunner A-D, Koch S, Koch H, Lubeck M, Krause M, Goedecke N, Decker J, Kosinski T, Park MA, Bache N, Hoerning O, Cox J, R&#xc4;ther O, Mann M, Online Parallel Accumulation-Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer. Mol. Cell. Proteomics 17, 2534&#x2013;2545 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6283298</ArticleId><ArticleId IdType="pubmed">30385480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H, Averick M, Bryan J, Chang W, D&#x2019; L, Mcgowan A, Fran&#xe7;ois R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Lin Pedersen T, Miller E, Bache SM, M&#xfc;ller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H, RStudio 2 cynkra 3 Redbubble 4 Erasmus University Rotterdam 5 Flatiron Health 6 Department of Integrative Biology. J. Open Source Softw 4, 1686 (2019).</Citation></Reference><Reference><Citation>Benaglia T, Chauveau D, Hunter DR, Young DS, Mixtools: An R package for analyzing finite mixture models. J. Stat. Softw 32, 1&#x2013;29 (2009).</Citation></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK, limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37127299</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Sex-dependent effects of acute stress on amyloid-&#x3b2; in male and female mice.</ArticleTitle><Pagination><StartPage>2268</StartPage><EndPage>2274</EndPage><MedlinePgn>2268-2274</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad052</ELocationID><Abstract><AbstractText>The risk of developing Alzheimer's disease is mediated by a combination of genetics and environmental factors, such as stress, sleep abnormalities and traumatic brain injury. Women are at a higher risk of developing Alzheimer's disease than men, even when controlling for differences in lifespan. Women are also more likely to report high levels of stress than men. Sex differences in response to stress may play a role in the increased risk of Alzheimer's disease in women. In this study, we use in vivo microdialysis to measure levels of A&#x3b2; in response to acute stress in male and female mice. We show that A&#x3b2; levels are altered differently between female and male mice (APP/PS1 and wild-type) in response to stress, with females showing significantly increased levels of A&#x3b2; while most males do not show a significant change. This response is mediated through &#x3b2;-arrestin involvement in Corticotrophin Releasing Factor receptor signalling pathway differences in male and female mice as male mice lacking &#x3b2;-arrestin show increase in A&#x3b2; in response to stress similar to females.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Hannah M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Clare E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardiner</LastName><ForeName>Woodrow D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doherty</LastName><ForeName>Brookelyn M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrigan</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuede</LastName><ForeName>Kayla M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuede</LastName><ForeName>Carla M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG064902</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047902</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG079867</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071557">beta-Arrestins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071557" MajorTopicYN="N">beta-Arrestins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">corticotropin releasing factor</Keyword><Keyword MajorTopicYN="N">sexual dimorphism</Keyword><Keyword MajorTopicYN="N">stress</Keyword><Keyword MajorTopicYN="N">&#x3b2;-arrestin</Keyword></KeywordList><CoiStatement>The authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37127299</ArticleId><ArticleId IdType="pmc">PMC10232275</ArticleId><ArticleId IdType="doi">10.1093/brain/awad052</ArticleId><ArticleId IdType="pii">7097860</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McCormick CM, Thomas CM, Sheridan CS, Nixon F, Flynn JA, Mathews IZ. Social instability stress in adolescent male rats alters hippocampal neurogenesis and produces deficits in spatial location memory in adulthood. Hippocampus. 2012;22:1300&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">21805526</ArticleId></ArticleIdList></Reference><Reference><Citation>Devilbiss DM, Jenison RL, Berridge CW. Stress-induced impairment of a working memory task: Role of spiking rate and spiking history predicted discharge. PLoS Comput Biol. 2012;8:e1002681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3441423</ArticleId><ArticleId IdType="pubmed">23028279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell T, Hill N, Mogle J, Sweeder L, Bhargava S. Longitudinal evaluation of perceived stress and memory complaints in the Einstein Aging Study. Anxiety Stress Coping. 2021;34:37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7769894</ArticleId><ArticleId IdType="pubmed">33108888</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202533</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, Iba M, Bangasser DA, et al. . Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci Off J Soc Neurosci. 2011;31:14436&#x2013;14449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230070</ArticleId><ArticleId IdType="pubmed">21976528</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Yuede CM, Yoo H-S, et al. . Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience. 2008;155:154&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664643</ArticleId><ArticleId IdType="pubmed">18571864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer&#x2019;s disease in old age. Neuroepidemiology. 2006;27:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16974109</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry. 2012;69:493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704214</ArticleId><ArticleId IdType="pubmed">22566581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay J, Laurin D, Verreault R, et al. . Risk factors for Alzheimer&#x2019;s disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolen-Hoeksema S, Larson J, Grayson C. Explaining the gender difference in depressive symptoms. J Pers Soc Psychol. 1999;77:1061&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573880</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters L, Issakidis C, Slade T, Andrews G. Gender differences in the prevalence of DSM-IV and ICD-10 PTSD. Psychol Med. 2006;36:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">16356294</ArticleId></ArticleIdList></Reference><Reference><Citation>Canet G, Chevallier N, Zussy C, Desrumaux C, Givalois L. Central role of glucocorticoid receptors in Alzheimer&#x2019;s disease and depression. Front Neurosci. 2018;12:739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6232776</ArticleId><ArticleId IdType="pubmed">30459541</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer&#x2019;s disease. J Neurosci Off J Soc Neurosci. 2006;26:9047&#x2013;9056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675335</ArticleId><ArticleId IdType="pubmed">16943563</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Dong H, Fagan AM, et al. . Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry. 2006;163:2164&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780275</ArticleId><ArticleId IdType="pubmed">17151169</ArticleId></ArticleIdList></Reference><Reference><Citation>Behan DP, Heinrichs SC, Troncoso JC, et al. . Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer&#x2019;s disease. Nature. 1995;378:284&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangasser DA, Dong H, Carroll J, et al. . Corticotropin-releasing factor overexpression gives rise to sex differences in Alzheimer&#x2019;s disease-related signaling. Mol Psychiatry. 2017;22:1126&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395355</ArticleId><ArticleId IdType="pubmed">27752081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangasser DA, Curtis A, Reyes BAS, et al. . Sex differences in corticotropin-releasing factor receptor signaling and trafficking: Potential role in female vulnerability to stress-related psychopathology. Mol Psychiatry. 2010;15:896&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935505</ArticleId><ArticleId IdType="pubmed">20548297</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra-Mercado GK, Fuentes-Gonzalez AM, Hernandez-Aranda J, et al. . CRF1 receptor signaling via the ERK1/2-MAP and Akt kinase cascades: Roles of src, EGF receptor, and PI3-kinase mechanisms. Front Endocrinol. 2019;10:869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921279</ArticleId><ArticleId IdType="pubmed">31920979</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanat MJ, Hopf FW, Stuber GD, Phillips PEM, Bonci A. Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J Physiol. 2008;586:2157&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2465205</ArticleId><ArticleId IdType="pubmed">18308824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-&#x3b2; via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104:10673&#x2013;10678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965571</ArticleId><ArticleId IdType="pubmed">17551018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, et al. . In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci Off J Soc Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley RH, Olivares-Reyes JA, Hudson CC, Flores-Vega F, Dautzenberg FM, Hauger RL. Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: A mechanism regulating stress and anxiety responses. Am J Physiol Regul Integr Comp Physiol. 2007;293:R209&#x2013;R222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102763</ArticleId><ArticleId IdType="pubmed">17363685</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, et al. . Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis AL, Bethea T, Valentino RJ. Sexually dimorphic responses of the brain norepinephrine system to stress and corticotropin-releasing factor. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2006;31:544&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">16123744</ArticleId></ArticleIdList></Reference><Reference><Citation>Thathiah A, Horr&#xe9; K, Snellinx A, et al. . &#x3b2;-arrestin 2 regulates A&#x3b2; generation and &#x3b3;-secretase activity in Alzheimer&#x2019;s disease. Nat Med. 2013;19:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23202293</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhao X, Zeng X, et al. . &#x3b2;-arrestin1 regulates &#x3b3;-secretase complex assembly and modulates amyloid-&#x3b2; pathology. Cell Res. 2013;23:351&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587707</ArticleId><ArticleId IdType="pubmed">23208420</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JA, Yan Y, Kee TR, et al. . &#x3b2;-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy. Life Sci Alliance. 2022;5:e202101183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8675912</ArticleId><ArticleId IdType="pubmed">34862271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Tanila H, Puoliv&#xe4;li J, Kadish I, van Groen T. Gender differences in the amount and deposition of amyloid beta in APPswe and PS1 double transgenic mice. Neurobiol Dis. 2003; 14:318&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37167969</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>13</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Abundant A&#x3b2; fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains.</ArticleTitle><Pagination><StartPage>2012</StartPage><EndPage>2020.e4</EndPage><MedlinePgn>2012-2020.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2023.04.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(23)00269-6</ELocationID><Abstract><AbstractText>Soluble oligomers of amyloid &#x3b2;-protein (A&#x3b2;) have been defined as aggregates in supernatants following ultracentrifugation of aqueous extracts from Alzheimer's disease (AD) brains and are believed to be upstream initiators of synaptic dysfunction, but little is known about their structures. We now report the unexpected presence of A&#x3b2; fibrils in synaptotoxic high-speed supernatants from AD brains extracted by soaking in an aqueous buffer. The fibrils did not appear to form during preparation, and their counts by EM correlated with A&#x3b2;&#xa0;ELISA quantification. Cryo-EM structures of aqueous A&#x3b2; fibrils were identical to those from sarkosyl-insoluble homogenates. The fibrils in aqueous extracts were labeled by lecanemab, an A&#x3b2; aggregate-directed antibody reported to improve AD cognitive outcomes. Lecanemab provided protection against aqueous fibril synaptotoxicity. We conclude that fibrils are abundant in aqueous extracts from AD brains and have the same structures as those from plaques. These findings have implications for AD pathogenesis and drug design.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Shanxue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Keitaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meunier</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yuqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ericsson</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Harvard Medical School Electron Microscopy Facility, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address: dselkoe@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K08 NS128329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_A025_1012</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid &#x3b2;</Keyword><Keyword MajorTopicYN="N">fibril</Keyword><Keyword MajorTopicYN="N">lecanemab</Keyword><Keyword MajorTopicYN="N">oligomer</Keyword><Keyword MajorTopicYN="N">protofibril</Keyword><Keyword MajorTopicYN="N">therapeutic antibody</Keyword></KeywordList><CoiStatement>Declaration of interests D.J.S. is a founding director and consultant of Prothena Biosciences. L.L. is a consultant for Korro Bio.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37167969</ArticleId><ArticleId IdType="mid">NIHMS1903686</ArticleId><ArticleId IdType="pmc">PMC10330525</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2023.04.007</ArticleId><ArticleId IdType="pii">S0896-6273(23)00269-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. (2008). Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med 14, 837&#x2013;842. 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes C, Choi ML, Yi J-H, Kim S-C, Drews A, George-Hyslop PS, Bryant C, Gandhi S, Cho K, and Klenerman D. (2020). Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat neuronal cell death. Commun Biol 3, 79. 10.1038/s42003-020-0792-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-0792-9</ArticleId><ArticleId IdType="pmc">PMC7028984</ArticleId><ArticleId IdType="pubmed">32071389</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, and Selkoe D. (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788&#x2013;801. 10.1016/j.neuron.2009.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.05.012</ArticleId><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, and Selkoe DJ (2011). Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108, 5819&#x2013;5824. 10.1073/pnas.1017033108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017033108</ArticleId><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, O&#x2019;Nuallain B, Hong W, Boyd J, Lagomarsino VN, O&#x2019;Malley TT, Liu W, Vanderburg CR, Frosch MP, Young-Pearse T, et al. (2018). An in vitro paradigm to assess potential anti-A&#x3b2; antibodies for Alzheimer&#x2019;s disease. Nat Commun 9, 2676. 10.1038/s41467-018-05068-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05068-w</ArticleId><ArticleId IdType="pmc">PMC6041266</ArticleId><ArticleId IdType="pubmed">29992960</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, et al. (2008). Alzheimer&#x2019;s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 29, 1334&#x2013;1347. 10.1016/j.neurobiolaging.2007.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.029</ArticleId><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Forny-Germano L, Lyra e Silva NM, Batista AF, Brito-Moreira J, Gralle M, Boehnke SE, Coe BC, Lablans A, Marques SA, Martinez AMB, et al. (2014). Alzheimer&#x2019;s disease-like pathology induced by amyloid-&#x3b2; oligomers in nonhuman primates. J Neurosci 34, 13629&#x2013;13643. 10.1523/JNEUROSCI.1353-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1353-14.2014</ArticleId><ArticleId IdType="pmc">PMC6608380</ArticleId><ArticleId IdType="pubmed">25297091</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, and Jucker M. (2011). Soluble A&#x3b2; seeds are potent inducers of cerebral &#x3b2;-amyloid deposition. Journal of Neuroscience 31, 14488&#x2013;14495. 10.1523/JNEUROSCI.3088-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3088-11.2011</ArticleId><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzmarski N, Ziegler-Waldkirch S, Scheffler N, Witt C, Abou-Ajram C, Nuscher B, Prinz M, Haass C, and Meyer-Luehmann M. (2020). A&#x3b2; oligomers trigger and accelerate A&#x3b2; seeding. Brain Pathology 30, 36&#x2013;45. 10.1111/BPA.12734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/BPA.12734</ArticleId><ArticleId IdType="pmc">PMC6916291</ArticleId><ArticleId IdType="pubmed">31099449</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, Nicholls SB, Carlson GA, Pitstick R, Nobuhara CK, et al. (2015). Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat Commun 6, 8490. 10.1038/ncomms9490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9490</ArticleId><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath T. v, de Los Santos MB, Klickstein N, Corjuc DL, Corjuc BT, et al. (2020). Tau molecular diversity contributes to clinical heterogeneity in Alzheimer&#x2019;s disease. Nat Med 26, 1256&#x2013;1263. 10.1038/s41591-020-0938-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0938-9</ArticleId><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. (2022). Lecanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 10.1056/NEJMOA2212948/SUPPL_FILE/NEJMOA2212948_APPENDIX.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2212948/SUPPL_FILE/NEJMOA2212948_APPENDIX.PDF</ArticleId><ArticleId IdType="pubmed">36449413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker S, M&#xf6;ller C, Tegerstedt K, Lord A, Laudon H, Sj&#xf6;dahl J, S&#xf6;derberg L, Spens E, Sahlin C, Waara ER, et al. (2015). The murine version of BAN2401 (mAb158) selectively reduces amyloid-&#x3b2; protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. Journal of Alzheimer&#x2019;s Disease 43, 575&#x2013;588. 10.3233/JAD-140741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140741</ArticleId><ArticleId IdType="pubmed">25096615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, M&#xf6;ller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, and Gellerfors P. (2014). Perspectives on future Alzheimer therapies: amyloid-&#x3b2; protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer&#x2019;s disease. Alzheimers Res Ther 6, 16. 10.1186/alzrt246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt246</ArticleId><ArticleId IdType="pmc">PMC4054967</ArticleId><ArticleId IdType="pubmed">25031633</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, and de Strooper B. (2012). The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat Neurosci 15, 349&#x2013;357. 10.1038/nn.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3028</ArticleId><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Diana A, Wenjuan Z, Melissa H, Sofia L, Manuel S, Abhay K, G. MA Y. P-CS, Jennifer M, et al. (2022). Cryo-EM structures of amyloid-&#x3b2; 42 filaments from human brains. Science (1979) 375, 167&#x2013;172. 10.1126/science.abm7285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm7285</ArticleId><ArticleId IdType="pmc">PMC7612234</ArticleId><ArticleId IdType="pubmed">35025654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, O&#x2019;Malley TT, Liu W, Mably AJ, Brinkmalm G, Portelius E, Wittbold WM, Frosch MP, and Walsh DM (2015). The aqueous phase of Alzheimer&#x2019;s disease brain contains assemblies built from &#x223c;4 and &#x223c;7 kDa A&#x3b2; species. Alzheimer&#x2019;s &amp; Dementia 11, 1286&#x2013;1305. 10.1016/j.jalz.2015.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.01.005</ArticleId><ArticleId IdType="pmc">PMC4592782</ArticleId><ArticleId IdType="pubmed">25846299</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Li S, Xu H, Walsh DM, and Selkoe DJ (2017). Large soluble oligomers of amyloid &#x3b2;-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci 37, 152&#x2013;163. 10.1523/JNEUROSCI.1698-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1698-16.2016</ArticleId><ArticleId IdType="pmc">PMC5214627</ArticleId><ArticleId IdType="pubmed">28053038</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G, Hong W, Wang Z, Liu W, O&#x2019;Malley TT, Sun X, Frosch MP, Selkoe DJ, Portelius E, Zetterberg H, et al. (2019). Identification of neurotoxic cross-linked amyloid-&#x3b2; dimers in the Alzheimer&#x2019;s brain. Brain 142, 1441&#x2013;1457. 10.1093/brain/awz066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz066</ArticleId><ArticleId IdType="pmc">PMC6487330</ArticleId><ArticleId IdType="pubmed">31032851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W, Wang Z, Liu W, O&#x2019;Malley TT, Jin M, Willem M, Haass C, Frosch MP, and Walsh DM (2018). Diffusible, highly bioactive oligomers represent a critical minority of soluble A&#x3b2; in Alzheimer&#x2019;s disease brain. Acta Neuropathol 136, 19&#x2013;40. 10.1007/s00401-018-1846-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1846-7</ArticleId><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="pubmed">29687257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sideris DI, Danial JSH, Emin D, Ruggeri FS, Xia Z, Zhang YP, Lobanova E, Dakin H, De S, Miller A, et al. (2021). Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer&#x2019;s disease. Brain Commun 3, fcab147&#x2013;fcab147. 10.1093/braincomms/fcab147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab147</ArticleId><ArticleId IdType="pmc">PMC8361392</ArticleId><ArticleId IdType="pubmed">34396107</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern AM, Liu L, Jin S, Liu W, Meunier AL, Ericsson M, Miller MB, Batson M, Sun T, Kathuria S, et al. (2022). A calcium-sensitive antibody isolates soluble amyloid-&#x3b2; aggregates and fibrils from Alzheimer&#x2019;s disease brain. Brain 147, 2528&#x2013;2540. 10.1093/brain/awac023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac023</ArticleId><ArticleId IdType="pmc">PMC9337809</ArticleId><ArticleId IdType="pubmed">35084489</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, O&#x2019;Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H, Hyman BT, Walsh DM, and Selkoe DJ (2015). A highly sensitive novel immunoassay specifically detects low levels of soluble A&#x3b2; oligomers in human cerebrospinal fluid. Alzheimers Res Ther 7, 14. 10.1186/s13195-015-0100-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0100-y</ArticleId><ArticleId IdType="pmc">PMC4369838</ArticleId><ArticleId IdType="pubmed">25802556</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Kwak H, Lawton TR, Jin S, Meunier AL, Dang Y, Ostaszewski B, Pietras A, Stern AM, and Selkoe DJ (2022). An ultra-sensitive immunoassay detects and quantifies soluble A&#x3b2; oligomers in human plasma. Alzheimer&#x2019;s &amp; Dementia 18, 1186&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938295</ArticleId><ArticleId IdType="pubmed">34550630</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Wildburger NC, Jiang H, Gangolli M, Cairns NJ, Bateman RJ, and Brody DL (2016). Soluble amyloid-beta aggregates from human Alzheimer&#x2019;s disease brains. Sci Rep 6, 38187. 10.1038/srep38187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38187</ArticleId><ArticleId IdType="pmc">PMC5137165</ArticleId><ArticleId IdType="pubmed">27917876</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, and Selkoe DJ (2015). Systematic analysis of time-dependent neural effects of soluble amyloid &#x3b2; oligomers in culture and in vivo: Prevention by scyllo-inositol. Neurobiol Dis 82, 152&#x2013;163. 10.1016/j.nbd.2015.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.05.020</ArticleId><ArticleId IdType="pmc">PMC4640956</ArticleId><ArticleId IdType="pubmed">26054438</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Golomb R, Jurewicz A, Antel JP, and Fraser PE (2000). Inositol Stereoisomers Stabilize an Oligomeric Aggregate of Alzheimer Amyloid &#x3b2; Peptide and Inhibit A&#x3b2;-induced Toxicity*. Journal of Biological Chemistry 275, 18495&#x2013;18502. 10.1074/jbc.M906994199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M906994199</ArticleId><ArticleId IdType="pubmed">10764800</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, and Scheres SHW (2017). Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190. 10.1038/nature23002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23002</ArticleId><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, et al. (2001). The &#x201c;Arctic&#x201d; APP mutation (E693G) causes Alzheimer&#x2019;s disease by enhanced A&#x3b2; protofibril formation. Nat Neurosci 4, 887&#x2013;893. 10.1038/nn0901-887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn0901-887</ArticleId><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, M&#xf6;ller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, and Gellerfors P. (2014). Perspectives on future Alzheimer therapies: amyloid-&#x3b2; protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer&#x2019;s disease. Alzheimers Res Ther 6, 16. 10.1186/alzrt246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt246</ArticleId><ArticleId IdType="pmc">PMC4054967</ArticleId><ArticleId IdType="pubmed">25031633</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson M, Sahlin C, S&#xf6;derberg L, Basun H, F&#xe4;lting J, M&#xf6;ller C, Zachrisson O, Sunnemark D, Svensson A, Odergren T, et al. (2021). Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer&#x2019;s disease. Molecular and Cellular Neuroscience 114, 103641. 10.1016/J.MCN.2021.103641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MCN.2021.103641</ArticleId><ArticleId IdType="pubmed">34091073</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SX, Liu L, Li S, Meunier AL, and Selkoe DJ (2022). A&#x3b2; oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this. Neurobiol Dis 172, 105816. 10.1016/J.NBD.2022.105816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NBD.2022.105816</ArticleId><ArticleId IdType="pmc">PMC9809147</ArticleId><ArticleId IdType="pubmed">35820646</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, et al. (2009). Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106, 4012&#x2013;4017. 10.1073/pnas.0811698106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811698106</ArticleId><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Ngu H, Gogineni A, Lalehzadeh G, Lee S-H, Srinivasan K, Imperio J, Wu T, Weber M, Kruse AJ, et al. (2020). Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the A&#x3b2;42:A&#x3b2;40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer's mouse model. The Journal of Neuroscience, 1819&#x2013;1871. 10.1523/JNEUROSCI.1871-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1871-19.2019</ArticleId><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Casali BT, MacPherson KP, Reed-Geaghan EG, and Landreth GE (2020). Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis 142, 104956. 10.1016/j.nbd.2020.104956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104956</ArticleId><ArticleId IdType="pmc">PMC7526856</ArticleId><ArticleId IdType="pubmed">32479996</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, et al. (2019). Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci 22, 191&#x2013;204. 10.1038/s41593-018-0296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, et al. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer&#x2019;s disease with lecanemab, an anti-A&#x3b2; protofibril antibody. Alzheimers Res Ther 13, 80. 10.1186/s13195-021-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00813-8</ArticleId><ArticleId IdType="pmc">PMC8053280</ArticleId><ArticleId IdType="pubmed">33865446</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, Ghetti B, Scheres SHW, and Goedert M. (2018). Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol 136, 699&#x2013;708. 10.1007/S00401-018-1914-Z/FIGURES/5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00401-018-1914-Z/FIGURES/5</ArticleId><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SJ, Kerridge C, Cooper J, Cavallini A, Falcon B, Cella CV, Landi A, Szekeres PG, Murray TK, Ahmed Z, et al. (2016). Short fibrils constitute the major species of seed-competent tau in the brains of mice transgenic for human P301S tau. Journal of Neuroscience 36, 762&#x2013;772. 10.1523/JNEUROSCI.3542-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3542-15.2016</ArticleId><ArticleId IdType="pmc">PMC4719013</ArticleId><ArticleId IdType="pubmed">26791207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, and Scheres SH (2019). A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ 6, 5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, and Grigorieff N. (2015). CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol 192, 216&#x2013;221. 10.1016/j.jsb.2015.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2015.08.008</ArticleId><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, and Scheres SHW (2020). Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ2 7, 253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, and Scheres SHW (2017). Helical reconstruction in RELION. J Struct Biol 198, 163&#x2013;176. 10.1016/j.jsb.2017.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2017.02.003</ArticleId><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, McMullan G, Faruqi AR, Murshudov GN, Short JM, Scheres SHW, and Henderson R. (2013). High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24&#x2013;35. 10.1016/j.ultramic.2013.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ultramic.2013.06.004</ArticleId><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;al A, Lohkamp B, and Emsley P. (2020). Current developments in Coot for macromolecular model building of Electron Cryo-microscopy and Crystallographic Data. Protein Science 29, 1055&#x2013;1064. 10.1002/pro.3791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3791</ArticleId><ArticleId IdType="pmc">PMC7096722</ArticleId><ArticleId IdType="pubmed">31730249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita K, Palmer CM, Burnley T, and Murshudov GN (2021). Cryo-EM single-particle structure refinement and map calculation using Servalcat. Acta Crystallographica Section D 77, 1282&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489229</ArticleId><ArticleId IdType="pubmed">34605431</ArticleId></ArticleIdList></Reference><Reference><Citation>Alger BE (2022). Neuroscience needs to test both statistical and scientific hypotheses. Journal of Neuroscience 42, 8432&#x2013;8438. 10.1523/JNEUROSCI.1134-22.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1134-22.2022</ArticleId><ArticleId IdType="pmc">PMC9665931</ArticleId><ArticleId IdType="pubmed">36351823</ArticleId></ArticleIdList></Reference><Reference><Citation>Calin-Jageman RJ (2022). Better inference in neuroscience: test less, estimate more. Journal of Neuroscience 42, 8427&#x2013;8431. 10.1523/JNEUROSCI.1133-22.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1133-22.2022</ArticleId><ArticleId IdType="pmc">PMC9665913</ArticleId><ArticleId IdType="pubmed">36351833</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37172564</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>186</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>An in&#xa0;vivo neuroimmune organoid model to study human microglia phenotypes.</ArticleTitle><Pagination><StartPage>2111</StartPage><EndPage>2126.e20</EndPage><MedlinePgn>2111-2126.e20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2023.04.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(23)00418-X</ELocationID><Abstract><AbstractText>Microglia are specialized brain-resident macrophages that play crucial roles in brain development, homeostasis, and disease. However, until now, the ability to model interactions between the human brain environment and microglia has been severely limited. To overcome these limitations, we developed an in&#xa0;vivo xenotransplantation approach that allows us to study functionally mature human microglia (hMGs) that operate within a physiologically relevant, vascularized immunocompetent human brain organoid (iHBO) model. Our data show that organoid-resident hMGs gain human-specific transcriptomic signatures that closely resemble their in&#xa0;vivo counterparts. In&#xa0;vivo two-photon imaging reveals that hMGs actively engage in surveilling the human brain environment, react to local injuries, and respond to systemic inflammatory cues. Finally, we demonstrate that the transplanted iHBOs developed here offer the unprecedented opportunity to study functional human microglia phenotypes in health and disease and provide experimental evidence for a brain-environment-induced immune response in a patient-specific model of autism with macrocephaly.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>Simon T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, 81675 Munich, Germany; Center for Organoid Systems, Technical University of Munich, 85748 Garching, Germany; TranslaTUM - Organoid Hub, Technical University of Munich, 81675 Munich, Germany. Electronic address: simon.schafer@tum.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansour</LastName><ForeName>Abed AlFatah</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA; Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel. Electronic address: abed.mansour@mail.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlachetzki</LastName><ForeName>Johannes C M</ForeName><Initials>JCM</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pena</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, 81675 Munich, Germany; Center for Organoid Systems, Technical University of Munich, 85748 Garching, Germany; TranslaTUM - Organoid Hub, Technical University of Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghassemzadeh</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mar</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quang</LastName><ForeName>Daphne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stumpf</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Irene Santisteban</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, 81675 Munich, Germany; Center for Organoid Systems, Technical University of Munich, 85748 Garching, Germany; TranslaTUM - Organoid Hub, Technical University of Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lana</LastName><ForeName>Addison J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaghal</LastName><ForeName>Raghad</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Christopher K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nimmerjahn</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Waitt Advanced Biophotonics Center, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA. Electronic address: gage@salk.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG056306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS108034</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 NS123719</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2023 Jul 6;30(7):909-910. doi: 10.1016/j.stem.2023.05.013.</RefSource><PMID Version="1">37419102</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="Y">Organoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Human microglia</Keyword><Keyword MajorTopicYN="N">autism spectrum disorders</Keyword><Keyword MajorTopicYN="N">brain organoids</Keyword><Keyword MajorTopicYN="N">iPSCs</Keyword><Keyword MajorTopicYN="N">microglia in vivo identity</Keyword><Keyword MajorTopicYN="N">microglia surveillance</Keyword><Keyword MajorTopicYN="N">neuro-immune interactions</Keyword><Keyword MajorTopicYN="N">organoid transplantation</Keyword><Keyword MajorTopicYN="N">xenotransplantation</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>18</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37172564</ArticleId><ArticleId IdType="mid">NIHMS1894854</ArticleId><ArticleId IdType="pmc">PMC10284271</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2023.04.022</ArticleId><ArticleId IdType="pii">S0092-8674(23)00418-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Monier A, Evrard P, Gressens P, and Verney C (2006). Distribution and differentiation of microglia in the human encephalon during the first two trimesters of gestation. Journal of Comparative Neurology 499, 565&#x2013;582. 10.1002/cne.21123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21123</ArticleId><ArticleId IdType="pubmed">17029271</ArticleId></ArticleIdList></Reference><Reference><Citation>Monier A, Adle-Biassette H, Delezoide A-L, Evrard P, Gressens P, and Verney C (2007). Entry and Distribution of Microglial Cells in Human Embryonic and Fetal Cerebral Cortex. J Neuropathol Exp Neurol 66, 372&#x2013;382. 10.1097/nen.0b013e3180517b46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e3180517b46</ArticleId><ArticleId IdType="pubmed">17483694</ArticleId></ArticleIdList></Reference><Reference><Citation>Verney C, Monier A, Fallet-Bianco C, and Gressens P (2010). Early microglial colonization of the human forebrain and possible involvement in periventricular white-matter injury of preterm infants. J Anat 217, 436&#x2013;448. 10.1111/j.1469-7580.2010.01245.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7580.2010.01245.x</ArticleId><ArticleId IdType="pmc">PMC2992419</ArticleId><ArticleId IdType="pubmed">20557401</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, and Pardo CA (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology 57, 67&#x2013;81. 10.1002/ana.20315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20315</ArticleId><ArticleId IdType="pubmed">15546155</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, Courchesne E, and Everall IP (2010). Microglial Activation and Increased Microglial Density Observed in the Dorsolateral Prefrontal Cortex in Autism. Biological Psychiatry 68, 368&#x2013;376. 10.1016/j.biopsych.2010.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2010.05.024</ArticleId><ArticleId IdType="pubmed">20674603</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetreault NA, Hakeem AY, Jiang S, Williams BA, Allman E, Wold BJ, and Allman JM (2012). Microglia in the Cerebral Cortex in Autism. J Autism Dev Disord 42, 2569&#x2013;2584. 10.1007/s10803-012-1513-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10803-012-1513-0</ArticleId><ArticleId IdType="pubmed">22466688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AS, Azmitia EC, and Whitaker-Azmitia PM (2017). Developmental microglial priming in postmortem autism spectrum disorder temporal cortex. Brain, Behavior, and Immunity 62, 193&#x2013;202. 10.1016/j.bbi.2017.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.01.019</ArticleId><ArticleId IdType="pubmed">28159644</ArticleId></ArticleIdList></Reference><Reference><Citation>Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor RM, Blencowe BJ, and Geschwind DH (2011). Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474, 380&#x2013;384. 10.1038/nature10110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10110</ArticleId><ArticleId IdType="pmc">PMC3607626</ArticleId><ArticleId IdType="pubmed">21614001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, West AB, and Arking DE (2014). Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nature Communications 5, 5748. 10.1038/ncomms6748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6748</ArticleId><ArticleId IdType="pmc">PMC4270294</ArticleId><ArticleId IdType="pubmed">25494366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, Won H, Bakel H. van, Varghese, M, Wang Y, et al. (2018). Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 362, eaat8127. 10.1126/science.aat8127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat8127</ArticleId><ArticleId IdType="pmc">PMC6443102</ArticleId><ArticleId IdType="pubmed">30545856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett FC, Bennett ML, Yaqoob F, Mulinyawe SB, Grant GA, Gephart MH, Plowey ED, and Barres BA (2018). A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98, 1170&#x2013;1183.e8. 10.1016/j.neuron.2018.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.014</ArticleId><ArticleId IdType="pmc">PMC6023731</ArticleId><ArticleId IdType="pubmed">29861285</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O&#x2019;Connor C, Fitzpatrick C, Pasillas MP, et al. (2017). An environment-dependent transcriptional network specifies human microglia identity. Science 356. 10.1126/science.aal3222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3222</ArticleId><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, and Amit I (2014). Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment. Cell 159, 1312&#x2013;1326. 10.1016/j.cell.2014.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.11.018</ArticleId><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, and Barres BA (2017). Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures. Neuron 94, 759&#x2013;773.e8. 10.1016/j.neuron.2017.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A, Yoon S-J, Tran SS, Makinson CD, Park JY, Andersen J, Valencia AM, Horvath S, Xiao X, Huguenard JR, et al. (2021). Long-term maturation of human cortical organoids matches key early postnatal transitions. Nat Neurosci 24, 331&#x2013;342. 10.1038/s41593-021-00802-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00802-y</ArticleId><ArticleId IdType="pmc">PMC8109149</ArticleId><ArticleId IdType="pubmed">33619405</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X (2016). Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell 165, 1238&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900885</ArticleId><ArticleId IdType="pubmed">27118425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour AA, Schafer ST, and Gage FH (2020). Cellular complexity in brain organoids: Current progress and unsolved issues. Seminars in Cell &amp; Developmental Biology. 10.1016/j.semcdb.2020.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2020.05.013</ArticleId><ArticleId IdType="pubmed">32499191</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, et al. (2017). iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron 94, 278&#x2013;293.e9. 10.1016/j.neuron.2017.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Douvaras P, Sun B, Wang M, Kruglikov I, Lallos G, Zimmer M, Terrenoire C, Zhang B, Gandy S, Schadt E, et al. (2017). Directed Differentiation of Human Pluripotent Stem Cells to Microglia. Stem Cell Reports 8, 1516&#x2013;1524. 10.1016/j.stemcr.2017.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.04.023</ArticleId><ArticleId IdType="pmc">PMC5470097</ArticleId><ArticleId IdType="pubmed">28528700</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W, Sansom SN, Buchrieser J, Newey SE, Moore CS, Nicholls FJ, Chintawar S, Schnell C, Antel JP, Allen ND, et al. (2017). A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response. Stem Cell Reports 8, 1727&#x2013;1742. 10.1016/j.stemcr.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.05.017</ArticleId><ArticleId IdType="pmc">PMC5470330</ArticleId><ArticleId IdType="pubmed">28591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, Bakiasi G, Tsai L-H, Aubourg P, Ransohoff RM, et al. (2016). Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med advance online publication. 10.1038/nm.4189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4189</ArticleId><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya H, Shen MJ, Ichikawa DM, Sedlock AB, Choi Y, Johnson KR, Kim G, Brown MA, Elkahloun AG, Maric D, et al. (2017). Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat Neurosci advance online publication. 10.1038/nn.4534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4534</ArticleId><ArticleId IdType="pmc">PMC5404968</ArticleId><ArticleId IdType="pubmed">28253233</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee P, Paza E, Perkins EM, James OG, Kenkhuis B, Lloyd AF, Burr K, Story D, Yusuf D, He X, et al. (2020). Generation of pure monocultures of human microglia-like cells from induced pluripotent stem cells. Stem Cell Research 49, 102046. 10.1016/j.scr.2020.102046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2020.102046</ArticleId><ArticleId IdType="pubmed">33096385</ArticleId></ArticleIdList></Reference><Reference><Citation>Abreu CM, Gama L, Krasemann S, Chesnut M, Odwin-Dacosta S, Hogberg HT, Hartung T, and Pamies D (2018). Microglia Increase Inflammatory Responses in iPSC-Derived Human BrainSpheres. Front Microbiol 9. 10.3389/fmicb.2018.02766.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02766</ArticleId><ArticleId IdType="pmc">PMC6296317</ArticleId><ArticleId IdType="pubmed">30619100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-T, Seo J, Gao F, Feldman HM, Wen H-L, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, et al. (2018). APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron 98, 1141&#x2013;1154.e7. 10.1016/j.neuron.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmann J, Coburn MA, England W, Figueroa Velez DX, Kiani Shabestari S, Tu CH, McQuade A, Kolahdouzan M, Echeverria K, Claes C, et al. (2019). Development of a Chimeric Model to Study and Manipulate Human Microglia In Vivo. Neuron 103, 1016&#x2013;1033.e10. 10.1016/j.neuron.2019.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.002</ArticleId><ArticleId IdType="pmc">PMC7138101</ArticleId><ArticleId IdType="pubmed">31375314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Daele JVD, Fattorelli N, Wolfs L, Balusu S, Burton O, Liston A, Sierksma A, Fourne Y, Poovathingal S, et al. (2019). Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat Neurosci 22, 2111&#x2013;2116. 10.1038/s41593-019-0525-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0525-x</ArticleId><ArticleId IdType="pmc">PMC7616913</ArticleId><ArticleId IdType="pubmed">31659342</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Li X, Boreland AJ, Posyton A, Kwan K, Hart RP, and Jiang P (2020). Human iPSC-derived mature microglia retain their identity and functionally integrate in the chimeric mouse brain. Nature Communications 11, 1&#x2013;16. 10.1038/s41467-020-15411-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15411-9</ArticleId><ArticleId IdType="pmc">PMC7101330</ArticleId><ArticleId IdType="pubmed">32221280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattorelli N, Martinez-Muriana A, Wolfs L, Geric I, De Strooper B, and Mancuso R (2021). Stem-cell-derived human microglia transplanted into mouse brain to study human disease. Nat Protoc 16, 1013&#x2013;1033. 10.1038/s41596-020-00447-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-00447-4</ArticleId><ArticleId IdType="pubmed">33424025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour AA, Gon&#xe7;alves JT, Bloyd CW, Li H, Fernandes S, Quang D, Johnston S, Parylak SL, Jin X, and Gage FH (2018). An in vivo model of functional and vascularized human brain organoids. Nature Biotechnology 36, 432&#x2013;441. 10.1038/nbt.4127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4127</ArticleId><ArticleId IdType="pmc">PMC6331203</ArticleId><ArticleId IdType="pubmed">29658944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kracht L, Borggrewe M, Eskandar S, Brouwer N, Lopes SMC de S, Laman JD, Scherjon SA, Prins JR, Kooistra SM, and Eggen BJL (2020). Human fetal microglia acquire homeostatic immune-sensing properties early in development. Science 369, 530&#x2013;537. 10.1126/science.aba5906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba5906</ArticleId><ArticleId IdType="pubmed">32732419</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sankowski R, Staszewski O, B&#xf6;ttcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, Loo G. van, et al. (2019). Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388&#x2013;392. 10.1038/s41586-019-0924-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0924-x</ArticleId><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Popova G, Soliman SS, Kim CN, Keefe MG, Hennick KM, Jain S, Li T, Tejera D, Shin D, Chhun BB, et al. (2021). Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids. Cell Stem Cell. 10.1016/j.stem.2021.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.08.015</ArticleId><ArticleId IdType="pmc">PMC8642295</ArticleId><ArticleId IdType="pubmed">34536354</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie P, Dean A, Male D, and Ulfig N (2005). Microglia in the Cerebral Wall of the Human Telencephalon at Second Trimester. Cerebral Cortex 15, 938&#x2013;949. 10.1093/cercor/bhh194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhh194</ArticleId><ArticleId IdType="pubmed">15483047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong S, Zhang S, Fan X, Wu Q, Yan L, Dong J, Zhang H, Li L, Sun L, Pan N, et al. (2018). A single-cell RNA-seq survey of the developmental landscape of the human prefrontal cortex. Nature 555, 524&#x2013;528. 10.1038/nature25980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25980</ArticleId><ArticleId IdType="pubmed">29539641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson LJ, Perry VH, Dri P, and Gordon S (1990). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151&#x2013;170. 10.1016/0306-4522(90)90229-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(90)90229-w</ArticleId><ArticleId IdType="pubmed">2089275</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Platas SG, Comeau S, Rachalski A, Bo GD, Cruceanu C, Turecki G, Giros B, and Mechawar N (2014). Morphometric characterization of microglial phenotypes in human cerebral cortex. J Neuroinflammation 11, 12. 10.1186/1742-2094-11-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-12</ArticleId><ArticleId IdType="pmc">PMC3906907</ArticleId><ArticleId IdType="pubmed">24447857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kongsui R, Beynon SB, Johnson SJ, and Walker FR (2014). Quantitative assessment of microglial morphology and density reveals remarkable consistency in the distribution and morphology of cells within the healthy prefrontal cortex of the rat. J Neuroinflammation 11. 10.1186/s12974-014-0182-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0182-7</ArticleId><ArticleId IdType="pmc">PMC4213482</ArticleId><ArticleId IdType="pubmed">25343964</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonk F, Roux P, Flamant P, Fiette L, Bozza FA, Simard S, Lemaire M, Plaud B, Shorte SL, Sharshar T, et al. (2016). Phenotypic clustering: a novel method for microglial morphology analysis. J Neuroinflammation 13, 153. 10.1186/s12974-016-0614-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0614-7</ArticleId><ArticleId IdType="pmc">PMC4912769</ArticleId><ArticleId IdType="pubmed">27317566</ArticleId></ArticleIdList></Reference><Reference><Citation>Home :: BrainSpan: Atlas of the Developing Human Brain
http://www.brainspan.org/.</Citation></Reference><Reference><Citation>Matcovitch-Natan O, Winter DR, Giladi A, Aguilar SV, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Gonz&#xe1;lez FZ, Perrin P, et al. (2016). Microglia development follows a stepwise program to regulate brain homeostasis. Science, aad8670. 10.1126/science.aad8670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8670</ArticleId><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian Z, Gong Y, Huang T, Lee CZW, Bian L, Bai Z, Shi H, Zeng Y, Liu C, He J, et al. (2020). Deciphering human macrophage development at single-cell resolution. Nature 582, 571&#x2013;576. 10.1038/s41586-020-2316-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2316-7</ArticleId><ArticleId IdType="pubmed">32499656</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902.e21. 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang L, Means TK, and El Khoury J (2013). The microglial sensome revealed by direct RNA sequencing. Nature Neuroscience 16, 1896&#x2013;1905. 10.1038/nn.3554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3554</ArticleId><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankowski R, B&#xf6;ttcher C, Masuda T, Geirsdottir L, Sagar, Sindram E, Seredenina T, Muhs A, Scheiwe C, Shah MJ, et al. (2019). Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat Neurosci 22, 2098&#x2013;2110. 10.1038/s41593-019-0532-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0532-y</ArticleId><ArticleId IdType="pubmed">31740814</ArticleId></ArticleIdList></Reference><Reference><Citation>Geirsdottir L, David E, Keren-Shaul H, Weiner A, Bohlen SC, Neuber J, Balic A, Giladi A, Sheban F, Dutertre C-A, et al. (2019). Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program. Cell 179, 1609&#x2013;1622.e16. 10.1016/j.cell.2019.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.11.010</ArticleId><ArticleId IdType="pubmed">31835035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, and Helmchen F (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318. 10.1126/science.1110647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110647</ArticleId><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, and Gan W-B (2005). ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8, 752&#x2013;758. 10.1038/nn1472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1472</ArticleId><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, and Natoli G (2015). Molecular control of activation and priming in macrophages. Nat Immunol 17, 26&#x2013;33. 10.1038/ni.3306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3306</ArticleId><ArticleId IdType="pmc">PMC4795476</ArticleId><ArticleId IdType="pubmed">26681459</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer ST, Paquola ACM, Stern S, Gosselin D, Ku M, Pena M, Kuret TJM, Liyanage M, Mansour AA, Jaeger BN, et al. (2019). Pathological priming causes developmental gene network heterochronicity in autistic subject-derived neurons. Nature Neuroscience 22, 243. 10.1038/s41593-018-0295-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0295-x</ArticleId><ArticleId IdType="pmc">PMC6402576</ArticleId><ArticleId IdType="pubmed">30617258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage FH, and Fisher LJ (1991). Intracerebral grafting: A tool for the neurobiologist. Neuron 6, 1&#x2013;12. 10.1016/0896-6273(91)90116-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(91)90116-H</ArticleId><ArticleId IdType="pubmed">1986771</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage FH, Bj&#xf6;klund A, and Stenevi U (1984). Denervation releases a neuronal survival factor in adult rat hippocampus. Nature 308, 637&#x2013;639. 10.1038/308637a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/308637a0</ArticleId><ArticleId IdType="pubmed">6424029</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenevi U, Bj&#xf6;rklund A, and Svendgaard N-A (1976). Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival. Brain Research 114, 1&#x2013;20. 10.1016/0006-8993(76)91003-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(76)91003-9</ArticleId><ArticleId IdType="pubmed">963534</ArticleId></ArticleIdList></Reference><Reference><Citation>Daviaud N, Friedel RH, and Zou H (2018). Vascularization and Engraftment of Transplanted Human Cerebral Organoids in Mouse Cortex. eNeuro 5, ENEURO.0219&#x2013;18.2018. 10.1523/ENEURO.0219-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0219-18.2018</ArticleId><ArticleId IdType="pmc">PMC6243198</ArticleId><ArticleId IdType="pubmed">30460331</ArticleId></ArticleIdList></Reference><Reference><Citation>Revah O, Gore F, Kelley KW, Andersen J, Sakai N, Chen X, Li M-Y, Birey F, Yang X, Saw NL, et al. (2022). Maturation and circuit integration of transplanted human cortical organoids. Nature 610, 319&#x2013;326. 10.1038/s41586-022-05277-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05277-w</ArticleId><ArticleId IdType="pmc">PMC9556304</ArticleId><ArticleId IdType="pubmed">36224417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelava I, and Lancaster MA (2016). Stem Cell Models of Human Brain Development. Cell Stem Cell 18, 736&#x2013;748. 10.1016/j.stem.2016.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2016.05.022</ArticleId><ArticleId IdType="pubmed">27257762</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X, Song H, and Ming G (2019). Brain organoids: advances, applications and challenges. Development 146, dev166074. 10.1242/dev.166074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.166074</ArticleId><ArticleId IdType="pmc">PMC6503989</ArticleId><ArticleId IdType="pubmed">30992274</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormel PR, S&#xe1; RV, Bodegraven EJ, Karst H, Harschnitz O, Sneeboer MAM, Johansen LE, Dijk RE, Scheefhals N, Berlekom AB, et al. (2018). Microglia innately develop within cerebral organoids. Nat Commun 9, 1&#x2013;14. 10.1038/s41467-018-06684-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06684-2</ArticleId><ArticleId IdType="pmc">PMC6177485</ArticleId><ArticleId IdType="pubmed">30301888</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, Yoshihara Y, Omata K, Matsumoto K, Tsuchiya KJ, et al. (2013). Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 70, 49&#x2013;58. 10.1001/jamapsychiatry.2013.272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2013.272</ArticleId><ArticleId IdType="pubmed">23404112</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K, and Persico AM (2008). Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 30, 303&#x2013;311. 10.1016/j.nbd.2008.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.01.012</ArticleId><ArticleId IdType="pmc">PMC2693090</ArticleId><ArticleId IdType="pubmed">18378158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, West AB, and Arking DE (2014). Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun 5, 5748. 10.1038/ncomms6748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6748</ArticleId><ArticleId IdType="pmc">PMC4270294</ArticleId><ArticleId IdType="pubmed">25494366</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett BA, Kantor AB, Schulman H, Walker WL, Lit L, Ashwood P, Rocke DM, and Sharp FR (2007). A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Molecular Psychiatry 12, 292&#x2013;306. 10.1038/sj.mp.4001943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001943</ArticleId><ArticleId IdType="pubmed">17189958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chez MG, Dowling T, Patel PB, Khanna P, and Kominsky M (2007). Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 36, 361&#x2013;365. 10.1016/j.pediatrneurol.2007.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2007.01.012</ArticleId><ArticleId IdType="pubmed">17560496</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A, and Heyes MP (2005). Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 33, 195&#x2013;201. 10.1016/j.pediatrneurol.2005.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2005.03.014</ArticleId><ArticleId IdType="pubmed">16139734</ArticleId></ArticleIdList></Reference><Reference><Citation>Werling DM, and Geschwind DH (2013). Sex differences in autism spectrum disorders. Current opinion in neurology 26, 146. 10.1097/WCO.0b013e32835ee548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32835ee548</ArticleId><ArticleId IdType="pmc">PMC4164392</ArticleId><ArticleId IdType="pubmed">23406909</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, M&#xf6;ller T, et al. (2017). Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat Neurosci 20, 1162&#x2013;1171. 10.1038/nn.4597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X, Nguyen HN, Song MM, Hadiono C, Ogden SC, Hammack C, Yao B, Hamersky GR, Jacob F, Zhong C, et al. (2016). Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell 165, 1238&#x2013;1254. 10.1016/j.cell.2016.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.04.032</ArticleId><ArticleId IdType="pmc">PMC4900885</ArticleId><ArticleId IdType="pubmed">27118425</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves JT, Bloyd CW, Shtrahman M, Johnston ST, Schafer ST, Parylak SL, Tran T, Chang T, and Gage FH (2016). In vivo imaging of dendritic pruning in dentate granule cells. Nat. Neurosci. 19, 788&#x2013;791. 10.1038/nn.4301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4301</ArticleId><ArticleId IdType="pmc">PMC4941946</ArticleId><ArticleId IdType="pubmed">27135217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, Stender JD, Chun HB, Garner H, Geissmann F, et al. (2014). Environment Drives Selection and Function of Enhancers Controlling Tissue-Specific Macrophage Identities. Cell 159, 1327&#x2013;1340. 10.1016/j.cell.2014.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.11.023</ArticleId><ArticleId IdType="pmc">PMC4364385</ArticleId><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF, and Regev A (2015). Spatial reconstruction of single-cell gene expression. Nat Biotechnol 33, 495&#x2013;502. 10.1038/nbt.3192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3192</ArticleId><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C, and Satija R (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biology 20, 296. 10.1186/s13059-019-1874-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1874-1</ArticleId><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh P, and Raychaudhuri S (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nature Methods 16, 1289&#x2013;1296. 10.1038/s41592-019-0619-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0619-0</ArticleId><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, et al. (2015). MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biology 16, 278. 10.1186/s13059-015-0844-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, Purdom E, and Dudoit S (2018). Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 19, 477. 10.1186/s12864-018-4772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-018-4772-0</ArticleId><ArticleId IdType="pmc">PMC6007078</ArticleId><ArticleId IdType="pubmed">29914354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim MM, and Kramann R (2019). genesorteR: Feature Ranking in Clustered Single Cell Data. 676379. 10.1101/676379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/676379</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, and Horvath S (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559. 10.1186/1471-2105-9-559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito S, Miyoshi E, Michael N, Shahin S, Martini AC, Head E, Silva J, Leavy K, Perez-Rosendahl M, and Swarup V (2021). Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer&#x2019;s disease. Nat Genet 53, 1143&#x2013;1155. 10.1038/s41588-021-00894-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00894-z</ArticleId><ArticleId IdType="pmc">PMC8766217</ArticleId><ArticleId IdType="pubmed">34239132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>